data_6hkc_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6hkc _Structure_validation_residue.Date_analyzed 2019-01-18 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.9 m . . . . . 0 N--CA 1.449 -0.509 0 CA-C-O 121.306 0.574 . . . . 74.12 109.631 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -114.16 97.91 6.64 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.844 -0.617 . . . . 74.03 109.756 -177.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -163.16 171.1 38.82 Favored Glycine 0 N--CA 1.439 -1.113 0 C-N-CA 120.728 -0.749 . . . . 60.54 112.223 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 26.0 m -104.32 153.53 20.92 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.74 -0.467 . . . . 72.14 109.74 177.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -89.6 -178.86 5.66 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.927 0.394 . . . . 64.22 111.13 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.52 HD11 ' HB ' ' A' ' 31' ' ' ILE . 26.6 mt -87.98 120.55 37.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.928 -0.578 . . . . 73.43 110.022 177.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 63.1 mt -74.95 138.38 21.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.212 -0.904 . . . . 72.13 110.525 -178.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 81.1 m-70 -80.54 132.09 59.45 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 116.118 -0.492 . . . . 73.31 109.768 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.404 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.6 Cg_exo -51.05 113.18 0.98 Allowed 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 123.319 2.679 . . . . 71.32 112.838 -178.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 4.7 Cg_exo -76.51 -80.0 0.01 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.43 0 C-N-CA 122.881 2.388 . . . . 72.42 112.278 -178.615 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.0 t-105 -101.39 -178.09 3.63 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.602 -0.518 . . . . 72.24 109.602 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -58.71 100.54 0.07 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.133 0.492 . . . . 74.13 111.086 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.496 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . 175.81 -158.29 25.11 Favored Glycine 0 N--CA 1.443 -0.847 0 C-N-CA 120.854 -0.688 . . . . 71.54 112.009 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -161.1 -171.28 26.88 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 111.296 -0.721 . . . . 73.45 111.296 178.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.9 mt -125.68 131.4 72.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.792 0.806 . . . . 71.22 111.804 -178.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.764 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 23.3 tpp180 -93.51 110.65 22.23 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.317 -1.31 . . . . 74.22 109.935 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -90.95 -171.52 3.03 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.778 0.323 . . . . 74.51 110.358 177.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.451 ' NH2' ' HB2' ' A' ' 39' ' ' GLU . 97.8 mtt180 -109.72 -86.58 0.52 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.446 -0.343 . . . . 74.3 110.894 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -88.4 48.06 3.54 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 121.18 -0.533 . . . . 71.12 112.702 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 91.8 mt -137.91 133.41 33.77 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.09 -0.337 . . . . 64.52 110.09 178.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.4 t -95.99 179.55 5.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.745 -0.465 . . . . 75.32 109.745 174.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' GLN . 63.9 mtm-85 -79.54 -171.38 2.76 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.581 -0.282 . . . . 73.32 110.962 -177.438 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.471 ' O ' ' HE2' ' A' ' 29' ' ' LYS . 34.7 t70 68.5 -27.03 0.14 Allowed 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 123.329 0.652 . . . . 65.24 110.928 -170.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ARG . 19.4 mt-30 -90.33 -146.07 0.18 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.703 -0.681 . . . . 73.2 110.028 175.169 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 27' ' ' GLN . 4.8 m 54.26 19.75 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.509 1.123 . . . . 75.0 112.733 177.293 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.471 ' HE2' ' O ' ' A' ' 26' ' ' ASP . 49.9 mtmt -101.41 -74.85 0.61 Allowed 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.823 -0.436 . . . . 75.45 109.823 175.145 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.11 89.53 4.06 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.448 0.642 . . . . 75.11 111.253 178.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.52 ' HB ' HD11 ' A' ' 9' ' ' ILE . 64.9 mt -125.44 138.86 53.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.255 -0.884 . . . . 74.23 108.634 175.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 37.4 m-80 -74.39 -70.2 0.41 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.636 0.255 . . . . 73.04 110.864 -177.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -141.55 139.43 33.2 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.017 0.437 . . . . 74.1 111.301 -177.026 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -78.85 147.0 69.74 Favored Pre-proline 0 C--N 1.321 -0.646 0 N-CA-C 109.079 -0.711 . . . . 73.11 109.079 172.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -61.47 151.36 80.26 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.684 2.256 . . . . 63.24 112.26 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.2 p -61.13 138.24 22.22 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 CA-C-N 116.388 -0.369 . . . . 72.31 110.132 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 16.8 t70 61.97 75.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.817 0.818 . . . . 75.53 110.421 -172.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -133.28 124.68 27.75 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 107.464 -1.31 . . . . 75.21 107.464 175.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.7 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 39.5 mt-10 -111.98 124.9 53.38 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.099 0.476 . . . . 74.51 111.537 -172.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.476 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 32.6 pt -116.0 167.28 9.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.122 -0.944 . . . . 75.23 111.019 -177.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.764 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 44.7 tt0 -125.05 146.2 49.55 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.855 -0.611 . . . . 74.33 110.542 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.474 ' HE2' ' HG3' ' A' ' 56' ' ' ARG . 25.8 m-85 -97.67 103.07 14.97 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.323 -0.399 . . . . 75.13 110.762 178.078 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 32.7 m -97.58 157.45 3.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 120.825 0.345 . . . . 73.24 111.055 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.538 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 48.3 t -89.53 158.42 17.68 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-N 116.037 -0.529 . . . . 63.13 109.608 178.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . 0.496 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 31.3 ttt180 -58.13 121.24 10.21 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.858 -1.065 . . . . 71.44 111.873 -169.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 93.61 -128.95 9.67 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.874 -0.891 . . . . 62.21 110.874 -176.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -114.95 37.98 3.31 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.5 0.667 . . . . 71.43 110.009 172.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.538 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 27.3 mmt180 -88.84 146.44 24.96 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.434 -0.803 . . . . 74.21 109.356 178.194 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -103.46 166.18 10.58 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.04 0.448 . . . . 74.41 110.848 -177.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.539 HG12 ' HA ' ' A' ' 73' ' ' CYS . 35.4 m -132.97 145.96 33.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 115.921 -0.581 . . . . 70.42 109.835 177.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.6 p -108.18 95.81 4.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 122.195 0.998 . . . . 74.5 109.42 172.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.82 172.82 33.23 Favored Glycine 0 N--CA 1.443 -0.893 0 CA-C-N 114.47 -1.241 . . . . 74.22 110.801 -178.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.77 67.27 5.74 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.773 1.649 . . . . 70.42 110.552 172.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.538 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 31.9 pttt -84.32 87.65 7.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.36 -0.836 . . . . 75.22 111.532 -173.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -160.89 129.18 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.262 -0.881 . . . . 75.54 109.286 174.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.7 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 28.7 mmt85 -133.18 109.95 9.8 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 116.531 -0.304 . . . . 75.13 110.584 -177.261 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -96.66 118.6 33.48 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.822 -0.436 . . . . 74.13 109.822 178.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.8 t -62.62 132.74 53.37 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.919 -0.582 . . . . 74.1 110.954 177.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 90.2 mt -97.42 -178.58 4.2 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.873 -0.603 . . . . 75.32 110.61 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.19 -1.87 34.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.04 0.448 . . . . 70.22 111.043 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -119.63 169.78 9.78 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.41 -0.589 . . . . 74.35 109.41 177.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -75.33 62.35 2.65 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.079 -0.582 . . . . 74.22 113.35 -175.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 27.6 t -170.28 160.55 7.82 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.674 -0.491 . . . . 64.31 109.674 176.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 58.5 m95 -97.03 174.63 6.67 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.482 -0.562 . . . . 74.23 109.482 -177.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -49.89 -75.4 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.382 0 N-CA-C 112.815 0.672 . . . . 73.14 112.815 -176.026 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -115.89 94.76 4.81 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.377 -0.601 . . . . 71.12 109.377 176.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 13.5 tpt -93.42 75.35 4.49 Favored 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 119.192 -1.003 . . . . 72.34 110.253 -177.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -172.65 96.73 0.14 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.585 -1.188 . . . . 75.03 108.235 159.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.6 m -142.07 108.91 5.87 Favored Pre-proline 0 C--N 1.317 -0.846 0 C-N-CA 119.671 -0.812 . . . . 74.5 111.714 -172.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -77.56 93.84 1.08 Allowed 'Trans proline' 0 N--CA 1.458 -0.582 0 C-N-CA 122.62 2.213 . . . . 64.4 111.834 176.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 35.8 p -81.34 107.34 14.04 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.054 -0.521 . . . . 73.32 110.368 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -78.84 120.07 22.94 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.245 0.545 . . . . 75.3 110.477 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.539 ' HA ' HG12 ' A' ' 50' ' ' VAL . 24.0 t -72.32 110.1 6.51 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.559 -0.746 . . . . 74.22 109.799 -178.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 98.4 t -134.37 126.13 48.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.973 -0.558 . . . . 73.23 110.293 -174.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.229 -0.891 . . . . 74.41 109.79 178.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.3 m . . . . . 0 N--CA 1.449 -0.478 0 N-CA-C 109.499 -0.556 . . . . 74.12 109.499 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 49.1 mm-40 -83.11 109.19 16.94 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.986 -0.552 . . . . 74.03 110.538 -177.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.583 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -150.26 141.54 8.86 Favored Glycine 0 N--CA 1.443 -0.895 0 C-N-CA 120.737 -0.744 . . . . 60.54 112.365 -178.193 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 37.4 m -88.96 154.03 20.55 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 110.109 -0.33 . . . . 72.14 110.109 178.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -86.89 177.76 7.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.017 0.437 . . . . 64.22 111.681 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.55 HD11 ' HB ' ' A' ' 31' ' ' ILE . 72.0 mt -87.79 118.9 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.527 -0.76 . . . . 73.43 109.982 177.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 44.2 mt -71.25 145.36 12.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.904 -0.589 . . . . 72.13 110.923 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -81.02 137.78 49.7 Favored Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 109.587 -0.523 . . . . 73.31 109.587 174.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -64.11 116.47 3.73 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.457 2.105 . . . . 71.32 111.634 176.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.75 -85.01 0.01 OUTLIER 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.541 2.161 . . . . 72.42 112.134 -178.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.6 t-105 -101.97 -178.08 3.6 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.843 -0.799 . . . . 72.24 108.843 173.371 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -50.67 100.9 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.189 0.518 . . . . 74.13 111.761 178.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.81 -147.29 5.65 Favored Glycine 0 N--CA 1.444 -0.83 0 CA-C-N 115.485 -0.78 . . . . 71.54 111.325 178.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -178.5 -170.86 41.13 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 120.869 -0.682 . . . . 73.45 111.42 177.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mt -123.11 133.11 70.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.518 0.675 . . . . 71.22 111.325 -179.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.904 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 7.2 tpt180 -96.31 132.85 41.37 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.634 -1.166 . . . . 74.22 108.448 177.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.511 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 97.1 m-85 -103.77 -171.53 1.95 Allowed 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 120.417 -0.513 . . . . 74.51 111.636 -173.278 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.602 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 49.1 ttt180 -113.36 -44.04 3.28 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.576 -0.738 . . . . 74.3 110.263 -170.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -148.03 40.01 0.97 Allowed Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.647 -0.706 . . . . 71.12 111.968 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.943 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 84.7 mt -122.21 130.07 52.85 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.832 0.349 . . . . 64.52 110.504 179.463 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 11.0 t -90.72 -179.33 5.5 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.939 -0.573 . . . . 75.32 110.158 177.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 5.6 ptm180 -73.66 -173.49 1.49 Allowed 'General case' 0 C--O 1.234 0.286 0 CA-C-O 120.978 0.418 . . . . 73.32 112.125 -174.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 31.1 t70 56.17 12.77 1.03 Allowed 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 115.353 -0.839 . . . . 65.24 111.609 -174.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.478 ' O ' HG22 ' A' ' 28' ' ' VAL . 25.5 mt-30 -124.47 -162.69 1.1 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.849 -0.614 . . . . 73.2 109.538 -179.636 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.3 m 56.92 13.83 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.452 1.101 . . . . 75.0 112.892 174.53 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 53.0 pttt -96.34 -27.6 14.87 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.021 0.438 . . . . 75.45 109.856 176.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.49 95.29 2.42 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.74 -0.664 . . . . 75.11 110.412 177.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.55 ' HB ' HD11 ' A' ' 9' ' ' ILE . 62.7 mt -132.21 148.12 32.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 108.707 -0.849 . . . . 74.23 108.707 177.578 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.3 m-80 -75.77 -69.04 0.51 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.031 0.443 . . . . 73.04 109.967 -178.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.583 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 87.4 m-85 -141.44 150.15 41.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.872 -0.604 . . . . 74.1 110.713 -177.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -91.54 136.6 26.53 Favored Pre-proline 0 C--N 1.323 -0.55 0 N-CA-C 109.403 -0.591 . . . . 73.11 109.403 174.237 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.88 143.41 95.86 Favored 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 122.866 2.377 . . . . 63.24 113.055 -176.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.435 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 3.6 p -70.11 84.41 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 CA-C-O 122.031 0.919 . . . . 72.31 110.643 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.435 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 35.2 t70 167.2 -27.51 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.493 -1.23 . . . . 75.53 108.766 -174.553 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.943 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 4.2 t80 -64.86 137.38 57.73 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 114.681 -1.145 . . . . 75.21 111.713 -174.692 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.602 ' H ' ' HD2' ' A' ' 21' ' ' ARG . 41.4 mt-10 -120.29 139.16 53.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.928 -0.578 . . . . 74.51 109.593 177.239 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.469 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 37.3 pt -126.2 162.72 29.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.121 0.486 . . . . 75.23 112.019 -178.673 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.904 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.9 tt0 -124.57 153.69 41.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.231 -0.895 . . . . 74.33 109.811 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.587 ' O ' HG11 ' A' ' 50' ' ' VAL . 97.2 m-85 -101.9 101.59 12.04 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.439 0.162 . . . . 75.13 110.996 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.477 HG12 ' HB2' ' A' ' 19' ' ' ARG . 15.5 m -97.13 170.96 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 120.861 0.363 . . . . 73.24 111.24 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 26.5 t -114.73 171.15 7.81 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.015 -0.539 . . . . 63.13 109.922 -176.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 14.4 mmm180 -72.57 110.67 7.11 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 120.798 0.332 . . . . 71.44 110.547 179.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.17 -108.83 3.02 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.717 -0.754 . . . . 62.21 112.073 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -155.11 49.07 0.56 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.185 0.517 . . . . 71.43 111.269 -177.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.559 ' CB ' ' HB2' ' A' ' 73' ' ' CYS . 17.3 mmt180 -88.31 145.71 25.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.152 -0.477 . . . . 74.21 110.072 177.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.4 mm-40 -80.62 112.88 18.4 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.005 0.431 . . . . 74.41 109.977 176.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.587 HG11 ' O ' ' A' ' 42' ' ' TYR . 3.8 p -92.67 115.73 32.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.293 0.568 . . . . 70.42 110.769 -178.471 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.7 p -100.61 97.3 5.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 122.125 0.964 . . . . 74.5 110.613 178.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.91 170.68 32.56 Favored Glycine 0 N--CA 1.441 -0.989 0 CA-C-N 114.71 -1.132 . . . . 74.22 110.284 175.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -71.96 67.0 3.26 Favored 'Trans proline' 0 C--O 1.235 0.334 0 C-N-CA 122.047 1.831 . . . . 70.42 110.529 170.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.504 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 41.5 pttt -84.75 87.3 7.3 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.552 0.691 . . . . 75.22 112.086 -170.277 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.516 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.6 p -161.05 127.05 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.556 -0.747 . . . . 75.54 109.226 171.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.557 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 28.3 mmt180 -133.15 112.85 12.09 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.103 -0.332 . . . . 75.13 110.103 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.42 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 38.6 ttmt -101.52 123.92 46.34 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 109.375 -0.602 . . . . 74.13 109.375 179.368 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.3 t -67.3 119.52 12.3 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.233 -0.44 . . . . 74.1 110.246 -179.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 80.1 mt -101.28 -179.93 4.18 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.897 -0.592 . . . . 75.32 110.369 -177.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.81 59.5 3.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.129 0.49 . . . . 70.22 111.15 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.4 p-10 -161.78 167.4 24.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.328 -0.851 . . . . 74.35 108.786 175.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -82.83 36.93 2.66 Favored Glycine 0 CA--C 1.521 0.409 0 C-N-CA 120.699 -0.762 . . . . 74.22 113.45 -174.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.4 m -156.43 157.24 35.18 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.93 0.365 . . . . 64.31 110.176 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 87.3 m95 -83.36 179.17 7.75 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.53 -0.305 . . . . 74.23 110.464 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.8 m -56.74 -53.22 60.24 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 116.025 -0.534 . . . . 73.14 112.053 -176.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -148.03 129.66 15.03 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.514 -0.55 . . . . 71.12 109.514 -177.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 56.1 mtm -133.64 78.25 1.76 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 119.21 -0.996 . . . . 72.34 110.759 172.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -168.82 89.16 0.21 Allowed 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 106.942 -1.503 . . . . 75.03 106.942 162.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 3.6 m -139.82 121.28 9.65 Favored Pre-proline 0 C--N 1.312 -1.023 0 C-N-CA 119.837 -0.745 . . . . 74.5 111.984 -165.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -77.24 58.13 6.12 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.094 2.529 . . . . 64.4 111.635 177.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.4 p -78.76 101.29 7.5 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.121 -0.49 . . . . 73.32 110.355 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.422 HH11 ' HD2' ' A' ' 72' ' ' ARG . 7.5 ptp85 -91.55 142.02 28.1 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.981 -0.554 . . . . 75.3 110.044 -178.123 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.559 ' HB2' ' CB ' ' A' ' 48' ' ' ARG . 2.0 p -106.65 99.91 9.46 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.427 0.632 . . . . 74.22 109.681 173.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.6 p -121.0 153.68 24.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.341 -0.845 . . . . 73.23 111.011 -170.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 65.8 ttt-85 . . . . . 0 C--O 1.245 0.862 0 CA-C-O 118.582 -0.723 . . . . 74.41 109.701 176.299 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 21.7 m . . . . . 0 N--CA 1.446 -0.652 0 N-CA-C 109.421 -0.585 . . . . 74.12 109.421 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -123.83 112.74 17.65 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.905 -0.588 . . . . 74.03 109.491 -177.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.651 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.5 163.35 33.96 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.576 -0.821 . . . . 60.54 111.759 179.05 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 83.9 m -84.03 134.29 34.63 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 110.062 -0.347 . . . . 72.14 110.062 177.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -77.39 179.37 6.49 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.172 0.51 . . . . 64.22 111.609 -176.183 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.526 HD11 ' HB ' ' A' ' 31' ' ' ILE . 59.5 mt -88.07 119.1 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.191 -0.913 . . . . 73.43 110.295 178.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.6 mt -82.69 131.5 33.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.853 -0.612 . . . . 72.13 109.984 178.25 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 83.7 m-70 -84.07 117.94 70.0 Favored Pre-proline 0 C--N 1.323 -0.557 0 N-CA-C 109.59 -0.522 . . . . 73.31 109.59 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.53 110.1 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 122.985 2.457 . . . . 71.32 112.153 -178.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -69.2 -56.81 0.14 Allowed 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.924 2.416 . . . . 72.42 112.295 -176.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.403 ' HA ' ' CE3' ' A' ' 14' ' ' TRP . 6.0 t-105 -100.07 -177.8 3.65 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.868 -0.605 . . . . 72.24 109.807 -176.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -68.7 -5.05 18.15 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.858 0.361 . . . . 74.13 111.329 178.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.07 121.92 5.76 Favored Glycine 0 N--CA 1.444 -0.784 0 N-CA-C 110.832 -0.907 . . . . 71.54 110.832 171.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -95.72 -170.7 35.72 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.529 -0.844 . . . . 73.45 112.447 -175.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.494 HD13 HD12 ' A' ' 40' ' ' ILE . 27.3 mt -115.45 129.25 72.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.632 0.73 . . . . 71.22 111.124 -178.426 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -97.21 144.54 26.93 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.597 -1.183 . . . . 74.22 109.593 -178.071 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -115.88 -170.73 1.84 Allowed 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.346 -0.613 . . . . 74.51 109.346 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 -115.6 -53.84 2.56 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.5 -0.48 . . . . 74.3 110.309 178.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -110.19 26.43 13.66 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.727 -0.749 . . . . 71.12 112.634 -177.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.66 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 95.9 mt -119.86 121.91 40.12 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.888 -0.412 . . . . 64.52 109.888 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.41 ' O ' ' HB2' ' A' ' 27' ' ' GLN . 15.2 t -105.71 -178.79 3.75 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.779 -0.646 . . . . 75.32 112.17 -171.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 49.6 mtp180 -57.49 125.33 22.39 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.359 -0.837 . . . . 73.32 111.603 177.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.402 ' O ' ' HD2' ' A' ' 29' ' ' LYS . 33.7 t70 92.91 3.96 0.06 Allowed 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.735 1.214 . . . . 65.24 110.353 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.443 ' O ' HG22 ' A' ' 28' ' ' VAL . 10.4 mm100 -94.57 -178.88 4.7 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 108.925 -0.769 . . . . 73.2 108.925 170.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.443 HG13 HD13 ' A' ' 23' ' ' LEU . 3.7 m 52.36 18.78 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 124.238 1.015 . . . . 75.0 113.064 178.707 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.402 ' HD2' ' O ' ' A' ' 26' ' ' ASP . 18.1 ptmt -82.62 -19.47 38.28 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.789 -0.449 . . . . 75.45 109.789 178.67 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -168.03 107.81 0.54 Allowed 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.602 -0.726 . . . . 75.11 110.477 175.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.526 ' HB ' HD11 ' A' ' 9' ' ' ILE . 55.6 mt -138.14 151.86 25.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.155 -0.683 . . . . 74.23 109.155 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -89.19 -66.34 0.93 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.717 0.294 . . . . 73.04 110.467 175.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.651 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 71.1 m-85 -136.66 143.06 43.25 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.827 0.346 . . . . 74.1 110.821 -178.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.9 mm? -84.8 144.0 41.45 Favored Pre-proline 0 C--N 1.323 -0.555 0 CA-C-N 115.86 -0.609 . . . . 73.11 109.654 175.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 34' ' ' LEU . 27.0 Cg_exo -62.26 154.7 61.45 Favored 'Trans proline' 0 C--O 1.235 0.352 0 C-N-CA 122.913 2.409 . . . . 63.24 112.599 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 8.4 p -61.22 140.14 19.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.658 -0.701 . . . . 72.31 111.135 -177.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 66.63 16.88 10.51 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.395 -0.82 . . . . 75.53 112.878 178.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.66 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 40.6 t80 -71.8 146.69 47.87 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.011 -0.737 . . . . 75.21 109.011 172.102 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -116.22 126.31 53.45 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.695 0.283 . . . . 74.51 111.246 -172.731 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.536 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 46.9 pt -121.72 155.99 25.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.28 -0.418 . . . . 75.23 110.316 175.726 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -130.73 147.0 52.34 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.381 -0.372 . . . . 74.33 110.533 -175.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.554 ' HB2' ' HB3' ' A' ' 54' ' ' LYS . 27.6 m-85 -96.44 101.85 13.54 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.326 -0.25 . . . . 75.13 110.326 178.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.9 m -113.79 170.07 4.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.025 0.44 . . . . 73.24 111.38 -176.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.674 ' HB2' HG12 ' A' ' 50' ' ' VAL . 16.7 t -95.37 127.23 41.25 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 109.282 -0.636 . . . . 63.13 109.282 177.101 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 47.0 ttt180 -59.41 121.94 12.73 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.853 -1.067 . . . . 71.44 111.057 -176.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 113.0 -128.3 8.34 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-N 115.845 -0.616 . . . . 62.21 111.977 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -122.17 11.91 10.22 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.247 0.546 . . . . 71.43 110.666 -179.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 19.2 mmm180 -89.34 160.18 16.99 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.616 -0.72 . . . . 74.21 109.562 177.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.57 ' HB2' ' HG2' ' A' ' 75' ' ' ARG . 39.4 mt-10 -121.22 163.94 17.73 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.996 0.427 . . . . 74.41 111.359 -174.086 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.674 HG12 ' HB2' ' A' ' 44' ' ' CYS . 26.8 m -128.51 150.27 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.618 -0.719 . . . . 70.42 110.093 -178.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.421 HG13 ' HD2' ' A' ' 72' ' ' ARG . 3.1 p -119.57 96.59 4.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 122.059 0.933 . . . . 74.5 109.921 171.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.24 172.8 32.83 Favored Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 114.636 -1.166 . . . . 74.22 110.925 -178.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -78.55 60.66 7.67 Favored 'Trans proline' 0 N--CA 1.46 -0.448 0 C-N-CA 122.097 1.865 . . . . 70.42 110.455 174.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.554 ' HB3' ' HB2' ' A' ' 42' ' ' TYR . 0.0 OUTLIER -86.31 86.39 7.34 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-N 115.333 -0.849 . . . . 75.22 112.028 -171.369 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -162.41 128.99 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 115.316 -0.856 . . . . 75.54 109.557 173.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.536 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 4.8 mmt85 -130.58 120.57 24.21 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.712 -0.477 . . . . 75.13 109.712 176.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 22.6 ttpp -103.61 125.31 50.05 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 109.159 -0.682 . . . . 74.13 109.159 177.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 49.6 t -64.75 149.23 49.62 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.743 0.306 . . . . 74.1 110.334 179.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 87.0 mt -116.22 -179.0 3.54 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.167 -0.47 . . . . 75.32 110.166 -178.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -81.44 -0.76 43.03 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.97 0.414 . . . . 70.22 110.539 178.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -113.58 164.65 13.39 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.399 -0.593 . . . . 74.35 109.399 175.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -79.43 51.9 4.02 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.012 -0.613 . . . . 74.22 113.541 -173.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 28.2 m -156.62 146.87 21.29 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.92 -0.4 . . . . 64.31 109.92 177.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 89.8 m95 -82.01 177.54 8.78 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.227 -0.657 . . . . 74.23 109.227 175.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.8 p -66.59 -27.5 67.76 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 112.276 0.473 . . . . 73.14 112.276 -177.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -160.48 140.1 10.98 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.95 -0.389 . . . . 71.12 109.95 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 66.9 mtt -129.95 76.38 1.72 Allowed 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 119.814 -0.755 . . . . 72.34 110.164 165.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -170.61 89.18 0.14 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.335 -0.848 . . . . 75.03 108.803 161.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.2 m -148.12 102.96 3.57 Favored Pre-proline 0 C--N 1.317 -0.819 0 C-N-CA 119.936 -0.706 . . . . 74.5 111.399 -176.09 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.24 95.7 1.01 Allowed 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 122.998 2.466 . . . . 64.4 111.44 175.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 10.6 p -75.57 113.37 12.91 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.12 -0.491 . . . . 73.32 110.479 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.421 ' HD2' HG13 ' A' ' 51' ' ' VAL . 5.3 ptp180 -79.68 114.77 18.85 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.155 0.502 . . . . 75.3 111.151 -178.045 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.533 ' HA ' HG13 ' A' ' 50' ' ' VAL . 48.9 t -80.08 100.95 8.44 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.962 -0.563 . . . . 74.22 109.902 176.831 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.2 p -165.2 141.31 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.544 -0.753 . . . . 73.23 109.564 -178.448 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.57 ' HG2' ' HB2' ' A' ' 49' ' ' GLU . 1.5 tmm_? . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.697 -0.668 . . . . 74.41 110.248 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.6 m . . . . . 0 N--CA 1.451 -0.396 0 CA-C-O 121.254 0.55 . . . . 74.12 109.585 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -126.44 109.26 12.01 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.724 -0.671 . . . . 74.03 109.286 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.719 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -157.5 159.98 30.23 Favored Glycine 0 N--CA 1.438 -1.227 0 C-N-CA 120.066 -1.064 . . . . 60.54 112.841 -176.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.0 m -105.9 142.58 35.38 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.531 -0.544 . . . . 72.14 109.531 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.422 HE21 ' HB2' ' A' ' 8' ' ' GLN . 2.1 pt20 -74.77 -178.4 3.66 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.247 0.546 . . . . 64.22 111.929 -175.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.483 HD13 ' HB ' ' A' ' 31' ' ' ILE . 41.8 mt -88.25 119.37 35.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.524 -0.762 . . . . 73.43 110.316 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.459 HD11 ' CD1' ' A' ' 64' ' ' TRP . 47.4 mt -76.86 142.44 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.603 -0.726 . . . . 72.13 110.825 -177.016 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -79.85 126.8 79.34 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 73.31 109.867 175.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_exo -62.73 113.65 2.06 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 122.46 2.107 . . . . 71.32 111.417 175.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -65.55 -69.19 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.491 2.127 . . . . 72.42 112.481 -177.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 19.5 t-105 -100.39 -179.3 4.07 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.108 -0.701 . . . . 72.24 109.108 178.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.3 mm-40 -65.54 92.47 0.14 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.577 0.703 . . . . 74.13 111.413 -177.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.552 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . -160.31 -153.78 7.07 Favored Glycine 0 N--CA 1.442 -0.94 0 CA-C-N 114.85 -1.068 . . . . 71.54 110.458 178.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.17 -171.74 31.77 Favored Glycine 0 N--CA 1.443 -0.88 0 C-N-CA 120.224 -0.989 . . . . 73.45 112.02 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.1 mt -128.78 134.93 63.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.681 0.753 . . . . 71.22 111.422 -179.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.771 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 16.9 tpp180 -99.33 126.63 45.23 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 114.684 -1.144 . . . . 74.22 110.326 -178.363 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -99.01 -170.84 1.98 Allowed 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.218 -0.66 . . . . 74.51 109.218 175.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 43.4 ttm-85 -103.4 -65.71 0.99 Allowed 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.34 -0.544 . . . . 74.3 110.421 -179.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -110.58 47.5 1.04 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.669 -0.777 . . . . 71.12 112.116 -179.027 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 94.3 mt -135.74 104.45 5.77 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.809 0.338 . . . . 64.52 110.842 -178.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.7 t -87.14 -177.78 6.09 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.745 -0.662 . . . . 75.32 110.019 174.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.421 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 34.7 ptt180 -64.77 -173.05 0.09 Allowed 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 111.922 0.342 . . . . 73.32 111.922 -176.695 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.421 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 13.0 t70 68.63 -45.74 0.54 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 123.477 0.711 . . . . 65.24 110.854 -170.66 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.409 ' H ' ' C ' ' A' ' 25' ' ' ARG . 25.1 mt-30 -76.42 -155.92 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.301 -0.409 . . . . 73.2 110.495 175.056 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 m 49.31 27.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 124.225 1.01 . . . . 75.0 111.987 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 34.9 pttt -97.02 -28.92 13.94 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.429 -0.805 . . . . 75.45 110.652 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.12 95.66 1.63 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.378 0.609 . . . . 75.11 111.055 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.483 ' HB ' HD13 ' A' ' 9' ' ' ILE . 46.8 mt -129.33 140.45 49.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.491 -0.929 . . . . 74.23 108.491 175.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.6 m-80 -107.56 -36.68 6.39 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 120.614 -0.434 . . . . 73.04 110.513 -178.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.719 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 90.6 m-85 -135.74 109.24 7.93 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.753 0.311 . . . . 74.1 111.097 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -80.17 122.62 83.13 Favored Pre-proline 0 C--N 1.325 -0.463 0 N-CA-C 108.463 -0.94 . . . . 73.11 108.463 169.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.425 ' O ' ' HB2' ' A' ' 38' ' ' TYR . 5.9 Cg_endo -47.31 138.72 17.33 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 123.378 2.719 . . . . 63.24 113.618 -172.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.401 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 7.2 p -50.3 143.51 2.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.651 -0.704 . . . . 72.31 111.008 175.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 27.6 t70 80.16 -4.0 1.91 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 123.685 0.794 . . . . 75.53 111.727 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.425 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 17.6 t80 -66.68 141.29 57.82 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 109.475 -0.565 . . . . 75.21 109.475 175.347 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.686 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.8 mt-10 -118.49 120.57 37.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.681 0.277 . . . . 74.51 111.181 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.512 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 46.3 pt -112.9 161.38 11.86 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 CA-C-N 116.335 -0.393 . . . . 75.23 110.599 177.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.771 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.0 tt0 -125.61 152.36 45.25 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.965 -0.561 . . . . 74.33 111.031 -175.699 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.542 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 25.3 m-85 -101.3 102.51 13.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.343 -0.39 . . . . 75.13 111.089 -179.289 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.3 m -103.93 166.83 2.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 116.232 -0.44 . . . . 73.24 110.365 177.01 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.546 ' HB2' HG11 ' A' ' 50' ' ' VAL . 34.8 t -91.6 172.31 8.58 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.603 -0.517 . . . . 63.13 109.603 178.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . 0.552 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -76.98 98.19 4.87 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.928 0.394 . . . . 71.44 110.692 -175.557 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.32 -122.02 7.44 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.975 -0.631 . . . . 62.21 113.341 172.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -105.1 32.91 3.91 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.25 0.548 . . . . 71.43 110.96 -174.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.535 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 28.4 mmm180 -113.19 144.03 43.38 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.759 -0.655 . . . . 74.21 109.351 178.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.1 mp0 -106.67 164.35 12.16 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.254 0.55 . . . . 74.41 111.696 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.546 HG11 ' HB2' ' A' ' 44' ' ' CYS . 35.3 m -129.15 152.5 37.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.349 -0.841 . . . . 70.42 110.105 -178.315 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.422 HG12 ' O ' ' A' ' 51' ' ' VAL . 7.2 p -115.22 97.5 5.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.751 0.786 . . . . 74.5 109.922 171.312 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.0 166.75 32.6 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-N 115.68 -0.691 . . . . 74.22 112.086 178.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -74.53 65.57 5.6 Favored 'Trans proline' 0 CA--C 1.531 0.346 0 C-N-CA 122.326 2.017 . . . . 70.42 110.676 169.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.542 ' HB2' ' H ' ' A' ' 42' ' ' TYR . 16.0 pttp -77.8 89.47 4.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.297 -0.865 . . . . 75.22 111.605 -174.445 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -160.44 129.44 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.611 -0.722 . . . . 75.54 110.288 176.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.686 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 25.8 mmt180 -129.98 136.37 49.36 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.097 -0.501 . . . . 75.13 110.131 177.283 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.424 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 37.2 ttmt -123.36 124.42 42.9 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.193 -0.669 . . . . 74.13 109.193 174.166 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.3 t -67.41 137.5 55.97 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.148 -0.478 . . . . 74.1 110.703 -177.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.409 ' C ' ' H ' ' A' ' 61' ' ' ASN . 93.6 mt -103.46 -179.05 3.84 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.0 -0.546 . . . . 75.32 110.868 -176.711 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.4 22.41 0.56 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.08 0.467 . . . . 70.22 111.183 178.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.409 ' H ' ' C ' ' A' ' 59' ' ' LEU . 3.7 p-10 -139.07 171.8 13.77 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.194 -0.669 . . . . 74.35 109.194 178.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -79.23 52.4 4.04 Favored Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.995 -0.621 . . . . 74.22 113.664 -174.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 11.9 t -170.48 159.52 6.95 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.898 -0.408 . . . . 64.31 109.898 177.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.459 ' CD1' HD11 ' A' ' 10' ' ' ILE . 69.9 m95 -87.06 178.97 6.76 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.228 -0.442 . . . . 74.23 110.086 -178.328 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -57.76 -35.41 70.71 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 112.622 0.601 . . . . 73.14 112.622 -176.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -149.72 144.55 26.15 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 110.193 -0.299 . . . . 71.12 110.193 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 63.3 mtt -136.39 76.56 1.6 Allowed 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.11 -0.636 . . . . 72.34 109.943 163.036 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -169.88 89.29 0.17 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.133 -0.94 . . . . 75.03 108.613 163.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.44 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 10.5 m -144.56 113.51 5.1 Favored Pre-proline 0 C--N 1.314 -0.946 0 C-N-CA 120.302 -0.559 . . . . 74.5 110.731 -175.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 4.3 Cg_exo -77.23 59.77 6.72 Favored 'Trans proline' 0 N--CA 1.463 -0.29 0 C-N-CA 123.415 2.743 . . . . 64.4 112.489 -178.241 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.9 p -70.37 98.83 1.47 Allowed 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.367 -0.605 . . . . 73.32 109.367 175.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' A' ' 72' ' ' ARG . 5.0 ptp180 -101.69 141.34 34.7 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.635 -0.711 . . . . 75.3 111.679 -172.674 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 58.9 m -75.61 115.37 15.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.316 -0.856 . . . . 74.22 109.977 178.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.6 p -149.6 128.44 3.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.124 0.488 . . . . 73.23 110.095 -178.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.335 -0.841 . . . . 74.41 110.162 -177.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 20.2 m . . . . . 0 N--CA 1.446 -0.645 0 N-CA-C 109.386 -0.598 . . . . 74.12 109.386 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -88.87 114.6 25.67 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.862 -0.608 . . . . 74.03 110.044 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -148.42 -179.82 24.68 Favored Glycine 0 N--CA 1.44 -1.058 0 CA-C-N 115.527 -0.76 . . . . 60.54 111.432 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.0 m -97.47 136.12 38.35 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 110.122 -0.325 . . . . 72.14 110.122 -179.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -72.82 177.57 4.76 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.228 0.537 . . . . 64.22 111.464 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.547 HD11 ' HB ' ' A' ' 31' ' ' ILE . 52.4 mt -88.29 116.39 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-N 115.728 -0.669 . . . . 73.43 110.172 177.179 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 41.5 mt -69.65 140.93 17.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.395 -0.82 . . . . 72.13 109.861 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 23.4 m170 -73.55 137.37 77.56 Favored Pre-proline 0 C--N 1.323 -0.544 0 N-CA-C 109.503 -0.554 . . . . 73.31 109.503 175.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -57.12 117.48 4.18 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.544 2.162 . . . . 71.32 111.57 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 83.9 Cg_endo -78.23 -146.22 0.03 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.809 2.339 . . . . 72.42 111.748 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.407 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 67.9 t-105 -56.56 148.56 19.33 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.74 -0.467 . . . . 72.24 109.74 177.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 33.9 mm-40 -44.2 101.31 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.793 1.034 . . . . 74.13 113.793 -172.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.97 -120.91 0.79 Allowed Glycine 0 N--CA 1.442 -0.908 0 CA-C-N 114.283 -1.326 . . . . 71.54 110.131 174.382 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 179.86 -171.85 43.41 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.781 -0.723 . . . . 73.45 111.644 173.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 mt -142.28 129.35 19.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.549 0.69 . . . . 71.22 110.929 177.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.712 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 5.8 tpt180 -102.09 140.67 36.07 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.821 -1.082 . . . . 74.22 108.687 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.508 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 88.7 m-85 -107.15 -173.51 2.31 Favored 'General case' 0 C--N 1.319 -0.758 0 C-N-CA 120.077 -0.649 . . . . 74.51 110.263 -178.335 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -132.89 -14.89 2.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.129 0.49 . . . . 74.3 110.521 -175.106 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -145.82 27.14 1.77 Allowed Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 111.568 -0.613 . . . . 71.12 111.568 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.537 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 89.3 mt -143.54 132.82 23.22 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.683 0.278 . . . . 64.52 110.281 -178.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.9 t -91.45 -178.55 5.14 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.008 -0.542 . . . . 75.32 109.999 177.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 66.5 mtm180 -73.05 -174.14 1.45 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.901 0.382 . . . . 73.32 111.843 -175.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.6 t70 51.29 33.01 9.03 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.665 0.745 . . . . 65.24 111.474 -177.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 -132.59 -164.62 1.49 Allowed 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.091 -0.504 . . . . 73.2 110.386 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.524 HG11 HD12 ' A' ' 31' ' ' ILE . 32.3 m 48.76 36.57 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 O-C-N 124.251 0.97 . . . . 75.0 112.384 177.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -78.8 -39.91 34.43 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.378 0.608 . . . . 75.45 109.413 177.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.07 89.01 1.49 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.49 -0.777 . . . . 75.11 110.644 176.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.547 ' HB ' HD11 ' A' ' 9' ' ' ILE . 52.1 mt -120.62 136.16 58.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.93 -0.767 . . . . 74.23 108.93 175.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -79.73 -49.27 12.31 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.753 0.311 . . . . 73.04 110.921 -175.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -139.37 138.03 36.23 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.186 -0.461 . . . . 74.1 111.275 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -85.96 138.5 35.0 Favored Pre-proline 0 C--N 1.321 -0.631 0 N-CA-C 108.717 -0.845 . . . . 73.11 108.717 170.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.29 145.46 97.75 Favored 'Trans proline' 0 CA--C 1.529 0.25 0 C-N-CA 122.677 2.252 . . . . 63.24 112.822 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.441 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 7.4 p -62.68 145.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.988 -0.551 . . . . 72.31 110.34 177.104 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.441 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 35.3 t70 79.18 3.44 2.34 Favored 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.776 0.672 . . . . 75.53 110.864 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.537 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 47.3 t80 -79.17 148.69 32.2 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.003 -0.369 . . . . 75.21 110.003 175.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.424 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 26.2 mt-10 -124.16 144.25 50.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.314 -0.403 . . . . 74.51 110.884 -176.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.609 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 25.4 pt -136.54 153.93 31.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-N 116.342 -0.39 . . . . 75.23 110.634 174.153 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.712 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.6 tt0 -116.67 155.68 28.4 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.948 -0.569 . . . . 74.33 110.179 -178.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.486 ' HE2' ' CG ' ' A' ' 56' ' ' ARG . 34.2 m-85 -104.81 101.1 10.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.595 0.236 . . . . 75.13 110.818 176.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.477 HG11 ' HB2' ' A' ' 19' ' ' ARG . 26.8 m -90.91 170.37 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 109.8 -0.444 . . . . 73.24 109.8 176.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.509 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 7.3 t -100.39 173.11 6.74 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.27 -0.641 . . . . 63.13 109.27 178.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 15.4 mmt180 -59.88 116.12 3.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.111 0.482 . . . . 71.44 110.769 178.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.21 -132.71 11.33 Favored Glycine 0 N--CA 1.446 -0.645 0 CA-C-N 115.723 -0.671 . . . . 62.21 111.996 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -114.88 34.88 4.56 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.14 0.495 . . . . 71.43 111.237 -177.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.509 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 15.0 mmm180 -89.65 120.15 30.68 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.768 -0.651 . . . . 74.21 109.371 177.2 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -78.86 147.48 33.14 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.161 0.505 . . . . 74.41 110.311 -178.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.6 m -115.24 145.95 20.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.064 -0.516 . . . . 70.42 110.824 -178.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.42 ' O ' HG12 ' A' ' 51' ' ' VAL . 4.5 p -104.8 96.26 4.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 122.017 0.913 . . . . 74.5 109.333 171.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.84 171.82 33.2 Favored Glycine 0 N--CA 1.441 -1.0 0 CA-C-N 115.225 -0.898 . . . . 74.22 111.748 -177.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.513 ' HG2' HG21 ' A' ' 69' ' ' THR . 64.3 Cg_endo -74.66 56.45 4.05 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.757 2.305 . . . . 70.42 110.329 171.083 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.452 ' HD2' ' CG ' ' A' ' 41' ' ' GLU . 43.7 pttt -77.83 86.2 4.08 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.32 -0.855 . . . . 75.22 111.717 -172.292 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -162.47 128.39 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.264 -0.88 . . . . 75.54 109.928 172.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.609 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 24.5 mmt180 -117.85 119.63 35.44 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 108.91 -0.774 . . . . 75.13 108.91 174.439 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -104.62 120.6 41.69 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.455 -0.572 . . . . 74.13 109.455 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 16.5 t -78.54 133.19 37.38 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.923 0.392 . . . . 74.1 109.995 -179.386 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 85.4 mt -117.05 -178.61 3.48 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.013 -0.539 . . . . 75.32 110.85 -173.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.26 -9.29 58.72 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.127 0.489 . . . . 70.22 110.518 178.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -94.44 151.64 19.22 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.214 -0.661 . . . . 74.35 109.214 172.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -77.27 54.02 3.54 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 121.09 -0.576 . . . . 74.22 113.762 -173.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 67.4 p -166.98 154.02 8.8 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.403 -0.592 . . . . 64.31 109.403 177.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.532 ' HB2' ' HB3' ' A' ' 67' ' ' MET . 84.3 m95 -75.02 165.83 24.63 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.802 -0.444 . . . . 74.23 109.802 178.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -50.57 -42.78 55.95 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 113.052 0.76 . . . . 73.14 113.052 -176.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -157.93 74.88 0.74 Allowed 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.574 -0.528 . . . . 71.12 109.574 177.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' MET . . . . . 0.532 ' HB3' ' HB2' ' A' ' 64' ' ' TRP . 22.3 ptt? -88.7 80.24 7.3 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 118.837 -1.145 . . . . 72.34 111.497 -173.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -167.96 88.95 0.27 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.271 -1.331 . . . . 75.03 107.757 163.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.513 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.2 OUTLIER -158.43 115.77 1.74 Allowed Pre-proline 0 C--N 1.317 -0.846 0 C-N-CA 120.461 -0.496 . . . . 74.5 111.221 -169.35 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -81.52 124.91 4.84 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.497 2.131 . . . . 64.4 111.807 174.364 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 12.6 p -81.01 133.29 35.46 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.992 0.425 . . . . 73.32 110.085 177.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 38.3 mtp180 -96.34 99.26 10.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.312 -0.404 . . . . 75.3 111.364 -171.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 8.7 m -69.12 101.98 1.56 Allowed 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.799 -0.445 . . . . 74.22 109.799 177.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 94.7 t -136.41 120.15 23.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 121.026 0.441 . . . . 73.23 111.805 -173.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 67.8 mtt180 . . . . . 0 C--O 1.244 0.797 0 CA-C-N 115.627 -0.715 . . . . 74.41 109.694 170.892 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.1 m . . . . . 0 N--CA 1.45 -0.461 0 N-CA-C 108.882 -0.784 . . . . 74.12 108.882 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -95.58 109.09 21.38 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.176 0.512 . . . . 74.03 110.949 -174.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.519 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -161.21 -179.6 36.04 Favored Glycine 0 N--CA 1.443 -0.899 0 CA-C-N 115.299 -0.864 . . . . 60.54 111.323 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 15.0 m -99.12 145.1 27.52 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 109.912 -0.403 . . . . 72.14 109.912 178.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -88.36 -177.82 5.74 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.668 0.271 . . . . 64.22 110.522 179.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.0 mt -87.95 123.78 40.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.16 0.505 . . . . 73.43 110.041 178.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.444 HD11 ' CD1' ' A' ' 64' ' ' TRP . 9.8 mt -79.93 150.53 4.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.782 -0.645 . . . . 72.13 110.347 -178.347 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 16.2 p80 -62.54 141.07 96.81 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 109.525 -0.546 . . . . 73.31 109.525 172.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.425 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 23.5 Cg_exo -64.8 149.47 89.58 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.459 2.106 . . . . 71.32 111.715 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.47 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 3.0 Cg_exo -76.88 -132.04 0.01 OUTLIER 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.979 2.453 . . . . 72.42 110.998 174.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.47 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 3.8 t-105 -75.38 -179.57 4.61 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.433 -0.58 . . . . 72.24 109.433 176.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -43.95 101.05 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 112.742 0.645 . . . . 74.13 112.742 -176.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 174.74 -143.71 7.0 Favored Glycine 0 N--CA 1.441 -1.028 0 N-CA-C 110.869 -0.893 . . . . 71.54 110.869 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.74 -169.97 35.94 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.655 -0.783 . . . . 73.45 112.174 177.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.2 mt -118.81 125.39 74.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 121.364 0.602 . . . . 71.22 110.891 179.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.3 tpt180 -99.79 114.27 27.31 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.129 -0.941 . . . . 74.22 109.077 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.481 ' HA ' HG21 ' A' ' 40' ' ' ILE . 88.6 m-85 -76.75 -172.4 2.24 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.588 -0.278 . . . . 74.51 110.905 -175.644 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -87.49 -40.61 14.17 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.15 0.5 . . . . 74.3 110.417 -174.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -152.94 60.01 0.4 Allowed Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.881 -0.676 . . . . 71.12 112.208 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.763 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 76.1 mt -135.03 128.98 33.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.121 0.486 . . . . 64.52 110.998 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.2 t -96.15 -176.4 3.66 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.373 -0.83 . . . . 75.32 110.296 176.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.532 ' C ' ' H ' ' A' ' 27' ' ' GLN . 22.1 mmt180 -60.7 -172.08 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 116.351 -0.386 . . . . 73.32 111.512 178.31 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.417 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 23.9 t70 69.4 -35.86 0.32 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.191 0.597 . . . . 65.24 111.447 -175.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.532 ' H ' ' C ' ' A' ' 25' ' ' ARG . 13.7 mt-30 -90.48 -169.08 2.28 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.806 -0.634 . . . . 73.2 111.067 -178.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.519 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.8 m 59.45 11.88 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 125.073 1.349 . . . . 75.0 112.754 173.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 36.3 pttt -77.87 -27.64 49.76 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.28 0.562 . . . . 75.45 110.341 176.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.13 91.16 0.46 Allowed 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.442 -0.799 . . . . 75.11 110.339 177.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 57.9 mt -109.94 125.84 67.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 108.973 -0.751 . . . . 74.23 108.973 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -79.67 -46.45 17.11 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.138 -0.483 . . . . 73.04 110.187 -175.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.519 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 95.7 m-85 -146.47 121.31 9.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.992 -0.549 . . . . 74.1 111.127 -178.51 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -78.57 151.91 77.69 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.191 -0.459 . . . . 73.11 109.834 173.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -64.82 160.35 41.24 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.618 2.212 . . . . 63.24 112.449 177.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 14.3 p -71.06 145.94 12.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.334 -0.394 . . . . 72.31 110.938 -177.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 38.3 t70 69.93 9.61 7.17 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 123.65 0.78 . . . . 75.53 111.245 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.763 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 25.3 t80 -72.03 139.32 48.47 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 108.719 -0.845 . . . . 75.21 108.719 174.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.59 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.9 mt-10 -126.38 154.66 43.27 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.805 0.336 . . . . 74.51 111.007 -175.46 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.481 HG21 ' HA ' ' A' ' 20' ' ' TYR . 24.3 pt -133.7 162.72 39.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.418 0 CA-C-N 116.06 -0.518 . . . . 75.23 111.776 -177.156 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.434 ' HG3' ' HD2' ' A' ' 54' ' ' LYS . 78.1 tt0 -122.37 149.08 44.28 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.518 -0.765 . . . . 74.33 110.14 177.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -95.5 102.5 14.31 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.201 -0.454 . . . . 75.13 110.152 177.214 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 16.8 m -101.18 144.1 13.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.903 0.382 . . . . 73.24 111.013 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.426 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 28.9 t -91.46 176.74 6.44 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.264 -0.643 . . . . 63.13 109.264 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.95 129.68 41.44 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.63 0.252 . . . . 71.44 111.492 -178.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 62.84 -131.71 43.29 Favored Glycine 0 N--CA 1.45 -0.427 0 CA-C-N 115.855 -0.611 . . . . 62.21 112.237 178.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -98.5 83.81 3.08 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.739 0.78 . . . . 71.43 110.4 176.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.619 HH11 ' HB3' ' A' ' 75' ' ' ARG . 30.2 mmt180 -145.2 132.52 20.62 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.182 -0.917 . . . . 74.21 109.943 178.307 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.2 mp0 -102.21 152.53 20.93 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.049 -0.523 . . . . 74.41 110.548 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.54 HG12 ' HA ' ' A' ' 73' ' ' CYS . 34.7 m -114.58 120.52 64.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.68 -0.691 . . . . 70.42 109.257 171.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.4 ' O ' HG13 ' A' ' 51' ' ' VAL . 6.3 p -83.71 94.24 3.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 122.503 1.144 . . . . 74.5 109.617 178.16 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.22 172.53 33.47 Favored Glycine 0 N--CA 1.441 -0.991 0 CA-C-N 114.34 -1.3 . . . . 74.22 110.764 -177.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -73.3 58.59 3.68 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.225 1.95 . . . . 70.42 110.646 173.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.434 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 42.3 pttt -78.09 85.6 4.29 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-O 121.691 0.758 . . . . 75.22 111.46 -174.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.478 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 6.1 p -162.68 128.61 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.227 -0.897 . . . . 75.54 109.015 171.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.59 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 20.4 mmt180 -130.6 124.42 31.71 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.591 -0.522 . . . . 75.13 109.591 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.466 ' O ' HG23 ' A' ' 65' ' ' THR . 23.7 ttmm -99.68 131.52 45.61 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.875 -0.417 . . . . 74.13 109.875 178.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 48.1 t -80.2 137.64 36.71 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 109.638 -0.504 . . . . 74.1 109.638 176.206 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 89.0 mt -115.25 -178.96 3.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.41 -0.359 . . . . 75.32 110.322 -178.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -66.42 -27.48 67.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.133 0.492 . . . . 70.22 110.61 178.148 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -79.55 150.92 30.96 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.457 -0.571 . . . . 74.35 109.457 174.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -75.6 66.03 2.41 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 121.033 -0.603 . . . . 74.22 113.528 -175.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 13.8 t -174.19 149.09 1.38 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.674 -0.491 . . . . 64.31 109.674 175.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.608 ' H ' ' HE3' ' A' ' 67' ' ' MET . 64.9 m95 -77.27 157.4 30.8 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.199 -0.667 . . . . 74.23 109.199 177.313 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.466 HG23 ' O ' ' A' ' 57' ' ' LYS . 16.0 p -50.71 -46.72 59.09 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 113.319 0.859 . . . . 73.14 113.319 -173.689 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -128.52 118.17 22.57 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.704 -0.226 . . . . 71.12 110.495 -173.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' MET . . . . . 0.608 ' HE3' ' H ' ' A' ' 64' ' ' TRP . 55.5 mtt -125.76 78.31 1.73 Allowed 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 119.346 -0.941 . . . . 72.34 110.741 168.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -170.26 89.05 0.15 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.618 -0.719 . . . . 75.03 109.143 163.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 60.3 m -160.29 107.88 1.38 Allowed Pre-proline 0 C--N 1.321 -0.645 0 CA-C-O 120.874 0.368 . . . . 74.5 111.463 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -76.92 91.92 1.14 Allowed 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.175 1.917 . . . . 64.4 110.943 170.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 16.8 p -70.42 110.9 5.6 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.803 -0.635 . . . . 73.32 110.577 -177.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 21.4 ptt-85 -79.26 119.21 22.01 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.381 0.61 . . . . 75.3 111.137 -176.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.54 ' HA ' HG12 ' A' ' 50' ' ' VAL . 42.5 t -80.37 110.14 15.53 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.363 -0.835 . . . . 74.22 109.502 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.7 p -155.98 130.45 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.375 0.607 . . . . 73.23 111.521 -174.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.619 ' HB3' HH11 ' A' ' 48' ' ' ARG . 22.3 ttm180 . . . . . 0 C--O 1.247 0.934 0 CA-C-N 115.601 -0.727 . . . . 74.41 109.095 175.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.4 m . . . . . 0 N--CA 1.453 -0.307 0 CA-C-O 121.205 0.526 . . . . 74.12 111.602 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -118.86 100.23 7.25 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.674 -0.694 . . . . 74.03 109.339 173.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.727 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -158.89 147.33 14.74 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.039 -1.077 . . . . 60.54 113.231 -177.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.6 m -83.47 157.8 22.28 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.87 -0.418 . . . . 72.14 109.87 176.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -84.85 -178.23 6.79 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.124 0.488 . . . . 64.22 111.265 179.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.573 HD11 ' H ' ' A' ' 31' ' ' ILE . 56.5 mt -87.05 117.05 30.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.617 -0.72 . . . . 73.43 109.371 174.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.641 ' HB ' ' HE3' ' A' ' 67' ' ' MET . 12.9 pt -90.18 149.23 4.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.528 -0.76 . . . . 72.13 110.665 -178.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . 0.409 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 19.9 m-70 -88.32 143.47 32.61 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 116.246 -0.434 . . . . 73.31 111.24 -175.211 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 16.7 Cg_exo -67.82 135.06 34.22 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 123.053 2.502 . . . . 71.32 111.963 178.056 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.437 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 82.4 Cg_endo -88.07 -150.22 0.04 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 123.002 2.468 . . . . 72.42 112.475 179.525 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.437 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 12.0 t-105 -63.48 -177.59 0.22 Allowed 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 115.812 -0.631 . . . . 72.24 110.697 178.058 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -38.82 100.33 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 123.876 0.87 . . . . 74.13 112.928 -173.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.85 -172.43 43.75 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 114.989 -1.005 . . . . 71.54 110.722 -178.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -156.91 -171.12 22.64 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.747 -0.74 . . . . 73.45 112.07 179.183 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.3 mt -129.7 137.37 56.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.381 0.61 . . . . 71.22 111.24 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -117.08 119.14 34.34 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.164 -0.925 . . . . 74.22 109.776 -177.612 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.407 ' HA ' HG23 ' A' ' 40' ' ' ILE . 95.0 m-85 -84.69 -171.7 3.78 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.749 0.309 . . . . 74.51 110.623 -178.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.1 ttm180 -93.26 -55.85 3.16 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.985 0.421 . . . . 74.3 109.993 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -144.89 67.74 0.42 Allowed Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.753 -0.737 . . . . 71.12 112.325 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.736 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 76.5 mt -139.07 118.33 12.72 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.995 -0.372 . . . . 64.52 109.995 177.533 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.2 t -81.0 178.9 8.13 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.297 -0.41 . . . . 75.32 110.189 178.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.461 ' C ' ' H ' ' A' ' 27' ' ' GLN . 95.2 mtt180 -78.09 -171.92 2.54 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 120.491 0.186 . . . . 73.32 111.343 -175.396 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 11.6 t70 67.38 -42.79 0.44 Allowed 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 123.305 0.642 . . . . 65.24 110.885 -168.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.539 ' O ' HG22 ' A' ' 28' ' ' VAL . 21.0 mt-30 -70.57 -170.34 0.4 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.217 -0.447 . . . . 73.2 110.137 173.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.9 m 57.9 9.38 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.272 1.029 . . . . 75.0 112.134 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 52.7 pttt -83.49 -19.98 34.8 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.789 -0.819 . . . . 75.45 108.789 172.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.14 102.05 2.11 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 114.885 -1.052 . . . . 75.11 110.026 177.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.573 ' H ' HD11 ' A' ' 9' ' ' ILE . 57.3 mt -120.83 144.72 28.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 109.031 -0.729 . . . . 74.23 109.031 176.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -88.69 -65.61 1.0 Allowed 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.94 -0.393 . . . . 73.04 109.94 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.727 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 56.0 m-85 -143.42 140.84 30.61 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.239 -0.437 . . . . 74.1 110.487 177.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.449 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.7 mm? -82.82 132.23 52.01 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 109.331 -0.618 . . . . 73.11 109.331 174.013 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -58.24 139.34 90.14 Favored 'Trans proline' 0 C--O 1.236 0.382 0 C-N-CA 122.615 2.21 . . . . 63.24 112.227 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 p -67.3 84.59 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 CA-C-O 121.905 0.86 . . . . 72.31 111.272 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.6 t70 165.59 -30.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.179 -1.373 . . . . 75.53 108.925 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.736 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 9.3 t80 -57.22 138.18 55.0 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.895 -1.048 . . . . 75.21 111.277 -174.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 18.9 mt-10 -122.54 139.38 53.96 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.511 -0.768 . . . . 74.51 110.39 -176.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.484 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 35.5 pt -128.17 156.95 40.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.354 -0.384 . . . . 75.23 110.856 178.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -119.83 151.58 38.62 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.016 -0.538 . . . . 74.33 110.508 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -99.05 102.47 14.19 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.072 -0.513 . . . . 75.13 111.052 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.4 m -96.82 163.82 2.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 N-CA-C 110.028 -0.36 . . . . 73.24 110.028 175.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.556 ' HB2' HG11 ' A' ' 50' ' ' VAL . 31.5 t -89.68 175.11 7.38 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.457 -0.572 . . . . 63.13 109.457 178.127 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.66 119.2 19.37 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.95 0.405 . . . . 71.44 110.797 -174.5 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.06 -100.27 2.65 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.846 -0.616 . . . . 62.21 112.863 174.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -133.81 21.8 3.88 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.987 0.422 . . . . 71.43 111.233 -174.077 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.542 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 11.4 mmt180 -96.35 142.88 27.95 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.168 -0.469 . . . . 74.21 110.972 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.796 ' HB2' ' HD2' ' A' ' 75' ' ' ARG . 2.2 mp0 -94.37 153.78 17.81 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.125 -0.489 . . . . 74.41 110.867 177.071 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.556 HG11 ' HB2' ' A' ' 44' ' ' CYS . 28.0 m -118.49 151.31 20.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.688 -0.687 . . . . 70.42 109.882 176.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.9 p -114.9 96.19 4.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.913 0.863 . . . . 74.5 110.008 173.215 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.11 170.91 33.31 Favored Glycine 0 N--CA 1.445 -0.711 0 CA-C-N 115.2 -0.909 . . . . 74.22 111.602 179.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -73.59 60.01 4.17 Favored 'Trans proline' 0 CA--C 1.531 0.353 0 C-N-CA 122.482 2.121 . . . . 70.42 110.88 170.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 44.3 pttt -77.23 89.44 3.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.583 -0.735 . . . . 75.22 112.392 -171.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.9 p -160.8 135.11 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.892 -0.595 . . . . 75.54 109.605 171.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.493 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 24.6 mmt180 -131.12 120.8 23.88 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.41 -0.359 . . . . 75.13 110.537 177.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.455 ' HB3' ' CG2' ' A' ' 65' ' ' THR . 39.4 ttmt -102.73 129.63 49.42 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 109.094 -0.706 . . . . 74.13 109.094 174.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 45.6 t -67.92 143.51 55.64 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.469 -0.332 . . . . 74.1 110.327 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.411 HD13 ' HA ' ' A' ' 65' ' ' THR . 88.6 mt -110.89 -178.38 3.46 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.369 -0.378 . . . . 75.32 110.615 -176.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -79.82 14.56 1.7 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.974 0.416 . . . . 70.22 111.161 178.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.43 ' ND2' ' H ' ' A' ' 63' ' ' SER . 4.6 p-10 -141.44 -178.62 5.71 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.772 -0.649 . . . . 74.35 109.62 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -66.04 -29.68 75.47 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 114.771 0.668 . . . . 74.22 114.771 -171.252 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.43 ' H ' ' ND2' ' A' ' 61' ' ' ASN . 78.5 p -93.23 163.27 13.68 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.473 0.636 . . . . 64.31 111.458 -175.659 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -92.89 -179.86 5.25 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.877 -0.601 . . . . 74.23 110.005 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.455 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 3.2 p -49.59 -69.72 0.11 Allowed 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 113.558 0.947 . . . . 73.14 113.558 -174.169 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -133.21 48.59 2.38 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.649 -0.501 . . . . 71.12 109.649 -177.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' MET . . . . . 0.641 ' HE3' ' HB ' ' A' ' 10' ' ' ILE . 28.0 ttt -80.65 81.92 6.78 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.382 -0.927 . . . . 72.34 111.831 -170.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -166.65 87.6 0.32 Allowed 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 106.72 -1.585 . . . . 75.03 106.72 158.196 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.5 m -157.79 113.41 1.81 Allowed Pre-proline 0 C--N 1.316 -0.889 0 CA-C-N 116.284 -0.416 . . . . 74.5 110.051 -168.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -66.68 97.6 0.39 Allowed 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.61 2.206 . . . . 64.4 112.164 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.1 p -78.73 101.63 7.66 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.212 -0.662 . . . . 73.32 109.212 173.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -78.94 126.58 30.88 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.315 0.579 . . . . 75.3 111.091 -171.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.533 ' HA ' HG12 ' A' ' 50' ' ' VAL . 41.8 t -82.03 98.74 8.77 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.499 -0.773 . . . . 74.22 109.865 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.3 p -176.98 152.44 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.992 -0.744 . . . . 73.23 108.992 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.796 ' HD2' ' HB2' ' A' ' 49' ' ' GLU . 2.5 ptm180 . . . . . 0 C--O 1.245 0.859 0 CA-C-O 119.168 -0.444 . . . . 74.41 110.367 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.4 m . . . . . 0 N--CA 1.448 -0.535 0 N-CA-C 110.209 -0.293 . . . . 74.12 110.209 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . 0.417 ' H ' ' CD ' ' A' ' 5' ' ' GLU . 0.9 OUTLIER -70.03 107.57 3.68 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.833 -0.803 . . . . 74.03 108.833 175.863 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.804 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -157.63 126.28 1.7 Allowed Glycine 0 N--CA 1.443 -0.847 0 C-N-CA 120.288 -0.958 . . . . 60.54 113.035 -176.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 64.8 m -90.59 152.32 20.94 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.546 -0.539 . . . . 72.14 109.546 175.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -81.77 -178.02 6.81 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.916 0.389 . . . . 64.22 111.233 -178.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.559 HD11 ' HB ' ' A' ' 31' ' ' ILE . 46.2 mt -87.39 121.6 38.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.873 -0.603 . . . . 73.43 110.691 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 56.9 mt -73.86 114.21 13.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.03 -0.532 . . . . 72.13 109.581 175.051 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 31.9 m-70 -75.44 129.08 82.95 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 110.09 -0.337 . . . . 73.31 110.09 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.471 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 7.3 Cg_endo -49.19 118.77 3.83 Favored 'Trans proline' 0 C--N 1.349 0.556 0 C-N-CA 123.447 2.765 . . . . 71.32 112.429 -177.222 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.471 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 4.0 Cg_exo -76.38 -84.03 0.0 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 122.996 2.464 . . . . 72.42 112.325 -177.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.7 t-105 -100.93 -178.36 3.73 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.228 -0.442 . . . . 72.24 109.925 -177.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -47.68 102.31 0.03 OUTLIER 'General case' 0 C--O 1.234 0.275 0 O-C-N 123.791 0.682 . . . . 74.13 112.242 177.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.07 -157.14 28.97 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.352 -0.84 . . . . 71.54 111.099 -179.211 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -161.13 -171.08 26.63 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 111.338 -0.705 . . . . 73.45 111.338 177.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.5 mt -127.77 129.43 70.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.669 0.747 . . . . 71.22 111.363 -179.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.87 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 5.1 tpt180 -93.62 132.75 37.64 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 114.438 -1.256 . . . . 74.22 109.486 -179.021 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.474 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 97.1 m-85 -106.55 -171.28 1.86 Allowed 'General case' 0 C--N 1.32 -0.678 0 C-N-CA 120.845 -0.342 . . . . 74.51 110.735 -178.032 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 19.1 ttt-85 -114.68 -51.69 2.73 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.944 0.402 . . . . 74.3 110.264 -174.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -136.83 30.57 2.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 71.12 112.807 -177.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.925 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 80.3 mt -109.72 129.7 55.59 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 122.595 -0.356 . . . . 64.52 110.255 177.544 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.4 t -80.33 -179.81 7.31 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.112 -0.495 . . . . 75.32 110.1 178.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.436 ' C ' ' H ' ' A' ' 27' ' ' GLN . 38.3 ptt180 -73.48 -174.16 1.6 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.325 -0.398 . . . . 73.32 110.752 -178.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 21.8 t70 67.32 -44.5 0.46 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.859 0.864 . . . . 65.24 111.619 -177.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.628 ' O ' HG22 ' A' ' 28' ' ' VAL . 28.1 mt-30 -68.03 -163.62 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 122.896 0.478 . . . . 73.2 111.554 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.628 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.0 m 61.11 13.93 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 124.538 1.135 . . . . 75.0 111.347 -177.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -90.99 -29.02 17.63 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.342 -0.614 . . . . 75.45 109.342 176.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.65 89.68 1.27 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.714 -0.676 . . . . 75.11 111.003 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.559 ' HB ' HD11 ' A' ' 9' ' ' ILE . 57.3 mt -126.66 134.28 66.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 108.818 -0.808 . . . . 74.23 108.818 175.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -77.54 -56.42 4.54 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.815 0.34 . . . . 73.04 111.043 -177.093 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.804 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 65.9 m-85 -136.33 145.61 45.63 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.082 0.467 . . . . 74.1 111.375 -175.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.58 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.7 mm? -103.8 139.11 19.8 Favored Pre-proline 0 C--N 1.323 -0.564 0 N-CA-C 108.993 -0.743 . . . . 73.11 108.993 170.223 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -58.89 159.76 20.28 Favored 'Trans proline' 0 N--CA 1.476 0.5 0 C-N-CA 123.203 2.602 . . . . 63.24 113.315 -176.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 9.9 p -71.64 2.75 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 CA-C-O 121.648 0.737 . . . . 72.31 111.473 -176.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -134.4 92.78 2.97 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.093 0.473 . . . . 75.53 109.798 170.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.925 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 20.2 t80 -157.18 135.02 10.86 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.633 -0.712 . . . . 75.21 109.301 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.492 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 38.9 mt-10 -113.4 130.29 56.33 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.242 0.339 . . . . 74.51 110.784 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.556 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 43.6 pt -121.68 158.09 25.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.369 -0.378 . . . . 75.23 110.89 175.583 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.87 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 41.3 tt0 -127.19 154.36 44.9 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.868 -0.605 . . . . 74.33 110.598 -177.692 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 65.3 m-85 -100.03 102.29 13.6 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.328 -0.396 . . . . 75.13 110.612 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.3 m -109.2 164.78 5.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.371 -0.377 . . . . 73.24 111.202 -178.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.509 ' HB2' ' HB2' ' A' ' 48' ' ' ARG . 86.3 m -110.85 179.32 4.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.1 -0.5 . . . . 63.13 110.388 177.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -76.92 102.36 6.35 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.071 0.463 . . . . 71.44 110.375 178.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.35 -166.81 25.76 Favored Glycine 0 N--CA 1.445 -0.704 0 N-CA-C 111.05 -0.82 . . . . 62.21 111.05 -176.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -82.59 77.66 9.32 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.526 0.679 . . . . 71.43 111.281 178.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.509 ' HB2' ' HB2' ' A' ' 44' ' ' CYS . 14.1 mtm-85 -127.87 118.34 23.46 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.754 -0.832 . . . . 74.21 108.754 176.463 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -88.2 154.11 20.7 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.064 -0.516 . . . . 74.41 111.099 -172.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.547 HG11 ' HA ' ' A' ' 73' ' ' CYS . 27.2 m -119.23 130.77 73.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.798 -0.637 . . . . 70.42 109.969 178.48 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.0 p -95.04 94.08 4.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-O 122.217 1.008 . . . . 74.5 109.857 175.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -157.26 170.9 34.51 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 114.223 -1.353 . . . . 74.22 110.514 177.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.509 ' HG2' HG23 ' A' ' 69' ' ' THR . 55.9 Cg_endo -75.19 77.88 3.08 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.621 1.547 . . . . 70.42 110.536 168.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.578 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 43.6 pttt -86.84 88.48 7.69 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.656 0.741 . . . . 75.22 111.048 -174.392 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.508 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 6.8 p -160.19 128.99 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.496 -0.775 . . . . 75.54 109.814 176.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.556 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 23.1 mmt180 -137.12 125.65 23.61 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.924 -0.58 . . . . 75.13 110.028 178.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.57 ' HA ' ' O ' ' A' ' 38' ' ' TYR . 35.4 ttmt -124.6 137.4 54.39 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 108.775 -0.824 . . . . 74.13 108.775 168.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.5 t -67.27 142.86 56.75 Favored 'General case' 0 C--N 1.323 -0.575 0 O-C-N 123.337 0.398 . . . . 74.1 110.279 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.9 mt -119.46 -178.1 3.52 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.141 -0.481 . . . . 75.32 110.228 -177.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.62 -4.98 43.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.066 0.46 . . . . 70.22 110.884 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -99.62 163.38 12.52 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.774 -0.648 . . . . 74.35 109.422 173.535 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -78.53 47.96 3.09 Favored Glycine 0 CA--C 1.521 0.449 0 C-N-CA 120.917 -0.659 . . . . 74.22 113.678 -174.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.0 t -165.9 170.55 13.64 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.259 -0.645 . . . . 64.31 109.259 178.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 61.1 m95 -87.44 178.12 6.91 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.836 -0.431 . . . . 74.23 109.836 -177.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.9 p -49.86 -50.8 44.3 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 113.394 0.887 . . . . 73.14 113.394 -173.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -148.25 66.08 1.08 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.569 0.224 . . . . 71.12 110.445 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 60.1 ttp -87.1 79.83 8.53 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 118.921 -1.112 . . . . 72.34 110.934 -176.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -169.31 89.67 0.2 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.446 -1.252 . . . . 75.03 107.72 162.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.509 HG23 ' HG2' ' A' ' 53' ' ' PRO . 1.4 m -151.39 127.29 5.02 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 120.314 -0.554 . . . . 74.5 111.339 -170.354 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -78.61 93.95 1.08 Allowed 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.574 2.182 . . . . 64.4 112.159 175.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.9 p -92.9 114.61 27.22 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.081 -0.509 . . . . 73.32 110.782 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.7 ptp85 -94.28 128.67 40.9 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.056 -0.52 . . . . 75.3 111.045 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.547 ' HA ' HG11 ' A' ' 50' ' ' VAL . 18.2 t -89.44 112.2 23.28 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.001 -0.545 . . . . 74.22 109.748 179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.97 115.03 14.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.478 -0.328 . . . . 73.23 111.168 -174.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 . . . . . 0 C--O 1.244 0.795 0 CA-C-O 118.479 -0.772 . . . . 74.41 109.723 174.16 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 28.1 m . . . . . 0 N--CA 1.451 -0.399 0 N-CA-C 109.683 -0.488 . . . . 74.12 109.683 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -76.19 105.41 7.22 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.106 -0.497 . . . . 74.03 109.795 -179.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.712 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -149.53 143.1 10.4 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.624 -0.798 . . . . 60.54 112.529 -178.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 69.2 m -92.47 151.83 20.0 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 110.213 -0.292 . . . . 72.14 110.213 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.412 ' H ' ' HG3' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -87.15 -179.43 6.45 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.633 -0.258 . . . . 64.22 111.521 -177.683 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 40.4 mt -88.61 112.57 24.13 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.246 -0.434 . . . . 73.43 111.294 -171.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 38.7 mt -70.82 146.12 12.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.74 -0.663 . . . . 72.13 110.443 179.139 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . 0.423 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 72.2 m-70 -88.24 141.85 31.23 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 116.524 -0.307 . . . . 73.31 110.39 177.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 12.8 Cg_exo -71.4 122.08 8.32 Favored 'Trans proline' 0 CA--C 1.529 0.253 0 C-N-CA 122.934 2.423 . . . . 71.32 111.644 176.071 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -91.19 -94.73 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 123.008 2.472 . . . . 72.42 112.782 -177.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -89.99 -176.0 4.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.088 -0.708 . . . . 72.24 109.088 178.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -57.48 -16.21 9.02 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 112.11 0.411 . . . . 74.13 112.11 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.38 91.41 0.3 Allowed Glycine 0 N--CA 1.448 -0.502 0 N-CA-C 110.648 -0.981 . . . . 71.54 110.648 167.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -91.16 -170.21 42.58 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 121.168 -0.539 . . . . 73.45 112.982 -173.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -115.55 136.23 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 CA-C-O 121.72 0.772 . . . . 71.22 112.083 -174.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.791 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 15.4 tpt180 -116.4 145.8 42.98 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.182 -1.372 . . . . 74.22 109.049 -178.047 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 68.6 m-85 -108.95 -172.89 2.14 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.805 -0.442 . . . . 74.51 109.805 178.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 25.6 mtm180 -98.41 -38.48 9.2 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.57 -0.452 . . . . 74.3 110.885 -178.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -160.56 52.95 0.34 Allowed Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.644 -0.789 . . . . 71.12 112.467 178.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 93.7 mt -116.73 115.94 26.57 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.942 0.401 . . . . 64.52 110.352 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.6 t -80.79 -179.2 7.16 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.656 -0.702 . . . . 75.32 110.307 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.534 ' C ' ' H ' ' A' ' 27' ' ' GLN . 39.5 mmt180 -67.4 -174.99 0.44 Allowed 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.684 0.278 . . . . 73.32 111.308 -176.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 23.4 t70 65.64 -34.26 0.19 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.638 0.775 . . . . 65.24 112.172 -175.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.534 ' H ' ' C ' ' A' ' 25' ' ' ARG . 20.6 mt-30 -80.89 -166.3 1.09 Allowed 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 122.542 0.337 . . . . 73.2 110.664 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.453 HG22 ' O ' ' A' ' 27' ' ' GLN . 5.8 m 52.89 18.5 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 124.548 1.139 . . . . 75.0 113.068 177.009 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 50.8 pttt -111.37 -21.85 11.62 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.808 0.337 . . . . 75.45 110.285 177.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.74 16.03 2.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.346 -0.388 . . . . 75.11 111.664 -178.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 60.8 mt -73.22 103.38 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 109.404 -0.591 . . . . 74.23 109.404 176.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -58.01 -50.07 74.66 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.145 -0.48 . . . . 73.04 112.184 -173.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.712 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 91.0 m-85 -133.31 128.54 35.96 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.818 0.342 . . . . 74.1 110.821 -177.24 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -83.23 126.87 70.93 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 108.485 -0.931 . . . . 73.11 108.485 171.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -51.24 145.46 26.77 Favored 'Trans proline' 0 C--O 1.234 0.283 0 C-N-CA 123.361 2.707 . . . . 63.24 112.92 -176.118 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 p -59.74 142.41 15.21 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 CA-C-N 115.792 -0.64 . . . . 72.31 110.99 -178.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.8 t70 78.75 -11.96 1.14 Allowed 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.238 -0.892 . . . . 75.53 111.947 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 47.3 t80 -67.05 120.31 13.46 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 108.877 -0.786 . . . . 75.21 108.877 176.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.453 ' HG2' ' HA ' ' A' ' 57' ' ' LYS . 43.6 mt-10 -104.77 146.84 28.4 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.131 -0.486 . . . . 74.51 110.836 -176.147 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.592 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 21.1 pt -120.2 155.56 23.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.824 -0.626 . . . . 75.23 110.415 177.748 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.791 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.4 tt0 -107.21 165.84 11.07 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.588 -0.733 . . . . 74.33 110.268 -174.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -120.47 101.43 7.77 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.775 0.321 . . . . 75.13 110.838 178.048 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 20.3 m -103.01 168.15 2.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.139 -0.482 . . . . 73.24 110.429 178.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.598 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 28.3 t -90.57 140.76 29.44 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.472 -0.566 . . . . 63.13 109.472 178.52 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -59.12 117.12 4.36 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.818 -0.628 . . . . 71.44 110.218 -176.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 114.18 -112.91 2.92 Favored Glycine 0 N--CA 1.444 -0.808 0 N-CA-C 111.093 -0.803 . . . . 62.21 111.093 -176.051 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -149.77 65.76 0.99 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.347 0.594 . . . . 71.43 110.834 177.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.598 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 35.0 mmt180 -126.57 136.27 52.34 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.265 -0.425 . . . . 74.21 110.047 179.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.52 157.01 27.52 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.958 -0.386 . . . . 74.41 109.958 176.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.495 HG13 ' HB3' ' A' ' 73' ' ' CYS . 33.2 m -130.29 149.69 33.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.245 -0.434 . . . . 70.42 110.68 -177.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -116.34 95.47 3.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 122.298 1.047 . . . . 74.5 108.929 169.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.47 172.33 33.61 Favored Glycine 0 N--CA 1.444 -0.824 0 CA-C-N 114.496 -1.229 . . . . 74.22 111.173 -178.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.479 ' HG2' HG22 ' A' ' 69' ' ' THR . 69.3 Cg_endo -75.91 60.02 5.96 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.326 2.017 . . . . 70.42 110.782 173.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.584 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 40.0 pttt -71.65 88.93 0.98 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.452 -0.794 . . . . 75.22 111.328 -175.516 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -161.88 131.89 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 116.046 -0.525 . . . . 75.54 110.946 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.592 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 22.3 mmt180 -127.78 111.07 13.24 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.504 -0.924 . . . . 75.13 108.504 169.649 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.453 ' HA ' ' HG2' ' A' ' 39' ' ' GLU . 20.5 ttmm -97.99 122.39 41.05 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.954 -0.387 . . . . 74.13 109.954 -178.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 49.8 t -69.65 126.97 31.33 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.772 -0.455 . . . . 74.1 109.772 177.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 95.0 mt -97.03 -178.94 4.37 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.054 -0.521 . . . . 75.32 110.831 -175.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.29 -17.03 61.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 70.22 110.687 178.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.3 p-10 -101.18 165.8 11.11 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.305 -0.628 . . . . 74.35 109.305 174.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.97 52.42 3.28 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 121.026 -0.607 . . . . 74.22 113.51 -174.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.8 m -157.5 157.7 34.35 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.523 -0.547 . . . . 64.31 109.523 177.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -88.27 173.51 8.73 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.603 -0.517 . . . . 74.23 109.603 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.412 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 3.0 p -57.73 -73.18 0.08 Allowed 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 112.27 0.47 . . . . 73.14 112.27 -177.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -125.31 121.13 33.09 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.215 -0.661 . . . . 71.12 109.215 178.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 62.3 mtm -120.45 79.6 1.5 Allowed 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 119.259 -0.976 . . . . 72.34 111.149 173.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -168.34 89.79 0.26 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 114.735 -1.121 . . . . 75.03 108.316 162.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.479 HG22 ' HG2' ' A' ' 53' ' ' PRO . 0.2 OUTLIER -159.02 102.23 1.58 Allowed Pre-proline 0 C--N 1.315 -0.932 0 C-N-CA 120.581 -0.448 . . . . 74.5 110.693 -171.814 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -75.33 105.17 2.03 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.359 2.039 . . . . 64.4 111.576 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 7.6 p -75.22 102.41 4.99 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.228 0.537 . . . . 73.32 110.852 -178.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.1 ptp180 -79.97 115.61 19.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.696 -0.684 . . . . 75.3 111.252 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.535 ' HB3' ' HB2' ' A' ' 44' ' ' CYS . 0.7 OUTLIER -87.25 99.04 11.67 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.984 -0.553 . . . . 74.22 110.689 174.761 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.7 p -115.53 129.13 72.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.611 -0.722 . . . . 73.23 109.54 176.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.637 -0.697 . . . . 74.41 109.875 -176.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.0 m . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 108.794 -0.817 . . . . 74.12 108.794 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -119.1 99.2 6.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.698 -0.683 . . . . 74.03 110.524 -174.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.46 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -161.74 165.54 35.74 Favored Glycine 0 N--CA 1.437 -1.235 0 CA-C-N 115.612 -0.722 . . . . 60.54 111.363 178.234 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 13.3 m -84.61 139.74 31.86 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 110.078 -0.341 . . . . 72.14 110.078 178.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -83.14 -178.67 7.18 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.204 0.526 . . . . 64.22 111.087 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.52 HD11 ' HB ' ' A' ' 31' ' ' ILE . 58.2 mt -87.43 105.04 14.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.809 -0.632 . . . . 73.43 109.366 178.087 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.462 HD12 ' HE1' ' A' ' 67' ' ' MET . 20.8 pt -72.18 169.93 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 114.721 -1.127 . . . . 72.13 111.556 -177.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -69.39 135.79 88.72 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.009 -0.541 . . . . 73.31 109.745 173.576 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -59.78 143.99 99.53 Favored 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.117 1.878 . . . . 71.32 111.147 172.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.21 -160.05 0.09 OUTLIER 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.489 2.126 . . . . 72.42 112.441 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 14.9 t-105 -68.8 -175.94 0.76 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.969 -0.56 . . . . 72.24 109.787 177.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 66.9 mm-40 -37.86 100.53 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.553 0.741 . . . . 74.13 112.655 -172.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.522 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . 163.6 -132.39 2.72 Favored Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.322 -0.853 . . . . 71.54 111.643 -179.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -179.64 -166.2 34.93 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.495 -0.642 . . . . 73.45 111.495 178.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.3 mt -127.95 130.11 69.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.463 0.649 . . . . 71.22 111.189 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.726 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 23.2 tpt180 -96.64 135.3 38.75 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 114.759 -1.109 . . . . 74.22 109.255 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.573 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 98.0 m-85 -93.17 -171.23 2.61 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.836 -0.346 . . . . 74.51 110.613 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.525 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 49.1 ttt180 -106.43 -75.86 0.62 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 120.757 0.313 . . . . 74.3 110.893 -170.346 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -114.19 43.68 1.65 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.886 -0.597 . . . . 71.12 112.097 -177.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.424 ' CG ' ' HH ' ' A' ' 38' ' ' TYR . 75.1 mt -133.69 144.67 49.3 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 110.243 -0.28 . . . . 64.52 110.243 178.094 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.0 t -97.04 175.01 6.48 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.062 -0.517 . . . . 75.32 109.821 176.007 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.479 ' C ' ' H ' ' A' ' 27' ' ' GLN . 34.7 ptt180 -74.43 -172.42 1.46 Allowed 'General case' 0 C--O 1.236 0.389 0 C-N-CA 121.439 -0.104 . . . . 73.32 110.815 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 27.4 t70 69.27 -2.27 1.9 Allowed 'General case' 0 N--CA 1.474 0.774 0 CA-C-O 122.055 0.931 . . . . 65.24 109.945 -175.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.479 ' H ' ' C ' ' A' ' 25' ' ' ARG . 21.6 mt-30 -119.98 -156.51 0.67 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.777 -1.102 . . . . 73.2 108.518 178.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.2 m 47.83 27.57 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.778 0.831 . . . . 75.0 112.263 176.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.424 ' H ' ' HG2' ' A' ' 29' ' ' LYS . 26.3 pttt -92.74 -22.44 19.37 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.39 -0.823 . . . . 75.45 110.445 -175.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.6 81.54 0.66 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.809 -0.632 . . . . 75.11 110.677 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.52 ' HB ' HD11 ' A' ' 9' ' ' ILE . 48.0 mt -103.4 146.78 10.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.829 -0.623 . . . . 74.23 109.533 178.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -85.56 -67.92 0.77 Allowed 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.978 -0.379 . . . . 73.04 109.978 177.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.46 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 75.8 m-85 -136.32 145.72 45.8 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.021 -0.536 . . . . 74.1 110.641 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -92.32 142.59 26.25 Favored Pre-proline 0 C--N 1.321 -0.645 0 N-CA-C 109.762 -0.459 . . . . 73.11 109.762 175.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -62.77 147.15 95.05 Favored 'Trans proline' 0 C--O 1.237 0.442 0 C-N-CA 122.725 2.284 . . . . 63.24 113.03 -178.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 6.4 p -70.39 80.75 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 CA-C-O 122.159 0.98 . . . . 72.31 110.502 177.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.0 t70 172.94 -27.78 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 114.461 -1.245 . . . . 75.53 108.739 -175.095 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.573 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 7.9 t80 -72.15 142.9 49.09 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 114.751 -1.113 . . . . 75.21 111.185 -176.166 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.525 ' H ' ' HD2' ' A' ' 21' ' ' ARG . 54.9 mt-10 -124.61 153.76 41.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.032 -0.531 . . . . 74.51 109.93 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.515 HD12 ' HE3' ' A' ' 67' ' ' MET . 35.0 pt -126.68 165.65 24.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 120.763 0.316 . . . . 75.23 111.435 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.726 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.7 tt0 -130.89 147.47 52.54 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.955 -0.566 . . . . 74.33 110.268 178.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -94.84 102.27 14.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.285 -0.416 . . . . 75.13 110.678 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.5 m -103.48 170.67 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 120.9 0.381 . . . . 73.24 111.141 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.426 ' HA ' ' CA ' ' A' ' 16' ' ' GLY . 49.7 t -115.9 175.18 5.65 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.301 -0.409 . . . . 63.13 110.055 -178.378 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . 0.522 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 2.0 tmt_? -77.09 99.63 5.43 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.631 -0.507 . . . . 71.44 109.631 -178.185 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.18 -160.63 28.44 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.929 -0.653 . . . . 62.21 111.691 -178.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -85.18 69.52 10.77 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.745 0.783 . . . . 71.43 111.002 -179.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 26.5 mmm180 -124.51 107.72 11.36 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.139 -1.059 . . . . 74.21 108.139 174.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -79.8 139.31 37.28 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.999 0.428 . . . . 74.41 111.508 -170.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.56 ' HA ' ' HA ' ' A' ' 73' ' ' CYS . 33.7 m -94.53 150.12 4.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.707 -0.678 . . . . 70.42 111.292 -176.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -114.42 95.06 3.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.822 0.82 . . . . 74.5 109.17 169.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.57 171.66 33.63 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.155 -0.93 . . . . 74.22 111.664 -178.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -83.58 71.25 6.03 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.158 1.905 . . . . 70.42 110.336 169.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.45 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 21.1 pttp -81.61 86.95 6.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.655 0.741 . . . . 75.22 111.629 -170.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.6 p -161.9 128.0 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.362 -0.836 . . . . 75.54 109.315 172.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.481 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 35.1 mmt180 -145.19 118.22 8.83 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.322 -0.622 . . . . 75.13 109.322 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -106.03 139.7 40.16 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.958 0.409 . . . . 74.13 109.958 177.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.9 t -70.47 149.66 46.98 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.556 -0.747 . . . . 74.1 111.911 -175.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.3 mt -113.15 -178.02 3.28 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.187 -0.915 . . . . 75.32 109.943 179.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -83.44 28.97 0.52 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.869 0.366 . . . . 70.22 111.277 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -146.56 169.85 18.11 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.161 -0.472 . . . . 74.35 109.946 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -69.2 -34.44 75.46 Favored Glycine 0 C--N 1.33 0.236 0 C-N-CA 121.348 -0.453 . . . . 74.22 114.039 -169.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.8 m -89.79 142.06 28.04 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 121.124 0.488 . . . . 64.31 111.054 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 59.7 m95 -73.82 -179.29 3.59 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.086 -0.507 . . . . 74.23 110.732 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.9 p -56.33 -56.12 25.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.312 -0.404 . . . . 73.14 111.792 -178.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.423 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 10.6 t70 -142.66 127.0 17.66 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.742 -0.466 . . . . 71.12 109.742 174.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' MET . . . . . 0.515 ' HE3' HD12 ' A' ' 40' ' ' ILE . 24.2 mmt -127.75 78.68 1.84 Allowed 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 119.112 -1.035 . . . . 72.34 110.531 165.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -167.08 87.85 0.3 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 113.843 -1.526 . . . . 75.03 107.544 159.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 91.5 m -160.33 109.0 1.37 Allowed Pre-proline 0 C--N 1.317 -0.825 0 N-CA-C 109.651 -0.5 . . . . 74.5 109.651 -172.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.53 99.52 0.94 Allowed 'Trans proline' 0 C--O 1.233 0.24 0 C-N-CA 122.68 2.253 . . . . 64.4 113.213 -174.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 11.8 p -91.58 98.58 11.74 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.519 -0.548 . . . . 73.32 109.519 173.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.411 HH11 ' HD2' ' A' ' 72' ' ' ARG . 7.0 ptp180 -91.29 140.66 29.57 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.163 -0.471 . . . . 75.3 110.852 -175.493 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.56 ' HA ' ' HA ' ' A' ' 50' ' ' VAL . 3.4 p -106.59 122.25 45.95 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.847 -0.615 . . . . 74.22 111.119 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 18.4 t -127.14 -95.64 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 108.892 -0.781 . . . . 73.23 108.892 175.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.536 -0.745 . . . . 74.41 109.673 178.208 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.5 m . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 109.829 -0.434 . . . . 74.12 109.829 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -96.74 96.69 8.77 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.644 -0.502 . . . . 74.03 109.644 178.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.8 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -164.15 136.91 4.46 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.742 -0.742 . . . . 60.54 112.565 -179.131 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.8 m -80.01 133.84 36.18 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.81 -0.811 . . . . 72.14 108.81 172.073 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.579 ' HA ' ' O ' ' A' ' 32' ' ' ASN . 2.2 pt20 -73.31 177.62 5.05 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.624 0.726 . . . . 64.22 112.41 -174.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.3 mt -88.97 127.09 41.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.876 -1.056 . . . . 73.43 110.326 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 58.6 mt -76.21 140.92 16.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.502 -0.772 . . . . 72.13 110.75 -177.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -62.9 138.0 97.06 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 115.49 -0.777 . . . . 73.31 110.188 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.447 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 75.6 Cg_exo -41.48 118.85 0.88 Allowed 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 123.852 3.034 . . . . 71.32 113.74 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 6.7 Cg_endo -88.79 -145.18 0.03 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.657 0 C-N-CA 123.685 2.924 . . . . 72.42 112.436 -178.551 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.44 ' CG ' ' N ' ' A' ' 15' ' ' GLU . 69.0 t-105 -68.36 -179.67 1.38 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 115.907 -0.588 . . . . 72.24 110.893 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.44 ' N ' ' CG ' ' A' ' 14' ' ' TRP . 16.8 mm-40 -47.99 101.5 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.182 0 C-N-CA 123.972 0.909 . . . . 74.13 112.336 178.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 153.56 -142.58 9.3 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 120.722 -0.751 . . . . 71.54 111.911 178.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -168.72 -169.99 32.82 Favored Glycine 0 N--CA 1.442 -0.959 0 N-CA-C 111.459 -0.656 . . . . 73.45 111.459 -179.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.5 mt -113.81 128.17 70.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.735 0.778 . . . . 71.22 111.432 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.834 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 20.5 tpp180 -86.24 113.14 22.01 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 114.54 -1.209 . . . . 74.22 109.541 179.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.412 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 86.2 m-85 -86.71 -171.54 3.58 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.953 0.406 . . . . 74.51 110.875 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -108.34 -32.51 7.42 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.131 0.491 . . . . 74.3 110.066 -177.47 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -158.62 54.51 0.37 Allowed Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.799 -0.715 . . . . 71.12 112.155 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.633 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 88.8 mt -138.61 111.62 7.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.681 0.277 . . . . 64.52 110.95 -179.401 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.7 t -85.28 -179.91 7.07 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.166 -0.47 . . . . 75.32 109.859 175.229 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.49 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 9.5 ptp85 -72.77 -171.36 0.83 Allowed 'General case' 0 C--O 1.237 0.398 0 N-CA-C 110.027 -0.361 . . . . 73.32 110.027 178.001 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.49 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 9.7 t70 73.24 -40.77 0.48 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 121.251 0.548 . . . . 65.24 110.071 -176.191 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.457 ' H ' ' C ' ' A' ' 25' ' ' ARG . 24.6 mt-30 -85.33 -164.64 1.03 Allowed 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 115.497 -0.774 . . . . 73.2 109.156 171.357 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.478 HG12 HD13 ' A' ' 31' ' ' ILE . 9.0 m 50.87 20.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 C-N-CA 124.079 0.952 . . . . 75.0 112.432 178.802 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 17.9 ptmt -79.78 -18.99 49.69 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.803 -0.635 . . . . 75.45 110.525 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.95 35.97 0.05 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.315 -0.857 . . . . 75.11 110.753 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.478 HD13 HG12 ' A' ' 28' ' ' VAL . 45.6 mt -75.69 136.88 23.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 109.003 -0.74 . . . . 74.23 109.003 175.052 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.579 ' O ' ' HA ' ' A' ' 8' ' ' GLN . 87.4 m-20 -115.76 -25.06 7.93 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 111.981 0.363 . . . . 73.04 111.981 -172.781 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.8 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 41.5 m-85 -132.01 109.48 10.06 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.958 0.408 . . . . 74.1 111.673 -174.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.66 129.63 50.08 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 109.355 -0.609 . . . . 73.11 109.355 173.054 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -62.21 161.34 27.08 Favored 'Trans proline' 0 N--CA 1.472 0.261 0 C-N-CA 122.868 2.378 . . . . 63.24 113.538 -175.365 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.456 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 12.4 p -63.1 157.68 3.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 CA-C-N 115.355 -0.839 . . . . 72.31 110.602 179.026 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.456 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 32.2 t70 77.12 -3.85 2.42 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.424 0.69 . . . . 75.53 111.004 178.623 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.633 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 4.4 t80 -80.39 123.56 28.13 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.133 -0.485 . . . . 75.21 110.18 -179.185 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.471 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.6 mt-10 -116.37 141.74 47.77 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 110.014 -0.365 . . . . 74.51 110.014 175.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.509 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 33.6 pt -121.26 160.89 21.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 120.965 0.412 . . . . 75.23 111.503 -177.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.834 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 46.2 tt0 -120.52 152.07 38.53 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.546 -0.752 . . . . 74.33 110.101 179.715 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -101.7 102.83 13.56 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.742 0.306 . . . . 75.13 110.982 179.155 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.446 HG13 ' HE ' ' A' ' 19' ' ' ARG . 30.7 m -102.23 152.75 5.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.16 0.505 . . . . 73.24 111.318 -179.044 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.423 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 19.1 t -100.49 -179.83 4.22 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.126 -0.694 . . . . 63.13 109.126 -178.39 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -65.2 110.08 2.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.772 0.32 . . . . 71.44 111.397 -179.403 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.96 -149.01 24.98 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 121.0 -0.619 . . . . 62.21 111.855 179.194 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -91.56 37.51 0.96 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.365 0.603 . . . . 71.43 110.464 179.465 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 29.8 mmm180 -88.49 108.26 19.3 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.81 -0.811 . . . . 74.21 108.81 176.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -77.95 145.39 36.11 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.676 -0.693 . . . . 74.41 111.113 -171.56 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.535 ' HA ' ' HA ' ' A' ' 73' ' ' CYS . 34.8 m -101.33 149.98 6.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.672 -0.694 . . . . 70.42 110.387 179.115 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.0 p -117.47 95.28 3.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 122.003 0.906 . . . . 74.5 109.405 169.043 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.26 171.83 33.46 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.735 -1.121 . . . . 74.22 111.382 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.531 ' HG2' HG23 ' A' ' 69' ' ' THR . 48.1 Cg_endo -77.06 71.92 6.07 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 121.756 1.637 . . . . 70.42 110.359 170.168 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.678 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 43.2 pttt -78.98 89.57 4.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.531 -0.759 . . . . 75.22 111.398 -173.172 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.39 128.57 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.578 0.704 . . . . 75.54 110.877 174.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.637 ' CZ ' ' HA ' ' A' ' 67' ' ' MET . 28.9 mmt85 -138.23 104.41 5.19 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.276 -0.875 . . . . 75.13 109.106 176.72 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -97.47 138.96 34.11 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.412 -0.358 . . . . 74.13 110.182 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.7 t -97.88 128.56 44.56 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.014 -0.539 . . . . 74.1 110.349 176.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 30.7 mt -108.13 -176.6 3.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.797 -0.638 . . . . 75.32 110.414 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -54.43 -35.08 62.56 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 121.037 0.446 . . . . 70.22 110.886 176.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -83.18 140.5 32.54 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.345 -0.613 . . . . 74.35 109.345 174.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.402 ' C ' ' HG ' ' A' ' 63' ' ' SER . . . -79.14 67.19 3.32 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 121.025 -0.607 . . . . 74.22 113.631 -172.034 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.402 ' HG ' ' C ' ' A' ' 62' ' ' GLY . 32.2 m -155.38 139.31 16.32 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.839 -0.43 . . . . 64.31 109.839 174.073 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 66.4 m95 -72.28 129.6 38.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.03 -0.73 . . . . 74.23 109.03 177.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.6 p -70.78 13.94 0.16 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 115.24 1.57 . . . . 73.14 115.24 -166.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -159.03 42.96 0.24 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.302 -0.629 . . . . 71.12 109.302 177.036 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' MET . . . . . 0.637 ' HA ' ' CZ ' ' A' ' 56' ' ' ARG . 26.4 ttt -83.75 77.38 9.89 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 122.074 0.94 . . . . 72.34 111.38 -171.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -170.32 88.97 0.15 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 113.905 -1.498 . . . . 75.03 107.361 159.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.531 HG23 ' HG2' ' A' ' 53' ' ' PRO . 7.5 m -127.58 112.38 20.89 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 119.847 -0.741 . . . . 74.5 112.51 -167.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -74.05 114.77 4.12 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 122.913 2.408 . . . . 64.4 110.811 172.304 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.4 p -135.64 145.74 47.13 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.403 -0.362 . . . . 73.32 110.844 -175.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.5 ptp180 -140.8 136.42 32.44 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.204 -0.453 . . . . 75.3 110.122 -178.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.535 ' HA ' ' HA ' ' A' ' 50' ' ' VAL . 0.9 OUTLIER -97.18 99.73 11.21 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.462 0.649 . . . . 74.22 111.101 176.783 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -131.94 134.09 60.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.028 -0.987 . . . . 73.23 108.837 178.128 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.381 -0.819 . . . . 74.41 110.948 -172.189 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.7 m . . . . . 0 N--CA 1.451 -0.404 0 N-CA-C 109.495 -0.557 . . . . 74.12 109.495 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -118.03 100.23 7.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.557 -0.747 . . . . 74.03 110.261 -175.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.873 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.54 145.32 10.96 Favored Glycine 0 N--CA 1.444 -0.833 0 N-CA-C 111.373 -0.691 . . . . 60.54 111.373 178.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 56.7 m -81.16 132.01 35.33 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 110.176 -0.305 . . . . 72.14 110.176 -179.459 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -80.3 -176.55 5.69 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.995 0.426 . . . . 64.22 111.302 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 73.0 mt -84.86 136.34 22.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.498 -0.773 . . . . 73.43 109.046 178.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.441 ' CD1' ' HE3' ' A' ' 67' ' ' MET . 14.1 mt -94.76 148.33 5.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 116.102 -0.499 . . . . 72.13 111.614 -169.074 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 10.8 p80 -61.69 136.29 94.64 Favored Pre-proline 0 C--O 1.233 0.211 0 CA-C-N 116.051 -0.522 . . . . 73.31 109.875 172.156 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.9 119.77 6.82 Favored 'Trans proline' 0 N--CA 1.464 -0.248 0 C-N-CA 122.526 2.151 . . . . 71.32 111.951 179.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -77.76 -129.8 0.01 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.272 0 C-N-CA 123.043 2.495 . . . . 72.42 111.49 178.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 39.3 t-105 -63.86 174.77 1.34 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 109.594 -0.521 . . . . 72.24 109.594 175.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -68.91 76.37 0.31 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.497 0.665 . . . . 74.13 112.321 -176.096 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.27 155.32 25.97 Favored Glycine 0 N--CA 1.438 -1.188 0 N-CA-C 109.729 -1.349 . . . . 71.54 109.729 173.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -106.06 -172.3 23.38 Favored Glycine 0 N--CA 1.44 -1.085 0 C-N-CA 119.811 -1.185 . . . . 73.45 112.017 -178.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.8 mt -132.16 131.75 61.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.197 0.523 . . . . 71.22 109.987 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' A' ' 19' ' ' ARG . 0.2 OUTLIER -113.41 122.28 46.87 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.39 -0.823 . . . . 74.22 109.341 -179.307 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -88.52 -172.71 3.86 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.878 0.371 . . . . 74.51 110.552 -175.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.5 ttm180 -89.18 -51.59 5.5 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.219 -0.446 . . . . 74.3 110.27 -177.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -137.27 13.07 3.8 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.805 -0.712 . . . . 71.12 112.736 -178.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.708 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 80.3 mt -89.96 129.29 36.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.106 0.479 . . . . 64.52 110.805 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.1 t -102.74 -178.27 3.62 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.577 -0.738 . . . . 75.32 110.085 178.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.516 ' C ' ' H ' ' A' ' 27' ' ' GLN . 60.6 mtp180 -69.3 -173.07 0.5 Allowed 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.535 -0.302 . . . . 73.32 111.28 -176.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 24.3 t70 69.79 -40.33 0.46 Allowed 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.444 0.698 . . . . 65.24 110.505 -172.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.516 ' H ' ' C ' ' A' ' 25' ' ' ARG . 18.1 mt-30 -86.6 -161.12 0.63 Allowed 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.36 -0.836 . . . . 73.2 110.3 177.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.506 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.6 m 54.73 10.0 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.674 1.19 . . . . 75.0 113.247 177.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -97.25 -19.84 18.3 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.021 0.439 . . . . 75.45 110.027 175.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.64 94.07 1.85 Allowed 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.552 -0.749 . . . . 75.11 110.377 178.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -131.58 136.62 56.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.109 -0.7 . . . . 74.23 109.109 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -76.77 -67.02 0.74 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.959 0.409 . . . . 73.04 110.892 -177.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.873 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 61.8 m-85 -133.91 126.67 30.89 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.832 -0.622 . . . . 74.1 111.119 -175.742 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -85.13 134.11 41.58 Favored Pre-proline 0 C--N 1.324 -0.525 0 N-CA-C 108.969 -0.752 . . . . 73.11 108.969 171.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -63.08 141.18 82.34 Favored 'Trans proline' 0 C--O 1.239 0.545 0 C-N-CA 122.816 2.344 . . . . 63.24 112.906 -176.502 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.421 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 3.1 p -69.84 82.07 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 CA-C-O 121.719 0.771 . . . . 72.31 110.25 176.281 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.421 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 6.2 t70 172.44 -26.39 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.635 -1.166 . . . . 75.53 108.544 -175.873 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.708 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 6.1 t80 -74.04 146.38 43.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.217 -0.901 . . . . 75.21 110.822 -177.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -124.69 158.64 32.71 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 115.911 -0.586 . . . . 74.51 110.564 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.466 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 31.0 pt -139.5 149.27 22.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.15 -0.477 . . . . 75.23 110.67 177.017 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.55 ' HG2' ' H ' ' A' ' 42' ' ' TYR . 24.2 tt0 -112.81 167.37 10.55 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.161 -0.472 . . . . 74.33 109.902 178.272 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.55 ' H ' ' HG2' ' A' ' 41' ' ' GLU . 69.1 m-85 -112.44 102.42 10.54 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.077 0.465 . . . . 75.13 111.998 -177.195 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.0 m -96.21 153.6 3.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 109.074 -0.713 . . . . 73.24 109.074 171.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.578 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 34.2 t -89.07 167.49 13.1 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.138 -0.69 . . . . 63.13 109.138 179.554 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -59.25 117.09 4.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.024 0.44 . . . . 71.44 110.151 -176.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.76 -120.77 6.53 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 110.958 -0.857 . . . . 62.21 110.958 -176.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -130.04 25.61 5.24 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.359 0.6 . . . . 71.43 110.212 177.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.578 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 29.8 mmm180 -88.47 136.06 33.18 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.823 -0.626 . . . . 74.21 109.8 -177.435 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -95.47 159.19 15.12 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.046 -0.525 . . . . 74.41 109.811 -179.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.526 HG13 ' HA ' ' A' ' 73' ' ' CYS . 27.9 m -122.28 150.14 25.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.523 -0.308 . . . . 70.42 110.422 179.517 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 p -100.83 96.89 5.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 122.039 0.923 . . . . 74.5 109.295 171.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.23 172.11 33.45 Favored Glycine 0 N--CA 1.441 -0.997 0 CA-C-N 114.973 -1.012 . . . . 74.22 111.612 -176.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -74.07 55.69 3.5 Favored 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.249 1.966 . . . . 70.42 110.523 171.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.455 ' HD2' ' HG2' ' A' ' 41' ' ' GLU . 43.0 pttt -75.41 87.46 2.58 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 115.74 -0.664 . . . . 75.22 111.515 -173.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -161.41 129.21 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.439 -0.8 . . . . 75.54 109.45 172.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.503 HH22 ' CB ' ' A' ' 69' ' ' THR . 31.8 mmt180 -132.61 140.29 48.16 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.918 -0.401 . . . . 75.13 109.918 179.165 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -130.76 137.56 49.53 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.598 -0.519 . . . . 74.13 109.598 176.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 50.4 t -70.83 146.5 49.65 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.114 -0.494 . . . . 74.1 110.26 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 94.3 mt -116.86 -179.61 3.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.136 -0.484 . . . . 75.32 110.381 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.03 -8.39 59.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.917 0.389 . . . . 70.22 111.038 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -100.54 166.16 11.06 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.434 -0.58 . . . . 74.35 109.434 175.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.02 57.76 3.14 Favored Glycine 0 CA--C 1.516 0.131 0 C-N-CA 120.987 -0.625 . . . . 74.22 113.091 -177.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.2 t -172.96 171.03 4.35 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.209 -0.663 . . . . 64.31 109.209 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 40.5 m95 -99.98 -179.01 4.02 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 109.714 -0.476 . . . . 74.23 109.714 -178.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.0 p -49.63 -53.31 24.88 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.579 0.585 . . . . 73.14 112.579 -176.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -153.77 129.95 10.41 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.026 -1.102 . . . . 71.12 108.026 177.227 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' MET . . . . . 0.441 ' HE3' ' CD1' ' A' ' 10' ' ' ILE . 22.9 mmt -131.81 78.4 1.82 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 118.992 -1.083 . . . . 72.34 112.136 174.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 30.0 t0 -168.94 88.39 0.19 Allowed 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 107.805 -1.183 . . . . 75.03 107.805 157.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.503 ' CB ' HH22 ' A' ' 56' ' ' ARG . 1.3 m -149.32 94.6 3.92 Favored Pre-proline 0 C--N 1.314 -0.948 0 C-N-CA 120.913 -0.315 . . . . 74.5 110.313 -172.5 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.95 92.81 0.32 Allowed 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 122.487 2.125 . . . . 64.4 112.26 -179.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 17.0 m -79.68 115.8 19.49 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.942 -0.572 . . . . 73.32 109.811 177.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.5 ptp180 -79.68 133.73 36.39 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.715 -0.675 . . . . 75.3 111.655 -174.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.526 ' HA ' HG13 ' A' ' 50' ' ' VAL . 71.2 m -83.08 98.87 9.53 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.761 -0.654 . . . . 74.22 110.592 178.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.5 p -148.88 114.47 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.635 -0.711 . . . . 73.23 109.534 176.42 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 2.4 tmt_? . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.288 -0.863 . . . . 74.41 109.488 -173.206 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.7 m . . . . . 0 N--CA 1.446 -0.636 0 N-CA-C 109.485 -0.561 . . . . 74.12 109.485 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 33.3 mm-40 -98.82 118.41 35.5 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.892 -0.595 . . . . 74.03 109.466 -179.562 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.503 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -153.73 152.14 23.78 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.124 -1.036 . . . . 60.54 113.152 -176.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.8 m -97.14 149.39 22.04 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.432 -0.581 . . . . 72.14 109.432 177.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -72.82 173.98 8.38 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.129 0.49 . . . . 64.22 112.171 -175.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.545 HD13 ' HB ' ' A' ' 31' ' ' ILE . 54.5 mt -88.5 126.9 41.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.522 -0.763 . . . . 73.43 110.458 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.1 mt -84.05 127.92 39.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.051 -0.522 . . . . 72.13 109.847 177.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -79.5 133.4 59.74 Favored Pre-proline 0 C--N 1.323 -0.583 0 N-CA-C 109.631 -0.507 . . . . 73.31 109.631 -177.355 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.402 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 72.3 Cg_exo -49.3 113.3 0.88 Allowed 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 123.451 2.767 . . . . 71.32 113.005 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.496 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 4.9 Cg_exo -80.52 -101.4 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 123.194 2.596 . . . . 72.42 112.827 -177.06 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.496 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 55.7 t-105 -80.76 177.11 9.24 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.777 -0.453 . . . . 72.24 109.777 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -54.84 101.21 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.409 0.623 . . . . 74.13 111.733 179.462 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.06 -145.43 9.44 Favored Glycine 0 N--CA 1.443 -0.872 0 CA-C-N 115.095 -0.957 . . . . 71.54 110.714 -177.473 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -176.42 -170.01 38.54 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 120.473 -0.87 . . . . 73.45 111.914 178.384 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.9 mt -125.52 125.65 69.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.272 0.558 . . . . 71.22 110.838 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.38 160.57 14.6 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.994 -1.003 . . . . 74.22 108.893 178.089 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -123.26 -171.12 2.24 Favored 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 120.797 -0.361 . . . . 74.51 110.398 -176.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.403 ' HB3' ' CE2' ' A' ' 38' ' ' TYR . 39.9 ttm180 -82.56 -36.58 26.12 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.46 -0.336 . . . . 74.3 110.345 -178.116 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.94 71.21 0.19 Allowed Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.588 -0.815 . . . . 71.12 112.53 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 62.5 mt -139.79 139.15 36.35 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.796 0.331 . . . . 64.52 110.751 178.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.3 t -92.67 -178.28 4.82 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.863 -0.608 . . . . 75.32 109.848 178.242 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.587 ' C ' ' H ' ' A' ' 27' ' ' GLN . 49.7 ptt85 -68.78 -175.89 0.75 Allowed 'General case' 0 C--O 1.234 0.285 0 C-N-CA 121.188 -0.205 . . . . 73.32 110.671 177.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.406 ' O ' ' HD3' ' A' ' 29' ' ' LYS . 28.7 t70 62.64 -26.83 0.06 Allowed 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 123.725 0.81 . . . . 65.24 112.116 -173.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.587 ' H ' ' C ' ' A' ' 25' ' ' ARG . 8.1 mm100 -71.25 178.7 3.2 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 123.227 0.611 . . . . 73.2 110.482 178.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.2 m 50.53 20.7 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 C-N-CA 124.364 1.065 . . . . 75.0 113.016 177.022 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.406 ' HD3' ' O ' ' A' ' 26' ' ' ASP . 38.1 pttt -73.51 -23.29 60.01 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.041 0.448 . . . . 75.45 109.927 176.627 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.99 102.65 0.66 Allowed 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.281 -0.872 . . . . 75.11 110.373 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.545 ' HB ' HD13 ' A' ' 9' ' ' ILE . 50.6 mt -130.21 157.86 42.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 N-CA-C 108.315 -0.995 . . . . 74.23 108.315 175.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -88.92 -58.22 2.63 Favored 'General case' 0 C--N 1.321 -0.67 0 C-N-CA 120.825 -0.35 . . . . 73.04 110.45 179.424 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.503 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 86.7 m-85 -143.54 146.75 33.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.886 0.374 . . . . 74.1 111.067 -178.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.448 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.4 mm? -84.37 130.9 52.14 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 108.575 -0.898 . . . . 73.11 108.575 173.295 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.448 ' HD3' ' HA ' ' A' ' 34' ' ' LEU . 17.4 Cg_exo -64.08 147.11 91.62 Favored 'Trans proline' 0 CA--C 1.527 0.15 0 C-N-CA 122.473 2.116 . . . . 63.24 112.848 -174.399 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.54 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 8.9 p -53.39 148.35 2.01 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 CA-C-N 115.832 -0.622 . . . . 72.31 110.413 173.469 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.54 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 7.9 t70 82.48 -28.93 0.1 Allowed 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.583 0.753 . . . . 75.53 111.513 -178.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.403 ' CE2' ' HB3' ' A' ' 21' ' ' ARG . 32.4 t80 -66.84 141.38 57.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.787 0.327 . . . . 75.21 110.544 -178.438 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.466 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 41.2 mt-10 -114.78 145.65 41.87 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.066 -0.515 . . . . 74.51 111.515 -177.21 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.539 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 43.8 pt -122.46 164.86 19.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.451 -0.795 . . . . 75.23 109.595 172.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.431 ' CG ' ' HD2' ' A' ' 54' ' ' LYS . 35.3 tt0 -135.89 142.71 44.75 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.987 0.422 . . . . 74.33 110.785 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -88.45 102.32 14.78 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.107 -0.497 . . . . 75.13 110.59 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.9 m -102.2 162.78 3.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.168 0.509 . . . . 73.24 110.856 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.57 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 15.8 t -104.0 -176.58 3.12 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.859 -0.61 . . . . 63.13 110.229 -176.566 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.5 mmt180 -56.27 121.43 9.49 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.111 -0.495 . . . . 71.44 111.419 -177.423 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 71.73 -95.86 0.64 Allowed Glycine 0 N--CA 1.446 -0.698 0 CA-C-N 115.724 -0.671 . . . . 62.21 111.998 178.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -146.83 47.52 1.17 Allowed 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.69 0.757 . . . . 71.43 109.716 177.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.57 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 13.3 mmm-85 -87.43 129.15 35.15 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.197 -0.91 . . . . 74.21 109.478 176.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.447 ' HB2' ' HB3' ' A' ' 75' ' ' ARG . 41.1 mt-10 -78.35 149.17 33.47 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.376 -0.374 . . . . 74.41 110.001 -179.615 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.458 HG12 ' HA ' ' A' ' 73' ' ' CYS . 34.9 m -127.06 150.14 32.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.96 -0.564 . . . . 70.42 110.678 -177.279 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 p -106.34 96.83 4.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.972 0.891 . . . . 74.5 109.235 171.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.764 ' HA3' ' HB3' ' A' ' 71' ' ' SER . . . -154.73 170.83 33.08 Favored Glycine 0 N--CA 1.441 -0.994 0 CA-C-N 114.831 -1.077 . . . . 74.22 111.175 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.24 60.33 7.4 Favored 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 122.282 1.988 . . . . 70.42 110.703 173.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.431 ' HD2' ' CG ' ' A' ' 41' ' ' GLU . 45.3 pttt -80.7 84.42 6.25 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-O 121.723 0.773 . . . . 75.22 111.436 -172.651 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.1 m -158.66 126.48 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 114.594 -1.185 . . . . 75.54 108.462 172.308 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.539 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 32.3 mmt180 -141.1 100.07 3.73 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 110.073 -0.343 . . . . 75.13 110.073 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -92.5 125.32 37.09 Favored 'General case' 0 C--N 1.317 -0.822 0 N-CA-C 109.002 -0.74 . . . . 74.13 109.002 174.104 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 48.9 t -64.52 136.6 57.21 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.008 0.432 . . . . 74.1 110.247 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 76.6 mt -98.78 -178.92 4.12 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.661 -0.699 . . . . 75.32 110.717 -174.236 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -71.45 -9.71 58.62 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.449 0.642 . . . . 70.22 110.363 176.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -110.21 158.62 18.17 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 108.93 -0.767 . . . . 74.35 108.93 174.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -78.29 53.23 3.84 Favored Glycine 0 CA--C 1.519 0.333 0 C-N-CA 120.993 -0.622 . . . . 74.22 113.464 -173.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 18.6 m -155.06 161.92 41.19 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.37 -0.604 . . . . 64.31 109.37 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 70.5 m95 -91.89 179.51 5.59 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.835 -0.431 . . . . 74.23 109.835 -178.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 33.0 p -61.67 -38.79 89.06 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.923 0.392 . . . . 73.14 111.197 -178.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -146.59 136.26 23.12 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.06 -0.718 . . . . 71.12 109.06 178.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 10.4 tpt -119.54 74.38 1.0 Allowed 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 118.602 -1.239 . . . . 72.34 109.882 171.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -170.68 89.2 0.14 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.206 -1.361 . . . . 75.03 107.575 160.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.473 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 4.6 m -108.77 108.81 61.06 Favored Pre-proline 0 C--N 1.313 -1.017 0 C-N-CA 119.959 -0.696 . . . . 74.5 111.078 -170.642 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . 0.473 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 14.8 Cg_endo -92.56 46.48 0.41 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 124.061 3.174 . . . . 64.4 112.803 -177.345 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.764 ' HB3' ' HA3' ' A' ' 52' ' ' GLY . 0.1 OUTLIER -73.91 126.21 29.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.5 -0.318 . . . . 73.32 110.687 177.561 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -109.55 149.05 30.21 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 110.177 -0.305 . . . . 75.3 110.177 -178.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.458 ' HA ' HG12 ' A' ' 50' ' ' VAL . 29.6 m -87.52 113.75 23.5 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.502 -0.317 . . . . 74.22 111.458 -175.635 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.1 p -155.8 134.94 3.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.576 -0.284 . . . . 73.23 110.563 179.078 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.447 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 3.0 ptm180 . . . . . 0 C--O 1.25 1.087 0 CA-C-N 116.318 -0.401 . . . . 74.41 109.971 178.019 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.4 m . . . . . 0 N--CA 1.455 -0.2 0 N-CA-C 109.51 -0.552 . . . . 74.12 109.51 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -96.22 97.27 9.39 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.626 -0.509 . . . . 74.03 109.626 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -161.76 164.18 35.09 Favored Glycine 0 N--CA 1.441 -0.986 0 C-N-CA 120.807 -0.711 . . . . 60.54 112.396 -177.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.6 m -97.59 154.02 17.81 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 110.203 -0.295 . . . . 72.14 110.203 179.068 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 -82.42 -179.69 7.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.338 0.589 . . . . 64.22 111.329 -178.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.3 mt -89.42 121.38 39.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.425 -0.807 . . . . 73.43 110.306 178.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 55.5 mt -72.15 129.03 35.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.915 -0.584 . . . . 72.13 110.111 178.391 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.5 t-80 -67.39 121.26 78.02 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 116.192 -0.458 . . . . 73.31 110.366 -178.114 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.517 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.4 Cg_exo -48.69 120.76 5.61 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.212 2.608 . . . . 71.32 112.783 -179.407 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.517 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 5.8 Cg_endo -86.68 -138.74 0.02 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 123.569 2.846 . . . . 72.42 112.656 -176.305 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.515 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 13.1 t-105 -66.85 -177.5 0.62 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 115.891 -0.595 . . . . 72.24 110.853 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -39.88 101.35 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.689 0.796 . . . . 74.13 112.835 -176.051 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.54 -168.56 33.25 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 111.341 -0.704 . . . . 71.54 111.341 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.82 24.0 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.942 -0.647 . . . . 73.45 111.563 179.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.4 mt -116.93 136.49 53.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.559 0.695 . . . . 71.22 111.216 -178.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.853 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 13.7 tpt180 -103.03 140.1 37.72 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.661 -1.154 . . . . 74.22 109.246 -179.681 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -108.29 -171.98 1.97 Allowed 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.591 -0.444 . . . . 74.51 110.765 -178.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.06 -45.33 9.22 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.001 0.429 . . . . 74.3 110.603 -174.284 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -151.09 53.38 0.49 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.811 -0.709 . . . . 71.12 112.181 -178.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.453 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 89.5 mt -136.55 127.55 27.73 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.607 0.241 . . . . 64.52 110.794 179.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.0 t -86.39 -179.77 6.73 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.531 -0.544 . . . . 75.32 109.531 175.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.8 mpp_? -80.47 -172.85 3.77 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.818 -0.353 . . . . 73.32 111.456 -175.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.437 ' O ' ' HE2' ' A' ' 29' ' ' LYS . 28.7 t70 60.44 15.25 5.37 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 122.357 1.075 . . . . 65.24 109.583 -168.435 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.516 ' O ' HG22 ' A' ' 28' ' ' VAL . 24.3 mt-30 -134.57 -173.7 3.36 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.668 -1.151 . . . . 73.2 108.287 178.273 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.516 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.0 m 54.4 9.22 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 124.127 0.971 . . . . 75.0 112.51 -178.323 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.437 ' HE2' ' O ' ' A' ' 26' ' ' ASP . 46.3 pttt -79.41 -21.82 45.1 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.98 -0.555 . . . . 75.45 110.081 177.502 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.31 81.15 0.98 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.351 -0.84 . . . . 75.11 110.37 178.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 54.8 mt -119.61 139.11 48.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 108.939 -0.763 . . . . 74.23 108.939 176.338 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -69.54 -64.2 0.92 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.764 0.316 . . . . 73.04 111.115 -176.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -143.56 141.73 30.8 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.192 -0.458 . . . . 74.1 110.867 -177.371 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -92.01 115.71 65.13 Favored Pre-proline 0 C--N 1.321 -0.671 0 N-CA-C 108.564 -0.902 . . . . 73.11 108.564 172.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.59 142.71 38.97 Favored 'Trans proline' 0 C--O 1.238 0.515 0 C-N-CA 123.419 2.746 . . . . 63.24 113.217 -174.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.459 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 2.7 p -65.22 86.14 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-O 121.512 0.673 . . . . 72.31 111.173 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.459 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 31.6 t70 168.94 -26.84 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.834 -1.075 . . . . 75.53 108.28 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.453 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 6.9 t80 -68.74 144.82 54.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 114.618 -1.173 . . . . 75.21 110.486 179.418 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -127.09 145.53 50.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.274 -0.421 . . . . 74.51 110.121 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.478 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 38.0 pt -128.45 167.9 22.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-O 121.084 0.469 . . . . 75.23 111.86 -177.622 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.853 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 44.4 tt0 -131.82 164.81 25.22 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 115.374 -0.83 . . . . 74.33 110.13 -177.221 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.499 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 96.9 m-85 -117.1 102.93 9.72 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 122.354 0.262 . . . . 75.13 111.142 -178.584 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.8 m -98.26 157.41 3.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 120.766 0.317 . . . . 73.24 110.74 178.501 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.572 ' HB3' ' O ' ' A' ' 48' ' ' ARG . 43.5 t -92.21 177.89 6.02 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.976 -0.379 . . . . 63.13 109.976 178.51 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . 0.496 ' HD3' ' C ' ' A' ' 45' ' ' ARG . 0.1 OUTLIER -69.59 117.04 10.69 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 116.171 -0.468 . . . . 71.44 110.469 -176.241 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 89.63 -125.23 7.74 Favored Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.972 -0.632 . . . . 62.21 112.352 175.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -116.23 26.02 10.23 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.002 0.429 . . . . 71.43 110.533 -179.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.572 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 28.6 mmm180 -88.64 119.02 28.72 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.829 -0.804 . . . . 74.21 108.829 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -79.26 159.98 27.04 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.04 0.448 . . . . 74.41 111.058 -177.325 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.54 HG11 ' HA ' ' A' ' 73' ' ' CYS . 27.5 m -126.83 139.15 52.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.796 -0.638 . . . . 70.42 110.369 179.083 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.9 p -103.19 95.53 3.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 122.093 0.949 . . . . 74.5 109.366 172.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.46 171.26 32.94 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 115.005 -0.998 . . . . 74.22 111.446 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -78.07 52.01 3.88 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.486 2.124 . . . . 70.42 111.145 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.68 ' HD3' ' HG3' ' A' ' 41' ' ' GLU . 0.0 OUTLIER -76.66 86.83 3.31 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 122.118 0.961 . . . . 75.22 111.972 -173.397 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -161.96 130.12 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 114.989 -1.005 . . . . 75.54 109.229 174.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.478 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 29.0 mmt180 -129.43 131.52 46.77 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 120.662 0.268 . . . . 75.13 110.484 178.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.451 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 35.2 ttmt -106.58 134.19 50.1 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.071 -0.715 . . . . 74.13 109.071 176.112 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.3 t -74.53 145.18 43.68 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.92 0.39 . . . . 74.1 110.734 -178.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.427 ' C ' ' H ' ' A' ' 61' ' ' ASN . 97.6 mt -112.87 -178.67 3.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.788 -0.642 . . . . 75.32 110.114 -177.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.25 27.54 0.33 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.019 0.438 . . . . 70.22 111.077 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.427 ' H ' ' C ' ' A' ' 59' ' ' LEU . 5.4 p-10 -147.65 172.75 13.55 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.235 -0.654 . . . . 74.35 109.235 -179.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -68.36 -19.03 72.11 Favored Glycine 0 CA--C 1.52 0.375 0 C-N-CA 120.815 -0.707 . . . . 74.22 113.755 -172.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 14.9 m -99.36 146.27 26.47 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.046 0.45 . . . . 64.31 111.089 -178.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.493 ' H ' ' HE2' ' A' ' 67' ' ' MET . 63.8 m95 -77.89 -179.05 5.79 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.732 -0.667 . . . . 74.23 110.481 179.687 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.447 HG22 ' O ' ' A' ' 57' ' ' LYS . 3.1 p -54.05 -49.93 67.87 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 113.064 0.764 . . . . 73.14 113.064 -176.547 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.438 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 14.0 t70 -140.06 141.7 36.21 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.57 -0.286 . . . . 71.12 110.26 -177.562 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' MET . . . . . 0.493 ' HE2' ' H ' ' A' ' 64' ' ' TRP . 65.9 mtt -140.07 80.01 1.74 Allowed 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 119.969 -0.692 . . . . 72.34 111.502 166.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -168.03 88.45 0.25 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.301 -1.0 . . . . 75.03 108.301 157.415 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.8 m -152.78 101.24 2.7 Favored Pre-proline 0 C--N 1.316 -0.848 0 C-N-CA 120.372 -0.531 . . . . 74.5 111.274 -172.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.66 114.64 4.01 Favored 'Trans proline' 0 C--O 1.237 0.438 0 C-N-CA 122.627 2.218 . . . . 64.4 111.553 175.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 t -92.42 134.44 34.95 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.162 0.506 . . . . 73.32 109.972 -179.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.0 ptp85 -101.88 123.32 45.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.801 -0.636 . . . . 75.3 110.811 -176.607 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.54 ' HA ' HG11 ' A' ' 50' ' ' VAL . 60.9 m -76.08 98.17 4.27 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.419 -0.586 . . . . 74.22 109.419 176.616 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 10.7 p 177.04 151.76 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.088 -0.96 . . . . 73.23 108.412 -176.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.417 HH11 ' HD3' ' A' ' 75' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.943 0 CA-C-O 118.335 -0.841 . . . . 74.41 110.292 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.6 p . . . . . 0 N--CA 1.451 -0.42 0 CA-C-O 120.711 0.291 . . . . 74.12 110.42 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -70.22 116.63 10.79 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.852 0.358 . . . . 74.03 110.36 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.457 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.12 160.21 31.44 Favored Glycine 0 N--CA 1.44 -1.059 0 CA-C-N 115.66 -0.7 . . . . 60.54 111.374 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 38.1 m -92.74 147.17 23.08 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 110.185 -0.302 . . . . 72.14 110.185 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -85.53 -177.65 6.48 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.073 0.463 . . . . 64.22 110.826 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 51.9 mt -86.77 125.43 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 CA-C-N 115.989 -0.55 . . . . 73.43 109.8 175.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 56.1 mt -80.12 136.63 23.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.572 -0.74 . . . . 72.13 110.106 -179.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 45.5 m170 -54.49 128.57 60.74 Favored Pre-proline 0 C--N 1.329 -0.295 0 N-CA-C 109.843 -0.429 . . . . 73.31 109.843 173.178 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.431 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.5 Cg_exo -51.24 122.45 10.1 Favored 'Trans proline' 0 N--CA 1.461 -0.408 0 C-N-CA 122.501 2.134 . . . . 71.32 111.479 177.704 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 15.7 Cg_exo -69.09 -159.05 0.05 OUTLIER 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 123.081 2.52 . . . . 72.42 111.747 179.838 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -59.93 159.81 8.67 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.557 -0.534 . . . . 72.24 109.557 176.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -39.42 100.9 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 113.687 0.995 . . . . 74.13 113.687 -169.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -167.76 -140.2 2.86 Favored Glycine 0 N--CA 1.444 -0.821 0 CA-C-N 114.287 -1.324 . . . . 71.54 110.368 179.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -170.28 -171.01 35.3 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.521 -0.847 . . . . 73.45 112.088 176.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 18.5 mt -136.49 136.17 48.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.299 0.571 . . . . 71.22 111.005 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.789 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 19.1 tpt85 -107.86 119.23 38.87 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 115.266 -0.879 . . . . 74.22 110.179 -176.591 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.639 ' HB3' ' HE1' ' A' ' 38' ' ' TYR . 99.5 m-85 -96.2 -171.3 2.28 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.223 -0.444 . . . . 74.51 110.872 -179.474 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.424 HH11 ' HD3' ' A' ' 21' ' ' ARG . 1.5 mmp_? -91.39 -72.2 0.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.981 -0.554 . . . . 74.3 111.466 -178.395 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -128.2 63.85 0.61 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.494 -0.86 . . . . 71.12 112.157 -176.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.482 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 75.4 mt -125.15 121.29 33.79 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.895 0.379 . . . . 64.52 110.832 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.5 t -83.01 -179.47 7.45 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 115.664 -0.698 . . . . 75.32 109.944 176.238 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 10.3 mmt180 -76.09 -174.56 2.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.093 0.473 . . . . 73.32 111.817 -175.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 24.4 t70 55.2 27.69 10.04 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.121 -0.945 . . . . 65.24 110.169 -175.447 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.458 ' O ' HG22 ' A' ' 28' ' ' VAL . 26.9 mt-30 -134.03 -164.32 1.48 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.519 -0.764 . . . . 73.2 110.271 -178.097 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 27' ' ' GLN . 4.6 m 53.59 15.0 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 124.757 1.223 . . . . 75.0 112.765 178.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -89.46 -19.11 25.51 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.419 -0.355 . . . . 75.45 110.687 178.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.47 86.96 0.81 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.008 0.432 . . . . 75.11 111.037 178.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.5 mt -128.45 106.88 15.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 108.855 -0.794 . . . . 74.23 108.855 176.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -73.14 -40.0 65.26 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.261 -0.427 . . . . 73.04 111.855 -172.276 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.457 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 81.9 m-85 -135.55 116.9 14.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.085 0.469 . . . . 74.1 111.929 -176.267 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -81.58 135.78 49.28 Favored Pre-proline 0 C--N 1.321 -0.633 0 N-CA-C 108.883 -0.784 . . . . 73.11 108.883 169.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.36 153.3 61.34 Favored 'Trans proline' 0 C--O 1.238 0.481 0 C-N-CA 122.327 2.018 . . . . 63.24 112.929 -176.068 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.482 HG21 ' HA ' ' A' ' 59' ' ' LEU . 2.9 p -68.19 85.72 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.351 0 CA-C-O 122.04 0.924 . . . . 72.31 109.629 174.781 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 16.6 t70 175.32 -39.46 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.86 -1.064 . . . . 75.53 109.666 -170.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.639 ' HE1' ' HB3' ' A' ' 20' ' ' TYR . 0.2 OUTLIER -74.02 126.86 31.43 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.987 -1.006 . . . . 75.21 112.405 -171.979 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.541 ' HG2' ' HB2' ' A' ' 57' ' ' LYS . 40.9 mt-10 -107.84 127.52 53.79 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.427 -0.806 . . . . 74.51 109.278 172.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 44.8 pt -110.0 142.82 21.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.005 0.431 . . . . 75.23 111.441 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.789 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.3 tt0 -107.54 147.87 29.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.706 -0.679 . . . . 74.33 109.918 176.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.438 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 94.4 m-85 -103.83 101.88 11.69 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.406 -0.361 . . . . 75.13 110.046 177.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -95.2 170.45 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.714 0.292 . . . . 73.24 111.006 -178.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.557 ' HB2' HG12 ' A' ' 50' ' ' VAL . 26.1 t -93.27 179.8 5.3 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.644 -0.502 . . . . 63.13 109.644 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 2.0 tmt_? -78.59 93.37 4.83 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.847 0.356 . . . . 71.44 110.932 -175.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.49 -136.16 13.35 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.742 -0.742 . . . . 62.21 112.445 175.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 8.0 mp0 -89.89 14.88 10.95 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.269 0.557 . . . . 71.43 109.736 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.475 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 15.7 mmt-85 -88.56 137.53 32.24 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.53 -0.759 . . . . 74.21 109.203 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -105.46 165.06 11.4 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.054 0.454 . . . . 74.41 110.614 176.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.557 HG12 ' HB2' ' A' ' 44' ' ' CYS . 34.2 m -121.87 136.09 59.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.793 -0.639 . . . . 70.42 109.486 177.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.418 HG11 ' O ' ' A' ' 51' ' ' VAL . 7.2 p -93.0 95.75 5.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 122.275 1.036 . . . . 74.5 109.018 174.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.87 171.8 33.22 Favored Glycine 0 N--CA 1.443 -0.863 0 CA-C-N 114.567 -1.197 . . . . 74.22 111.375 -178.547 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -82.28 42.22 1.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.594 2.196 . . . . 70.42 110.387 175.641 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.601 ' HD3' ' HG3' ' A' ' 41' ' ' GLU . 0.0 OUTLIER -75.13 86.39 2.39 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.796 0.807 . . . . 75.22 112.871 -170.394 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.459 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.4 p -161.85 126.5 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-N 114.903 -1.044 . . . . 75.54 109.026 169.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.459 ' HD3' ' O ' ' A' ' 55' ' ' VAL . 22.4 mmt180 -134.89 128.43 32.59 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.28 -0.418 . . . . 75.13 110.076 -178.19 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.541 ' HB2' ' HG2' ' A' ' 39' ' ' GLU . 38.4 ttpt -107.23 136.4 47.13 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 116.05 -0.523 . . . . 74.13 110.031 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 43.8 t -77.53 134.35 38.32 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.203 -0.453 . . . . 74.1 110.179 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.482 ' HA ' HG21 ' A' ' 36' ' ' VAL . 97.8 mt -102.9 -178.74 3.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.127 -0.488 . . . . 75.32 109.811 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.42 51.76 0.9 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.328 0.585 . . . . 70.22 111.029 179.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -160.65 170.67 20.36 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.279 -0.873 . . . . 74.35 108.926 177.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -85.46 38.53 3.01 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 120.721 -0.752 . . . . 74.22 113.802 -173.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.3 m -156.67 151.71 26.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 117.229 0.515 . . . . 64.31 110.537 178.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 71.2 m95 -79.29 167.91 20.27 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.179 -0.464 . . . . 74.23 109.975 178.068 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 17.8 p -55.19 -65.29 0.61 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.043 0.449 . . . . 73.14 111.99 -177.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -125.85 97.19 5.03 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.976 -0.75 . . . . 71.12 108.976 176.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 27.0 ttt -100.69 76.25 1.79 Allowed 'General case' 0 C--N 1.321 -0.663 0 C-N-CA 118.817 -1.153 . . . . 72.34 110.7 -178.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -171.76 89.89 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.276 -1.329 . . . . 75.03 108.568 160.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.5 m -135.46 119.41 13.07 Favored Pre-proline 0 C--N 1.317 -0.832 0 C-N-CA 119.758 -0.777 . . . . 74.5 112.004 -172.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -83.1 106.85 1.44 Allowed 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.867 2.378 . . . . 64.4 112.576 178.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.475 ' HB2' HG21 ' A' ' 50' ' ' VAL . 12.1 p -95.39 105.41 17.37 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.042 0.449 . . . . 73.32 110.813 178.634 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.8 ptp85 -89.18 125.18 34.95 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.159 -0.473 . . . . 75.3 110.955 -177.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.412 ' HA ' HG13 ' A' ' 50' ' ' VAL . 59.7 m -72.44 122.06 20.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.123 -0.49 . . . . 74.22 110.572 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 85.8 t -137.56 136.15 46.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.763 -0.458 . . . . 73.23 109.763 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.247 0.939 0 CA-C-O 119.079 -0.486 . . . . 74.41 110.669 -179.093 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.448 -0.556 0 CA-C-O 121.238 0.542 . . . . 74.12 110.579 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -101.85 99.13 9.32 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.696 -0.853 . . . . 74.03 108.696 174.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -160.64 164.34 34.55 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.535 -0.84 . . . . 60.54 112.573 -174.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.429 ' N ' ' SG ' ' A' ' 58' ' ' CYS . 35.2 m -105.06 150.41 25.01 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 109.49 -0.559 . . . . 72.14 109.49 -178.612 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.4 pt20 -73.44 179.67 3.91 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.113 0.483 . . . . 64.22 110.607 177.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.4 tt -88.24 140.64 15.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.755 -0.657 . . . . 73.43 110.201 -178.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 57.3 mt -96.25 135.91 28.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.388 -0.369 . . . . 72.13 110.937 -176.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.5 t-80 -89.29 130.94 42.14 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 115.928 -0.578 . . . . 73.31 109.485 178.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -57.86 109.99 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.795 2.33 . . . . 71.32 112.393 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -75.67 -59.09 0.04 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.437 0 C-N-CA 122.691 2.261 . . . . 72.42 112.298 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.43 ' C ' ' H ' ' A' ' 16' ' ' GLY . 5.5 t-105 -91.59 -178.43 5.08 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.102 -0.499 . . . . 72.24 109.851 -176.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -71.29 15.64 0.12 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 112.237 0.458 . . . . 74.13 112.237 -177.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.517 ' HA2' ' H ' ' A' ' 45' ' ' ARG . . . -96.65 -147.56 22.83 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.508 -0.637 . . . . 71.54 111.508 175.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.74 -170.56 30.84 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 121.071 -0.585 . . . . 73.45 111.78 179.524 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.1 mt -129.38 134.89 62.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.093 0.473 . . . . 71.22 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -106.77 135.41 48.34 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.44 -0.8 . . . . 74.22 109.931 -178.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.492 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 91.4 m-85 -101.02 -171.35 1.98 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.305 -0.407 . . . . 74.51 110.017 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 21.6 mtt180 -80.17 -44.49 19.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.814 0.34 . . . . 74.3 111.435 -179.014 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.38 61.61 0.24 Allowed Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.583 -0.818 . . . . 71.12 112.13 -178.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 80.7 mt -120.81 116.76 25.82 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.79 0.329 . . . . 64.52 110.456 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.3 t -78.89 -179.44 6.6 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.636 -0.711 . . . . 75.32 109.734 175.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.452 ' C ' ' H ' ' A' ' 27' ' ' GLN . 99.4 mtt180 -67.8 -172.75 0.29 Allowed 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.741 0.305 . . . . 73.32 111.479 -177.418 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 30.5 t70 68.09 -42.79 0.47 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.629 0.772 . . . . 65.24 110.882 -171.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.561 ' O ' HG22 ' A' ' 28' ' ' VAL . 20.4 mt-30 -71.87 -179.49 2.72 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.328 -0.396 . . . . 73.2 110.806 176.594 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.561 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.8 m 57.45 9.88 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 124.559 1.144 . . . . 75.0 112.347 -178.609 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -82.71 -17.73 43.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.272 0.558 . . . . 75.45 109.896 175.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -161.9 94.53 0.94 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.091 -0.959 . . . . 75.11 110.191 179.127 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 57.8 mt -131.98 130.27 61.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.578 -0.737 . . . . 74.23 109.42 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -89.95 -51.87 5.26 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.379 -0.373 . . . . 73.04 111.301 -175.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -134.72 131.48 37.69 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.296 0.569 . . . . 74.1 112.133 -175.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -97.59 117.42 65.39 Favored Pre-proline 0 C--N 1.322 -0.622 0 N-CA-C 107.876 -1.157 . . . . 73.11 107.876 168.201 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -56.52 147.13 71.23 Favored 'Trans proline' 0 C--O 1.237 0.434 0 C-N-CA 123.205 2.603 . . . . 63.24 113.373 -173.196 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.55 83.87 0.05 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.323 0 CA-C-O 121.85 0.833 . . . . 72.31 110.771 177.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.8 t70 168.45 -33.46 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 114.578 -1.192 . . . . 75.53 108.942 -176.484 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.492 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 14.1 t80 -67.56 141.11 56.95 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.324 -0.853 . . . . 75.21 110.636 -177.227 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.429 ' HG2' ' HE2' ' A' ' 57' ' ' LYS . 10.5 mt-10 -125.36 142.15 51.67 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.53 -0.759 . . . . 74.51 110.083 -177.029 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.631 HG13 ' HB2' ' A' ' 56' ' ' ARG . 46.4 pt -130.65 169.31 21.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.715 0.293 . . . . 75.23 110.694 178.748 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -128.52 139.24 52.41 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.189 -0.459 . . . . 74.33 110.981 -178.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.401 ' O ' HG23 ' A' ' 50' ' ' VAL . 5.1 m-30 -83.65 102.32 12.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.765 -0.652 . . . . 75.13 110.349 176.161 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.9 m -108.31 170.93 2.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 120.898 0.38 . . . . 73.24 110.909 -178.535 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.666 ' HB2' HG11 ' A' ' 50' ' ' VAL . 10.5 t -109.64 143.63 39.12 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.06 -0.718 . . . . 63.13 109.06 175.012 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . 0.517 ' H ' ' HA2' ' A' ' 16' ' ' GLY . 75.7 ttt180 -77.58 133.68 38.42 Favored 'General case' 0 N--CA 1.44 -0.974 0 CA-C-N 115.029 -0.987 . . . . 71.44 110.588 -172.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.13 -149.84 18.81 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.799 -0.715 . . . . 62.21 111.688 -178.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -93.66 16.08 14.72 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.406 0.622 . . . . 71.43 109.646 176.799 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.644 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 40.8 mmm-85 -89.22 118.94 29.28 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.317 -0.856 . . . . 74.21 109.169 178.074 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.497 ' HB2' ' HA ' ' A' ' 75' ' ' ARG . 48.8 mt-10 -95.92 171.37 8.68 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.991 -0.374 . . . . 74.41 109.991 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.666 HG11 ' HB2' ' A' ' 44' ' ' CYS . 5.5 m -129.86 126.25 62.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.948 0.404 . . . . 70.42 111.545 -177.593 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.585 HG12 ' HB ' ' A' ' 74' ' ' VAL . 3.5 p -96.37 95.76 5.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 108.463 -0.94 . . . . 74.5 108.463 167.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.51 172.73 33.01 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.373 -0.83 . . . . 74.22 112.497 -173.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -75.27 52.98 3.31 Favored 'Trans proline' 0 N--CA 1.462 -0.335 0 C-N-CA 123.012 2.475 . . . . 70.42 110.734 173.341 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 19.4 pttp -72.11 89.54 1.15 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.512 -0.767 . . . . 75.22 111.863 -174.163 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -160.54 132.24 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.821 -0.627 . . . . 75.54 110.574 176.581 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.631 ' HB2' HG13 ' A' ' 40' ' ' ILE . 55.1 mmt-85 -138.35 126.8 23.24 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.933 -0.576 . . . . 75.13 110.195 176.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.429 ' HE2' ' HG2' ' A' ' 39' ' ' GLU . 37.3 ttmt -125.08 137.48 54.2 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.007 -0.738 . . . . 74.13 109.007 175.149 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 7' ' ' CYS . 53.3 t -81.31 144.17 31.7 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.894 0.378 . . . . 74.1 111.073 -176.117 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 94.4 mt -100.95 -179.07 3.94 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.716 -0.675 . . . . 75.32 111.005 -178.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.92 -20.58 60.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.185 0.517 . . . . 70.22 110.374 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -101.43 169.1 9.1 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.397 -0.82 . . . . 74.35 109.313 175.283 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.75 60.56 3.36 Favored Glycine 0 CA--C 1.518 0.253 0 C-N-CA 120.83 -0.7 . . . . 74.22 113.28 -175.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 49.4 m -158.63 144.31 16.65 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 122.789 0.436 . . . . 64.31 109.939 177.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 75.7 m95 -81.19 161.65 23.93 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.75 -0.463 . . . . 74.23 109.75 177.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 p -52.9 -39.14 62.47 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.221 0.823 . . . . 73.14 113.221 -174.152 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -134.03 140.86 46.95 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 110.186 -0.302 . . . . 71.12 110.186 178.588 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 50.5 mtt -144.36 80.01 1.63 Allowed 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.367 -0.533 . . . . 72.34 111.453 167.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -168.6 88.85 0.22 Allowed 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.416 -0.957 . . . . 75.03 108.416 156.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.8 m -155.83 90.11 2.83 Favored Pre-proline 0 C--N 1.317 -0.823 0 C-N-CA 120.283 -0.567 . . . . 74.5 111.283 -172.076 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -74.18 90.28 1.0 Allowed 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.689 2.26 . . . . 64.4 110.396 172.407 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.2 t -69.26 116.93 10.25 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.985 -0.552 . . . . 73.32 110.724 -175.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.0 ptp180 -79.57 130.67 35.6 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.534 -0.757 . . . . 75.3 110.409 179.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.524 ' HA ' HG12 ' A' ' 50' ' ' VAL . 73.6 m -81.02 97.89 7.71 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.309 0.576 . . . . 74.22 110.013 178.261 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.585 ' HB ' HG12 ' A' ' 51' ' ' VAL . 59.6 t -136.68 117.99 18.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.184 -0.916 . . . . 73.23 108.653 177.773 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.497 ' HA ' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.556 -0.735 . . . . 74.41 111.161 -176.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.45 -0.438 0 N-CA-C 109.74 -0.467 . . . . 74.12 109.74 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -75.43 99.44 4.17 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.222 -0.445 . . . . 74.03 110.617 -178.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.56 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -159.91 152.56 23.44 Favored Glycine 0 N--CA 1.441 -1.002 0 C-N-CA 120.572 -0.823 . . . . 60.54 112.694 -179.144 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.1 m -86.52 158.76 19.47 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 110.13 -0.322 . . . . 72.14 110.13 178.137 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.8 pt20 -88.86 -177.19 5.44 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.052 0.453 . . . . 64.22 111.192 -179.106 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.509 HD13 ' HB ' ' A' ' 31' ' ' ILE . 60.7 mt -87.49 138.16 19.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.615 -0.72 . . . . 73.43 110.487 -177.715 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 64.8 mt -99.78 131.06 47.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.18 -0.464 . . . . 72.13 109.929 178.199 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -76.55 126.09 86.59 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.868 -0.605 . . . . 73.31 110.171 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_endo -58.51 112.69 1.26 Allowed 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.72 2.28 . . . . 71.32 111.921 179.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -74.87 -87.6 0.0 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.393 0 C-N-CA 122.481 2.121 . . . . 72.42 113.091 -176.059 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 27.8 t-105 -101.37 -177.84 3.56 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.999 -0.371 . . . . 72.24 109.999 -178.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 56.7 mm-40 -39.81 101.93 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.746 0.818 . . . . 74.13 111.98 177.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.424 ' HA2' ' HA ' ' A' ' 44' ' ' CYS . . . 171.32 -167.6 40.72 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.39 -0.91 . . . . 71.54 112.637 177.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -159.17 -170.52 23.81 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.989 -0.844 . . . . 73.45 110.989 178.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.436 HG21 ' HB ' ' A' ' 40' ' ' ILE . 16.6 mt -135.05 135.59 52.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.449 0.642 . . . . 71.22 111.835 -177.06 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.452 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 55.6 ttm-85 -99.49 138.56 36.4 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.081 -0.963 . . . . 74.22 110.578 178.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.508 ' HB3' ' HE1' ' A' ' 38' ' ' TYR . 89.1 m-85 -110.76 -168.03 1.26 Allowed 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.132 -0.321 . . . . 74.51 110.132 177.565 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -62.04 -57.82 10.2 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 120.88 0.371 . . . . 74.3 110.487 178.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -161.55 67.76 0.24 Allowed Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 121.055 -0.593 . . . . 71.12 111.872 178.489 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 92.7 mt -118.12 126.77 52.91 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.965 0.412 . . . . 64.52 110.949 -179.18 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.8 t -85.03 -176.71 6.32 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.387 -0.824 . . . . 75.32 110.46 176.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.428 ' C ' ' H ' ' A' ' 27' ' ' GLN . 29.9 ptt180 -61.94 -173.51 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 115.923 -0.58 . . . . 73.32 111.818 -177.116 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.9 t70 65.06 -46.14 0.35 Allowed 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 123.894 0.878 . . . . 65.24 112.263 -179.116 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.551 ' O ' HG21 ' A' ' 28' ' ' VAL . 18.4 mt-30 -68.96 -169.76 0.19 Allowed 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 123.079 0.552 . . . . 73.2 111.257 -179.284 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.551 HG21 ' O ' ' A' ' 27' ' ' GLN . 3.2 m 55.61 15.66 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 124.264 1.026 . . . . 75.0 111.832 -178.206 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 40.1 pttt -81.42 -14.33 57.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.829 -0.623 . . . . 75.45 110.066 175.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -161.21 117.48 2.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.601 -0.727 . . . . 75.11 110.436 177.154 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.509 ' HB ' HD13 ' A' ' 9' ' ' ILE . 42.1 mt -138.6 152.71 25.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 109.105 -0.702 . . . . 74.23 109.105 179.161 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -105.07 -65.09 1.07 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.673 0.273 . . . . 73.04 110.646 179.018 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.56 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 96.5 m-85 -140.73 128.61 21.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.412 -0.358 . . . . 74.1 110.704 -179.203 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -88.08 119.59 70.43 Favored Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 109.158 -0.682 . . . . 73.11 109.158 175.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.01 152.47 43.76 Favored 'Trans proline' 0 C--O 1.236 0.402 0 C-N-CA 122.899 2.4 . . . . 63.24 113.29 -176.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.456 HG21 ' HA ' ' A' ' 59' ' ' LEU . 3.5 p -62.63 94.93 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-O 121.707 0.765 . . . . 72.31 111.023 178.235 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.0 t70 173.85 -43.41 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.574 -1.194 . . . . 75.53 109.36 -177.424 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.508 ' HE1' ' HB3' ' A' ' 20' ' ' TYR . 5.3 m-85 -50.41 123.01 7.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.039 -0.982 . . . . 75.21 112.596 -175.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.583 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 35.2 mt-10 -114.18 100.01 8.05 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.849 -1.069 . . . . 74.51 108.575 172.349 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.567 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 34.7 pt -90.7 143.64 10.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.142 0.496 . . . . 75.23 111.3 -175.772 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.452 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 42.5 tt0 -109.82 136.49 49.05 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.481 -0.781 . . . . 74.33 110.269 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.42 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 95.5 m-85 -85.43 100.58 11.97 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 116.216 -0.447 . . . . 75.13 110.051 175.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.3 m -100.98 163.39 3.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.045 -0.525 . . . . 73.24 110.199 179.389 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.803 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 3.4 t -90.38 147.07 23.68 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 107.93 -1.137 . . . . 63.13 107.93 173.112 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -59.72 108.61 0.77 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.17 0.509 . . . . 71.44 110.942 -170.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.21 -137.21 13.13 Favored Glycine 0 N--CA 1.448 -0.563 0 CA-C-N 115.703 -0.68 . . . . 62.21 112.086 178.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.413 ' H ' ' CD ' ' A' ' 47' ' ' GLU . 0.5 OUTLIER -101.22 33.53 2.85 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.301 0.572 . . . . 71.43 110.278 -179.274 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.803 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 30.1 mmm180 -89.22 145.49 25.37 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.786 -0.643 . . . . 74.21 109.974 179.682 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.589 ' HB2' ' HB3' ' A' ' 75' ' ' ARG . 43.1 mt-10 -91.57 148.96 21.9 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.231 0.538 . . . . 74.41 112.201 -174.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.726 HG13 ' HB2' ' A' ' 44' ' ' CYS . 11.6 m -138.64 150.46 23.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.368 -0.833 . . . . 70.42 110.131 178.083 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -135.65 97.35 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 122.019 0.914 . . . . 74.5 109.558 170.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.42 173.09 32.26 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-N 114.462 -1.245 . . . . 74.22 110.6 -177.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.456 ' HG2' HG23 ' A' ' 69' ' ' THR . 69.9 Cg_endo -77.17 57.38 5.81 Favored 'Trans proline' 0 C--O 1.235 0.358 0 C-N-CA 122.068 1.845 . . . . 70.42 110.733 176.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.42 ' HB2' ' H ' ' A' ' 42' ' ' TYR . 20.9 pttp -76.4 87.04 3.16 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.383 -0.826 . . . . 75.22 111.608 -173.08 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -162.57 128.54 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.397 -0.82 . . . . 75.54 109.906 172.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.583 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 26.9 mmt180 -130.1 123.69 31.0 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.622 -0.51 . . . . 75.13 109.622 175.281 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.7 ttmm -105.08 122.7 46.42 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.537 -0.542 . . . . 74.13 109.537 178.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.5 t -74.56 142.51 44.71 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.309 -0.405 . . . . 74.1 110.635 -179.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.456 ' HA ' HG21 ' A' ' 36' ' ' VAL . 94.7 mt -128.64 -179.24 4.95 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.844 -0.616 . . . . 75.32 109.516 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.02 59.27 2.13 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.367 0.603 . . . . 70.22 111.654 -177.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -160.52 165.05 31.55 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.802 -0.814 . . . . 74.35 108.802 175.328 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -80.73 40.27 2.45 Favored Glycine 0 CA--C 1.517 0.214 0 C-N-CA 120.662 -0.78 . . . . 74.22 113.067 -175.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 27.6 t -161.84 163.32 29.4 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.234 -0.654 . . . . 64.31 109.234 -178.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 52.8 m95 -97.16 -179.8 4.65 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 110.033 -0.358 . . . . 74.23 110.033 -176.486 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -56.35 -24.73 46.02 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 112.776 0.658 . . . . 73.14 112.776 -176.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.521 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 11.2 t70 -160.71 137.02 8.54 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.384 -0.599 . . . . 71.12 109.384 178.304 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 65.9 mtt -130.38 77.0 1.76 Allowed 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.436 -0.906 . . . . 72.34 110.611 164.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -170.83 88.63 0.12 Allowed 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 108.855 -0.795 . . . . 75.03 108.855 157.482 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.456 HG23 ' HG2' ' A' ' 53' ' ' PRO . 4.7 m -153.5 107.32 2.56 Favored Pre-proline 0 C--N 1.317 -0.809 0 C-N-CA 120.817 -0.353 . . . . 74.5 110.681 -176.867 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -70.21 95.52 0.59 Allowed 'Trans proline' 0 N--CA 1.462 -0.329 0 C-N-CA 122.694 2.263 . . . . 64.4 112.031 178.002 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 m -78.36 109.44 12.51 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.175 0.512 . . . . 73.32 109.775 177.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.1 ptt180 -97.51 130.6 44.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.574 -0.739 . . . . 75.3 112.085 -172.204 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.499 ' HA ' HG11 ' A' ' 50' ' ' VAL . 81.2 m -82.66 118.25 23.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.665 -0.698 . . . . 74.22 109.824 175.03 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 p -156.36 136.44 4.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 121.082 0.467 . . . . 73.23 110.309 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.589 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 16.1 ptm180 . . . . . 0 C--O 1.244 0.765 0 CA-C-N 115.693 -0.685 . . . . 74.41 109.626 -178.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.6 m . . . . . 0 N--CA 1.451 -0.395 0 N-CA-C 109.8 -0.444 . . . . 74.12 109.8 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -112.98 98.42 7.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.911 -0.586 . . . . 74.03 109.614 -177.512 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.73 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -162.2 152.57 22.94 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.492 -0.861 . . . . 60.54 112.7 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 60.7 m -90.11 147.53 23.56 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.985 -0.376 . . . . 72.14 109.985 176.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -85.81 -179.54 6.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.777 0.322 . . . . 64.22 110.892 -179.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.554 HD11 ' HB ' ' A' ' 31' ' ' ILE . 56.3 mt -88.16 130.62 37.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.939 -0.573 . . . . 73.43 110.313 176.831 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 68.7 mt -73.25 136.18 26.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.745 -0.661 . . . . 72.13 110.239 179.032 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.6 t-80 -68.81 138.1 90.39 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 115.989 -0.55 . . . . 73.31 109.936 -178.03 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_exo -40.97 118.87 0.72 Allowed 'Trans proline' 0 C--N 1.351 0.694 0 C-N-CA 123.716 2.944 . . . . 71.32 113.826 -176.723 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.448 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 81.7 Cg_endo -87.5 -149.02 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.128 2.552 . . . . 72.42 112.728 -179.51 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.448 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 9.1 t-105 -75.15 -179.01 4.14 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.69 -0.686 . . . . 72.24 110.516 -177.773 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -46.03 100.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 123.234 0.613 . . . . 74.13 112.172 177.267 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.13 -156.86 28.99 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.331 -0.708 . . . . 71.54 111.331 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.85 -171.23 24.4 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.562 -0.828 . . . . 73.45 111.925 178.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.63 131.44 66.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.651 0.738 . . . . 71.22 111.531 -178.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.678 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 7.9 tpm_? -96.92 104.56 16.58 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 114.298 -1.319 . . . . 74.22 110.064 -178.285 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.454 ' HA ' HG22 ' A' ' 40' ' ' ILE . 97.7 m-85 -80.5 -171.46 3.07 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.519 -0.309 . . . . 74.51 110.187 177.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.7 ttm180 -78.96 -65.35 1.01 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.67 0.272 . . . . 74.3 110.411 -178.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -136.16 37.4 1.89 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.423 -0.894 . . . . 71.12 112.275 -178.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.445 HD11 HG13 ' A' ' 28' ' ' VAL . 80.6 mt -102.52 119.73 39.32 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.925 0.393 . . . . 64.52 111.359 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.4 t -94.64 -177.2 4.13 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.712 -0.676 . . . . 75.32 109.662 175.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 77.5 mtt180 -66.88 -173.43 0.24 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.047 0.451 . . . . 73.32 111.627 -176.466 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.0 t0 59.07 19.24 7.1 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 122.029 0.919 . . . . 65.24 110.183 -177.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 23.4 mt-30 -140.35 -165.19 1.86 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.887 -1.052 . . . . 73.2 109.971 -178.39 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.445 HG13 HD11 ' A' ' 23' ' ' LEU . 11.5 m 49.44 24.01 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.312 1.045 . . . . 75.0 112.29 178.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -88.54 -22.38 23.61 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.789 -0.641 . . . . 75.45 110.758 -179.318 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.42 101.07 0.6 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.884 -0.598 . . . . 75.11 110.434 176.6 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.554 ' HB ' HD11 ' A' ' 9' ' ' ILE . 69.0 mt -127.99 138.24 55.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.155 -0.683 . . . . 74.23 109.155 177.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -79.83 -58.25 3.26 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.864 0.364 . . . . 73.04 110.543 -176.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.73 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 82.2 m-85 -139.27 138.4 36.73 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.971 -0.559 . . . . 74.1 110.953 -176.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.95 142.65 32.35 Favored Pre-proline 0 C--N 1.322 -0.593 0 N-CA-C 109.11 -0.7 . . . . 73.11 109.11 172.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -61.33 161.68 22.73 Favored 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 122.648 2.232 . . . . 63.24 112.727 -179.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 p -68.11 143.62 15.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.763 -0.653 . . . . 72.31 110.886 -178.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.5 t70 68.13 19.73 9.13 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.663 0.744 . . . . 75.53 110.942 -178.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -78.12 132.02 37.49 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.742 -0.836 . . . . 75.21 108.742 173.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -123.1 138.28 54.71 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.461 -0.336 . . . . 74.51 110.404 -175.147 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.607 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 14.5 pt -129.88 150.17 34.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.807 -0.633 . . . . 75.23 110.684 -177.69 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.678 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 37.7 tt0 -115.44 152.3 33.17 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.946 -0.57 . . . . 74.33 110.551 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -100.11 101.87 13.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.256 -0.429 . . . . 75.13 110.854 178.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.3 m -94.55 155.02 3.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 120.727 0.299 . . . . 73.24 110.244 177.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 9.8 t -90.91 -179.3 5.45 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.405 -0.591 . . . . 63.13 109.405 -178.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . 0.45 ' HA ' ' HD3' ' A' ' 45' ' ' ARG . 2.3 mmt180 -81.5 153.99 26.53 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.744 -0.382 . . . . 71.44 111.342 -179.167 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.12 -138.44 24.47 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 110.856 -0.898 . . . . 62.21 110.856 -174.175 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -111.08 19.83 18.04 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.475 0.655 . . . . 71.43 109.389 174.545 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.547 ' HA ' ' HD2' ' A' ' 75' ' ' ARG . 7.4 mmm180 -88.9 150.9 22.64 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.269 -0.878 . . . . 74.21 109.556 -177.408 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.437 ' H ' ' HB3' ' A' ' 75' ' ' ARG . 37.6 mt-10 -120.99 170.44 9.51 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.868 0.366 . . . . 74.41 111.005 -171.277 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 22.7 m -118.3 150.5 20.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.202 -0.453 . . . . 70.42 110.903 -177.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.649 HG11 ' HB ' ' A' ' 74' ' ' VAL . 6.4 p -113.01 96.76 4.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 122.156 0.979 . . . . 74.5 109.116 170.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.55 173.4 33.01 Favored Glycine 0 N--CA 1.442 -0.966 0 CA-C-N 114.834 -1.076 . . . . 74.22 110.874 -177.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.469 ' HG2' HG23 ' A' ' 69' ' ' THR . 47.9 Cg_endo -72.39 60.32 3.3 Favored 'Trans proline' 0 CA--C 1.529 0.26 0 C-N-CA 122.191 1.927 . . . . 70.42 110.304 170.008 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.555 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 32.1 pttt -73.62 89.52 1.74 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.139 -0.937 . . . . 75.22 111.209 -175.411 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.9 p -160.08 132.71 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.727 -0.67 . . . . 75.54 110.51 178.183 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.607 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 24.2 mmt180 -125.68 114.96 19.36 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.185 -0.672 . . . . 75.13 109.185 173.126 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 41.9 tptt -102.54 116.95 33.64 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.459 -0.791 . . . . 74.13 109.914 -176.147 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . 0.55 ' HB2' ' CZ3' ' A' ' 64' ' ' TRP . 49.3 t -87.91 124.5 33.74 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.137 -0.483 . . . . 74.1 110.074 177.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.404 HD12 HG21 ' A' ' 65' ' ' THR . 41.9 mt -105.08 -177.55 3.4 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.814 -0.63 . . . . 75.32 109.43 176.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -56.63 -32.29 65.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.091 0.472 . . . . 70.22 110.431 174.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -81.06 132.08 35.34 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.44 -0.578 . . . . 74.35 109.44 172.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -77.82 64.1 3.38 Favored Glycine 0 N--CA 1.451 -0.313 0 N-CA-C 114.299 0.479 . . . . 74.22 114.299 -171.164 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 58.2 m -157.14 142.27 17.11 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.539 -0.541 . . . . 64.31 109.539 172.278 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.55 ' CZ3' ' HB2' ' A' ' 58' ' ' CYS . 23.1 m95 -78.19 124.4 28.02 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.05 -0.722 . . . . 74.23 109.05 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.404 HG21 HD12 ' A' ' 59' ' ' LEU . 17.2 p -75.62 33.03 0.11 Allowed 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 114.358 1.244 . . . . 73.14 114.358 -167.805 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -160.75 13.91 0.11 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.865 0.364 . . . . 71.12 110.056 176.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 26.1 ttt -76.65 78.94 3.3 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-O 121.875 0.845 . . . . 72.34 112.416 -165.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -169.68 88.88 0.17 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 114.382 -1.281 . . . . 75.03 107.783 159.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.469 HG23 ' HG2' ' A' ' 53' ' ' PRO . 0.7 OUTLIER -152.78 117.86 2.93 Favored Pre-proline 0 C--N 1.318 -0.801 0 C-N-CA 120.19 -0.604 . . . . 74.5 111.345 -169.751 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -78.72 100.53 1.37 Allowed 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.885 2.39 . . . . 64.4 111.318 174.399 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.7 p -79.39 116.83 19.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.051 0.453 . . . . 73.32 111.112 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.8 ptp180 -89.47 129.2 36.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.729 -0.668 . . . . 75.3 111.285 -177.223 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 62.3 m -82.88 105.5 13.94 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.718 -0.475 . . . . 74.22 109.718 178.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.649 ' HB ' HG11 ' A' ' 51' ' ' VAL . 49.1 t -128.33 84.27 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 121.072 0.463 . . . . 73.23 109.76 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.547 ' HD2' ' HA ' ' A' ' 48' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.751 0 N-CA-C 108.54 -0.911 . . . . 74.41 108.54 -178.728 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.3 m . . . . . 0 N--CA 1.451 -0.422 0 N-CA-C 108.354 -0.98 . . . . 74.12 108.354 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -78.2 99.88 6.41 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.275 0.56 . . . . 74.03 111.195 -172.145 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.59 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -159.47 146.96 13.64 Favored Glycine 0 N--CA 1.44 -1.054 0 CA-C-N 115.239 -0.891 . . . . 60.54 111.678 179.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.9 m -92.88 142.93 26.77 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 110.05 -0.352 . . . . 72.14 110.05 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -76.02 -177.62 3.99 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.884 0.374 . . . . 64.22 111.055 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 61.3 mt -87.38 137.66 20.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.057 -0.52 . . . . 73.43 111.176 -175.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 27.5 mt -84.13 156.57 3.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.5 -0.773 . . . . 72.13 110.217 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -82.68 141.47 44.77 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.64 -0.255 . . . . 73.31 110.67 -177.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.54 131.32 21.3 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.74 2.293 . . . . 71.32 112.462 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.452 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 76.2 Cg_endo -87.6 -140.1 0.02 OUTLIER 'Trans proline' 0 CA--C 1.533 0.43 0 C-N-CA 123.176 2.584 . . . . 72.42 112.393 -179.691 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.528 ' HD1' ' H ' ' A' ' 15' ' ' GLU . 1.9 t90 -67.54 -179.44 1.08 Allowed 'General case' 0 CA--C 1.537 0.452 0 CA-C-N 116.071 -0.513 . . . . 72.24 109.641 178.248 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.528 ' H ' ' HD1' ' A' ' 14' ' ' TRP . 29.3 mm-40 -43.2 102.38 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 123.629 0.772 . . . . 74.13 112.886 -176.343 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.08 -154.82 25.66 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 110.224 -1.15 . . . . 71.54 110.224 -177.285 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.95 -171.36 37.61 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.224 -0.989 . . . . 73.45 112.064 176.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.7 mt -111.54 128.88 67.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.745 0.783 . . . . 71.22 111.279 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . 0.729 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 9.2 tpt180 -96.76 127.3 42.61 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.581 -1.191 . . . . 74.22 108.966 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.509 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 77.4 m-85 -91.02 -172.46 3.34 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.341 -0.544 . . . . 74.51 110.021 178.647 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 21' ' ' ARG . 18.9 ttt85 -80.69 -62.78 1.57 Allowed 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.602 -0.439 . . . . 74.3 110.753 -172.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -146.98 57.02 0.5 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.693 -0.765 . . . . 71.12 111.986 177.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 93.2 mt -119.41 139.5 51.92 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.975 0.417 . . . . 64.52 111.246 -176.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.8 t -86.47 173.11 9.84 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.928 -0.578 . . . . 75.32 109.49 174.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.493 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 31.7 ptt180 -79.83 -171.52 2.91 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 121.12 -0.232 . . . . 73.32 110.581 -177.135 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.493 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 12.6 t70 72.77 -38.9 0.43 Allowed 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 109.178 -0.675 . . . . 65.24 109.178 -168.663 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.496 ' O ' HG22 ' A' ' 28' ' ' VAL . 24.0 mt-30 -83.33 -169.12 2.38 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.602 -0.888 . . . . 73.2 108.602 167.096 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.496 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.2 m 55.6 9.54 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 C-N-CA 124.219 1.008 . . . . 75.0 113.593 174.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -92.99 -29.13 16.0 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.076 0.465 . . . . 75.45 109.827 176.541 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.36 91.8 1.63 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.766 -0.652 . . . . 75.11 110.561 177.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.9 mt -115.79 135.7 55.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.706 -0.679 . . . . 74.23 109.209 177.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 15.5 m120 -72.94 -59.76 2.56 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.684 0.278 . . . . 73.04 110.925 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.59 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 74.4 m-85 -131.88 129.9 40.94 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.819 0.343 . . . . 74.1 111.171 -177.163 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.403 ' HA ' ' HD2' ' A' ' 35' ' ' PRO . 3.7 mm? -90.96 113.05 56.81 Favored Pre-proline 0 C--N 1.322 -0.619 0 N-CA-C 108.181 -1.044 . . . . 73.11 108.181 169.026 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 34' ' ' LEU . 11.6 Cg_endo -53.61 156.27 11.88 Favored 'Trans proline' 0 C--O 1.234 0.28 0 C-N-CA 123.432 2.755 . . . . 63.24 113.549 -172.516 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.517 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 13.3 p -54.78 147.44 3.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.484 -0.78 . . . . 72.31 111.098 178.861 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.517 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 15.0 m-20 79.23 5.05 2.23 Favored 'General case' 0 N--CA 1.467 0.425 0 C-N-CA 123.654 0.782 . . . . 75.53 111.571 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.509 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 24.3 t80 -82.75 144.97 29.82 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.808 0.337 . . . . 75.21 110.241 178.406 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.525 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 37.0 mt-10 -135.25 138.16 43.27 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.916 -0.584 . . . . 74.51 110.283 -177.374 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.635 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 20.3 pt -125.76 158.94 34.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 120.805 0.335 . . . . 75.23 110.77 177.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.729 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 49.8 tt0 -116.16 149.86 38.37 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.859 -0.61 . . . . 74.33 110.976 -174.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.408 ' HE2' ' CG ' ' A' ' 56' ' ' ARG . 8.2 m-85 -94.33 102.01 13.99 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.28 -0.418 . . . . 75.13 110.185 175.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.583 HG13 HH11 ' A' ' 19' ' ' ARG . 18.2 m -108.42 156.43 8.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.109 0.481 . . . . 73.24 111.63 -177.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.526 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 5.2 t -96.35 158.47 15.42 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.193 -1.04 . . . . 63.13 108.193 178.437 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -65.59 117.72 8.47 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.26 0.467 . . . . 71.44 112.26 -174.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.34 -137.32 13.65 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.587 -0.733 . . . . 62.21 111.807 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -98.79 22.67 9.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.864 0.84 . . . . 71.43 109.077 174.223 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.582 ' HD2' ' OXT' ' A' ' 75' ' ' ARG . 10.7 mmm180 -88.18 134.19 33.84 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.642 -1.163 . . . . 74.21 109.184 -178.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.58 ' H ' ' HB3' ' A' ' 75' ' ' ARG . 46.4 mt-10 -116.66 170.1 8.85 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 120.98 0.419 . . . . 74.41 110.924 -179.06 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.539 HG13 ' HA ' ' A' ' 73' ' ' CYS . 28.9 m -116.85 149.53 19.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.405 -0.816 . . . . 70.42 109.206 174.199 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -106.12 95.09 3.52 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 122.035 0.922 . . . . 74.5 108.681 170.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.74 172.58 33.8 Favored Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 114.607 -1.179 . . . . 74.22 111.667 -176.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.494 ' HG2' ' CG2' ' A' ' 69' ' ' THR . 56.5 Cg_endo -73.72 53.1 2.68 Favored 'Trans proline' 0 CA--C 1.532 0.413 0 C-N-CA 122.494 2.129 . . . . 70.42 110.713 171.076 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.402 ' HG3' ' O ' ' A' ' 54' ' ' LYS . 48.2 pttt -69.03 91.34 0.48 Allowed 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 114.805 -1.089 . . . . 75.22 111.948 -173.436 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.2 p -160.83 132.11 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.553 0.692 . . . . 75.54 110.912 175.057 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.635 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 42.9 mmt180 -121.23 113.82 20.5 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.528 -0.76 . . . . 75.13 109.128 172.402 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -108.78 129.78 55.38 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.155 -0.475 . . . . 74.13 110.084 -177.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 52.4 t -96.72 113.86 25.45 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.26 -0.427 . . . . 74.1 110.244 178.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.541 ' HB2' ' OD1' ' A' ' 61' ' ' ASN . 35.9 mt -96.45 -176.05 3.51 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.121 -0.696 . . . . 75.32 109.121 177.439 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -71.4 55.81 0.23 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-O 121.214 0.53 . . . . 70.22 111.18 177.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.541 ' OD1' ' HB2' ' A' ' 59' ' ' LEU . 4.4 p-10 -160.34 167.64 26.99 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.706 -0.85 . . . . 74.35 108.706 178.914 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -91.79 47.15 2.73 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.488 -0.863 . . . . 74.22 113.62 -171.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 38.9 m -160.59 136.33 8.22 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 117.041 0.42 . . . . 64.31 110.797 178.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . 0.42 ' HB2' ' CG ' ' A' ' 67' ' ' MET . 63.0 m95 -71.41 123.22 21.88 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.02 -1.104 . . . . 74.23 108.02 171.628 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.504 HG21 ' CD1' ' A' ' 59' ' ' LEU . 13.6 p -77.23 38.23 0.22 Allowed 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 115.074 1.509 . . . . 73.14 115.074 -164.329 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -162.51 20.16 0.09 Allowed 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 120.413 -0.515 . . . . 71.12 111.818 173.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' MET . . . . . 0.42 ' CG ' ' HB2' ' A' ' 64' ' ' TRP . 58.3 mtm -76.28 79.53 3.05 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 119.311 -0.956 . . . . 72.34 112.412 -168.793 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -169.76 89.27 0.17 Allowed 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 107.495 -1.298 . . . . 75.03 107.495 161.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.494 ' CG2' ' HG2' ' A' ' 53' ' ' PRO . 2.8 m -147.2 124.63 5.84 Favored Pre-proline 0 C--N 1.321 -0.65 0 C-N-CA 119.595 -0.842 . . . . 74.5 112.387 -168.265 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . 0.458 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 9.6 Cg_endo -89.21 90.49 0.38 Allowed 'Trans proline' 0 N--CA 1.451 -0.989 0 C-N-CA 123.388 2.725 . . . . 64.4 111.62 174.471 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.1 m -90.31 118.17 29.6 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.263 -0.426 . . . . 73.32 110.149 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.5 ptp180 -89.15 119.47 29.68 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.054 -0.521 . . . . 75.3 111.334 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.539 ' HA ' HG13 ' A' ' 50' ' ' VAL . 41.1 t -72.52 105.5 4.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.068 -0.515 . . . . 74.22 110.243 179.155 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.5 t -135.69 100.53 2.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.899 -0.591 . . . . 73.23 110.503 -177.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.582 ' OXT' ' HD2' ' A' ' 48' ' ' ARG . 15.1 ttm180 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 118.451 -0.785 . . . . 74.41 109.558 176.159 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.8 m . . . . . 0 N--CA 1.453 -0.289 0 CA-C-O 120.847 0.356 . . . . 74.12 111.212 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -121.67 103.8 9.15 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.497 -0.557 . . . . 74.03 109.497 176.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -159.87 171.15 36.16 Favored Glycine 0 N--CA 1.443 -0.894 0 C-N-CA 120.481 -0.866 . . . . 60.54 112.86 -175.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 58.3 m -106.47 148.06 28.62 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.843 -0.429 . . . . 72.14 109.843 -178.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -84.21 -179.9 7.32 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.001 0.429 . . . . 64.22 111.192 -178.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.506 HD13 ' H ' ' A' ' 31' ' ' ILE . 42.1 mt -88.68 143.67 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.596 -0.729 . . . . 73.43 110.343 177.686 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.411 HG22 ' H ' ' A' ' 11' ' ' HIS . 12.1 mt -98.91 166.66 2.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.705 -0.68 . . . . 72.13 109.968 -177.117 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . 0.411 ' H ' HG22 ' A' ' 10' ' ' ILE . 76.5 m-70 -89.71 138.66 27.96 Favored Pre-proline 0 C--N 1.325 -0.458 0 N-CA-C 109.899 -0.408 . . . . 73.31 109.899 178.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -72.36 106.34 2.05 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.29 1.993 . . . . 71.32 111.384 174.512 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -88.85 -74.96 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 123.054 2.502 . . . . 72.42 113.566 -174.114 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 32.9 t-105 -100.29 -176.46 3.23 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.19 -0.459 . . . . 72.24 109.834 -175.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -49.85 -29.36 7.92 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 122.896 0.478 . . . . 74.13 111.539 178.092 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.25 102.3 1.35 Allowed Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.715 -0.755 . . . . 71.54 111.813 176.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -88.98 -169.74 44.81 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 121.148 -0.549 . . . . 73.45 112.052 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 28.4 mt -116.11 137.95 48.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.795 0.807 . . . . 71.22 112.337 -174.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -116.59 132.78 56.59 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 114.287 -1.324 . . . . 74.22 108.825 -179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.567 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 56.0 m-85 -92.33 -172.03 2.98 Favored 'General case' 0 C--N 1.318 -0.772 0 C-N-CA 120.703 -0.399 . . . . 74.51 110.604 -179.578 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.506 ' HB2' ' O ' ' A' ' 39' ' ' GLU . 7.4 tmm_? -112.64 -42.21 3.68 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.126 0.489 . . . . 74.3 110.287 -171.75 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -146.09 56.54 0.52 Allowed Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 121.008 -0.615 . . . . 71.12 111.716 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.707 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 40.9 mt -143.15 141.68 31.25 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.946 0.403 . . . . 64.52 110.555 179.263 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -99.65 -178.95 4.04 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.691 -0.686 . . . . 75.32 110.197 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.512 ' C ' ' H ' ' A' ' 27' ' ' GLN . 33.0 ptt180 -66.55 -172.63 0.17 Allowed 'General case' 0 C--O 1.234 0.243 0 CA-C-N 116.051 -0.522 . . . . 73.32 111.409 -179.411 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.6 t70 70.24 -38.67 0.42 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.318 0.647 . . . . 65.24 111.043 -176.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.533 ' O ' HG21 ' A' ' 28' ' ' VAL . 17.7 mt-30 -94.73 -153.25 0.38 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.605 -0.725 . . . . 73.2 109.847 176.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.533 HG21 ' O ' ' A' ' 27' ' ' GLN . 3.6 m 57.8 13.16 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 124.584 1.154 . . . . 75.0 112.939 176.349 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 56.7 mtpt -106.1 -38.42 6.29 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.928 0.394 . . . . 75.45 110.218 176.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.22 86.71 2.25 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.032 -0.531 . . . . 75.11 110.704 177.071 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.506 ' H ' HD13 ' A' ' 9' ' ' ILE . 70.7 mt -134.68 121.98 37.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 N-CA-C 108.521 -0.918 . . . . 74.23 108.521 176.524 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -84.1 -24.46 30.31 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 113.229 0.826 . . . . 73.04 113.229 -170.334 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 -140.15 109.42 6.16 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 113.06 0.763 . . . . 74.1 113.06 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.45 112.18 48.32 Favored Pre-proline 0 C--N 1.323 -0.548 0 N-CA-C 107.77 -1.196 . . . . 73.11 107.77 165.166 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -58.85 152.0 60.7 Favored 'Trans proline' 0 N--CA 1.474 0.362 0 C-N-CA 123.057 2.504 . . . . 63.24 113.63 -170.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.47 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 2.5 p -61.48 94.92 0.08 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 115.559 -0.746 . . . . 72.31 110.58 175.697 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.47 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 18.3 t70 160.92 -29.9 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 114.488 -1.233 . . . . 75.53 108.367 -174.815 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.707 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 6.4 t80 -73.72 146.66 44.24 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.625 -1.171 . . . . 75.21 111.818 -173.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.506 ' O ' ' HB2' ' A' ' 21' ' ' ARG . 27.0 mt-10 -125.74 150.47 47.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.5 -0.773 . . . . 74.51 109.883 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.607 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 38.3 pt -132.99 149.31 31.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.948 0.404 . . . . 75.23 110.879 174.17 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.43 ' HG3' ' HD3' ' A' ' 54' ' ' LYS . 41.3 tt0 -118.64 171.44 8.19 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.476 -0.783 . . . . 74.33 109.396 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . 0.403 ' N ' ' HG2' ' A' ' 41' ' ' GLU . 73.1 m-85 -113.65 100.86 8.8 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.869 0.366 . . . . 75.13 111.176 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.6 m -96.98 132.1 42.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.013 0.435 . . . . 73.24 109.94 175.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.502 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 39.1 t -89.16 148.51 23.61 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.265 0.555 . . . . 63.13 110.941 -174.085 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -59.11 133.62 56.26 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.579 -1.191 . . . . 71.44 110.702 -176.239 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 86.29 -119.24 5.09 Favored Glycine 0 N--CA 1.444 -0.823 0 N-CA-C 110.67 -0.972 . . . . 62.21 110.67 -173.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -141.5 83.1 1.85 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.411 0.624 . . . . 71.43 109.812 173.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.615 ' HB3' ' HB2' ' A' ' 73' ' ' CYS . 42.7 mmt180 -132.89 130.05 39.18 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.434 -0.803 . . . . 74.21 110.081 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -86.25 139.69 30.8 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 109.958 -0.386 . . . . 74.41 109.958 178.04 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.44 HG12 ' HB3' ' A' ' 73' ' ' CYS . 30.5 m -97.82 127.32 50.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.224 -0.444 . . . . 70.42 111.096 -178.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.8 p -98.68 94.08 3.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 122.246 1.022 . . . . 74.5 109.287 174.042 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -156.82 171.06 34.29 Favored Glycine 0 N--CA 1.44 -1.059 0 CA-C-N 114.485 -1.234 . . . . 74.22 111.292 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -73.19 55.07 2.88 Favored 'Trans proline' 0 CA--C 1.531 0.341 0 C-N-CA 122.553 2.168 . . . . 70.42 110.255 168.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.572 ' O ' ' HD2' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -72.04 93.54 1.41 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.899 0.856 . . . . 75.22 112.718 -170.878 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.492 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.2 p -161.57 128.75 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 115.527 -0.76 . . . . 75.54 109.862 170.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.607 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 29.1 mmt180 -132.83 115.62 15.52 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.303 -0.629 . . . . 75.13 109.303 177.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.414 ' O ' HG22 ' A' ' 65' ' ' THR . 37.2 ttmt -115.02 136.91 52.61 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 108.986 -0.746 . . . . 74.13 108.986 178.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.7 t -73.78 139.95 45.54 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.826 0.346 . . . . 74.1 110.856 -176.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.509 ' C ' ' H ' ' A' ' 61' ' ' ASN . 87.3 mt -96.57 -179.53 4.64 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.779 -0.646 . . . . 75.32 110.548 -178.372 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.47 36.98 0.26 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-O 121.877 0.846 . . . . 70.22 109.304 174.128 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.509 ' H ' ' C ' ' A' ' 59' ' ' LEU . 0.9 OUTLIER -157.33 155.99 31.58 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.408 -1.269 . . . . 74.35 108.226 -172.37 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -74.45 50.31 2.06 Favored Glycine 0 CA--C 1.52 0.368 0 C-N-CA 121.114 -0.565 . . . . 74.22 113.215 -176.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 55.6 m -159.32 149.86 19.41 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 123.088 0.555 . . . . 64.31 109.518 178.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -83.53 175.19 9.96 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 110.171 -0.307 . . . . 74.23 110.171 -176.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.414 HG22 ' O ' ' A' ' 57' ' ' LYS . 1.4 p -50.56 -48.21 57.5 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.444 0.535 . . . . 73.14 112.444 -177.55 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -153.86 140.45 18.89 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.673 -0.862 . . . . 71.12 108.673 179.512 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' MET . . . . . 0.406 ' HE2' HD11 ' A' ' 10' ' ' ILE . 23.1 mmt -139.59 79.54 1.72 Allowed 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 120.235 -0.586 . . . . 72.34 110.557 168.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -168.48 87.93 0.21 Allowed 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 108.032 -1.099 . . . . 75.03 108.032 163.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.4 ' CB ' HH22 ' A' ' 56' ' ' ARG . 1.1 m -152.42 128.96 5.38 Favored Pre-proline 0 C--N 1.319 -0.751 0 C-N-CA 120.433 -0.507 . . . . 74.5 111.064 -169.82 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -74.99 69.29 5.58 Favored 'Trans proline' 0 CA--C 1.532 0.398 0 C-N-CA 122.772 2.315 . . . . 64.4 112.596 177.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 8.5 p -78.28 121.11 23.99 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.748 -0.464 . . . . 73.32 109.748 175.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.2 ptp85 -133.28 141.62 48.09 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.8 0.333 . . . . 75.3 111.624 -174.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.615 ' HB2' ' HB3' ' A' ' 48' ' ' ARG . 1.8 p -107.58 104.22 13.71 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.819 -0.628 . . . . 74.22 110.373 178.219 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.82 9.02 5.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.443 0.639 . . . . 73.23 110.755 -174.626 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.6 ttp180 . . . . . 0 C--O 1.246 0.901 0 CA-C-O 118.659 -0.686 . . . . 74.41 109.998 178.371 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.716 0 N-CA-C 111.677 -0.569 . . . . 72.35 111.677 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -75.33 142.14 26.53 Favored 'Trans proline' 0 C--O 1.235 0.369 0 C-N-CA 122.778 2.319 . . . . 73.25 112.279 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 40.0 p -102.98 113.33 26.7 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.333 -0.394 . . . . 75.23 110.411 177.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.9 m -79.97 98.86 7.36 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.306 0.574 . . . . 74.12 109.631 177.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -114.16 97.91 6.64 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.844 -0.617 . . . . 74.03 109.756 -177.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -163.16 171.1 38.82 Favored Glycine 0 N--CA 1.439 -1.113 0 C-N-CA 120.728 -0.749 . . . . 60.54 112.223 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 26.0 m -104.32 153.53 20.92 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.74 -0.467 . . . . 72.14 109.74 177.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -89.6 -178.86 5.66 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.927 0.394 . . . . 64.22 111.13 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.52 HD11 ' HB ' ' A' ' 31' ' ' ILE . 26.6 mt -87.98 120.55 37.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.928 -0.578 . . . . 73.43 110.022 177.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 63.1 mt -74.95 138.38 21.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.212 -0.904 . . . . 72.13 110.525 -178.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 81.1 m-70 -80.54 132.09 59.45 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 116.118 -0.492 . . . . 73.31 109.768 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.404 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.6 Cg_exo -51.05 113.18 0.98 Allowed 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 123.319 2.679 . . . . 71.32 112.838 -178.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 4.7 Cg_exo -76.51 -80.0 0.01 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.43 0 C-N-CA 122.881 2.388 . . . . 72.42 112.278 -178.615 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.0 t-105 -101.39 -178.09 3.63 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.602 -0.518 . . . . 72.24 109.602 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -58.71 100.54 0.07 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.133 0.492 . . . . 74.13 111.086 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.496 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . 175.81 -158.29 25.11 Favored Glycine 0 N--CA 1.443 -0.847 0 C-N-CA 120.854 -0.688 . . . . 71.54 112.009 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -161.1 -171.28 26.88 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 111.296 -0.721 . . . . 73.45 111.296 178.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.9 mt -125.68 131.4 72.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.792 0.806 . . . . 71.22 111.804 -178.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.764 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 23.3 tpp180 -93.51 110.65 22.23 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.317 -1.31 . . . . 74.22 109.935 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -90.95 -171.52 3.03 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.778 0.323 . . . . 74.51 110.358 177.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.451 ' NH2' ' HB2' ' A' ' 39' ' ' GLU . 97.8 mtt180 -109.72 -86.58 0.52 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.446 -0.343 . . . . 74.3 110.894 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -88.4 48.06 3.54 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 121.18 -0.533 . . . . 71.12 112.702 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 91.8 mt -137.91 133.41 33.77 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.09 -0.337 . . . . 64.52 110.09 178.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.4 t -95.99 179.55 5.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.745 -0.465 . . . . 75.32 109.745 174.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' GLN . 63.9 mtm-85 -79.54 -171.38 2.76 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.581 -0.282 . . . . 73.32 110.962 -177.438 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.471 ' O ' ' HE2' ' A' ' 29' ' ' LYS . 34.7 t70 68.5 -27.03 0.14 Allowed 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 123.329 0.652 . . . . 65.24 110.928 -170.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ARG . 19.4 mt-30 -90.33 -146.07 0.18 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.703 -0.681 . . . . 73.2 110.028 175.169 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 27' ' ' GLN . 4.8 m 54.26 19.75 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.509 1.123 . . . . 75.0 112.733 177.293 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.471 ' HE2' ' O ' ' A' ' 26' ' ' ASP . 49.9 mtmt -101.41 -74.85 0.61 Allowed 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.823 -0.436 . . . . 75.45 109.823 175.145 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.11 89.53 4.06 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.448 0.642 . . . . 75.11 111.253 178.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.52 ' HB ' HD11 ' A' ' 9' ' ' ILE . 64.9 mt -125.44 138.86 53.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.255 -0.884 . . . . 74.23 108.634 175.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 37.4 m-80 -74.39 -70.2 0.41 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.636 0.255 . . . . 73.04 110.864 -177.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -141.55 139.43 33.2 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.017 0.437 . . . . 74.1 111.301 -177.026 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -78.85 147.0 69.74 Favored Pre-proline 0 C--N 1.321 -0.646 0 N-CA-C 109.079 -0.711 . . . . 73.11 109.079 172.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -61.47 151.36 80.26 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.684 2.256 . . . . 63.24 112.26 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.2 p -61.13 138.24 22.22 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 CA-C-N 116.388 -0.369 . . . . 72.31 110.132 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 16.8 t70 61.97 75.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.817 0.818 . . . . 75.53 110.421 -172.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -133.28 124.68 27.75 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 107.464 -1.31 . . . . 75.21 107.464 175.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.7 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 39.5 mt-10 -111.98 124.9 53.38 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.099 0.476 . . . . 74.51 111.537 -172.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.476 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 32.6 pt -116.0 167.28 9.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.122 -0.944 . . . . 75.23 111.019 -177.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.764 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 44.7 tt0 -125.05 146.2 49.55 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.855 -0.611 . . . . 74.33 110.542 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.474 ' HE2' ' HG3' ' A' ' 56' ' ' ARG . 25.8 m-85 -97.67 103.07 14.97 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.323 -0.399 . . . . 75.13 110.762 178.078 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 32.7 m -97.58 157.45 3.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 120.825 0.345 . . . . 73.24 111.055 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.538 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 48.3 t -89.53 158.42 17.68 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-N 116.037 -0.529 . . . . 63.13 109.608 178.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.496 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 31.3 ttt180 -58.13 121.24 10.21 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.858 -1.065 . . . . 71.44 111.873 -169.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 93.61 -128.95 9.67 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.874 -0.891 . . . . 62.21 110.874 -176.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -114.95 37.98 3.31 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.5 0.667 . . . . 71.43 110.009 172.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.538 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 27.3 mmt180 -88.84 146.44 24.96 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.434 -0.803 . . . . 74.21 109.356 178.194 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -103.46 166.18 10.58 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.04 0.448 . . . . 74.41 110.848 -177.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.539 HG12 ' HA ' ' A' ' 73' ' ' CYS . 35.4 m -132.97 145.96 33.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 115.921 -0.581 . . . . 70.42 109.835 177.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.6 p -108.18 95.81 4.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 122.195 0.998 . . . . 74.5 109.42 172.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.82 172.82 33.23 Favored Glycine 0 N--CA 1.443 -0.893 0 CA-C-N 114.47 -1.241 . . . . 74.22 110.801 -178.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.77 67.27 5.74 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.773 1.649 . . . . 70.42 110.552 172.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.538 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 31.9 pttt -84.32 87.65 7.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.36 -0.836 . . . . 75.22 111.532 -173.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -160.89 129.18 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.262 -0.881 . . . . 75.54 109.286 174.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.7 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 28.7 mmt85 -133.18 109.95 9.8 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 116.531 -0.304 . . . . 75.13 110.584 -177.261 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -96.66 118.6 33.48 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.822 -0.436 . . . . 74.13 109.822 178.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.8 t -62.62 132.74 53.37 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.919 -0.582 . . . . 74.1 110.954 177.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 90.2 mt -97.42 -178.58 4.2 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.873 -0.603 . . . . 75.32 110.61 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.19 -1.87 34.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.04 0.448 . . . . 70.22 111.043 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -119.63 169.78 9.78 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.41 -0.589 . . . . 74.35 109.41 177.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -75.33 62.35 2.65 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.079 -0.582 . . . . 74.22 113.35 -175.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 27.6 t -170.28 160.55 7.82 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.674 -0.491 . . . . 64.31 109.674 176.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 58.5 m95 -97.03 174.63 6.67 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.482 -0.562 . . . . 74.23 109.482 -177.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -49.89 -75.4 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.382 0 N-CA-C 112.815 0.672 . . . . 73.14 112.815 -176.026 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -115.89 94.76 4.81 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.377 -0.601 . . . . 71.12 109.377 176.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 13.5 tpt -93.42 75.35 4.49 Favored 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 119.192 -1.003 . . . . 72.34 110.253 -177.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -172.65 96.73 0.14 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.585 -1.188 . . . . 75.03 108.235 159.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.6 m -142.07 108.91 5.87 Favored Pre-proline 0 C--N 1.317 -0.846 0 C-N-CA 119.671 -0.812 . . . . 74.5 111.714 -172.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -77.56 93.84 1.08 Allowed 'Trans proline' 0 N--CA 1.458 -0.582 0 C-N-CA 122.62 2.213 . . . . 64.4 111.834 176.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 35.8 p -81.34 107.34 14.04 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.054 -0.521 . . . . 73.32 110.368 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -78.84 120.07 22.94 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.245 0.545 . . . . 75.3 110.477 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.539 ' HA ' HG12 ' A' ' 50' ' ' VAL . 24.0 t -72.32 110.1 6.51 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.559 -0.746 . . . . 74.22 109.799 -178.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 98.4 t -134.37 126.13 48.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.973 -0.558 . . . . 73.23 110.293 -174.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.229 -0.891 . . . . 74.41 109.79 178.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.738 0 N-CA-C 111.844 -0.502 . . . . 72.35 111.844 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -68.23 93.08 0.4 Allowed 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.696 2.264 . . . . 73.25 111.353 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 2.5 p -78.76 99.58 6.74 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.742 -0.663 . . . . 75.23 111.417 -175.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.3 m -118.53 100.67 7.6 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.693 -0.685 . . . . 74.12 109.499 176.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 49.1 mm-40 -83.11 109.19 16.94 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.986 -0.552 . . . . 74.03 110.538 -177.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.583 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -150.26 141.54 8.86 Favored Glycine 0 N--CA 1.443 -0.895 0 C-N-CA 120.737 -0.744 . . . . 60.54 112.365 -178.193 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 37.4 m -88.96 154.03 20.55 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 110.109 -0.33 . . . . 72.14 110.109 178.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -86.89 177.76 7.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.017 0.437 . . . . 64.22 111.681 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.55 HD11 ' HB ' ' A' ' 31' ' ' ILE . 72.0 mt -87.79 118.9 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.527 -0.76 . . . . 73.43 109.982 177.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 44.2 mt -71.25 145.36 12.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.904 -0.589 . . . . 72.13 110.923 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -81.02 137.78 49.7 Favored Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 109.587 -0.523 . . . . 73.31 109.587 174.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -64.11 116.47 3.73 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.457 2.105 . . . . 71.32 111.634 176.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.75 -85.01 0.01 OUTLIER 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.541 2.161 . . . . 72.42 112.134 -178.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.6 t-105 -101.97 -178.08 3.6 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.843 -0.799 . . . . 72.24 108.843 173.371 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -50.67 100.9 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.189 0.518 . . . . 74.13 111.761 178.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.81 -147.29 5.65 Favored Glycine 0 N--CA 1.444 -0.83 0 CA-C-N 115.485 -0.78 . . . . 71.54 111.325 178.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -178.5 -170.86 41.13 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 120.869 -0.682 . . . . 73.45 111.42 177.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mt -123.11 133.11 70.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.518 0.675 . . . . 71.22 111.325 -179.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.904 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 7.2 tpt180 -96.31 132.85 41.37 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.634 -1.166 . . . . 74.22 108.448 177.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.511 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 97.1 m-85 -103.77 -171.53 1.95 Allowed 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 120.417 -0.513 . . . . 74.51 111.636 -173.278 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.602 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 49.1 ttt180 -113.36 -44.04 3.28 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.576 -0.738 . . . . 74.3 110.263 -170.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -148.03 40.01 0.97 Allowed Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.647 -0.706 . . . . 71.12 111.968 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.943 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 84.7 mt -122.21 130.07 52.85 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.832 0.349 . . . . 64.52 110.504 179.463 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 11.0 t -90.72 -179.33 5.5 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.939 -0.573 . . . . 75.32 110.158 177.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 5.6 ptm180 -73.66 -173.49 1.49 Allowed 'General case' 0 C--O 1.234 0.286 0 CA-C-O 120.978 0.418 . . . . 73.32 112.125 -174.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 31.1 t70 56.17 12.77 1.03 Allowed 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 115.353 -0.839 . . . . 65.24 111.609 -174.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.478 ' O ' HG22 ' A' ' 28' ' ' VAL . 25.5 mt-30 -124.47 -162.69 1.1 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.849 -0.614 . . . . 73.2 109.538 -179.636 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.3 m 56.92 13.83 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.452 1.101 . . . . 75.0 112.892 174.53 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 53.0 pttt -96.34 -27.6 14.87 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.021 0.438 . . . . 75.45 109.856 176.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.49 95.29 2.42 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.74 -0.664 . . . . 75.11 110.412 177.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.55 ' HB ' HD11 ' A' ' 9' ' ' ILE . 62.7 mt -132.21 148.12 32.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 108.707 -0.849 . . . . 74.23 108.707 177.578 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.3 m-80 -75.77 -69.04 0.51 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.031 0.443 . . . . 73.04 109.967 -178.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.583 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 87.4 m-85 -141.44 150.15 41.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.872 -0.604 . . . . 74.1 110.713 -177.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -91.54 136.6 26.53 Favored Pre-proline 0 C--N 1.323 -0.55 0 N-CA-C 109.403 -0.591 . . . . 73.11 109.403 174.237 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.88 143.41 95.86 Favored 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 122.866 2.377 . . . . 63.24 113.055 -176.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.435 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 3.6 p -70.11 84.41 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 CA-C-O 122.031 0.919 . . . . 72.31 110.643 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.435 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 35.2 t70 167.2 -27.51 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.493 -1.23 . . . . 75.53 108.766 -174.553 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.943 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 4.2 t80 -64.86 137.38 57.73 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 114.681 -1.145 . . . . 75.21 111.713 -174.692 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.602 ' H ' ' HD2' ' A' ' 21' ' ' ARG . 41.4 mt-10 -120.29 139.16 53.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.928 -0.578 . . . . 74.51 109.593 177.239 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.469 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 37.3 pt -126.2 162.72 29.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.121 0.486 . . . . 75.23 112.019 -178.673 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.904 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.9 tt0 -124.57 153.69 41.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.231 -0.895 . . . . 74.33 109.811 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.587 ' O ' HG11 ' A' ' 50' ' ' VAL . 97.2 m-85 -101.9 101.59 12.04 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.439 0.162 . . . . 75.13 110.996 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.477 HG12 ' HB2' ' A' ' 19' ' ' ARG . 15.5 m -97.13 170.96 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 120.861 0.363 . . . . 73.24 111.24 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 26.5 t -114.73 171.15 7.81 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.015 -0.539 . . . . 63.13 109.922 -176.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 14.4 mmm180 -72.57 110.67 7.11 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 120.798 0.332 . . . . 71.44 110.547 179.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.17 -108.83 3.02 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.717 -0.754 . . . . 62.21 112.073 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -155.11 49.07 0.56 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.185 0.517 . . . . 71.43 111.269 -177.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.559 ' CB ' ' HB2' ' A' ' 73' ' ' CYS . 17.3 mmt180 -88.31 145.71 25.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.152 -0.477 . . . . 74.21 110.072 177.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.4 mm-40 -80.62 112.88 18.4 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.005 0.431 . . . . 74.41 109.977 176.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.587 HG11 ' O ' ' A' ' 42' ' ' TYR . 3.8 p -92.67 115.73 32.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.293 0.568 . . . . 70.42 110.769 -178.471 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.7 p -100.61 97.3 5.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 122.125 0.964 . . . . 74.5 110.613 178.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.91 170.68 32.56 Favored Glycine 0 N--CA 1.441 -0.989 0 CA-C-N 114.71 -1.132 . . . . 74.22 110.284 175.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -71.96 67.0 3.26 Favored 'Trans proline' 0 C--O 1.235 0.334 0 C-N-CA 122.047 1.831 . . . . 70.42 110.529 170.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.504 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 41.5 pttt -84.75 87.3 7.3 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.552 0.691 . . . . 75.22 112.086 -170.277 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.516 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.6 p -161.05 127.05 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.556 -0.747 . . . . 75.54 109.226 171.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.557 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 28.3 mmt180 -133.15 112.85 12.09 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.103 -0.332 . . . . 75.13 110.103 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.42 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 38.6 ttmt -101.52 123.92 46.34 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 109.375 -0.602 . . . . 74.13 109.375 179.368 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.3 t -67.3 119.52 12.3 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.233 -0.44 . . . . 74.1 110.246 -179.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 80.1 mt -101.28 -179.93 4.18 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.897 -0.592 . . . . 75.32 110.369 -177.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.81 59.5 3.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.129 0.49 . . . . 70.22 111.15 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.4 p-10 -161.78 167.4 24.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.328 -0.851 . . . . 74.35 108.786 175.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -82.83 36.93 2.66 Favored Glycine 0 CA--C 1.521 0.409 0 C-N-CA 120.699 -0.762 . . . . 74.22 113.45 -174.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.4 m -156.43 157.24 35.18 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.93 0.365 . . . . 64.31 110.176 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 87.3 m95 -83.36 179.17 7.75 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.53 -0.305 . . . . 74.23 110.464 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.8 m -56.74 -53.22 60.24 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 116.025 -0.534 . . . . 73.14 112.053 -176.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -148.03 129.66 15.03 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.514 -0.55 . . . . 71.12 109.514 -177.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 56.1 mtm -133.64 78.25 1.76 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 119.21 -0.996 . . . . 72.34 110.759 172.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -168.82 89.16 0.21 Allowed 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 106.942 -1.503 . . . . 75.03 106.942 162.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 3.6 m -139.82 121.28 9.65 Favored Pre-proline 0 C--N 1.312 -1.023 0 C-N-CA 119.837 -0.745 . . . . 74.5 111.984 -165.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -77.24 58.13 6.12 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.094 2.529 . . . . 64.4 111.635 177.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.4 p -78.76 101.29 7.5 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.121 -0.49 . . . . 73.32 110.355 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.422 HH11 ' HD2' ' A' ' 72' ' ' ARG . 7.5 ptp85 -91.55 142.02 28.1 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.981 -0.554 . . . . 75.3 110.044 -178.123 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.559 ' HB2' ' CB ' ' A' ' 48' ' ' ARG . 2.0 p -106.65 99.91 9.46 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.427 0.632 . . . . 74.22 109.681 173.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.6 p -121.0 153.68 24.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.341 -0.845 . . . . 73.23 111.011 -170.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 65.8 ttt-85 . . . . . 0 C--O 1.245 0.862 0 CA-C-O 118.582 -0.723 . . . . 74.41 109.701 176.299 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.711 0 N-CA-C 111.842 -0.503 . . . . 72.35 111.842 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -79.02 2.21 8.49 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.793 2.329 . . . . 73.25 112.469 -177.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 7.2 p -79.46 99.54 7.27 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.625 -0.716 . . . . 75.23 111.515 -176.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 21.7 m -105.31 96.15 6.32 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.421 -0.585 . . . . 74.12 109.421 173.399 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -123.83 112.74 17.65 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.905 -0.588 . . . . 74.03 109.491 -177.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.651 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.5 163.35 33.96 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.576 -0.821 . . . . 60.54 111.759 179.05 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 83.9 m -84.03 134.29 34.63 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 110.062 -0.347 . . . . 72.14 110.062 177.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -77.39 179.37 6.49 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.172 0.51 . . . . 64.22 111.609 -176.183 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.526 HD11 ' HB ' ' A' ' 31' ' ' ILE . 59.5 mt -88.07 119.1 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.191 -0.913 . . . . 73.43 110.295 178.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.6 mt -82.69 131.5 33.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.853 -0.612 . . . . 72.13 109.984 178.25 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 83.7 m-70 -84.07 117.94 70.0 Favored Pre-proline 0 C--N 1.323 -0.557 0 N-CA-C 109.59 -0.522 . . . . 73.31 109.59 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.53 110.1 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 122.985 2.457 . . . . 71.32 112.153 -178.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -69.2 -56.81 0.14 Allowed 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.924 2.416 . . . . 72.42 112.295 -176.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.403 ' HA ' ' CE3' ' A' ' 14' ' ' TRP . 6.0 t-105 -100.07 -177.8 3.65 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.868 -0.605 . . . . 72.24 109.807 -176.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -68.7 -5.05 18.15 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.858 0.361 . . . . 74.13 111.329 178.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.07 121.92 5.76 Favored Glycine 0 N--CA 1.444 -0.784 0 N-CA-C 110.832 -0.907 . . . . 71.54 110.832 171.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -95.72 -170.7 35.72 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.529 -0.844 . . . . 73.45 112.447 -175.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.494 HD13 HD12 ' A' ' 40' ' ' ILE . 27.3 mt -115.45 129.25 72.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.632 0.73 . . . . 71.22 111.124 -178.426 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -97.21 144.54 26.93 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.597 -1.183 . . . . 74.22 109.593 -178.071 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -115.88 -170.73 1.84 Allowed 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.346 -0.613 . . . . 74.51 109.346 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 -115.6 -53.84 2.56 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.5 -0.48 . . . . 74.3 110.309 178.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -110.19 26.43 13.66 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.727 -0.749 . . . . 71.12 112.634 -177.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.66 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 95.9 mt -119.86 121.91 40.12 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.888 -0.412 . . . . 64.52 109.888 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.41 ' O ' ' HB2' ' A' ' 27' ' ' GLN . 15.2 t -105.71 -178.79 3.75 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.779 -0.646 . . . . 75.32 112.17 -171.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 49.6 mtp180 -57.49 125.33 22.39 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.359 -0.837 . . . . 73.32 111.603 177.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.402 ' O ' ' HD2' ' A' ' 29' ' ' LYS . 33.7 t70 92.91 3.96 0.06 Allowed 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.735 1.214 . . . . 65.24 110.353 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.443 ' O ' HG22 ' A' ' 28' ' ' VAL . 10.4 mm100 -94.57 -178.88 4.7 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 108.925 -0.769 . . . . 73.2 108.925 170.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.443 HG13 HD13 ' A' ' 23' ' ' LEU . 3.7 m 52.36 18.78 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 124.238 1.015 . . . . 75.0 113.064 178.707 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.402 ' HD2' ' O ' ' A' ' 26' ' ' ASP . 18.1 ptmt -82.62 -19.47 38.28 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.789 -0.449 . . . . 75.45 109.789 178.67 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -168.03 107.81 0.54 Allowed 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.602 -0.726 . . . . 75.11 110.477 175.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.526 ' HB ' HD11 ' A' ' 9' ' ' ILE . 55.6 mt -138.14 151.86 25.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.155 -0.683 . . . . 74.23 109.155 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -89.19 -66.34 0.93 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.717 0.294 . . . . 73.04 110.467 175.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.651 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 71.1 m-85 -136.66 143.06 43.25 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.827 0.346 . . . . 74.1 110.821 -178.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.9 mm? -84.8 144.0 41.45 Favored Pre-proline 0 C--N 1.323 -0.555 0 CA-C-N 115.86 -0.609 . . . . 73.11 109.654 175.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 34' ' ' LEU . 27.0 Cg_exo -62.26 154.7 61.45 Favored 'Trans proline' 0 C--O 1.235 0.352 0 C-N-CA 122.913 2.409 . . . . 63.24 112.599 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 8.4 p -61.22 140.14 19.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.658 -0.701 . . . . 72.31 111.135 -177.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 66.63 16.88 10.51 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.395 -0.82 . . . . 75.53 112.878 178.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.66 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 40.6 t80 -71.8 146.69 47.87 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.011 -0.737 . . . . 75.21 109.011 172.102 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -116.22 126.31 53.45 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.695 0.283 . . . . 74.51 111.246 -172.731 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.536 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 46.9 pt -121.72 155.99 25.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.28 -0.418 . . . . 75.23 110.316 175.726 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -130.73 147.0 52.34 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.381 -0.372 . . . . 74.33 110.533 -175.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.554 ' HB2' ' HB3' ' A' ' 54' ' ' LYS . 27.6 m-85 -96.44 101.85 13.54 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.326 -0.25 . . . . 75.13 110.326 178.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.9 m -113.79 170.07 4.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.025 0.44 . . . . 73.24 111.38 -176.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.674 ' HB2' HG12 ' A' ' 50' ' ' VAL . 16.7 t -95.37 127.23 41.25 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 109.282 -0.636 . . . . 63.13 109.282 177.101 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 47.0 ttt180 -59.41 121.94 12.73 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.853 -1.067 . . . . 71.44 111.057 -176.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 113.0 -128.3 8.34 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-N 115.845 -0.616 . . . . 62.21 111.977 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -122.17 11.91 10.22 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.247 0.546 . . . . 71.43 110.666 -179.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 19.2 mmm180 -89.34 160.18 16.99 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.616 -0.72 . . . . 74.21 109.562 177.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.57 ' HB2' ' HG2' ' A' ' 75' ' ' ARG . 39.4 mt-10 -121.22 163.94 17.73 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.996 0.427 . . . . 74.41 111.359 -174.086 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.674 HG12 ' HB2' ' A' ' 44' ' ' CYS . 26.8 m -128.51 150.27 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.618 -0.719 . . . . 70.42 110.093 -178.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.421 HG13 ' HD2' ' A' ' 72' ' ' ARG . 3.1 p -119.57 96.59 4.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 122.059 0.933 . . . . 74.5 109.921 171.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.24 172.8 32.83 Favored Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 114.636 -1.166 . . . . 74.22 110.925 -178.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -78.55 60.66 7.67 Favored 'Trans proline' 0 N--CA 1.46 -0.448 0 C-N-CA 122.097 1.865 . . . . 70.42 110.455 174.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.554 ' HB3' ' HB2' ' A' ' 42' ' ' TYR . 0.0 OUTLIER -86.31 86.39 7.34 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-N 115.333 -0.849 . . . . 75.22 112.028 -171.369 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -162.41 128.99 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 115.316 -0.856 . . . . 75.54 109.557 173.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.536 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 4.8 mmt85 -130.58 120.57 24.21 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.712 -0.477 . . . . 75.13 109.712 176.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 22.6 ttpp -103.61 125.31 50.05 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 109.159 -0.682 . . . . 74.13 109.159 177.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 49.6 t -64.75 149.23 49.62 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.743 0.306 . . . . 74.1 110.334 179.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 87.0 mt -116.22 -179.0 3.54 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.167 -0.47 . . . . 75.32 110.166 -178.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -81.44 -0.76 43.03 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.97 0.414 . . . . 70.22 110.539 178.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -113.58 164.65 13.39 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.399 -0.593 . . . . 74.35 109.399 175.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -79.43 51.9 4.02 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.012 -0.613 . . . . 74.22 113.541 -173.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 28.2 m -156.62 146.87 21.29 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.92 -0.4 . . . . 64.31 109.92 177.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 89.8 m95 -82.01 177.54 8.78 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.227 -0.657 . . . . 74.23 109.227 175.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.8 p -66.59 -27.5 67.76 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 112.276 0.473 . . . . 73.14 112.276 -177.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -160.48 140.1 10.98 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.95 -0.389 . . . . 71.12 109.95 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 66.9 mtt -129.95 76.38 1.72 Allowed 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 119.814 -0.755 . . . . 72.34 110.164 165.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -170.61 89.18 0.14 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.335 -0.848 . . . . 75.03 108.803 161.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.2 m -148.12 102.96 3.57 Favored Pre-proline 0 C--N 1.317 -0.819 0 C-N-CA 119.936 -0.706 . . . . 74.5 111.399 -176.09 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.24 95.7 1.01 Allowed 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 122.998 2.466 . . . . 64.4 111.44 175.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 10.6 p -75.57 113.37 12.91 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.12 -0.491 . . . . 73.32 110.479 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.421 ' HD2' HG13 ' A' ' 51' ' ' VAL . 5.3 ptp180 -79.68 114.77 18.85 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.155 0.502 . . . . 75.3 111.151 -178.045 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.533 ' HA ' HG13 ' A' ' 50' ' ' VAL . 48.9 t -80.08 100.95 8.44 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.962 -0.563 . . . . 74.22 109.902 176.831 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.2 p -165.2 141.31 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.544 -0.753 . . . . 73.23 109.564 -178.448 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.57 ' HG2' ' HB2' ' A' ' 49' ' ' GLU . 1.5 tmm_? . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.697 -0.668 . . . . 74.41 110.248 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.775 0 N-CA-C 111.651 -0.58 . . . . 72.35 111.651 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -74.84 99.86 1.29 Allowed 'Trans proline' 0 C--O 1.236 0.386 0 C-N-CA 122.401 2.067 . . . . 73.25 111.939 177.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 20.7 p -121.48 121.56 37.79 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.332 0.587 . . . . 75.23 111.959 -177.462 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.6 m -125.59 98.67 5.67 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.941 -0.572 . . . . 74.12 109.585 169.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -126.44 109.26 12.01 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.724 -0.671 . . . . 74.03 109.286 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.719 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -157.5 159.98 30.23 Favored Glycine 0 N--CA 1.438 -1.227 0 C-N-CA 120.066 -1.064 . . . . 60.54 112.841 -176.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.0 m -105.9 142.58 35.38 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.531 -0.544 . . . . 72.14 109.531 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.422 HE21 ' HB2' ' A' ' 8' ' ' GLN . 2.1 pt20 -74.77 -178.4 3.66 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.247 0.546 . . . . 64.22 111.929 -175.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.483 HD13 ' HB ' ' A' ' 31' ' ' ILE . 41.8 mt -88.25 119.37 35.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.524 -0.762 . . . . 73.43 110.316 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.459 HD11 ' CD1' ' A' ' 64' ' ' TRP . 47.4 mt -76.86 142.44 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.603 -0.726 . . . . 72.13 110.825 -177.016 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -79.85 126.8 79.34 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 73.31 109.867 175.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_exo -62.73 113.65 2.06 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 122.46 2.107 . . . . 71.32 111.417 175.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -65.55 -69.19 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.491 2.127 . . . . 72.42 112.481 -177.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 19.5 t-105 -100.39 -179.3 4.07 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.108 -0.701 . . . . 72.24 109.108 178.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.3 mm-40 -65.54 92.47 0.14 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.577 0.703 . . . . 74.13 111.413 -177.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.552 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . -160.31 -153.78 7.07 Favored Glycine 0 N--CA 1.442 -0.94 0 CA-C-N 114.85 -1.068 . . . . 71.54 110.458 178.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.17 -171.74 31.77 Favored Glycine 0 N--CA 1.443 -0.88 0 C-N-CA 120.224 -0.989 . . . . 73.45 112.02 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.1 mt -128.78 134.93 63.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.681 0.753 . . . . 71.22 111.422 -179.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.771 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 16.9 tpp180 -99.33 126.63 45.23 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 114.684 -1.144 . . . . 74.22 110.326 -178.363 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -99.01 -170.84 1.98 Allowed 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.218 -0.66 . . . . 74.51 109.218 175.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 43.4 ttm-85 -103.4 -65.71 0.99 Allowed 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.34 -0.544 . . . . 74.3 110.421 -179.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -110.58 47.5 1.04 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.669 -0.777 . . . . 71.12 112.116 -179.027 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 94.3 mt -135.74 104.45 5.77 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.809 0.338 . . . . 64.52 110.842 -178.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.7 t -87.14 -177.78 6.09 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.745 -0.662 . . . . 75.32 110.019 174.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.421 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 34.7 ptt180 -64.77 -173.05 0.09 Allowed 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 111.922 0.342 . . . . 73.32 111.922 -176.695 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.421 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 13.0 t70 68.63 -45.74 0.54 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 123.477 0.711 . . . . 65.24 110.854 -170.66 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.409 ' H ' ' C ' ' A' ' 25' ' ' ARG . 25.1 mt-30 -76.42 -155.92 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.301 -0.409 . . . . 73.2 110.495 175.056 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 m 49.31 27.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 124.225 1.01 . . . . 75.0 111.987 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 34.9 pttt -97.02 -28.92 13.94 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.429 -0.805 . . . . 75.45 110.652 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.12 95.66 1.63 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.378 0.609 . . . . 75.11 111.055 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.483 ' HB ' HD13 ' A' ' 9' ' ' ILE . 46.8 mt -129.33 140.45 49.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.491 -0.929 . . . . 74.23 108.491 175.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.6 m-80 -107.56 -36.68 6.39 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 120.614 -0.434 . . . . 73.04 110.513 -178.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.719 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 90.6 m-85 -135.74 109.24 7.93 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.753 0.311 . . . . 74.1 111.097 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -80.17 122.62 83.13 Favored Pre-proline 0 C--N 1.325 -0.463 0 N-CA-C 108.463 -0.94 . . . . 73.11 108.463 169.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.425 ' O ' ' HB2' ' A' ' 38' ' ' TYR . 5.9 Cg_endo -47.31 138.72 17.33 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 123.378 2.719 . . . . 63.24 113.618 -172.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.401 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 7.2 p -50.3 143.51 2.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.651 -0.704 . . . . 72.31 111.008 175.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 27.6 t70 80.16 -4.0 1.91 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 123.685 0.794 . . . . 75.53 111.727 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.425 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 17.6 t80 -66.68 141.29 57.82 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 109.475 -0.565 . . . . 75.21 109.475 175.347 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.686 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.8 mt-10 -118.49 120.57 37.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.681 0.277 . . . . 74.51 111.181 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.512 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 46.3 pt -112.9 161.38 11.86 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 CA-C-N 116.335 -0.393 . . . . 75.23 110.599 177.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.771 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.0 tt0 -125.61 152.36 45.25 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.965 -0.561 . . . . 74.33 111.031 -175.699 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.542 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 25.3 m-85 -101.3 102.51 13.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.343 -0.39 . . . . 75.13 111.089 -179.289 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.3 m -103.93 166.83 2.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 116.232 -0.44 . . . . 73.24 110.365 177.01 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.546 ' HB2' HG11 ' A' ' 50' ' ' VAL . 34.8 t -91.6 172.31 8.58 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.603 -0.517 . . . . 63.13 109.603 178.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.552 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -76.98 98.19 4.87 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.928 0.394 . . . . 71.44 110.692 -175.557 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.32 -122.02 7.44 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.975 -0.631 . . . . 62.21 113.341 172.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -105.1 32.91 3.91 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.25 0.548 . . . . 71.43 110.96 -174.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.535 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 28.4 mmm180 -113.19 144.03 43.38 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.759 -0.655 . . . . 74.21 109.351 178.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.1 mp0 -106.67 164.35 12.16 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.254 0.55 . . . . 74.41 111.696 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.546 HG11 ' HB2' ' A' ' 44' ' ' CYS . 35.3 m -129.15 152.5 37.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.349 -0.841 . . . . 70.42 110.105 -178.315 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.422 HG12 ' O ' ' A' ' 51' ' ' VAL . 7.2 p -115.22 97.5 5.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.751 0.786 . . . . 74.5 109.922 171.312 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.0 166.75 32.6 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-N 115.68 -0.691 . . . . 74.22 112.086 178.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -74.53 65.57 5.6 Favored 'Trans proline' 0 CA--C 1.531 0.346 0 C-N-CA 122.326 2.017 . . . . 70.42 110.676 169.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.542 ' HB2' ' H ' ' A' ' 42' ' ' TYR . 16.0 pttp -77.8 89.47 4.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.297 -0.865 . . . . 75.22 111.605 -174.445 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -160.44 129.44 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.611 -0.722 . . . . 75.54 110.288 176.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.686 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 25.8 mmt180 -129.98 136.37 49.36 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.097 -0.501 . . . . 75.13 110.131 177.283 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.424 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 37.2 ttmt -123.36 124.42 42.9 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.193 -0.669 . . . . 74.13 109.193 174.166 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.3 t -67.41 137.5 55.97 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.148 -0.478 . . . . 74.1 110.703 -177.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.409 ' C ' ' H ' ' A' ' 61' ' ' ASN . 93.6 mt -103.46 -179.05 3.84 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.0 -0.546 . . . . 75.32 110.868 -176.711 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.4 22.41 0.56 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.08 0.467 . . . . 70.22 111.183 178.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.409 ' H ' ' C ' ' A' ' 59' ' ' LEU . 3.7 p-10 -139.07 171.8 13.77 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.194 -0.669 . . . . 74.35 109.194 178.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -79.23 52.4 4.04 Favored Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.995 -0.621 . . . . 74.22 113.664 -174.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 11.9 t -170.48 159.52 6.95 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.898 -0.408 . . . . 64.31 109.898 177.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.459 ' CD1' HD11 ' A' ' 10' ' ' ILE . 69.9 m95 -87.06 178.97 6.76 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.228 -0.442 . . . . 74.23 110.086 -178.328 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -57.76 -35.41 70.71 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 112.622 0.601 . . . . 73.14 112.622 -176.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -149.72 144.55 26.15 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 110.193 -0.299 . . . . 71.12 110.193 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 63.3 mtt -136.39 76.56 1.6 Allowed 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.11 -0.636 . . . . 72.34 109.943 163.036 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -169.88 89.29 0.17 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.133 -0.94 . . . . 75.03 108.613 163.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.44 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 10.5 m -144.56 113.51 5.1 Favored Pre-proline 0 C--N 1.314 -0.946 0 C-N-CA 120.302 -0.559 . . . . 74.5 110.731 -175.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 4.3 Cg_exo -77.23 59.77 6.72 Favored 'Trans proline' 0 N--CA 1.463 -0.29 0 C-N-CA 123.415 2.743 . . . . 64.4 112.489 -178.241 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.9 p -70.37 98.83 1.47 Allowed 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.367 -0.605 . . . . 73.32 109.367 175.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' A' ' 72' ' ' ARG . 5.0 ptp180 -101.69 141.34 34.7 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.635 -0.711 . . . . 75.3 111.679 -172.674 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 58.9 m -75.61 115.37 15.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.316 -0.856 . . . . 74.22 109.977 178.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.6 p -149.6 128.44 3.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.124 0.488 . . . . 73.23 110.095 -178.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.335 -0.841 . . . . 74.41 110.162 -177.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.638 0 N-CA-C 111.92 -0.472 . . . . 72.35 111.92 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -68.29 92.86 0.4 Allowed 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.877 2.384 . . . . 73.25 111.712 178.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 6.9 p -96.17 143.12 27.57 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.933 -0.576 . . . . 75.23 111.233 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 20.2 m -146.25 98.79 3.14 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.386 -0.598 . . . . 74.12 109.386 175.34 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -88.87 114.6 25.67 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.862 -0.608 . . . . 74.03 110.044 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -148.42 -179.82 24.68 Favored Glycine 0 N--CA 1.44 -1.058 0 CA-C-N 115.527 -0.76 . . . . 60.54 111.432 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.0 m -97.47 136.12 38.35 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 110.122 -0.325 . . . . 72.14 110.122 -179.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -72.82 177.57 4.76 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.228 0.537 . . . . 64.22 111.464 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.547 HD11 ' HB ' ' A' ' 31' ' ' ILE . 52.4 mt -88.29 116.39 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-N 115.728 -0.669 . . . . 73.43 110.172 177.179 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 41.5 mt -69.65 140.93 17.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.395 -0.82 . . . . 72.13 109.861 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 23.4 m170 -73.55 137.37 77.56 Favored Pre-proline 0 C--N 1.323 -0.544 0 N-CA-C 109.503 -0.554 . . . . 73.31 109.503 175.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -57.12 117.48 4.18 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.544 2.162 . . . . 71.32 111.57 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 83.9 Cg_endo -78.23 -146.22 0.03 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.809 2.339 . . . . 72.42 111.748 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.407 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 67.9 t-105 -56.56 148.56 19.33 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.74 -0.467 . . . . 72.24 109.74 177.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 33.9 mm-40 -44.2 101.31 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.793 1.034 . . . . 74.13 113.793 -172.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.97 -120.91 0.79 Allowed Glycine 0 N--CA 1.442 -0.908 0 CA-C-N 114.283 -1.326 . . . . 71.54 110.131 174.382 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 179.86 -171.85 43.41 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.781 -0.723 . . . . 73.45 111.644 173.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 mt -142.28 129.35 19.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.549 0.69 . . . . 71.22 110.929 177.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.712 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 5.8 tpt180 -102.09 140.67 36.07 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.821 -1.082 . . . . 74.22 108.687 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.508 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 88.7 m-85 -107.15 -173.51 2.31 Favored 'General case' 0 C--N 1.319 -0.758 0 C-N-CA 120.077 -0.649 . . . . 74.51 110.263 -178.335 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -132.89 -14.89 2.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.129 0.49 . . . . 74.3 110.521 -175.106 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -145.82 27.14 1.77 Allowed Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 111.568 -0.613 . . . . 71.12 111.568 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.537 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 89.3 mt -143.54 132.82 23.22 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.683 0.278 . . . . 64.52 110.281 -178.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.9 t -91.45 -178.55 5.14 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.008 -0.542 . . . . 75.32 109.999 177.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 66.5 mtm180 -73.05 -174.14 1.45 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.901 0.382 . . . . 73.32 111.843 -175.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.6 t70 51.29 33.01 9.03 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.665 0.745 . . . . 65.24 111.474 -177.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 -132.59 -164.62 1.49 Allowed 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.091 -0.504 . . . . 73.2 110.386 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.524 HG11 HD12 ' A' ' 31' ' ' ILE . 32.3 m 48.76 36.57 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 O-C-N 124.251 0.97 . . . . 75.0 112.384 177.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -78.8 -39.91 34.43 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.378 0.608 . . . . 75.45 109.413 177.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.07 89.01 1.49 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.49 -0.777 . . . . 75.11 110.644 176.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.547 ' HB ' HD11 ' A' ' 9' ' ' ILE . 52.1 mt -120.62 136.16 58.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.93 -0.767 . . . . 74.23 108.93 175.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -79.73 -49.27 12.31 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.753 0.311 . . . . 73.04 110.921 -175.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -139.37 138.03 36.23 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.186 -0.461 . . . . 74.1 111.275 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -85.96 138.5 35.0 Favored Pre-proline 0 C--N 1.321 -0.631 0 N-CA-C 108.717 -0.845 . . . . 73.11 108.717 170.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.29 145.46 97.75 Favored 'Trans proline' 0 CA--C 1.529 0.25 0 C-N-CA 122.677 2.252 . . . . 63.24 112.822 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.441 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 7.4 p -62.68 145.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.988 -0.551 . . . . 72.31 110.34 177.104 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.441 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 35.3 t70 79.18 3.44 2.34 Favored 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.776 0.672 . . . . 75.53 110.864 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.537 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 47.3 t80 -79.17 148.69 32.2 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.003 -0.369 . . . . 75.21 110.003 175.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.424 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 26.2 mt-10 -124.16 144.25 50.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.314 -0.403 . . . . 74.51 110.884 -176.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.609 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 25.4 pt -136.54 153.93 31.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-N 116.342 -0.39 . . . . 75.23 110.634 174.153 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.712 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.6 tt0 -116.67 155.68 28.4 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.948 -0.569 . . . . 74.33 110.179 -178.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.486 ' HE2' ' CG ' ' A' ' 56' ' ' ARG . 34.2 m-85 -104.81 101.1 10.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.595 0.236 . . . . 75.13 110.818 176.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.477 HG11 ' HB2' ' A' ' 19' ' ' ARG . 26.8 m -90.91 170.37 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 109.8 -0.444 . . . . 73.24 109.8 176.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.509 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 7.3 t -100.39 173.11 6.74 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.27 -0.641 . . . . 63.13 109.27 178.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 15.4 mmt180 -59.88 116.12 3.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.111 0.482 . . . . 71.44 110.769 178.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.21 -132.71 11.33 Favored Glycine 0 N--CA 1.446 -0.645 0 CA-C-N 115.723 -0.671 . . . . 62.21 111.996 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -114.88 34.88 4.56 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.14 0.495 . . . . 71.43 111.237 -177.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.509 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 15.0 mmm180 -89.65 120.15 30.68 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.768 -0.651 . . . . 74.21 109.371 177.2 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -78.86 147.48 33.14 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.161 0.505 . . . . 74.41 110.311 -178.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.6 m -115.24 145.95 20.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.064 -0.516 . . . . 70.42 110.824 -178.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.42 ' O ' HG12 ' A' ' 51' ' ' VAL . 4.5 p -104.8 96.26 4.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 122.017 0.913 . . . . 74.5 109.333 171.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.84 171.82 33.2 Favored Glycine 0 N--CA 1.441 -1.0 0 CA-C-N 115.225 -0.898 . . . . 74.22 111.748 -177.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.513 ' HG2' HG21 ' A' ' 69' ' ' THR . 64.3 Cg_endo -74.66 56.45 4.05 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.757 2.305 . . . . 70.42 110.329 171.083 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.452 ' HD2' ' CG ' ' A' ' 41' ' ' GLU . 43.7 pttt -77.83 86.2 4.08 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.32 -0.855 . . . . 75.22 111.717 -172.292 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -162.47 128.39 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.264 -0.88 . . . . 75.54 109.928 172.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.609 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 24.5 mmt180 -117.85 119.63 35.44 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 108.91 -0.774 . . . . 75.13 108.91 174.439 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -104.62 120.6 41.69 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.455 -0.572 . . . . 74.13 109.455 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 16.5 t -78.54 133.19 37.38 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.923 0.392 . . . . 74.1 109.995 -179.386 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 85.4 mt -117.05 -178.61 3.48 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.013 -0.539 . . . . 75.32 110.85 -173.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.26 -9.29 58.72 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.127 0.489 . . . . 70.22 110.518 178.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -94.44 151.64 19.22 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.214 -0.661 . . . . 74.35 109.214 172.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -77.27 54.02 3.54 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 121.09 -0.576 . . . . 74.22 113.762 -173.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 67.4 p -166.98 154.02 8.8 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.403 -0.592 . . . . 64.31 109.403 177.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.532 ' HB2' ' HB3' ' A' ' 67' ' ' MET . 84.3 m95 -75.02 165.83 24.63 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.802 -0.444 . . . . 74.23 109.802 178.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -50.57 -42.78 55.95 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 113.052 0.76 . . . . 73.14 113.052 -176.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -157.93 74.88 0.74 Allowed 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.574 -0.528 . . . . 71.12 109.574 177.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' MET . . . . . 0.532 ' HB3' ' HB2' ' A' ' 64' ' ' TRP . 22.3 ptt? -88.7 80.24 7.3 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 118.837 -1.145 . . . . 72.34 111.497 -173.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -167.96 88.95 0.27 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.271 -1.331 . . . . 75.03 107.757 163.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.513 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.2 OUTLIER -158.43 115.77 1.74 Allowed Pre-proline 0 C--N 1.317 -0.846 0 C-N-CA 120.461 -0.496 . . . . 74.5 111.221 -169.35 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -81.52 124.91 4.84 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.497 2.131 . . . . 64.4 111.807 174.364 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 12.6 p -81.01 133.29 35.46 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.992 0.425 . . . . 73.32 110.085 177.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 38.3 mtp180 -96.34 99.26 10.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.312 -0.404 . . . . 75.3 111.364 -171.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 8.7 m -69.12 101.98 1.56 Allowed 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.799 -0.445 . . . . 74.22 109.799 177.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 94.7 t -136.41 120.15 23.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 121.026 0.441 . . . . 73.23 111.805 -173.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 67.8 mtt180 . . . . . 0 C--O 1.244 0.797 0 CA-C-N 115.627 -0.715 . . . . 74.41 109.694 170.892 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.822 0 N-CA-C 111.967 -0.453 . . . . 72.35 111.967 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -60.04 113.38 1.63 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.694 2.262 . . . . 73.25 111.55 176.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 23.3 p -108.97 138.11 45.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.991 0.424 . . . . 75.23 111.598 -176.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.1 m -105.74 99.49 9.09 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.882 -0.784 . . . . 74.12 108.882 172.487 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -95.58 109.09 21.38 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.176 0.512 . . . . 74.03 110.949 -174.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.519 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -161.21 -179.6 36.04 Favored Glycine 0 N--CA 1.443 -0.899 0 CA-C-N 115.299 -0.864 . . . . 60.54 111.323 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 15.0 m -99.12 145.1 27.52 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 109.912 -0.403 . . . . 72.14 109.912 178.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -88.36 -177.82 5.74 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.668 0.271 . . . . 64.22 110.522 179.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.0 mt -87.95 123.78 40.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.16 0.505 . . . . 73.43 110.041 178.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.444 HD11 ' CD1' ' A' ' 64' ' ' TRP . 9.8 mt -79.93 150.53 4.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.782 -0.645 . . . . 72.13 110.347 -178.347 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 16.2 p80 -62.54 141.07 96.81 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 109.525 -0.546 . . . . 73.31 109.525 172.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.425 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 23.5 Cg_exo -64.8 149.47 89.58 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.459 2.106 . . . . 71.32 111.715 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.47 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 3.0 Cg_exo -76.88 -132.04 0.01 OUTLIER 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.979 2.453 . . . . 72.42 110.998 174.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.47 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 3.8 t-105 -75.38 -179.57 4.61 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.433 -0.58 . . . . 72.24 109.433 176.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -43.95 101.05 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 112.742 0.645 . . . . 74.13 112.742 -176.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 174.74 -143.71 7.0 Favored Glycine 0 N--CA 1.441 -1.028 0 N-CA-C 110.869 -0.893 . . . . 71.54 110.869 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.74 -169.97 35.94 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.655 -0.783 . . . . 73.45 112.174 177.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.2 mt -118.81 125.39 74.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 121.364 0.602 . . . . 71.22 110.891 179.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.3 tpt180 -99.79 114.27 27.31 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.129 -0.941 . . . . 74.22 109.077 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.481 ' HA ' HG21 ' A' ' 40' ' ' ILE . 88.6 m-85 -76.75 -172.4 2.24 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.588 -0.278 . . . . 74.51 110.905 -175.644 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -87.49 -40.61 14.17 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.15 0.5 . . . . 74.3 110.417 -174.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -152.94 60.01 0.4 Allowed Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.881 -0.676 . . . . 71.12 112.208 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.763 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 76.1 mt -135.03 128.98 33.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.121 0.486 . . . . 64.52 110.998 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.2 t -96.15 -176.4 3.66 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.373 -0.83 . . . . 75.32 110.296 176.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.532 ' C ' ' H ' ' A' ' 27' ' ' GLN . 22.1 mmt180 -60.7 -172.08 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 116.351 -0.386 . . . . 73.32 111.512 178.31 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.417 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 23.9 t70 69.4 -35.86 0.32 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.191 0.597 . . . . 65.24 111.447 -175.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.532 ' H ' ' C ' ' A' ' 25' ' ' ARG . 13.7 mt-30 -90.48 -169.08 2.28 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.806 -0.634 . . . . 73.2 111.067 -178.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.519 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.8 m 59.45 11.88 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 125.073 1.349 . . . . 75.0 112.754 173.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 36.3 pttt -77.87 -27.64 49.76 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.28 0.562 . . . . 75.45 110.341 176.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.13 91.16 0.46 Allowed 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.442 -0.799 . . . . 75.11 110.339 177.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 57.9 mt -109.94 125.84 67.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 108.973 -0.751 . . . . 74.23 108.973 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -79.67 -46.45 17.11 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.138 -0.483 . . . . 73.04 110.187 -175.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.519 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 95.7 m-85 -146.47 121.31 9.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.992 -0.549 . . . . 74.1 111.127 -178.51 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -78.57 151.91 77.69 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.191 -0.459 . . . . 73.11 109.834 173.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -64.82 160.35 41.24 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.618 2.212 . . . . 63.24 112.449 177.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 14.3 p -71.06 145.94 12.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.334 -0.394 . . . . 72.31 110.938 -177.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 38.3 t70 69.93 9.61 7.17 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 123.65 0.78 . . . . 75.53 111.245 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.763 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 25.3 t80 -72.03 139.32 48.47 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 108.719 -0.845 . . . . 75.21 108.719 174.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.59 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.9 mt-10 -126.38 154.66 43.27 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.805 0.336 . . . . 74.51 111.007 -175.46 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.481 HG21 ' HA ' ' A' ' 20' ' ' TYR . 24.3 pt -133.7 162.72 39.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.418 0 CA-C-N 116.06 -0.518 . . . . 75.23 111.776 -177.156 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.434 ' HG3' ' HD2' ' A' ' 54' ' ' LYS . 78.1 tt0 -122.37 149.08 44.28 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.518 -0.765 . . . . 74.33 110.14 177.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -95.5 102.5 14.31 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.201 -0.454 . . . . 75.13 110.152 177.214 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 16.8 m -101.18 144.1 13.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.903 0.382 . . . . 73.24 111.013 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.426 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 28.9 t -91.46 176.74 6.44 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.264 -0.643 . . . . 63.13 109.264 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.95 129.68 41.44 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.63 0.252 . . . . 71.44 111.492 -178.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 62.84 -131.71 43.29 Favored Glycine 0 N--CA 1.45 -0.427 0 CA-C-N 115.855 -0.611 . . . . 62.21 112.237 178.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -98.5 83.81 3.08 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.739 0.78 . . . . 71.43 110.4 176.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.619 HH11 ' HB3' ' A' ' 75' ' ' ARG . 30.2 mmt180 -145.2 132.52 20.62 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.182 -0.917 . . . . 74.21 109.943 178.307 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.2 mp0 -102.21 152.53 20.93 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.049 -0.523 . . . . 74.41 110.548 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.54 HG12 ' HA ' ' A' ' 73' ' ' CYS . 34.7 m -114.58 120.52 64.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.68 -0.691 . . . . 70.42 109.257 171.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.4 ' O ' HG13 ' A' ' 51' ' ' VAL . 6.3 p -83.71 94.24 3.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 122.503 1.144 . . . . 74.5 109.617 178.16 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.22 172.53 33.47 Favored Glycine 0 N--CA 1.441 -0.991 0 CA-C-N 114.34 -1.3 . . . . 74.22 110.764 -177.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -73.3 58.59 3.68 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.225 1.95 . . . . 70.42 110.646 173.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.434 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 42.3 pttt -78.09 85.6 4.29 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-O 121.691 0.758 . . . . 75.22 111.46 -174.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.478 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 6.1 p -162.68 128.61 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.227 -0.897 . . . . 75.54 109.015 171.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.59 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 20.4 mmt180 -130.6 124.42 31.71 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.591 -0.522 . . . . 75.13 109.591 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.466 ' O ' HG23 ' A' ' 65' ' ' THR . 23.7 ttmm -99.68 131.52 45.61 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.875 -0.417 . . . . 74.13 109.875 178.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 48.1 t -80.2 137.64 36.71 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 109.638 -0.504 . . . . 74.1 109.638 176.206 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 89.0 mt -115.25 -178.96 3.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.41 -0.359 . . . . 75.32 110.322 -178.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -66.42 -27.48 67.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.133 0.492 . . . . 70.22 110.61 178.148 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -79.55 150.92 30.96 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.457 -0.571 . . . . 74.35 109.457 174.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -75.6 66.03 2.41 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 121.033 -0.603 . . . . 74.22 113.528 -175.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 13.8 t -174.19 149.09 1.38 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.674 -0.491 . . . . 64.31 109.674 175.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.608 ' H ' ' HE3' ' A' ' 67' ' ' MET . 64.9 m95 -77.27 157.4 30.8 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.199 -0.667 . . . . 74.23 109.199 177.313 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.466 HG23 ' O ' ' A' ' 57' ' ' LYS . 16.0 p -50.71 -46.72 59.09 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 113.319 0.859 . . . . 73.14 113.319 -173.689 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -128.52 118.17 22.57 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.704 -0.226 . . . . 71.12 110.495 -173.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' MET . . . . . 0.608 ' HE3' ' H ' ' A' ' 64' ' ' TRP . 55.5 mtt -125.76 78.31 1.73 Allowed 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 119.346 -0.941 . . . . 72.34 110.741 168.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -170.26 89.05 0.15 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.618 -0.719 . . . . 75.03 109.143 163.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 60.3 m -160.29 107.88 1.38 Allowed Pre-proline 0 C--N 1.321 -0.645 0 CA-C-O 120.874 0.368 . . . . 74.5 111.463 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -76.92 91.92 1.14 Allowed 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.175 1.917 . . . . 64.4 110.943 170.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 16.8 p -70.42 110.9 5.6 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.803 -0.635 . . . . 73.32 110.577 -177.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 21.4 ptt-85 -79.26 119.21 22.01 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.381 0.61 . . . . 75.3 111.137 -176.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.54 ' HA ' HG12 ' A' ' 50' ' ' VAL . 42.5 t -80.37 110.14 15.53 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.363 -0.835 . . . . 74.22 109.502 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.7 p -155.98 130.45 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.375 0.607 . . . . 73.23 111.521 -174.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.619 ' HB3' HH11 ' A' ' 48' ' ' ARG . 22.3 ttm180 . . . . . 0 C--O 1.247 0.934 0 CA-C-N 115.601 -0.727 . . . . 74.41 109.095 175.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.753 0 N-CA-C 111.861 -0.496 . . . . 72.35 111.861 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -78.96 33.55 0.49 Allowed 'Trans proline' 0 CA--C 1.531 0.342 0 C-N-CA 123.085 2.523 . . . . 73.25 113.094 -178.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 2.5 p -79.47 162.3 25.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.63 -0.259 . . . . 75.23 110.713 178.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.4 m -124.54 98.99 5.97 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.205 0.526 . . . . 74.12 111.602 -175.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -118.86 100.23 7.25 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.674 -0.694 . . . . 74.03 109.339 173.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.727 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -158.89 147.33 14.74 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.039 -1.077 . . . . 60.54 113.231 -177.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.6 m -83.47 157.8 22.28 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.87 -0.418 . . . . 72.14 109.87 176.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -84.85 -178.23 6.79 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.124 0.488 . . . . 64.22 111.265 179.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.573 HD11 ' H ' ' A' ' 31' ' ' ILE . 56.5 mt -87.05 117.05 30.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.617 -0.72 . . . . 73.43 109.371 174.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.641 ' HB ' ' HE3' ' A' ' 67' ' ' MET . 12.9 pt -90.18 149.23 4.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.528 -0.76 . . . . 72.13 110.665 -178.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . 0.409 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 19.9 m-70 -88.32 143.47 32.61 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 116.246 -0.434 . . . . 73.31 111.24 -175.211 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 16.7 Cg_exo -67.82 135.06 34.22 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 123.053 2.502 . . . . 71.32 111.963 178.056 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.437 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 82.4 Cg_endo -88.07 -150.22 0.04 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 123.002 2.468 . . . . 72.42 112.475 179.525 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.437 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 12.0 t-105 -63.48 -177.59 0.22 Allowed 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 115.812 -0.631 . . . . 72.24 110.697 178.058 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -38.82 100.33 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 123.876 0.87 . . . . 74.13 112.928 -173.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.85 -172.43 43.75 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 114.989 -1.005 . . . . 71.54 110.722 -178.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -156.91 -171.12 22.64 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.747 -0.74 . . . . 73.45 112.07 179.183 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.3 mt -129.7 137.37 56.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.381 0.61 . . . . 71.22 111.24 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -117.08 119.14 34.34 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.164 -0.925 . . . . 74.22 109.776 -177.612 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.407 ' HA ' HG23 ' A' ' 40' ' ' ILE . 95.0 m-85 -84.69 -171.7 3.78 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.749 0.309 . . . . 74.51 110.623 -178.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.1 ttm180 -93.26 -55.85 3.16 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.985 0.421 . . . . 74.3 109.993 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -144.89 67.74 0.42 Allowed Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.753 -0.737 . . . . 71.12 112.325 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.736 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 76.5 mt -139.07 118.33 12.72 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.995 -0.372 . . . . 64.52 109.995 177.533 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.2 t -81.0 178.9 8.13 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.297 -0.41 . . . . 75.32 110.189 178.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.461 ' C ' ' H ' ' A' ' 27' ' ' GLN . 95.2 mtt180 -78.09 -171.92 2.54 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 120.491 0.186 . . . . 73.32 111.343 -175.396 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 11.6 t70 67.38 -42.79 0.44 Allowed 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 123.305 0.642 . . . . 65.24 110.885 -168.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.539 ' O ' HG22 ' A' ' 28' ' ' VAL . 21.0 mt-30 -70.57 -170.34 0.4 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.217 -0.447 . . . . 73.2 110.137 173.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.9 m 57.9 9.38 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.272 1.029 . . . . 75.0 112.134 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 52.7 pttt -83.49 -19.98 34.8 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.789 -0.819 . . . . 75.45 108.789 172.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.14 102.05 2.11 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 114.885 -1.052 . . . . 75.11 110.026 177.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.573 ' H ' HD11 ' A' ' 9' ' ' ILE . 57.3 mt -120.83 144.72 28.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 109.031 -0.729 . . . . 74.23 109.031 176.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -88.69 -65.61 1.0 Allowed 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.94 -0.393 . . . . 73.04 109.94 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.727 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 56.0 m-85 -143.42 140.84 30.61 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.239 -0.437 . . . . 74.1 110.487 177.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.449 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.7 mm? -82.82 132.23 52.01 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 109.331 -0.618 . . . . 73.11 109.331 174.013 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -58.24 139.34 90.14 Favored 'Trans proline' 0 C--O 1.236 0.382 0 C-N-CA 122.615 2.21 . . . . 63.24 112.227 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 p -67.3 84.59 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 CA-C-O 121.905 0.86 . . . . 72.31 111.272 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.6 t70 165.59 -30.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.179 -1.373 . . . . 75.53 108.925 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.736 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 9.3 t80 -57.22 138.18 55.0 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.895 -1.048 . . . . 75.21 111.277 -174.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 18.9 mt-10 -122.54 139.38 53.96 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.511 -0.768 . . . . 74.51 110.39 -176.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.484 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 35.5 pt -128.17 156.95 40.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.354 -0.384 . . . . 75.23 110.856 178.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -119.83 151.58 38.62 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.016 -0.538 . . . . 74.33 110.508 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -99.05 102.47 14.19 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.072 -0.513 . . . . 75.13 111.052 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.4 m -96.82 163.82 2.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 N-CA-C 110.028 -0.36 . . . . 73.24 110.028 175.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.556 ' HB2' HG11 ' A' ' 50' ' ' VAL . 31.5 t -89.68 175.11 7.38 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.457 -0.572 . . . . 63.13 109.457 178.127 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.66 119.2 19.37 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.95 0.405 . . . . 71.44 110.797 -174.5 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.06 -100.27 2.65 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.846 -0.616 . . . . 62.21 112.863 174.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -133.81 21.8 3.88 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.987 0.422 . . . . 71.43 111.233 -174.077 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.542 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 11.4 mmt180 -96.35 142.88 27.95 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.168 -0.469 . . . . 74.21 110.972 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.796 ' HB2' ' HD2' ' A' ' 75' ' ' ARG . 2.2 mp0 -94.37 153.78 17.81 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.125 -0.489 . . . . 74.41 110.867 177.071 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.556 HG11 ' HB2' ' A' ' 44' ' ' CYS . 28.0 m -118.49 151.31 20.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.688 -0.687 . . . . 70.42 109.882 176.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.9 p -114.9 96.19 4.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.913 0.863 . . . . 74.5 110.008 173.215 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.11 170.91 33.31 Favored Glycine 0 N--CA 1.445 -0.711 0 CA-C-N 115.2 -0.909 . . . . 74.22 111.602 179.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -73.59 60.01 4.17 Favored 'Trans proline' 0 CA--C 1.531 0.353 0 C-N-CA 122.482 2.121 . . . . 70.42 110.88 170.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 44.3 pttt -77.23 89.44 3.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.583 -0.735 . . . . 75.22 112.392 -171.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.9 p -160.8 135.11 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.892 -0.595 . . . . 75.54 109.605 171.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.493 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 24.6 mmt180 -131.12 120.8 23.88 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.41 -0.359 . . . . 75.13 110.537 177.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.455 ' HB3' ' CG2' ' A' ' 65' ' ' THR . 39.4 ttmt -102.73 129.63 49.42 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 109.094 -0.706 . . . . 74.13 109.094 174.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 45.6 t -67.92 143.51 55.64 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.469 -0.332 . . . . 74.1 110.327 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.411 HD13 ' HA ' ' A' ' 65' ' ' THR . 88.6 mt -110.89 -178.38 3.46 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.369 -0.378 . . . . 75.32 110.615 -176.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -79.82 14.56 1.7 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.974 0.416 . . . . 70.22 111.161 178.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.43 ' ND2' ' H ' ' A' ' 63' ' ' SER . 4.6 p-10 -141.44 -178.62 5.71 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.772 -0.649 . . . . 74.35 109.62 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -66.04 -29.68 75.47 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 114.771 0.668 . . . . 74.22 114.771 -171.252 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.43 ' H ' ' ND2' ' A' ' 61' ' ' ASN . 78.5 p -93.23 163.27 13.68 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.473 0.636 . . . . 64.31 111.458 -175.659 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -92.89 -179.86 5.25 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.877 -0.601 . . . . 74.23 110.005 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.455 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 3.2 p -49.59 -69.72 0.11 Allowed 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 113.558 0.947 . . . . 73.14 113.558 -174.169 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -133.21 48.59 2.38 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.649 -0.501 . . . . 71.12 109.649 -177.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' MET . . . . . 0.641 ' HE3' ' HB ' ' A' ' 10' ' ' ILE . 28.0 ttt -80.65 81.92 6.78 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.382 -0.927 . . . . 72.34 111.831 -170.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -166.65 87.6 0.32 Allowed 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 106.72 -1.585 . . . . 75.03 106.72 158.196 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.5 m -157.79 113.41 1.81 Allowed Pre-proline 0 C--N 1.316 -0.889 0 CA-C-N 116.284 -0.416 . . . . 74.5 110.051 -168.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -66.68 97.6 0.39 Allowed 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.61 2.206 . . . . 64.4 112.164 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.1 p -78.73 101.63 7.66 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.212 -0.662 . . . . 73.32 109.212 173.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -78.94 126.58 30.88 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.315 0.579 . . . . 75.3 111.091 -171.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.533 ' HA ' HG12 ' A' ' 50' ' ' VAL . 41.8 t -82.03 98.74 8.77 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.499 -0.773 . . . . 74.22 109.865 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.3 p -176.98 152.44 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.992 -0.744 . . . . 73.23 108.992 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.796 ' HD2' ' HB2' ' A' ' 49' ' ' GLU . 2.5 ptm180 . . . . . 0 C--O 1.245 0.859 0 CA-C-O 119.168 -0.444 . . . . 74.41 110.367 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.668 0 N-CA-C 111.23 -0.748 . . . . 72.35 111.23 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -61.65 141.83 92.32 Favored 'Trans proline' 0 N--CA 1.462 -0.357 0 C-N-CA 122.296 1.997 . . . . 73.25 111.1 177.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 52.5 p -78.57 99.45 6.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.102 0.477 . . . . 75.23 110.544 -179.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.4 m -101.23 116.56 33.08 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.758 -0.656 . . . . 74.12 110.209 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . 0.417 ' H ' ' CD ' ' A' ' 5' ' ' GLU . 0.9 OUTLIER -70.03 107.57 3.68 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.833 -0.803 . . . . 74.03 108.833 175.863 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.804 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -157.63 126.28 1.7 Allowed Glycine 0 N--CA 1.443 -0.847 0 C-N-CA 120.288 -0.958 . . . . 60.54 113.035 -176.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 64.8 m -90.59 152.32 20.94 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.546 -0.539 . . . . 72.14 109.546 175.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -81.77 -178.02 6.81 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.916 0.389 . . . . 64.22 111.233 -178.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.559 HD11 ' HB ' ' A' ' 31' ' ' ILE . 46.2 mt -87.39 121.6 38.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.873 -0.603 . . . . 73.43 110.691 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 56.9 mt -73.86 114.21 13.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.03 -0.532 . . . . 72.13 109.581 175.051 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 31.9 m-70 -75.44 129.08 82.95 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 110.09 -0.337 . . . . 73.31 110.09 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.471 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 7.3 Cg_endo -49.19 118.77 3.83 Favored 'Trans proline' 0 C--N 1.349 0.556 0 C-N-CA 123.447 2.765 . . . . 71.32 112.429 -177.222 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.471 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 4.0 Cg_exo -76.38 -84.03 0.0 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 122.996 2.464 . . . . 72.42 112.325 -177.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.7 t-105 -100.93 -178.36 3.73 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.228 -0.442 . . . . 72.24 109.925 -177.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -47.68 102.31 0.03 OUTLIER 'General case' 0 C--O 1.234 0.275 0 O-C-N 123.791 0.682 . . . . 74.13 112.242 177.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.07 -157.14 28.97 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.352 -0.84 . . . . 71.54 111.099 -179.211 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -161.13 -171.08 26.63 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 111.338 -0.705 . . . . 73.45 111.338 177.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.5 mt -127.77 129.43 70.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.669 0.747 . . . . 71.22 111.363 -179.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.87 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 5.1 tpt180 -93.62 132.75 37.64 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 114.438 -1.256 . . . . 74.22 109.486 -179.021 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.474 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 97.1 m-85 -106.55 -171.28 1.86 Allowed 'General case' 0 C--N 1.32 -0.678 0 C-N-CA 120.845 -0.342 . . . . 74.51 110.735 -178.032 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 19.1 ttt-85 -114.68 -51.69 2.73 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.944 0.402 . . . . 74.3 110.264 -174.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -136.83 30.57 2.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 71.12 112.807 -177.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.925 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 80.3 mt -109.72 129.7 55.59 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 122.595 -0.356 . . . . 64.52 110.255 177.544 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.4 t -80.33 -179.81 7.31 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.112 -0.495 . . . . 75.32 110.1 178.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.436 ' C ' ' H ' ' A' ' 27' ' ' GLN . 38.3 ptt180 -73.48 -174.16 1.6 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.325 -0.398 . . . . 73.32 110.752 -178.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 21.8 t70 67.32 -44.5 0.46 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.859 0.864 . . . . 65.24 111.619 -177.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.628 ' O ' HG22 ' A' ' 28' ' ' VAL . 28.1 mt-30 -68.03 -163.62 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 122.896 0.478 . . . . 73.2 111.554 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.628 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.0 m 61.11 13.93 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 124.538 1.135 . . . . 75.0 111.347 -177.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -90.99 -29.02 17.63 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.342 -0.614 . . . . 75.45 109.342 176.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.65 89.68 1.27 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.714 -0.676 . . . . 75.11 111.003 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.559 ' HB ' HD11 ' A' ' 9' ' ' ILE . 57.3 mt -126.66 134.28 66.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 108.818 -0.808 . . . . 74.23 108.818 175.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -77.54 -56.42 4.54 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.815 0.34 . . . . 73.04 111.043 -177.093 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.804 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 65.9 m-85 -136.33 145.61 45.63 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.082 0.467 . . . . 74.1 111.375 -175.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.58 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.7 mm? -103.8 139.11 19.8 Favored Pre-proline 0 C--N 1.323 -0.564 0 N-CA-C 108.993 -0.743 . . . . 73.11 108.993 170.223 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -58.89 159.76 20.28 Favored 'Trans proline' 0 N--CA 1.476 0.5 0 C-N-CA 123.203 2.602 . . . . 63.24 113.315 -176.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 9.9 p -71.64 2.75 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 CA-C-O 121.648 0.737 . . . . 72.31 111.473 -176.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -134.4 92.78 2.97 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.093 0.473 . . . . 75.53 109.798 170.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.925 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 20.2 t80 -157.18 135.02 10.86 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.633 -0.712 . . . . 75.21 109.301 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.492 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 38.9 mt-10 -113.4 130.29 56.33 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.242 0.339 . . . . 74.51 110.784 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.556 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 43.6 pt -121.68 158.09 25.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.369 -0.378 . . . . 75.23 110.89 175.583 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.87 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 41.3 tt0 -127.19 154.36 44.9 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.868 -0.605 . . . . 74.33 110.598 -177.692 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 65.3 m-85 -100.03 102.29 13.6 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.328 -0.396 . . . . 75.13 110.612 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.3 m -109.2 164.78 5.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.371 -0.377 . . . . 73.24 111.202 -178.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.509 ' HB2' ' HB2' ' A' ' 48' ' ' ARG . 86.3 m -110.85 179.32 4.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.1 -0.5 . . . . 63.13 110.388 177.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -76.92 102.36 6.35 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.071 0.463 . . . . 71.44 110.375 178.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.35 -166.81 25.76 Favored Glycine 0 N--CA 1.445 -0.704 0 N-CA-C 111.05 -0.82 . . . . 62.21 111.05 -176.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -82.59 77.66 9.32 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.526 0.679 . . . . 71.43 111.281 178.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.509 ' HB2' ' HB2' ' A' ' 44' ' ' CYS . 14.1 mtm-85 -127.87 118.34 23.46 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.754 -0.832 . . . . 74.21 108.754 176.463 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -88.2 154.11 20.7 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.064 -0.516 . . . . 74.41 111.099 -172.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.547 HG11 ' HA ' ' A' ' 73' ' ' CYS . 27.2 m -119.23 130.77 73.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.798 -0.637 . . . . 70.42 109.969 178.48 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.0 p -95.04 94.08 4.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-O 122.217 1.008 . . . . 74.5 109.857 175.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -157.26 170.9 34.51 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 114.223 -1.353 . . . . 74.22 110.514 177.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.509 ' HG2' HG23 ' A' ' 69' ' ' THR . 55.9 Cg_endo -75.19 77.88 3.08 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.621 1.547 . . . . 70.42 110.536 168.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.578 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 43.6 pttt -86.84 88.48 7.69 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.656 0.741 . . . . 75.22 111.048 -174.392 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.508 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 6.8 p -160.19 128.99 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.496 -0.775 . . . . 75.54 109.814 176.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.556 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 23.1 mmt180 -137.12 125.65 23.61 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.924 -0.58 . . . . 75.13 110.028 178.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.57 ' HA ' ' O ' ' A' ' 38' ' ' TYR . 35.4 ttmt -124.6 137.4 54.39 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 108.775 -0.824 . . . . 74.13 108.775 168.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.5 t -67.27 142.86 56.75 Favored 'General case' 0 C--N 1.323 -0.575 0 O-C-N 123.337 0.398 . . . . 74.1 110.279 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.9 mt -119.46 -178.1 3.52 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.141 -0.481 . . . . 75.32 110.228 -177.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.62 -4.98 43.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.066 0.46 . . . . 70.22 110.884 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -99.62 163.38 12.52 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.774 -0.648 . . . . 74.35 109.422 173.535 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -78.53 47.96 3.09 Favored Glycine 0 CA--C 1.521 0.449 0 C-N-CA 120.917 -0.659 . . . . 74.22 113.678 -174.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.0 t -165.9 170.55 13.64 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.259 -0.645 . . . . 64.31 109.259 178.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 61.1 m95 -87.44 178.12 6.91 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.836 -0.431 . . . . 74.23 109.836 -177.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.9 p -49.86 -50.8 44.3 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 113.394 0.887 . . . . 73.14 113.394 -173.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -148.25 66.08 1.08 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.569 0.224 . . . . 71.12 110.445 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 60.1 ttp -87.1 79.83 8.53 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 118.921 -1.112 . . . . 72.34 110.934 -176.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -169.31 89.67 0.2 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.446 -1.252 . . . . 75.03 107.72 162.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.509 HG23 ' HG2' ' A' ' 53' ' ' PRO . 1.4 m -151.39 127.29 5.02 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 120.314 -0.554 . . . . 74.5 111.339 -170.354 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -78.61 93.95 1.08 Allowed 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.574 2.182 . . . . 64.4 112.159 175.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.9 p -92.9 114.61 27.22 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.081 -0.509 . . . . 73.32 110.782 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.7 ptp85 -94.28 128.67 40.9 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.056 -0.52 . . . . 75.3 111.045 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.547 ' HA ' HG11 ' A' ' 50' ' ' VAL . 18.2 t -89.44 112.2 23.28 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.001 -0.545 . . . . 74.22 109.748 179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.97 115.03 14.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.478 -0.328 . . . . 73.23 111.168 -174.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 . . . . . 0 C--O 1.244 0.795 0 CA-C-O 118.479 -0.772 . . . . 74.41 109.723 174.16 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.798 0 N-CA-C 111.809 -0.517 . . . . 72.35 111.809 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -78.62 113.82 3.37 Favored 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.911 2.407 . . . . 73.25 112.2 178.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 3.1 p -144.44 153.59 42.07 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.82 0.343 . . . . 75.23 110.845 178.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 28.1 m -149.07 104.48 3.43 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.683 -0.488 . . . . 74.12 109.683 177.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -76.19 105.41 7.22 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.106 -0.497 . . . . 74.03 109.795 -179.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.712 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -149.53 143.1 10.4 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.624 -0.798 . . . . 60.54 112.529 -178.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 69.2 m -92.47 151.83 20.0 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 110.213 -0.292 . . . . 72.14 110.213 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.412 ' H ' ' HG3' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -87.15 -179.43 6.45 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.633 -0.258 . . . . 64.22 111.521 -177.683 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 40.4 mt -88.61 112.57 24.13 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.246 -0.434 . . . . 73.43 111.294 -171.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 38.7 mt -70.82 146.12 12.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.74 -0.663 . . . . 72.13 110.443 179.139 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . 0.423 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 72.2 m-70 -88.24 141.85 31.23 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 116.524 -0.307 . . . . 73.31 110.39 177.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 12.8 Cg_exo -71.4 122.08 8.32 Favored 'Trans proline' 0 CA--C 1.529 0.253 0 C-N-CA 122.934 2.423 . . . . 71.32 111.644 176.071 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -91.19 -94.73 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 123.008 2.472 . . . . 72.42 112.782 -177.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -89.99 -176.0 4.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.088 -0.708 . . . . 72.24 109.088 178.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -57.48 -16.21 9.02 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 112.11 0.411 . . . . 74.13 112.11 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.38 91.41 0.3 Allowed Glycine 0 N--CA 1.448 -0.502 0 N-CA-C 110.648 -0.981 . . . . 71.54 110.648 167.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -91.16 -170.21 42.58 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 121.168 -0.539 . . . . 73.45 112.982 -173.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -115.55 136.23 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 CA-C-O 121.72 0.772 . . . . 71.22 112.083 -174.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.791 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 15.4 tpt180 -116.4 145.8 42.98 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.182 -1.372 . . . . 74.22 109.049 -178.047 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 68.6 m-85 -108.95 -172.89 2.14 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.805 -0.442 . . . . 74.51 109.805 178.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 25.6 mtm180 -98.41 -38.48 9.2 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.57 -0.452 . . . . 74.3 110.885 -178.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -160.56 52.95 0.34 Allowed Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.644 -0.789 . . . . 71.12 112.467 178.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 93.7 mt -116.73 115.94 26.57 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.942 0.401 . . . . 64.52 110.352 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.6 t -80.79 -179.2 7.16 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.656 -0.702 . . . . 75.32 110.307 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.534 ' C ' ' H ' ' A' ' 27' ' ' GLN . 39.5 mmt180 -67.4 -174.99 0.44 Allowed 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.684 0.278 . . . . 73.32 111.308 -176.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 23.4 t70 65.64 -34.26 0.19 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.638 0.775 . . . . 65.24 112.172 -175.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.534 ' H ' ' C ' ' A' ' 25' ' ' ARG . 20.6 mt-30 -80.89 -166.3 1.09 Allowed 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 122.542 0.337 . . . . 73.2 110.664 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.453 HG22 ' O ' ' A' ' 27' ' ' GLN . 5.8 m 52.89 18.5 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 124.548 1.139 . . . . 75.0 113.068 177.009 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 50.8 pttt -111.37 -21.85 11.62 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.808 0.337 . . . . 75.45 110.285 177.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.74 16.03 2.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.346 -0.388 . . . . 75.11 111.664 -178.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 60.8 mt -73.22 103.38 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 109.404 -0.591 . . . . 74.23 109.404 176.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -58.01 -50.07 74.66 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.145 -0.48 . . . . 73.04 112.184 -173.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.712 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 91.0 m-85 -133.31 128.54 35.96 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.818 0.342 . . . . 74.1 110.821 -177.24 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -83.23 126.87 70.93 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 108.485 -0.931 . . . . 73.11 108.485 171.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -51.24 145.46 26.77 Favored 'Trans proline' 0 C--O 1.234 0.283 0 C-N-CA 123.361 2.707 . . . . 63.24 112.92 -176.118 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 p -59.74 142.41 15.21 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 CA-C-N 115.792 -0.64 . . . . 72.31 110.99 -178.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.8 t70 78.75 -11.96 1.14 Allowed 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.238 -0.892 . . . . 75.53 111.947 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 47.3 t80 -67.05 120.31 13.46 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 108.877 -0.786 . . . . 75.21 108.877 176.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.453 ' HG2' ' HA ' ' A' ' 57' ' ' LYS . 43.6 mt-10 -104.77 146.84 28.4 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.131 -0.486 . . . . 74.51 110.836 -176.147 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.592 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 21.1 pt -120.2 155.56 23.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.824 -0.626 . . . . 75.23 110.415 177.748 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.791 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.4 tt0 -107.21 165.84 11.07 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.588 -0.733 . . . . 74.33 110.268 -174.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -120.47 101.43 7.77 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.775 0.321 . . . . 75.13 110.838 178.048 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 20.3 m -103.01 168.15 2.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.139 -0.482 . . . . 73.24 110.429 178.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.598 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 28.3 t -90.57 140.76 29.44 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.472 -0.566 . . . . 63.13 109.472 178.52 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -59.12 117.12 4.36 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.818 -0.628 . . . . 71.44 110.218 -176.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 114.18 -112.91 2.92 Favored Glycine 0 N--CA 1.444 -0.808 0 N-CA-C 111.093 -0.803 . . . . 62.21 111.093 -176.051 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -149.77 65.76 0.99 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.347 0.594 . . . . 71.43 110.834 177.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.598 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 35.0 mmt180 -126.57 136.27 52.34 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.265 -0.425 . . . . 74.21 110.047 179.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.52 157.01 27.52 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.958 -0.386 . . . . 74.41 109.958 176.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.495 HG13 ' HB3' ' A' ' 73' ' ' CYS . 33.2 m -130.29 149.69 33.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.245 -0.434 . . . . 70.42 110.68 -177.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -116.34 95.47 3.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 122.298 1.047 . . . . 74.5 108.929 169.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.47 172.33 33.61 Favored Glycine 0 N--CA 1.444 -0.824 0 CA-C-N 114.496 -1.229 . . . . 74.22 111.173 -178.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.479 ' HG2' HG22 ' A' ' 69' ' ' THR . 69.3 Cg_endo -75.91 60.02 5.96 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.326 2.017 . . . . 70.42 110.782 173.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.584 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 40.0 pttt -71.65 88.93 0.98 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.452 -0.794 . . . . 75.22 111.328 -175.516 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -161.88 131.89 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 116.046 -0.525 . . . . 75.54 110.946 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.592 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 22.3 mmt180 -127.78 111.07 13.24 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.504 -0.924 . . . . 75.13 108.504 169.649 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.453 ' HA ' ' HG2' ' A' ' 39' ' ' GLU . 20.5 ttmm -97.99 122.39 41.05 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.954 -0.387 . . . . 74.13 109.954 -178.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 49.8 t -69.65 126.97 31.33 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.772 -0.455 . . . . 74.1 109.772 177.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 95.0 mt -97.03 -178.94 4.37 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.054 -0.521 . . . . 75.32 110.831 -175.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.29 -17.03 61.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 70.22 110.687 178.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.3 p-10 -101.18 165.8 11.11 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.305 -0.628 . . . . 74.35 109.305 174.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.97 52.42 3.28 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 121.026 -0.607 . . . . 74.22 113.51 -174.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.8 m -157.5 157.7 34.35 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.523 -0.547 . . . . 64.31 109.523 177.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -88.27 173.51 8.73 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.603 -0.517 . . . . 74.23 109.603 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.412 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 3.0 p -57.73 -73.18 0.08 Allowed 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 112.27 0.47 . . . . 73.14 112.27 -177.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -125.31 121.13 33.09 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.215 -0.661 . . . . 71.12 109.215 178.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 62.3 mtm -120.45 79.6 1.5 Allowed 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 119.259 -0.976 . . . . 72.34 111.149 173.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -168.34 89.79 0.26 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 114.735 -1.121 . . . . 75.03 108.316 162.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.479 HG22 ' HG2' ' A' ' 53' ' ' PRO . 0.2 OUTLIER -159.02 102.23 1.58 Allowed Pre-proline 0 C--N 1.315 -0.932 0 C-N-CA 120.581 -0.448 . . . . 74.5 110.693 -171.814 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -75.33 105.17 2.03 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.359 2.039 . . . . 64.4 111.576 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 7.6 p -75.22 102.41 4.99 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.228 0.537 . . . . 73.32 110.852 -178.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.1 ptp180 -79.97 115.61 19.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.696 -0.684 . . . . 75.3 111.252 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.535 ' HB3' ' HB2' ' A' ' 44' ' ' CYS . 0.7 OUTLIER -87.25 99.04 11.67 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.984 -0.553 . . . . 74.22 110.689 174.761 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.7 p -115.53 129.13 72.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.611 -0.722 . . . . 73.23 109.54 176.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.637 -0.697 . . . . 74.41 109.875 -176.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.664 0 N-CA-C 111.441 -0.664 . . . . 72.35 111.441 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_exo -66.34 95.29 0.32 Allowed 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.825 2.35 . . . . 73.25 111.725 -179.441 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 7.5 p -96.22 129.88 43.42 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.044 -0.526 . . . . 75.23 111.242 -178.349 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.0 m -93.39 98.12 11.01 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.794 -0.817 . . . . 74.12 108.794 173.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -119.1 99.2 6.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.698 -0.683 . . . . 74.03 110.524 -174.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.46 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -161.74 165.54 35.74 Favored Glycine 0 N--CA 1.437 -1.235 0 CA-C-N 115.612 -0.722 . . . . 60.54 111.363 178.234 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 13.3 m -84.61 139.74 31.86 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 110.078 -0.341 . . . . 72.14 110.078 178.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -83.14 -178.67 7.18 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.204 0.526 . . . . 64.22 111.087 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.52 HD11 ' HB ' ' A' ' 31' ' ' ILE . 58.2 mt -87.43 105.04 14.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.809 -0.632 . . . . 73.43 109.366 178.087 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.462 HD12 ' HE1' ' A' ' 67' ' ' MET . 20.8 pt -72.18 169.93 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 114.721 -1.127 . . . . 72.13 111.556 -177.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -69.39 135.79 88.72 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.009 -0.541 . . . . 73.31 109.745 173.576 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -59.78 143.99 99.53 Favored 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.117 1.878 . . . . 71.32 111.147 172.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.21 -160.05 0.09 OUTLIER 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.489 2.126 . . . . 72.42 112.441 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 14.9 t-105 -68.8 -175.94 0.76 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.969 -0.56 . . . . 72.24 109.787 177.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 66.9 mm-40 -37.86 100.53 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.553 0.741 . . . . 74.13 112.655 -172.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.522 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . 163.6 -132.39 2.72 Favored Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.322 -0.853 . . . . 71.54 111.643 -179.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -179.64 -166.2 34.93 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.495 -0.642 . . . . 73.45 111.495 178.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.3 mt -127.95 130.11 69.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.463 0.649 . . . . 71.22 111.189 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.726 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 23.2 tpt180 -96.64 135.3 38.75 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 114.759 -1.109 . . . . 74.22 109.255 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.573 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 98.0 m-85 -93.17 -171.23 2.61 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.836 -0.346 . . . . 74.51 110.613 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.525 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 49.1 ttt180 -106.43 -75.86 0.62 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 120.757 0.313 . . . . 74.3 110.893 -170.346 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -114.19 43.68 1.65 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.886 -0.597 . . . . 71.12 112.097 -177.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.424 ' CG ' ' HH ' ' A' ' 38' ' ' TYR . 75.1 mt -133.69 144.67 49.3 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 110.243 -0.28 . . . . 64.52 110.243 178.094 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.0 t -97.04 175.01 6.48 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.062 -0.517 . . . . 75.32 109.821 176.007 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.479 ' C ' ' H ' ' A' ' 27' ' ' GLN . 34.7 ptt180 -74.43 -172.42 1.46 Allowed 'General case' 0 C--O 1.236 0.389 0 C-N-CA 121.439 -0.104 . . . . 73.32 110.815 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 27.4 t70 69.27 -2.27 1.9 Allowed 'General case' 0 N--CA 1.474 0.774 0 CA-C-O 122.055 0.931 . . . . 65.24 109.945 -175.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.479 ' H ' ' C ' ' A' ' 25' ' ' ARG . 21.6 mt-30 -119.98 -156.51 0.67 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.777 -1.102 . . . . 73.2 108.518 178.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.2 m 47.83 27.57 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.778 0.831 . . . . 75.0 112.263 176.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.424 ' H ' ' HG2' ' A' ' 29' ' ' LYS . 26.3 pttt -92.74 -22.44 19.37 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.39 -0.823 . . . . 75.45 110.445 -175.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.6 81.54 0.66 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.809 -0.632 . . . . 75.11 110.677 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.52 ' HB ' HD11 ' A' ' 9' ' ' ILE . 48.0 mt -103.4 146.78 10.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.829 -0.623 . . . . 74.23 109.533 178.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -85.56 -67.92 0.77 Allowed 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.978 -0.379 . . . . 73.04 109.978 177.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.46 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 75.8 m-85 -136.32 145.72 45.8 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.021 -0.536 . . . . 74.1 110.641 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -92.32 142.59 26.25 Favored Pre-proline 0 C--N 1.321 -0.645 0 N-CA-C 109.762 -0.459 . . . . 73.11 109.762 175.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -62.77 147.15 95.05 Favored 'Trans proline' 0 C--O 1.237 0.442 0 C-N-CA 122.725 2.284 . . . . 63.24 113.03 -178.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 6.4 p -70.39 80.75 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 CA-C-O 122.159 0.98 . . . . 72.31 110.502 177.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.0 t70 172.94 -27.78 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 114.461 -1.245 . . . . 75.53 108.739 -175.095 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.573 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 7.9 t80 -72.15 142.9 49.09 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 114.751 -1.113 . . . . 75.21 111.185 -176.166 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.525 ' H ' ' HD2' ' A' ' 21' ' ' ARG . 54.9 mt-10 -124.61 153.76 41.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.032 -0.531 . . . . 74.51 109.93 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.515 HD12 ' HE3' ' A' ' 67' ' ' MET . 35.0 pt -126.68 165.65 24.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 120.763 0.316 . . . . 75.23 111.435 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.726 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.7 tt0 -130.89 147.47 52.54 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.955 -0.566 . . . . 74.33 110.268 178.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -94.84 102.27 14.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.285 -0.416 . . . . 75.13 110.678 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.5 m -103.48 170.67 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 120.9 0.381 . . . . 73.24 111.141 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.426 ' HA ' ' CA ' ' A' ' 16' ' ' GLY . 49.7 t -115.9 175.18 5.65 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.301 -0.409 . . . . 63.13 110.055 -178.378 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.522 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 2.0 tmt_? -77.09 99.63 5.43 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.631 -0.507 . . . . 71.44 109.631 -178.185 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.18 -160.63 28.44 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.929 -0.653 . . . . 62.21 111.691 -178.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -85.18 69.52 10.77 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.745 0.783 . . . . 71.43 111.002 -179.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 26.5 mmm180 -124.51 107.72 11.36 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.139 -1.059 . . . . 74.21 108.139 174.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -79.8 139.31 37.28 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.999 0.428 . . . . 74.41 111.508 -170.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.56 ' HA ' ' HA ' ' A' ' 73' ' ' CYS . 33.7 m -94.53 150.12 4.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.707 -0.678 . . . . 70.42 111.292 -176.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -114.42 95.06 3.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.822 0.82 . . . . 74.5 109.17 169.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.57 171.66 33.63 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.155 -0.93 . . . . 74.22 111.664 -178.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -83.58 71.25 6.03 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.158 1.905 . . . . 70.42 110.336 169.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.45 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 21.1 pttp -81.61 86.95 6.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.655 0.741 . . . . 75.22 111.629 -170.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.6 p -161.9 128.0 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.362 -0.836 . . . . 75.54 109.315 172.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.481 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 35.1 mmt180 -145.19 118.22 8.83 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.322 -0.622 . . . . 75.13 109.322 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -106.03 139.7 40.16 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.958 0.409 . . . . 74.13 109.958 177.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.9 t -70.47 149.66 46.98 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.556 -0.747 . . . . 74.1 111.911 -175.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.3 mt -113.15 -178.02 3.28 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.187 -0.915 . . . . 75.32 109.943 179.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -83.44 28.97 0.52 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.869 0.366 . . . . 70.22 111.277 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -146.56 169.85 18.11 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.161 -0.472 . . . . 74.35 109.946 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -69.2 -34.44 75.46 Favored Glycine 0 C--N 1.33 0.236 0 C-N-CA 121.348 -0.453 . . . . 74.22 114.039 -169.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.8 m -89.79 142.06 28.04 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 121.124 0.488 . . . . 64.31 111.054 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 59.7 m95 -73.82 -179.29 3.59 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.086 -0.507 . . . . 74.23 110.732 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.9 p -56.33 -56.12 25.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.312 -0.404 . . . . 73.14 111.792 -178.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.423 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 10.6 t70 -142.66 127.0 17.66 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.742 -0.466 . . . . 71.12 109.742 174.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' MET . . . . . 0.515 ' HE3' HD12 ' A' ' 40' ' ' ILE . 24.2 mmt -127.75 78.68 1.84 Allowed 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 119.112 -1.035 . . . . 72.34 110.531 165.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -167.08 87.85 0.3 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 113.843 -1.526 . . . . 75.03 107.544 159.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 91.5 m -160.33 109.0 1.37 Allowed Pre-proline 0 C--N 1.317 -0.825 0 N-CA-C 109.651 -0.5 . . . . 74.5 109.651 -172.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.53 99.52 0.94 Allowed 'Trans proline' 0 C--O 1.233 0.24 0 C-N-CA 122.68 2.253 . . . . 64.4 113.213 -174.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 11.8 p -91.58 98.58 11.74 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.519 -0.548 . . . . 73.32 109.519 173.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.411 HH11 ' HD2' ' A' ' 72' ' ' ARG . 7.0 ptp180 -91.29 140.66 29.57 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.163 -0.471 . . . . 75.3 110.852 -175.493 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.56 ' HA ' ' HA ' ' A' ' 50' ' ' VAL . 3.4 p -106.59 122.25 45.95 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.847 -0.615 . . . . 74.22 111.119 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 18.4 t -127.14 -95.64 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 108.892 -0.781 . . . . 73.23 108.892 175.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.536 -0.745 . . . . 74.41 109.673 178.208 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.79 0 N-CA-C 112.089 -0.404 . . . . 72.35 112.089 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -73.63 88.36 1.04 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.745 2.297 . . . . 73.25 111.862 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 59.7 m -122.72 115.99 23.01 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.972 -0.558 . . . . 75.23 110.421 178.438 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.5 m -105.59 101.58 11.09 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.753 -0.658 . . . . 74.12 109.829 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -96.74 96.69 8.77 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.644 -0.502 . . . . 74.03 109.644 178.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.8 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -164.15 136.91 4.46 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.742 -0.742 . . . . 60.54 112.565 -179.131 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.8 m -80.01 133.84 36.18 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.81 -0.811 . . . . 72.14 108.81 172.073 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.579 ' HA ' ' O ' ' A' ' 32' ' ' ASN . 2.2 pt20 -73.31 177.62 5.05 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.624 0.726 . . . . 64.22 112.41 -174.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.3 mt -88.97 127.09 41.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.876 -1.056 . . . . 73.43 110.326 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 58.6 mt -76.21 140.92 16.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.502 -0.772 . . . . 72.13 110.75 -177.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -62.9 138.0 97.06 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 115.49 -0.777 . . . . 73.31 110.188 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.447 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 75.6 Cg_exo -41.48 118.85 0.88 Allowed 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 123.852 3.034 . . . . 71.32 113.74 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 6.7 Cg_endo -88.79 -145.18 0.03 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.657 0 C-N-CA 123.685 2.924 . . . . 72.42 112.436 -178.551 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.44 ' CG ' ' N ' ' A' ' 15' ' ' GLU . 69.0 t-105 -68.36 -179.67 1.38 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 115.907 -0.588 . . . . 72.24 110.893 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.44 ' N ' ' CG ' ' A' ' 14' ' ' TRP . 16.8 mm-40 -47.99 101.5 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.182 0 C-N-CA 123.972 0.909 . . . . 74.13 112.336 178.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 153.56 -142.58 9.3 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 120.722 -0.751 . . . . 71.54 111.911 178.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -168.72 -169.99 32.82 Favored Glycine 0 N--CA 1.442 -0.959 0 N-CA-C 111.459 -0.656 . . . . 73.45 111.459 -179.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.5 mt -113.81 128.17 70.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.735 0.778 . . . . 71.22 111.432 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.834 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 20.5 tpp180 -86.24 113.14 22.01 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 114.54 -1.209 . . . . 74.22 109.541 179.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.412 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 86.2 m-85 -86.71 -171.54 3.58 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.953 0.406 . . . . 74.51 110.875 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -108.34 -32.51 7.42 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.131 0.491 . . . . 74.3 110.066 -177.47 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -158.62 54.51 0.37 Allowed Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.799 -0.715 . . . . 71.12 112.155 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.633 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 88.8 mt -138.61 111.62 7.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.681 0.277 . . . . 64.52 110.95 -179.401 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.7 t -85.28 -179.91 7.07 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.166 -0.47 . . . . 75.32 109.859 175.229 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.49 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 9.5 ptp85 -72.77 -171.36 0.83 Allowed 'General case' 0 C--O 1.237 0.398 0 N-CA-C 110.027 -0.361 . . . . 73.32 110.027 178.001 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.49 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 9.7 t70 73.24 -40.77 0.48 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 121.251 0.548 . . . . 65.24 110.071 -176.191 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.457 ' H ' ' C ' ' A' ' 25' ' ' ARG . 24.6 mt-30 -85.33 -164.64 1.03 Allowed 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 115.497 -0.774 . . . . 73.2 109.156 171.357 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.478 HG12 HD13 ' A' ' 31' ' ' ILE . 9.0 m 50.87 20.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 C-N-CA 124.079 0.952 . . . . 75.0 112.432 178.802 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 17.9 ptmt -79.78 -18.99 49.69 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.803 -0.635 . . . . 75.45 110.525 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.95 35.97 0.05 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.315 -0.857 . . . . 75.11 110.753 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.478 HD13 HG12 ' A' ' 28' ' ' VAL . 45.6 mt -75.69 136.88 23.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 109.003 -0.74 . . . . 74.23 109.003 175.052 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.579 ' O ' ' HA ' ' A' ' 8' ' ' GLN . 87.4 m-20 -115.76 -25.06 7.93 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 111.981 0.363 . . . . 73.04 111.981 -172.781 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.8 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 41.5 m-85 -132.01 109.48 10.06 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.958 0.408 . . . . 74.1 111.673 -174.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.66 129.63 50.08 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 109.355 -0.609 . . . . 73.11 109.355 173.054 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -62.21 161.34 27.08 Favored 'Trans proline' 0 N--CA 1.472 0.261 0 C-N-CA 122.868 2.378 . . . . 63.24 113.538 -175.365 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.456 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 12.4 p -63.1 157.68 3.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 CA-C-N 115.355 -0.839 . . . . 72.31 110.602 179.026 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.456 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 32.2 t70 77.12 -3.85 2.42 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.424 0.69 . . . . 75.53 111.004 178.623 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.633 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 4.4 t80 -80.39 123.56 28.13 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.133 -0.485 . . . . 75.21 110.18 -179.185 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.471 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.6 mt-10 -116.37 141.74 47.77 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 110.014 -0.365 . . . . 74.51 110.014 175.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.509 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 33.6 pt -121.26 160.89 21.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 120.965 0.412 . . . . 75.23 111.503 -177.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.834 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 46.2 tt0 -120.52 152.07 38.53 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.546 -0.752 . . . . 74.33 110.101 179.715 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -101.7 102.83 13.56 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.742 0.306 . . . . 75.13 110.982 179.155 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.446 HG13 ' HE ' ' A' ' 19' ' ' ARG . 30.7 m -102.23 152.75 5.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.16 0.505 . . . . 73.24 111.318 -179.044 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.423 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 19.1 t -100.49 -179.83 4.22 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.126 -0.694 . . . . 63.13 109.126 -178.39 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -65.2 110.08 2.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.772 0.32 . . . . 71.44 111.397 -179.403 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.96 -149.01 24.98 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 121.0 -0.619 . . . . 62.21 111.855 179.194 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -91.56 37.51 0.96 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.365 0.603 . . . . 71.43 110.464 179.465 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 29.8 mmm180 -88.49 108.26 19.3 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.81 -0.811 . . . . 74.21 108.81 176.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -77.95 145.39 36.11 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.676 -0.693 . . . . 74.41 111.113 -171.56 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.535 ' HA ' ' HA ' ' A' ' 73' ' ' CYS . 34.8 m -101.33 149.98 6.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.672 -0.694 . . . . 70.42 110.387 179.115 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.0 p -117.47 95.28 3.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 122.003 0.906 . . . . 74.5 109.405 169.043 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.26 171.83 33.46 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.735 -1.121 . . . . 74.22 111.382 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.531 ' HG2' HG23 ' A' ' 69' ' ' THR . 48.1 Cg_endo -77.06 71.92 6.07 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 121.756 1.637 . . . . 70.42 110.359 170.168 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.678 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 43.2 pttt -78.98 89.57 4.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.531 -0.759 . . . . 75.22 111.398 -173.172 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.39 128.57 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.578 0.704 . . . . 75.54 110.877 174.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.637 ' CZ ' ' HA ' ' A' ' 67' ' ' MET . 28.9 mmt85 -138.23 104.41 5.19 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.276 -0.875 . . . . 75.13 109.106 176.72 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -97.47 138.96 34.11 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.412 -0.358 . . . . 74.13 110.182 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.7 t -97.88 128.56 44.56 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.014 -0.539 . . . . 74.1 110.349 176.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 30.7 mt -108.13 -176.6 3.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.797 -0.638 . . . . 75.32 110.414 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -54.43 -35.08 62.56 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 121.037 0.446 . . . . 70.22 110.886 176.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -83.18 140.5 32.54 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.345 -0.613 . . . . 74.35 109.345 174.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.402 ' C ' ' HG ' ' A' ' 63' ' ' SER . . . -79.14 67.19 3.32 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 121.025 -0.607 . . . . 74.22 113.631 -172.034 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.402 ' HG ' ' C ' ' A' ' 62' ' ' GLY . 32.2 m -155.38 139.31 16.32 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.839 -0.43 . . . . 64.31 109.839 174.073 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 66.4 m95 -72.28 129.6 38.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.03 -0.73 . . . . 74.23 109.03 177.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.6 p -70.78 13.94 0.16 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 115.24 1.57 . . . . 73.14 115.24 -166.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -159.03 42.96 0.24 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.302 -0.629 . . . . 71.12 109.302 177.036 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' MET . . . . . 0.637 ' HA ' ' CZ ' ' A' ' 56' ' ' ARG . 26.4 ttt -83.75 77.38 9.89 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 122.074 0.94 . . . . 72.34 111.38 -171.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -170.32 88.97 0.15 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 113.905 -1.498 . . . . 75.03 107.361 159.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.531 HG23 ' HG2' ' A' ' 53' ' ' PRO . 7.5 m -127.58 112.38 20.89 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 119.847 -0.741 . . . . 74.5 112.51 -167.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -74.05 114.77 4.12 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 122.913 2.408 . . . . 64.4 110.811 172.304 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.4 p -135.64 145.74 47.13 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.403 -0.362 . . . . 73.32 110.844 -175.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.5 ptp180 -140.8 136.42 32.44 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.204 -0.453 . . . . 75.3 110.122 -178.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.535 ' HA ' ' HA ' ' A' ' 50' ' ' VAL . 0.9 OUTLIER -97.18 99.73 11.21 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.462 0.649 . . . . 74.22 111.101 176.783 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -131.94 134.09 60.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.028 -0.987 . . . . 73.23 108.837 178.128 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.381 -0.819 . . . . 74.41 110.948 -172.189 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.459 ' HA2' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.48 1.626 0 N-CA-C 111.465 -0.654 . . . . 72.35 111.465 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.459 ' HD3' ' HA2' ' A' ' 1' ' ' GLY . 11.6 Cg_exo -69.99 136.0 31.3 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.796 2.331 . . . . 73.25 111.844 -178.68 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 1.2 p -79.03 137.27 37.48 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.038 -0.528 . . . . 75.23 110.771 178.02 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.7 m -78.84 99.33 6.69 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.495 -0.557 . . . . 74.12 109.495 176.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -118.03 100.23 7.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.557 -0.747 . . . . 74.03 110.261 -175.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.873 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.54 145.32 10.96 Favored Glycine 0 N--CA 1.444 -0.833 0 N-CA-C 111.373 -0.691 . . . . 60.54 111.373 178.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 56.7 m -81.16 132.01 35.33 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 110.176 -0.305 . . . . 72.14 110.176 -179.459 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -80.3 -176.55 5.69 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.995 0.426 . . . . 64.22 111.302 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 73.0 mt -84.86 136.34 22.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.498 -0.773 . . . . 73.43 109.046 178.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.441 ' CD1' ' HE3' ' A' ' 67' ' ' MET . 14.1 mt -94.76 148.33 5.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 116.102 -0.499 . . . . 72.13 111.614 -169.074 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 10.8 p80 -61.69 136.29 94.64 Favored Pre-proline 0 C--O 1.233 0.211 0 CA-C-N 116.051 -0.522 . . . . 73.31 109.875 172.156 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.9 119.77 6.82 Favored 'Trans proline' 0 N--CA 1.464 -0.248 0 C-N-CA 122.526 2.151 . . . . 71.32 111.951 179.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -77.76 -129.8 0.01 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.272 0 C-N-CA 123.043 2.495 . . . . 72.42 111.49 178.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 39.3 t-105 -63.86 174.77 1.34 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 109.594 -0.521 . . . . 72.24 109.594 175.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -68.91 76.37 0.31 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.497 0.665 . . . . 74.13 112.321 -176.096 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.27 155.32 25.97 Favored Glycine 0 N--CA 1.438 -1.188 0 N-CA-C 109.729 -1.349 . . . . 71.54 109.729 173.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -106.06 -172.3 23.38 Favored Glycine 0 N--CA 1.44 -1.085 0 C-N-CA 119.811 -1.185 . . . . 73.45 112.017 -178.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.8 mt -132.16 131.75 61.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.197 0.523 . . . . 71.22 109.987 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' A' ' 19' ' ' ARG . 0.2 OUTLIER -113.41 122.28 46.87 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.39 -0.823 . . . . 74.22 109.341 -179.307 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -88.52 -172.71 3.86 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.878 0.371 . . . . 74.51 110.552 -175.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.5 ttm180 -89.18 -51.59 5.5 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.219 -0.446 . . . . 74.3 110.27 -177.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -137.27 13.07 3.8 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.805 -0.712 . . . . 71.12 112.736 -178.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.708 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 80.3 mt -89.96 129.29 36.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.106 0.479 . . . . 64.52 110.805 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.1 t -102.74 -178.27 3.62 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.577 -0.738 . . . . 75.32 110.085 178.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.516 ' C ' ' H ' ' A' ' 27' ' ' GLN . 60.6 mtp180 -69.3 -173.07 0.5 Allowed 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.535 -0.302 . . . . 73.32 111.28 -176.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 24.3 t70 69.79 -40.33 0.46 Allowed 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.444 0.698 . . . . 65.24 110.505 -172.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.516 ' H ' ' C ' ' A' ' 25' ' ' ARG . 18.1 mt-30 -86.6 -161.12 0.63 Allowed 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.36 -0.836 . . . . 73.2 110.3 177.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.506 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.6 m 54.73 10.0 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.674 1.19 . . . . 75.0 113.247 177.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -97.25 -19.84 18.3 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.021 0.439 . . . . 75.45 110.027 175.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.64 94.07 1.85 Allowed 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.552 -0.749 . . . . 75.11 110.377 178.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -131.58 136.62 56.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.109 -0.7 . . . . 74.23 109.109 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -76.77 -67.02 0.74 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.959 0.409 . . . . 73.04 110.892 -177.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.873 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 61.8 m-85 -133.91 126.67 30.89 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.832 -0.622 . . . . 74.1 111.119 -175.742 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -85.13 134.11 41.58 Favored Pre-proline 0 C--N 1.324 -0.525 0 N-CA-C 108.969 -0.752 . . . . 73.11 108.969 171.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -63.08 141.18 82.34 Favored 'Trans proline' 0 C--O 1.239 0.545 0 C-N-CA 122.816 2.344 . . . . 63.24 112.906 -176.502 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.421 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 3.1 p -69.84 82.07 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 CA-C-O 121.719 0.771 . . . . 72.31 110.25 176.281 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.421 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 6.2 t70 172.44 -26.39 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.635 -1.166 . . . . 75.53 108.544 -175.873 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.708 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 6.1 t80 -74.04 146.38 43.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.217 -0.901 . . . . 75.21 110.822 -177.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -124.69 158.64 32.71 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 115.911 -0.586 . . . . 74.51 110.564 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.466 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 31.0 pt -139.5 149.27 22.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.15 -0.477 . . . . 75.23 110.67 177.017 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.55 ' HG2' ' H ' ' A' ' 42' ' ' TYR . 24.2 tt0 -112.81 167.37 10.55 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.161 -0.472 . . . . 74.33 109.902 178.272 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.55 ' H ' ' HG2' ' A' ' 41' ' ' GLU . 69.1 m-85 -112.44 102.42 10.54 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.077 0.465 . . . . 75.13 111.998 -177.195 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.0 m -96.21 153.6 3.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 109.074 -0.713 . . . . 73.24 109.074 171.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.578 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 34.2 t -89.07 167.49 13.1 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.138 -0.69 . . . . 63.13 109.138 179.554 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -59.25 117.09 4.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.024 0.44 . . . . 71.44 110.151 -176.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.76 -120.77 6.53 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 110.958 -0.857 . . . . 62.21 110.958 -176.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -130.04 25.61 5.24 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.359 0.6 . . . . 71.43 110.212 177.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.578 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 29.8 mmm180 -88.47 136.06 33.18 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.823 -0.626 . . . . 74.21 109.8 -177.435 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -95.47 159.19 15.12 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.046 -0.525 . . . . 74.41 109.811 -179.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.526 HG13 ' HA ' ' A' ' 73' ' ' CYS . 27.9 m -122.28 150.14 25.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.523 -0.308 . . . . 70.42 110.422 179.517 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 p -100.83 96.89 5.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 122.039 0.923 . . . . 74.5 109.295 171.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.23 172.11 33.45 Favored Glycine 0 N--CA 1.441 -0.997 0 CA-C-N 114.973 -1.012 . . . . 74.22 111.612 -176.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -74.07 55.69 3.5 Favored 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.249 1.966 . . . . 70.42 110.523 171.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.455 ' HD2' ' HG2' ' A' ' 41' ' ' GLU . 43.0 pttt -75.41 87.46 2.58 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 115.74 -0.664 . . . . 75.22 111.515 -173.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -161.41 129.21 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.439 -0.8 . . . . 75.54 109.45 172.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.503 HH22 ' CB ' ' A' ' 69' ' ' THR . 31.8 mmt180 -132.61 140.29 48.16 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.918 -0.401 . . . . 75.13 109.918 179.165 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -130.76 137.56 49.53 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.598 -0.519 . . . . 74.13 109.598 176.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 50.4 t -70.83 146.5 49.65 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.114 -0.494 . . . . 74.1 110.26 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 94.3 mt -116.86 -179.61 3.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.136 -0.484 . . . . 75.32 110.381 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.03 -8.39 59.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.917 0.389 . . . . 70.22 111.038 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -100.54 166.16 11.06 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.434 -0.58 . . . . 74.35 109.434 175.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.02 57.76 3.14 Favored Glycine 0 CA--C 1.516 0.131 0 C-N-CA 120.987 -0.625 . . . . 74.22 113.091 -177.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.2 t -172.96 171.03 4.35 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.209 -0.663 . . . . 64.31 109.209 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 40.5 m95 -99.98 -179.01 4.02 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 109.714 -0.476 . . . . 74.23 109.714 -178.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.0 p -49.63 -53.31 24.88 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.579 0.585 . . . . 73.14 112.579 -176.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -153.77 129.95 10.41 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.026 -1.102 . . . . 71.12 108.026 177.227 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' MET . . . . . 0.441 ' HE3' ' CD1' ' A' ' 10' ' ' ILE . 22.9 mmt -131.81 78.4 1.82 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 118.992 -1.083 . . . . 72.34 112.136 174.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 30.0 t0 -168.94 88.39 0.19 Allowed 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 107.805 -1.183 . . . . 75.03 107.805 157.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.503 ' CB ' HH22 ' A' ' 56' ' ' ARG . 1.3 m -149.32 94.6 3.92 Favored Pre-proline 0 C--N 1.314 -0.948 0 C-N-CA 120.913 -0.315 . . . . 74.5 110.313 -172.5 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.95 92.81 0.32 Allowed 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 122.487 2.125 . . . . 64.4 112.26 -179.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 17.0 m -79.68 115.8 19.49 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.942 -0.572 . . . . 73.32 109.811 177.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.5 ptp180 -79.68 133.73 36.39 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.715 -0.675 . . . . 75.3 111.655 -174.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.526 ' HA ' HG13 ' A' ' 50' ' ' VAL . 71.2 m -83.08 98.87 9.53 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.761 -0.654 . . . . 74.22 110.592 178.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.5 p -148.88 114.47 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.635 -0.711 . . . . 73.23 109.534 176.42 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 2.4 tmt_? . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.288 -0.863 . . . . 74.41 109.488 -173.206 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.801 0 N-CA-C 111.835 -0.506 . . . . 72.35 111.835 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -80.34 44.82 1.81 Allowed 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 123.091 2.527 . . . . 73.25 111.756 -179.063 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 12.3 p -117.61 139.88 50.4 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.564 -0.744 . . . . 75.23 111.039 -177.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.7 m -142.28 97.94 3.22 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.485 -0.561 . . . . 74.12 109.485 172.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 33.3 mm-40 -98.82 118.41 35.5 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.892 -0.595 . . . . 74.03 109.466 -179.562 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.503 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -153.73 152.14 23.78 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.124 -1.036 . . . . 60.54 113.152 -176.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.8 m -97.14 149.39 22.04 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.432 -0.581 . . . . 72.14 109.432 177.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -72.82 173.98 8.38 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.129 0.49 . . . . 64.22 112.171 -175.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.545 HD13 ' HB ' ' A' ' 31' ' ' ILE . 54.5 mt -88.5 126.9 41.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.522 -0.763 . . . . 73.43 110.458 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.1 mt -84.05 127.92 39.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.051 -0.522 . . . . 72.13 109.847 177.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -79.5 133.4 59.74 Favored Pre-proline 0 C--N 1.323 -0.583 0 N-CA-C 109.631 -0.507 . . . . 73.31 109.631 -177.355 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.402 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 72.3 Cg_exo -49.3 113.3 0.88 Allowed 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 123.451 2.767 . . . . 71.32 113.005 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.496 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 4.9 Cg_exo -80.52 -101.4 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 123.194 2.596 . . . . 72.42 112.827 -177.06 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.496 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 55.7 t-105 -80.76 177.11 9.24 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.777 -0.453 . . . . 72.24 109.777 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -54.84 101.21 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.409 0.623 . . . . 74.13 111.733 179.462 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.06 -145.43 9.44 Favored Glycine 0 N--CA 1.443 -0.872 0 CA-C-N 115.095 -0.957 . . . . 71.54 110.714 -177.473 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -176.42 -170.01 38.54 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 120.473 -0.87 . . . . 73.45 111.914 178.384 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.9 mt -125.52 125.65 69.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.272 0.558 . . . . 71.22 110.838 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.38 160.57 14.6 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.994 -1.003 . . . . 74.22 108.893 178.089 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -123.26 -171.12 2.24 Favored 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 120.797 -0.361 . . . . 74.51 110.398 -176.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.403 ' HB3' ' CE2' ' A' ' 38' ' ' TYR . 39.9 ttm180 -82.56 -36.58 26.12 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.46 -0.336 . . . . 74.3 110.345 -178.116 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.94 71.21 0.19 Allowed Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.588 -0.815 . . . . 71.12 112.53 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 62.5 mt -139.79 139.15 36.35 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.796 0.331 . . . . 64.52 110.751 178.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.3 t -92.67 -178.28 4.82 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.863 -0.608 . . . . 75.32 109.848 178.242 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.587 ' C ' ' H ' ' A' ' 27' ' ' GLN . 49.7 ptt85 -68.78 -175.89 0.75 Allowed 'General case' 0 C--O 1.234 0.285 0 C-N-CA 121.188 -0.205 . . . . 73.32 110.671 177.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.406 ' O ' ' HD3' ' A' ' 29' ' ' LYS . 28.7 t70 62.64 -26.83 0.06 Allowed 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 123.725 0.81 . . . . 65.24 112.116 -173.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.587 ' H ' ' C ' ' A' ' 25' ' ' ARG . 8.1 mm100 -71.25 178.7 3.2 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 123.227 0.611 . . . . 73.2 110.482 178.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.2 m 50.53 20.7 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 C-N-CA 124.364 1.065 . . . . 75.0 113.016 177.022 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.406 ' HD3' ' O ' ' A' ' 26' ' ' ASP . 38.1 pttt -73.51 -23.29 60.01 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.041 0.448 . . . . 75.45 109.927 176.627 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.99 102.65 0.66 Allowed 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.281 -0.872 . . . . 75.11 110.373 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.545 ' HB ' HD13 ' A' ' 9' ' ' ILE . 50.6 mt -130.21 157.86 42.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 N-CA-C 108.315 -0.995 . . . . 74.23 108.315 175.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -88.92 -58.22 2.63 Favored 'General case' 0 C--N 1.321 -0.67 0 C-N-CA 120.825 -0.35 . . . . 73.04 110.45 179.424 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.503 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 86.7 m-85 -143.54 146.75 33.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.886 0.374 . . . . 74.1 111.067 -178.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.448 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.4 mm? -84.37 130.9 52.14 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 108.575 -0.898 . . . . 73.11 108.575 173.295 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.448 ' HD3' ' HA ' ' A' ' 34' ' ' LEU . 17.4 Cg_exo -64.08 147.11 91.62 Favored 'Trans proline' 0 CA--C 1.527 0.15 0 C-N-CA 122.473 2.116 . . . . 63.24 112.848 -174.399 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.54 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 8.9 p -53.39 148.35 2.01 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 CA-C-N 115.832 -0.622 . . . . 72.31 110.413 173.469 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.54 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 7.9 t70 82.48 -28.93 0.1 Allowed 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.583 0.753 . . . . 75.53 111.513 -178.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.403 ' CE2' ' HB3' ' A' ' 21' ' ' ARG . 32.4 t80 -66.84 141.38 57.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.787 0.327 . . . . 75.21 110.544 -178.438 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.466 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 41.2 mt-10 -114.78 145.65 41.87 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.066 -0.515 . . . . 74.51 111.515 -177.21 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.539 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 43.8 pt -122.46 164.86 19.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.451 -0.795 . . . . 75.23 109.595 172.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.431 ' CG ' ' HD2' ' A' ' 54' ' ' LYS . 35.3 tt0 -135.89 142.71 44.75 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.987 0.422 . . . . 74.33 110.785 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -88.45 102.32 14.78 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.107 -0.497 . . . . 75.13 110.59 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.9 m -102.2 162.78 3.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.168 0.509 . . . . 73.24 110.856 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.57 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 15.8 t -104.0 -176.58 3.12 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.859 -0.61 . . . . 63.13 110.229 -176.566 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.5 mmt180 -56.27 121.43 9.49 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.111 -0.495 . . . . 71.44 111.419 -177.423 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 71.73 -95.86 0.64 Allowed Glycine 0 N--CA 1.446 -0.698 0 CA-C-N 115.724 -0.671 . . . . 62.21 111.998 178.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -146.83 47.52 1.17 Allowed 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.69 0.757 . . . . 71.43 109.716 177.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.57 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 13.3 mmm-85 -87.43 129.15 35.15 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.197 -0.91 . . . . 74.21 109.478 176.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.447 ' HB2' ' HB3' ' A' ' 75' ' ' ARG . 41.1 mt-10 -78.35 149.17 33.47 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.376 -0.374 . . . . 74.41 110.001 -179.615 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.458 HG12 ' HA ' ' A' ' 73' ' ' CYS . 34.9 m -127.06 150.14 32.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.96 -0.564 . . . . 70.42 110.678 -177.279 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 p -106.34 96.83 4.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.972 0.891 . . . . 74.5 109.235 171.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.764 ' HA3' ' HB3' ' A' ' 71' ' ' SER . . . -154.73 170.83 33.08 Favored Glycine 0 N--CA 1.441 -0.994 0 CA-C-N 114.831 -1.077 . . . . 74.22 111.175 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.24 60.33 7.4 Favored 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 122.282 1.988 . . . . 70.42 110.703 173.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.431 ' HD2' ' CG ' ' A' ' 41' ' ' GLU . 45.3 pttt -80.7 84.42 6.25 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-O 121.723 0.773 . . . . 75.22 111.436 -172.651 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.1 m -158.66 126.48 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 114.594 -1.185 . . . . 75.54 108.462 172.308 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.539 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 32.3 mmt180 -141.1 100.07 3.73 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 110.073 -0.343 . . . . 75.13 110.073 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -92.5 125.32 37.09 Favored 'General case' 0 C--N 1.317 -0.822 0 N-CA-C 109.002 -0.74 . . . . 74.13 109.002 174.104 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 48.9 t -64.52 136.6 57.21 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.008 0.432 . . . . 74.1 110.247 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 76.6 mt -98.78 -178.92 4.12 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.661 -0.699 . . . . 75.32 110.717 -174.236 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -71.45 -9.71 58.62 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.449 0.642 . . . . 70.22 110.363 176.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -110.21 158.62 18.17 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 108.93 -0.767 . . . . 74.35 108.93 174.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -78.29 53.23 3.84 Favored Glycine 0 CA--C 1.519 0.333 0 C-N-CA 120.993 -0.622 . . . . 74.22 113.464 -173.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 18.6 m -155.06 161.92 41.19 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.37 -0.604 . . . . 64.31 109.37 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 70.5 m95 -91.89 179.51 5.59 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.835 -0.431 . . . . 74.23 109.835 -178.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 33.0 p -61.67 -38.79 89.06 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.923 0.392 . . . . 73.14 111.197 -178.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -146.59 136.26 23.12 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.06 -0.718 . . . . 71.12 109.06 178.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 10.4 tpt -119.54 74.38 1.0 Allowed 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 118.602 -1.239 . . . . 72.34 109.882 171.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -170.68 89.2 0.14 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.206 -1.361 . . . . 75.03 107.575 160.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.473 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 4.6 m -108.77 108.81 61.06 Favored Pre-proline 0 C--N 1.313 -1.017 0 C-N-CA 119.959 -0.696 . . . . 74.5 111.078 -170.642 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . 0.473 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 14.8 Cg_endo -92.56 46.48 0.41 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 124.061 3.174 . . . . 64.4 112.803 -177.345 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.764 ' HB3' ' HA3' ' A' ' 52' ' ' GLY . 0.1 OUTLIER -73.91 126.21 29.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.5 -0.318 . . . . 73.32 110.687 177.561 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -109.55 149.05 30.21 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 110.177 -0.305 . . . . 75.3 110.177 -178.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.458 ' HA ' HG12 ' A' ' 50' ' ' VAL . 29.6 m -87.52 113.75 23.5 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.502 -0.317 . . . . 74.22 111.458 -175.635 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.1 p -155.8 134.94 3.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.576 -0.284 . . . . 73.23 110.563 179.078 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.447 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 3.0 ptm180 . . . . . 0 C--O 1.25 1.087 0 CA-C-N 116.318 -0.401 . . . . 74.41 109.971 178.019 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 1.496 0 N-CA-C 111.759 -0.536 . . . . 72.35 111.759 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.17 127.79 20.11 Favored 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 122.72 2.28 . . . . 73.25 111.499 176.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 5.7 t -134.1 99.36 4.39 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.803 0.811 . . . . 75.23 110.959 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.4 m -150.09 149.57 30.49 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.554 -0.748 . . . . 74.12 109.51 179.031 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -96.22 97.27 9.39 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.626 -0.509 . . . . 74.03 109.626 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -161.76 164.18 35.09 Favored Glycine 0 N--CA 1.441 -0.986 0 C-N-CA 120.807 -0.711 . . . . 60.54 112.396 -177.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.6 m -97.59 154.02 17.81 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 110.203 -0.295 . . . . 72.14 110.203 179.068 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 -82.42 -179.69 7.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.338 0.589 . . . . 64.22 111.329 -178.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.3 mt -89.42 121.38 39.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.425 -0.807 . . . . 73.43 110.306 178.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 55.5 mt -72.15 129.03 35.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.915 -0.584 . . . . 72.13 110.111 178.391 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.5 t-80 -67.39 121.26 78.02 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 116.192 -0.458 . . . . 73.31 110.366 -178.114 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.517 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.4 Cg_exo -48.69 120.76 5.61 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.212 2.608 . . . . 71.32 112.783 -179.407 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.517 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 5.8 Cg_endo -86.68 -138.74 0.02 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 123.569 2.846 . . . . 72.42 112.656 -176.305 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.515 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 13.1 t-105 -66.85 -177.5 0.62 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 115.891 -0.595 . . . . 72.24 110.853 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -39.88 101.35 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.689 0.796 . . . . 74.13 112.835 -176.051 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.54 -168.56 33.25 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 111.341 -0.704 . . . . 71.54 111.341 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.82 24.0 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.942 -0.647 . . . . 73.45 111.563 179.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.4 mt -116.93 136.49 53.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.559 0.695 . . . . 71.22 111.216 -178.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.853 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 13.7 tpt180 -103.03 140.1 37.72 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.661 -1.154 . . . . 74.22 109.246 -179.681 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -108.29 -171.98 1.97 Allowed 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.591 -0.444 . . . . 74.51 110.765 -178.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.06 -45.33 9.22 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.001 0.429 . . . . 74.3 110.603 -174.284 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -151.09 53.38 0.49 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.811 -0.709 . . . . 71.12 112.181 -178.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.453 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 89.5 mt -136.55 127.55 27.73 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.607 0.241 . . . . 64.52 110.794 179.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.0 t -86.39 -179.77 6.73 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.531 -0.544 . . . . 75.32 109.531 175.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.8 mpp_? -80.47 -172.85 3.77 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.818 -0.353 . . . . 73.32 111.456 -175.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.437 ' O ' ' HE2' ' A' ' 29' ' ' LYS . 28.7 t70 60.44 15.25 5.37 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 122.357 1.075 . . . . 65.24 109.583 -168.435 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.516 ' O ' HG22 ' A' ' 28' ' ' VAL . 24.3 mt-30 -134.57 -173.7 3.36 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.668 -1.151 . . . . 73.2 108.287 178.273 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.516 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.0 m 54.4 9.22 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 124.127 0.971 . . . . 75.0 112.51 -178.323 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.437 ' HE2' ' O ' ' A' ' 26' ' ' ASP . 46.3 pttt -79.41 -21.82 45.1 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.98 -0.555 . . . . 75.45 110.081 177.502 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.31 81.15 0.98 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.351 -0.84 . . . . 75.11 110.37 178.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 54.8 mt -119.61 139.11 48.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 108.939 -0.763 . . . . 74.23 108.939 176.338 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -69.54 -64.2 0.92 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.764 0.316 . . . . 73.04 111.115 -176.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -143.56 141.73 30.8 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.192 -0.458 . . . . 74.1 110.867 -177.371 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -92.01 115.71 65.13 Favored Pre-proline 0 C--N 1.321 -0.671 0 N-CA-C 108.564 -0.902 . . . . 73.11 108.564 172.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.59 142.71 38.97 Favored 'Trans proline' 0 C--O 1.238 0.515 0 C-N-CA 123.419 2.746 . . . . 63.24 113.217 -174.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.459 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 2.7 p -65.22 86.14 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-O 121.512 0.673 . . . . 72.31 111.173 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.459 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 31.6 t70 168.94 -26.84 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.834 -1.075 . . . . 75.53 108.28 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.453 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 6.9 t80 -68.74 144.82 54.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 114.618 -1.173 . . . . 75.21 110.486 179.418 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -127.09 145.53 50.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.274 -0.421 . . . . 74.51 110.121 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.478 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 38.0 pt -128.45 167.9 22.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-O 121.084 0.469 . . . . 75.23 111.86 -177.622 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.853 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 44.4 tt0 -131.82 164.81 25.22 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 115.374 -0.83 . . . . 74.33 110.13 -177.221 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.499 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 96.9 m-85 -117.1 102.93 9.72 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 122.354 0.262 . . . . 75.13 111.142 -178.584 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.8 m -98.26 157.41 3.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 120.766 0.317 . . . . 73.24 110.74 178.501 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.572 ' HB3' ' O ' ' A' ' 48' ' ' ARG . 43.5 t -92.21 177.89 6.02 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.976 -0.379 . . . . 63.13 109.976 178.51 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.496 ' HD3' ' C ' ' A' ' 45' ' ' ARG . 0.1 OUTLIER -69.59 117.04 10.69 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 116.171 -0.468 . . . . 71.44 110.469 -176.241 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 89.63 -125.23 7.74 Favored Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.972 -0.632 . . . . 62.21 112.352 175.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -116.23 26.02 10.23 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.002 0.429 . . . . 71.43 110.533 -179.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.572 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 28.6 mmm180 -88.64 119.02 28.72 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.829 -0.804 . . . . 74.21 108.829 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -79.26 159.98 27.04 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.04 0.448 . . . . 74.41 111.058 -177.325 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.54 HG11 ' HA ' ' A' ' 73' ' ' CYS . 27.5 m -126.83 139.15 52.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.796 -0.638 . . . . 70.42 110.369 179.083 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.9 p -103.19 95.53 3.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 122.093 0.949 . . . . 74.5 109.366 172.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.46 171.26 32.94 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 115.005 -0.998 . . . . 74.22 111.446 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -78.07 52.01 3.88 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.486 2.124 . . . . 70.42 111.145 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.68 ' HD3' ' HG3' ' A' ' 41' ' ' GLU . 0.0 OUTLIER -76.66 86.83 3.31 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 122.118 0.961 . . . . 75.22 111.972 -173.397 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -161.96 130.12 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 114.989 -1.005 . . . . 75.54 109.229 174.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.478 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 29.0 mmt180 -129.43 131.52 46.77 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 120.662 0.268 . . . . 75.13 110.484 178.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.451 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 35.2 ttmt -106.58 134.19 50.1 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.071 -0.715 . . . . 74.13 109.071 176.112 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.3 t -74.53 145.18 43.68 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.92 0.39 . . . . 74.1 110.734 -178.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.427 ' C ' ' H ' ' A' ' 61' ' ' ASN . 97.6 mt -112.87 -178.67 3.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.788 -0.642 . . . . 75.32 110.114 -177.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.25 27.54 0.33 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.019 0.438 . . . . 70.22 111.077 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.427 ' H ' ' C ' ' A' ' 59' ' ' LEU . 5.4 p-10 -147.65 172.75 13.55 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.235 -0.654 . . . . 74.35 109.235 -179.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -68.36 -19.03 72.11 Favored Glycine 0 CA--C 1.52 0.375 0 C-N-CA 120.815 -0.707 . . . . 74.22 113.755 -172.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 14.9 m -99.36 146.27 26.47 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.046 0.45 . . . . 64.31 111.089 -178.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.493 ' H ' ' HE2' ' A' ' 67' ' ' MET . 63.8 m95 -77.89 -179.05 5.79 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.732 -0.667 . . . . 74.23 110.481 179.687 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.447 HG22 ' O ' ' A' ' 57' ' ' LYS . 3.1 p -54.05 -49.93 67.87 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 113.064 0.764 . . . . 73.14 113.064 -176.547 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.438 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 14.0 t70 -140.06 141.7 36.21 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.57 -0.286 . . . . 71.12 110.26 -177.562 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' MET . . . . . 0.493 ' HE2' ' H ' ' A' ' 64' ' ' TRP . 65.9 mtt -140.07 80.01 1.74 Allowed 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 119.969 -0.692 . . . . 72.34 111.502 166.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -168.03 88.45 0.25 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.301 -1.0 . . . . 75.03 108.301 157.415 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.8 m -152.78 101.24 2.7 Favored Pre-proline 0 C--N 1.316 -0.848 0 C-N-CA 120.372 -0.531 . . . . 74.5 111.274 -172.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.66 114.64 4.01 Favored 'Trans proline' 0 C--O 1.237 0.438 0 C-N-CA 122.627 2.218 . . . . 64.4 111.553 175.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 t -92.42 134.44 34.95 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.162 0.506 . . . . 73.32 109.972 -179.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.0 ptp85 -101.88 123.32 45.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.801 -0.636 . . . . 75.3 110.811 -176.607 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.54 ' HA ' HG11 ' A' ' 50' ' ' VAL . 60.9 m -76.08 98.17 4.27 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.419 -0.586 . . . . 74.22 109.419 176.616 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 10.7 p 177.04 151.76 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.088 -0.96 . . . . 73.23 108.412 -176.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.417 HH11 ' HD3' ' A' ' 75' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.943 0 CA-C-O 118.335 -0.841 . . . . 74.41 110.292 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.704 0 N-CA-C 111.91 -0.476 . . . . 72.35 111.91 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -83.73 16.74 1.83 Allowed 'Trans proline' 0 CA--C 1.531 0.363 0 C-N-CA 122.978 2.452 . . . . 73.25 113.044 -177.418 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 2.6 p -85.22 111.82 20.18 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.256 -0.429 . . . . 75.23 111.22 179.088 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.6 p -133.16 102.66 5.67 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.125 -0.489 . . . . 74.12 110.42 177.515 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -70.22 116.63 10.79 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.852 0.358 . . . . 74.03 110.36 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.457 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.12 160.21 31.44 Favored Glycine 0 N--CA 1.44 -1.059 0 CA-C-N 115.66 -0.7 . . . . 60.54 111.374 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 38.1 m -92.74 147.17 23.08 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 110.185 -0.302 . . . . 72.14 110.185 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -85.53 -177.65 6.48 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.073 0.463 . . . . 64.22 110.826 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 51.9 mt -86.77 125.43 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 CA-C-N 115.989 -0.55 . . . . 73.43 109.8 175.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 56.1 mt -80.12 136.63 23.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.572 -0.74 . . . . 72.13 110.106 -179.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 45.5 m170 -54.49 128.57 60.74 Favored Pre-proline 0 C--N 1.329 -0.295 0 N-CA-C 109.843 -0.429 . . . . 73.31 109.843 173.178 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.431 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.5 Cg_exo -51.24 122.45 10.1 Favored 'Trans proline' 0 N--CA 1.461 -0.408 0 C-N-CA 122.501 2.134 . . . . 71.32 111.479 177.704 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 15.7 Cg_exo -69.09 -159.05 0.05 OUTLIER 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 123.081 2.52 . . . . 72.42 111.747 179.838 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -59.93 159.81 8.67 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.557 -0.534 . . . . 72.24 109.557 176.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -39.42 100.9 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 113.687 0.995 . . . . 74.13 113.687 -169.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -167.76 -140.2 2.86 Favored Glycine 0 N--CA 1.444 -0.821 0 CA-C-N 114.287 -1.324 . . . . 71.54 110.368 179.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -170.28 -171.01 35.3 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.521 -0.847 . . . . 73.45 112.088 176.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 18.5 mt -136.49 136.17 48.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.299 0.571 . . . . 71.22 111.005 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.789 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 19.1 tpt85 -107.86 119.23 38.87 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 115.266 -0.879 . . . . 74.22 110.179 -176.591 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.639 ' HB3' ' HE1' ' A' ' 38' ' ' TYR . 99.5 m-85 -96.2 -171.3 2.28 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.223 -0.444 . . . . 74.51 110.872 -179.474 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.424 HH11 ' HD3' ' A' ' 21' ' ' ARG . 1.5 mmp_? -91.39 -72.2 0.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.981 -0.554 . . . . 74.3 111.466 -178.395 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -128.2 63.85 0.61 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.494 -0.86 . . . . 71.12 112.157 -176.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.482 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 75.4 mt -125.15 121.29 33.79 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.895 0.379 . . . . 64.52 110.832 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.5 t -83.01 -179.47 7.45 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 115.664 -0.698 . . . . 75.32 109.944 176.238 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 10.3 mmt180 -76.09 -174.56 2.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.093 0.473 . . . . 73.32 111.817 -175.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 24.4 t70 55.2 27.69 10.04 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.121 -0.945 . . . . 65.24 110.169 -175.447 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.458 ' O ' HG22 ' A' ' 28' ' ' VAL . 26.9 mt-30 -134.03 -164.32 1.48 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.519 -0.764 . . . . 73.2 110.271 -178.097 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 27' ' ' GLN . 4.6 m 53.59 15.0 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 124.757 1.223 . . . . 75.0 112.765 178.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -89.46 -19.11 25.51 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.419 -0.355 . . . . 75.45 110.687 178.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.47 86.96 0.81 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.008 0.432 . . . . 75.11 111.037 178.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.5 mt -128.45 106.88 15.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 108.855 -0.794 . . . . 74.23 108.855 176.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -73.14 -40.0 65.26 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.261 -0.427 . . . . 73.04 111.855 -172.276 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.457 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 81.9 m-85 -135.55 116.9 14.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.085 0.469 . . . . 74.1 111.929 -176.267 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -81.58 135.78 49.28 Favored Pre-proline 0 C--N 1.321 -0.633 0 N-CA-C 108.883 -0.784 . . . . 73.11 108.883 169.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.36 153.3 61.34 Favored 'Trans proline' 0 C--O 1.238 0.481 0 C-N-CA 122.327 2.018 . . . . 63.24 112.929 -176.068 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.482 HG21 ' HA ' ' A' ' 59' ' ' LEU . 2.9 p -68.19 85.72 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.351 0 CA-C-O 122.04 0.924 . . . . 72.31 109.629 174.781 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 16.6 t70 175.32 -39.46 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.86 -1.064 . . . . 75.53 109.666 -170.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.639 ' HE1' ' HB3' ' A' ' 20' ' ' TYR . 0.2 OUTLIER -74.02 126.86 31.43 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.987 -1.006 . . . . 75.21 112.405 -171.979 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.541 ' HG2' ' HB2' ' A' ' 57' ' ' LYS . 40.9 mt-10 -107.84 127.52 53.79 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.427 -0.806 . . . . 74.51 109.278 172.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 44.8 pt -110.0 142.82 21.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.005 0.431 . . . . 75.23 111.441 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.789 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.3 tt0 -107.54 147.87 29.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.706 -0.679 . . . . 74.33 109.918 176.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.438 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 94.4 m-85 -103.83 101.88 11.69 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.406 -0.361 . . . . 75.13 110.046 177.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -95.2 170.45 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.714 0.292 . . . . 73.24 111.006 -178.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.557 ' HB2' HG12 ' A' ' 50' ' ' VAL . 26.1 t -93.27 179.8 5.3 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.644 -0.502 . . . . 63.13 109.644 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 2.0 tmt_? -78.59 93.37 4.83 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.847 0.356 . . . . 71.44 110.932 -175.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.49 -136.16 13.35 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.742 -0.742 . . . . 62.21 112.445 175.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 8.0 mp0 -89.89 14.88 10.95 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.269 0.557 . . . . 71.43 109.736 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.475 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 15.7 mmt-85 -88.56 137.53 32.24 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.53 -0.759 . . . . 74.21 109.203 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -105.46 165.06 11.4 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.054 0.454 . . . . 74.41 110.614 176.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.557 HG12 ' HB2' ' A' ' 44' ' ' CYS . 34.2 m -121.87 136.09 59.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.793 -0.639 . . . . 70.42 109.486 177.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.418 HG11 ' O ' ' A' ' 51' ' ' VAL . 7.2 p -93.0 95.75 5.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 122.275 1.036 . . . . 74.5 109.018 174.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.87 171.8 33.22 Favored Glycine 0 N--CA 1.443 -0.863 0 CA-C-N 114.567 -1.197 . . . . 74.22 111.375 -178.547 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -82.28 42.22 1.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.594 2.196 . . . . 70.42 110.387 175.641 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.601 ' HD3' ' HG3' ' A' ' 41' ' ' GLU . 0.0 OUTLIER -75.13 86.39 2.39 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.796 0.807 . . . . 75.22 112.871 -170.394 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.459 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.4 p -161.85 126.5 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-N 114.903 -1.044 . . . . 75.54 109.026 169.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.459 ' HD3' ' O ' ' A' ' 55' ' ' VAL . 22.4 mmt180 -134.89 128.43 32.59 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.28 -0.418 . . . . 75.13 110.076 -178.19 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.541 ' HB2' ' HG2' ' A' ' 39' ' ' GLU . 38.4 ttpt -107.23 136.4 47.13 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 116.05 -0.523 . . . . 74.13 110.031 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 43.8 t -77.53 134.35 38.32 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.203 -0.453 . . . . 74.1 110.179 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.482 ' HA ' HG21 ' A' ' 36' ' ' VAL . 97.8 mt -102.9 -178.74 3.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.127 -0.488 . . . . 75.32 109.811 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.42 51.76 0.9 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.328 0.585 . . . . 70.22 111.029 179.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -160.65 170.67 20.36 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.279 -0.873 . . . . 74.35 108.926 177.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -85.46 38.53 3.01 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 120.721 -0.752 . . . . 74.22 113.802 -173.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.3 m -156.67 151.71 26.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 117.229 0.515 . . . . 64.31 110.537 178.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 71.2 m95 -79.29 167.91 20.27 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.179 -0.464 . . . . 74.23 109.975 178.068 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 17.8 p -55.19 -65.29 0.61 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.043 0.449 . . . . 73.14 111.99 -177.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -125.85 97.19 5.03 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.976 -0.75 . . . . 71.12 108.976 176.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 27.0 ttt -100.69 76.25 1.79 Allowed 'General case' 0 C--N 1.321 -0.663 0 C-N-CA 118.817 -1.153 . . . . 72.34 110.7 -178.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -171.76 89.89 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.276 -1.329 . . . . 75.03 108.568 160.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.5 m -135.46 119.41 13.07 Favored Pre-proline 0 C--N 1.317 -0.832 0 C-N-CA 119.758 -0.777 . . . . 74.5 112.004 -172.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -83.1 106.85 1.44 Allowed 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.867 2.378 . . . . 64.4 112.576 178.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.475 ' HB2' HG21 ' A' ' 50' ' ' VAL . 12.1 p -95.39 105.41 17.37 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.042 0.449 . . . . 73.32 110.813 178.634 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.8 ptp85 -89.18 125.18 34.95 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.159 -0.473 . . . . 75.3 110.955 -177.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.412 ' HA ' HG13 ' A' ' 50' ' ' VAL . 59.7 m -72.44 122.06 20.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.123 -0.49 . . . . 74.22 110.572 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 85.8 t -137.56 136.15 46.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.763 -0.458 . . . . 73.23 109.763 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.247 0.939 0 CA-C-O 119.079 -0.486 . . . . 74.41 110.669 -179.093 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.623 0 N-CA-C 111.812 -0.515 . . . . 72.35 111.812 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -84.83 30.95 0.5 Allowed 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 123.188 2.592 . . . . 73.25 112.462 -176.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 30.4 p -79.59 98.97 7.11 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.927 0.394 . . . . 75.23 110.183 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 27.5 m -128.36 98.63 5.12 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.238 0.542 . . . . 74.12 110.579 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -101.85 99.13 9.32 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.696 -0.853 . . . . 74.03 108.696 174.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -160.64 164.34 34.55 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.535 -0.84 . . . . 60.54 112.573 -174.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.429 ' N ' ' SG ' ' A' ' 58' ' ' CYS . 35.2 m -105.06 150.41 25.01 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 109.49 -0.559 . . . . 72.14 109.49 -178.612 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.4 pt20 -73.44 179.67 3.91 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.113 0.483 . . . . 64.22 110.607 177.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.4 tt -88.24 140.64 15.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.755 -0.657 . . . . 73.43 110.201 -178.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 57.3 mt -96.25 135.91 28.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.388 -0.369 . . . . 72.13 110.937 -176.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.5 t-80 -89.29 130.94 42.14 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 115.928 -0.578 . . . . 73.31 109.485 178.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -57.86 109.99 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.795 2.33 . . . . 71.32 112.393 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -75.67 -59.09 0.04 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.437 0 C-N-CA 122.691 2.261 . . . . 72.42 112.298 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.43 ' C ' ' H ' ' A' ' 16' ' ' GLY . 5.5 t-105 -91.59 -178.43 5.08 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.102 -0.499 . . . . 72.24 109.851 -176.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -71.29 15.64 0.12 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 112.237 0.458 . . . . 74.13 112.237 -177.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.517 ' HA2' ' H ' ' A' ' 45' ' ' ARG . . . -96.65 -147.56 22.83 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.508 -0.637 . . . . 71.54 111.508 175.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.74 -170.56 30.84 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 121.071 -0.585 . . . . 73.45 111.78 179.524 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.1 mt -129.38 134.89 62.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.093 0.473 . . . . 71.22 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -106.77 135.41 48.34 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.44 -0.8 . . . . 74.22 109.931 -178.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.492 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 91.4 m-85 -101.02 -171.35 1.98 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.305 -0.407 . . . . 74.51 110.017 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 21.6 mtt180 -80.17 -44.49 19.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.814 0.34 . . . . 74.3 111.435 -179.014 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.38 61.61 0.24 Allowed Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.583 -0.818 . . . . 71.12 112.13 -178.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 80.7 mt -120.81 116.76 25.82 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.79 0.329 . . . . 64.52 110.456 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.3 t -78.89 -179.44 6.6 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.636 -0.711 . . . . 75.32 109.734 175.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.452 ' C ' ' H ' ' A' ' 27' ' ' GLN . 99.4 mtt180 -67.8 -172.75 0.29 Allowed 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.741 0.305 . . . . 73.32 111.479 -177.418 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 30.5 t70 68.09 -42.79 0.47 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.629 0.772 . . . . 65.24 110.882 -171.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.561 ' O ' HG22 ' A' ' 28' ' ' VAL . 20.4 mt-30 -71.87 -179.49 2.72 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.328 -0.396 . . . . 73.2 110.806 176.594 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.561 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.8 m 57.45 9.88 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 124.559 1.144 . . . . 75.0 112.347 -178.609 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -82.71 -17.73 43.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.272 0.558 . . . . 75.45 109.896 175.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -161.9 94.53 0.94 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.091 -0.959 . . . . 75.11 110.191 179.127 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 57.8 mt -131.98 130.27 61.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.578 -0.737 . . . . 74.23 109.42 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -89.95 -51.87 5.26 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.379 -0.373 . . . . 73.04 111.301 -175.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -134.72 131.48 37.69 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.296 0.569 . . . . 74.1 112.133 -175.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -97.59 117.42 65.39 Favored Pre-proline 0 C--N 1.322 -0.622 0 N-CA-C 107.876 -1.157 . . . . 73.11 107.876 168.201 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -56.52 147.13 71.23 Favored 'Trans proline' 0 C--O 1.237 0.434 0 C-N-CA 123.205 2.603 . . . . 63.24 113.373 -173.196 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.55 83.87 0.05 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.323 0 CA-C-O 121.85 0.833 . . . . 72.31 110.771 177.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.8 t70 168.45 -33.46 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 114.578 -1.192 . . . . 75.53 108.942 -176.484 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.492 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 14.1 t80 -67.56 141.11 56.95 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.324 -0.853 . . . . 75.21 110.636 -177.227 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.429 ' HG2' ' HE2' ' A' ' 57' ' ' LYS . 10.5 mt-10 -125.36 142.15 51.67 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.53 -0.759 . . . . 74.51 110.083 -177.029 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.631 HG13 ' HB2' ' A' ' 56' ' ' ARG . 46.4 pt -130.65 169.31 21.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.715 0.293 . . . . 75.23 110.694 178.748 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -128.52 139.24 52.41 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.189 -0.459 . . . . 74.33 110.981 -178.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.401 ' O ' HG23 ' A' ' 50' ' ' VAL . 5.1 m-30 -83.65 102.32 12.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.765 -0.652 . . . . 75.13 110.349 176.161 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.9 m -108.31 170.93 2.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 120.898 0.38 . . . . 73.24 110.909 -178.535 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.666 ' HB2' HG11 ' A' ' 50' ' ' VAL . 10.5 t -109.64 143.63 39.12 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.06 -0.718 . . . . 63.13 109.06 175.012 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.517 ' H ' ' HA2' ' A' ' 16' ' ' GLY . 75.7 ttt180 -77.58 133.68 38.42 Favored 'General case' 0 N--CA 1.44 -0.974 0 CA-C-N 115.029 -0.987 . . . . 71.44 110.588 -172.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.13 -149.84 18.81 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.799 -0.715 . . . . 62.21 111.688 -178.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -93.66 16.08 14.72 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.406 0.622 . . . . 71.43 109.646 176.799 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.644 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 40.8 mmm-85 -89.22 118.94 29.28 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.317 -0.856 . . . . 74.21 109.169 178.074 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.497 ' HB2' ' HA ' ' A' ' 75' ' ' ARG . 48.8 mt-10 -95.92 171.37 8.68 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.991 -0.374 . . . . 74.41 109.991 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.666 HG11 ' HB2' ' A' ' 44' ' ' CYS . 5.5 m -129.86 126.25 62.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.948 0.404 . . . . 70.42 111.545 -177.593 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.585 HG12 ' HB ' ' A' ' 74' ' ' VAL . 3.5 p -96.37 95.76 5.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 108.463 -0.94 . . . . 74.5 108.463 167.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.51 172.73 33.01 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.373 -0.83 . . . . 74.22 112.497 -173.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -75.27 52.98 3.31 Favored 'Trans proline' 0 N--CA 1.462 -0.335 0 C-N-CA 123.012 2.475 . . . . 70.42 110.734 173.341 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 19.4 pttp -72.11 89.54 1.15 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.512 -0.767 . . . . 75.22 111.863 -174.163 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -160.54 132.24 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.821 -0.627 . . . . 75.54 110.574 176.581 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.631 ' HB2' HG13 ' A' ' 40' ' ' ILE . 55.1 mmt-85 -138.35 126.8 23.24 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.933 -0.576 . . . . 75.13 110.195 176.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.429 ' HE2' ' HG2' ' A' ' 39' ' ' GLU . 37.3 ttmt -125.08 137.48 54.2 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.007 -0.738 . . . . 74.13 109.007 175.149 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 7' ' ' CYS . 53.3 t -81.31 144.17 31.7 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.894 0.378 . . . . 74.1 111.073 -176.117 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 94.4 mt -100.95 -179.07 3.94 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.716 -0.675 . . . . 75.32 111.005 -178.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.92 -20.58 60.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.185 0.517 . . . . 70.22 110.374 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -101.43 169.1 9.1 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.397 -0.82 . . . . 74.35 109.313 175.283 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.75 60.56 3.36 Favored Glycine 0 CA--C 1.518 0.253 0 C-N-CA 120.83 -0.7 . . . . 74.22 113.28 -175.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 49.4 m -158.63 144.31 16.65 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 122.789 0.436 . . . . 64.31 109.939 177.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 75.7 m95 -81.19 161.65 23.93 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.75 -0.463 . . . . 74.23 109.75 177.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 p -52.9 -39.14 62.47 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.221 0.823 . . . . 73.14 113.221 -174.152 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -134.03 140.86 46.95 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 110.186 -0.302 . . . . 71.12 110.186 178.588 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 50.5 mtt -144.36 80.01 1.63 Allowed 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.367 -0.533 . . . . 72.34 111.453 167.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -168.6 88.85 0.22 Allowed 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.416 -0.957 . . . . 75.03 108.416 156.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.8 m -155.83 90.11 2.83 Favored Pre-proline 0 C--N 1.317 -0.823 0 C-N-CA 120.283 -0.567 . . . . 74.5 111.283 -172.076 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -74.18 90.28 1.0 Allowed 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.689 2.26 . . . . 64.4 110.396 172.407 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.2 t -69.26 116.93 10.25 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.985 -0.552 . . . . 73.32 110.724 -175.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.0 ptp180 -79.57 130.67 35.6 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.534 -0.757 . . . . 75.3 110.409 179.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.524 ' HA ' HG12 ' A' ' 50' ' ' VAL . 73.6 m -81.02 97.89 7.71 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.309 0.576 . . . . 74.22 110.013 178.261 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.585 ' HB ' HG12 ' A' ' 51' ' ' VAL . 59.6 t -136.68 117.99 18.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.184 -0.916 . . . . 73.23 108.653 177.773 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.497 ' HA ' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.556 -0.735 . . . . 74.41 111.161 -176.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.769 0 N-CA-C 111.67 -0.572 . . . . 72.35 111.67 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -70.08 92.81 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.796 2.331 . . . . 73.25 111.549 177.151 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 27.1 m -151.82 139.31 19.56 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.036 -0.529 . . . . 75.23 109.984 -178.01 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.0 m -143.06 99.5 3.47 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.74 -0.467 . . . . 74.12 109.74 177.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -75.43 99.44 4.17 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.222 -0.445 . . . . 74.03 110.617 -178.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.56 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -159.91 152.56 23.44 Favored Glycine 0 N--CA 1.441 -1.002 0 C-N-CA 120.572 -0.823 . . . . 60.54 112.694 -179.144 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.1 m -86.52 158.76 19.47 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 110.13 -0.322 . . . . 72.14 110.13 178.137 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.8 pt20 -88.86 -177.19 5.44 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.052 0.453 . . . . 64.22 111.192 -179.106 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.509 HD13 ' HB ' ' A' ' 31' ' ' ILE . 60.7 mt -87.49 138.16 19.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.615 -0.72 . . . . 73.43 110.487 -177.715 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 64.8 mt -99.78 131.06 47.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.18 -0.464 . . . . 72.13 109.929 178.199 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -76.55 126.09 86.59 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.868 -0.605 . . . . 73.31 110.171 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_endo -58.51 112.69 1.26 Allowed 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.72 2.28 . . . . 71.32 111.921 179.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -74.87 -87.6 0.0 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.393 0 C-N-CA 122.481 2.121 . . . . 72.42 113.091 -176.059 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 27.8 t-105 -101.37 -177.84 3.56 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.999 -0.371 . . . . 72.24 109.999 -178.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 56.7 mm-40 -39.81 101.93 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.746 0.818 . . . . 74.13 111.98 177.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.424 ' HA2' ' HA ' ' A' ' 44' ' ' CYS . . . 171.32 -167.6 40.72 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.39 -0.91 . . . . 71.54 112.637 177.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -159.17 -170.52 23.81 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.989 -0.844 . . . . 73.45 110.989 178.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.436 HG21 ' HB ' ' A' ' 40' ' ' ILE . 16.6 mt -135.05 135.59 52.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.449 0.642 . . . . 71.22 111.835 -177.06 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.452 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 55.6 ttm-85 -99.49 138.56 36.4 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.081 -0.963 . . . . 74.22 110.578 178.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.508 ' HB3' ' HE1' ' A' ' 38' ' ' TYR . 89.1 m-85 -110.76 -168.03 1.26 Allowed 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.132 -0.321 . . . . 74.51 110.132 177.565 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -62.04 -57.82 10.2 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 120.88 0.371 . . . . 74.3 110.487 178.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -161.55 67.76 0.24 Allowed Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 121.055 -0.593 . . . . 71.12 111.872 178.489 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 92.7 mt -118.12 126.77 52.91 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.965 0.412 . . . . 64.52 110.949 -179.18 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.8 t -85.03 -176.71 6.32 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.387 -0.824 . . . . 75.32 110.46 176.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.428 ' C ' ' H ' ' A' ' 27' ' ' GLN . 29.9 ptt180 -61.94 -173.51 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 115.923 -0.58 . . . . 73.32 111.818 -177.116 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.9 t70 65.06 -46.14 0.35 Allowed 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 123.894 0.878 . . . . 65.24 112.263 -179.116 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.551 ' O ' HG21 ' A' ' 28' ' ' VAL . 18.4 mt-30 -68.96 -169.76 0.19 Allowed 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 123.079 0.552 . . . . 73.2 111.257 -179.284 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.551 HG21 ' O ' ' A' ' 27' ' ' GLN . 3.2 m 55.61 15.66 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 124.264 1.026 . . . . 75.0 111.832 -178.206 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 40.1 pttt -81.42 -14.33 57.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.829 -0.623 . . . . 75.45 110.066 175.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -161.21 117.48 2.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.601 -0.727 . . . . 75.11 110.436 177.154 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.509 ' HB ' HD13 ' A' ' 9' ' ' ILE . 42.1 mt -138.6 152.71 25.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 109.105 -0.702 . . . . 74.23 109.105 179.161 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -105.07 -65.09 1.07 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.673 0.273 . . . . 73.04 110.646 179.018 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.56 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 96.5 m-85 -140.73 128.61 21.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.412 -0.358 . . . . 74.1 110.704 -179.203 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -88.08 119.59 70.43 Favored Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 109.158 -0.682 . . . . 73.11 109.158 175.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.01 152.47 43.76 Favored 'Trans proline' 0 C--O 1.236 0.402 0 C-N-CA 122.899 2.4 . . . . 63.24 113.29 -176.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.456 HG21 ' HA ' ' A' ' 59' ' ' LEU . 3.5 p -62.63 94.93 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-O 121.707 0.765 . . . . 72.31 111.023 178.235 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.0 t70 173.85 -43.41 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.574 -1.194 . . . . 75.53 109.36 -177.424 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.508 ' HE1' ' HB3' ' A' ' 20' ' ' TYR . 5.3 m-85 -50.41 123.01 7.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.039 -0.982 . . . . 75.21 112.596 -175.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.583 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 35.2 mt-10 -114.18 100.01 8.05 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.849 -1.069 . . . . 74.51 108.575 172.349 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.567 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 34.7 pt -90.7 143.64 10.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.142 0.496 . . . . 75.23 111.3 -175.772 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.452 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 42.5 tt0 -109.82 136.49 49.05 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.481 -0.781 . . . . 74.33 110.269 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.42 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 95.5 m-85 -85.43 100.58 11.97 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 116.216 -0.447 . . . . 75.13 110.051 175.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.3 m -100.98 163.39 3.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.045 -0.525 . . . . 73.24 110.199 179.389 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.803 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 3.4 t -90.38 147.07 23.68 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 107.93 -1.137 . . . . 63.13 107.93 173.112 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -59.72 108.61 0.77 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.17 0.509 . . . . 71.44 110.942 -170.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.21 -137.21 13.13 Favored Glycine 0 N--CA 1.448 -0.563 0 CA-C-N 115.703 -0.68 . . . . 62.21 112.086 178.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.413 ' H ' ' CD ' ' A' ' 47' ' ' GLU . 0.5 OUTLIER -101.22 33.53 2.85 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.301 0.572 . . . . 71.43 110.278 -179.274 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.803 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 30.1 mmm180 -89.22 145.49 25.37 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.786 -0.643 . . . . 74.21 109.974 179.682 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.589 ' HB2' ' HB3' ' A' ' 75' ' ' ARG . 43.1 mt-10 -91.57 148.96 21.9 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.231 0.538 . . . . 74.41 112.201 -174.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.726 HG13 ' HB2' ' A' ' 44' ' ' CYS . 11.6 m -138.64 150.46 23.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.368 -0.833 . . . . 70.42 110.131 178.083 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -135.65 97.35 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 122.019 0.914 . . . . 74.5 109.558 170.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.42 173.09 32.26 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-N 114.462 -1.245 . . . . 74.22 110.6 -177.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.456 ' HG2' HG23 ' A' ' 69' ' ' THR . 69.9 Cg_endo -77.17 57.38 5.81 Favored 'Trans proline' 0 C--O 1.235 0.358 0 C-N-CA 122.068 1.845 . . . . 70.42 110.733 176.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.42 ' HB2' ' H ' ' A' ' 42' ' ' TYR . 20.9 pttp -76.4 87.04 3.16 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.383 -0.826 . . . . 75.22 111.608 -173.08 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -162.57 128.54 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.397 -0.82 . . . . 75.54 109.906 172.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.583 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 26.9 mmt180 -130.1 123.69 31.0 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.622 -0.51 . . . . 75.13 109.622 175.281 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.7 ttmm -105.08 122.7 46.42 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.537 -0.542 . . . . 74.13 109.537 178.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.5 t -74.56 142.51 44.71 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.309 -0.405 . . . . 74.1 110.635 -179.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.456 ' HA ' HG21 ' A' ' 36' ' ' VAL . 94.7 mt -128.64 -179.24 4.95 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.844 -0.616 . . . . 75.32 109.516 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.02 59.27 2.13 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.367 0.603 . . . . 70.22 111.654 -177.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -160.52 165.05 31.55 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.802 -0.814 . . . . 74.35 108.802 175.328 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -80.73 40.27 2.45 Favored Glycine 0 CA--C 1.517 0.214 0 C-N-CA 120.662 -0.78 . . . . 74.22 113.067 -175.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 27.6 t -161.84 163.32 29.4 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.234 -0.654 . . . . 64.31 109.234 -178.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 52.8 m95 -97.16 -179.8 4.65 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 110.033 -0.358 . . . . 74.23 110.033 -176.486 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -56.35 -24.73 46.02 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 112.776 0.658 . . . . 73.14 112.776 -176.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.521 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 11.2 t70 -160.71 137.02 8.54 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.384 -0.599 . . . . 71.12 109.384 178.304 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 65.9 mtt -130.38 77.0 1.76 Allowed 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.436 -0.906 . . . . 72.34 110.611 164.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -170.83 88.63 0.12 Allowed 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 108.855 -0.795 . . . . 75.03 108.855 157.482 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.456 HG23 ' HG2' ' A' ' 53' ' ' PRO . 4.7 m -153.5 107.32 2.56 Favored Pre-proline 0 C--N 1.317 -0.809 0 C-N-CA 120.817 -0.353 . . . . 74.5 110.681 -176.867 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -70.21 95.52 0.59 Allowed 'Trans proline' 0 N--CA 1.462 -0.329 0 C-N-CA 122.694 2.263 . . . . 64.4 112.031 178.002 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 m -78.36 109.44 12.51 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.175 0.512 . . . . 73.32 109.775 177.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.1 ptt180 -97.51 130.6 44.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.574 -0.739 . . . . 75.3 112.085 -172.204 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.499 ' HA ' HG11 ' A' ' 50' ' ' VAL . 81.2 m -82.66 118.25 23.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.665 -0.698 . . . . 74.22 109.824 175.03 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 p -156.36 136.44 4.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 121.082 0.467 . . . . 73.23 110.309 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.589 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 16.1 ptm180 . . . . . 0 C--O 1.244 0.765 0 CA-C-N 115.693 -0.685 . . . . 74.41 109.626 -178.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.545 0 N-CA-C 112.066 -0.413 . . . . 72.35 112.066 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -74.87 74.32 3.97 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.49 2.127 . . . . 73.25 112.845 -177.014 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 37.2 p -104.51 115.98 31.3 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.006 -0.543 . . . . 75.23 110.292 175.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.6 m -109.82 98.02 7.43 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.8 -0.444 . . . . 74.12 109.8 179.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -112.98 98.42 7.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.911 -0.586 . . . . 74.03 109.614 -177.512 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.73 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -162.2 152.57 22.94 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.492 -0.861 . . . . 60.54 112.7 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 60.7 m -90.11 147.53 23.56 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.985 -0.376 . . . . 72.14 109.985 176.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -85.81 -179.54 6.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.777 0.322 . . . . 64.22 110.892 -179.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.554 HD11 ' HB ' ' A' ' 31' ' ' ILE . 56.3 mt -88.16 130.62 37.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.939 -0.573 . . . . 73.43 110.313 176.831 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 68.7 mt -73.25 136.18 26.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.745 -0.661 . . . . 72.13 110.239 179.032 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.6 t-80 -68.81 138.1 90.39 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 115.989 -0.55 . . . . 73.31 109.936 -178.03 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_exo -40.97 118.87 0.72 Allowed 'Trans proline' 0 C--N 1.351 0.694 0 C-N-CA 123.716 2.944 . . . . 71.32 113.826 -176.723 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.448 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 81.7 Cg_endo -87.5 -149.02 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.128 2.552 . . . . 72.42 112.728 -179.51 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.448 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 9.1 t-105 -75.15 -179.01 4.14 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.69 -0.686 . . . . 72.24 110.516 -177.773 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -46.03 100.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 123.234 0.613 . . . . 74.13 112.172 177.267 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.13 -156.86 28.99 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.331 -0.708 . . . . 71.54 111.331 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.85 -171.23 24.4 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.562 -0.828 . . . . 73.45 111.925 178.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.63 131.44 66.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.651 0.738 . . . . 71.22 111.531 -178.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.678 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 7.9 tpm_? -96.92 104.56 16.58 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 114.298 -1.319 . . . . 74.22 110.064 -178.285 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.454 ' HA ' HG22 ' A' ' 40' ' ' ILE . 97.7 m-85 -80.5 -171.46 3.07 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.519 -0.309 . . . . 74.51 110.187 177.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.7 ttm180 -78.96 -65.35 1.01 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.67 0.272 . . . . 74.3 110.411 -178.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -136.16 37.4 1.89 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.423 -0.894 . . . . 71.12 112.275 -178.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.445 HD11 HG13 ' A' ' 28' ' ' VAL . 80.6 mt -102.52 119.73 39.32 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.925 0.393 . . . . 64.52 111.359 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.4 t -94.64 -177.2 4.13 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.712 -0.676 . . . . 75.32 109.662 175.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 77.5 mtt180 -66.88 -173.43 0.24 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.047 0.451 . . . . 73.32 111.627 -176.466 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.0 t0 59.07 19.24 7.1 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 122.029 0.919 . . . . 65.24 110.183 -177.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 23.4 mt-30 -140.35 -165.19 1.86 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.887 -1.052 . . . . 73.2 109.971 -178.39 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.445 HG13 HD11 ' A' ' 23' ' ' LEU . 11.5 m 49.44 24.01 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.312 1.045 . . . . 75.0 112.29 178.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -88.54 -22.38 23.61 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.789 -0.641 . . . . 75.45 110.758 -179.318 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.42 101.07 0.6 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.884 -0.598 . . . . 75.11 110.434 176.6 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.554 ' HB ' HD11 ' A' ' 9' ' ' ILE . 69.0 mt -127.99 138.24 55.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.155 -0.683 . . . . 74.23 109.155 177.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -79.83 -58.25 3.26 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.864 0.364 . . . . 73.04 110.543 -176.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.73 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 82.2 m-85 -139.27 138.4 36.73 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.971 -0.559 . . . . 74.1 110.953 -176.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.95 142.65 32.35 Favored Pre-proline 0 C--N 1.322 -0.593 0 N-CA-C 109.11 -0.7 . . . . 73.11 109.11 172.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -61.33 161.68 22.73 Favored 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 122.648 2.232 . . . . 63.24 112.727 -179.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 p -68.11 143.62 15.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.763 -0.653 . . . . 72.31 110.886 -178.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.5 t70 68.13 19.73 9.13 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.663 0.744 . . . . 75.53 110.942 -178.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -78.12 132.02 37.49 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.742 -0.836 . . . . 75.21 108.742 173.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -123.1 138.28 54.71 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.461 -0.336 . . . . 74.51 110.404 -175.147 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.607 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 14.5 pt -129.88 150.17 34.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.807 -0.633 . . . . 75.23 110.684 -177.69 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.678 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 37.7 tt0 -115.44 152.3 33.17 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.946 -0.57 . . . . 74.33 110.551 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -100.11 101.87 13.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.256 -0.429 . . . . 75.13 110.854 178.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.3 m -94.55 155.02 3.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 120.727 0.299 . . . . 73.24 110.244 177.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 9.8 t -90.91 -179.3 5.45 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.405 -0.591 . . . . 63.13 109.405 -178.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.45 ' HA ' ' HD3' ' A' ' 45' ' ' ARG . 2.3 mmt180 -81.5 153.99 26.53 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.744 -0.382 . . . . 71.44 111.342 -179.167 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.12 -138.44 24.47 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 110.856 -0.898 . . . . 62.21 110.856 -174.175 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -111.08 19.83 18.04 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.475 0.655 . . . . 71.43 109.389 174.545 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.547 ' HA ' ' HD2' ' A' ' 75' ' ' ARG . 7.4 mmm180 -88.9 150.9 22.64 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.269 -0.878 . . . . 74.21 109.556 -177.408 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.437 ' H ' ' HB3' ' A' ' 75' ' ' ARG . 37.6 mt-10 -120.99 170.44 9.51 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.868 0.366 . . . . 74.41 111.005 -171.277 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 22.7 m -118.3 150.5 20.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.202 -0.453 . . . . 70.42 110.903 -177.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.649 HG11 ' HB ' ' A' ' 74' ' ' VAL . 6.4 p -113.01 96.76 4.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 122.156 0.979 . . . . 74.5 109.116 170.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.55 173.4 33.01 Favored Glycine 0 N--CA 1.442 -0.966 0 CA-C-N 114.834 -1.076 . . . . 74.22 110.874 -177.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.469 ' HG2' HG23 ' A' ' 69' ' ' THR . 47.9 Cg_endo -72.39 60.32 3.3 Favored 'Trans proline' 0 CA--C 1.529 0.26 0 C-N-CA 122.191 1.927 . . . . 70.42 110.304 170.008 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.555 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 32.1 pttt -73.62 89.52 1.74 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.139 -0.937 . . . . 75.22 111.209 -175.411 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.9 p -160.08 132.71 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.727 -0.67 . . . . 75.54 110.51 178.183 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.607 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 24.2 mmt180 -125.68 114.96 19.36 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.185 -0.672 . . . . 75.13 109.185 173.126 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 41.9 tptt -102.54 116.95 33.64 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.459 -0.791 . . . . 74.13 109.914 -176.147 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . 0.55 ' HB2' ' CZ3' ' A' ' 64' ' ' TRP . 49.3 t -87.91 124.5 33.74 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.137 -0.483 . . . . 74.1 110.074 177.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.404 HD12 HG21 ' A' ' 65' ' ' THR . 41.9 mt -105.08 -177.55 3.4 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.814 -0.63 . . . . 75.32 109.43 176.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -56.63 -32.29 65.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.091 0.472 . . . . 70.22 110.431 174.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -81.06 132.08 35.34 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.44 -0.578 . . . . 74.35 109.44 172.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -77.82 64.1 3.38 Favored Glycine 0 N--CA 1.451 -0.313 0 N-CA-C 114.299 0.479 . . . . 74.22 114.299 -171.164 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 58.2 m -157.14 142.27 17.11 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.539 -0.541 . . . . 64.31 109.539 172.278 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.55 ' CZ3' ' HB2' ' A' ' 58' ' ' CYS . 23.1 m95 -78.19 124.4 28.02 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.05 -0.722 . . . . 74.23 109.05 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.404 HG21 HD12 ' A' ' 59' ' ' LEU . 17.2 p -75.62 33.03 0.11 Allowed 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 114.358 1.244 . . . . 73.14 114.358 -167.805 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -160.75 13.91 0.11 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.865 0.364 . . . . 71.12 110.056 176.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 26.1 ttt -76.65 78.94 3.3 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-O 121.875 0.845 . . . . 72.34 112.416 -165.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -169.68 88.88 0.17 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 114.382 -1.281 . . . . 75.03 107.783 159.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.469 HG23 ' HG2' ' A' ' 53' ' ' PRO . 0.7 OUTLIER -152.78 117.86 2.93 Favored Pre-proline 0 C--N 1.318 -0.801 0 C-N-CA 120.19 -0.604 . . . . 74.5 111.345 -169.751 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -78.72 100.53 1.37 Allowed 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.885 2.39 . . . . 64.4 111.318 174.399 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.7 p -79.39 116.83 19.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.051 0.453 . . . . 73.32 111.112 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.8 ptp180 -89.47 129.2 36.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.729 -0.668 . . . . 75.3 111.285 -177.223 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 62.3 m -82.88 105.5 13.94 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.718 -0.475 . . . . 74.22 109.718 178.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.649 ' HB ' HG11 ' A' ' 51' ' ' VAL . 49.1 t -128.33 84.27 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 121.072 0.463 . . . . 73.23 109.76 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.547 ' HD2' ' HA ' ' A' ' 48' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.751 0 N-CA-C 108.54 -0.911 . . . . 74.41 108.54 -178.728 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.582 0 N-CA-C 111.964 -0.454 . . . . 72.35 111.964 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -69.6 92.9 0.5 Allowed 'Trans proline' 0 C--O 1.236 0.413 0 C-N-CA 122.723 2.282 . . . . 73.25 111.098 176.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 16.9 p -91.82 99.26 12.16 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.941 -0.572 . . . . 75.23 112.369 -173.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.3 m -95.24 107.59 19.7 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.354 -0.98 . . . . 74.12 108.354 169.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -78.2 99.88 6.41 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.275 0.56 . . . . 74.03 111.195 -172.145 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.59 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -159.47 146.96 13.64 Favored Glycine 0 N--CA 1.44 -1.054 0 CA-C-N 115.239 -0.891 . . . . 60.54 111.678 179.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.9 m -92.88 142.93 26.77 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 110.05 -0.352 . . . . 72.14 110.05 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -76.02 -177.62 3.99 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.884 0.374 . . . . 64.22 111.055 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 61.3 mt -87.38 137.66 20.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.057 -0.52 . . . . 73.43 111.176 -175.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 27.5 mt -84.13 156.57 3.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.5 -0.773 . . . . 72.13 110.217 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -82.68 141.47 44.77 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.64 -0.255 . . . . 73.31 110.67 -177.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.54 131.32 21.3 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.74 2.293 . . . . 71.32 112.462 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.452 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 76.2 Cg_endo -87.6 -140.1 0.02 OUTLIER 'Trans proline' 0 CA--C 1.533 0.43 0 C-N-CA 123.176 2.584 . . . . 72.42 112.393 -179.691 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.528 ' HD1' ' H ' ' A' ' 15' ' ' GLU . 1.9 t90 -67.54 -179.44 1.08 Allowed 'General case' 0 CA--C 1.537 0.452 0 CA-C-N 116.071 -0.513 . . . . 72.24 109.641 178.248 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.528 ' H ' ' HD1' ' A' ' 14' ' ' TRP . 29.3 mm-40 -43.2 102.38 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 123.629 0.772 . . . . 74.13 112.886 -176.343 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.08 -154.82 25.66 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 110.224 -1.15 . . . . 71.54 110.224 -177.285 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.95 -171.36 37.61 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.224 -0.989 . . . . 73.45 112.064 176.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.7 mt -111.54 128.88 67.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.745 0.783 . . . . 71.22 111.279 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.729 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 9.2 tpt180 -96.76 127.3 42.61 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.581 -1.191 . . . . 74.22 108.966 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.509 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 77.4 m-85 -91.02 -172.46 3.34 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.341 -0.544 . . . . 74.51 110.021 178.647 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 21' ' ' ARG . 18.9 ttt85 -80.69 -62.78 1.57 Allowed 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.602 -0.439 . . . . 74.3 110.753 -172.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -146.98 57.02 0.5 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.693 -0.765 . . . . 71.12 111.986 177.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 93.2 mt -119.41 139.5 51.92 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.975 0.417 . . . . 64.52 111.246 -176.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.8 t -86.47 173.11 9.84 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.928 -0.578 . . . . 75.32 109.49 174.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.493 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 31.7 ptt180 -79.83 -171.52 2.91 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 121.12 -0.232 . . . . 73.32 110.581 -177.135 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.493 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 12.6 t70 72.77 -38.9 0.43 Allowed 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 109.178 -0.675 . . . . 65.24 109.178 -168.663 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.496 ' O ' HG22 ' A' ' 28' ' ' VAL . 24.0 mt-30 -83.33 -169.12 2.38 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.602 -0.888 . . . . 73.2 108.602 167.096 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.496 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.2 m 55.6 9.54 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 C-N-CA 124.219 1.008 . . . . 75.0 113.593 174.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -92.99 -29.13 16.0 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.076 0.465 . . . . 75.45 109.827 176.541 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.36 91.8 1.63 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.766 -0.652 . . . . 75.11 110.561 177.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.9 mt -115.79 135.7 55.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.706 -0.679 . . . . 74.23 109.209 177.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 15.5 m120 -72.94 -59.76 2.56 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.684 0.278 . . . . 73.04 110.925 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.59 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 74.4 m-85 -131.88 129.9 40.94 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.819 0.343 . . . . 74.1 111.171 -177.163 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.403 ' HA ' ' HD2' ' A' ' 35' ' ' PRO . 3.7 mm? -90.96 113.05 56.81 Favored Pre-proline 0 C--N 1.322 -0.619 0 N-CA-C 108.181 -1.044 . . . . 73.11 108.181 169.026 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 34' ' ' LEU . 11.6 Cg_endo -53.61 156.27 11.88 Favored 'Trans proline' 0 C--O 1.234 0.28 0 C-N-CA 123.432 2.755 . . . . 63.24 113.549 -172.516 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.517 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 13.3 p -54.78 147.44 3.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.484 -0.78 . . . . 72.31 111.098 178.861 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.517 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 15.0 m-20 79.23 5.05 2.23 Favored 'General case' 0 N--CA 1.467 0.425 0 C-N-CA 123.654 0.782 . . . . 75.53 111.571 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.509 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 24.3 t80 -82.75 144.97 29.82 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.808 0.337 . . . . 75.21 110.241 178.406 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.525 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 37.0 mt-10 -135.25 138.16 43.27 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.916 -0.584 . . . . 74.51 110.283 -177.374 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.635 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 20.3 pt -125.76 158.94 34.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 120.805 0.335 . . . . 75.23 110.77 177.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.729 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 49.8 tt0 -116.16 149.86 38.37 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.859 -0.61 . . . . 74.33 110.976 -174.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.408 ' HE2' ' CG ' ' A' ' 56' ' ' ARG . 8.2 m-85 -94.33 102.01 13.99 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.28 -0.418 . . . . 75.13 110.185 175.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.583 HG13 HH11 ' A' ' 19' ' ' ARG . 18.2 m -108.42 156.43 8.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.109 0.481 . . . . 73.24 111.63 -177.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.526 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 5.2 t -96.35 158.47 15.42 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.193 -1.04 . . . . 63.13 108.193 178.437 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -65.59 117.72 8.47 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.26 0.467 . . . . 71.44 112.26 -174.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.34 -137.32 13.65 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.587 -0.733 . . . . 62.21 111.807 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -98.79 22.67 9.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.864 0.84 . . . . 71.43 109.077 174.223 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.582 ' HD2' ' OXT' ' A' ' 75' ' ' ARG . 10.7 mmm180 -88.18 134.19 33.84 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.642 -1.163 . . . . 74.21 109.184 -178.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.58 ' H ' ' HB3' ' A' ' 75' ' ' ARG . 46.4 mt-10 -116.66 170.1 8.85 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 120.98 0.419 . . . . 74.41 110.924 -179.06 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.539 HG13 ' HA ' ' A' ' 73' ' ' CYS . 28.9 m -116.85 149.53 19.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.405 -0.816 . . . . 70.42 109.206 174.199 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -106.12 95.09 3.52 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 122.035 0.922 . . . . 74.5 108.681 170.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.74 172.58 33.8 Favored Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 114.607 -1.179 . . . . 74.22 111.667 -176.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.494 ' HG2' ' CG2' ' A' ' 69' ' ' THR . 56.5 Cg_endo -73.72 53.1 2.68 Favored 'Trans proline' 0 CA--C 1.532 0.413 0 C-N-CA 122.494 2.129 . . . . 70.42 110.713 171.076 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.402 ' HG3' ' O ' ' A' ' 54' ' ' LYS . 48.2 pttt -69.03 91.34 0.48 Allowed 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 114.805 -1.089 . . . . 75.22 111.948 -173.436 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.2 p -160.83 132.11 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.553 0.692 . . . . 75.54 110.912 175.057 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.635 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 42.9 mmt180 -121.23 113.82 20.5 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.528 -0.76 . . . . 75.13 109.128 172.402 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -108.78 129.78 55.38 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.155 -0.475 . . . . 74.13 110.084 -177.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 52.4 t -96.72 113.86 25.45 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.26 -0.427 . . . . 74.1 110.244 178.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.541 ' HB2' ' OD1' ' A' ' 61' ' ' ASN . 35.9 mt -96.45 -176.05 3.51 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.121 -0.696 . . . . 75.32 109.121 177.439 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -71.4 55.81 0.23 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-O 121.214 0.53 . . . . 70.22 111.18 177.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.541 ' OD1' ' HB2' ' A' ' 59' ' ' LEU . 4.4 p-10 -160.34 167.64 26.99 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.706 -0.85 . . . . 74.35 108.706 178.914 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -91.79 47.15 2.73 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.488 -0.863 . . . . 74.22 113.62 -171.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 38.9 m -160.59 136.33 8.22 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 117.041 0.42 . . . . 64.31 110.797 178.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . 0.42 ' HB2' ' CG ' ' A' ' 67' ' ' MET . 63.0 m95 -71.41 123.22 21.88 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.02 -1.104 . . . . 74.23 108.02 171.628 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.504 HG21 ' CD1' ' A' ' 59' ' ' LEU . 13.6 p -77.23 38.23 0.22 Allowed 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 115.074 1.509 . . . . 73.14 115.074 -164.329 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -162.51 20.16 0.09 Allowed 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 120.413 -0.515 . . . . 71.12 111.818 173.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' MET . . . . . 0.42 ' CG ' ' HB2' ' A' ' 64' ' ' TRP . 58.3 mtm -76.28 79.53 3.05 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 119.311 -0.956 . . . . 72.34 112.412 -168.793 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -169.76 89.27 0.17 Allowed 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 107.495 -1.298 . . . . 75.03 107.495 161.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.494 ' CG2' ' HG2' ' A' ' 53' ' ' PRO . 2.8 m -147.2 124.63 5.84 Favored Pre-proline 0 C--N 1.321 -0.65 0 C-N-CA 119.595 -0.842 . . . . 74.5 112.387 -168.265 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . 0.458 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 9.6 Cg_endo -89.21 90.49 0.38 Allowed 'Trans proline' 0 N--CA 1.451 -0.989 0 C-N-CA 123.388 2.725 . . . . 64.4 111.62 174.471 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.1 m -90.31 118.17 29.6 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.263 -0.426 . . . . 73.32 110.149 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.5 ptp180 -89.15 119.47 29.68 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.054 -0.521 . . . . 75.3 111.334 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.539 ' HA ' HG13 ' A' ' 50' ' ' VAL . 41.1 t -72.52 105.5 4.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.068 -0.515 . . . . 74.22 110.243 179.155 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.5 t -135.69 100.53 2.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.899 -0.591 . . . . 73.23 110.503 -177.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.582 ' OXT' ' HD2' ' A' ' 48' ' ' ARG . 15.1 ttm180 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 118.451 -0.785 . . . . 74.41 109.558 176.159 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.471 ' HA2' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.485 1.93 0 N-CA-C 111.807 -0.517 . . . . 72.35 111.807 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.471 ' HD3' ' HA2' ' A' ' 1' ' ' GLY . 1.0 OUTLIER -82.01 86.61 1.52 Allowed 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 123.15 2.567 . . . . 73.25 112.507 -177.831 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 20.7 p -116.0 99.44 7.27 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.277 0.56 . . . . 75.23 110.728 178.007 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.8 m -126.41 99.75 5.97 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.106 -0.497 . . . . 74.12 111.212 -176.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -121.67 103.8 9.15 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.497 -0.557 . . . . 74.03 109.497 176.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -159.87 171.15 36.16 Favored Glycine 0 N--CA 1.443 -0.894 0 C-N-CA 120.481 -0.866 . . . . 60.54 112.86 -175.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 58.3 m -106.47 148.06 28.62 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.843 -0.429 . . . . 72.14 109.843 -178.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -84.21 -179.9 7.32 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.001 0.429 . . . . 64.22 111.192 -178.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.506 HD13 ' H ' ' A' ' 31' ' ' ILE . 42.1 mt -88.68 143.67 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.596 -0.729 . . . . 73.43 110.343 177.686 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.411 HG22 ' H ' ' A' ' 11' ' ' HIS . 12.1 mt -98.91 166.66 2.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.705 -0.68 . . . . 72.13 109.968 -177.117 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . 0.411 ' H ' HG22 ' A' ' 10' ' ' ILE . 76.5 m-70 -89.71 138.66 27.96 Favored Pre-proline 0 C--N 1.325 -0.458 0 N-CA-C 109.899 -0.408 . . . . 73.31 109.899 178.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -72.36 106.34 2.05 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.29 1.993 . . . . 71.32 111.384 174.512 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -88.85 -74.96 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 123.054 2.502 . . . . 72.42 113.566 -174.114 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 32.9 t-105 -100.29 -176.46 3.23 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.19 -0.459 . . . . 72.24 109.834 -175.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -49.85 -29.36 7.92 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 122.896 0.478 . . . . 74.13 111.539 178.092 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.25 102.3 1.35 Allowed Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.715 -0.755 . . . . 71.54 111.813 176.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -88.98 -169.74 44.81 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 121.148 -0.549 . . . . 73.45 112.052 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 28.4 mt -116.11 137.95 48.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.795 0.807 . . . . 71.22 112.337 -174.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -116.59 132.78 56.59 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 114.287 -1.324 . . . . 74.22 108.825 -179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.567 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 56.0 m-85 -92.33 -172.03 2.98 Favored 'General case' 0 C--N 1.318 -0.772 0 C-N-CA 120.703 -0.399 . . . . 74.51 110.604 -179.578 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.506 ' HB2' ' O ' ' A' ' 39' ' ' GLU . 7.4 tmm_? -112.64 -42.21 3.68 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.126 0.489 . . . . 74.3 110.287 -171.75 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -146.09 56.54 0.52 Allowed Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 121.008 -0.615 . . . . 71.12 111.716 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.707 ' HG ' ' HH ' ' A' ' 38' ' ' TYR . 40.9 mt -143.15 141.68 31.25 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.946 0.403 . . . . 64.52 110.555 179.263 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -99.65 -178.95 4.04 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.691 -0.686 . . . . 75.32 110.197 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.512 ' C ' ' H ' ' A' ' 27' ' ' GLN . 33.0 ptt180 -66.55 -172.63 0.17 Allowed 'General case' 0 C--O 1.234 0.243 0 CA-C-N 116.051 -0.522 . . . . 73.32 111.409 -179.411 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.6 t70 70.24 -38.67 0.42 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.318 0.647 . . . . 65.24 111.043 -176.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.533 ' O ' HG21 ' A' ' 28' ' ' VAL . 17.7 mt-30 -94.73 -153.25 0.38 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.605 -0.725 . . . . 73.2 109.847 176.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.533 HG21 ' O ' ' A' ' 27' ' ' GLN . 3.6 m 57.8 13.16 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 124.584 1.154 . . . . 75.0 112.939 176.349 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 56.7 mtpt -106.1 -38.42 6.29 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.928 0.394 . . . . 75.45 110.218 176.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.22 86.71 2.25 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.032 -0.531 . . . . 75.11 110.704 177.071 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.506 ' H ' HD13 ' A' ' 9' ' ' ILE . 70.7 mt -134.68 121.98 37.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 N-CA-C 108.521 -0.918 . . . . 74.23 108.521 176.524 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -84.1 -24.46 30.31 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 113.229 0.826 . . . . 73.04 113.229 -170.334 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 -140.15 109.42 6.16 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 113.06 0.763 . . . . 74.1 113.06 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.45 112.18 48.32 Favored Pre-proline 0 C--N 1.323 -0.548 0 N-CA-C 107.77 -1.196 . . . . 73.11 107.77 165.166 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -58.85 152.0 60.7 Favored 'Trans proline' 0 N--CA 1.474 0.362 0 C-N-CA 123.057 2.504 . . . . 63.24 113.63 -170.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.47 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 2.5 p -61.48 94.92 0.08 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 115.559 -0.746 . . . . 72.31 110.58 175.697 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.47 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 18.3 t70 160.92 -29.9 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 114.488 -1.233 . . . . 75.53 108.367 -174.815 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.707 ' HH ' ' HG ' ' A' ' 23' ' ' LEU . 6.4 t80 -73.72 146.66 44.24 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.625 -1.171 . . . . 75.21 111.818 -173.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.506 ' O ' ' HB2' ' A' ' 21' ' ' ARG . 27.0 mt-10 -125.74 150.47 47.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.5 -0.773 . . . . 74.51 109.883 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.607 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 38.3 pt -132.99 149.31 31.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.948 0.404 . . . . 75.23 110.879 174.17 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.43 ' HG3' ' HD3' ' A' ' 54' ' ' LYS . 41.3 tt0 -118.64 171.44 8.19 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.476 -0.783 . . . . 74.33 109.396 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . 0.403 ' N ' ' HG2' ' A' ' 41' ' ' GLU . 73.1 m-85 -113.65 100.86 8.8 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.869 0.366 . . . . 75.13 111.176 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.6 m -96.98 132.1 42.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.013 0.435 . . . . 73.24 109.94 175.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.502 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 39.1 t -89.16 148.51 23.61 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.265 0.555 . . . . 63.13 110.941 -174.085 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -59.11 133.62 56.26 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.579 -1.191 . . . . 71.44 110.702 -176.239 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 86.29 -119.24 5.09 Favored Glycine 0 N--CA 1.444 -0.823 0 N-CA-C 110.67 -0.972 . . . . 62.21 110.67 -173.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -141.5 83.1 1.85 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.411 0.624 . . . . 71.43 109.812 173.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.615 ' HB3' ' HB2' ' A' ' 73' ' ' CYS . 42.7 mmt180 -132.89 130.05 39.18 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.434 -0.803 . . . . 74.21 110.081 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -86.25 139.69 30.8 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 109.958 -0.386 . . . . 74.41 109.958 178.04 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.44 HG12 ' HB3' ' A' ' 73' ' ' CYS . 30.5 m -97.82 127.32 50.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.224 -0.444 . . . . 70.42 111.096 -178.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.8 p -98.68 94.08 3.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 122.246 1.022 . . . . 74.5 109.287 174.042 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -156.82 171.06 34.29 Favored Glycine 0 N--CA 1.44 -1.059 0 CA-C-N 114.485 -1.234 . . . . 74.22 111.292 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -73.19 55.07 2.88 Favored 'Trans proline' 0 CA--C 1.531 0.341 0 C-N-CA 122.553 2.168 . . . . 70.42 110.255 168.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.572 ' O ' ' HD2' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -72.04 93.54 1.41 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.899 0.856 . . . . 75.22 112.718 -170.878 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.492 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.2 p -161.57 128.75 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 115.527 -0.76 . . . . 75.54 109.862 170.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.607 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 29.1 mmt180 -132.83 115.62 15.52 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.303 -0.629 . . . . 75.13 109.303 177.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.414 ' O ' HG22 ' A' ' 65' ' ' THR . 37.2 ttmt -115.02 136.91 52.61 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 108.986 -0.746 . . . . 74.13 108.986 178.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.7 t -73.78 139.95 45.54 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.826 0.346 . . . . 74.1 110.856 -176.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.509 ' C ' ' H ' ' A' ' 61' ' ' ASN . 87.3 mt -96.57 -179.53 4.64 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.779 -0.646 . . . . 75.32 110.548 -178.372 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.47 36.98 0.26 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-O 121.877 0.846 . . . . 70.22 109.304 174.128 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.509 ' H ' ' C ' ' A' ' 59' ' ' LEU . 0.9 OUTLIER -157.33 155.99 31.58 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.408 -1.269 . . . . 74.35 108.226 -172.37 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -74.45 50.31 2.06 Favored Glycine 0 CA--C 1.52 0.368 0 C-N-CA 121.114 -0.565 . . . . 74.22 113.215 -176.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 55.6 m -159.32 149.86 19.41 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 123.088 0.555 . . . . 64.31 109.518 178.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -83.53 175.19 9.96 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 110.171 -0.307 . . . . 74.23 110.171 -176.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.414 HG22 ' O ' ' A' ' 57' ' ' LYS . 1.4 p -50.56 -48.21 57.5 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.444 0.535 . . . . 73.14 112.444 -177.55 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -153.86 140.45 18.89 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.673 -0.862 . . . . 71.12 108.673 179.512 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' MET . . . . . 0.406 ' HE2' HD11 ' A' ' 10' ' ' ILE . 23.1 mmt -139.59 79.54 1.72 Allowed 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 120.235 -0.586 . . . . 72.34 110.557 168.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -168.48 87.93 0.21 Allowed 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 108.032 -1.099 . . . . 75.03 108.032 163.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.4 ' CB ' HH22 ' A' ' 56' ' ' ARG . 1.1 m -152.42 128.96 5.38 Favored Pre-proline 0 C--N 1.319 -0.751 0 C-N-CA 120.433 -0.507 . . . . 74.5 111.064 -169.82 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -74.99 69.29 5.58 Favored 'Trans proline' 0 CA--C 1.532 0.398 0 C-N-CA 122.772 2.315 . . . . 64.4 112.596 177.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 8.5 p -78.28 121.11 23.99 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.748 -0.464 . . . . 73.32 109.748 175.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.2 ptp85 -133.28 141.62 48.09 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.8 0.333 . . . . 75.3 111.624 -174.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.615 ' HB2' ' HB3' ' A' ' 48' ' ' ARG . 1.8 p -107.58 104.22 13.71 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.819 -0.628 . . . . 74.22 110.373 178.219 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.82 9.02 5.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.443 0.639 . . . . 73.23 110.755 -174.626 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.6 ttp180 . . . . . 0 C--O 1.246 0.901 0 CA-C-O 118.659 -0.686 . . . . 74.41 109.998 178.371 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.9 m . . . . . 0 N--CA 1.449 -0.509 0 CA-C-O 121.306 0.574 . . . . 74.12 109.631 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -114.16 97.91 6.64 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.844 -0.617 . . . . 74.03 109.756 -177.443 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -163.16 171.1 38.82 Favored Glycine 0 N--CA 1.439 -1.113 0 C-N-CA 120.728 -0.749 . . . . 52.24 112.223 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 26.0 m -104.32 153.53 20.92 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.74 -0.467 . . . . 72.14 109.74 177.035 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 21.6 pt20 -89.6 -178.86 5.66 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.927 0.394 . . . . 64.22 111.13 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.617 HD11 ' HB ' ' A' ' 31' ' ' ILE . 26.6 mt -87.98 120.55 37.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.928 -0.578 . . . . 73.43 110.022 177.213 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 63.1 mt -74.95 138.38 21.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.212 -0.904 . . . . 53.14 110.525 -178.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 81.1 m-70 -80.54 132.09 59.45 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 116.118 -0.492 . . . . 73.31 109.768 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.463 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.6 Cg_exo -51.05 113.18 0.98 Allowed 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 123.319 2.679 . . . . 62.52 112.838 -178.551 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 4.7 Cg_exo -76.51 -80.0 0.01 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.43 0 C-N-CA 122.881 2.388 . . . . 72.42 112.278 -178.615 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.0 t-105 -101.39 -178.09 3.63 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.602 -0.518 . . . . 72.24 109.602 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -58.71 100.54 0.07 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.133 0.492 . . . . 74.13 111.086 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.509 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . 175.81 -158.29 25.11 Favored Glycine 0 N--CA 1.443 -0.847 0 C-N-CA 120.854 -0.688 . . . . 71.54 112.009 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -161.1 -171.28 26.88 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 111.296 -0.721 . . . . 73.45 111.296 178.63 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.9 mt -125.68 131.4 72.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.792 0.806 . . . . 70.34 111.804 -178.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.797 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 23.3 tpp180 -93.51 110.65 22.23 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.317 -1.31 . . . . 74.22 109.935 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -90.95 -171.52 3.03 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.778 0.323 . . . . 74.35 110.358 177.716 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.456 ' NH2' ' HB2' ' A' ' 39' ' ' GLU . 97.8 mtt180 -109.72 -86.58 0.52 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.446 -0.343 . . . . 74.3 110.894 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -88.4 48.06 3.54 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 121.18 -0.533 . . . . 71.12 112.702 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 91.8 mt -137.91 133.41 33.77 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.09 -0.337 . . . . 52.44 110.09 178.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.4 t -95.99 179.55 5.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.745 -0.465 . . . . 75.32 109.745 174.643 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' GLN . 63.9 mtm-85 -79.54 -171.38 2.76 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.581 -0.282 . . . . 73.32 110.962 -177.438 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.474 ' O ' ' HE2' ' A' ' 29' ' ' LYS . 34.7 t70 68.5 -27.03 0.14 Allowed 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 123.329 0.652 . . . . 54.04 110.928 -170.663 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ARG . 93.1 mt-30 -90.33 -146.07 0.18 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.703 -0.681 . . . . 70.15 110.028 175.169 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.467 HG22 ' O ' ' A' ' 27' ' ' GLN . 4.8 m 54.26 19.75 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.509 1.123 . . . . 75.0 112.733 177.293 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.474 ' HE2' ' O ' ' A' ' 26' ' ' ASP . 49.9 mtmt -101.41 -74.85 0.61 Allowed 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.823 -0.436 . . . . 71.12 109.823 175.145 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.11 89.53 4.06 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.448 0.642 . . . . 75.11 111.253 178.38 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.617 ' HB ' HD11 ' A' ' 9' ' ' ILE . 64.9 mt -125.44 138.86 53.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.255 -0.884 . . . . 74.23 108.634 175.286 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 37.4 m-80 -74.39 -70.2 0.41 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.636 0.255 . . . . 73.04 110.864 -177.509 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -141.55 139.43 33.2 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.017 0.437 . . . . 71.25 111.301 -177.026 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -78.85 147.0 69.74 Favored Pre-proline 0 C--N 1.321 -0.646 0 N-CA-C 109.079 -0.711 . . . . 73.11 109.079 172.91 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -61.47 151.36 80.26 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.684 2.256 . . . . 63.24 112.26 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.2 p -61.13 138.24 22.22 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 CA-C-N 116.388 -0.369 . . . . 72.31 110.132 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 16.8 t70 61.97 75.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.817 0.818 . . . . 75.53 110.421 -172.489 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -133.28 124.68 27.75 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 107.464 -1.31 . . . . 74.11 107.464 175.526 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.714 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 39.5 mt-10 -111.98 124.9 53.38 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.099 0.476 . . . . 72.52 111.537 -172.711 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.489 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 32.6 pt -116.0 167.28 9.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.122 -0.944 . . . . 75.11 111.019 -177.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.797 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 44.7 tt0 -125.05 146.2 49.55 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.855 -0.611 . . . . 74.33 110.542 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.494 ' HE2' ' HG3' ' A' ' 56' ' ' ARG . 25.8 m-85 -97.67 103.07 14.97 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.323 -0.399 . . . . 75.13 110.762 178.078 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 32.7 m -97.58 157.45 3.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 120.825 0.345 . . . . 43.53 111.055 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.541 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 48.3 t -89.53 158.42 17.68 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-N 116.037 -0.529 . . . . 51.42 109.608 178.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ARG . . . . . 0.509 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 31.3 ttt180 -58.13 121.24 10.21 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.858 -1.065 . . . . 71.44 111.873 -169.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 93.61 -128.95 9.67 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.874 -0.891 . . . . 62.21 110.874 -176.239 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -114.95 37.98 3.31 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.5 0.667 . . . . 71.43 110.009 172.135 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.541 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 27.3 mmt180 -88.84 146.44 24.96 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.434 -0.803 . . . . 74.21 109.356 178.194 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -103.46 166.18 10.58 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.04 0.448 . . . . 74.41 110.848 -177.693 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.571 HG12 ' HA ' ' A' ' 73' ' ' CYS . 35.4 m -132.97 145.96 33.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 115.921 -0.581 . . . . 54.31 109.835 177.633 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.6 p -108.18 95.81 4.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 122.195 0.998 . . . . 73.23 109.42 172.246 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.82 172.82 33.23 Favored Glycine 0 N--CA 1.443 -0.893 0 CA-C-N 114.47 -1.241 . . . . 43.0 110.801 -178.641 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.77 67.27 5.74 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.773 1.649 . . . . 70.42 110.552 172.576 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.555 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 31.9 pttt -84.32 87.65 7.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.36 -0.836 . . . . 72.35 111.532 -173.542 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -160.89 129.18 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.262 -0.881 . . . . 74.12 109.286 174.21 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.714 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 28.7 mmt85 -133.18 109.95 9.8 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 116.531 -0.304 . . . . 73.32 110.584 -177.261 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -96.66 118.6 33.48 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.822 -0.436 . . . . 71.3 109.822 178.038 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.8 t -62.62 132.74 53.37 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.919 -0.582 . . . . 74.1 110.954 177.772 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 90.2 mt -97.42 -178.58 4.2 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.873 -0.603 . . . . 75.32 110.61 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.19 -1.87 34.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.04 0.448 . . . . 34.01 111.043 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -119.63 169.78 9.78 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.41 -0.589 . . . . 74.35 109.41 177.344 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -75.33 62.35 2.65 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.079 -0.582 . . . . 74.22 113.35 -175.266 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 27.6 t -170.28 160.55 7.82 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.674 -0.491 . . . . 64.31 109.674 176.289 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 58.5 m95 -97.03 174.63 6.67 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.482 -0.562 . . . . 65.43 109.482 -177.453 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -49.89 -75.4 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.382 0 N-CA-C 112.815 0.672 . . . . 71.12 112.815 -176.026 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -115.89 94.76 4.81 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.377 -0.601 . . . . 71.12 109.377 176.449 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 13.5 tpt -93.42 75.35 4.49 Favored 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 119.192 -1.003 . . . . 72.34 110.253 -177.809 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -172.65 96.73 0.14 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.585 -1.188 . . . . 63.14 108.235 159.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.6 m -142.07 108.91 5.87 Favored Pre-proline 0 C--N 1.317 -0.846 0 C-N-CA 119.671 -0.812 . . . . 74.33 111.714 -172.33 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -77.56 93.84 1.08 Allowed 'Trans proline' 0 N--CA 1.458 -0.582 0 C-N-CA 122.62 2.213 . . . . 64.14 111.834 176.684 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 35.8 p -81.34 107.34 14.04 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.054 -0.521 . . . . 73.3 110.368 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -78.84 120.07 22.94 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.245 0.545 . . . . 75.3 110.477 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.571 ' HA ' HG12 ' A' ' 50' ' ' VAL . 24.0 t -72.32 110.1 6.51 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.559 -0.746 . . . . 74.22 109.799 -178.683 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 98.4 t -134.37 126.13 48.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.973 -0.558 . . . . 70.53 110.293 -174.187 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 75' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.229 -0.891 . . . . 74.41 109.79 178.415 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.3 m . . . . . 0 N--CA 1.449 -0.478 0 N-CA-C 109.499 -0.556 . . . . 74.12 109.499 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 49.1 mm-40 -83.11 109.19 16.94 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.986 -0.552 . . . . 74.03 110.538 -177.499 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.602 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -150.26 141.54 8.86 Favored Glycine 0 N--CA 1.443 -0.895 0 C-N-CA 120.737 -0.744 . . . . 52.24 112.365 -178.193 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 37.4 m -88.96 154.03 20.55 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 110.109 -0.33 . . . . 72.14 110.109 178.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 -86.89 177.76 7.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.017 0.437 . . . . 64.22 111.681 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.575 HD11 ' HB ' ' A' ' 31' ' ' ILE . 72.0 mt -87.79 118.9 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.527 -0.76 . . . . 73.43 109.982 177.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 44.2 mt -71.25 145.36 12.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.904 -0.589 . . . . 53.14 110.923 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -81.02 137.78 49.7 Favored Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 109.587 -0.523 . . . . 73.31 109.587 174.187 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -64.11 116.47 3.73 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.457 2.105 . . . . 62.52 111.634 176.516 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.75 -85.01 0.01 OUTLIER 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.541 2.161 . . . . 72.42 112.134 -178.753 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.6 t-105 -101.97 -178.08 3.6 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.843 -0.799 . . . . 72.24 108.843 173.371 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -50.67 100.9 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.189 0.518 . . . . 74.13 111.761 178.779 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.81 -147.29 5.65 Favored Glycine 0 N--CA 1.444 -0.83 0 CA-C-N 115.485 -0.78 . . . . 71.54 111.325 178.44 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -178.5 -170.86 41.13 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 120.869 -0.682 . . . . 73.45 111.42 177.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mt -123.11 133.11 70.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.518 0.675 . . . . 70.34 111.325 -179.132 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.926 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 7.2 tpt180 -96.31 132.85 41.37 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.634 -1.166 . . . . 74.22 108.448 177.766 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.542 ' HB3' ' HH ' ' A' ' 38' ' ' TYR . 97.1 m-85 -103.77 -171.53 1.95 Allowed 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 120.417 -0.513 . . . . 74.35 111.636 -173.278 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.68 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 49.1 ttt180 -113.36 -44.04 3.28 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.576 -0.738 . . . . 74.3 110.263 -170.756 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -148.03 40.01 0.97 Allowed Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.647 -0.706 . . . . 71.12 111.968 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.435 HD13 HG12 ' A' ' 28' ' ' VAL . 84.7 mt -122.21 130.07 52.85 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.832 0.349 . . . . 52.44 110.504 179.463 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 11.0 t -90.72 -179.33 5.5 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.939 -0.573 . . . . 75.32 110.158 177.714 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 5.6 ptm180 -73.66 -173.49 1.49 Allowed 'General case' 0 C--O 1.234 0.286 0 CA-C-O 120.978 0.418 . . . . 73.32 112.125 -174.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 31.1 t70 56.17 12.77 1.03 Allowed 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 115.353 -0.839 . . . . 54.04 111.609 -174.694 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.504 ' O ' HG22 ' A' ' 28' ' ' VAL . 98.6 mt-30 -124.47 -162.69 1.1 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.849 -0.614 . . . . 70.15 109.538 -179.636 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.504 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.3 m 56.92 13.83 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.452 1.101 . . . . 75.0 112.892 174.53 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 53.0 pttt -96.34 -27.6 14.87 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.021 0.438 . . . . 71.12 109.856 176.264 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.49 95.29 2.42 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.74 -0.664 . . . . 75.11 110.412 177.167 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.575 ' HB ' HD11 ' A' ' 9' ' ' ILE . 62.7 mt -132.21 148.12 32.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 108.707 -0.849 . . . . 74.23 108.707 177.578 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.3 m-80 -75.77 -69.04 0.51 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.031 0.443 . . . . 73.04 109.967 -178.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.602 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 87.4 m-85 -141.44 150.15 41.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.872 -0.604 . . . . 71.25 110.713 -177.498 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -91.54 136.6 26.53 Favored Pre-proline 0 C--N 1.323 -0.55 0 N-CA-C 109.403 -0.591 . . . . 73.11 109.403 174.237 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.88 143.41 95.86 Favored 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 122.866 2.377 . . . . 63.24 113.055 -176.702 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.447 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 3.6 p -70.11 84.41 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 CA-C-O 122.031 0.919 . . . . 72.31 110.643 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.447 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 35.2 t70 167.2 -27.51 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.493 -1.23 . . . . 75.53 108.766 -174.553 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.542 ' HH ' ' HB3' ' A' ' 20' ' ' TYR . 4.2 t80 -64.86 137.38 57.73 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 114.681 -1.145 . . . . 74.11 111.713 -174.692 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.68 ' H ' ' HD2' ' A' ' 21' ' ' ARG . 41.4 mt-10 -120.29 139.16 53.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.928 -0.578 . . . . 72.52 109.593 177.239 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.481 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 37.3 pt -126.2 162.72 29.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.121 0.486 . . . . 75.11 112.019 -178.673 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.926 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.9 tt0 -124.57 153.69 41.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.231 -0.895 . . . . 74.33 109.811 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.601 ' O ' HG11 ' A' ' 50' ' ' VAL . 97.2 m-85 -101.9 101.59 12.04 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.439 0.162 . . . . 75.13 110.996 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.541 HG13 ' HB2' ' A' ' 19' ' ' ARG . 15.5 m -97.13 170.96 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 120.861 0.363 . . . . 43.53 111.24 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.403 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 26.5 t -114.73 171.15 7.81 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.015 -0.539 . . . . 51.42 109.922 -176.533 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 14.4 mmm180 -72.57 110.67 7.11 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 120.798 0.332 . . . . 71.44 110.547 179.532 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.17 -108.83 3.02 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.717 -0.754 . . . . 62.21 112.073 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -155.11 49.07 0.56 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.185 0.517 . . . . 71.43 111.269 -177.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.574 ' HB2' ' HB2' ' A' ' 73' ' ' CYS . 17.3 mmt180 -88.31 145.71 25.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.152 -0.477 . . . . 74.21 110.072 177.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.4 mm-40 -80.62 112.88 18.4 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.005 0.431 . . . . 74.41 109.977 176.786 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.601 HG11 ' O ' ' A' ' 42' ' ' TYR . 3.8 p -92.67 115.73 32.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.293 0.568 . . . . 54.31 110.769 -178.471 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.7 p -100.61 97.3 5.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 122.125 0.964 . . . . 73.23 110.613 178.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.91 170.68 32.56 Favored Glycine 0 N--CA 1.441 -0.989 0 CA-C-N 114.71 -1.132 . . . . 43.0 110.284 175.699 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -71.96 67.0 3.26 Favored 'Trans proline' 0 C--O 1.235 0.334 0 C-N-CA 122.047 1.831 . . . . 70.42 110.529 170.048 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.525 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 41.5 pttt -84.75 87.3 7.3 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.552 0.691 . . . . 72.35 112.086 -170.277 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.514 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.6 p -161.05 127.05 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.556 -0.747 . . . . 74.12 109.226 171.16 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.57 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 28.3 mmt180 -133.15 112.85 12.09 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.103 -0.332 . . . . 73.32 110.103 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.426 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 38.6 ttmt -101.52 123.92 46.34 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 109.375 -0.602 . . . . 71.3 109.375 179.368 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.3 t -67.3 119.52 12.3 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.233 -0.44 . . . . 74.1 110.246 -179.636 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 80.1 mt -101.28 -179.93 4.18 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.897 -0.592 . . . . 75.32 110.369 -177.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.81 59.5 3.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.129 0.49 . . . . 34.01 111.15 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.4 p-10 -161.78 167.4 24.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.328 -0.851 . . . . 74.35 108.786 175.087 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -82.83 36.93 2.66 Favored Glycine 0 CA--C 1.521 0.409 0 C-N-CA 120.699 -0.762 . . . . 74.22 113.45 -174.44 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.4 m -156.43 157.24 35.18 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.93 0.365 . . . . 64.31 110.176 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 87.3 m95 -83.36 179.17 7.75 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.53 -0.305 . . . . 65.43 110.464 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.8 m -56.74 -53.22 60.24 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 116.025 -0.534 . . . . 71.12 112.053 -176.699 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -148.03 129.66 15.03 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.514 -0.55 . . . . 71.12 109.514 -177.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 56.1 mtm -133.64 78.25 1.76 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 119.21 -0.996 . . . . 72.34 110.759 172.729 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -168.82 89.16 0.21 Allowed 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 106.942 -1.503 . . . . 63.14 106.942 162.329 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.42 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 3.6 m -139.82 121.28 9.65 Favored Pre-proline 0 C--N 1.312 -1.023 0 C-N-CA 119.837 -0.745 . . . . 74.33 111.984 -165.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 5.1 Cg_exo -77.24 58.13 6.12 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.094 2.529 . . . . 64.14 111.635 177.12 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.4 p -78.76 101.29 7.5 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.121 -0.49 . . . . 73.3 110.355 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.434 HH11 ' HD2' ' A' ' 72' ' ' ARG . 7.5 ptp85 -91.55 142.02 28.1 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.981 -0.554 . . . . 75.3 110.044 -178.123 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.574 ' HB2' ' HB2' ' A' ' 48' ' ' ARG . 2.0 p -106.65 99.91 9.46 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.427 0.632 . . . . 74.22 109.681 173.886 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.6 p -121.0 153.68 24.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.341 -0.845 . . . . 70.53 111.011 -170.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 65.8 ttt-85 . . . . . 0 C--O 1.245 0.862 0 CA-C-O 118.582 -0.723 . . . . 74.41 109.701 176.299 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 21.7 m . . . . . 0 N--CA 1.446 -0.652 0 N-CA-C 109.421 -0.585 . . . . 74.12 109.421 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -123.83 112.74 17.65 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.905 -0.588 . . . . 74.03 109.491 -177.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.656 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.5 163.35 33.96 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.576 -0.821 . . . . 52.24 111.759 179.05 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 83.9 m -84.03 134.29 34.63 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 110.062 -0.347 . . . . 72.14 110.062 177.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -77.39 179.37 6.49 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.172 0.51 . . . . 64.22 111.609 -176.183 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.562 HD11 ' HB ' ' A' ' 31' ' ' ILE . 59.5 mt -88.07 119.1 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.191 -0.913 . . . . 73.43 110.295 178.294 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.6 mt -82.69 131.5 33.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.853 -0.612 . . . . 53.14 109.984 178.25 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 83.7 m-70 -84.07 117.94 70.0 Favored Pre-proline 0 C--N 1.323 -0.557 0 N-CA-C 109.59 -0.522 . . . . 73.31 109.59 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.418 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 52.1 Cg_exo -54.53 110.1 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 122.985 2.457 . . . . 62.52 112.153 -178.5 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 14.0 Cg_exo -69.2 -56.81 0.14 Allowed 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.924 2.416 . . . . 72.42 112.295 -176.224 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.428 ' HA ' ' CE3' ' A' ' 14' ' ' TRP . 6.0 t-105 -100.07 -177.8 3.65 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.868 -0.605 . . . . 72.24 109.807 -176.586 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -68.7 -5.05 18.15 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.858 0.361 . . . . 74.13 111.329 178.108 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.07 121.92 5.76 Favored Glycine 0 N--CA 1.444 -0.784 0 N-CA-C 110.832 -0.907 . . . . 71.54 110.832 171.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -95.72 -170.7 35.72 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.529 -0.844 . . . . 73.45 112.447 -175.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.515 HD13 HD12 ' A' ' 40' ' ' ILE . 27.3 mt -115.45 129.25 72.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.632 0.73 . . . . 70.34 111.124 -178.426 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -97.21 144.54 26.93 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.597 -1.183 . . . . 74.22 109.593 -178.071 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -115.88 -170.73 1.84 Allowed 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.346 -0.613 . . . . 74.35 109.346 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 -115.6 -53.84 2.56 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.5 -0.48 . . . . 74.3 110.309 178.624 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -110.19 26.43 13.66 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.727 -0.749 . . . . 71.12 112.634 -177.261 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.464 HD13 HG12 ' A' ' 28' ' ' VAL . 95.9 mt -119.86 121.91 40.12 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.888 -0.412 . . . . 52.44 109.888 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.2 t -105.71 -178.79 3.75 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.779 -0.646 . . . . 75.32 112.17 -171.692 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.41 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 49.6 mtp180 -57.49 125.33 22.39 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.359 -0.837 . . . . 73.32 111.603 177.671 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.421 ' O ' ' HD2' ' A' ' 29' ' ' LYS . 33.7 t70 92.91 3.96 0.06 Allowed 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.735 1.214 . . . . 54.04 110.353 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.456 ' O ' HG22 ' A' ' 28' ' ' VAL . 10.4 mm100 -94.57 -178.88 4.7 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 108.925 -0.769 . . . . 70.15 108.925 170.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.464 HG12 HD13 ' A' ' 23' ' ' LEU . 3.7 m 52.36 18.78 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 124.238 1.015 . . . . 75.0 113.064 178.707 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.421 ' HD2' ' O ' ' A' ' 26' ' ' ASP . 18.1 ptmt -82.62 -19.47 38.28 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.789 -0.449 . . . . 71.12 109.789 178.67 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -168.03 107.81 0.54 Allowed 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.602 -0.726 . . . . 75.11 110.477 175.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.562 ' HB ' HD11 ' A' ' 9' ' ' ILE . 55.6 mt -138.14 151.86 25.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.155 -0.683 . . . . 74.23 109.155 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -89.19 -66.34 0.93 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.717 0.294 . . . . 73.04 110.467 175.463 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.656 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 71.1 m-85 -136.66 143.06 43.25 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.827 0.346 . . . . 71.25 110.821 -178.941 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.416 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.9 mm? -84.8 144.0 41.45 Favored Pre-proline 0 C--N 1.323 -0.555 0 CA-C-N 115.86 -0.609 . . . . 73.11 109.654 175.572 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 34' ' ' LEU . 27.0 Cg_exo -62.26 154.7 61.45 Favored 'Trans proline' 0 C--O 1.235 0.352 0 C-N-CA 122.913 2.409 . . . . 63.24 112.599 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 8.4 p -61.22 140.14 19.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.658 -0.701 . . . . 72.31 111.135 -177.849 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 66.63 16.88 10.51 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.395 -0.82 . . . . 75.53 112.878 178.388 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 40.6 t80 -71.8 146.69 47.87 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.011 -0.737 . . . . 74.11 109.011 172.102 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -116.22 126.31 53.45 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.695 0.283 . . . . 72.52 111.246 -172.731 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.545 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 46.9 pt -121.72 155.99 25.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.28 -0.418 . . . . 75.11 110.316 175.726 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -130.73 147.0 52.34 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.381 -0.372 . . . . 74.33 110.533 -175.222 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.592 ' HB2' ' HB3' ' A' ' 54' ' ' LYS . 27.6 m-85 -96.44 101.85 13.54 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.326 -0.25 . . . . 75.13 110.326 178.658 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.9 m -113.79 170.07 4.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.025 0.44 . . . . 43.53 111.38 -176.122 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.668 ' HB2' HG13 ' A' ' 50' ' ' VAL . 16.7 t -95.37 127.23 41.25 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 109.282 -0.636 . . . . 51.42 109.282 177.101 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 47.0 ttt180 -59.41 121.94 12.73 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.853 -1.067 . . . . 71.44 111.057 -176.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 113.0 -128.3 8.34 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-N 115.845 -0.616 . . . . 62.21 111.977 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -122.17 11.91 10.22 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.247 0.546 . . . . 71.43 110.666 -179.067 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 19.2 mmm180 -89.34 160.18 16.99 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.616 -0.72 . . . . 74.21 109.562 177.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.612 ' HB2' ' HG2' ' A' ' 75' ' ' ARG . 39.4 mt-10 -121.22 163.94 17.73 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.996 0.427 . . . . 74.41 111.359 -174.086 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.668 HG13 ' HB2' ' A' ' 44' ' ' CYS . 26.8 m -128.51 150.27 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.618 -0.719 . . . . 54.31 110.093 -178.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.435 HG13 ' HD2' ' A' ' 72' ' ' ARG . 3.1 p -119.57 96.59 4.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 122.059 0.933 . . . . 73.23 109.921 171.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.24 172.8 32.83 Favored Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 114.636 -1.166 . . . . 43.0 110.925 -178.322 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -78.55 60.66 7.67 Favored 'Trans proline' 0 N--CA 1.46 -0.448 0 C-N-CA 122.097 1.865 . . . . 70.42 110.455 174.535 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.592 ' HB3' ' HB2' ' A' ' 42' ' ' TYR . 0.0 OUTLIER -86.31 86.39 7.34 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-N 115.333 -0.849 . . . . 72.35 112.028 -171.369 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -162.41 128.99 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 115.316 -0.856 . . . . 74.12 109.557 173.185 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.545 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 4.8 mmt85 -130.58 120.57 24.21 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.712 -0.477 . . . . 73.32 109.712 176.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 22.6 ttpp -103.61 125.31 50.05 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 109.159 -0.682 . . . . 71.3 109.159 177.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 49.6 t -64.75 149.23 49.62 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.743 0.306 . . . . 74.1 110.334 179.107 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 87.0 mt -116.22 -179.0 3.54 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.167 -0.47 . . . . 75.32 110.166 -178.143 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -81.44 -0.76 43.03 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.97 0.414 . . . . 34.01 110.539 178.564 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -113.58 164.65 13.39 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.399 -0.593 . . . . 74.35 109.399 175.535 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 6' ' ' GLY . . . -79.43 51.9 4.02 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.012 -0.613 . . . . 74.22 113.541 -173.783 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 28.2 m -156.62 146.87 21.29 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.92 -0.4 . . . . 64.31 109.92 177.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 89.8 m95 -82.01 177.54 8.78 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.227 -0.657 . . . . 65.43 109.227 175.244 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.8 p -66.59 -27.5 67.76 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 112.276 0.473 . . . . 71.12 112.276 -177.152 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -160.48 140.1 10.98 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.95 -0.389 . . . . 71.12 109.95 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 66.9 mtt -129.95 76.38 1.72 Allowed 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 119.814 -0.755 . . . . 72.34 110.164 165.011 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -170.61 89.18 0.14 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.335 -0.848 . . . . 63.14 108.803 161.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.2 m -148.12 102.96 3.57 Favored Pre-proline 0 C--N 1.317 -0.819 0 C-N-CA 119.936 -0.706 . . . . 74.33 111.399 -176.09 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.24 95.7 1.01 Allowed 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 122.998 2.466 . . . . 64.14 111.44 175.84 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 10.6 p -75.57 113.37 12.91 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.12 -0.491 . . . . 73.3 110.479 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.435 ' HD2' HG13 ' A' ' 51' ' ' VAL . 5.3 ptp180 -79.68 114.77 18.85 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.155 0.502 . . . . 75.3 111.151 -178.045 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.593 ' HA ' HG12 ' A' ' 50' ' ' VAL . 48.9 t -80.08 100.95 8.44 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.962 -0.563 . . . . 74.22 109.902 176.831 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.2 p -165.2 141.31 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.544 -0.753 . . . . 70.53 109.564 -178.448 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.612 ' HG2' ' HB2' ' A' ' 49' ' ' GLU . 1.5 tmm_? . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.697 -0.668 . . . . 74.41 110.248 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.6 m . . . . . 0 N--CA 1.451 -0.396 0 CA-C-O 121.254 0.55 . . . . 74.12 109.585 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -126.44 109.26 12.01 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.724 -0.671 . . . . 74.03 109.286 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.723 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -157.5 159.98 30.23 Favored Glycine 0 N--CA 1.438 -1.227 0 C-N-CA 120.066 -1.064 . . . . 52.24 112.841 -176.412 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.0 m -105.9 142.58 35.38 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.531 -0.544 . . . . 72.14 109.531 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 19.5 pt20 -74.77 -178.4 3.66 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.247 0.546 . . . . 64.22 111.929 -175.43 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.502 HD11 ' HB ' ' A' ' 31' ' ' ILE . 41.8 mt -88.25 119.37 35.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.524 -0.762 . . . . 73.43 110.316 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.467 HD11 ' CD1' ' A' ' 64' ' ' TRP . 47.4 mt -76.86 142.44 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.603 -0.726 . . . . 53.14 110.825 -177.016 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -79.85 126.8 79.34 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 73.31 109.867 175.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.429 ' HA ' ' HD2' ' A' ' 13' ' ' PRO . 27.2 Cg_exo -62.73 113.65 2.06 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 122.46 2.107 . . . . 62.52 111.417 175.28 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 12' ' ' PRO . 30.4 Cg_endo -65.55 -69.19 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.491 2.127 . . . . 72.42 112.481 -177.416 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 19.5 t-105 -100.39 -179.3 4.07 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.108 -0.701 . . . . 72.24 109.108 178.07 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.3 mm-40 -65.54 92.47 0.14 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.577 0.703 . . . . 74.13 111.413 -177.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.558 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . -160.31 -153.78 7.07 Favored Glycine 0 N--CA 1.442 -0.94 0 CA-C-N 114.85 -1.068 . . . . 71.54 110.458 178.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.17 -171.74 31.77 Favored Glycine 0 N--CA 1.443 -0.88 0 C-N-CA 120.224 -0.989 . . . . 73.45 112.02 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.402 HD13 HD12 ' A' ' 40' ' ' ILE . 22.1 mt -128.78 134.93 63.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.681 0.753 . . . . 70.34 111.422 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.801 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 16.9 tpp180 -99.33 126.63 45.23 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 114.684 -1.144 . . . . 74.22 110.326 -178.363 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -99.01 -170.84 1.98 Allowed 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.218 -0.66 . . . . 74.35 109.218 175.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 43.4 ttm-85 -103.4 -65.71 0.99 Allowed 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.34 -0.544 . . . . 74.3 110.421 -179.332 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -110.58 47.5 1.04 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.669 -0.777 . . . . 71.12 112.116 -179.027 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 94.3 mt -135.74 104.45 5.77 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.809 0.338 . . . . 52.44 110.842 -178.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.7 t -87.14 -177.78 6.09 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.745 -0.662 . . . . 75.32 110.019 174.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.426 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 34.7 ptt180 -64.77 -173.05 0.09 Allowed 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 111.922 0.342 . . . . 73.32 111.922 -176.695 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.426 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 13.0 t70 68.63 -45.74 0.54 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 123.477 0.711 . . . . 54.04 110.854 -170.66 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.404 ' HB3' ' H ' ' A' ' 28' ' ' VAL . 99.0 mt-30 -76.42 -155.92 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.301 -0.409 . . . . 70.15 110.495 175.056 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.404 ' H ' ' HB3' ' A' ' 27' ' ' GLN . 11.2 m 49.31 27.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 124.225 1.01 . . . . 75.0 111.987 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 34.9 pttt -97.02 -28.92 13.94 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.429 -0.805 . . . . 71.12 110.652 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.12 95.66 1.63 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.378 0.609 . . . . 75.11 111.055 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.502 ' HB ' HD11 ' A' ' 9' ' ' ILE . 46.8 mt -129.33 140.45 49.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.491 -0.929 . . . . 74.23 108.491 175.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.6 m-80 -107.56 -36.68 6.39 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 120.614 -0.434 . . . . 73.04 110.513 -178.076 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.723 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 90.6 m-85 -135.74 109.24 7.93 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.753 0.311 . . . . 71.25 111.097 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -80.17 122.62 83.13 Favored Pre-proline 0 C--N 1.325 -0.463 0 N-CA-C 108.463 -0.94 . . . . 73.11 108.463 169.554 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.453 ' O ' ' HB2' ' A' ' 38' ' ' TYR . 5.9 Cg_endo -47.31 138.72 17.33 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 123.378 2.719 . . . . 63.24 113.618 -172.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.413 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 7.2 p -50.3 143.51 2.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.651 -0.704 . . . . 72.31 111.008 175.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.413 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 27.6 t70 80.16 -4.0 1.91 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 123.685 0.794 . . . . 75.53 111.727 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.453 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 17.6 t80 -66.68 141.29 57.82 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 109.475 -0.565 . . . . 74.11 109.475 175.347 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.692 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.8 mt-10 -118.49 120.57 37.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.681 0.277 . . . . 72.52 111.181 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.521 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 46.3 pt -112.9 161.38 11.86 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 CA-C-N 116.335 -0.393 . . . . 75.11 110.599 177.43 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.801 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.0 tt0 -125.61 152.36 45.25 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.965 -0.561 . . . . 74.33 111.031 -175.699 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.623 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 25.3 m-85 -101.3 102.51 13.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.343 -0.39 . . . . 75.13 111.089 -179.289 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.3 m -103.93 166.83 2.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 116.232 -0.44 . . . . 43.53 110.365 177.01 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.561 ' HB3' ' O ' ' A' ' 48' ' ' ARG . 34.8 t -91.6 172.31 8.58 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.603 -0.517 . . . . 51.42 109.603 178.519 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ARG . . . . . 0.558 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -76.98 98.19 4.87 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.928 0.394 . . . . 71.44 110.692 -175.557 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.32 -122.02 7.44 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.975 -0.631 . . . . 62.21 113.341 172.668 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -105.1 32.91 3.91 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.25 0.548 . . . . 71.43 110.96 -174.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.561 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 28.4 mmm180 -113.19 144.03 43.38 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.759 -0.655 . . . . 74.21 109.351 178.67 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.1 mp0 -106.67 164.35 12.16 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.254 0.55 . . . . 74.41 111.696 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.56 HG13 ' HB2' ' A' ' 44' ' ' CYS . 35.3 m -129.15 152.5 37.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.349 -0.841 . . . . 54.31 110.105 -178.315 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.2 p -115.22 97.5 5.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.751 0.786 . . . . 73.23 109.922 171.312 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.0 166.75 32.6 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-N 115.68 -0.691 . . . . 43.0 112.086 178.874 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -74.53 65.57 5.6 Favored 'Trans proline' 0 CA--C 1.531 0.346 0 C-N-CA 122.326 2.017 . . . . 70.42 110.676 169.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.623 ' HB2' ' H ' ' A' ' 42' ' ' TYR . 16.0 pttp -77.8 89.47 4.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.297 -0.865 . . . . 72.35 111.605 -174.445 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -160.44 129.44 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.611 -0.722 . . . . 74.12 110.288 176.593 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.692 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 25.8 mmt180 -129.98 136.37 49.36 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.097 -0.501 . . . . 73.32 110.131 177.283 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.42 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 37.2 ttmt -123.36 124.42 42.9 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.193 -0.669 . . . . 71.3 109.193 174.166 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.3 t -67.41 137.5 55.97 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.148 -0.478 . . . . 74.1 110.703 -177.756 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 93.6 mt -103.46 -179.05 3.84 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.0 -0.546 . . . . 75.32 110.868 -176.711 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.4 22.41 0.56 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.08 0.467 . . . . 34.01 111.183 178.458 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -139.07 171.8 13.77 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.194 -0.669 . . . . 74.35 109.194 178.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -79.23 52.4 4.04 Favored Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.995 -0.621 . . . . 74.22 113.664 -174.175 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 11.9 t -170.48 159.52 6.95 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.898 -0.408 . . . . 64.31 109.898 177.165 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.467 ' CD1' HD11 ' A' ' 10' ' ' ILE . 69.9 m95 -87.06 178.97 6.76 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.228 -0.442 . . . . 65.43 110.086 -178.328 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -57.76 -35.41 70.71 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 112.622 0.601 . . . . 71.12 112.622 -176.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -149.72 144.55 26.15 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 110.193 -0.299 . . . . 71.12 110.193 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 63.3 mtt -136.39 76.56 1.6 Allowed 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.11 -0.636 . . . . 72.34 109.943 163.036 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -169.88 89.29 0.17 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.133 -0.94 . . . . 63.14 108.613 163.032 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.445 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 10.5 m -144.56 113.51 5.1 Favored Pre-proline 0 C--N 1.314 -0.946 0 C-N-CA 120.302 -0.559 . . . . 74.33 110.731 -175.681 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 4.3 Cg_exo -77.23 59.77 6.72 Favored 'Trans proline' 0 N--CA 1.463 -0.29 0 C-N-CA 123.415 2.743 . . . . 64.14 112.489 -178.241 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.9 p -70.37 98.83 1.47 Allowed 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.367 -0.605 . . . . 73.3 109.367 175.057 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 72' ' ' ARG . 5.0 ptp180 -101.69 141.34 34.7 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.635 -0.711 . . . . 75.3 111.679 -172.674 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 58.9 m -75.61 115.37 15.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.316 -0.856 . . . . 74.22 109.977 178.567 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.6 p -149.6 128.44 3.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.124 0.488 . . . . 70.53 110.095 -178.572 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.335 -0.841 . . . . 74.41 110.162 -177.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 20.2 m . . . . . 0 N--CA 1.446 -0.645 0 N-CA-C 109.386 -0.598 . . . . 74.12 109.386 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -88.87 114.6 25.67 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.862 -0.608 . . . . 74.03 110.044 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -148.42 -179.82 24.68 Favored Glycine 0 N--CA 1.44 -1.058 0 CA-C-N 115.527 -0.76 . . . . 52.24 111.432 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.0 m -97.47 136.12 38.35 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 110.122 -0.325 . . . . 72.14 110.122 -179.033 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -72.82 177.57 4.76 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.228 0.537 . . . . 64.22 111.464 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.572 HD11 ' HB ' ' A' ' 31' ' ' ILE . 52.4 mt -88.29 116.39 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-N 115.728 -0.669 . . . . 73.43 110.172 177.179 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 41.5 mt -69.65 140.93 17.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.395 -0.82 . . . . 53.14 109.861 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 23.4 m170 -73.55 137.37 77.56 Favored Pre-proline 0 C--N 1.323 -0.544 0 N-CA-C 109.503 -0.554 . . . . 73.31 109.503 175.563 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -57.12 117.48 4.18 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.544 2.162 . . . . 62.52 111.57 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.465 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 83.9 Cg_endo -78.23 -146.22 0.03 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.809 2.339 . . . . 72.42 111.748 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.465 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 67.9 t-105 -56.56 148.56 19.33 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.74 -0.467 . . . . 72.24 109.74 177.466 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 33.9 mm-40 -44.2 101.31 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.793 1.034 . . . . 74.13 113.793 -172.308 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.97 -120.91 0.79 Allowed Glycine 0 N--CA 1.442 -0.908 0 CA-C-N 114.283 -1.326 . . . . 71.54 110.131 174.382 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 179.86 -171.85 43.41 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.781 -0.723 . . . . 73.45 111.644 173.387 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 mt -142.28 129.35 19.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.549 0.69 . . . . 70.34 110.929 177.615 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.742 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 5.8 tpt180 -102.09 140.67 36.07 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.821 -1.082 . . . . 74.22 108.687 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.52 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 88.7 m-85 -107.15 -173.51 2.31 Favored 'General case' 0 C--N 1.319 -0.758 0 C-N-CA 120.077 -0.649 . . . . 74.35 110.263 -178.335 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -132.89 -14.89 2.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.129 0.49 . . . . 74.3 110.521 -175.106 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -145.82 27.14 1.77 Allowed Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 111.568 -0.613 . . . . 71.12 111.568 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 89.3 mt -143.54 132.82 23.22 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.683 0.278 . . . . 52.44 110.281 -178.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.9 t -91.45 -178.55 5.14 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.008 -0.542 . . . . 75.32 109.999 177.062 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 66.5 mtm180 -73.05 -174.14 1.45 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.901 0.382 . . . . 73.32 111.843 -175.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.6 t70 51.29 33.01 9.03 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.665 0.745 . . . . 54.04 111.474 -177.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 81.6 mt-30 -132.59 -164.62 1.49 Allowed 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.091 -0.504 . . . . 70.15 110.386 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.509 HG12 HD12 ' A' ' 31' ' ' ILE . 32.3 m 48.76 36.57 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 O-C-N 124.251 0.97 . . . . 75.0 112.384 177.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -78.8 -39.91 34.43 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.378 0.608 . . . . 71.12 109.413 177.235 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.07 89.01 1.49 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.49 -0.777 . . . . 75.11 110.644 176.76 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.572 ' HB ' HD11 ' A' ' 9' ' ' ILE . 52.1 mt -120.62 136.16 58.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.93 -0.767 . . . . 74.23 108.93 175.462 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -79.73 -49.27 12.31 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.753 0.311 . . . . 73.04 110.921 -175.146 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -139.37 138.03 36.23 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.186 -0.461 . . . . 71.25 111.275 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -85.96 138.5 35.0 Favored Pre-proline 0 C--N 1.321 -0.631 0 N-CA-C 108.717 -0.845 . . . . 73.11 108.717 170.398 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.29 145.46 97.75 Favored 'Trans proline' 0 CA--C 1.529 0.25 0 C-N-CA 122.677 2.252 . . . . 63.24 112.822 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.453 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 7.4 p -62.68 145.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.988 -0.551 . . . . 72.31 110.34 177.104 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.453 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 35.3 t70 79.18 3.44 2.34 Favored 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.776 0.672 . . . . 75.53 110.864 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.52 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 47.3 t80 -79.17 148.69 32.2 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.003 -0.369 . . . . 74.11 110.003 175.902 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.433 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 26.2 mt-10 -124.16 144.25 50.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.314 -0.403 . . . . 72.52 110.884 -176.751 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.619 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 25.4 pt -136.54 153.93 31.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-N 116.342 -0.39 . . . . 75.11 110.634 174.153 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.742 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.6 tt0 -116.67 155.68 28.4 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.948 -0.569 . . . . 74.33 110.179 -178.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.485 ' HE2' ' CG ' ' A' ' 56' ' ' ARG . 34.2 m-85 -104.81 101.1 10.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.595 0.236 . . . . 75.13 110.818 176.848 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.501 HG13 ' HB2' ' A' ' 19' ' ' ARG . 26.8 m -90.91 170.37 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 109.8 -0.444 . . . . 43.53 109.8 176.693 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.528 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 7.3 t -100.39 173.11 6.74 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.27 -0.641 . . . . 51.42 109.27 178.797 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 15.4 mmt180 -59.88 116.12 3.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.111 0.482 . . . . 71.44 110.769 178.545 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.21 -132.71 11.33 Favored Glycine 0 N--CA 1.446 -0.645 0 CA-C-N 115.723 -0.671 . . . . 62.21 111.996 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -114.88 34.88 4.56 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.14 0.495 . . . . 71.43 111.237 -177.374 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.528 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 15.0 mmm180 -89.65 120.15 30.68 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.768 -0.651 . . . . 74.21 109.371 177.2 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -78.86 147.48 33.14 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.161 0.505 . . . . 74.41 110.311 -178.807 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.42 HG12 ' HA ' ' A' ' 73' ' ' CYS . 21.6 m -115.24 145.95 20.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.064 -0.516 . . . . 54.31 110.824 -178.693 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 51' ' ' VAL . 4.5 p -104.8 96.26 4.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 122.017 0.913 . . . . 73.23 109.333 171.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.84 171.82 33.2 Favored Glycine 0 N--CA 1.441 -1.0 0 CA-C-N 115.225 -0.898 . . . . 43.0 111.748 -177.273 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.573 ' HG2' HG21 ' A' ' 69' ' ' THR . 64.3 Cg_endo -74.66 56.45 4.05 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.757 2.305 . . . . 70.42 110.329 171.083 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.449 ' HD2' ' CG ' ' A' ' 41' ' ' GLU . 43.7 pttt -77.83 86.2 4.08 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.32 -0.855 . . . . 72.35 111.717 -172.292 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -162.47 128.39 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.264 -0.88 . . . . 74.12 109.928 172.216 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.619 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 24.5 mmt180 -117.85 119.63 35.44 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 108.91 -0.774 . . . . 73.32 108.91 174.439 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.407 ' HB3' ' CG2' ' A' ' 65' ' ' THR . 37.2 ttmt -104.62 120.6 41.69 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.455 -0.572 . . . . 71.3 109.455 178.61 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 16.5 t -78.54 133.19 37.38 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.923 0.392 . . . . 74.1 109.995 -179.386 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 85.4 mt -117.05 -178.61 3.48 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.013 -0.539 . . . . 75.32 110.85 -173.604 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.26 -9.29 58.72 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.127 0.489 . . . . 34.01 110.518 178.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -94.44 151.64 19.22 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.214 -0.661 . . . . 74.35 109.214 172.691 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -77.27 54.02 3.54 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 121.09 -0.576 . . . . 74.22 113.762 -173.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 67.4 p -166.98 154.02 8.8 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.403 -0.592 . . . . 64.31 109.403 177.405 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.538 ' HB2' ' HB3' ' A' ' 67' ' ' MET . 84.3 m95 -75.02 165.83 24.63 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.802 -0.444 . . . . 65.43 109.802 178.542 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.407 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 0.9 OUTLIER -50.57 -42.78 55.95 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 113.052 0.76 . . . . 71.12 113.052 -176.915 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -157.93 74.88 0.74 Allowed 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.574 -0.528 . . . . 71.12 109.574 177.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' MET . . . . . 0.538 ' HB3' ' HB2' ' A' ' 64' ' ' TRP . 22.3 ptt? -88.7 80.24 7.3 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 118.837 -1.145 . . . . 72.34 111.497 -173.496 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -167.96 88.95 0.27 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.271 -1.331 . . . . 63.14 107.757 163.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.573 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.2 OUTLIER -158.43 115.77 1.74 Allowed Pre-proline 0 C--N 1.317 -0.846 0 C-N-CA 120.461 -0.496 . . . . 74.33 111.221 -169.35 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -81.52 124.91 4.84 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.497 2.131 . . . . 64.14 111.807 174.364 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 12.6 p -81.01 133.29 35.46 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.992 0.425 . . . . 73.3 110.085 177.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 38.3 mtp180 -96.34 99.26 10.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.312 -0.404 . . . . 75.3 111.364 -171.353 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.42 ' HA ' HG12 ' A' ' 50' ' ' VAL . 8.7 m -69.12 101.98 1.56 Allowed 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.799 -0.445 . . . . 74.22 109.799 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 94.7 t -136.41 120.15 23.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 121.026 0.441 . . . . 70.53 111.805 -173.731 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 67.8 mtt180 . . . . . 0 C--O 1.244 0.797 0 CA-C-N 115.627 -0.715 . . . . 74.41 109.694 170.892 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.1 m . . . . . 0 N--CA 1.45 -0.461 0 N-CA-C 108.882 -0.784 . . . . 74.12 108.882 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -95.58 109.09 21.38 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.176 0.512 . . . . 74.03 110.949 -174.799 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.517 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -161.21 -179.6 36.04 Favored Glycine 0 N--CA 1.443 -0.899 0 CA-C-N 115.299 -0.864 . . . . 52.24 111.323 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 15.0 m -99.12 145.1 27.52 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 109.912 -0.403 . . . . 72.14 109.912 178.182 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -88.36 -177.82 5.74 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.668 0.271 . . . . 64.22 110.522 179.53 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.0 mt -87.95 123.78 40.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.16 0.505 . . . . 73.43 110.041 178.075 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.449 HD11 ' CD1' ' A' ' 64' ' ' TRP . 9.8 mt -79.93 150.53 4.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.782 -0.645 . . . . 53.14 110.347 -178.347 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 16.2 p80 -62.54 141.07 96.81 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 109.525 -0.546 . . . . 73.31 109.525 172.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.45 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 23.5 Cg_exo -64.8 149.47 89.58 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.459 2.106 . . . . 62.52 111.715 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.461 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 3.0 Cg_exo -76.88 -132.04 0.01 OUTLIER 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.979 2.453 . . . . 72.42 110.998 174.549 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.461 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 3.8 t-105 -75.38 -179.57 4.61 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.433 -0.58 . . . . 72.24 109.433 176.581 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -43.95 101.05 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 112.742 0.645 . . . . 74.13 112.742 -176.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 174.74 -143.71 7.0 Favored Glycine 0 N--CA 1.441 -1.028 0 N-CA-C 110.869 -0.893 . . . . 71.54 110.869 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.74 -169.97 35.94 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.655 -0.783 . . . . 73.45 112.174 177.54 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.2 mt -118.81 125.39 74.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 121.364 0.602 . . . . 70.34 110.891 179.175 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.3 tpt180 -99.79 114.27 27.31 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.129 -0.941 . . . . 74.22 109.077 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.499 ' HA ' HG22 ' A' ' 40' ' ' ILE . 88.6 m-85 -76.75 -172.4 2.24 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.588 -0.278 . . . . 74.35 110.905 -175.644 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -87.49 -40.61 14.17 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.15 0.5 . . . . 74.3 110.417 -174.281 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -152.94 60.01 0.4 Allowed Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.881 -0.676 . . . . 71.12 112.208 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.471 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 76.1 mt -135.03 128.98 33.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.121 0.486 . . . . 52.44 110.998 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.2 t -96.15 -176.4 3.66 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.373 -0.83 . . . . 75.32 110.296 176.462 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.498 ' C ' ' H ' ' A' ' 27' ' ' GLN . 22.1 mmt180 -60.7 -172.08 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 116.351 -0.386 . . . . 73.32 111.512 178.31 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.425 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 23.9 t70 69.4 -35.86 0.32 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.191 0.597 . . . . 54.04 111.447 -175.399 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.529 ' O ' HG22 ' A' ' 28' ' ' VAL . 83.6 mt-30 -90.48 -169.08 2.28 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.806 -0.634 . . . . 70.15 111.067 -178.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.8 m 59.45 11.88 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 125.073 1.349 . . . . 75.0 112.754 173.685 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.403 ' HG2' ' H ' ' A' ' 29' ' ' LYS . 36.3 pttt -77.87 -27.64 49.76 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.28 0.562 . . . . 71.12 110.341 176.713 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.13 91.16 0.46 Allowed 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.442 -0.799 . . . . 75.11 110.339 177.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 57.9 mt -109.94 125.84 67.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 108.973 -0.751 . . . . 74.23 108.973 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -79.67 -46.45 17.11 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.138 -0.483 . . . . 73.04 110.187 -175.781 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.517 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 95.7 m-85 -146.47 121.31 9.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.992 -0.549 . . . . 71.25 111.127 -178.51 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -78.57 151.91 77.69 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.191 -0.459 . . . . 73.11 109.834 173.297 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -64.82 160.35 41.24 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.618 2.212 . . . . 63.24 112.449 177.735 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 14.3 p -71.06 145.94 12.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.334 -0.394 . . . . 72.31 110.938 -177.493 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 38.3 t70 69.93 9.61 7.17 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 123.65 0.78 . . . . 75.53 111.245 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.471 ' OH ' ' HG ' ' A' ' 23' ' ' LEU . 25.3 t80 -72.03 139.32 48.47 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 108.719 -0.845 . . . . 74.11 108.719 174.507 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.606 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.9 mt-10 -126.38 154.66 43.27 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.805 0.336 . . . . 72.52 111.007 -175.46 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.499 HG22 ' HA ' ' A' ' 20' ' ' TYR . 24.3 pt -133.7 162.72 39.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.418 0 CA-C-N 116.06 -0.518 . . . . 75.11 111.776 -177.156 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.453 ' HG3' ' HD2' ' A' ' 54' ' ' LYS . 78.1 tt0 -122.37 149.08 44.28 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.518 -0.765 . . . . 74.33 110.14 177.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -95.5 102.5 14.31 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.201 -0.454 . . . . 75.13 110.152 177.214 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 16.8 m -101.18 144.1 13.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.903 0.382 . . . . 43.53 111.013 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.438 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 28.9 t -91.46 176.74 6.44 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.264 -0.643 . . . . 51.42 109.264 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.95 129.68 41.44 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.63 0.252 . . . . 71.44 111.492 -178.78 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 62.84 -131.71 43.29 Favored Glycine 0 N--CA 1.45 -0.427 0 CA-C-N 115.855 -0.611 . . . . 62.21 112.237 178.501 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -98.5 83.81 3.08 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.739 0.78 . . . . 71.43 110.4 176.27 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.642 HH11 ' HB3' ' A' ' 75' ' ' ARG . 30.2 mmt180 -145.2 132.52 20.62 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.182 -0.917 . . . . 74.21 109.943 178.307 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.2 mp0 -102.21 152.53 20.93 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.049 -0.523 . . . . 74.41 110.548 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.577 HG12 ' HA ' ' A' ' 73' ' ' CYS . 34.7 m -114.58 120.52 64.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.68 -0.691 . . . . 54.31 109.257 171.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.418 ' O ' HG13 ' A' ' 51' ' ' VAL . 6.3 p -83.71 94.24 3.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 122.503 1.144 . . . . 73.23 109.617 178.16 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.22 172.53 33.47 Favored Glycine 0 N--CA 1.441 -0.991 0 CA-C-N 114.34 -1.3 . . . . 43.0 110.764 -177.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -73.3 58.59 3.68 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.225 1.95 . . . . 70.42 110.646 173.239 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.453 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 42.3 pttt -78.09 85.6 4.29 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-O 121.691 0.758 . . . . 72.35 111.46 -174.453 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.48 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 6.1 p -162.68 128.61 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.227 -0.897 . . . . 74.12 109.015 171.653 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.606 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 20.4 mmt180 -130.6 124.42 31.71 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.591 -0.522 . . . . 73.32 109.591 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.475 ' O ' HG23 ' A' ' 65' ' ' THR . 23.7 ttmm -99.68 131.52 45.61 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.875 -0.417 . . . . 71.3 109.875 178.761 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 48.1 t -80.2 137.64 36.71 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 109.638 -0.504 . . . . 74.1 109.638 176.206 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 89.0 mt -115.25 -178.96 3.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.41 -0.359 . . . . 75.32 110.322 -178.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -66.42 -27.48 67.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.133 0.492 . . . . 34.01 110.61 178.148 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -79.55 150.92 30.96 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.457 -0.571 . . . . 74.35 109.457 174.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -75.6 66.03 2.41 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 121.033 -0.603 . . . . 74.22 113.528 -175.571 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 13.8 t -174.19 149.09 1.38 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.674 -0.491 . . . . 64.31 109.674 175.618 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.449 ' CD1' HD11 ' A' ' 10' ' ' ILE . 64.9 m95 -77.27 157.4 30.8 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.199 -0.667 . . . . 65.43 109.199 177.313 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.475 HG23 ' O ' ' A' ' 57' ' ' LYS . 16.0 p -50.71 -46.72 59.09 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 113.319 0.859 . . . . 71.12 113.319 -173.689 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -128.52 118.17 22.57 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.704 -0.226 . . . . 71.12 110.495 -173.623 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 55.5 mtt -125.76 78.31 1.73 Allowed 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 119.346 -0.941 . . . . 72.34 110.741 168.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -170.26 89.05 0.15 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.618 -0.719 . . . . 63.14 109.143 163.243 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 60.3 m -160.29 107.88 1.38 Allowed Pre-proline 0 C--N 1.321 -0.645 0 CA-C-O 120.874 0.368 . . . . 74.33 111.463 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -76.92 91.92 1.14 Allowed 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.175 1.917 . . . . 64.14 110.943 170.522 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 16.8 p -70.42 110.9 5.6 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.803 -0.635 . . . . 73.3 110.577 -177.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 21.4 ptt-85 -79.26 119.21 22.01 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.381 0.61 . . . . 75.3 111.137 -176.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.577 ' HA ' HG12 ' A' ' 50' ' ' VAL . 42.5 t -80.37 110.14 15.53 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.363 -0.835 . . . . 74.22 109.502 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.7 p -155.98 130.45 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.375 0.607 . . . . 70.53 111.521 -174.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.642 ' HB3' HH11 ' A' ' 48' ' ' ARG . 22.3 ttm180 . . . . . 0 C--O 1.247 0.934 0 CA-C-N 115.601 -0.727 . . . . 74.41 109.095 175.53 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.4 m . . . . . 0 N--CA 1.453 -0.307 0 CA-C-O 121.205 0.526 . . . . 74.12 111.602 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -118.86 100.23 7.25 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.674 -0.694 . . . . 74.03 109.339 173.636 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.74 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -158.89 147.33 14.74 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.039 -1.077 . . . . 52.24 113.231 -177.504 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.6 m -83.47 157.8 22.28 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.87 -0.418 . . . . 72.14 109.87 176.108 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -84.85 -178.23 6.79 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.124 0.488 . . . . 64.22 111.265 179.753 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.66 HD11 ' H ' ' A' ' 31' ' ' ILE . 56.5 mt -87.05 117.05 30.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.617 -0.72 . . . . 73.43 109.371 174.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.9 pt -90.18 149.23 4.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.528 -0.76 . . . . 53.14 110.665 -178.379 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' HIS . . . . . 0.431 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 19.9 m-70 -88.32 143.47 32.61 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 116.246 -0.434 . . . . 73.31 111.24 -175.211 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 16.7 Cg_exo -67.82 135.06 34.22 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 123.053 2.502 . . . . 62.52 111.963 178.056 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 82.4 Cg_endo -88.07 -150.22 0.04 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 123.002 2.468 . . . . 72.42 112.475 179.525 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.0 t-105 -63.48 -177.59 0.22 Allowed 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 115.812 -0.631 . . . . 72.24 110.697 178.058 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -38.82 100.33 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 123.876 0.87 . . . . 74.13 112.928 -173.065 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.85 -172.43 43.75 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 114.989 -1.005 . . . . 71.54 110.722 -178.291 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -156.91 -171.12 22.64 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.747 -0.74 . . . . 73.45 112.07 179.183 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.3 mt -129.7 137.37 56.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.381 0.61 . . . . 70.34 111.24 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.417 HH11 ' HD2' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -117.08 119.14 34.34 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.164 -0.925 . . . . 74.22 109.776 -177.612 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.424 ' HA ' HG22 ' A' ' 40' ' ' ILE . 95.0 m-85 -84.69 -171.7 3.78 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.749 0.309 . . . . 74.35 110.623 -178.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.1 ttm180 -93.26 -55.85 3.16 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.985 0.421 . . . . 74.3 109.993 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -144.89 67.74 0.42 Allowed Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.753 -0.737 . . . . 71.12 112.325 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 76.5 mt -139.07 118.33 12.72 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.995 -0.372 . . . . 52.44 109.995 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.2 t -81.0 178.9 8.13 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.297 -0.41 . . . . 75.32 110.189 178.699 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.429 ' C ' ' H ' ' A' ' 27' ' ' GLN . 95.2 mtt180 -78.09 -171.92 2.54 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 120.491 0.186 . . . . 73.32 111.343 -175.396 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.402 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 11.6 t70 67.38 -42.79 0.44 Allowed 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 123.305 0.642 . . . . 54.04 110.885 -168.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' HG22 ' A' ' 28' ' ' VAL . 95.7 mt-30 -70.57 -170.34 0.4 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.217 -0.447 . . . . 70.15 110.137 173.48 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.9 m 57.9 9.38 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.272 1.029 . . . . 75.0 112.134 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 52.7 pttt -83.49 -19.98 34.8 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.789 -0.819 . . . . 71.12 108.789 172.16 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.14 102.05 2.11 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 114.885 -1.052 . . . . 75.11 110.026 177.839 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.66 ' H ' HD11 ' A' ' 9' ' ' ILE . 57.3 mt -120.83 144.72 28.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 109.031 -0.729 . . . . 74.23 109.031 176.717 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -88.69 -65.61 1.0 Allowed 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.94 -0.393 . . . . 73.04 109.94 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.74 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 56.0 m-85 -143.42 140.84 30.61 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.239 -0.437 . . . . 71.25 110.487 177.448 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.463 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.7 mm? -82.82 132.23 52.01 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 109.331 -0.618 . . . . 73.11 109.331 174.013 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -58.24 139.34 90.14 Favored 'Trans proline' 0 C--O 1.236 0.382 0 C-N-CA 122.615 2.21 . . . . 63.24 112.227 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 p -67.3 84.59 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 CA-C-O 121.905 0.86 . . . . 72.31 111.272 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.6 t70 165.59 -30.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.179 -1.373 . . . . 75.53 108.925 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.405 ' HH ' ' HB3' ' A' ' 20' ' ' TYR . 9.3 t80 -57.22 138.18 55.0 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.895 -1.048 . . . . 74.11 111.277 -174.655 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.51 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 18.9 mt-10 -122.54 139.38 53.96 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.511 -0.768 . . . . 72.52 110.39 -176.704 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.493 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 35.5 pt -128.17 156.95 40.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.354 -0.384 . . . . 75.11 110.856 178.536 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -119.83 151.58 38.62 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.016 -0.538 . . . . 74.33 110.508 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -99.05 102.47 14.19 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.072 -0.513 . . . . 75.13 111.052 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.4 m -96.82 163.82 2.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 N-CA-C 110.028 -0.36 . . . . 43.53 110.028 175.342 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.574 ' HB2' HG13 ' A' ' 50' ' ' VAL . 31.5 t -89.68 175.11 7.38 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.457 -0.572 . . . . 51.42 109.457 178.127 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.66 119.2 19.37 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.95 0.405 . . . . 71.44 110.797 -174.5 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.06 -100.27 2.65 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.846 -0.616 . . . . 62.21 112.863 174.422 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -133.81 21.8 3.88 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.987 0.422 . . . . 71.43 111.233 -174.077 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.562 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 11.4 mmt180 -96.35 142.88 27.95 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.168 -0.469 . . . . 74.21 110.972 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.824 ' HB2' ' HD2' ' A' ' 75' ' ' ARG . 2.2 mp0 -94.37 153.78 17.81 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.125 -0.489 . . . . 74.41 110.867 177.071 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.574 HG13 ' HB2' ' A' ' 44' ' ' CYS . 28.0 m -118.49 151.31 20.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.688 -0.687 . . . . 54.31 109.882 176.841 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.9 p -114.9 96.19 4.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.913 0.863 . . . . 73.23 110.008 173.215 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.11 170.91 33.31 Favored Glycine 0 N--CA 1.445 -0.711 0 CA-C-N 115.2 -0.909 . . . . 43.0 111.602 179.321 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -73.59 60.01 4.17 Favored 'Trans proline' 0 CA--C 1.531 0.353 0 C-N-CA 122.482 2.121 . . . . 70.42 110.88 170.449 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 44.3 pttt -77.23 89.44 3.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.583 -0.735 . . . . 72.35 112.392 -171.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.9 p -160.8 135.11 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.892 -0.595 . . . . 74.12 109.605 171.343 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.51 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 24.6 mmt180 -131.12 120.8 23.88 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.41 -0.359 . . . . 73.32 110.537 177.901 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.464 ' HB3' ' CG2' ' A' ' 65' ' ' THR . 39.4 ttmt -102.73 129.63 49.42 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 109.094 -0.706 . . . . 71.3 109.094 174.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 45.6 t -67.92 143.51 55.64 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.469 -0.332 . . . . 74.1 110.327 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.451 HD11 ' HA ' ' A' ' 65' ' ' THR . 88.6 mt -110.89 -178.38 3.46 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.369 -0.378 . . . . 75.32 110.615 -176.56 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -79.82 14.56 1.7 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.974 0.416 . . . . 34.01 111.161 178.654 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -141.44 -178.62 5.71 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.772 -0.649 . . . . 74.35 109.62 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -66.04 -29.68 75.47 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 114.771 0.668 . . . . 74.22 114.771 -171.252 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 78.5 p -93.23 163.27 13.68 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.473 0.636 . . . . 64.31 111.458 -175.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -92.89 -179.86 5.25 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.877 -0.601 . . . . 65.43 110.005 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.464 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 3.2 p -49.59 -69.72 0.11 Allowed 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 113.558 0.947 . . . . 71.12 113.558 -174.169 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -133.21 48.59 2.38 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.649 -0.501 . . . . 71.12 109.649 -177.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 28.0 ttt -80.65 81.92 6.78 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.382 -0.927 . . . . 72.34 111.831 -170.655 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -166.65 87.6 0.32 Allowed 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 106.72 -1.585 . . . . 63.14 106.72 158.196 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.404 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 1.5 m -157.79 113.41 1.81 Allowed Pre-proline 0 C--N 1.316 -0.889 0 CA-C-N 116.284 -0.416 . . . . 74.33 110.051 -168.891 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 16.8 Cg_exo -66.68 97.6 0.39 Allowed 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.61 2.206 . . . . 64.14 112.164 179.169 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.1 p -78.73 101.63 7.66 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.212 -0.662 . . . . 73.3 109.212 173.18 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -78.94 126.58 30.88 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.315 0.579 . . . . 75.3 111.091 -171.529 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.556 ' HA ' HG12 ' A' ' 50' ' ' VAL . 41.8 t -82.03 98.74 8.77 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.499 -0.773 . . . . 74.22 109.865 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.3 p -176.98 152.44 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.992 -0.744 . . . . 70.53 108.992 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.824 ' HD2' ' HB2' ' A' ' 49' ' ' GLU . 2.5 ptm180 . . . . . 0 C--O 1.245 0.859 0 CA-C-O 119.168 -0.444 . . . . 74.41 110.367 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.4 m . . . . . 0 N--CA 1.448 -0.535 0 N-CA-C 110.209 -0.293 . . . . 74.12 110.209 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLU . . . . . 0.465 ' CD ' ' H ' ' A' ' 5' ' ' GLU . 0.9 OUTLIER -70.03 107.57 3.68 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.833 -0.803 . . . . 74.03 108.833 175.863 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.822 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -157.63 126.28 1.7 Allowed Glycine 0 N--CA 1.443 -0.847 0 C-N-CA 120.288 -0.958 . . . . 52.24 113.035 -176.191 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 64.8 m -90.59 152.32 20.94 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.546 -0.539 . . . . 72.14 109.546 175.589 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 -81.77 -178.02 6.81 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.916 0.389 . . . . 64.22 111.233 -178.413 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.598 HD11 ' HB ' ' A' ' 31' ' ' ILE . 46.2 mt -87.39 121.6 38.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.873 -0.603 . . . . 73.43 110.691 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 56.9 mt -73.86 114.21 13.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.03 -0.532 . . . . 53.14 109.581 175.051 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 31.9 m-70 -75.44 129.08 82.95 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 110.09 -0.337 . . . . 73.31 110.09 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.511 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 7.3 Cg_endo -49.19 118.77 3.83 Favored 'Trans proline' 0 C--N 1.349 0.556 0 C-N-CA 123.447 2.765 . . . . 62.52 112.429 -177.222 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.511 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 4.0 Cg_exo -76.38 -84.03 0.0 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 122.996 2.464 . . . . 72.42 112.325 -177.747 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.7 t-105 -100.93 -178.36 3.73 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.228 -0.442 . . . . 72.24 109.925 -177.786 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -47.68 102.31 0.03 OUTLIER 'General case' 0 C--O 1.234 0.275 0 O-C-N 123.791 0.682 . . . . 74.13 112.242 177.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.07 -157.14 28.97 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.352 -0.84 . . . . 71.54 111.099 -179.211 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -161.13 -171.08 26.63 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 111.338 -0.705 . . . . 73.45 111.338 177.138 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.5 mt -127.77 129.43 70.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.669 0.747 . . . . 70.34 111.363 -179.526 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.895 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 5.1 tpt180 -93.62 132.75 37.64 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 114.438 -1.256 . . . . 74.22 109.486 -179.021 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.515 ' HB3' ' HH ' ' A' ' 38' ' ' TYR . 97.1 m-85 -106.55 -171.28 1.86 Allowed 'General case' 0 C--N 1.32 -0.678 0 C-N-CA 120.845 -0.342 . . . . 74.35 110.735 -178.032 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.411 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 19.1 ttt-85 -114.68 -51.69 2.73 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.944 0.402 . . . . 74.3 110.264 -174.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -136.83 30.57 2.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 71.12 112.807 -177.328 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 80.3 mt -109.72 129.7 55.59 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 122.595 -0.356 . . . . 52.44 110.255 177.544 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.4 t -80.33 -179.81 7.31 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.112 -0.495 . . . . 75.32 110.1 178.459 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.404 ' C ' ' H ' ' A' ' 27' ' ' GLN . 38.3 ptt180 -73.48 -174.16 1.6 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.325 -0.398 . . . . 73.32 110.752 -178.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 21.8 t70 67.32 -44.5 0.46 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.859 0.864 . . . . 54.04 111.619 -177.171 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.637 ' O ' HG22 ' A' ' 28' ' ' VAL . 94.0 mt-30 -68.03 -163.62 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 122.896 0.478 . . . . 70.15 111.554 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.637 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.0 m 61.11 13.93 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 124.538 1.135 . . . . 75.0 111.347 -177.816 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -90.99 -29.02 17.63 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.342 -0.614 . . . . 71.12 109.342 176.284 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.65 89.68 1.27 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.714 -0.676 . . . . 75.11 111.003 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.598 ' HB ' HD11 ' A' ' 9' ' ' ILE . 57.3 mt -126.66 134.28 66.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 108.818 -0.808 . . . . 74.23 108.818 175.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -77.54 -56.42 4.54 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.815 0.34 . . . . 73.04 111.043 -177.093 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.822 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 65.9 m-85 -136.33 145.61 45.63 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.082 0.467 . . . . 71.25 111.375 -175.414 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.594 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.7 mm? -103.8 139.11 19.8 Favored Pre-proline 0 C--N 1.323 -0.564 0 N-CA-C 108.993 -0.743 . . . . 73.11 108.993 170.223 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -58.89 159.76 20.28 Favored 'Trans proline' 0 N--CA 1.476 0.5 0 C-N-CA 123.203 2.602 . . . . 63.24 113.315 -176.426 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.4 ' HB ' ' HB2' ' A' ' 5' ' ' GLU . 9.9 p -71.64 2.75 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 CA-C-O 121.648 0.737 . . . . 72.31 111.473 -176.7 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -134.4 92.78 2.97 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.093 0.473 . . . . 75.53 109.798 170.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.589 ' O ' ' HA ' ' A' ' 57' ' ' LYS . 20.2 t80 -157.18 135.02 10.86 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.633 -0.712 . . . . 74.11 109.301 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 38.9 mt-10 -113.4 130.29 56.33 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.242 0.339 . . . . 72.52 110.784 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.574 HG12 ' HB2' ' A' ' 56' ' ' ARG . 43.6 pt -121.68 158.09 25.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.369 -0.378 . . . . 75.11 110.89 175.583 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.895 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 41.3 tt0 -127.19 154.36 44.9 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.868 -0.605 . . . . 74.33 110.598 -177.692 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 65.3 m-85 -100.03 102.29 13.6 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.328 -0.396 . . . . 75.13 110.612 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.3 m -109.2 164.78 5.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.371 -0.377 . . . . 43.53 111.202 -178.696 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.512 ' HB2' ' HB2' ' A' ' 48' ' ' ARG . 86.3 m -110.85 179.32 4.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.1 -0.5 . . . . 51.42 110.388 177.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -76.92 102.36 6.35 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.071 0.463 . . . . 71.44 110.375 178.191 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.35 -166.81 25.76 Favored Glycine 0 N--CA 1.445 -0.704 0 N-CA-C 111.05 -0.82 . . . . 62.21 111.05 -176.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -82.59 77.66 9.32 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.526 0.679 . . . . 71.43 111.281 178.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.512 ' HB2' ' HB2' ' A' ' 44' ' ' CYS . 14.1 mtm-85 -127.87 118.34 23.46 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.754 -0.832 . . . . 74.21 108.754 176.463 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -88.2 154.11 20.7 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.064 -0.516 . . . . 74.41 111.099 -172.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.588 HG12 ' HA ' ' A' ' 73' ' ' CYS . 27.2 m -119.23 130.77 73.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.798 -0.637 . . . . 54.31 109.969 178.48 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.0 p -95.04 94.08 4.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-O 122.217 1.008 . . . . 73.23 109.857 175.686 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -157.26 170.9 34.51 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 114.223 -1.353 . . . . 43.0 110.514 177.098 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.514 ' HG2' HG21 ' A' ' 69' ' ' THR . 55.9 Cg_endo -75.19 77.88 3.08 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.621 1.547 . . . . 70.42 110.536 168.569 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.603 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 43.6 pttt -86.84 88.48 7.69 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.656 0.741 . . . . 72.35 111.048 -174.392 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.508 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 6.8 p -160.19 128.99 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.496 -0.775 . . . . 74.12 109.814 176.56 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.574 ' HB2' HG12 ' A' ' 40' ' ' ILE . 23.1 mmt180 -137.12 125.65 23.61 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.924 -0.58 . . . . 73.32 110.028 178.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 38' ' ' TYR . 35.4 ttmt -124.6 137.4 54.39 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 108.775 -0.824 . . . . 71.3 108.775 168.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.5 t -67.27 142.86 56.75 Favored 'General case' 0 C--N 1.323 -0.575 0 O-C-N 123.337 0.398 . . . . 74.1 110.279 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.9 mt -119.46 -178.1 3.52 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.141 -0.481 . . . . 75.32 110.228 -177.852 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.62 -4.98 43.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.066 0.46 . . . . 34.01 110.884 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -99.62 163.38 12.52 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.774 -0.648 . . . . 74.35 109.422 173.535 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -78.53 47.96 3.09 Favored Glycine 0 CA--C 1.521 0.449 0 C-N-CA 120.917 -0.659 . . . . 74.22 113.678 -174.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.0 t -165.9 170.55 13.64 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.259 -0.645 . . . . 64.31 109.259 178.067 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 61.1 m95 -87.44 178.12 6.91 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.836 -0.431 . . . . 65.43 109.836 -177.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.401 HG23 ' O ' ' A' ' 57' ' ' LYS . 2.9 p -49.86 -50.8 44.3 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 113.394 0.887 . . . . 71.12 113.394 -173.064 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -148.25 66.08 1.08 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.569 0.224 . . . . 71.12 110.445 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 60.1 ttp -87.1 79.83 8.53 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 118.921 -1.112 . . . . 72.34 110.934 -176.137 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -169.31 89.67 0.2 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.446 -1.252 . . . . 63.14 107.72 162.521 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.514 HG21 ' HG2' ' A' ' 53' ' ' PRO . 1.4 m -151.39 127.29 5.02 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 120.314 -0.554 . . . . 74.33 111.339 -170.354 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -78.61 93.95 1.08 Allowed 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.574 2.182 . . . . 64.14 112.159 175.865 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.9 p -92.9 114.61 27.22 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.081 -0.509 . . . . 73.3 110.782 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.7 ptp85 -94.28 128.67 40.9 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.056 -0.52 . . . . 75.3 111.045 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.588 ' HA ' HG12 ' A' ' 50' ' ' VAL . 18.2 t -89.44 112.2 23.28 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.001 -0.545 . . . . 74.22 109.748 179.513 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.97 115.03 14.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.478 -0.328 . . . . 70.53 111.168 -174.015 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.4 ' HA ' ' HD2' ' A' ' 75' ' ' ARG . 12.0 tpt180 . . . . . 0 C--O 1.244 0.795 0 CA-C-O 118.479 -0.772 . . . . 74.41 109.723 174.16 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 28.1 m . . . . . 0 N--CA 1.451 -0.399 0 N-CA-C 109.683 -0.488 . . . . 74.12 109.683 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -76.19 105.41 7.22 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.106 -0.497 . . . . 74.03 109.795 -179.172 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.727 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -149.53 143.1 10.4 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.624 -0.798 . . . . 52.24 112.529 -178.537 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 69.2 m -92.47 151.83 20.0 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 110.213 -0.292 . . . . 72.14 110.213 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.452 ' H ' ' HG3' ' A' ' 8' ' ' GLN . 3.2 pp0? -87.15 -179.43 6.45 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.633 -0.258 . . . . 64.22 111.521 -177.683 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 40.4 mt -88.61 112.57 24.13 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.246 -0.434 . . . . 73.43 111.294 -171.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 38.7 mt -70.82 146.12 12.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.74 -0.663 . . . . 53.14 110.443 179.139 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' HIS . . . . . 0.43 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 72.2 m-70 -88.24 141.85 31.23 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 116.524 -0.307 . . . . 73.31 110.39 177.422 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 12.8 Cg_exo -71.4 122.08 8.32 Favored 'Trans proline' 0 CA--C 1.529 0.253 0 C-N-CA 122.934 2.423 . . . . 62.52 111.644 176.071 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 59.8 Cg_endo -91.19 -94.73 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 123.008 2.472 . . . . 72.42 112.782 -177.6 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -89.99 -176.0 4.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.088 -0.708 . . . . 72.24 109.088 178.132 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -57.48 -16.21 9.02 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 112.11 0.411 . . . . 74.13 112.11 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.38 91.41 0.3 Allowed Glycine 0 N--CA 1.448 -0.502 0 N-CA-C 110.648 -0.981 . . . . 71.54 110.648 167.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -91.16 -170.21 42.58 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 121.168 -0.539 . . . . 73.45 112.982 -173.543 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -115.55 136.23 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 CA-C-O 121.72 0.772 . . . . 70.34 112.083 -174.632 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.786 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 15.4 tpt180 -116.4 145.8 42.98 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.182 -1.372 . . . . 74.22 109.049 -178.047 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 68.6 m-85 -108.95 -172.89 2.14 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.805 -0.442 . . . . 74.35 109.805 178.771 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 25.6 mtm180 -98.41 -38.48 9.2 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.57 -0.452 . . . . 74.3 110.885 -178.646 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -160.56 52.95 0.34 Allowed Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.644 -0.789 . . . . 71.12 112.467 178.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 93.7 mt -116.73 115.94 26.57 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.942 0.401 . . . . 52.44 110.352 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.6 t -80.79 -179.2 7.16 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.656 -0.702 . . . . 75.32 110.307 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.5 ' C ' ' H ' ' A' ' 27' ' ' GLN . 39.5 mmt180 -67.4 -174.99 0.44 Allowed 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.684 0.278 . . . . 73.32 111.308 -176.045 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 23.4 t70 65.64 -34.26 0.19 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.638 0.775 . . . . 54.04 112.172 -175.759 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.5 ' H ' ' C ' ' A' ' 25' ' ' ARG . 95.7 mt-30 -80.89 -166.3 1.09 Allowed 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 122.542 0.337 . . . . 70.15 110.664 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 27' ' ' GLN . 5.8 m 52.89 18.5 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 124.548 1.139 . . . . 75.0 113.068 177.009 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 50.8 pttt -111.37 -21.85 11.62 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.808 0.337 . . . . 71.12 110.285 177.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.74 16.03 2.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.346 -0.388 . . . . 75.11 111.664 -178.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 60.8 mt -73.22 103.38 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 109.404 -0.591 . . . . 74.23 109.404 176.661 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -58.01 -50.07 74.66 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.145 -0.48 . . . . 73.04 112.184 -173.066 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.727 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 91.0 m-85 -133.31 128.54 35.96 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.818 0.342 . . . . 71.25 110.821 -177.24 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -83.23 126.87 70.93 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 108.485 -0.931 . . . . 73.11 108.485 171.474 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -51.24 145.46 26.77 Favored 'Trans proline' 0 C--O 1.234 0.283 0 C-N-CA 123.361 2.707 . . . . 63.24 112.92 -176.118 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 p -59.74 142.41 15.21 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 CA-C-N 115.792 -0.64 . . . . 72.31 110.99 -178.823 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.8 t70 78.75 -11.96 1.14 Allowed 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.238 -0.892 . . . . 75.53 111.947 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 47.3 t80 -67.05 120.31 13.46 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 108.877 -0.786 . . . . 74.11 108.877 176.228 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.477 ' HG2' ' HA ' ' A' ' 57' ' ' LYS . 43.6 mt-10 -104.77 146.84 28.4 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.131 -0.486 . . . . 72.52 110.836 -176.147 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.598 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 21.1 pt -120.2 155.56 23.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.824 -0.626 . . . . 75.11 110.415 177.748 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.786 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.4 tt0 -107.21 165.84 11.07 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.588 -0.733 . . . . 74.33 110.268 -174.57 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.441 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 5.2 m-85 -120.47 101.43 7.77 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.775 0.321 . . . . 75.13 110.838 178.048 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 20.3 m -103.01 168.15 2.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.139 -0.482 . . . . 43.53 110.429 178.77 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.598 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 28.3 t -90.57 140.76 29.44 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.472 -0.566 . . . . 51.42 109.472 178.52 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -59.12 117.12 4.36 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.818 -0.628 . . . . 71.44 110.218 -176.691 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 114.18 -112.91 2.92 Favored Glycine 0 N--CA 1.444 -0.808 0 N-CA-C 111.093 -0.803 . . . . 62.21 111.093 -176.051 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -149.77 65.76 0.99 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.347 0.594 . . . . 71.43 110.834 177.466 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.598 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 35.0 mmt180 -126.57 136.27 52.34 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.265 -0.425 . . . . 74.21 110.047 179.358 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.52 157.01 27.52 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.958 -0.386 . . . . 74.41 109.958 176.255 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.53 HG12 ' HB3' ' A' ' 73' ' ' CYS . 33.2 m -130.29 149.69 33.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.245 -0.434 . . . . 54.31 110.68 -177.807 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -116.34 95.47 3.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 122.298 1.047 . . . . 73.23 108.929 169.733 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.47 172.33 33.61 Favored Glycine 0 N--CA 1.444 -0.824 0 CA-C-N 114.496 -1.229 . . . . 43.0 111.173 -178.015 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.5 ' HG2' HG21 ' A' ' 69' ' ' THR . 69.3 Cg_endo -75.91 60.02 5.96 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.326 2.017 . . . . 70.42 110.782 173.098 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.602 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 40.0 pttt -71.65 88.93 0.98 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.452 -0.794 . . . . 72.35 111.328 -175.516 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -161.88 131.89 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 116.046 -0.525 . . . . 74.12 110.946 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.598 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 22.3 mmt180 -127.78 111.07 13.24 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.504 -0.924 . . . . 73.32 108.504 169.649 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.477 ' HA ' ' HG2' ' A' ' 39' ' ' GLU . 20.5 ttmm -97.99 122.39 41.05 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.954 -0.387 . . . . 71.3 109.954 -178.648 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 49.8 t -69.65 126.97 31.33 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.772 -0.455 . . . . 74.1 109.772 177.337 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 95.0 mt -97.03 -178.94 4.37 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.054 -0.521 . . . . 75.32 110.831 -175.158 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.29 -17.03 61.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 34.01 110.687 178.836 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.6 p30 -101.18 165.8 11.11 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.305 -0.628 . . . . 74.35 109.305 174.523 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.97 52.42 3.28 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 121.026 -0.607 . . . . 74.22 113.51 -174.038 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.8 m -157.5 157.7 34.35 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.523 -0.547 . . . . 64.31 109.523 177.001 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -88.27 173.51 8.73 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.603 -0.517 . . . . 65.43 109.603 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.425 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 3.0 p -57.73 -73.18 0.08 Allowed 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 112.27 0.47 . . . . 71.12 112.27 -177.536 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -125.31 121.13 33.09 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.215 -0.661 . . . . 71.12 109.215 178.695 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 62.3 mtm -120.45 79.6 1.5 Allowed 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 119.259 -0.976 . . . . 72.34 111.149 173.738 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -168.34 89.79 0.26 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 114.735 -1.121 . . . . 63.14 108.316 162.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.5 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.2 OUTLIER -159.02 102.23 1.58 Allowed Pre-proline 0 C--N 1.315 -0.932 0 C-N-CA 120.581 -0.448 . . . . 74.33 110.693 -171.814 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -75.33 105.17 2.03 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.359 2.039 . . . . 64.14 111.576 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 7.6 p -75.22 102.41 4.99 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.228 0.537 . . . . 73.3 110.852 -178.784 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.1 ptp180 -79.97 115.61 19.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.696 -0.684 . . . . 75.3 111.252 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.53 ' HB3' HG12 ' A' ' 50' ' ' VAL . 0.7 OUTLIER -87.25 99.04 11.67 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.984 -0.553 . . . . 74.22 110.689 174.761 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.7 p -115.53 129.13 72.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.611 -0.722 . . . . 70.53 109.54 176.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.637 -0.697 . . . . 74.41 109.875 -176.276 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.0 m . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 108.794 -0.817 . . . . 74.12 108.794 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -119.1 99.2 6.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.698 -0.683 . . . . 74.03 110.524 -174.144 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.468 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -161.74 165.54 35.74 Favored Glycine 0 N--CA 1.437 -1.235 0 CA-C-N 115.612 -0.722 . . . . 52.24 111.363 178.234 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 13.3 m -84.61 139.74 31.86 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 110.078 -0.341 . . . . 72.14 110.078 178.476 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -83.14 -178.67 7.18 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.204 0.526 . . . . 64.22 111.087 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.544 HD11 ' HB ' ' A' ' 31' ' ' ILE . 58.2 mt -87.43 105.04 14.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.809 -0.632 . . . . 73.43 109.366 178.087 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 20.8 pt -72.18 169.93 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 114.721 -1.127 . . . . 53.14 111.556 -177.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -69.39 135.79 88.72 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.009 -0.541 . . . . 73.31 109.745 173.576 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -59.78 143.99 99.53 Favored 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.117 1.878 . . . . 62.52 111.147 172.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.21 -160.05 0.09 OUTLIER 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.489 2.126 . . . . 72.42 112.441 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 14.9 t-105 -68.8 -175.94 0.76 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.969 -0.56 . . . . 72.24 109.787 177.543 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 66.9 mm-40 -37.86 100.53 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.553 0.741 . . . . 74.13 112.655 -172.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.532 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . 163.6 -132.39 2.72 Favored Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.322 -0.853 . . . . 71.54 111.643 -179.149 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -179.64 -166.2 34.93 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.495 -0.642 . . . . 73.45 111.495 178.491 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.3 mt -127.95 130.11 69.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.463 0.649 . . . . 70.34 111.189 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.741 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 23.2 tpt180 -96.64 135.3 38.75 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 114.759 -1.109 . . . . 74.22 109.255 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.588 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 98.0 m-85 -93.17 -171.23 2.61 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.836 -0.346 . . . . 74.35 110.613 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.598 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 49.1 ttt180 -106.43 -75.86 0.62 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 120.757 0.313 . . . . 74.3 110.893 -170.346 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -114.19 43.68 1.65 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.886 -0.597 . . . . 71.12 112.097 -177.753 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 75.1 mt -133.69 144.67 49.3 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 110.243 -0.28 . . . . 52.44 110.243 178.094 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.0 t -97.04 175.01 6.48 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.062 -0.517 . . . . 75.32 109.821 176.007 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.458 ' C ' ' H ' ' A' ' 27' ' ' GLN . 34.7 ptt180 -74.43 -172.42 1.46 Allowed 'General case' 0 C--O 1.236 0.389 0 C-N-CA 121.439 -0.104 . . . . 73.32 110.815 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 27.4 t70 69.27 -2.27 1.9 Allowed 'General case' 0 N--CA 1.474 0.774 0 CA-C-O 122.055 0.931 . . . . 54.04 109.945 -175.589 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.458 ' H ' ' C ' ' A' ' 25' ' ' ARG . 97.2 mt-30 -119.98 -156.51 0.67 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.777 -1.102 . . . . 70.15 108.518 178.302 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.423 HG12 HD11 ' A' ' 31' ' ' ILE . 15.2 m 47.83 27.57 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.778 0.831 . . . . 75.0 112.263 176.343 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.413 ' H ' ' HG2' ' A' ' 29' ' ' LYS . 26.3 pttt -92.74 -22.44 19.37 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.39 -0.823 . . . . 71.12 110.445 -175.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.6 81.54 0.66 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.809 -0.632 . . . . 75.11 110.677 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.544 ' HB ' HD11 ' A' ' 9' ' ' ILE . 48.0 mt -103.4 146.78 10.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.829 -0.623 . . . . 74.23 109.533 178.396 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -85.56 -67.92 0.77 Allowed 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.978 -0.379 . . . . 73.04 109.978 177.382 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.468 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 75.8 m-85 -136.32 145.72 45.8 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.021 -0.536 . . . . 71.25 110.641 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -92.32 142.59 26.25 Favored Pre-proline 0 C--N 1.321 -0.645 0 N-CA-C 109.762 -0.459 . . . . 73.11 109.762 175.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -62.77 147.15 95.05 Favored 'Trans proline' 0 C--O 1.237 0.442 0 C-N-CA 122.725 2.284 . . . . 63.24 113.03 -178.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 6.4 p -70.39 80.75 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 CA-C-O 122.159 0.98 . . . . 72.31 110.502 177.673 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.0 t70 172.94 -27.78 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 114.461 -1.245 . . . . 75.53 108.739 -175.095 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.588 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 7.9 t80 -72.15 142.9 49.09 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 114.751 -1.113 . . . . 74.11 111.185 -176.166 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.598 ' H ' ' HD2' ' A' ' 21' ' ' ARG . 54.9 mt-10 -124.61 153.76 41.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.032 -0.531 . . . . 72.52 109.93 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.645 HD11 ' HE1' ' A' ' 67' ' ' MET . 35.0 pt -126.68 165.65 24.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 120.763 0.316 . . . . 75.11 111.435 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.741 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.7 tt0 -130.89 147.47 52.54 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.955 -0.566 . . . . 74.33 110.268 178.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -94.84 102.27 14.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.285 -0.416 . . . . 75.13 110.678 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.5 m -103.48 170.67 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 120.9 0.381 . . . . 43.53 111.141 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 49.7 t -115.9 175.18 5.65 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.301 -0.409 . . . . 51.42 110.055 -178.378 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ARG . . . . . 0.532 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 2.0 tmt_? -77.09 99.63 5.43 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.631 -0.507 . . . . 71.44 109.631 -178.185 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.18 -160.63 28.44 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.929 -0.653 . . . . 62.21 111.691 -178.651 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -85.18 69.52 10.77 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.745 0.783 . . . . 71.43 111.002 -179.404 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 26.5 mmm180 -124.51 107.72 11.36 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.139 -1.059 . . . . 74.21 108.139 174.584 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -79.8 139.31 37.28 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.999 0.428 . . . . 74.41 111.508 -170.553 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' A' ' 73' ' ' CYS . 33.7 m -94.53 150.12 4.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.707 -0.678 . . . . 54.31 111.292 -176.515 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -114.42 95.06 3.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.822 0.82 . . . . 73.23 109.17 169.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.57 171.66 33.63 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.155 -0.93 . . . . 43.0 111.664 -178.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -83.58 71.25 6.03 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.158 1.905 . . . . 70.42 110.336 169.747 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.462 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 21.1 pttp -81.61 86.95 6.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.655 0.741 . . . . 72.35 111.629 -170.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.6 p -161.9 128.0 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.362 -0.836 . . . . 74.12 109.315 172.339 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.493 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 35.1 mmt180 -145.19 118.22 8.83 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.322 -0.622 . . . . 73.32 109.322 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -106.03 139.7 40.16 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.958 0.409 . . . . 71.3 109.958 177.301 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.9 t -70.47 149.66 46.98 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.556 -0.747 . . . . 74.1 111.911 -175.382 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.3 mt -113.15 -178.02 3.28 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.187 -0.915 . . . . 75.32 109.943 179.307 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -83.44 28.97 0.52 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.869 0.366 . . . . 34.01 111.277 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -146.56 169.85 18.11 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.161 -0.472 . . . . 74.35 109.946 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -69.2 -34.44 75.46 Favored Glycine 0 C--N 1.33 0.236 0 C-N-CA 121.348 -0.453 . . . . 74.22 114.039 -169.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.8 m -89.79 142.06 28.04 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 121.124 0.488 . . . . 64.31 111.054 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 59.7 m95 -73.82 -179.29 3.59 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.086 -0.507 . . . . 65.43 110.732 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.9 p -56.33 -56.12 25.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.312 -0.404 . . . . 71.12 111.792 -178.587 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.44 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 10.6 t70 -142.66 127.0 17.66 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.742 -0.466 . . . . 71.12 109.742 174.294 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' MET . . . . . 0.645 ' HE1' HD11 ' A' ' 40' ' ' ILE . 24.2 mmt -127.75 78.68 1.84 Allowed 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 119.112 -1.035 . . . . 72.34 110.531 165.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -167.08 87.85 0.3 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 113.843 -1.526 . . . . 63.14 107.544 159.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 91.5 m -160.33 109.0 1.37 Allowed Pre-proline 0 C--N 1.317 -0.825 0 N-CA-C 109.651 -0.5 . . . . 74.33 109.651 -172.427 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.53 99.52 0.94 Allowed 'Trans proline' 0 C--O 1.233 0.24 0 C-N-CA 122.68 2.253 . . . . 64.14 113.213 -174.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 11.8 p -91.58 98.58 11.74 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.519 -0.548 . . . . 73.3 109.519 173.812 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.424 HH11 ' HD2' ' A' ' 72' ' ' ARG . 7.0 ptp180 -91.29 140.66 29.57 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.163 -0.471 . . . . 75.3 110.852 -175.493 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.599 ' HA ' ' HA ' ' A' ' 50' ' ' VAL . 3.4 p -106.59 122.25 45.95 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.847 -0.615 . . . . 74.22 111.119 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 18.4 t -127.14 -95.64 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 108.892 -0.781 . . . . 70.53 108.892 175.639 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.536 -0.745 . . . . 74.41 109.673 178.208 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.5 m . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 109.829 -0.434 . . . . 74.12 109.829 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -96.74 96.69 8.77 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.644 -0.502 . . . . 74.03 109.644 178.925 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.81 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -164.15 136.91 4.46 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.742 -0.742 . . . . 52.24 112.565 -179.131 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.8 m -80.01 133.84 36.18 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.81 -0.811 . . . . 72.14 108.81 172.073 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.577 ' HA ' ' O ' ' A' ' 32' ' ' ASN . 18.7 pt20 -73.31 177.62 5.05 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.624 0.726 . . . . 64.22 112.41 -174.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.3 mt -88.97 127.09 41.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.876 -1.056 . . . . 73.43 110.326 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 58.6 mt -76.21 140.92 16.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.502 -0.772 . . . . 53.14 110.75 -177.197 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 14.6 t60 -62.9 138.0 97.06 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 115.49 -0.777 . . . . 73.31 110.188 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.496 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 75.6 Cg_exo -41.48 118.85 0.88 Allowed 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 123.852 3.034 . . . . 62.52 113.74 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.496 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 6.7 Cg_endo -88.79 -145.18 0.03 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.657 0 C-N-CA 123.685 2.924 . . . . 72.42 112.436 -178.551 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.442 ' CG ' ' N ' ' A' ' 15' ' ' GLU . 69.0 t-105 -68.36 -179.67 1.38 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 115.907 -0.588 . . . . 72.24 110.893 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.442 ' N ' ' CG ' ' A' ' 14' ' ' TRP . 16.8 mm-40 -47.99 101.5 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.182 0 C-N-CA 123.972 0.909 . . . . 74.13 112.336 178.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 153.56 -142.58 9.3 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 120.722 -0.751 . . . . 71.54 111.911 178.782 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -168.72 -169.99 32.82 Favored Glycine 0 N--CA 1.442 -0.959 0 N-CA-C 111.459 -0.656 . . . . 73.45 111.459 -179.347 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.5 mt -113.81 128.17 70.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.735 0.778 . . . . 70.34 111.432 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.855 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 20.5 tpp180 -86.24 113.14 22.01 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 114.54 -1.209 . . . . 74.22 109.541 179.606 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.42 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 86.2 m-85 -86.71 -171.54 3.58 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.953 0.406 . . . . 74.35 110.875 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -108.34 -32.51 7.42 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.131 0.491 . . . . 74.3 110.066 -177.47 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -158.62 54.51 0.37 Allowed Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.799 -0.715 . . . . 71.12 112.155 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 88.8 mt -138.61 111.62 7.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.681 0.277 . . . . 52.44 110.95 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.7 t -85.28 -179.91 7.07 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.166 -0.47 . . . . 75.32 109.859 175.229 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.499 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 9.5 ptp85 -72.77 -171.36 0.83 Allowed 'General case' 0 C--O 1.237 0.398 0 N-CA-C 110.027 -0.361 . . . . 73.32 110.027 178.001 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.499 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 9.7 t70 73.24 -40.77 0.48 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 121.251 0.548 . . . . 54.04 110.071 -176.191 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.425 ' O ' HG22 ' A' ' 28' ' ' VAL . 97.3 mt-30 -85.33 -164.64 1.03 Allowed 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 115.497 -0.774 . . . . 70.15 109.156 171.357 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.493 HG12 HD12 ' A' ' 31' ' ' ILE . 9.0 m 50.87 20.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 C-N-CA 124.079 0.952 . . . . 75.0 112.432 178.802 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 17.9 ptmt -79.78 -18.99 49.69 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.803 -0.635 . . . . 71.12 110.525 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.95 35.97 0.05 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.315 -0.857 . . . . 75.11 110.753 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.493 HD12 HG12 ' A' ' 28' ' ' VAL . 45.6 mt -75.69 136.88 23.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 109.003 -0.74 . . . . 74.23 109.003 175.052 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.577 ' O ' ' HA ' ' A' ' 8' ' ' GLN . 87.4 m-20 -115.76 -25.06 7.93 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 111.981 0.363 . . . . 73.04 111.981 -172.781 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.81 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 41.5 m-85 -132.01 109.48 10.06 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.958 0.408 . . . . 71.25 111.673 -174.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.405 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.8 mm? -87.66 129.63 50.08 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 109.355 -0.609 . . . . 73.11 109.355 173.054 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -62.21 161.34 27.08 Favored 'Trans proline' 0 N--CA 1.472 0.261 0 C-N-CA 122.868 2.378 . . . . 63.24 113.538 -175.365 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.465 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 12.4 p -63.1 157.68 3.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 CA-C-N 115.355 -0.839 . . . . 72.31 110.602 179.026 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.465 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 32.2 t70 77.12 -3.85 2.42 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.424 0.69 . . . . 75.53 111.004 178.623 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.42 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 4.4 t80 -80.39 123.56 28.13 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.133 -0.485 . . . . 74.11 110.18 -179.185 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.483 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.6 mt-10 -116.37 141.74 47.77 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 110.014 -0.365 . . . . 72.52 110.014 175.889 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.525 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 33.6 pt -121.26 160.89 21.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 120.965 0.412 . . . . 75.11 111.503 -177.917 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.855 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 46.2 tt0 -120.52 152.07 38.53 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.546 -0.752 . . . . 74.33 110.101 179.715 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -101.7 102.83 13.56 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.742 0.306 . . . . 75.13 110.982 179.155 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.512 HG11 ' HE ' ' A' ' 19' ' ' ARG . 30.7 m -102.23 152.75 5.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.16 0.505 . . . . 43.53 111.318 -179.044 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.428 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 19.1 t -100.49 -179.83 4.22 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.126 -0.694 . . . . 51.42 109.126 -178.39 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ARG . . . . . 0.4 ' HD3' ' HA ' ' A' ' 45' ' ' ARG . 37.5 mmt180 -65.2 110.08 2.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.772 0.32 . . . . 71.44 111.397 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.96 -149.01 24.98 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 121.0 -0.619 . . . . 62.21 111.855 179.194 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -91.56 37.51 0.96 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.365 0.603 . . . . 71.43 110.464 179.465 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 29.8 mmm180 -88.49 108.26 19.3 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.81 -0.811 . . . . 74.21 108.81 176.886 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -77.95 145.39 36.11 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.676 -0.693 . . . . 74.41 111.113 -171.56 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.563 ' HA ' ' HA ' ' A' ' 73' ' ' CYS . 34.8 m -101.33 149.98 6.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.672 -0.694 . . . . 54.31 110.387 179.115 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.0 p -117.47 95.28 3.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 122.003 0.906 . . . . 73.23 109.405 169.043 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.26 171.83 33.46 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.735 -1.121 . . . . 43.0 111.382 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.549 ' HG2' HG23 ' A' ' 69' ' ' THR . 48.1 Cg_endo -77.06 71.92 6.07 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 121.756 1.637 . . . . 70.42 110.359 170.168 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.704 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 43.2 pttt -78.98 89.57 4.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.531 -0.759 . . . . 72.35 111.398 -173.172 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.39 128.57 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.578 0.704 . . . . 74.12 110.877 174.633 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.647 ' CZ ' ' HA ' ' A' ' 67' ' ' MET . 28.9 mmt85 -138.23 104.41 5.19 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.276 -0.875 . . . . 73.32 109.106 176.72 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -97.47 138.96 34.11 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.412 -0.358 . . . . 71.3 110.182 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.7 t -97.88 128.56 44.56 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.014 -0.539 . . . . 74.1 110.349 176.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 30.7 mt -108.13 -176.6 3.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.797 -0.638 . . . . 75.32 110.414 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -54.43 -35.08 62.56 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 121.037 0.446 . . . . 34.01 110.886 176.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -83.18 140.5 32.54 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.345 -0.613 . . . . 74.35 109.345 174.871 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -79.14 67.19 3.32 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 121.025 -0.607 . . . . 74.22 113.631 -172.034 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 32.2 m -155.38 139.31 16.32 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.839 -0.43 . . . . 64.31 109.839 174.073 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 66.4 m95 -72.28 129.6 38.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.03 -0.73 . . . . 65.43 109.03 177.33 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.6 p -70.78 13.94 0.16 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 115.24 1.57 . . . . 71.12 115.24 -166.555 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -159.03 42.96 0.24 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.302 -0.629 . . . . 71.12 109.302 177.036 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' MET . . . . . 0.647 ' HA ' ' CZ ' ' A' ' 56' ' ' ARG . 26.4 ttt -83.75 77.38 9.89 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 122.074 0.94 . . . . 72.34 111.38 -171.596 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -170.32 88.97 0.15 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 113.905 -1.498 . . . . 63.14 107.361 159.368 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.549 HG23 ' HG2' ' A' ' 53' ' ' PRO . 7.5 m -127.58 112.38 20.89 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 119.847 -0.741 . . . . 74.33 112.51 -167.363 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -74.05 114.77 4.12 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 122.913 2.408 . . . . 64.14 110.811 172.304 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.4 p -135.64 145.74 47.13 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.403 -0.362 . . . . 73.3 110.844 -175.619 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.5 ptp180 -140.8 136.42 32.44 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.204 -0.453 . . . . 75.3 110.122 -178.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 50' ' ' VAL . 0.9 OUTLIER -97.18 99.73 11.21 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.462 0.649 . . . . 74.22 111.101 176.783 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -131.94 134.09 60.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.028 -0.987 . . . . 70.53 108.837 178.128 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.381 -0.819 . . . . 74.41 110.948 -172.189 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.7 m . . . . . 0 N--CA 1.451 -0.404 0 N-CA-C 109.495 -0.557 . . . . 74.12 109.495 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -118.03 100.23 7.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.557 -0.747 . . . . 74.03 110.261 -175.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.881 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.54 145.32 10.96 Favored Glycine 0 N--CA 1.444 -0.833 0 N-CA-C 111.373 -0.691 . . . . 52.24 111.373 178.788 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 56.7 m -81.16 132.01 35.33 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 110.176 -0.305 . . . . 72.14 110.176 -179.459 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 -80.3 -176.55 5.69 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.995 0.426 . . . . 64.22 111.302 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 73.0 mt -84.86 136.34 22.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.498 -0.773 . . . . 73.43 109.046 178.392 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 14.1 mt -94.76 148.33 5.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 116.102 -0.499 . . . . 53.14 111.614 -169.074 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 10.8 p80 -61.69 136.29 94.64 Favored Pre-proline 0 C--O 1.233 0.211 0 CA-C-N 116.051 -0.522 . . . . 73.31 109.875 172.156 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.421 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 38.2 Cg_endo -66.9 119.77 6.82 Favored 'Trans proline' 0 N--CA 1.464 -0.248 0 C-N-CA 122.526 2.151 . . . . 62.52 111.951 179.148 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.48 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 5.1 Cg_exo -77.76 -129.8 0.01 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.272 0 C-N-CA 123.043 2.495 . . . . 72.42 111.49 178.052 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.48 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 39.3 t-105 -63.86 174.77 1.34 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 109.594 -0.521 . . . . 72.24 109.594 175.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -68.91 76.37 0.31 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.497 0.665 . . . . 74.13 112.321 -176.096 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.27 155.32 25.97 Favored Glycine 0 N--CA 1.438 -1.188 0 N-CA-C 109.729 -1.349 . . . . 71.54 109.729 173.082 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -106.06 -172.3 23.38 Favored Glycine 0 N--CA 1.44 -1.085 0 C-N-CA 119.811 -1.185 . . . . 73.45 112.017 -178.428 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.8 mt -132.16 131.75 61.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.197 0.523 . . . . 70.34 109.987 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.426 HH11 ' HD2' ' A' ' 19' ' ' ARG . 0.2 OUTLIER -113.41 122.28 46.87 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.39 -0.823 . . . . 74.22 109.341 -179.307 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -88.52 -172.71 3.86 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.878 0.371 . . . . 74.35 110.552 -175.082 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.5 ttm180 -89.18 -51.59 5.5 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.219 -0.446 . . . . 74.3 110.27 -177.39 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -137.27 13.07 3.8 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.805 -0.712 . . . . 71.12 112.736 -178.251 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 80.3 mt -89.96 129.29 36.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.106 0.479 . . . . 52.44 110.805 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.1 t -102.74 -178.27 3.62 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.577 -0.738 . . . . 75.32 110.085 178.601 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.484 ' C ' ' H ' ' A' ' 27' ' ' GLN . 60.6 mtp180 -69.3 -173.07 0.5 Allowed 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.535 -0.302 . . . . 73.32 111.28 -176.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 24.3 t70 69.79 -40.33 0.46 Allowed 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.444 0.698 . . . . 54.04 110.505 -172.383 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.49 ' O ' HG22 ' A' ' 28' ' ' VAL . 88.4 mt-30 -86.6 -161.12 0.63 Allowed 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.36 -0.836 . . . . 70.15 110.3 177.374 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.49 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.6 m 54.73 10.0 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.674 1.19 . . . . 75.0 113.247 177.185 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -97.25 -19.84 18.3 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.021 0.439 . . . . 71.12 110.027 175.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.64 94.07 1.85 Allowed 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.552 -0.749 . . . . 75.11 110.377 178.334 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -131.58 136.62 56.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.109 -0.7 . . . . 74.23 109.109 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -76.77 -67.02 0.74 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.959 0.409 . . . . 73.04 110.892 -177.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.881 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 61.8 m-85 -133.91 126.67 30.89 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.832 -0.622 . . . . 71.25 111.119 -175.742 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -85.13 134.11 41.58 Favored Pre-proline 0 C--N 1.324 -0.525 0 N-CA-C 108.969 -0.752 . . . . 73.11 108.969 171.234 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -63.08 141.18 82.34 Favored 'Trans proline' 0 C--O 1.239 0.545 0 C-N-CA 122.816 2.344 . . . . 63.24 112.906 -176.502 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.426 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 3.1 p -69.84 82.07 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 CA-C-O 121.719 0.771 . . . . 72.31 110.25 176.281 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.426 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 6.2 t70 172.44 -26.39 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.635 -1.166 . . . . 75.53 108.544 -175.873 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.459 ' OH ' ' HG ' ' A' ' 23' ' ' LEU . 6.1 t80 -74.04 146.38 43.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.217 -0.901 . . . . 74.11 110.822 -177.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -124.69 158.64 32.71 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 115.911 -0.586 . . . . 72.52 110.564 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.476 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 31.0 pt -139.5 149.27 22.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.15 -0.477 . . . . 75.11 110.67 177.017 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.542 ' HG2' ' H ' ' A' ' 42' ' ' TYR . 24.2 tt0 -112.81 167.37 10.55 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.161 -0.472 . . . . 74.33 109.902 178.272 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.542 ' H ' ' HG2' ' A' ' 41' ' ' GLU . 69.1 m-85 -112.44 102.42 10.54 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.077 0.465 . . . . 75.13 111.998 -177.195 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.0 m -96.21 153.6 3.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 109.074 -0.713 . . . . 43.53 109.074 171.384 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.591 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 34.2 t -89.07 167.49 13.1 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.138 -0.69 . . . . 51.42 109.138 179.554 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -59.25 117.09 4.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.024 0.44 . . . . 71.44 110.151 -176.427 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.76 -120.77 6.53 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 110.958 -0.857 . . . . 62.21 110.958 -176.436 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -130.04 25.61 5.24 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.359 0.6 . . . . 71.43 110.212 177.423 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.591 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 29.8 mmm180 -88.47 136.06 33.18 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.823 -0.626 . . . . 74.21 109.8 -177.435 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -95.47 159.19 15.12 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.046 -0.525 . . . . 74.41 109.811 -179.528 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.548 HG12 ' HA ' ' A' ' 73' ' ' CYS . 27.9 m -122.28 150.14 25.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.523 -0.308 . . . . 54.31 110.422 179.517 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 p -100.83 96.89 5.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 122.039 0.923 . . . . 73.23 109.295 171.837 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.23 172.11 33.45 Favored Glycine 0 N--CA 1.441 -0.997 0 CA-C-N 114.973 -1.012 . . . . 43.0 111.612 -176.675 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -74.07 55.69 3.5 Favored 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.249 1.966 . . . . 70.42 110.523 171.318 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.479 ' HD2' ' HG2' ' A' ' 41' ' ' GLU . 43.0 pttt -75.41 87.46 2.58 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 115.74 -0.664 . . . . 72.35 111.515 -173.689 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -161.41 129.21 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.439 -0.8 . . . . 74.12 109.45 172.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.521 HH22 ' CB ' ' A' ' 69' ' ' THR . 31.8 mmt180 -132.61 140.29 48.16 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.918 -0.401 . . . . 73.32 109.918 179.165 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -130.76 137.56 49.53 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.598 -0.519 . . . . 71.3 109.598 176.552 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 50.4 t -70.83 146.5 49.65 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.114 -0.494 . . . . 74.1 110.26 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 94.3 mt -116.86 -179.61 3.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.136 -0.484 . . . . 75.32 110.381 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.03 -8.39 59.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.917 0.389 . . . . 34.01 111.038 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -100.54 166.16 11.06 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.434 -0.58 . . . . 74.35 109.434 175.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.02 57.76 3.14 Favored Glycine 0 CA--C 1.516 0.131 0 C-N-CA 120.987 -0.625 . . . . 74.22 113.091 -177.193 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.2 t -172.96 171.03 4.35 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.209 -0.663 . . . . 64.31 109.209 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 40.5 m95 -99.98 -179.01 4.02 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 109.714 -0.476 . . . . 65.43 109.714 -178.716 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.0 p -49.63 -53.31 24.88 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.579 0.585 . . . . 71.12 112.579 -176.771 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -153.77 129.95 10.41 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.026 -1.102 . . . . 71.12 108.026 177.227 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 22.9 mmt -131.81 78.4 1.82 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 118.992 -1.083 . . . . 72.34 112.136 174.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 30.0 t0 -168.94 88.39 0.19 Allowed 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 107.805 -1.183 . . . . 63.14 107.805 157.326 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.521 ' CB ' HH22 ' A' ' 56' ' ' ARG . 1.3 m -149.32 94.6 3.92 Favored Pre-proline 0 C--N 1.314 -0.948 0 C-N-CA 120.913 -0.315 . . . . 74.33 110.313 -172.5 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.95 92.81 0.32 Allowed 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 122.487 2.125 . . . . 64.14 112.26 -179.061 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 17.0 m -79.68 115.8 19.49 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.942 -0.572 . . . . 73.3 109.811 177.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.5 ptp180 -79.68 133.73 36.39 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.715 -0.675 . . . . 75.3 111.655 -174.726 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.548 ' HA ' HG12 ' A' ' 50' ' ' VAL . 71.2 m -83.08 98.87 9.53 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.761 -0.654 . . . . 74.22 110.592 178.499 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.5 p -148.88 114.47 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.635 -0.711 . . . . 70.53 109.534 176.42 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 2.4 tmt_? . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.288 -0.863 . . . . 74.41 109.488 -173.206 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.7 m . . . . . 0 N--CA 1.446 -0.636 0 N-CA-C 109.485 -0.561 . . . . 74.12 109.485 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 33.3 mm-40 -98.82 118.41 35.5 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.892 -0.595 . . . . 74.03 109.466 -179.562 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.521 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -153.73 152.14 23.78 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.124 -1.036 . . . . 52.24 113.152 -176.632 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.8 m -97.14 149.39 22.04 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.432 -0.581 . . . . 72.14 109.432 177.799 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -72.82 173.98 8.38 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.129 0.49 . . . . 64.22 112.171 -175.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.58 HD11 ' HB ' ' A' ' 31' ' ' ILE . 54.5 mt -88.5 126.9 41.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.522 -0.763 . . . . 73.43 110.458 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.1 mt -84.05 127.92 39.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.051 -0.522 . . . . 53.14 109.847 177.67 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -79.5 133.4 59.74 Favored Pre-proline 0 C--N 1.323 -0.583 0 N-CA-C 109.631 -0.507 . . . . 73.31 109.631 -177.355 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.451 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 72.3 Cg_exo -49.3 113.3 0.88 Allowed 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 123.451 2.767 . . . . 62.52 113.005 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.465 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 4.9 Cg_exo -80.52 -101.4 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 123.194 2.596 . . . . 72.42 112.827 -177.06 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.465 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 55.7 t-105 -80.76 177.11 9.24 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.777 -0.453 . . . . 72.24 109.777 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -54.84 101.21 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.409 0.623 . . . . 74.13 111.733 179.462 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.06 -145.43 9.44 Favored Glycine 0 N--CA 1.443 -0.872 0 CA-C-N 115.095 -0.957 . . . . 71.54 110.714 -177.473 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -176.42 -170.01 38.54 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 120.473 -0.87 . . . . 73.45 111.914 178.384 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.9 mt -125.52 125.65 69.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.272 0.558 . . . . 70.34 110.838 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.38 160.57 14.6 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.994 -1.003 . . . . 74.22 108.893 178.089 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -123.26 -171.12 2.24 Favored 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 120.797 -0.361 . . . . 74.35 110.398 -176.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.416 ' HB3' ' CE2' ' A' ' 38' ' ' TYR . 39.9 ttm180 -82.56 -36.58 26.12 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.46 -0.336 . . . . 74.3 110.345 -178.116 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.94 71.21 0.19 Allowed Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.588 -0.815 . . . . 71.12 112.53 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 62.5 mt -139.79 139.15 36.35 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.796 0.331 . . . . 52.44 110.751 178.594 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.3 t -92.67 -178.28 4.82 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.863 -0.608 . . . . 75.32 109.848 178.242 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.563 ' C ' ' H ' ' A' ' 27' ' ' GLN . 49.7 ptt85 -68.78 -175.89 0.75 Allowed 'General case' 0 C--O 1.234 0.285 0 C-N-CA 121.188 -0.205 . . . . 73.32 110.671 177.886 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 28.7 t70 62.64 -26.83 0.06 Allowed 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 123.725 0.81 . . . . 54.04 112.116 -173.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.563 ' H ' ' C ' ' A' ' 25' ' ' ARG . 10.0 mm-40 -71.25 178.7 3.2 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 123.227 0.611 . . . . 70.15 110.482 178.612 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.2 m 50.53 20.7 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 C-N-CA 124.364 1.065 . . . . 75.0 113.016 177.022 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 38.1 pttt -73.51 -23.29 60.01 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.041 0.448 . . . . 71.12 109.927 176.627 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.99 102.65 0.66 Allowed 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.281 -0.872 . . . . 75.11 110.373 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.58 ' HB ' HD11 ' A' ' 9' ' ' ILE . 50.6 mt -130.21 157.86 42.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 N-CA-C 108.315 -0.995 . . . . 74.23 108.315 175.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -88.92 -58.22 2.63 Favored 'General case' 0 C--N 1.321 -0.67 0 C-N-CA 120.825 -0.35 . . . . 73.04 110.45 179.424 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.521 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 86.7 m-85 -143.54 146.75 33.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.886 0.374 . . . . 71.25 111.067 -178.782 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.45 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.4 mm? -84.37 130.9 52.14 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 108.575 -0.898 . . . . 73.11 108.575 173.295 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 34' ' ' LEU . 17.4 Cg_exo -64.08 147.11 91.62 Favored 'Trans proline' 0 CA--C 1.527 0.15 0 C-N-CA 122.473 2.116 . . . . 63.24 112.848 -174.399 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.55 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 8.9 p -53.39 148.35 2.01 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 CA-C-N 115.832 -0.622 . . . . 72.31 110.413 173.469 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.55 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 7.9 t70 82.48 -28.93 0.1 Allowed 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.583 0.753 . . . . 75.53 111.513 -178.423 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.416 ' CE2' ' HB3' ' A' ' 21' ' ' ARG . 32.4 t80 -66.84 141.38 57.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.787 0.327 . . . . 74.11 110.544 -178.438 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 41.2 mt-10 -114.78 145.65 41.87 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.066 -0.515 . . . . 72.52 111.515 -177.21 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.554 HG12 ' HB2' ' A' ' 56' ' ' ARG . 43.8 pt -122.46 164.86 19.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.451 -0.795 . . . . 75.11 109.595 172.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.431 ' CG ' ' HD2' ' A' ' 54' ' ' LYS . 35.3 tt0 -135.89 142.71 44.75 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.987 0.422 . . . . 74.33 110.785 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -88.45 102.32 14.78 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.107 -0.497 . . . . 75.13 110.59 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.9 m -102.2 162.78 3.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.168 0.509 . . . . 43.53 110.856 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.584 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 15.8 t -104.0 -176.58 3.12 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.859 -0.61 . . . . 51.42 110.229 -176.566 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.5 mmt180 -56.27 121.43 9.49 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.111 -0.495 . . . . 71.44 111.419 -177.423 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 71.73 -95.86 0.64 Allowed Glycine 0 N--CA 1.446 -0.698 0 CA-C-N 115.724 -0.671 . . . . 62.21 111.998 178.549 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -146.83 47.52 1.17 Allowed 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.69 0.757 . . . . 71.43 109.716 177.375 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.584 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 13.3 mmm-85 -87.43 129.15 35.15 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.197 -0.91 . . . . 74.21 109.478 176.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.464 ' HB2' ' HB3' ' A' ' 75' ' ' ARG . 41.1 mt-10 -78.35 149.17 33.47 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.376 -0.374 . . . . 74.41 110.001 -179.615 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.456 HG12 ' HA ' ' A' ' 73' ' ' CYS . 34.9 m -127.06 150.14 32.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.96 -0.564 . . . . 54.31 110.678 -177.279 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 p -106.34 96.83 4.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.972 0.891 . . . . 73.23 109.235 171.187 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.773 ' HA3' ' HB3' ' A' ' 71' ' ' SER . . . -154.73 170.83 33.08 Favored Glycine 0 N--CA 1.441 -0.994 0 CA-C-N 114.831 -1.077 . . . . 43.0 111.175 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.24 60.33 7.4 Favored 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 122.282 1.988 . . . . 70.42 110.703 173.657 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.431 ' HD2' ' CG ' ' A' ' 41' ' ' GLU . 45.3 pttt -80.7 84.42 6.25 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-O 121.723 0.773 . . . . 72.35 111.436 -172.651 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.408 HG13 ' O ' ' A' ' 54' ' ' LYS . 1.1 m -158.66 126.48 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 114.594 -1.185 . . . . 74.12 108.462 172.308 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.554 ' HB2' HG12 ' A' ' 40' ' ' ILE . 32.3 mmt180 -141.1 100.07 3.73 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 110.073 -0.343 . . . . 73.32 110.073 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -92.5 125.32 37.09 Favored 'General case' 0 C--N 1.317 -0.822 0 N-CA-C 109.002 -0.74 . . . . 71.3 109.002 174.104 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 48.9 t -64.52 136.6 57.21 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.008 0.432 . . . . 74.1 110.247 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 76.6 mt -98.78 -178.92 4.12 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.661 -0.699 . . . . 75.32 110.717 -174.236 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -71.45 -9.71 58.62 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.449 0.642 . . . . 34.01 110.363 176.76 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -110.21 158.62 18.17 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 108.93 -0.767 . . . . 74.35 108.93 174.316 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -78.29 53.23 3.84 Favored Glycine 0 CA--C 1.519 0.333 0 C-N-CA 120.993 -0.622 . . . . 74.22 113.464 -173.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 18.6 m -155.06 161.92 41.19 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.37 -0.604 . . . . 64.31 109.37 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 70.5 m95 -91.89 179.51 5.59 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.835 -0.431 . . . . 65.43 109.835 -178.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 33.0 p -61.67 -38.79 89.06 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.923 0.392 . . . . 71.12 111.197 -178.611 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -146.59 136.26 23.12 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.06 -0.718 . . . . 71.12 109.06 178.341 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 10.4 tpt -119.54 74.38 1.0 Allowed 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 118.602 -1.239 . . . . 72.34 109.882 171.301 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -170.68 89.2 0.14 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.206 -1.361 . . . . 63.14 107.575 160.493 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.483 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 4.6 m -108.77 108.81 61.06 Favored Pre-proline 0 C--N 1.313 -1.017 0 C-N-CA 119.959 -0.696 . . . . 74.33 111.078 -170.642 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 14.8 Cg_endo -92.56 46.48 0.41 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 124.061 3.174 . . . . 64.14 112.803 -177.345 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.773 ' HB3' ' HA3' ' A' ' 52' ' ' GLY . 0.1 OUTLIER -73.91 126.21 29.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.5 -0.318 . . . . 73.3 110.687 177.561 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -109.55 149.05 30.21 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 110.177 -0.305 . . . . 75.3 110.177 -178.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.456 ' HA ' HG12 ' A' ' 50' ' ' VAL . 29.6 m -87.52 113.75 23.5 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.502 -0.317 . . . . 74.22 111.458 -175.635 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.1 p -155.8 134.94 3.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.576 -0.284 . . . . 70.53 110.563 179.078 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.464 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 3.0 ptm180 . . . . . 0 C--O 1.25 1.087 0 CA-C-N 116.318 -0.401 . . . . 74.41 109.971 178.019 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.4 m . . . . . 0 N--CA 1.455 -0.2 0 N-CA-C 109.51 -0.552 . . . . 74.12 109.51 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -96.22 97.27 9.39 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.626 -0.509 . . . . 74.03 109.626 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -161.76 164.18 35.09 Favored Glycine 0 N--CA 1.441 -0.986 0 C-N-CA 120.807 -0.711 . . . . 52.24 112.396 -177.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.6 m -97.59 154.02 17.81 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 110.203 -0.295 . . . . 72.14 110.203 179.068 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -82.42 -179.69 7.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.338 0.589 . . . . 64.22 111.329 -178.466 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.3 mt -89.42 121.38 39.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.425 -0.807 . . . . 73.43 110.306 178.78 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 55.5 mt -72.15 129.03 35.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.915 -0.584 . . . . 53.14 110.111 178.391 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.5 t-80 -67.39 121.26 78.02 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 116.192 -0.458 . . . . 73.31 110.366 -178.114 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.544 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.4 Cg_exo -48.69 120.76 5.61 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.212 2.608 . . . . 62.52 112.783 -179.407 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.544 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 5.8 Cg_endo -86.68 -138.74 0.02 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 123.569 2.846 . . . . 72.42 112.656 -176.305 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.441 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 13.1 t-105 -66.85 -177.5 0.62 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 115.891 -0.595 . . . . 72.24 110.853 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -39.88 101.35 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.689 0.796 . . . . 74.13 112.835 -176.051 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.54 -168.56 33.25 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 111.341 -0.704 . . . . 71.54 111.341 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.82 24.0 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.942 -0.647 . . . . 73.45 111.563 179.402 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.4 mt -116.93 136.49 53.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.559 0.695 . . . . 70.34 111.216 -178.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.855 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 13.7 tpt180 -103.03 140.1 37.72 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.661 -1.154 . . . . 74.22 109.246 -179.681 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -108.29 -171.98 1.97 Allowed 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.591 -0.444 . . . . 74.35 110.765 -178.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.06 -45.33 9.22 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.001 0.429 . . . . 74.3 110.603 -174.284 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -151.09 53.38 0.49 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.811 -0.709 . . . . 71.12 112.181 -178.793 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 89.5 mt -136.55 127.55 27.73 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.607 0.241 . . . . 52.44 110.794 179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.0 t -86.39 -179.77 6.73 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.531 -0.544 . . . . 75.32 109.531 175.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.8 mpp_? -80.47 -172.85 3.77 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.818 -0.353 . . . . 73.32 111.456 -175.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.429 ' O ' ' HE2' ' A' ' 29' ' ' LYS . 28.7 t70 60.44 15.25 5.37 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 122.357 1.075 . . . . 54.04 109.583 -168.435 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.549 ' O ' HG22 ' A' ' 28' ' ' VAL . 98.8 mt-30 -134.57 -173.7 3.36 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.668 -1.151 . . . . 70.15 108.287 178.273 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.549 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.0 m 54.4 9.22 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 124.127 0.971 . . . . 75.0 112.51 -178.323 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.429 ' HE2' ' O ' ' A' ' 26' ' ' ASP . 46.3 pttt -79.41 -21.82 45.1 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.98 -0.555 . . . . 71.12 110.081 177.502 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.31 81.15 0.98 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.351 -0.84 . . . . 75.11 110.37 178.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 54.8 mt -119.61 139.11 48.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 108.939 -0.763 . . . . 74.23 108.939 176.338 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -69.54 -64.2 0.92 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.764 0.316 . . . . 73.04 111.115 -176.885 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -143.56 141.73 30.8 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.192 -0.458 . . . . 71.25 110.867 -177.371 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -92.01 115.71 65.13 Favored Pre-proline 0 C--N 1.321 -0.671 0 N-CA-C 108.564 -0.902 . . . . 73.11 108.564 172.14 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.59 142.71 38.97 Favored 'Trans proline' 0 C--O 1.238 0.515 0 C-N-CA 123.419 2.746 . . . . 63.24 113.217 -174.22 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.467 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 2.7 p -65.22 86.14 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-O 121.512 0.673 . . . . 72.31 111.173 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.467 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 31.6 t70 168.94 -26.84 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.834 -1.075 . . . . 75.53 108.28 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 6.9 t80 -68.74 144.82 54.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 114.618 -1.173 . . . . 74.11 110.486 179.418 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.408 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 40.0 mt-10 -127.09 145.53 50.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.274 -0.421 . . . . 72.52 110.121 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.486 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 38.0 pt -128.45 167.9 22.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-O 121.084 0.469 . . . . 75.11 111.86 -177.622 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.855 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 44.4 tt0 -131.82 164.81 25.22 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 115.374 -0.83 . . . . 74.33 110.13 -177.221 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.579 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 96.9 m-85 -117.1 102.93 9.72 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 122.354 0.262 . . . . 75.13 111.142 -178.584 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.8 m -98.26 157.41 3.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 120.766 0.317 . . . . 43.53 110.74 178.501 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.588 ' HB3' ' O ' ' A' ' 48' ' ' ARG . 43.5 t -92.21 177.89 6.02 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.976 -0.379 . . . . 51.42 109.976 178.51 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ARG . . . . . 0.498 ' C ' ' HD3' ' A' ' 45' ' ' ARG . 0.1 OUTLIER -69.59 117.04 10.69 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 116.171 -0.468 . . . . 71.44 110.469 -176.241 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 89.63 -125.23 7.74 Favored Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.972 -0.632 . . . . 62.21 112.352 175.559 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -116.23 26.02 10.23 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.002 0.429 . . . . 71.43 110.533 -179.787 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.588 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 28.6 mmm180 -88.64 119.02 28.72 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.829 -0.804 . . . . 74.21 108.829 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -79.26 159.98 27.04 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.04 0.448 . . . . 74.41 111.058 -177.325 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.589 HG12 ' HA ' ' A' ' 73' ' ' CYS . 27.5 m -126.83 139.15 52.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.796 -0.638 . . . . 54.31 110.369 179.083 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.9 p -103.19 95.53 3.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 122.093 0.949 . . . . 73.23 109.366 172.296 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.46 171.26 32.94 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 115.005 -0.998 . . . . 43.0 111.446 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -78.07 52.01 3.88 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.486 2.124 . . . . 70.42 111.145 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.709 ' HD3' ' HG3' ' A' ' 41' ' ' GLU . 0.0 OUTLIER -76.66 86.83 3.31 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 122.118 0.961 . . . . 72.35 111.972 -173.397 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -161.96 130.12 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 114.989 -1.005 . . . . 74.12 109.229 174.834 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.486 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 29.0 mmt180 -129.43 131.52 46.77 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 120.662 0.268 . . . . 73.32 110.484 178.462 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.458 ' HB2' ' HE3' ' A' ' 57' ' ' LYS . 35.2 ttmt -106.58 134.19 50.1 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.071 -0.715 . . . . 71.3 109.071 176.112 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.3 t -74.53 145.18 43.68 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.92 0.39 . . . . 74.1 110.734 -178.826 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.6 mt -112.87 -178.67 3.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.788 -0.642 . . . . 75.32 110.114 -177.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.25 27.54 0.33 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.019 0.438 . . . . 34.01 111.077 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -147.65 172.75 13.55 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.235 -0.654 . . . . 74.35 109.235 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -68.36 -19.03 72.11 Favored Glycine 0 CA--C 1.52 0.375 0 C-N-CA 120.815 -0.707 . . . . 74.22 113.755 -172.454 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 14.9 m -99.36 146.27 26.47 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.046 0.45 . . . . 64.31 111.089 -178.041 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.411 ' H ' ' HE3' ' A' ' 67' ' ' MET . 63.8 m95 -77.89 -179.05 5.79 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.732 -0.667 . . . . 65.43 110.481 179.687 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.456 HG23 ' O ' ' A' ' 57' ' ' LYS . 3.1 p -54.05 -49.93 67.87 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 113.064 0.764 . . . . 71.12 113.064 -176.547 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.447 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 14.0 t70 -140.06 141.7 36.21 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.57 -0.286 . . . . 71.12 110.26 -177.562 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' MET . . . . . 0.411 ' HE3' ' H ' ' A' ' 64' ' ' TRP . 65.9 mtt -140.07 80.01 1.74 Allowed 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 119.969 -0.692 . . . . 72.34 111.502 166.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -168.03 88.45 0.25 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.301 -1.0 . . . . 63.14 108.301 157.415 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.8 m -152.78 101.24 2.7 Favored Pre-proline 0 C--N 1.316 -0.848 0 C-N-CA 120.372 -0.531 . . . . 74.33 111.274 -172.858 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.66 114.64 4.01 Favored 'Trans proline' 0 C--O 1.237 0.438 0 C-N-CA 122.627 2.218 . . . . 64.14 111.553 175.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 t -92.42 134.44 34.95 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.162 0.506 . . . . 73.3 109.972 -179.554 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.0 ptp85 -101.88 123.32 45.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.801 -0.636 . . . . 75.3 110.811 -176.607 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.589 ' HA ' HG12 ' A' ' 50' ' ' VAL . 60.9 m -76.08 98.17 4.27 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.419 -0.586 . . . . 74.22 109.419 176.616 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 10.7 p 177.04 151.76 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.088 -0.96 . . . . 70.53 108.412 -176.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.424 HH11 ' HD3' ' A' ' 75' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.943 0 CA-C-O 118.335 -0.841 . . . . 74.41 110.292 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.6 p . . . . . 0 N--CA 1.451 -0.42 0 CA-C-O 120.711 0.291 . . . . 74.12 110.42 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -70.22 116.63 10.79 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.852 0.358 . . . . 74.03 110.36 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.458 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.12 160.21 31.44 Favored Glycine 0 N--CA 1.44 -1.059 0 CA-C-N 115.66 -0.7 . . . . 52.24 111.374 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 38.1 m -92.74 147.17 23.08 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 110.185 -0.302 . . . . 72.14 110.185 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -85.53 -177.65 6.48 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.073 0.463 . . . . 64.22 110.826 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 51.9 mt -86.77 125.43 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 CA-C-N 115.989 -0.55 . . . . 73.43 109.8 175.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 56.1 mt -80.12 136.63 23.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.572 -0.74 . . . . 53.14 110.106 -179.222 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 45.5 m170 -54.49 128.57 60.74 Favored Pre-proline 0 C--N 1.329 -0.295 0 N-CA-C 109.843 -0.429 . . . . 73.31 109.843 173.178 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.484 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.5 Cg_exo -51.24 122.45 10.1 Favored 'Trans proline' 0 N--CA 1.461 -0.408 0 C-N-CA 122.501 2.134 . . . . 62.52 111.479 177.704 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 15.7 Cg_exo -69.09 -159.05 0.05 OUTLIER 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 123.081 2.52 . . . . 72.42 111.747 179.838 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -59.93 159.81 8.67 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.557 -0.534 . . . . 72.24 109.557 176.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -39.42 100.9 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 113.687 0.995 . . . . 74.13 113.687 -169.348 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -167.76 -140.2 2.86 Favored Glycine 0 N--CA 1.444 -0.821 0 CA-C-N 114.287 -1.324 . . . . 71.54 110.368 179.3 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -170.28 -171.01 35.3 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.521 -0.847 . . . . 73.45 112.088 176.196 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 18.5 mt -136.49 136.17 48.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.299 0.571 . . . . 70.34 111.005 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.82 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 19.1 tpt85 -107.86 119.23 38.87 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 115.266 -0.879 . . . . 74.22 110.179 -176.591 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.637 ' HB3' ' HE1' ' A' ' 38' ' ' TYR . 99.5 m-85 -96.2 -171.3 2.28 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.223 -0.444 . . . . 74.35 110.872 -179.474 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.427 HH11 ' HD3' ' A' ' 21' ' ' ARG . 1.5 mmp_? -91.39 -72.2 0.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.981 -0.554 . . . . 74.3 111.466 -178.395 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -128.2 63.85 0.61 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.494 -0.86 . . . . 71.12 112.157 -176.712 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.485 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 75.4 mt -125.15 121.29 33.79 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.895 0.379 . . . . 52.44 110.832 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.5 t -83.01 -179.47 7.45 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 115.664 -0.698 . . . . 75.32 109.944 176.238 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' A' ' 25' ' ' ARG . 10.3 mmt180 -76.09 -174.56 2.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.093 0.473 . . . . 73.32 111.817 -175.654 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 24.4 t70 55.2 27.69 10.04 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.121 -0.945 . . . . 54.04 110.169 -175.447 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.466 ' O ' HG22 ' A' ' 28' ' ' VAL . 87.7 mt-30 -134.03 -164.32 1.48 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.519 -0.764 . . . . 70.15 110.271 -178.097 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.466 HG22 ' O ' ' A' ' 27' ' ' GLN . 4.6 m 53.59 15.0 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 124.757 1.223 . . . . 75.0 112.765 178.562 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -89.46 -19.11 25.51 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.419 -0.355 . . . . 71.12 110.687 178.152 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.47 86.96 0.81 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.008 0.432 . . . . 75.11 111.037 178.327 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.5 mt -128.45 106.88 15.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 108.855 -0.794 . . . . 74.23 108.855 176.436 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -73.14 -40.0 65.26 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.261 -0.427 . . . . 73.04 111.855 -172.276 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.458 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 81.9 m-85 -135.55 116.9 14.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.085 0.469 . . . . 71.25 111.929 -176.267 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -81.58 135.78 49.28 Favored Pre-proline 0 C--N 1.321 -0.633 0 N-CA-C 108.883 -0.784 . . . . 73.11 108.883 169.54 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.36 153.3 61.34 Favored 'Trans proline' 0 C--O 1.238 0.481 0 C-N-CA 122.327 2.018 . . . . 63.24 112.929 -176.068 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.496 HG23 ' HA ' ' A' ' 59' ' ' LEU . 2.9 p -68.19 85.72 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.351 0 CA-C-O 122.04 0.924 . . . . 72.31 109.629 174.781 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 16.6 t70 175.32 -39.46 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.86 -1.064 . . . . 75.53 109.666 -170.456 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.637 ' HE1' ' HB3' ' A' ' 20' ' ' TYR . 0.2 OUTLIER -74.02 126.86 31.43 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.987 -1.006 . . . . 74.11 112.405 -171.979 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.532 ' HG2' ' HB2' ' A' ' 57' ' ' LYS . 40.9 mt-10 -107.84 127.52 53.79 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.427 -0.806 . . . . 72.52 109.278 172.834 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 44.8 pt -110.0 142.82 21.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.005 0.431 . . . . 75.11 111.441 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.82 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.3 tt0 -107.54 147.87 29.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.706 -0.679 . . . . 74.33 109.918 176.314 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.521 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 94.4 m-85 -103.83 101.88 11.69 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.406 -0.361 . . . . 75.13 110.046 177.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -95.2 170.45 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.714 0.292 . . . . 43.53 111.006 -178.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.553 ' HB2' HG13 ' A' ' 50' ' ' VAL . 26.1 t -93.27 179.8 5.3 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.644 -0.502 . . . . 51.42 109.644 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 2.0 tmt_? -78.59 93.37 4.83 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.847 0.356 . . . . 71.44 110.932 -175.806 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.49 -136.16 13.35 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.742 -0.742 . . . . 62.21 112.445 175.075 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 8.0 mp0 -89.89 14.88 10.95 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.269 0.557 . . . . 71.43 109.736 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.493 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 15.7 mmt-85 -88.56 137.53 32.24 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.53 -0.759 . . . . 74.21 109.203 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -105.46 165.06 11.4 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.054 0.454 . . . . 74.41 110.614 176.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.553 HG13 ' HB2' ' A' ' 44' ' ' CYS . 34.2 m -121.87 136.09 59.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.793 -0.639 . . . . 54.31 109.486 177.899 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.418 HG13 ' O ' ' A' ' 51' ' ' VAL . 7.2 p -93.0 95.75 5.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 122.275 1.036 . . . . 73.23 109.018 174.341 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.87 171.8 33.22 Favored Glycine 0 N--CA 1.443 -0.863 0 CA-C-N 114.567 -1.197 . . . . 43.0 111.375 -178.547 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -82.28 42.22 1.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.594 2.196 . . . . 70.42 110.387 175.641 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.634 ' HD3' ' HG3' ' A' ' 41' ' ' GLU . 0.0 OUTLIER -75.13 86.39 2.39 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.796 0.807 . . . . 72.35 112.871 -170.394 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.454 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.4 p -161.85 126.5 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-N 114.903 -1.044 . . . . 74.12 109.026 169.359 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.454 ' HD3' ' O ' ' A' ' 55' ' ' VAL . 22.4 mmt180 -134.89 128.43 32.59 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.28 -0.418 . . . . 73.32 110.076 -178.19 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.532 ' HB2' ' HG2' ' A' ' 39' ' ' GLU . 38.4 ttpt -107.23 136.4 47.13 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 116.05 -0.523 . . . . 71.3 110.031 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 43.8 t -77.53 134.35 38.32 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.203 -0.453 . . . . 74.1 110.179 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.496 ' HA ' HG23 ' A' ' 36' ' ' VAL . 97.8 mt -102.9 -178.74 3.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.127 -0.488 . . . . 75.32 109.811 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.42 51.76 0.9 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.328 0.585 . . . . 34.01 111.029 179.662 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -160.65 170.67 20.36 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.279 -0.873 . . . . 74.35 108.926 177.852 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -85.46 38.53 3.01 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 120.721 -0.752 . . . . 74.22 113.802 -173.286 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.3 m -156.67 151.71 26.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 117.229 0.515 . . . . 64.31 110.537 178.377 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 71.2 m95 -79.29 167.91 20.27 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.179 -0.464 . . . . 65.43 109.975 178.068 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 17.8 p -55.19 -65.29 0.61 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.043 0.449 . . . . 71.12 111.99 -177.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -125.85 97.19 5.03 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.976 -0.75 . . . . 71.12 108.976 176.538 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 27.0 ttt -100.69 76.25 1.79 Allowed 'General case' 0 C--N 1.321 -0.663 0 C-N-CA 118.817 -1.153 . . . . 72.34 110.7 -178.325 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -171.76 89.89 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.276 -1.329 . . . . 63.14 108.568 160.733 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.5 m -135.46 119.41 13.07 Favored Pre-proline 0 C--N 1.317 -0.832 0 C-N-CA 119.758 -0.777 . . . . 74.33 112.004 -172.712 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -83.1 106.85 1.44 Allowed 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.867 2.378 . . . . 64.14 112.576 178.651 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.495 ' HB2' HG21 ' A' ' 50' ' ' VAL . 12.1 p -95.39 105.41 17.37 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.042 0.449 . . . . 73.3 110.813 178.634 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.8 ptp85 -89.18 125.18 34.95 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.159 -0.473 . . . . 75.3 110.955 -177.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.445 ' HA ' HG12 ' A' ' 50' ' ' VAL . 59.7 m -72.44 122.06 20.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.123 -0.49 . . . . 74.22 110.572 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 85.8 t -137.56 136.15 46.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.763 -0.458 . . . . 70.53 109.763 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.247 0.939 0 CA-C-O 119.079 -0.486 . . . . 74.41 110.669 -179.093 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.448 -0.556 0 CA-C-O 121.238 0.542 . . . . 74.12 110.579 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -101.85 99.13 9.32 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.696 -0.853 . . . . 74.03 108.696 174.234 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -160.64 164.34 34.55 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.535 -0.84 . . . . 52.24 112.573 -174.862 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.429 ' N ' ' SG ' ' A' ' 58' ' ' CYS . 35.2 m -105.06 150.41 25.01 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 109.49 -0.559 . . . . 72.14 109.49 -178.612 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -73.44 179.67 3.91 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.113 0.483 . . . . 64.22 110.607 177.262 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.4 tt -88.24 140.64 15.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.755 -0.657 . . . . 73.43 110.201 -178.643 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 57.3 mt -96.25 135.91 28.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.388 -0.369 . . . . 53.14 110.937 -176.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' HIS . . . . . 0.406 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 2.5 t-80 -89.29 130.94 42.14 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 115.928 -0.578 . . . . 73.31 109.485 178.487 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 33.5 Cg_exo -57.86 109.99 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.795 2.33 . . . . 62.52 112.393 -178.741 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -75.67 -59.09 0.04 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.437 0 C-N-CA 122.691 2.261 . . . . 72.42 112.298 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -91.59 -178.43 5.08 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.102 -0.499 . . . . 72.24 109.851 -176.664 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -71.29 15.64 0.12 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 112.237 0.458 . . . . 74.13 112.237 -177.623 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.542 ' HA2' ' H ' ' A' ' 45' ' ' ARG . . . -96.65 -147.56 22.83 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.508 -0.637 . . . . 71.54 111.508 175.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.74 -170.56 30.84 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 121.071 -0.585 . . . . 73.45 111.78 179.524 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.1 mt -129.38 134.89 62.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.093 0.473 . . . . 70.34 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -106.77 135.41 48.34 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.44 -0.8 . . . . 74.22 109.931 -178.861 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.501 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 91.4 m-85 -101.02 -171.35 1.98 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.305 -0.407 . . . . 74.35 110.017 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 21.6 mtt180 -80.17 -44.49 19.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.814 0.34 . . . . 74.3 111.435 -179.014 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.38 61.61 0.24 Allowed Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.583 -0.818 . . . . 71.12 112.13 -178.515 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 80.7 mt -120.81 116.76 25.82 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.79 0.329 . . . . 52.44 110.456 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.3 t -78.89 -179.44 6.6 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.636 -0.711 . . . . 75.32 109.734 175.774 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.426 ' C ' ' H ' ' A' ' 27' ' ' GLN . 99.4 mtt180 -67.8 -172.75 0.29 Allowed 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.741 0.305 . . . . 73.32 111.479 -177.418 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 30.5 t70 68.09 -42.79 0.47 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.629 0.772 . . . . 54.04 110.882 -171.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.573 ' O ' HG22 ' A' ' 28' ' ' VAL . 94.7 mt-30 -71.87 -179.49 2.72 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.328 -0.396 . . . . 70.15 110.806 176.594 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.8 m 57.45 9.88 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 124.559 1.144 . . . . 75.0 112.347 -178.609 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -82.71 -17.73 43.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.272 0.558 . . . . 71.12 109.896 175.17 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -161.9 94.53 0.94 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.091 -0.959 . . . . 75.11 110.191 179.127 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 57.8 mt -131.98 130.27 61.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.578 -0.737 . . . . 74.23 109.42 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -89.95 -51.87 5.26 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.379 -0.373 . . . . 73.04 111.301 -175.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -134.72 131.48 37.69 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.296 0.569 . . . . 71.25 112.133 -175.245 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -97.59 117.42 65.39 Favored Pre-proline 0 C--N 1.322 -0.622 0 N-CA-C 107.876 -1.157 . . . . 73.11 107.876 168.201 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -56.52 147.13 71.23 Favored 'Trans proline' 0 C--O 1.237 0.434 0 C-N-CA 123.205 2.603 . . . . 63.24 113.373 -173.196 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.55 83.87 0.05 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.323 0 CA-C-O 121.85 0.833 . . . . 72.31 110.771 177.132 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.8 t70 168.45 -33.46 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 114.578 -1.192 . . . . 75.53 108.942 -176.484 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.501 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 14.1 t80 -67.56 141.11 56.95 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.324 -0.853 . . . . 74.11 110.636 -177.227 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.457 ' HG2' ' HE2' ' A' ' 57' ' ' LYS . 10.5 mt-10 -125.36 142.15 51.67 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.53 -0.759 . . . . 72.52 110.083 -177.029 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.655 HG13 ' HB2' ' A' ' 56' ' ' ARG . 46.4 pt -130.65 169.31 21.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.715 0.293 . . . . 75.11 110.694 178.748 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -128.52 139.24 52.41 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.189 -0.459 . . . . 74.33 110.981 -178.781 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.41 ' O ' HG21 ' A' ' 50' ' ' VAL . 5.1 m-30 -83.65 102.32 12.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.765 -0.652 . . . . 75.13 110.349 176.161 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.9 m -108.31 170.93 2.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 120.898 0.38 . . . . 43.53 110.909 -178.535 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.714 ' HB2' HG13 ' A' ' 50' ' ' VAL . 10.5 t -109.64 143.63 39.12 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.06 -0.718 . . . . 51.42 109.06 175.012 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ARG . . . . . 0.542 ' H ' ' HA2' ' A' ' 16' ' ' GLY . 75.7 ttt180 -77.58 133.68 38.42 Favored 'General case' 0 N--CA 1.44 -0.974 0 CA-C-N 115.029 -0.987 . . . . 71.44 110.588 -172.818 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.13 -149.84 18.81 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.799 -0.715 . . . . 62.21 111.688 -178.77 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.455 ' CD ' ' H ' ' A' ' 47' ' ' GLU . 1.0 OUTLIER -93.66 16.08 14.72 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.406 0.622 . . . . 71.43 109.646 176.799 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.654 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 40.8 mmm-85 -89.22 118.94 29.28 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.317 -0.856 . . . . 74.21 109.169 178.074 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.523 ' HB2' ' HA ' ' A' ' 75' ' ' ARG . 48.8 mt-10 -95.92 171.37 8.68 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.991 -0.374 . . . . 74.41 109.991 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.714 HG13 ' HB2' ' A' ' 44' ' ' CYS . 5.5 m -129.86 126.25 62.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.948 0.404 . . . . 54.31 111.545 -177.593 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.601 HG12 ' HB ' ' A' ' 74' ' ' VAL . 3.5 p -96.37 95.76 5.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 108.463 -0.94 . . . . 73.23 108.463 167.642 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.51 172.73 33.01 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.373 -0.83 . . . . 43.0 112.497 -173.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -75.27 52.98 3.31 Favored 'Trans proline' 0 N--CA 1.462 -0.335 0 C-N-CA 123.012 2.475 . . . . 70.42 110.734 173.341 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.418 ' HD3' HG23 ' A' ' 50' ' ' VAL . 19.4 pttp -72.11 89.54 1.15 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.512 -0.767 . . . . 72.35 111.863 -174.163 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -160.54 132.24 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.821 -0.627 . . . . 74.12 110.574 176.581 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.655 ' HB2' HG13 ' A' ' 40' ' ' ILE . 55.1 mmt-85 -138.35 126.8 23.24 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.933 -0.576 . . . . 73.32 110.195 176.728 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.457 ' HE2' ' HG2' ' A' ' 39' ' ' GLU . 37.3 ttmt -125.08 137.48 54.2 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.007 -0.738 . . . . 71.3 109.007 175.149 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 7' ' ' CYS . 53.3 t -81.31 144.17 31.7 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.894 0.378 . . . . 74.1 111.073 -176.117 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 94.4 mt -100.95 -179.07 3.94 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.716 -0.675 . . . . 75.32 111.005 -178.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.92 -20.58 60.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.185 0.517 . . . . 34.01 110.374 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -101.43 169.1 9.1 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.397 -0.82 . . . . 74.35 109.313 175.283 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.75 60.56 3.36 Favored Glycine 0 CA--C 1.518 0.253 0 C-N-CA 120.83 -0.7 . . . . 74.22 113.28 -175.251 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 49.4 m -158.63 144.31 16.65 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 122.789 0.436 . . . . 64.31 109.939 177.747 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 75.7 m95 -81.19 161.65 23.93 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.75 -0.463 . . . . 65.43 109.75 177.47 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 p -52.9 -39.14 62.47 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.221 0.823 . . . . 71.12 113.221 -174.152 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -134.03 140.86 46.95 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 110.186 -0.302 . . . . 71.12 110.186 178.588 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 50.5 mtt -144.36 80.01 1.63 Allowed 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.367 -0.533 . . . . 72.34 111.453 167.814 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -168.6 88.85 0.22 Allowed 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.416 -0.957 . . . . 63.14 108.416 156.463 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.8 m -155.83 90.11 2.83 Favored Pre-proline 0 C--N 1.317 -0.823 0 C-N-CA 120.283 -0.567 . . . . 74.33 111.283 -172.076 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -74.18 90.28 1.0 Allowed 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.689 2.26 . . . . 64.14 110.396 172.407 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.2 t -69.26 116.93 10.25 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.985 -0.552 . . . . 73.3 110.724 -175.731 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.0 ptp180 -79.57 130.67 35.6 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.534 -0.757 . . . . 75.3 110.409 179.122 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.584 ' HA ' HG12 ' A' ' 50' ' ' VAL . 73.6 m -81.02 97.89 7.71 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.309 0.576 . . . . 74.22 110.013 178.261 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.601 ' HB ' HG12 ' A' ' 51' ' ' VAL . 59.6 t -136.68 117.99 18.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.184 -0.916 . . . . 70.53 108.653 177.773 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.523 ' HA ' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.556 -0.735 . . . . 74.41 111.161 -176.962 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.45 -0.438 0 N-CA-C 109.74 -0.467 . . . . 74.12 109.74 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -75.43 99.44 4.17 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.222 -0.445 . . . . 74.03 110.617 -178.647 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.57 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -159.91 152.56 23.44 Favored Glycine 0 N--CA 1.441 -1.002 0 C-N-CA 120.572 -0.823 . . . . 52.24 112.694 -179.144 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.1 m -86.52 158.76 19.47 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 110.13 -0.322 . . . . 72.14 110.13 178.137 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 -88.86 -177.19 5.44 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.052 0.453 . . . . 64.22 111.192 -179.106 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.543 HD11 ' HB ' ' A' ' 31' ' ' ILE . 60.7 mt -87.49 138.16 19.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.615 -0.72 . . . . 73.43 110.487 -177.715 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 64.8 mt -99.78 131.06 47.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.18 -0.464 . . . . 53.14 109.929 178.199 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -76.55 126.09 86.59 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.868 -0.605 . . . . 73.31 110.171 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_endo -58.51 112.69 1.26 Allowed 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.72 2.28 . . . . 62.52 111.921 179.266 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -74.87 -87.6 0.0 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.393 0 C-N-CA 122.481 2.121 . . . . 72.42 113.091 -176.059 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 27.8 t-105 -101.37 -177.84 3.56 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.999 -0.371 . . . . 72.24 109.999 -178.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 56.7 mm-40 -39.81 101.93 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.746 0.818 . . . . 74.13 111.98 177.688 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.436 ' HA2' ' HA ' ' A' ' 44' ' ' CYS . . . 171.32 -167.6 40.72 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.39 -0.91 . . . . 71.54 112.637 177.876 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -159.17 -170.52 23.81 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.989 -0.844 . . . . 73.45 110.989 178.806 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.464 HG23 ' HB ' ' A' ' 40' ' ' ILE . 16.6 mt -135.05 135.59 52.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.449 0.642 . . . . 70.34 111.835 -177.06 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.49 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 55.6 ttm-85 -99.49 138.56 36.4 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.081 -0.963 . . . . 74.22 110.578 178.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.506 ' HB3' ' HE1' ' A' ' 38' ' ' TYR . 89.1 m-85 -110.76 -168.03 1.26 Allowed 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.132 -0.321 . . . . 74.35 110.132 177.565 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -62.04 -57.82 10.2 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 120.88 0.371 . . . . 74.3 110.487 178.708 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -161.55 67.76 0.24 Allowed Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 121.055 -0.593 . . . . 71.12 111.872 178.489 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 92.7 mt -118.12 126.77 52.91 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.965 0.412 . . . . 52.44 110.949 -179.18 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.8 t -85.03 -176.71 6.32 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.387 -0.824 . . . . 75.32 110.46 176.43 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 29.9 ptt180 -61.94 -173.51 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 115.923 -0.58 . . . . 73.32 111.818 -177.116 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.9 t70 65.06 -46.14 0.35 Allowed 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 123.894 0.878 . . . . 54.04 112.263 -179.116 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.547 ' O ' HG22 ' A' ' 28' ' ' VAL . 91.7 mt-30 -68.96 -169.76 0.19 Allowed 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 123.079 0.552 . . . . 70.15 111.257 -179.284 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.547 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.2 m 55.61 15.66 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 124.264 1.026 . . . . 75.0 111.832 -178.206 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.416 ' H ' ' HG2' ' A' ' 29' ' ' LYS . 40.1 pttt -81.42 -14.33 57.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.829 -0.623 . . . . 71.12 110.066 175.822 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -161.21 117.48 2.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.601 -0.727 . . . . 75.11 110.436 177.154 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.543 ' HB ' HD11 ' A' ' 9' ' ' ILE . 42.1 mt -138.6 152.71 25.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 109.105 -0.702 . . . . 74.23 109.105 179.161 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -105.07 -65.09 1.07 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.673 0.273 . . . . 73.04 110.646 179.018 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.57 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 96.5 m-85 -140.73 128.61 21.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.412 -0.358 . . . . 71.25 110.704 -179.203 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -88.08 119.59 70.43 Favored Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 109.158 -0.682 . . . . 73.11 109.158 175.27 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.01 152.47 43.76 Favored 'Trans proline' 0 C--O 1.236 0.402 0 C-N-CA 122.899 2.4 . . . . 63.24 113.29 -176.681 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.433 HG23 ' HA ' ' A' ' 59' ' ' LEU . 3.5 p -62.63 94.93 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-O 121.707 0.765 . . . . 72.31 111.023 178.235 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.0 t70 173.85 -43.41 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.574 -1.194 . . . . 75.53 109.36 -177.424 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.506 ' HE1' ' HB3' ' A' ' 20' ' ' TYR . 5.3 m-85 -50.41 123.01 7.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.039 -0.982 . . . . 74.11 112.596 -175.742 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.586 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 35.2 mt-10 -114.18 100.01 8.05 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.849 -1.069 . . . . 72.52 108.575 172.349 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.576 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 34.7 pt -90.7 143.64 10.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.142 0.496 . . . . 75.11 111.3 -175.772 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.49 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 42.5 tt0 -109.82 136.49 49.05 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.481 -0.781 . . . . 74.33 110.269 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.485 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 95.5 m-85 -85.43 100.58 11.97 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 116.216 -0.447 . . . . 75.13 110.051 175.473 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.3 m -100.98 163.39 3.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.045 -0.525 . . . . 43.53 110.199 179.389 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.805 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 3.4 t -90.38 147.07 23.68 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 107.93 -1.137 . . . . 51.42 107.93 173.112 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -59.72 108.61 0.77 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.17 0.509 . . . . 71.44 110.942 -170.907 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.21 -137.21 13.13 Favored Glycine 0 N--CA 1.448 -0.563 0 CA-C-N 115.703 -0.68 . . . . 62.21 112.086 178.612 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.475 ' CD ' ' H ' ' A' ' 47' ' ' GLU . 0.5 OUTLIER -101.22 33.53 2.85 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.301 0.572 . . . . 71.43 110.278 -179.274 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.805 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 30.1 mmm180 -89.22 145.49 25.37 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.786 -0.643 . . . . 74.21 109.974 179.682 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.617 ' HB2' ' HB3' ' A' ' 75' ' ' ARG . 43.1 mt-10 -91.57 148.96 21.9 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.231 0.538 . . . . 74.41 112.201 -174.295 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.742 HG13 ' HB2' ' A' ' 44' ' ' CYS . 11.6 m -138.64 150.46 23.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.368 -0.833 . . . . 54.31 110.131 178.083 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -135.65 97.35 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 122.019 0.914 . . . . 73.23 109.558 170.863 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.42 173.09 32.26 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-N 114.462 -1.245 . . . . 43.0 110.6 -177.647 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.497 ' HG2' HG21 ' A' ' 69' ' ' THR . 69.9 Cg_endo -77.17 57.38 5.81 Favored 'Trans proline' 0 C--O 1.235 0.358 0 C-N-CA 122.068 1.845 . . . . 70.42 110.733 176.813 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.485 ' HB2' ' H ' ' A' ' 42' ' ' TYR . 20.9 pttp -76.4 87.04 3.16 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.383 -0.826 . . . . 72.35 111.608 -173.08 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -162.57 128.54 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.397 -0.82 . . . . 74.12 109.906 172.672 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.586 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 26.9 mmt180 -130.1 123.69 31.0 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.622 -0.51 . . . . 73.32 109.622 175.281 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.7 ttmm -105.08 122.7 46.42 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.537 -0.542 . . . . 71.3 109.537 178.805 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.5 t -74.56 142.51 44.71 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.309 -0.405 . . . . 74.1 110.635 -179.571 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.433 ' HA ' HG23 ' A' ' 36' ' ' VAL . 94.7 mt -128.64 -179.24 4.95 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.844 -0.616 . . . . 75.32 109.516 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.02 59.27 2.13 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.367 0.603 . . . . 34.01 111.654 -177.669 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -160.52 165.05 31.55 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.802 -0.814 . . . . 74.35 108.802 175.328 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -80.73 40.27 2.45 Favored Glycine 0 CA--C 1.517 0.214 0 C-N-CA 120.662 -0.78 . . . . 74.22 113.067 -175.676 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 27.6 t -161.84 163.32 29.4 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.234 -0.654 . . . . 64.31 109.234 -178.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 52.8 m95 -97.16 -179.8 4.65 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 110.033 -0.358 . . . . 65.43 110.033 -176.486 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -56.35 -24.73 46.02 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 112.776 0.658 . . . . 71.12 112.776 -176.814 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.529 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 11.2 t70 -160.71 137.02 8.54 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.384 -0.599 . . . . 71.12 109.384 178.304 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 65.9 mtt -130.38 77.0 1.76 Allowed 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.436 -0.906 . . . . 72.34 110.611 164.655 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -170.83 88.63 0.12 Allowed 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 108.855 -0.795 . . . . 63.14 108.855 157.482 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.497 HG21 ' HG2' ' A' ' 53' ' ' PRO . 4.7 m -153.5 107.32 2.56 Favored Pre-proline 0 C--N 1.317 -0.809 0 C-N-CA 120.817 -0.353 . . . . 74.33 110.681 -176.867 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -70.21 95.52 0.59 Allowed 'Trans proline' 0 N--CA 1.462 -0.329 0 C-N-CA 122.694 2.263 . . . . 64.14 112.031 178.002 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 m -78.36 109.44 12.51 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.175 0.512 . . . . 73.3 109.775 177.069 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.402 ' H ' ' HG2' ' A' ' 72' ' ' ARG . 11.1 ptt180 -97.51 130.6 44.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.574 -0.739 . . . . 75.3 112.085 -172.204 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.513 ' HA ' HG12 ' A' ' 50' ' ' VAL . 81.2 m -82.66 118.25 23.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.665 -0.698 . . . . 74.22 109.824 175.03 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 p -156.36 136.44 4.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 121.082 0.467 . . . . 70.53 110.309 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.617 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 16.1 ptm180 . . . . . 0 C--O 1.244 0.765 0 CA-C-N 115.693 -0.685 . . . . 74.41 109.626 -178.167 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.6 m . . . . . 0 N--CA 1.451 -0.395 0 N-CA-C 109.8 -0.444 . . . . 74.12 109.8 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -112.98 98.42 7.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.911 -0.586 . . . . 74.03 109.614 -177.512 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.741 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -162.2 152.57 22.94 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.492 -0.861 . . . . 52.24 112.7 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 60.7 m -90.11 147.53 23.56 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.985 -0.376 . . . . 72.14 109.985 176.77 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -85.81 -179.54 6.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.777 0.322 . . . . 64.22 110.892 -179.324 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.67 HD11 ' HB ' ' A' ' 31' ' ' ILE . 56.3 mt -88.16 130.62 37.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.939 -0.573 . . . . 73.43 110.313 176.831 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 68.7 mt -73.25 136.18 26.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.745 -0.661 . . . . 53.14 110.239 179.032 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.6 t-80 -68.81 138.1 90.39 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 115.989 -0.55 . . . . 73.31 109.936 -178.03 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_exo -40.97 118.87 0.72 Allowed 'Trans proline' 0 C--N 1.351 0.694 0 C-N-CA 123.716 2.944 . . . . 62.52 113.826 -176.723 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.457 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 81.7 Cg_endo -87.5 -149.02 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.128 2.552 . . . . 72.42 112.728 -179.51 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.457 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 9.1 t-105 -75.15 -179.01 4.14 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.69 -0.686 . . . . 72.24 110.516 -177.773 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -46.03 100.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 123.234 0.613 . . . . 74.13 112.172 177.267 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.13 -156.86 28.99 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.331 -0.708 . . . . 71.54 111.331 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.85 -171.23 24.4 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.562 -0.828 . . . . 73.45 111.925 178.028 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.63 131.44 66.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.651 0.738 . . . . 70.34 111.531 -178.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.707 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 7.9 tpm_? -96.92 104.56 16.58 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 114.298 -1.319 . . . . 74.22 110.064 -178.285 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.472 ' HA ' HG22 ' A' ' 40' ' ' ILE . 97.7 m-85 -80.5 -171.46 3.07 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.519 -0.309 . . . . 74.35 110.187 177.782 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.7 ttm180 -78.96 -65.35 1.01 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.67 0.272 . . . . 74.3 110.411 -178.843 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -136.16 37.4 1.89 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.423 -0.894 . . . . 71.12 112.275 -178.694 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.461 HD13 HG12 ' A' ' 28' ' ' VAL . 80.6 mt -102.52 119.73 39.32 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.925 0.393 . . . . 52.44 111.359 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.4 t -94.64 -177.2 4.13 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.712 -0.676 . . . . 75.32 109.662 175.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 77.5 mtt180 -66.88 -173.43 0.24 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.047 0.451 . . . . 73.32 111.627 -176.466 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.0 t0 59.07 19.24 7.1 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 122.029 0.919 . . . . 54.04 110.183 -177.796 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -140.35 -165.19 1.86 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.887 -1.052 . . . . 70.15 109.971 -178.39 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.461 HG12 HD13 ' A' ' 23' ' ' LEU . 11.5 m 49.44 24.01 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.312 1.045 . . . . 75.0 112.29 178.886 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -88.54 -22.38 23.61 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.789 -0.641 . . . . 71.12 110.758 -179.318 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.42 101.07 0.6 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.884 -0.598 . . . . 75.11 110.434 176.6 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.67 ' HB ' HD11 ' A' ' 9' ' ' ILE . 69.0 mt -127.99 138.24 55.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.155 -0.683 . . . . 74.23 109.155 177.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -79.83 -58.25 3.26 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.864 0.364 . . . . 73.04 110.543 -176.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.741 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 82.2 m-85 -139.27 138.4 36.73 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.971 -0.559 . . . . 71.25 110.953 -176.58 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.95 142.65 32.35 Favored Pre-proline 0 C--N 1.322 -0.593 0 N-CA-C 109.11 -0.7 . . . . 73.11 109.11 172.78 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -61.33 161.68 22.73 Favored 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 122.648 2.232 . . . . 63.24 112.727 -179.187 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 p -68.11 143.62 15.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.763 -0.653 . . . . 72.31 110.886 -178.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.5 t70 68.13 19.73 9.13 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.663 0.744 . . . . 75.53 110.942 -178.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -78.12 132.02 37.49 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.742 -0.836 . . . . 74.11 108.742 173.234 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -123.1 138.28 54.71 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.461 -0.336 . . . . 72.52 110.404 -175.147 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.615 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 14.5 pt -129.88 150.17 34.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.807 -0.633 . . . . 75.11 110.684 -177.69 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.707 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 37.7 tt0 -115.44 152.3 33.17 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.946 -0.57 . . . . 74.33 110.551 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.412 ' HE2' ' HG2' ' A' ' 56' ' ' ARG . 81.6 m-85 -100.11 101.87 13.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.256 -0.429 . . . . 75.13 110.854 178.122 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.3 m -94.55 155.02 3.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 120.727 0.299 . . . . 43.53 110.244 177.323 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 9.8 t -90.91 -179.3 5.45 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.405 -0.591 . . . . 51.42 109.405 -178.899 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ARG . . . . . 0.473 ' HD3' ' HA ' ' A' ' 45' ' ' ARG . 2.3 mmt180 -81.5 153.99 26.53 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.744 -0.382 . . . . 71.44 111.342 -179.167 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.12 -138.44 24.47 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 110.856 -0.898 . . . . 62.21 110.856 -174.175 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -111.08 19.83 18.04 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.475 0.655 . . . . 71.43 109.389 174.545 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.584 ' HA ' ' HD2' ' A' ' 75' ' ' ARG . 7.4 mmm180 -88.9 150.9 22.64 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.269 -0.878 . . . . 74.21 109.556 -177.408 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.496 ' H ' ' HB3' ' A' ' 75' ' ' ARG . 37.6 mt-10 -120.99 170.44 9.51 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.868 0.366 . . . . 74.41 111.005 -171.277 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.405 HG12 ' HA ' ' A' ' 73' ' ' CYS . 22.7 m -118.3 150.5 20.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.202 -0.453 . . . . 54.31 110.903 -177.634 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.66 HG12 ' HB ' ' A' ' 74' ' ' VAL . 6.4 p -113.01 96.76 4.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 122.156 0.979 . . . . 73.23 109.116 170.912 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.55 173.4 33.01 Favored Glycine 0 N--CA 1.442 -0.966 0 CA-C-N 114.834 -1.076 . . . . 43.0 110.874 -177.408 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.49 ' HG2' HG21 ' A' ' 69' ' ' THR . 47.9 Cg_endo -72.39 60.32 3.3 Favored 'Trans proline' 0 CA--C 1.529 0.26 0 C-N-CA 122.191 1.927 . . . . 70.42 110.304 170.008 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.569 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 32.1 pttt -73.62 89.52 1.74 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.139 -0.937 . . . . 72.35 111.209 -175.411 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.9 p -160.08 132.71 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.727 -0.67 . . . . 74.12 110.51 178.183 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.615 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 24.2 mmt180 -125.68 114.96 19.36 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.185 -0.672 . . . . 73.32 109.185 173.126 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 41.9 tptt -102.54 116.95 33.64 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.459 -0.791 . . . . 71.3 109.914 -176.147 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' CYS . . . . . 0.563 ' HB2' ' CZ3' ' A' ' 64' ' ' TRP . 49.3 t -87.91 124.5 33.74 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.137 -0.483 . . . . 74.1 110.074 177.779 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.415 HD11 HG21 ' A' ' 65' ' ' THR . 41.9 mt -105.08 -177.55 3.4 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.814 -0.63 . . . . 75.32 109.43 176.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -56.63 -32.29 65.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.091 0.472 . . . . 34.01 110.431 174.042 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -81.06 132.08 35.34 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.44 -0.578 . . . . 74.35 109.44 172.767 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -77.82 64.1 3.38 Favored Glycine 0 N--CA 1.451 -0.313 0 N-CA-C 114.299 0.479 . . . . 74.22 114.299 -171.164 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 58.2 m -157.14 142.27 17.11 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.539 -0.541 . . . . 64.31 109.539 172.278 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.563 ' CZ3' ' HB2' ' A' ' 58' ' ' CYS . 23.1 m95 -78.19 124.4 28.02 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.05 -0.722 . . . . 65.43 109.05 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.415 HG21 HD11 ' A' ' 59' ' ' LEU . 17.2 p -75.62 33.03 0.11 Allowed 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 114.358 1.244 . . . . 71.12 114.358 -167.805 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -160.75 13.91 0.11 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.865 0.364 . . . . 71.12 110.056 176.224 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 26.1 ttt -76.65 78.94 3.3 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-O 121.875 0.845 . . . . 72.34 112.416 -165.62 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -169.68 88.88 0.17 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 114.382 -1.281 . . . . 63.14 107.783 159.284 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.49 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.7 OUTLIER -152.78 117.86 2.93 Favored Pre-proline 0 C--N 1.318 -0.801 0 C-N-CA 120.19 -0.604 . . . . 74.33 111.345 -169.751 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -78.72 100.53 1.37 Allowed 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.885 2.39 . . . . 64.14 111.318 174.399 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.7 p -79.39 116.83 19.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.051 0.453 . . . . 73.3 111.112 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.8 ptp180 -89.47 129.2 36.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.729 -0.668 . . . . 75.3 111.285 -177.223 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.405 ' HA ' HG12 ' A' ' 50' ' ' VAL . 62.3 m -82.88 105.5 13.94 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.718 -0.475 . . . . 74.22 109.718 178.481 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.66 ' HB ' HG12 ' A' ' 51' ' ' VAL . 49.1 t -128.33 84.27 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 121.072 0.463 . . . . 70.53 109.76 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.584 ' HD2' ' HA ' ' A' ' 48' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.751 0 N-CA-C 108.54 -0.911 . . . . 74.41 108.54 -178.728 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.3 m . . . . . 0 N--CA 1.451 -0.422 0 N-CA-C 108.354 -0.98 . . . . 74.12 108.354 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -78.2 99.88 6.41 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.275 0.56 . . . . 74.03 111.195 -172.145 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.6 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -159.47 146.96 13.64 Favored Glycine 0 N--CA 1.44 -1.054 0 CA-C-N 115.239 -0.891 . . . . 52.24 111.678 179.464 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.9 m -92.88 142.93 26.77 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 110.05 -0.352 . . . . 72.14 110.05 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -76.02 -177.62 3.99 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.884 0.374 . . . . 64.22 111.055 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 61.3 mt -87.38 137.66 20.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.057 -0.52 . . . . 73.43 111.176 -175.838 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 27.5 mt -84.13 156.57 3.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.5 -0.773 . . . . 53.14 110.217 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -82.68 141.47 44.77 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.64 -0.255 . . . . 73.31 110.67 -177.559 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.54 131.32 21.3 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.74 2.293 . . . . 62.52 112.462 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -87.6 -140.1 0.02 OUTLIER 'Trans proline' 0 CA--C 1.533 0.43 0 C-N-CA 123.176 2.584 . . . . 72.42 112.393 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.523 ' HD1' ' H ' ' A' ' 15' ' ' GLU . 1.9 t90 -67.54 -179.44 1.08 Allowed 'General case' 0 CA--C 1.537 0.452 0 CA-C-N 116.071 -0.513 . . . . 72.24 109.641 178.248 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.523 ' H ' ' HD1' ' A' ' 14' ' ' TRP . 29.3 mm-40 -43.2 102.38 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 123.629 0.772 . . . . 74.13 112.886 -176.343 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.08 -154.82 25.66 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 110.224 -1.15 . . . . 71.54 110.224 -177.285 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.95 -171.36 37.61 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.224 -0.989 . . . . 73.45 112.064 176.668 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.7 mt -111.54 128.88 67.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.745 0.783 . . . . 70.34 111.279 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.76 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 9.2 tpt180 -96.76 127.3 42.61 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.581 -1.191 . . . . 74.22 108.966 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.525 ' HA ' HG22 ' A' ' 40' ' ' ILE . 77.4 m-85 -91.02 -172.46 3.34 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.341 -0.544 . . . . 74.35 110.021 178.647 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 21' ' ' ARG . 18.9 ttt85 -80.69 -62.78 1.57 Allowed 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.602 -0.439 . . . . 74.3 110.753 -172.893 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -146.98 57.02 0.5 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.693 -0.765 . . . . 71.12 111.986 177.768 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 93.2 mt -119.41 139.5 51.92 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.975 0.417 . . . . 52.44 111.246 -176.637 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.8 t -86.47 173.11 9.84 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.928 -0.578 . . . . 75.32 109.49 174.528 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.503 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 31.7 ptt180 -79.83 -171.52 2.91 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 121.12 -0.232 . . . . 73.32 110.581 -177.135 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.503 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 12.6 t70 72.77 -38.9 0.43 Allowed 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 109.178 -0.675 . . . . 54.04 109.178 -168.663 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.509 ' O ' HG22 ' A' ' 28' ' ' VAL . 96.6 mt-30 -83.33 -169.12 2.38 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.602 -0.888 . . . . 70.15 108.602 167.096 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.509 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.2 m 55.6 9.54 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 C-N-CA 124.219 1.008 . . . . 75.0 113.593 174.629 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -92.99 -29.13 16.0 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.076 0.465 . . . . 71.12 109.827 176.541 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.36 91.8 1.63 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.766 -0.652 . . . . 75.11 110.561 177.837 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.9 mt -115.79 135.7 55.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.706 -0.679 . . . . 74.23 109.209 177.764 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 15.5 m120 -72.94 -59.76 2.56 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.684 0.278 . . . . 73.04 110.925 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.6 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 74.4 m-85 -131.88 129.9 40.94 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.819 0.343 . . . . 71.25 111.171 -177.163 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.417 ' HA ' ' HD2' ' A' ' 35' ' ' PRO . 3.7 mm? -90.96 113.05 56.81 Favored Pre-proline 0 C--N 1.322 -0.619 0 N-CA-C 108.181 -1.044 . . . . 73.11 108.181 169.026 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.417 ' HD2' ' HA ' ' A' ' 34' ' ' LEU . 11.6 Cg_endo -53.61 156.27 11.88 Favored 'Trans proline' 0 C--O 1.234 0.28 0 C-N-CA 123.432 2.755 . . . . 63.24 113.549 -172.516 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.516 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 13.3 p -54.78 147.44 3.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.484 -0.78 . . . . 72.31 111.098 178.861 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.516 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 15.0 m-20 79.23 5.05 2.23 Favored 'General case' 0 N--CA 1.467 0.425 0 C-N-CA 123.654 0.782 . . . . 75.53 111.571 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.511 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 24.3 t80 -82.75 144.97 29.82 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.808 0.337 . . . . 74.11 110.241 178.406 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.537 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 37.0 mt-10 -135.25 138.16 43.27 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.916 -0.584 . . . . 72.52 110.283 -177.374 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.645 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 20.3 pt -125.76 158.94 34.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 120.805 0.335 . . . . 75.11 110.77 177.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.76 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 49.8 tt0 -116.16 149.86 38.37 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.859 -0.61 . . . . 74.33 110.976 -174.773 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.409 ' HE2' ' CG ' ' A' ' 56' ' ' ARG . 8.2 m-85 -94.33 102.01 13.99 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.28 -0.418 . . . . 75.13 110.185 175.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.602 HG11 HH11 ' A' ' 19' ' ' ARG . 18.2 m -108.42 156.43 8.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.109 0.481 . . . . 43.53 111.63 -177.46 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.546 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 5.2 t -96.35 158.47 15.42 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.193 -1.04 . . . . 51.42 108.193 178.437 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -65.59 117.72 8.47 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.26 0.467 . . . . 71.44 112.26 -174.407 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.34 -137.32 13.65 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.587 -0.733 . . . . 62.21 111.807 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -98.79 22.67 9.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.864 0.84 . . . . 71.43 109.077 174.223 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.594 ' HD2' ' OXT' ' A' ' 75' ' ' ARG . 10.7 mmm180 -88.18 134.19 33.84 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.642 -1.163 . . . . 74.21 109.184 -178.816 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.618 ' H ' ' HB3' ' A' ' 75' ' ' ARG . 46.4 mt-10 -116.66 170.1 8.85 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 120.98 0.419 . . . . 74.41 110.924 -179.06 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.54 HG12 ' HA ' ' A' ' 73' ' ' CYS . 28.9 m -116.85 149.53 19.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.405 -0.816 . . . . 54.31 109.206 174.199 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -106.12 95.09 3.52 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 122.035 0.922 . . . . 73.23 108.681 170.84 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.74 172.58 33.8 Favored Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 114.607 -1.179 . . . . 43.0 111.667 -176.041 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.506 ' HG2' ' CG2' ' A' ' 69' ' ' THR . 56.5 Cg_endo -73.72 53.1 2.68 Favored 'Trans proline' 0 CA--C 1.532 0.413 0 C-N-CA 122.494 2.129 . . . . 70.42 110.713 171.076 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 48.2 pttt -69.03 91.34 0.48 Allowed 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 114.805 -1.089 . . . . 72.35 111.948 -173.436 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.2 p -160.83 132.11 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.553 0.692 . . . . 74.12 110.912 175.057 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.645 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 42.9 mmt180 -121.23 113.82 20.5 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.528 -0.76 . . . . 73.32 109.128 172.402 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -108.78 129.78 55.38 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.155 -0.475 . . . . 71.3 110.084 -177.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 52.4 t -96.72 113.86 25.45 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.26 -0.427 . . . . 74.1 110.244 178.41 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.551 ' HB2' ' OD1' ' A' ' 61' ' ' ASN . 35.9 mt -96.45 -176.05 3.51 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.121 -0.696 . . . . 75.32 109.121 177.439 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -71.4 55.81 0.23 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-O 121.214 0.53 . . . . 34.01 111.18 177.685 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.551 ' OD1' ' HB2' ' A' ' 59' ' ' LEU . 4.4 p-10 -160.34 167.64 26.99 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.706 -0.85 . . . . 74.35 108.706 178.914 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -91.79 47.15 2.73 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.488 -0.863 . . . . 74.22 113.62 -171.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 38.9 m -160.59 136.33 8.22 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 117.041 0.42 . . . . 64.31 110.797 178.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' TRP . . . . . 0.433 ' HB2' ' CG ' ' A' ' 67' ' ' MET . 63.0 m95 -71.41 123.22 21.88 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.02 -1.104 . . . . 65.43 108.02 171.628 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.543 HG21 HD12 ' A' ' 59' ' ' LEU . 13.6 p -77.23 38.23 0.22 Allowed 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 115.074 1.509 . . . . 71.12 115.074 -164.329 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -162.51 20.16 0.09 Allowed 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 120.413 -0.515 . . . . 71.12 111.818 173.662 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' MET . . . . . 0.433 ' CG ' ' HB2' ' A' ' 64' ' ' TRP . 58.3 mtm -76.28 79.53 3.05 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 119.311 -0.956 . . . . 72.34 112.412 -168.793 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -169.76 89.27 0.17 Allowed 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 107.495 -1.298 . . . . 63.14 107.495 161.359 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.506 ' CG2' ' HG2' ' A' ' 53' ' ' PRO . 2.8 m -147.2 124.63 5.84 Favored Pre-proline 0 C--N 1.321 -0.65 0 C-N-CA 119.595 -0.842 . . . . 74.33 112.387 -168.265 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' PRO . . . . . 0.486 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 9.6 Cg_endo -89.21 90.49 0.38 Allowed 'Trans proline' 0 N--CA 1.451 -0.989 0 C-N-CA 123.388 2.725 . . . . 64.14 111.62 174.471 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.1 m -90.31 118.17 29.6 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.263 -0.426 . . . . 73.3 110.149 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.5 ptp180 -89.15 119.47 29.68 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.054 -0.521 . . . . 75.3 111.334 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.54 ' HA ' HG12 ' A' ' 50' ' ' VAL . 41.1 t -72.52 105.5 4.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.068 -0.515 . . . . 74.22 110.243 179.155 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.5 t -135.69 100.53 2.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.899 -0.591 . . . . 70.53 110.503 -177.778 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.618 ' HB3' ' H ' ' A' ' 49' ' ' GLU . 15.1 ttm180 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 118.451 -0.785 . . . . 74.41 109.558 176.159 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.8 m . . . . . 0 N--CA 1.453 -0.289 0 CA-C-O 120.847 0.356 . . . . 74.12 111.212 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -121.67 103.8 9.15 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.497 -0.557 . . . . 74.03 109.497 176.045 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -159.87 171.15 36.16 Favored Glycine 0 N--CA 1.443 -0.894 0 C-N-CA 120.481 -0.866 . . . . 52.24 112.86 -175.461 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 58.3 m -106.47 148.06 28.62 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.843 -0.429 . . . . 72.14 109.843 -178.907 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 19.2 pt20 -84.21 -179.9 7.32 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.001 0.429 . . . . 64.22 111.192 -178.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.584 HD12 ' H ' ' A' ' 31' ' ' ILE . 42.1 mt -88.68 143.67 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.596 -0.729 . . . . 73.43 110.343 177.686 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.1 mt -98.91 166.66 2.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.705 -0.68 . . . . 53.14 109.968 -177.117 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 76.5 m-70 -89.71 138.66 27.96 Favored Pre-proline 0 C--N 1.325 -0.458 0 N-CA-C 109.899 -0.408 . . . . 73.31 109.899 178.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.406 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 55.4 Cg_endo -72.36 106.34 2.05 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.29 1.993 . . . . 62.52 111.384 174.512 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 11.5 Cg_endo -88.85 -74.96 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 123.054 2.502 . . . . 72.42 113.566 -174.114 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 32.9 t-105 -100.29 -176.46 3.23 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.19 -0.459 . . . . 72.24 109.834 -175.526 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -49.85 -29.36 7.92 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 122.896 0.478 . . . . 74.13 111.539 178.092 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.25 102.3 1.35 Allowed Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.715 -0.755 . . . . 71.54 111.813 176.433 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -88.98 -169.74 44.81 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 121.148 -0.549 . . . . 73.45 112.052 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 28.4 mt -116.11 137.95 48.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.795 0.807 . . . . 70.34 112.337 -174.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 19' ' ' ARG . 11.2 tpt180 -116.59 132.78 56.59 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 114.287 -1.324 . . . . 74.22 108.825 -179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.573 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 56.0 m-85 -92.33 -172.03 2.98 Favored 'General case' 0 C--N 1.318 -0.772 0 C-N-CA 120.703 -0.399 . . . . 74.35 110.604 -179.578 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.521 ' HB2' ' O ' ' A' ' 39' ' ' GLU . 7.4 tmm_? -112.64 -42.21 3.68 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.126 0.489 . . . . 74.3 110.287 -171.75 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -146.09 56.54 0.52 Allowed Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 121.008 -0.615 . . . . 71.12 111.716 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 40.9 mt -143.15 141.68 31.25 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.946 0.403 . . . . 52.44 110.555 179.263 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -99.65 -178.95 4.04 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.691 -0.686 . . . . 75.32 110.197 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.475 ' C ' ' H ' ' A' ' 27' ' ' GLN . 33.0 ptt180 -66.55 -172.63 0.17 Allowed 'General case' 0 C--O 1.234 0.243 0 CA-C-N 116.051 -0.522 . . . . 73.32 111.409 -179.411 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.6 t70 70.24 -38.67 0.42 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.318 0.647 . . . . 54.04 111.043 -176.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.54 ' O ' HG22 ' A' ' 28' ' ' VAL . 90.2 mt-30 -94.73 -153.25 0.38 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.605 -0.725 . . . . 70.15 109.847 176.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.54 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.6 m 57.8 13.16 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 124.584 1.154 . . . . 75.0 112.939 176.349 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 56.7 mtpt -106.1 -38.42 6.29 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.928 0.394 . . . . 71.12 110.218 176.89 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.22 86.71 2.25 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.032 -0.531 . . . . 75.11 110.704 177.071 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.584 ' H ' HD12 ' A' ' 9' ' ' ILE . 70.7 mt -134.68 121.98 37.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 N-CA-C 108.521 -0.918 . . . . 74.23 108.521 176.524 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 15.0 p-10 -84.1 -24.46 30.31 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 113.229 0.826 . . . . 73.04 113.229 -170.334 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 -140.15 109.42 6.16 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 113.06 0.763 . . . . 71.25 113.06 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.45 112.18 48.32 Favored Pre-proline 0 C--N 1.323 -0.548 0 N-CA-C 107.77 -1.196 . . . . 73.11 107.77 165.166 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -58.85 152.0 60.7 Favored 'Trans proline' 0 N--CA 1.474 0.362 0 C-N-CA 123.057 2.504 . . . . 63.24 113.63 -170.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.482 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 2.5 p -61.48 94.92 0.08 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 115.559 -0.746 . . . . 72.31 110.58 175.697 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.482 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 18.3 t70 160.92 -29.9 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 114.488 -1.233 . . . . 75.53 108.367 -174.815 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.573 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 6.4 t80 -73.72 146.66 44.24 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.625 -1.171 . . . . 74.11 111.818 -173.891 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.521 ' O ' ' HB2' ' A' ' 21' ' ' ARG . 27.0 mt-10 -125.74 150.47 47.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.5 -0.773 . . . . 72.52 109.883 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.613 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 38.3 pt -132.99 149.31 31.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.948 0.404 . . . . 75.11 110.879 174.17 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.462 ' HG3' ' HD3' ' A' ' 54' ' ' LYS . 41.3 tt0 -118.64 171.44 8.19 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.476 -0.783 . . . . 74.33 109.396 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' TYR . . . . . 0.414 ' N ' ' HG2' ' A' ' 41' ' ' GLU . 73.1 m-85 -113.65 100.86 8.8 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.869 0.366 . . . . 75.13 111.176 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.6 m -96.98 132.1 42.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.013 0.435 . . . . 43.53 109.94 175.294 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.509 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 39.1 t -89.16 148.51 23.61 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.265 0.555 . . . . 51.42 110.941 -174.085 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -59.11 133.62 56.26 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.579 -1.191 . . . . 71.44 110.702 -176.239 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 86.29 -119.24 5.09 Favored Glycine 0 N--CA 1.444 -0.823 0 N-CA-C 110.67 -0.972 . . . . 62.21 110.67 -173.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -141.5 83.1 1.85 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.411 0.624 . . . . 71.43 109.812 173.149 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.647 ' HB3' ' HB2' ' A' ' 73' ' ' CYS . 42.7 mmt180 -132.89 130.05 39.18 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.434 -0.803 . . . . 74.21 110.081 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -86.25 139.69 30.8 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 109.958 -0.386 . . . . 74.41 109.958 178.04 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.444 HG12 ' HB3' ' A' ' 73' ' ' CYS . 30.5 m -97.82 127.32 50.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.224 -0.444 . . . . 54.31 111.096 -178.874 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.8 p -98.68 94.08 3.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 122.246 1.022 . . . . 73.23 109.287 174.042 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -156.82 171.06 34.29 Favored Glycine 0 N--CA 1.44 -1.059 0 CA-C-N 114.485 -1.234 . . . . 43.0 111.292 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -73.19 55.07 2.88 Favored 'Trans proline' 0 CA--C 1.531 0.341 0 C-N-CA 122.553 2.168 . . . . 70.42 110.255 168.252 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.585 ' O ' ' HD2' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -72.04 93.54 1.41 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.899 0.856 . . . . 72.35 112.718 -170.878 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.497 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.2 p -161.57 128.75 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 115.527 -0.76 . . . . 74.12 109.862 170.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.613 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 29.1 mmt180 -132.83 115.62 15.52 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.303 -0.629 . . . . 73.32 109.303 177.261 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.43 ' HE2' ' HG2' ' A' ' 39' ' ' GLU . 37.2 ttmt -115.02 136.91 52.61 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 108.986 -0.746 . . . . 71.3 108.986 178.328 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.7 t -73.78 139.95 45.54 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.826 0.346 . . . . 74.1 110.856 -176.333 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.481 ' C ' ' H ' ' A' ' 61' ' ' ASN . 87.3 mt -96.57 -179.53 4.64 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.779 -0.646 . . . . 75.32 110.548 -178.372 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.47 36.98 0.26 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-O 121.877 0.846 . . . . 34.01 109.304 174.128 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.481 ' H ' ' C ' ' A' ' 59' ' ' LEU . 0.9 OUTLIER -157.33 155.99 31.58 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.408 -1.269 . . . . 74.35 108.226 -172.37 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -74.45 50.31 2.06 Favored Glycine 0 CA--C 1.52 0.368 0 C-N-CA 121.114 -0.565 . . . . 74.22 113.215 -176.793 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 55.6 m -159.32 149.86 19.41 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 123.088 0.555 . . . . 64.31 109.518 178.787 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -83.53 175.19 9.96 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 110.171 -0.307 . . . . 65.43 110.171 -176.87 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 57' ' ' LYS . 1.4 p -50.56 -48.21 57.5 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.444 0.535 . . . . 71.12 112.444 -177.55 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -153.86 140.45 18.89 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.673 -0.862 . . . . 71.12 108.673 179.512 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 23.1 mmt -139.59 79.54 1.72 Allowed 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 120.235 -0.586 . . . . 72.34 110.557 168.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -168.48 87.93 0.21 Allowed 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 108.032 -1.099 . . . . 63.14 108.032 163.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.42 ' CB ' HH22 ' A' ' 56' ' ' ARG . 1.1 m -152.42 128.96 5.38 Favored Pre-proline 0 C--N 1.319 -0.751 0 C-N-CA 120.433 -0.507 . . . . 74.33 111.064 -169.82 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -74.99 69.29 5.58 Favored 'Trans proline' 0 CA--C 1.532 0.398 0 C-N-CA 122.772 2.315 . . . . 64.14 112.596 177.556 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 8.5 p -78.28 121.11 23.99 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.748 -0.464 . . . . 73.3 109.748 175.468 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.2 ptp85 -133.28 141.62 48.09 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.8 0.333 . . . . 75.3 111.624 -174.16 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.647 ' HB2' ' HB3' ' A' ' 48' ' ' ARG . 1.8 p -107.58 104.22 13.71 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.819 -0.628 . . . . 74.22 110.373 178.219 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.82 9.02 5.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.443 0.639 . . . . 70.53 110.755 -174.626 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.6 ttp180 . . . . . 0 C--O 1.246 0.901 0 CA-C-O 118.659 -0.686 . . . . 74.41 109.998 178.371 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.716 0 N-CA-C 111.677 -0.569 . . . . 72.35 111.677 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -75.33 142.14 26.53 Favored 'Trans proline' 0 C--O 1.235 0.369 0 C-N-CA 122.778 2.319 . . . . 72.1 112.279 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 40.0 p -102.98 113.33 26.7 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.333 -0.394 . . . . 75.23 110.411 177.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.9 m -79.97 98.86 7.36 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.306 0.574 . . . . 74.12 109.631 177.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -114.16 97.91 6.64 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.844 -0.617 . . . . 74.03 109.756 -177.443 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -163.16 171.1 38.82 Favored Glycine 0 N--CA 1.439 -1.113 0 C-N-CA 120.728 -0.749 . . . . 52.24 112.223 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 26.0 m -104.32 153.53 20.92 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.74 -0.467 . . . . 72.14 109.74 177.035 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 21.6 pt20 -89.6 -178.86 5.66 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.927 0.394 . . . . 64.22 111.13 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.617 HD11 ' HB ' ' A' ' 31' ' ' ILE . 26.6 mt -87.98 120.55 37.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.928 -0.578 . . . . 73.43 110.022 177.213 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 63.1 mt -74.95 138.38 21.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.212 -0.904 . . . . 53.14 110.525 -178.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 81.1 m-70 -80.54 132.09 59.45 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 116.118 -0.492 . . . . 73.31 109.768 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.463 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.6 Cg_exo -51.05 113.18 0.98 Allowed 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 123.319 2.679 . . . . 62.52 112.838 -178.551 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 4.7 Cg_exo -76.51 -80.0 0.01 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.43 0 C-N-CA 122.881 2.388 . . . . 72.42 112.278 -178.615 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.0 t-105 -101.39 -178.09 3.63 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.602 -0.518 . . . . 72.24 109.602 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -58.71 100.54 0.07 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.133 0.492 . . . . 74.13 111.086 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.509 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . 175.81 -158.29 25.11 Favored Glycine 0 N--CA 1.443 -0.847 0 C-N-CA 120.854 -0.688 . . . . 71.54 112.009 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -161.1 -171.28 26.88 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 111.296 -0.721 . . . . 73.45 111.296 178.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.9 mt -125.68 131.4 72.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.792 0.806 . . . . 70.34 111.804 -178.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.797 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 23.3 tpp180 -93.51 110.65 22.23 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.317 -1.31 . . . . 74.22 109.935 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -90.95 -171.52 3.03 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.778 0.323 . . . . 74.35 110.358 177.716 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.456 ' NH2' ' HB2' ' A' ' 39' ' ' GLU . 97.8 mtt180 -109.72 -86.58 0.52 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.446 -0.343 . . . . 74.3 110.894 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -88.4 48.06 3.54 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 121.18 -0.533 . . . . 71.12 112.702 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 91.8 mt -137.91 133.41 33.77 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.09 -0.337 . . . . 52.44 110.09 178.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.4 t -95.99 179.55 5.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.745 -0.465 . . . . 75.32 109.745 174.643 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' GLN . 63.9 mtm-85 -79.54 -171.38 2.76 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.581 -0.282 . . . . 73.32 110.962 -177.438 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.474 ' O ' ' HE2' ' A' ' 29' ' ' LYS . 34.7 t70 68.5 -27.03 0.14 Allowed 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 123.329 0.652 . . . . 54.04 110.928 -170.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ARG . 93.1 mt-30 -90.33 -146.07 0.18 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.703 -0.681 . . . . 70.15 110.028 175.169 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.467 HG22 ' O ' ' A' ' 27' ' ' GLN . 4.8 m 54.26 19.75 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.509 1.123 . . . . 75.0 112.733 177.293 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.474 ' HE2' ' O ' ' A' ' 26' ' ' ASP . 49.9 mtmt -101.41 -74.85 0.61 Allowed 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.823 -0.436 . . . . 71.12 109.823 175.145 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.11 89.53 4.06 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.448 0.642 . . . . 75.11 111.253 178.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.617 ' HB ' HD11 ' A' ' 9' ' ' ILE . 64.9 mt -125.44 138.86 53.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.255 -0.884 . . . . 74.23 108.634 175.286 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 37.4 m-80 -74.39 -70.2 0.41 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.636 0.255 . . . . 73.04 110.864 -177.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -141.55 139.43 33.2 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.017 0.437 . . . . 71.25 111.301 -177.026 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -78.85 147.0 69.74 Favored Pre-proline 0 C--N 1.321 -0.646 0 N-CA-C 109.079 -0.711 . . . . 73.11 109.079 172.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -61.47 151.36 80.26 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.684 2.256 . . . . 63.24 112.26 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.2 p -61.13 138.24 22.22 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 CA-C-N 116.388 -0.369 . . . . 72.31 110.132 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 16.8 t70 61.97 75.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.817 0.818 . . . . 75.53 110.421 -172.489 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -133.28 124.68 27.75 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 107.464 -1.31 . . . . 74.11 107.464 175.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.714 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 39.5 mt-10 -111.98 124.9 53.38 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.099 0.476 . . . . 72.52 111.537 -172.711 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.489 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 32.6 pt -116.0 167.28 9.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.122 -0.944 . . . . 75.11 111.019 -177.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.797 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 44.7 tt0 -125.05 146.2 49.55 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.855 -0.611 . . . . 74.33 110.542 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.494 ' HE2' ' HG3' ' A' ' 56' ' ' ARG . 25.8 m-85 -97.67 103.07 14.97 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.323 -0.399 . . . . 75.13 110.762 178.078 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 32.7 m -97.58 157.45 3.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 120.825 0.345 . . . . 43.53 111.055 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.541 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 48.3 t -89.53 158.42 17.68 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-N 116.037 -0.529 . . . . 51.42 109.608 178.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.509 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 31.3 ttt180 -58.13 121.24 10.21 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.858 -1.065 . . . . 71.44 111.873 -169.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 93.61 -128.95 9.67 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.874 -0.891 . . . . 62.21 110.874 -176.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -114.95 37.98 3.31 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.5 0.667 . . . . 71.43 110.009 172.135 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.541 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 27.3 mmt180 -88.84 146.44 24.96 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.434 -0.803 . . . . 74.21 109.356 178.194 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -103.46 166.18 10.58 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.04 0.448 . . . . 74.41 110.848 -177.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.571 HG12 ' HA ' ' A' ' 73' ' ' CYS . 35.4 m -132.97 145.96 33.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 115.921 -0.581 . . . . 54.31 109.835 177.633 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.6 p -108.18 95.81 4.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 122.195 0.998 . . . . 73.23 109.42 172.246 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.82 172.82 33.23 Favored Glycine 0 N--CA 1.443 -0.893 0 CA-C-N 114.47 -1.241 . . . . 43.0 110.801 -178.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.77 67.27 5.74 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.773 1.649 . . . . 70.42 110.552 172.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.555 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 31.9 pttt -84.32 87.65 7.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.36 -0.836 . . . . 72.35 111.532 -173.542 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -160.89 129.18 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.262 -0.881 . . . . 74.12 109.286 174.21 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.714 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 28.7 mmt85 -133.18 109.95 9.8 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 116.531 -0.304 . . . . 73.32 110.584 -177.261 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -96.66 118.6 33.48 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.822 -0.436 . . . . 71.3 109.822 178.038 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.8 t -62.62 132.74 53.37 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.919 -0.582 . . . . 74.1 110.954 177.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 90.2 mt -97.42 -178.58 4.2 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.873 -0.603 . . . . 75.32 110.61 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.19 -1.87 34.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.04 0.448 . . . . 34.01 111.043 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -119.63 169.78 9.78 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.41 -0.589 . . . . 74.35 109.41 177.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -75.33 62.35 2.65 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.079 -0.582 . . . . 74.22 113.35 -175.266 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 27.6 t -170.28 160.55 7.82 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.674 -0.491 . . . . 64.31 109.674 176.289 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 58.5 m95 -97.03 174.63 6.67 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.482 -0.562 . . . . 65.43 109.482 -177.453 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -49.89 -75.4 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.382 0 N-CA-C 112.815 0.672 . . . . 71.12 112.815 -176.026 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -115.89 94.76 4.81 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.377 -0.601 . . . . 71.12 109.377 176.449 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 13.5 tpt -93.42 75.35 4.49 Favored 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 119.192 -1.003 . . . . 72.34 110.253 -177.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -172.65 96.73 0.14 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.585 -1.188 . . . . 63.14 108.235 159.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.6 m -142.07 108.91 5.87 Favored Pre-proline 0 C--N 1.317 -0.846 0 C-N-CA 119.671 -0.812 . . . . 74.33 111.714 -172.33 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -77.56 93.84 1.08 Allowed 'Trans proline' 0 N--CA 1.458 -0.582 0 C-N-CA 122.62 2.213 . . . . 64.14 111.834 176.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 35.8 p -81.34 107.34 14.04 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.054 -0.521 . . . . 73.3 110.368 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -78.84 120.07 22.94 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.245 0.545 . . . . 75.3 110.477 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.571 ' HA ' HG12 ' A' ' 50' ' ' VAL . 24.0 t -72.32 110.1 6.51 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.559 -0.746 . . . . 74.22 109.799 -178.683 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 98.4 t -134.37 126.13 48.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.973 -0.558 . . . . 70.53 110.293 -174.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 75' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.229 -0.891 . . . . 74.41 109.79 178.415 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.738 0 N-CA-C 111.844 -0.502 . . . . 72.35 111.844 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -68.23 93.08 0.4 Allowed 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.696 2.264 . . . . 72.1 111.353 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 2.5 p -78.76 99.58 6.74 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.742 -0.663 . . . . 75.23 111.417 -175.819 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.3 m -118.53 100.67 7.6 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.693 -0.685 . . . . 74.12 109.499 176.429 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 49.1 mm-40 -83.11 109.19 16.94 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.986 -0.552 . . . . 74.03 110.538 -177.499 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.602 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -150.26 141.54 8.86 Favored Glycine 0 N--CA 1.443 -0.895 0 C-N-CA 120.737 -0.744 . . . . 52.24 112.365 -178.193 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 37.4 m -88.96 154.03 20.55 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 110.109 -0.33 . . . . 72.14 110.109 178.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 -86.89 177.76 7.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.017 0.437 . . . . 64.22 111.681 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.575 HD11 ' HB ' ' A' ' 31' ' ' ILE . 72.0 mt -87.79 118.9 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.527 -0.76 . . . . 73.43 109.982 177.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 44.2 mt -71.25 145.36 12.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.904 -0.589 . . . . 53.14 110.923 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -81.02 137.78 49.7 Favored Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 109.587 -0.523 . . . . 73.31 109.587 174.187 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -64.11 116.47 3.73 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.457 2.105 . . . . 62.52 111.634 176.516 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.75 -85.01 0.01 OUTLIER 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.541 2.161 . . . . 72.42 112.134 -178.753 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.6 t-105 -101.97 -178.08 3.6 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.843 -0.799 . . . . 72.24 108.843 173.371 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -50.67 100.9 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.189 0.518 . . . . 74.13 111.761 178.779 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.81 -147.29 5.65 Favored Glycine 0 N--CA 1.444 -0.83 0 CA-C-N 115.485 -0.78 . . . . 71.54 111.325 178.44 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -178.5 -170.86 41.13 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 120.869 -0.682 . . . . 73.45 111.42 177.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mt -123.11 133.11 70.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.518 0.675 . . . . 70.34 111.325 -179.132 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.926 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 7.2 tpt180 -96.31 132.85 41.37 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.634 -1.166 . . . . 74.22 108.448 177.766 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.542 ' HB3' ' HH ' ' A' ' 38' ' ' TYR . 97.1 m-85 -103.77 -171.53 1.95 Allowed 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 120.417 -0.513 . . . . 74.35 111.636 -173.278 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.68 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 49.1 ttt180 -113.36 -44.04 3.28 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.576 -0.738 . . . . 74.3 110.263 -170.756 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -148.03 40.01 0.97 Allowed Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.647 -0.706 . . . . 71.12 111.968 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.435 HD13 HG12 ' A' ' 28' ' ' VAL . 84.7 mt -122.21 130.07 52.85 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.832 0.349 . . . . 52.44 110.504 179.463 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 11.0 t -90.72 -179.33 5.5 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.939 -0.573 . . . . 75.32 110.158 177.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 5.6 ptm180 -73.66 -173.49 1.49 Allowed 'General case' 0 C--O 1.234 0.286 0 CA-C-O 120.978 0.418 . . . . 73.32 112.125 -174.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 31.1 t70 56.17 12.77 1.03 Allowed 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 115.353 -0.839 . . . . 54.04 111.609 -174.694 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.504 ' O ' HG22 ' A' ' 28' ' ' VAL . 98.6 mt-30 -124.47 -162.69 1.1 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.849 -0.614 . . . . 70.15 109.538 -179.636 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.504 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.3 m 56.92 13.83 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.452 1.101 . . . . 75.0 112.892 174.53 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 53.0 pttt -96.34 -27.6 14.87 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.021 0.438 . . . . 71.12 109.856 176.264 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.49 95.29 2.42 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.74 -0.664 . . . . 75.11 110.412 177.167 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.575 ' HB ' HD11 ' A' ' 9' ' ' ILE . 62.7 mt -132.21 148.12 32.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 108.707 -0.849 . . . . 74.23 108.707 177.578 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.3 m-80 -75.77 -69.04 0.51 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.031 0.443 . . . . 73.04 109.967 -178.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.602 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 87.4 m-85 -141.44 150.15 41.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.872 -0.604 . . . . 71.25 110.713 -177.498 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -91.54 136.6 26.53 Favored Pre-proline 0 C--N 1.323 -0.55 0 N-CA-C 109.403 -0.591 . . . . 73.11 109.403 174.237 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.88 143.41 95.86 Favored 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 122.866 2.377 . . . . 63.24 113.055 -176.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.447 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 3.6 p -70.11 84.41 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 CA-C-O 122.031 0.919 . . . . 72.31 110.643 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.447 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 35.2 t70 167.2 -27.51 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.493 -1.23 . . . . 75.53 108.766 -174.553 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.542 ' HH ' ' HB3' ' A' ' 20' ' ' TYR . 4.2 t80 -64.86 137.38 57.73 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 114.681 -1.145 . . . . 74.11 111.713 -174.692 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.68 ' H ' ' HD2' ' A' ' 21' ' ' ARG . 41.4 mt-10 -120.29 139.16 53.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.928 -0.578 . . . . 72.52 109.593 177.239 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.481 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 37.3 pt -126.2 162.72 29.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.121 0.486 . . . . 75.11 112.019 -178.673 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.926 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.9 tt0 -124.57 153.69 41.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.231 -0.895 . . . . 74.33 109.811 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.601 ' O ' HG11 ' A' ' 50' ' ' VAL . 97.2 m-85 -101.9 101.59 12.04 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.439 0.162 . . . . 75.13 110.996 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.541 HG13 ' HB2' ' A' ' 19' ' ' ARG . 15.5 m -97.13 170.96 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 120.861 0.363 . . . . 43.53 111.24 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.403 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 26.5 t -114.73 171.15 7.81 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.015 -0.539 . . . . 51.42 109.922 -176.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 14.4 mmm180 -72.57 110.67 7.11 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 120.798 0.332 . . . . 71.44 110.547 179.532 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.17 -108.83 3.02 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.717 -0.754 . . . . 62.21 112.073 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -155.11 49.07 0.56 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.185 0.517 . . . . 71.43 111.269 -177.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.574 ' HB2' ' HB2' ' A' ' 73' ' ' CYS . 17.3 mmt180 -88.31 145.71 25.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.152 -0.477 . . . . 74.21 110.072 177.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.4 mm-40 -80.62 112.88 18.4 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.005 0.431 . . . . 74.41 109.977 176.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.601 HG11 ' O ' ' A' ' 42' ' ' TYR . 3.8 p -92.67 115.73 32.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.293 0.568 . . . . 54.31 110.769 -178.471 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.7 p -100.61 97.3 5.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 122.125 0.964 . . . . 73.23 110.613 178.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.91 170.68 32.56 Favored Glycine 0 N--CA 1.441 -0.989 0 CA-C-N 114.71 -1.132 . . . . 43.0 110.284 175.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -71.96 67.0 3.26 Favored 'Trans proline' 0 C--O 1.235 0.334 0 C-N-CA 122.047 1.831 . . . . 70.42 110.529 170.048 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.525 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 41.5 pttt -84.75 87.3 7.3 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.552 0.691 . . . . 72.35 112.086 -170.277 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.514 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.6 p -161.05 127.05 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.556 -0.747 . . . . 74.12 109.226 171.16 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.57 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 28.3 mmt180 -133.15 112.85 12.09 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.103 -0.332 . . . . 73.32 110.103 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.426 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 38.6 ttmt -101.52 123.92 46.34 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 109.375 -0.602 . . . . 71.3 109.375 179.368 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.3 t -67.3 119.52 12.3 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.233 -0.44 . . . . 74.1 110.246 -179.636 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 80.1 mt -101.28 -179.93 4.18 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.897 -0.592 . . . . 75.32 110.369 -177.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.81 59.5 3.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.129 0.49 . . . . 34.01 111.15 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.4 p-10 -161.78 167.4 24.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.328 -0.851 . . . . 74.35 108.786 175.087 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -82.83 36.93 2.66 Favored Glycine 0 CA--C 1.521 0.409 0 C-N-CA 120.699 -0.762 . . . . 74.22 113.45 -174.44 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.4 m -156.43 157.24 35.18 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.93 0.365 . . . . 64.31 110.176 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 87.3 m95 -83.36 179.17 7.75 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.53 -0.305 . . . . 65.43 110.464 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.8 m -56.74 -53.22 60.24 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 116.025 -0.534 . . . . 71.12 112.053 -176.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -148.03 129.66 15.03 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.514 -0.55 . . . . 71.12 109.514 -177.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 56.1 mtm -133.64 78.25 1.76 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 119.21 -0.996 . . . . 72.34 110.759 172.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -168.82 89.16 0.21 Allowed 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 106.942 -1.503 . . . . 63.14 106.942 162.329 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.42 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 3.6 m -139.82 121.28 9.65 Favored Pre-proline 0 C--N 1.312 -1.023 0 C-N-CA 119.837 -0.745 . . . . 74.33 111.984 -165.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 5.1 Cg_exo -77.24 58.13 6.12 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.094 2.529 . . . . 64.14 111.635 177.12 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.4 p -78.76 101.29 7.5 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.121 -0.49 . . . . 73.3 110.355 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.434 HH11 ' HD2' ' A' ' 72' ' ' ARG . 7.5 ptp85 -91.55 142.02 28.1 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.981 -0.554 . . . . 75.3 110.044 -178.123 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.574 ' HB2' ' HB2' ' A' ' 48' ' ' ARG . 2.0 p -106.65 99.91 9.46 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.427 0.632 . . . . 74.22 109.681 173.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.6 p -121.0 153.68 24.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.341 -0.845 . . . . 70.53 111.011 -170.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 65.8 ttt-85 . . . . . 0 C--O 1.245 0.862 0 CA-C-O 118.582 -0.723 . . . . 74.41 109.701 176.299 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.711 0 N-CA-C 111.842 -0.503 . . . . 72.35 111.842 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -79.02 2.21 8.49 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.793 2.329 . . . . 72.1 112.469 -177.709 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 7.2 p -79.46 99.54 7.27 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.625 -0.716 . . . . 75.23 111.515 -176.239 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 21.7 m -105.31 96.15 6.32 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.421 -0.585 . . . . 74.12 109.421 173.399 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -123.83 112.74 17.65 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.905 -0.588 . . . . 74.03 109.491 -177.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.656 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.5 163.35 33.96 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.576 -0.821 . . . . 52.24 111.759 179.05 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 83.9 m -84.03 134.29 34.63 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 110.062 -0.347 . . . . 72.14 110.062 177.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -77.39 179.37 6.49 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.172 0.51 . . . . 64.22 111.609 -176.183 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.562 HD11 ' HB ' ' A' ' 31' ' ' ILE . 59.5 mt -88.07 119.1 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.191 -0.913 . . . . 73.43 110.295 178.294 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.6 mt -82.69 131.5 33.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.853 -0.612 . . . . 53.14 109.984 178.25 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 83.7 m-70 -84.07 117.94 70.0 Favored Pre-proline 0 C--N 1.323 -0.557 0 N-CA-C 109.59 -0.522 . . . . 73.31 109.59 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.418 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 52.1 Cg_exo -54.53 110.1 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 122.985 2.457 . . . . 62.52 112.153 -178.5 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 14.0 Cg_exo -69.2 -56.81 0.14 Allowed 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.924 2.416 . . . . 72.42 112.295 -176.224 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.428 ' HA ' ' CE3' ' A' ' 14' ' ' TRP . 6.0 t-105 -100.07 -177.8 3.65 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.868 -0.605 . . . . 72.24 109.807 -176.586 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -68.7 -5.05 18.15 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.858 0.361 . . . . 74.13 111.329 178.108 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.07 121.92 5.76 Favored Glycine 0 N--CA 1.444 -0.784 0 N-CA-C 110.832 -0.907 . . . . 71.54 110.832 171.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -95.72 -170.7 35.72 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.529 -0.844 . . . . 73.45 112.447 -175.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.515 HD13 HD12 ' A' ' 40' ' ' ILE . 27.3 mt -115.45 129.25 72.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.632 0.73 . . . . 70.34 111.124 -178.426 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -97.21 144.54 26.93 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.597 -1.183 . . . . 74.22 109.593 -178.071 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -115.88 -170.73 1.84 Allowed 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.346 -0.613 . . . . 74.35 109.346 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 -115.6 -53.84 2.56 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.5 -0.48 . . . . 74.3 110.309 178.624 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -110.19 26.43 13.66 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.727 -0.749 . . . . 71.12 112.634 -177.261 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.464 HD13 HG12 ' A' ' 28' ' ' VAL . 95.9 mt -119.86 121.91 40.12 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.888 -0.412 . . . . 52.44 109.888 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.2 t -105.71 -178.79 3.75 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.779 -0.646 . . . . 75.32 112.17 -171.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.41 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 49.6 mtp180 -57.49 125.33 22.39 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.359 -0.837 . . . . 73.32 111.603 177.671 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.421 ' O ' ' HD2' ' A' ' 29' ' ' LYS . 33.7 t70 92.91 3.96 0.06 Allowed 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.735 1.214 . . . . 54.04 110.353 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.456 ' O ' HG22 ' A' ' 28' ' ' VAL . 10.4 mm100 -94.57 -178.88 4.7 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 108.925 -0.769 . . . . 70.15 108.925 170.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.464 HG12 HD13 ' A' ' 23' ' ' LEU . 3.7 m 52.36 18.78 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 124.238 1.015 . . . . 75.0 113.064 178.707 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.421 ' HD2' ' O ' ' A' ' 26' ' ' ASP . 18.1 ptmt -82.62 -19.47 38.28 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.789 -0.449 . . . . 71.12 109.789 178.67 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -168.03 107.81 0.54 Allowed 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.602 -0.726 . . . . 75.11 110.477 175.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.562 ' HB ' HD11 ' A' ' 9' ' ' ILE . 55.6 mt -138.14 151.86 25.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.155 -0.683 . . . . 74.23 109.155 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -89.19 -66.34 0.93 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.717 0.294 . . . . 73.04 110.467 175.463 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.656 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 71.1 m-85 -136.66 143.06 43.25 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.827 0.346 . . . . 71.25 110.821 -178.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.416 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.9 mm? -84.8 144.0 41.45 Favored Pre-proline 0 C--N 1.323 -0.555 0 CA-C-N 115.86 -0.609 . . . . 73.11 109.654 175.572 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 34' ' ' LEU . 27.0 Cg_exo -62.26 154.7 61.45 Favored 'Trans proline' 0 C--O 1.235 0.352 0 C-N-CA 122.913 2.409 . . . . 63.24 112.599 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 8.4 p -61.22 140.14 19.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.658 -0.701 . . . . 72.31 111.135 -177.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 66.63 16.88 10.51 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.395 -0.82 . . . . 75.53 112.878 178.388 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 40.6 t80 -71.8 146.69 47.87 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.011 -0.737 . . . . 74.11 109.011 172.102 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -116.22 126.31 53.45 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.695 0.283 . . . . 72.52 111.246 -172.731 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.545 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 46.9 pt -121.72 155.99 25.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.28 -0.418 . . . . 75.11 110.316 175.726 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -130.73 147.0 52.34 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.381 -0.372 . . . . 74.33 110.533 -175.222 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.592 ' HB2' ' HB3' ' A' ' 54' ' ' LYS . 27.6 m-85 -96.44 101.85 13.54 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.326 -0.25 . . . . 75.13 110.326 178.658 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.9 m -113.79 170.07 4.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.025 0.44 . . . . 43.53 111.38 -176.122 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.668 ' HB2' HG13 ' A' ' 50' ' ' VAL . 16.7 t -95.37 127.23 41.25 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 109.282 -0.636 . . . . 51.42 109.282 177.101 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 47.0 ttt180 -59.41 121.94 12.73 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.853 -1.067 . . . . 71.44 111.057 -176.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 113.0 -128.3 8.34 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-N 115.845 -0.616 . . . . 62.21 111.977 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -122.17 11.91 10.22 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.247 0.546 . . . . 71.43 110.666 -179.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 19.2 mmm180 -89.34 160.18 16.99 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.616 -0.72 . . . . 74.21 109.562 177.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.612 ' HB2' ' HG2' ' A' ' 75' ' ' ARG . 39.4 mt-10 -121.22 163.94 17.73 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.996 0.427 . . . . 74.41 111.359 -174.086 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.668 HG13 ' HB2' ' A' ' 44' ' ' CYS . 26.8 m -128.51 150.27 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.618 -0.719 . . . . 54.31 110.093 -178.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.435 HG13 ' HD2' ' A' ' 72' ' ' ARG . 3.1 p -119.57 96.59 4.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 122.059 0.933 . . . . 73.23 109.921 171.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.24 172.8 32.83 Favored Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 114.636 -1.166 . . . . 43.0 110.925 -178.322 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -78.55 60.66 7.67 Favored 'Trans proline' 0 N--CA 1.46 -0.448 0 C-N-CA 122.097 1.865 . . . . 70.42 110.455 174.535 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.592 ' HB3' ' HB2' ' A' ' 42' ' ' TYR . 0.0 OUTLIER -86.31 86.39 7.34 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-N 115.333 -0.849 . . . . 72.35 112.028 -171.369 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -162.41 128.99 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 115.316 -0.856 . . . . 74.12 109.557 173.185 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.545 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 4.8 mmt85 -130.58 120.57 24.21 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.712 -0.477 . . . . 73.32 109.712 176.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 22.6 ttpp -103.61 125.31 50.05 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 109.159 -0.682 . . . . 71.3 109.159 177.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 49.6 t -64.75 149.23 49.62 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.743 0.306 . . . . 74.1 110.334 179.107 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 87.0 mt -116.22 -179.0 3.54 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.167 -0.47 . . . . 75.32 110.166 -178.143 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -81.44 -0.76 43.03 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.97 0.414 . . . . 34.01 110.539 178.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -113.58 164.65 13.39 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.399 -0.593 . . . . 74.35 109.399 175.535 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 6' ' ' GLY . . . -79.43 51.9 4.02 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.012 -0.613 . . . . 74.22 113.541 -173.783 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 28.2 m -156.62 146.87 21.29 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.92 -0.4 . . . . 64.31 109.92 177.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 89.8 m95 -82.01 177.54 8.78 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.227 -0.657 . . . . 65.43 109.227 175.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.8 p -66.59 -27.5 67.76 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 112.276 0.473 . . . . 71.12 112.276 -177.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -160.48 140.1 10.98 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.95 -0.389 . . . . 71.12 109.95 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 66.9 mtt -129.95 76.38 1.72 Allowed 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 119.814 -0.755 . . . . 72.34 110.164 165.011 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -170.61 89.18 0.14 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.335 -0.848 . . . . 63.14 108.803 161.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.2 m -148.12 102.96 3.57 Favored Pre-proline 0 C--N 1.317 -0.819 0 C-N-CA 119.936 -0.706 . . . . 74.33 111.399 -176.09 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.24 95.7 1.01 Allowed 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 122.998 2.466 . . . . 64.14 111.44 175.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 10.6 p -75.57 113.37 12.91 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.12 -0.491 . . . . 73.3 110.479 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.435 ' HD2' HG13 ' A' ' 51' ' ' VAL . 5.3 ptp180 -79.68 114.77 18.85 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.155 0.502 . . . . 75.3 111.151 -178.045 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.593 ' HA ' HG12 ' A' ' 50' ' ' VAL . 48.9 t -80.08 100.95 8.44 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.962 -0.563 . . . . 74.22 109.902 176.831 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.2 p -165.2 141.31 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.544 -0.753 . . . . 70.53 109.564 -178.448 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.612 ' HG2' ' HB2' ' A' ' 49' ' ' GLU . 1.5 tmm_? . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.697 -0.668 . . . . 74.41 110.248 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.775 0 N-CA-C 111.651 -0.58 . . . . 72.35 111.651 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -74.84 99.86 1.29 Allowed 'Trans proline' 0 C--O 1.236 0.386 0 C-N-CA 122.401 2.067 . . . . 72.1 111.939 177.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 20.7 p -121.48 121.56 37.79 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.332 0.587 . . . . 75.23 111.959 -177.462 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.6 m -125.59 98.67 5.67 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.941 -0.572 . . . . 74.12 109.585 169.228 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -126.44 109.26 12.01 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.724 -0.671 . . . . 74.03 109.286 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.723 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -157.5 159.98 30.23 Favored Glycine 0 N--CA 1.438 -1.227 0 C-N-CA 120.066 -1.064 . . . . 52.24 112.841 -176.412 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.0 m -105.9 142.58 35.38 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.531 -0.544 . . . . 72.14 109.531 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 19.5 pt20 -74.77 -178.4 3.66 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.247 0.546 . . . . 64.22 111.929 -175.43 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.502 HD11 ' HB ' ' A' ' 31' ' ' ILE . 41.8 mt -88.25 119.37 35.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.524 -0.762 . . . . 73.43 110.316 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.467 HD11 ' CD1' ' A' ' 64' ' ' TRP . 47.4 mt -76.86 142.44 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.603 -0.726 . . . . 53.14 110.825 -177.016 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -79.85 126.8 79.34 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 73.31 109.867 175.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.429 ' HA ' ' HD2' ' A' ' 13' ' ' PRO . 27.2 Cg_exo -62.73 113.65 2.06 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 122.46 2.107 . . . . 62.52 111.417 175.28 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 12' ' ' PRO . 30.4 Cg_endo -65.55 -69.19 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.491 2.127 . . . . 72.42 112.481 -177.416 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 19.5 t-105 -100.39 -179.3 4.07 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.108 -0.701 . . . . 72.24 109.108 178.07 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.3 mm-40 -65.54 92.47 0.14 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.577 0.703 . . . . 74.13 111.413 -177.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.558 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . -160.31 -153.78 7.07 Favored Glycine 0 N--CA 1.442 -0.94 0 CA-C-N 114.85 -1.068 . . . . 71.54 110.458 178.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.17 -171.74 31.77 Favored Glycine 0 N--CA 1.443 -0.88 0 C-N-CA 120.224 -0.989 . . . . 73.45 112.02 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.402 HD13 HD12 ' A' ' 40' ' ' ILE . 22.1 mt -128.78 134.93 63.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.681 0.753 . . . . 70.34 111.422 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.801 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 16.9 tpp180 -99.33 126.63 45.23 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 114.684 -1.144 . . . . 74.22 110.326 -178.363 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -99.01 -170.84 1.98 Allowed 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.218 -0.66 . . . . 74.35 109.218 175.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 43.4 ttm-85 -103.4 -65.71 0.99 Allowed 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.34 -0.544 . . . . 74.3 110.421 -179.332 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -110.58 47.5 1.04 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.669 -0.777 . . . . 71.12 112.116 -179.027 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 94.3 mt -135.74 104.45 5.77 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.809 0.338 . . . . 52.44 110.842 -178.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.7 t -87.14 -177.78 6.09 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.745 -0.662 . . . . 75.32 110.019 174.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.426 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 34.7 ptt180 -64.77 -173.05 0.09 Allowed 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 111.922 0.342 . . . . 73.32 111.922 -176.695 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.426 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 13.0 t70 68.63 -45.74 0.54 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 123.477 0.711 . . . . 54.04 110.854 -170.66 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.404 ' HB3' ' H ' ' A' ' 28' ' ' VAL . 99.0 mt-30 -76.42 -155.92 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.301 -0.409 . . . . 70.15 110.495 175.056 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.404 ' H ' ' HB3' ' A' ' 27' ' ' GLN . 11.2 m 49.31 27.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 124.225 1.01 . . . . 75.0 111.987 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 34.9 pttt -97.02 -28.92 13.94 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.429 -0.805 . . . . 71.12 110.652 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.12 95.66 1.63 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.378 0.609 . . . . 75.11 111.055 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.502 ' HB ' HD11 ' A' ' 9' ' ' ILE . 46.8 mt -129.33 140.45 49.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.491 -0.929 . . . . 74.23 108.491 175.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.6 m-80 -107.56 -36.68 6.39 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 120.614 -0.434 . . . . 73.04 110.513 -178.076 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.723 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 90.6 m-85 -135.74 109.24 7.93 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.753 0.311 . . . . 71.25 111.097 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -80.17 122.62 83.13 Favored Pre-proline 0 C--N 1.325 -0.463 0 N-CA-C 108.463 -0.94 . . . . 73.11 108.463 169.554 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.453 ' O ' ' HB2' ' A' ' 38' ' ' TYR . 5.9 Cg_endo -47.31 138.72 17.33 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 123.378 2.719 . . . . 63.24 113.618 -172.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.413 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 7.2 p -50.3 143.51 2.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.651 -0.704 . . . . 72.31 111.008 175.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.413 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 27.6 t70 80.16 -4.0 1.91 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 123.685 0.794 . . . . 75.53 111.727 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.453 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 17.6 t80 -66.68 141.29 57.82 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 109.475 -0.565 . . . . 74.11 109.475 175.347 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.692 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.8 mt-10 -118.49 120.57 37.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.681 0.277 . . . . 72.52 111.181 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.521 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 46.3 pt -112.9 161.38 11.86 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 CA-C-N 116.335 -0.393 . . . . 75.11 110.599 177.43 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.801 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.0 tt0 -125.61 152.36 45.25 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.965 -0.561 . . . . 74.33 111.031 -175.699 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.623 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 25.3 m-85 -101.3 102.51 13.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.343 -0.39 . . . . 75.13 111.089 -179.289 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.3 m -103.93 166.83 2.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 116.232 -0.44 . . . . 43.53 110.365 177.01 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.561 ' HB3' ' O ' ' A' ' 48' ' ' ARG . 34.8 t -91.6 172.31 8.58 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.603 -0.517 . . . . 51.42 109.603 178.519 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.558 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -76.98 98.19 4.87 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.928 0.394 . . . . 71.44 110.692 -175.557 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.32 -122.02 7.44 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.975 -0.631 . . . . 62.21 113.341 172.668 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -105.1 32.91 3.91 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.25 0.548 . . . . 71.43 110.96 -174.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.561 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 28.4 mmm180 -113.19 144.03 43.38 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.759 -0.655 . . . . 74.21 109.351 178.67 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.1 mp0 -106.67 164.35 12.16 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.254 0.55 . . . . 74.41 111.696 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.56 HG13 ' HB2' ' A' ' 44' ' ' CYS . 35.3 m -129.15 152.5 37.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.349 -0.841 . . . . 54.31 110.105 -178.315 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.2 p -115.22 97.5 5.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.751 0.786 . . . . 73.23 109.922 171.312 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.0 166.75 32.6 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-N 115.68 -0.691 . . . . 43.0 112.086 178.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -74.53 65.57 5.6 Favored 'Trans proline' 0 CA--C 1.531 0.346 0 C-N-CA 122.326 2.017 . . . . 70.42 110.676 169.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.623 ' HB2' ' H ' ' A' ' 42' ' ' TYR . 16.0 pttp -77.8 89.47 4.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.297 -0.865 . . . . 72.35 111.605 -174.445 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -160.44 129.44 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.611 -0.722 . . . . 74.12 110.288 176.593 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.692 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 25.8 mmt180 -129.98 136.37 49.36 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.097 -0.501 . . . . 73.32 110.131 177.283 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.42 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 37.2 ttmt -123.36 124.42 42.9 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.193 -0.669 . . . . 71.3 109.193 174.166 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.3 t -67.41 137.5 55.97 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.148 -0.478 . . . . 74.1 110.703 -177.756 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 93.6 mt -103.46 -179.05 3.84 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.0 -0.546 . . . . 75.32 110.868 -176.711 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.4 22.41 0.56 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.08 0.467 . . . . 34.01 111.183 178.458 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -139.07 171.8 13.77 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.194 -0.669 . . . . 74.35 109.194 178.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -79.23 52.4 4.04 Favored Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.995 -0.621 . . . . 74.22 113.664 -174.175 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 11.9 t -170.48 159.52 6.95 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.898 -0.408 . . . . 64.31 109.898 177.165 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.467 ' CD1' HD11 ' A' ' 10' ' ' ILE . 69.9 m95 -87.06 178.97 6.76 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.228 -0.442 . . . . 65.43 110.086 -178.328 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -57.76 -35.41 70.71 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 112.622 0.601 . . . . 71.12 112.622 -176.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -149.72 144.55 26.15 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 110.193 -0.299 . . . . 71.12 110.193 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 63.3 mtt -136.39 76.56 1.6 Allowed 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.11 -0.636 . . . . 72.34 109.943 163.036 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -169.88 89.29 0.17 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.133 -0.94 . . . . 63.14 108.613 163.032 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.445 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 10.5 m -144.56 113.51 5.1 Favored Pre-proline 0 C--N 1.314 -0.946 0 C-N-CA 120.302 -0.559 . . . . 74.33 110.731 -175.681 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 4.3 Cg_exo -77.23 59.77 6.72 Favored 'Trans proline' 0 N--CA 1.463 -0.29 0 C-N-CA 123.415 2.743 . . . . 64.14 112.489 -178.241 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.9 p -70.37 98.83 1.47 Allowed 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.367 -0.605 . . . . 73.3 109.367 175.057 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 72' ' ' ARG . 5.0 ptp180 -101.69 141.34 34.7 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.635 -0.711 . . . . 75.3 111.679 -172.674 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 58.9 m -75.61 115.37 15.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.316 -0.856 . . . . 74.22 109.977 178.567 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.6 p -149.6 128.44 3.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.124 0.488 . . . . 70.53 110.095 -178.572 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.335 -0.841 . . . . 74.41 110.162 -177.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.638 0 N-CA-C 111.92 -0.472 . . . . 72.35 111.92 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -68.29 92.86 0.4 Allowed 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.877 2.384 . . . . 72.1 111.712 178.131 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 6.9 p -96.17 143.12 27.57 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.933 -0.576 . . . . 75.23 111.233 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 20.2 m -146.25 98.79 3.14 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.386 -0.598 . . . . 74.12 109.386 175.34 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -88.87 114.6 25.67 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.862 -0.608 . . . . 74.03 110.044 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -148.42 -179.82 24.68 Favored Glycine 0 N--CA 1.44 -1.058 0 CA-C-N 115.527 -0.76 . . . . 52.24 111.432 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.0 m -97.47 136.12 38.35 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 110.122 -0.325 . . . . 72.14 110.122 -179.033 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -72.82 177.57 4.76 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.228 0.537 . . . . 64.22 111.464 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.572 HD11 ' HB ' ' A' ' 31' ' ' ILE . 52.4 mt -88.29 116.39 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-N 115.728 -0.669 . . . . 73.43 110.172 177.179 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 41.5 mt -69.65 140.93 17.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.395 -0.82 . . . . 53.14 109.861 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 23.4 m170 -73.55 137.37 77.56 Favored Pre-proline 0 C--N 1.323 -0.544 0 N-CA-C 109.503 -0.554 . . . . 73.31 109.503 175.563 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -57.12 117.48 4.18 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.544 2.162 . . . . 62.52 111.57 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.465 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 83.9 Cg_endo -78.23 -146.22 0.03 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.809 2.339 . . . . 72.42 111.748 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.465 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 67.9 t-105 -56.56 148.56 19.33 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.74 -0.467 . . . . 72.24 109.74 177.466 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 33.9 mm-40 -44.2 101.31 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.793 1.034 . . . . 74.13 113.793 -172.308 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.97 -120.91 0.79 Allowed Glycine 0 N--CA 1.442 -0.908 0 CA-C-N 114.283 -1.326 . . . . 71.54 110.131 174.382 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 179.86 -171.85 43.41 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.781 -0.723 . . . . 73.45 111.644 173.387 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 mt -142.28 129.35 19.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.549 0.69 . . . . 70.34 110.929 177.615 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.742 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 5.8 tpt180 -102.09 140.67 36.07 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.821 -1.082 . . . . 74.22 108.687 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.52 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 88.7 m-85 -107.15 -173.51 2.31 Favored 'General case' 0 C--N 1.319 -0.758 0 C-N-CA 120.077 -0.649 . . . . 74.35 110.263 -178.335 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -132.89 -14.89 2.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.129 0.49 . . . . 74.3 110.521 -175.106 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -145.82 27.14 1.77 Allowed Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 111.568 -0.613 . . . . 71.12 111.568 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 89.3 mt -143.54 132.82 23.22 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.683 0.278 . . . . 52.44 110.281 -178.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.9 t -91.45 -178.55 5.14 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.008 -0.542 . . . . 75.32 109.999 177.062 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 66.5 mtm180 -73.05 -174.14 1.45 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.901 0.382 . . . . 73.32 111.843 -175.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.6 t70 51.29 33.01 9.03 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.665 0.745 . . . . 54.04 111.474 -177.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 81.6 mt-30 -132.59 -164.62 1.49 Allowed 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.091 -0.504 . . . . 70.15 110.386 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.509 HG12 HD12 ' A' ' 31' ' ' ILE . 32.3 m 48.76 36.57 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 O-C-N 124.251 0.97 . . . . 75.0 112.384 177.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -78.8 -39.91 34.43 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.378 0.608 . . . . 71.12 109.413 177.235 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.07 89.01 1.49 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.49 -0.777 . . . . 75.11 110.644 176.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.572 ' HB ' HD11 ' A' ' 9' ' ' ILE . 52.1 mt -120.62 136.16 58.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.93 -0.767 . . . . 74.23 108.93 175.462 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -79.73 -49.27 12.31 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.753 0.311 . . . . 73.04 110.921 -175.146 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -139.37 138.03 36.23 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.186 -0.461 . . . . 71.25 111.275 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -85.96 138.5 35.0 Favored Pre-proline 0 C--N 1.321 -0.631 0 N-CA-C 108.717 -0.845 . . . . 73.11 108.717 170.398 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.29 145.46 97.75 Favored 'Trans proline' 0 CA--C 1.529 0.25 0 C-N-CA 122.677 2.252 . . . . 63.24 112.822 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.453 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 7.4 p -62.68 145.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.988 -0.551 . . . . 72.31 110.34 177.104 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.453 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 35.3 t70 79.18 3.44 2.34 Favored 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.776 0.672 . . . . 75.53 110.864 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.52 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 47.3 t80 -79.17 148.69 32.2 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.003 -0.369 . . . . 74.11 110.003 175.902 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.433 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 26.2 mt-10 -124.16 144.25 50.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.314 -0.403 . . . . 72.52 110.884 -176.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.619 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 25.4 pt -136.54 153.93 31.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-N 116.342 -0.39 . . . . 75.11 110.634 174.153 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.742 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.6 tt0 -116.67 155.68 28.4 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.948 -0.569 . . . . 74.33 110.179 -178.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.485 ' HE2' ' CG ' ' A' ' 56' ' ' ARG . 34.2 m-85 -104.81 101.1 10.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.595 0.236 . . . . 75.13 110.818 176.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.501 HG13 ' HB2' ' A' ' 19' ' ' ARG . 26.8 m -90.91 170.37 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 109.8 -0.444 . . . . 43.53 109.8 176.693 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.528 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 7.3 t -100.39 173.11 6.74 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.27 -0.641 . . . . 51.42 109.27 178.797 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 15.4 mmt180 -59.88 116.12 3.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.111 0.482 . . . . 71.44 110.769 178.545 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.21 -132.71 11.33 Favored Glycine 0 N--CA 1.446 -0.645 0 CA-C-N 115.723 -0.671 . . . . 62.21 111.996 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -114.88 34.88 4.56 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.14 0.495 . . . . 71.43 111.237 -177.374 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.528 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 15.0 mmm180 -89.65 120.15 30.68 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.768 -0.651 . . . . 74.21 109.371 177.2 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -78.86 147.48 33.14 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.161 0.505 . . . . 74.41 110.311 -178.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.42 HG12 ' HA ' ' A' ' 73' ' ' CYS . 21.6 m -115.24 145.95 20.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.064 -0.516 . . . . 54.31 110.824 -178.693 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 51' ' ' VAL . 4.5 p -104.8 96.26 4.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 122.017 0.913 . . . . 73.23 109.333 171.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.84 171.82 33.2 Favored Glycine 0 N--CA 1.441 -1.0 0 CA-C-N 115.225 -0.898 . . . . 43.0 111.748 -177.273 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.573 ' HG2' HG21 ' A' ' 69' ' ' THR . 64.3 Cg_endo -74.66 56.45 4.05 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.757 2.305 . . . . 70.42 110.329 171.083 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.449 ' HD2' ' CG ' ' A' ' 41' ' ' GLU . 43.7 pttt -77.83 86.2 4.08 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.32 -0.855 . . . . 72.35 111.717 -172.292 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -162.47 128.39 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.264 -0.88 . . . . 74.12 109.928 172.216 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.619 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 24.5 mmt180 -117.85 119.63 35.44 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 108.91 -0.774 . . . . 73.32 108.91 174.439 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.407 ' HB3' ' CG2' ' A' ' 65' ' ' THR . 37.2 ttmt -104.62 120.6 41.69 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.455 -0.572 . . . . 71.3 109.455 178.61 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 16.5 t -78.54 133.19 37.38 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.923 0.392 . . . . 74.1 109.995 -179.386 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 85.4 mt -117.05 -178.61 3.48 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.013 -0.539 . . . . 75.32 110.85 -173.604 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.26 -9.29 58.72 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.127 0.489 . . . . 34.01 110.518 178.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -94.44 151.64 19.22 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.214 -0.661 . . . . 74.35 109.214 172.691 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -77.27 54.02 3.54 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 121.09 -0.576 . . . . 74.22 113.762 -173.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 67.4 p -166.98 154.02 8.8 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.403 -0.592 . . . . 64.31 109.403 177.405 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.538 ' HB2' ' HB3' ' A' ' 67' ' ' MET . 84.3 m95 -75.02 165.83 24.63 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.802 -0.444 . . . . 65.43 109.802 178.542 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.407 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 0.9 OUTLIER -50.57 -42.78 55.95 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 113.052 0.76 . . . . 71.12 113.052 -176.915 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -157.93 74.88 0.74 Allowed 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.574 -0.528 . . . . 71.12 109.574 177.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' MET . . . . . 0.538 ' HB3' ' HB2' ' A' ' 64' ' ' TRP . 22.3 ptt? -88.7 80.24 7.3 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 118.837 -1.145 . . . . 72.34 111.497 -173.496 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -167.96 88.95 0.27 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.271 -1.331 . . . . 63.14 107.757 163.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.573 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.2 OUTLIER -158.43 115.77 1.74 Allowed Pre-proline 0 C--N 1.317 -0.846 0 C-N-CA 120.461 -0.496 . . . . 74.33 111.221 -169.35 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -81.52 124.91 4.84 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.497 2.131 . . . . 64.14 111.807 174.364 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 12.6 p -81.01 133.29 35.46 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.992 0.425 . . . . 73.3 110.085 177.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 38.3 mtp180 -96.34 99.26 10.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.312 -0.404 . . . . 75.3 111.364 -171.353 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.42 ' HA ' HG12 ' A' ' 50' ' ' VAL . 8.7 m -69.12 101.98 1.56 Allowed 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.799 -0.445 . . . . 74.22 109.799 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 94.7 t -136.41 120.15 23.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 121.026 0.441 . . . . 70.53 111.805 -173.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 67.8 mtt180 . . . . . 0 C--O 1.244 0.797 0 CA-C-N 115.627 -0.715 . . . . 74.41 109.694 170.892 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.822 0 N-CA-C 111.967 -0.453 . . . . 72.35 111.967 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -60.04 113.38 1.63 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.694 2.262 . . . . 72.1 111.55 176.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 23.3 p -108.97 138.11 45.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.991 0.424 . . . . 75.23 111.598 -176.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.1 m -105.74 99.49 9.09 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.882 -0.784 . . . . 74.12 108.882 172.487 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -95.58 109.09 21.38 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.176 0.512 . . . . 74.03 110.949 -174.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.517 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -161.21 -179.6 36.04 Favored Glycine 0 N--CA 1.443 -0.899 0 CA-C-N 115.299 -0.864 . . . . 52.24 111.323 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 15.0 m -99.12 145.1 27.52 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 109.912 -0.403 . . . . 72.14 109.912 178.182 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -88.36 -177.82 5.74 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.668 0.271 . . . . 64.22 110.522 179.53 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.0 mt -87.95 123.78 40.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.16 0.505 . . . . 73.43 110.041 178.075 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.449 HD11 ' CD1' ' A' ' 64' ' ' TRP . 9.8 mt -79.93 150.53 4.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.782 -0.645 . . . . 53.14 110.347 -178.347 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 16.2 p80 -62.54 141.07 96.81 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 109.525 -0.546 . . . . 73.31 109.525 172.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.45 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 23.5 Cg_exo -64.8 149.47 89.58 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.459 2.106 . . . . 62.52 111.715 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.461 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 3.0 Cg_exo -76.88 -132.04 0.01 OUTLIER 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.979 2.453 . . . . 72.42 110.998 174.549 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.461 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 3.8 t-105 -75.38 -179.57 4.61 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.433 -0.58 . . . . 72.24 109.433 176.581 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -43.95 101.05 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 112.742 0.645 . . . . 74.13 112.742 -176.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 174.74 -143.71 7.0 Favored Glycine 0 N--CA 1.441 -1.028 0 N-CA-C 110.869 -0.893 . . . . 71.54 110.869 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.74 -169.97 35.94 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.655 -0.783 . . . . 73.45 112.174 177.54 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.2 mt -118.81 125.39 74.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 121.364 0.602 . . . . 70.34 110.891 179.175 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.3 tpt180 -99.79 114.27 27.31 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.129 -0.941 . . . . 74.22 109.077 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.499 ' HA ' HG22 ' A' ' 40' ' ' ILE . 88.6 m-85 -76.75 -172.4 2.24 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.588 -0.278 . . . . 74.35 110.905 -175.644 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -87.49 -40.61 14.17 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.15 0.5 . . . . 74.3 110.417 -174.281 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -152.94 60.01 0.4 Allowed Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.881 -0.676 . . . . 71.12 112.208 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.471 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 76.1 mt -135.03 128.98 33.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.121 0.486 . . . . 52.44 110.998 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.2 t -96.15 -176.4 3.66 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.373 -0.83 . . . . 75.32 110.296 176.462 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.498 ' C ' ' H ' ' A' ' 27' ' ' GLN . 22.1 mmt180 -60.7 -172.08 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 116.351 -0.386 . . . . 73.32 111.512 178.31 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.425 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 23.9 t70 69.4 -35.86 0.32 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.191 0.597 . . . . 54.04 111.447 -175.399 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.529 ' O ' HG22 ' A' ' 28' ' ' VAL . 83.6 mt-30 -90.48 -169.08 2.28 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.806 -0.634 . . . . 70.15 111.067 -178.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.8 m 59.45 11.88 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 125.073 1.349 . . . . 75.0 112.754 173.685 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.403 ' HG2' ' H ' ' A' ' 29' ' ' LYS . 36.3 pttt -77.87 -27.64 49.76 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.28 0.562 . . . . 71.12 110.341 176.713 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.13 91.16 0.46 Allowed 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.442 -0.799 . . . . 75.11 110.339 177.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 57.9 mt -109.94 125.84 67.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 108.973 -0.751 . . . . 74.23 108.973 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -79.67 -46.45 17.11 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.138 -0.483 . . . . 73.04 110.187 -175.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.517 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 95.7 m-85 -146.47 121.31 9.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.992 -0.549 . . . . 71.25 111.127 -178.51 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -78.57 151.91 77.69 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.191 -0.459 . . . . 73.11 109.834 173.297 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -64.82 160.35 41.24 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.618 2.212 . . . . 63.24 112.449 177.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 14.3 p -71.06 145.94 12.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.334 -0.394 . . . . 72.31 110.938 -177.493 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 38.3 t70 69.93 9.61 7.17 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 123.65 0.78 . . . . 75.53 111.245 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.471 ' OH ' ' HG ' ' A' ' 23' ' ' LEU . 25.3 t80 -72.03 139.32 48.47 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 108.719 -0.845 . . . . 74.11 108.719 174.507 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.606 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.9 mt-10 -126.38 154.66 43.27 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.805 0.336 . . . . 72.52 111.007 -175.46 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.499 HG22 ' HA ' ' A' ' 20' ' ' TYR . 24.3 pt -133.7 162.72 39.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.418 0 CA-C-N 116.06 -0.518 . . . . 75.11 111.776 -177.156 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.453 ' HG3' ' HD2' ' A' ' 54' ' ' LYS . 78.1 tt0 -122.37 149.08 44.28 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.518 -0.765 . . . . 74.33 110.14 177.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -95.5 102.5 14.31 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.201 -0.454 . . . . 75.13 110.152 177.214 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 16.8 m -101.18 144.1 13.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.903 0.382 . . . . 43.53 111.013 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.438 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 28.9 t -91.46 176.74 6.44 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.264 -0.643 . . . . 51.42 109.264 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.95 129.68 41.44 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.63 0.252 . . . . 71.44 111.492 -178.78 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 62.84 -131.71 43.29 Favored Glycine 0 N--CA 1.45 -0.427 0 CA-C-N 115.855 -0.611 . . . . 62.21 112.237 178.501 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -98.5 83.81 3.08 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.739 0.78 . . . . 71.43 110.4 176.27 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.642 HH11 ' HB3' ' A' ' 75' ' ' ARG . 30.2 mmt180 -145.2 132.52 20.62 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.182 -0.917 . . . . 74.21 109.943 178.307 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.2 mp0 -102.21 152.53 20.93 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.049 -0.523 . . . . 74.41 110.548 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.577 HG12 ' HA ' ' A' ' 73' ' ' CYS . 34.7 m -114.58 120.52 64.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.68 -0.691 . . . . 54.31 109.257 171.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.418 ' O ' HG13 ' A' ' 51' ' ' VAL . 6.3 p -83.71 94.24 3.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 122.503 1.144 . . . . 73.23 109.617 178.16 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.22 172.53 33.47 Favored Glycine 0 N--CA 1.441 -0.991 0 CA-C-N 114.34 -1.3 . . . . 43.0 110.764 -177.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -73.3 58.59 3.68 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.225 1.95 . . . . 70.42 110.646 173.239 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.453 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 42.3 pttt -78.09 85.6 4.29 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-O 121.691 0.758 . . . . 72.35 111.46 -174.453 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.48 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 6.1 p -162.68 128.61 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.227 -0.897 . . . . 74.12 109.015 171.653 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.606 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 20.4 mmt180 -130.6 124.42 31.71 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.591 -0.522 . . . . 73.32 109.591 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.475 ' O ' HG23 ' A' ' 65' ' ' THR . 23.7 ttmm -99.68 131.52 45.61 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.875 -0.417 . . . . 71.3 109.875 178.761 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 48.1 t -80.2 137.64 36.71 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 109.638 -0.504 . . . . 74.1 109.638 176.206 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 89.0 mt -115.25 -178.96 3.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.41 -0.359 . . . . 75.32 110.322 -178.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -66.42 -27.48 67.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.133 0.492 . . . . 34.01 110.61 178.148 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -79.55 150.92 30.96 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.457 -0.571 . . . . 74.35 109.457 174.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -75.6 66.03 2.41 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 121.033 -0.603 . . . . 74.22 113.528 -175.571 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 13.8 t -174.19 149.09 1.38 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.674 -0.491 . . . . 64.31 109.674 175.618 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.449 ' CD1' HD11 ' A' ' 10' ' ' ILE . 64.9 m95 -77.27 157.4 30.8 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.199 -0.667 . . . . 65.43 109.199 177.313 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.475 HG23 ' O ' ' A' ' 57' ' ' LYS . 16.0 p -50.71 -46.72 59.09 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 113.319 0.859 . . . . 71.12 113.319 -173.689 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -128.52 118.17 22.57 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.704 -0.226 . . . . 71.12 110.495 -173.623 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 55.5 mtt -125.76 78.31 1.73 Allowed 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 119.346 -0.941 . . . . 72.34 110.741 168.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -170.26 89.05 0.15 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.618 -0.719 . . . . 63.14 109.143 163.243 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 60.3 m -160.29 107.88 1.38 Allowed Pre-proline 0 C--N 1.321 -0.645 0 CA-C-O 120.874 0.368 . . . . 74.33 111.463 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -76.92 91.92 1.14 Allowed 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.175 1.917 . . . . 64.14 110.943 170.522 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 16.8 p -70.42 110.9 5.6 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.803 -0.635 . . . . 73.3 110.577 -177.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 21.4 ptt-85 -79.26 119.21 22.01 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.381 0.61 . . . . 75.3 111.137 -176.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.577 ' HA ' HG12 ' A' ' 50' ' ' VAL . 42.5 t -80.37 110.14 15.53 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.363 -0.835 . . . . 74.22 109.502 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.7 p -155.98 130.45 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.375 0.607 . . . . 70.53 111.521 -174.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.642 ' HB3' HH11 ' A' ' 48' ' ' ARG . 22.3 ttm180 . . . . . 0 C--O 1.247 0.934 0 CA-C-N 115.601 -0.727 . . . . 74.41 109.095 175.53 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.753 0 N-CA-C 111.861 -0.496 . . . . 72.35 111.861 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -78.96 33.55 0.49 Allowed 'Trans proline' 0 CA--C 1.531 0.342 0 C-N-CA 123.085 2.523 . . . . 72.1 113.094 -178.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 2.5 p -79.47 162.3 25.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.63 -0.259 . . . . 75.23 110.713 178.284 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.4 m -124.54 98.99 5.97 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.205 0.526 . . . . 74.12 111.602 -175.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -118.86 100.23 7.25 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.674 -0.694 . . . . 74.03 109.339 173.636 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.74 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -158.89 147.33 14.74 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.039 -1.077 . . . . 52.24 113.231 -177.504 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.6 m -83.47 157.8 22.28 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.87 -0.418 . . . . 72.14 109.87 176.108 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -84.85 -178.23 6.79 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.124 0.488 . . . . 64.22 111.265 179.753 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.66 HD11 ' H ' ' A' ' 31' ' ' ILE . 56.5 mt -87.05 117.05 30.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.617 -0.72 . . . . 73.43 109.371 174.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.9 pt -90.18 149.23 4.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.528 -0.76 . . . . 53.14 110.665 -178.379 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' HIS . . . . . 0.431 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 19.9 m-70 -88.32 143.47 32.61 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 116.246 -0.434 . . . . 73.31 111.24 -175.211 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 16.7 Cg_exo -67.82 135.06 34.22 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 123.053 2.502 . . . . 62.52 111.963 178.056 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 82.4 Cg_endo -88.07 -150.22 0.04 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 123.002 2.468 . . . . 72.42 112.475 179.525 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.0 t-105 -63.48 -177.59 0.22 Allowed 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 115.812 -0.631 . . . . 72.24 110.697 178.058 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -38.82 100.33 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 123.876 0.87 . . . . 74.13 112.928 -173.065 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.85 -172.43 43.75 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 114.989 -1.005 . . . . 71.54 110.722 -178.291 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -156.91 -171.12 22.64 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.747 -0.74 . . . . 73.45 112.07 179.183 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.3 mt -129.7 137.37 56.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.381 0.61 . . . . 70.34 111.24 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.417 HH11 ' HD2' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -117.08 119.14 34.34 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.164 -0.925 . . . . 74.22 109.776 -177.612 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.424 ' HA ' HG22 ' A' ' 40' ' ' ILE . 95.0 m-85 -84.69 -171.7 3.78 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.749 0.309 . . . . 74.35 110.623 -178.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.1 ttm180 -93.26 -55.85 3.16 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.985 0.421 . . . . 74.3 109.993 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -144.89 67.74 0.42 Allowed Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.753 -0.737 . . . . 71.12 112.325 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 76.5 mt -139.07 118.33 12.72 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.995 -0.372 . . . . 52.44 109.995 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.2 t -81.0 178.9 8.13 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.297 -0.41 . . . . 75.32 110.189 178.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.429 ' C ' ' H ' ' A' ' 27' ' ' GLN . 95.2 mtt180 -78.09 -171.92 2.54 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 120.491 0.186 . . . . 73.32 111.343 -175.396 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.402 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 11.6 t70 67.38 -42.79 0.44 Allowed 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 123.305 0.642 . . . . 54.04 110.885 -168.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' HG22 ' A' ' 28' ' ' VAL . 95.7 mt-30 -70.57 -170.34 0.4 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.217 -0.447 . . . . 70.15 110.137 173.48 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.9 m 57.9 9.38 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.272 1.029 . . . . 75.0 112.134 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 52.7 pttt -83.49 -19.98 34.8 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.789 -0.819 . . . . 71.12 108.789 172.16 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.14 102.05 2.11 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 114.885 -1.052 . . . . 75.11 110.026 177.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.66 ' H ' HD11 ' A' ' 9' ' ' ILE . 57.3 mt -120.83 144.72 28.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 109.031 -0.729 . . . . 74.23 109.031 176.717 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -88.69 -65.61 1.0 Allowed 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.94 -0.393 . . . . 73.04 109.94 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.74 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 56.0 m-85 -143.42 140.84 30.61 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.239 -0.437 . . . . 71.25 110.487 177.448 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.463 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.7 mm? -82.82 132.23 52.01 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 109.331 -0.618 . . . . 73.11 109.331 174.013 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -58.24 139.34 90.14 Favored 'Trans proline' 0 C--O 1.236 0.382 0 C-N-CA 122.615 2.21 . . . . 63.24 112.227 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 p -67.3 84.59 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 CA-C-O 121.905 0.86 . . . . 72.31 111.272 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.6 t70 165.59 -30.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.179 -1.373 . . . . 75.53 108.925 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.405 ' HH ' ' HB3' ' A' ' 20' ' ' TYR . 9.3 t80 -57.22 138.18 55.0 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.895 -1.048 . . . . 74.11 111.277 -174.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.51 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 18.9 mt-10 -122.54 139.38 53.96 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.511 -0.768 . . . . 72.52 110.39 -176.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.493 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 35.5 pt -128.17 156.95 40.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.354 -0.384 . . . . 75.11 110.856 178.536 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -119.83 151.58 38.62 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.016 -0.538 . . . . 74.33 110.508 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -99.05 102.47 14.19 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.072 -0.513 . . . . 75.13 111.052 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.4 m -96.82 163.82 2.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 N-CA-C 110.028 -0.36 . . . . 43.53 110.028 175.342 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.574 ' HB2' HG13 ' A' ' 50' ' ' VAL . 31.5 t -89.68 175.11 7.38 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.457 -0.572 . . . . 51.42 109.457 178.127 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.66 119.2 19.37 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.95 0.405 . . . . 71.44 110.797 -174.5 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.06 -100.27 2.65 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.846 -0.616 . . . . 62.21 112.863 174.422 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -133.81 21.8 3.88 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.987 0.422 . . . . 71.43 111.233 -174.077 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.562 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 11.4 mmt180 -96.35 142.88 27.95 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.168 -0.469 . . . . 74.21 110.972 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.824 ' HB2' ' HD2' ' A' ' 75' ' ' ARG . 2.2 mp0 -94.37 153.78 17.81 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.125 -0.489 . . . . 74.41 110.867 177.071 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.574 HG13 ' HB2' ' A' ' 44' ' ' CYS . 28.0 m -118.49 151.31 20.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.688 -0.687 . . . . 54.31 109.882 176.841 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.9 p -114.9 96.19 4.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.913 0.863 . . . . 73.23 110.008 173.215 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.11 170.91 33.31 Favored Glycine 0 N--CA 1.445 -0.711 0 CA-C-N 115.2 -0.909 . . . . 43.0 111.602 179.321 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -73.59 60.01 4.17 Favored 'Trans proline' 0 CA--C 1.531 0.353 0 C-N-CA 122.482 2.121 . . . . 70.42 110.88 170.449 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 44.3 pttt -77.23 89.44 3.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.583 -0.735 . . . . 72.35 112.392 -171.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.9 p -160.8 135.11 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.892 -0.595 . . . . 74.12 109.605 171.343 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.51 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 24.6 mmt180 -131.12 120.8 23.88 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.41 -0.359 . . . . 73.32 110.537 177.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.464 ' HB3' ' CG2' ' A' ' 65' ' ' THR . 39.4 ttmt -102.73 129.63 49.42 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 109.094 -0.706 . . . . 71.3 109.094 174.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 45.6 t -67.92 143.51 55.64 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.469 -0.332 . . . . 74.1 110.327 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.451 HD11 ' HA ' ' A' ' 65' ' ' THR . 88.6 mt -110.89 -178.38 3.46 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.369 -0.378 . . . . 75.32 110.615 -176.56 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -79.82 14.56 1.7 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.974 0.416 . . . . 34.01 111.161 178.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -141.44 -178.62 5.71 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.772 -0.649 . . . . 74.35 109.62 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -66.04 -29.68 75.47 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 114.771 0.668 . . . . 74.22 114.771 -171.252 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 78.5 p -93.23 163.27 13.68 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.473 0.636 . . . . 64.31 111.458 -175.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -92.89 -179.86 5.25 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.877 -0.601 . . . . 65.43 110.005 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.464 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 3.2 p -49.59 -69.72 0.11 Allowed 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 113.558 0.947 . . . . 71.12 113.558 -174.169 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -133.21 48.59 2.38 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.649 -0.501 . . . . 71.12 109.649 -177.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 28.0 ttt -80.65 81.92 6.78 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.382 -0.927 . . . . 72.34 111.831 -170.655 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -166.65 87.6 0.32 Allowed 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 106.72 -1.585 . . . . 63.14 106.72 158.196 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.404 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 1.5 m -157.79 113.41 1.81 Allowed Pre-proline 0 C--N 1.316 -0.889 0 CA-C-N 116.284 -0.416 . . . . 74.33 110.051 -168.891 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 16.8 Cg_exo -66.68 97.6 0.39 Allowed 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.61 2.206 . . . . 64.14 112.164 179.169 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.1 p -78.73 101.63 7.66 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.212 -0.662 . . . . 73.3 109.212 173.18 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -78.94 126.58 30.88 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.315 0.579 . . . . 75.3 111.091 -171.529 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.556 ' HA ' HG12 ' A' ' 50' ' ' VAL . 41.8 t -82.03 98.74 8.77 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.499 -0.773 . . . . 74.22 109.865 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.3 p -176.98 152.44 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.992 -0.744 . . . . 70.53 108.992 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.824 ' HD2' ' HB2' ' A' ' 49' ' ' GLU . 2.5 ptm180 . . . . . 0 C--O 1.245 0.859 0 CA-C-O 119.168 -0.444 . . . . 74.41 110.367 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.668 0 N-CA-C 111.23 -0.748 . . . . 72.35 111.23 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -61.65 141.83 92.32 Favored 'Trans proline' 0 N--CA 1.462 -0.357 0 C-N-CA 122.296 1.997 . . . . 72.1 111.1 177.289 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 52.5 p -78.57 99.45 6.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.102 0.477 . . . . 75.23 110.544 -179.556 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.4 m -101.23 116.56 33.08 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.758 -0.656 . . . . 74.12 110.209 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLU . . . . . 0.465 ' CD ' ' H ' ' A' ' 5' ' ' GLU . 0.9 OUTLIER -70.03 107.57 3.68 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.833 -0.803 . . . . 74.03 108.833 175.863 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.822 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -157.63 126.28 1.7 Allowed Glycine 0 N--CA 1.443 -0.847 0 C-N-CA 120.288 -0.958 . . . . 52.24 113.035 -176.191 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 64.8 m -90.59 152.32 20.94 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.546 -0.539 . . . . 72.14 109.546 175.589 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 -81.77 -178.02 6.81 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.916 0.389 . . . . 64.22 111.233 -178.413 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.598 HD11 ' HB ' ' A' ' 31' ' ' ILE . 46.2 mt -87.39 121.6 38.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.873 -0.603 . . . . 73.43 110.691 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 56.9 mt -73.86 114.21 13.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.03 -0.532 . . . . 53.14 109.581 175.051 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 31.9 m-70 -75.44 129.08 82.95 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 110.09 -0.337 . . . . 73.31 110.09 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.511 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 7.3 Cg_endo -49.19 118.77 3.83 Favored 'Trans proline' 0 C--N 1.349 0.556 0 C-N-CA 123.447 2.765 . . . . 62.52 112.429 -177.222 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.511 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 4.0 Cg_exo -76.38 -84.03 0.0 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 122.996 2.464 . . . . 72.42 112.325 -177.747 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.7 t-105 -100.93 -178.36 3.73 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.228 -0.442 . . . . 72.24 109.925 -177.786 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -47.68 102.31 0.03 OUTLIER 'General case' 0 C--O 1.234 0.275 0 O-C-N 123.791 0.682 . . . . 74.13 112.242 177.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.07 -157.14 28.97 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.352 -0.84 . . . . 71.54 111.099 -179.211 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -161.13 -171.08 26.63 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 111.338 -0.705 . . . . 73.45 111.338 177.138 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.5 mt -127.77 129.43 70.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.669 0.747 . . . . 70.34 111.363 -179.526 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.895 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 5.1 tpt180 -93.62 132.75 37.64 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 114.438 -1.256 . . . . 74.22 109.486 -179.021 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.515 ' HB3' ' HH ' ' A' ' 38' ' ' TYR . 97.1 m-85 -106.55 -171.28 1.86 Allowed 'General case' 0 C--N 1.32 -0.678 0 C-N-CA 120.845 -0.342 . . . . 74.35 110.735 -178.032 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.411 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 19.1 ttt-85 -114.68 -51.69 2.73 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.944 0.402 . . . . 74.3 110.264 -174.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -136.83 30.57 2.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 71.12 112.807 -177.328 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 80.3 mt -109.72 129.7 55.59 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 122.595 -0.356 . . . . 52.44 110.255 177.544 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.4 t -80.33 -179.81 7.31 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.112 -0.495 . . . . 75.32 110.1 178.459 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.404 ' C ' ' H ' ' A' ' 27' ' ' GLN . 38.3 ptt180 -73.48 -174.16 1.6 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.325 -0.398 . . . . 73.32 110.752 -178.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 21.8 t70 67.32 -44.5 0.46 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.859 0.864 . . . . 54.04 111.619 -177.171 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.637 ' O ' HG22 ' A' ' 28' ' ' VAL . 94.0 mt-30 -68.03 -163.62 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 122.896 0.478 . . . . 70.15 111.554 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.637 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.0 m 61.11 13.93 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 124.538 1.135 . . . . 75.0 111.347 -177.816 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -90.99 -29.02 17.63 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.342 -0.614 . . . . 71.12 109.342 176.284 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.65 89.68 1.27 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.714 -0.676 . . . . 75.11 111.003 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.598 ' HB ' HD11 ' A' ' 9' ' ' ILE . 57.3 mt -126.66 134.28 66.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 108.818 -0.808 . . . . 74.23 108.818 175.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -77.54 -56.42 4.54 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.815 0.34 . . . . 73.04 111.043 -177.093 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.822 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 65.9 m-85 -136.33 145.61 45.63 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.082 0.467 . . . . 71.25 111.375 -175.414 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.594 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.7 mm? -103.8 139.11 19.8 Favored Pre-proline 0 C--N 1.323 -0.564 0 N-CA-C 108.993 -0.743 . . . . 73.11 108.993 170.223 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -58.89 159.76 20.28 Favored 'Trans proline' 0 N--CA 1.476 0.5 0 C-N-CA 123.203 2.602 . . . . 63.24 113.315 -176.426 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.4 ' HB ' ' HB2' ' A' ' 5' ' ' GLU . 9.9 p -71.64 2.75 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 CA-C-O 121.648 0.737 . . . . 72.31 111.473 -176.7 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -134.4 92.78 2.97 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.093 0.473 . . . . 75.53 109.798 170.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.589 ' O ' ' HA ' ' A' ' 57' ' ' LYS . 20.2 t80 -157.18 135.02 10.86 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.633 -0.712 . . . . 74.11 109.301 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 38.9 mt-10 -113.4 130.29 56.33 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.242 0.339 . . . . 72.52 110.784 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.574 HG12 ' HB2' ' A' ' 56' ' ' ARG . 43.6 pt -121.68 158.09 25.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.369 -0.378 . . . . 75.11 110.89 175.583 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.895 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 41.3 tt0 -127.19 154.36 44.9 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.868 -0.605 . . . . 74.33 110.598 -177.692 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 65.3 m-85 -100.03 102.29 13.6 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.328 -0.396 . . . . 75.13 110.612 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.3 m -109.2 164.78 5.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.371 -0.377 . . . . 43.53 111.202 -178.696 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.512 ' HB2' ' HB2' ' A' ' 48' ' ' ARG . 86.3 m -110.85 179.32 4.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.1 -0.5 . . . . 51.42 110.388 177.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -76.92 102.36 6.35 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.071 0.463 . . . . 71.44 110.375 178.191 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.35 -166.81 25.76 Favored Glycine 0 N--CA 1.445 -0.704 0 N-CA-C 111.05 -0.82 . . . . 62.21 111.05 -176.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -82.59 77.66 9.32 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.526 0.679 . . . . 71.43 111.281 178.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.512 ' HB2' ' HB2' ' A' ' 44' ' ' CYS . 14.1 mtm-85 -127.87 118.34 23.46 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.754 -0.832 . . . . 74.21 108.754 176.463 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -88.2 154.11 20.7 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.064 -0.516 . . . . 74.41 111.099 -172.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.588 HG12 ' HA ' ' A' ' 73' ' ' CYS . 27.2 m -119.23 130.77 73.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.798 -0.637 . . . . 54.31 109.969 178.48 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.0 p -95.04 94.08 4.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-O 122.217 1.008 . . . . 73.23 109.857 175.686 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -157.26 170.9 34.51 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 114.223 -1.353 . . . . 43.0 110.514 177.098 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.514 ' HG2' HG21 ' A' ' 69' ' ' THR . 55.9 Cg_endo -75.19 77.88 3.08 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.621 1.547 . . . . 70.42 110.536 168.569 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.603 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 43.6 pttt -86.84 88.48 7.69 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.656 0.741 . . . . 72.35 111.048 -174.392 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.508 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 6.8 p -160.19 128.99 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.496 -0.775 . . . . 74.12 109.814 176.56 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.574 ' HB2' HG12 ' A' ' 40' ' ' ILE . 23.1 mmt180 -137.12 125.65 23.61 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.924 -0.58 . . . . 73.32 110.028 178.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 38' ' ' TYR . 35.4 ttmt -124.6 137.4 54.39 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 108.775 -0.824 . . . . 71.3 108.775 168.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.5 t -67.27 142.86 56.75 Favored 'General case' 0 C--N 1.323 -0.575 0 O-C-N 123.337 0.398 . . . . 74.1 110.279 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.9 mt -119.46 -178.1 3.52 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.141 -0.481 . . . . 75.32 110.228 -177.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.62 -4.98 43.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.066 0.46 . . . . 34.01 110.884 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -99.62 163.38 12.52 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.774 -0.648 . . . . 74.35 109.422 173.535 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -78.53 47.96 3.09 Favored Glycine 0 CA--C 1.521 0.449 0 C-N-CA 120.917 -0.659 . . . . 74.22 113.678 -174.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.0 t -165.9 170.55 13.64 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.259 -0.645 . . . . 64.31 109.259 178.067 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 61.1 m95 -87.44 178.12 6.91 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.836 -0.431 . . . . 65.43 109.836 -177.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.401 HG23 ' O ' ' A' ' 57' ' ' LYS . 2.9 p -49.86 -50.8 44.3 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 113.394 0.887 . . . . 71.12 113.394 -173.064 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -148.25 66.08 1.08 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.569 0.224 . . . . 71.12 110.445 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 60.1 ttp -87.1 79.83 8.53 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 118.921 -1.112 . . . . 72.34 110.934 -176.137 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -169.31 89.67 0.2 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.446 -1.252 . . . . 63.14 107.72 162.521 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.514 HG21 ' HG2' ' A' ' 53' ' ' PRO . 1.4 m -151.39 127.29 5.02 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 120.314 -0.554 . . . . 74.33 111.339 -170.354 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -78.61 93.95 1.08 Allowed 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.574 2.182 . . . . 64.14 112.159 175.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.9 p -92.9 114.61 27.22 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.081 -0.509 . . . . 73.3 110.782 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.7 ptp85 -94.28 128.67 40.9 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.056 -0.52 . . . . 75.3 111.045 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.588 ' HA ' HG12 ' A' ' 50' ' ' VAL . 18.2 t -89.44 112.2 23.28 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.001 -0.545 . . . . 74.22 109.748 179.513 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.97 115.03 14.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.478 -0.328 . . . . 70.53 111.168 -174.015 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.4 ' HA ' ' HD2' ' A' ' 75' ' ' ARG . 12.0 tpt180 . . . . . 0 C--O 1.244 0.795 0 CA-C-O 118.479 -0.772 . . . . 74.41 109.723 174.16 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.798 0 N-CA-C 111.809 -0.517 . . . . 72.35 111.809 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -78.62 113.82 3.37 Favored 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.911 2.407 . . . . 72.1 112.2 178.702 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 3.1 p -144.44 153.59 42.07 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.82 0.343 . . . . 75.23 110.845 178.653 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 28.1 m -149.07 104.48 3.43 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.683 -0.488 . . . . 74.12 109.683 177.415 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -76.19 105.41 7.22 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.106 -0.497 . . . . 74.03 109.795 -179.172 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.727 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -149.53 143.1 10.4 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.624 -0.798 . . . . 52.24 112.529 -178.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 69.2 m -92.47 151.83 20.0 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 110.213 -0.292 . . . . 72.14 110.213 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.452 ' H ' ' HG3' ' A' ' 8' ' ' GLN . 3.2 pp0? -87.15 -179.43 6.45 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.633 -0.258 . . . . 64.22 111.521 -177.683 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 40.4 mt -88.61 112.57 24.13 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.246 -0.434 . . . . 73.43 111.294 -171.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 38.7 mt -70.82 146.12 12.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.74 -0.663 . . . . 53.14 110.443 179.139 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' HIS . . . . . 0.43 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 72.2 m-70 -88.24 141.85 31.23 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 116.524 -0.307 . . . . 73.31 110.39 177.422 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 12.8 Cg_exo -71.4 122.08 8.32 Favored 'Trans proline' 0 CA--C 1.529 0.253 0 C-N-CA 122.934 2.423 . . . . 62.52 111.644 176.071 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 59.8 Cg_endo -91.19 -94.73 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 123.008 2.472 . . . . 72.42 112.782 -177.6 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -89.99 -176.0 4.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.088 -0.708 . . . . 72.24 109.088 178.132 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -57.48 -16.21 9.02 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 112.11 0.411 . . . . 74.13 112.11 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.38 91.41 0.3 Allowed Glycine 0 N--CA 1.448 -0.502 0 N-CA-C 110.648 -0.981 . . . . 71.54 110.648 167.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -91.16 -170.21 42.58 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 121.168 -0.539 . . . . 73.45 112.982 -173.543 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -115.55 136.23 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 CA-C-O 121.72 0.772 . . . . 70.34 112.083 -174.632 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.786 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 15.4 tpt180 -116.4 145.8 42.98 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.182 -1.372 . . . . 74.22 109.049 -178.047 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 68.6 m-85 -108.95 -172.89 2.14 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.805 -0.442 . . . . 74.35 109.805 178.771 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 25.6 mtm180 -98.41 -38.48 9.2 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.57 -0.452 . . . . 74.3 110.885 -178.646 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -160.56 52.95 0.34 Allowed Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.644 -0.789 . . . . 71.12 112.467 178.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 93.7 mt -116.73 115.94 26.57 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.942 0.401 . . . . 52.44 110.352 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.6 t -80.79 -179.2 7.16 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.656 -0.702 . . . . 75.32 110.307 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.5 ' C ' ' H ' ' A' ' 27' ' ' GLN . 39.5 mmt180 -67.4 -174.99 0.44 Allowed 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.684 0.278 . . . . 73.32 111.308 -176.045 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 23.4 t70 65.64 -34.26 0.19 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.638 0.775 . . . . 54.04 112.172 -175.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.5 ' H ' ' C ' ' A' ' 25' ' ' ARG . 95.7 mt-30 -80.89 -166.3 1.09 Allowed 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 122.542 0.337 . . . . 70.15 110.664 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 27' ' ' GLN . 5.8 m 52.89 18.5 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 124.548 1.139 . . . . 75.0 113.068 177.009 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 50.8 pttt -111.37 -21.85 11.62 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.808 0.337 . . . . 71.12 110.285 177.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.74 16.03 2.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.346 -0.388 . . . . 75.11 111.664 -178.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 60.8 mt -73.22 103.38 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 109.404 -0.591 . . . . 74.23 109.404 176.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -58.01 -50.07 74.66 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.145 -0.48 . . . . 73.04 112.184 -173.066 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.727 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 91.0 m-85 -133.31 128.54 35.96 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.818 0.342 . . . . 71.25 110.821 -177.24 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -83.23 126.87 70.93 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 108.485 -0.931 . . . . 73.11 108.485 171.474 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -51.24 145.46 26.77 Favored 'Trans proline' 0 C--O 1.234 0.283 0 C-N-CA 123.361 2.707 . . . . 63.24 112.92 -176.118 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 p -59.74 142.41 15.21 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 CA-C-N 115.792 -0.64 . . . . 72.31 110.99 -178.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.8 t70 78.75 -11.96 1.14 Allowed 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.238 -0.892 . . . . 75.53 111.947 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 47.3 t80 -67.05 120.31 13.46 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 108.877 -0.786 . . . . 74.11 108.877 176.228 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.477 ' HG2' ' HA ' ' A' ' 57' ' ' LYS . 43.6 mt-10 -104.77 146.84 28.4 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.131 -0.486 . . . . 72.52 110.836 -176.147 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.598 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 21.1 pt -120.2 155.56 23.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.824 -0.626 . . . . 75.11 110.415 177.748 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.786 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.4 tt0 -107.21 165.84 11.07 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.588 -0.733 . . . . 74.33 110.268 -174.57 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.441 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 5.2 m-85 -120.47 101.43 7.77 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.775 0.321 . . . . 75.13 110.838 178.048 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 20.3 m -103.01 168.15 2.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.139 -0.482 . . . . 43.53 110.429 178.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.598 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 28.3 t -90.57 140.76 29.44 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.472 -0.566 . . . . 51.42 109.472 178.52 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -59.12 117.12 4.36 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.818 -0.628 . . . . 71.44 110.218 -176.691 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 114.18 -112.91 2.92 Favored Glycine 0 N--CA 1.444 -0.808 0 N-CA-C 111.093 -0.803 . . . . 62.21 111.093 -176.051 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -149.77 65.76 0.99 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.347 0.594 . . . . 71.43 110.834 177.466 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.598 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 35.0 mmt180 -126.57 136.27 52.34 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.265 -0.425 . . . . 74.21 110.047 179.358 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.52 157.01 27.52 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.958 -0.386 . . . . 74.41 109.958 176.255 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.53 HG12 ' HB3' ' A' ' 73' ' ' CYS . 33.2 m -130.29 149.69 33.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.245 -0.434 . . . . 54.31 110.68 -177.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -116.34 95.47 3.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 122.298 1.047 . . . . 73.23 108.929 169.733 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.47 172.33 33.61 Favored Glycine 0 N--CA 1.444 -0.824 0 CA-C-N 114.496 -1.229 . . . . 43.0 111.173 -178.015 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.5 ' HG2' HG21 ' A' ' 69' ' ' THR . 69.3 Cg_endo -75.91 60.02 5.96 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.326 2.017 . . . . 70.42 110.782 173.098 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.602 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 40.0 pttt -71.65 88.93 0.98 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.452 -0.794 . . . . 72.35 111.328 -175.516 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -161.88 131.89 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 116.046 -0.525 . . . . 74.12 110.946 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.598 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 22.3 mmt180 -127.78 111.07 13.24 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.504 -0.924 . . . . 73.32 108.504 169.649 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.477 ' HA ' ' HG2' ' A' ' 39' ' ' GLU . 20.5 ttmm -97.99 122.39 41.05 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.954 -0.387 . . . . 71.3 109.954 -178.648 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 49.8 t -69.65 126.97 31.33 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.772 -0.455 . . . . 74.1 109.772 177.337 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 95.0 mt -97.03 -178.94 4.37 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.054 -0.521 . . . . 75.32 110.831 -175.158 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.29 -17.03 61.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 34.01 110.687 178.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.6 p30 -101.18 165.8 11.11 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.305 -0.628 . . . . 74.35 109.305 174.523 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.97 52.42 3.28 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 121.026 -0.607 . . . . 74.22 113.51 -174.038 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.8 m -157.5 157.7 34.35 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.523 -0.547 . . . . 64.31 109.523 177.001 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -88.27 173.51 8.73 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.603 -0.517 . . . . 65.43 109.603 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.425 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 3.0 p -57.73 -73.18 0.08 Allowed 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 112.27 0.47 . . . . 71.12 112.27 -177.536 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -125.31 121.13 33.09 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.215 -0.661 . . . . 71.12 109.215 178.695 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 62.3 mtm -120.45 79.6 1.5 Allowed 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 119.259 -0.976 . . . . 72.34 111.149 173.738 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -168.34 89.79 0.26 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 114.735 -1.121 . . . . 63.14 108.316 162.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.5 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.2 OUTLIER -159.02 102.23 1.58 Allowed Pre-proline 0 C--N 1.315 -0.932 0 C-N-CA 120.581 -0.448 . . . . 74.33 110.693 -171.814 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -75.33 105.17 2.03 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.359 2.039 . . . . 64.14 111.576 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 7.6 p -75.22 102.41 4.99 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.228 0.537 . . . . 73.3 110.852 -178.784 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.1 ptp180 -79.97 115.61 19.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.696 -0.684 . . . . 75.3 111.252 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.53 ' HB3' HG12 ' A' ' 50' ' ' VAL . 0.7 OUTLIER -87.25 99.04 11.67 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.984 -0.553 . . . . 74.22 110.689 174.761 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.7 p -115.53 129.13 72.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.611 -0.722 . . . . 70.53 109.54 176.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.637 -0.697 . . . . 74.41 109.875 -176.276 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.664 0 N-CA-C 111.441 -0.664 . . . . 72.35 111.441 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_exo -66.34 95.29 0.32 Allowed 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.825 2.35 . . . . 72.1 111.725 -179.441 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 7.5 p -96.22 129.88 43.42 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.044 -0.526 . . . . 75.23 111.242 -178.349 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.0 m -93.39 98.12 11.01 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.794 -0.817 . . . . 74.12 108.794 173.57 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -119.1 99.2 6.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.698 -0.683 . . . . 74.03 110.524 -174.144 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.468 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -161.74 165.54 35.74 Favored Glycine 0 N--CA 1.437 -1.235 0 CA-C-N 115.612 -0.722 . . . . 52.24 111.363 178.234 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 13.3 m -84.61 139.74 31.86 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 110.078 -0.341 . . . . 72.14 110.078 178.476 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -83.14 -178.67 7.18 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.204 0.526 . . . . 64.22 111.087 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.544 HD11 ' HB ' ' A' ' 31' ' ' ILE . 58.2 mt -87.43 105.04 14.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.809 -0.632 . . . . 73.43 109.366 178.087 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 20.8 pt -72.18 169.93 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 114.721 -1.127 . . . . 53.14 111.556 -177.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -69.39 135.79 88.72 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.009 -0.541 . . . . 73.31 109.745 173.576 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -59.78 143.99 99.53 Favored 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.117 1.878 . . . . 62.52 111.147 172.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.21 -160.05 0.09 OUTLIER 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.489 2.126 . . . . 72.42 112.441 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 14.9 t-105 -68.8 -175.94 0.76 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.969 -0.56 . . . . 72.24 109.787 177.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 66.9 mm-40 -37.86 100.53 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.553 0.741 . . . . 74.13 112.655 -172.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.532 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . 163.6 -132.39 2.72 Favored Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.322 -0.853 . . . . 71.54 111.643 -179.149 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -179.64 -166.2 34.93 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.495 -0.642 . . . . 73.45 111.495 178.491 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.3 mt -127.95 130.11 69.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.463 0.649 . . . . 70.34 111.189 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.741 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 23.2 tpt180 -96.64 135.3 38.75 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 114.759 -1.109 . . . . 74.22 109.255 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.588 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 98.0 m-85 -93.17 -171.23 2.61 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.836 -0.346 . . . . 74.35 110.613 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.598 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 49.1 ttt180 -106.43 -75.86 0.62 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 120.757 0.313 . . . . 74.3 110.893 -170.346 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -114.19 43.68 1.65 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.886 -0.597 . . . . 71.12 112.097 -177.753 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 75.1 mt -133.69 144.67 49.3 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 110.243 -0.28 . . . . 52.44 110.243 178.094 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.0 t -97.04 175.01 6.48 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.062 -0.517 . . . . 75.32 109.821 176.007 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.458 ' C ' ' H ' ' A' ' 27' ' ' GLN . 34.7 ptt180 -74.43 -172.42 1.46 Allowed 'General case' 0 C--O 1.236 0.389 0 C-N-CA 121.439 -0.104 . . . . 73.32 110.815 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 27.4 t70 69.27 -2.27 1.9 Allowed 'General case' 0 N--CA 1.474 0.774 0 CA-C-O 122.055 0.931 . . . . 54.04 109.945 -175.589 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.458 ' H ' ' C ' ' A' ' 25' ' ' ARG . 97.2 mt-30 -119.98 -156.51 0.67 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.777 -1.102 . . . . 70.15 108.518 178.302 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.423 HG12 HD11 ' A' ' 31' ' ' ILE . 15.2 m 47.83 27.57 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.778 0.831 . . . . 75.0 112.263 176.343 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.413 ' H ' ' HG2' ' A' ' 29' ' ' LYS . 26.3 pttt -92.74 -22.44 19.37 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.39 -0.823 . . . . 71.12 110.445 -175.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.6 81.54 0.66 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.809 -0.632 . . . . 75.11 110.677 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.544 ' HB ' HD11 ' A' ' 9' ' ' ILE . 48.0 mt -103.4 146.78 10.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.829 -0.623 . . . . 74.23 109.533 178.396 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -85.56 -67.92 0.77 Allowed 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.978 -0.379 . . . . 73.04 109.978 177.382 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.468 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 75.8 m-85 -136.32 145.72 45.8 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.021 -0.536 . . . . 71.25 110.641 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -92.32 142.59 26.25 Favored Pre-proline 0 C--N 1.321 -0.645 0 N-CA-C 109.762 -0.459 . . . . 73.11 109.762 175.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -62.77 147.15 95.05 Favored 'Trans proline' 0 C--O 1.237 0.442 0 C-N-CA 122.725 2.284 . . . . 63.24 113.03 -178.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 6.4 p -70.39 80.75 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 CA-C-O 122.159 0.98 . . . . 72.31 110.502 177.673 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.0 t70 172.94 -27.78 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 114.461 -1.245 . . . . 75.53 108.739 -175.095 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.588 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 7.9 t80 -72.15 142.9 49.09 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 114.751 -1.113 . . . . 74.11 111.185 -176.166 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.598 ' H ' ' HD2' ' A' ' 21' ' ' ARG . 54.9 mt-10 -124.61 153.76 41.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.032 -0.531 . . . . 72.52 109.93 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.645 HD11 ' HE1' ' A' ' 67' ' ' MET . 35.0 pt -126.68 165.65 24.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 120.763 0.316 . . . . 75.11 111.435 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.741 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.7 tt0 -130.89 147.47 52.54 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.955 -0.566 . . . . 74.33 110.268 178.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -94.84 102.27 14.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.285 -0.416 . . . . 75.13 110.678 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.5 m -103.48 170.67 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 120.9 0.381 . . . . 43.53 111.141 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 49.7 t -115.9 175.18 5.65 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.301 -0.409 . . . . 51.42 110.055 -178.378 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.532 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 2.0 tmt_? -77.09 99.63 5.43 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.631 -0.507 . . . . 71.44 109.631 -178.185 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.18 -160.63 28.44 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.929 -0.653 . . . . 62.21 111.691 -178.651 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -85.18 69.52 10.77 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.745 0.783 . . . . 71.43 111.002 -179.404 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 26.5 mmm180 -124.51 107.72 11.36 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.139 -1.059 . . . . 74.21 108.139 174.584 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -79.8 139.31 37.28 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.999 0.428 . . . . 74.41 111.508 -170.553 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' A' ' 73' ' ' CYS . 33.7 m -94.53 150.12 4.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.707 -0.678 . . . . 54.31 111.292 -176.515 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -114.42 95.06 3.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.822 0.82 . . . . 73.23 109.17 169.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.57 171.66 33.63 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.155 -0.93 . . . . 43.0 111.664 -178.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -83.58 71.25 6.03 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.158 1.905 . . . . 70.42 110.336 169.747 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.462 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 21.1 pttp -81.61 86.95 6.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.655 0.741 . . . . 72.35 111.629 -170.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.6 p -161.9 128.0 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.362 -0.836 . . . . 74.12 109.315 172.339 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.493 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 35.1 mmt180 -145.19 118.22 8.83 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.322 -0.622 . . . . 73.32 109.322 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -106.03 139.7 40.16 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.958 0.409 . . . . 71.3 109.958 177.301 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.9 t -70.47 149.66 46.98 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.556 -0.747 . . . . 74.1 111.911 -175.382 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.3 mt -113.15 -178.02 3.28 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.187 -0.915 . . . . 75.32 109.943 179.307 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -83.44 28.97 0.52 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.869 0.366 . . . . 34.01 111.277 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -146.56 169.85 18.11 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.161 -0.472 . . . . 74.35 109.946 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -69.2 -34.44 75.46 Favored Glycine 0 C--N 1.33 0.236 0 C-N-CA 121.348 -0.453 . . . . 74.22 114.039 -169.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.8 m -89.79 142.06 28.04 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 121.124 0.488 . . . . 64.31 111.054 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 59.7 m95 -73.82 -179.29 3.59 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.086 -0.507 . . . . 65.43 110.732 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.9 p -56.33 -56.12 25.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.312 -0.404 . . . . 71.12 111.792 -178.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.44 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 10.6 t70 -142.66 127.0 17.66 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.742 -0.466 . . . . 71.12 109.742 174.294 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' MET . . . . . 0.645 ' HE1' HD11 ' A' ' 40' ' ' ILE . 24.2 mmt -127.75 78.68 1.84 Allowed 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 119.112 -1.035 . . . . 72.34 110.531 165.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -167.08 87.85 0.3 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 113.843 -1.526 . . . . 63.14 107.544 159.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 91.5 m -160.33 109.0 1.37 Allowed Pre-proline 0 C--N 1.317 -0.825 0 N-CA-C 109.651 -0.5 . . . . 74.33 109.651 -172.427 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.53 99.52 0.94 Allowed 'Trans proline' 0 C--O 1.233 0.24 0 C-N-CA 122.68 2.253 . . . . 64.14 113.213 -174.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 11.8 p -91.58 98.58 11.74 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.519 -0.548 . . . . 73.3 109.519 173.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.424 HH11 ' HD2' ' A' ' 72' ' ' ARG . 7.0 ptp180 -91.29 140.66 29.57 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.163 -0.471 . . . . 75.3 110.852 -175.493 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.599 ' HA ' ' HA ' ' A' ' 50' ' ' VAL . 3.4 p -106.59 122.25 45.95 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.847 -0.615 . . . . 74.22 111.119 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 18.4 t -127.14 -95.64 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 108.892 -0.781 . . . . 70.53 108.892 175.639 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.536 -0.745 . . . . 74.41 109.673 178.208 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.79 0 N-CA-C 112.089 -0.404 . . . . 72.35 112.089 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -73.63 88.36 1.04 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.745 2.297 . . . . 72.1 111.862 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 59.7 m -122.72 115.99 23.01 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.972 -0.558 . . . . 75.23 110.421 178.438 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.5 m -105.59 101.58 11.09 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.753 -0.658 . . . . 74.12 109.829 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -96.74 96.69 8.77 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.644 -0.502 . . . . 74.03 109.644 178.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.81 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -164.15 136.91 4.46 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.742 -0.742 . . . . 52.24 112.565 -179.131 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.8 m -80.01 133.84 36.18 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.81 -0.811 . . . . 72.14 108.81 172.073 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.577 ' HA ' ' O ' ' A' ' 32' ' ' ASN . 18.7 pt20 -73.31 177.62 5.05 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.624 0.726 . . . . 64.22 112.41 -174.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.3 mt -88.97 127.09 41.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.876 -1.056 . . . . 73.43 110.326 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 58.6 mt -76.21 140.92 16.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.502 -0.772 . . . . 53.14 110.75 -177.197 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 14.6 t60 -62.9 138.0 97.06 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 115.49 -0.777 . . . . 73.31 110.188 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.496 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 75.6 Cg_exo -41.48 118.85 0.88 Allowed 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 123.852 3.034 . . . . 62.52 113.74 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.496 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 6.7 Cg_endo -88.79 -145.18 0.03 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.657 0 C-N-CA 123.685 2.924 . . . . 72.42 112.436 -178.551 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.442 ' CG ' ' N ' ' A' ' 15' ' ' GLU . 69.0 t-105 -68.36 -179.67 1.38 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 115.907 -0.588 . . . . 72.24 110.893 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.442 ' N ' ' CG ' ' A' ' 14' ' ' TRP . 16.8 mm-40 -47.99 101.5 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.182 0 C-N-CA 123.972 0.909 . . . . 74.13 112.336 178.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 153.56 -142.58 9.3 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 120.722 -0.751 . . . . 71.54 111.911 178.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -168.72 -169.99 32.82 Favored Glycine 0 N--CA 1.442 -0.959 0 N-CA-C 111.459 -0.656 . . . . 73.45 111.459 -179.347 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.5 mt -113.81 128.17 70.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.735 0.778 . . . . 70.34 111.432 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.855 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 20.5 tpp180 -86.24 113.14 22.01 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 114.54 -1.209 . . . . 74.22 109.541 179.606 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.42 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 86.2 m-85 -86.71 -171.54 3.58 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.953 0.406 . . . . 74.35 110.875 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -108.34 -32.51 7.42 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.131 0.491 . . . . 74.3 110.066 -177.47 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -158.62 54.51 0.37 Allowed Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.799 -0.715 . . . . 71.12 112.155 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 88.8 mt -138.61 111.62 7.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.681 0.277 . . . . 52.44 110.95 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.7 t -85.28 -179.91 7.07 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.166 -0.47 . . . . 75.32 109.859 175.229 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.499 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 9.5 ptp85 -72.77 -171.36 0.83 Allowed 'General case' 0 C--O 1.237 0.398 0 N-CA-C 110.027 -0.361 . . . . 73.32 110.027 178.001 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.499 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 9.7 t70 73.24 -40.77 0.48 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 121.251 0.548 . . . . 54.04 110.071 -176.191 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.425 ' O ' HG22 ' A' ' 28' ' ' VAL . 97.3 mt-30 -85.33 -164.64 1.03 Allowed 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 115.497 -0.774 . . . . 70.15 109.156 171.357 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.493 HG12 HD12 ' A' ' 31' ' ' ILE . 9.0 m 50.87 20.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 C-N-CA 124.079 0.952 . . . . 75.0 112.432 178.802 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 17.9 ptmt -79.78 -18.99 49.69 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.803 -0.635 . . . . 71.12 110.525 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.95 35.97 0.05 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.315 -0.857 . . . . 75.11 110.753 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.493 HD12 HG12 ' A' ' 28' ' ' VAL . 45.6 mt -75.69 136.88 23.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 109.003 -0.74 . . . . 74.23 109.003 175.052 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.577 ' O ' ' HA ' ' A' ' 8' ' ' GLN . 87.4 m-20 -115.76 -25.06 7.93 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 111.981 0.363 . . . . 73.04 111.981 -172.781 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.81 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 41.5 m-85 -132.01 109.48 10.06 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.958 0.408 . . . . 71.25 111.673 -174.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.405 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.8 mm? -87.66 129.63 50.08 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 109.355 -0.609 . . . . 73.11 109.355 173.054 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -62.21 161.34 27.08 Favored 'Trans proline' 0 N--CA 1.472 0.261 0 C-N-CA 122.868 2.378 . . . . 63.24 113.538 -175.365 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.465 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 12.4 p -63.1 157.68 3.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 CA-C-N 115.355 -0.839 . . . . 72.31 110.602 179.026 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.465 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 32.2 t70 77.12 -3.85 2.42 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.424 0.69 . . . . 75.53 111.004 178.623 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.42 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 4.4 t80 -80.39 123.56 28.13 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.133 -0.485 . . . . 74.11 110.18 -179.185 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.483 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.6 mt-10 -116.37 141.74 47.77 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 110.014 -0.365 . . . . 72.52 110.014 175.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.525 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 33.6 pt -121.26 160.89 21.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 120.965 0.412 . . . . 75.11 111.503 -177.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.855 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 46.2 tt0 -120.52 152.07 38.53 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.546 -0.752 . . . . 74.33 110.101 179.715 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -101.7 102.83 13.56 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.742 0.306 . . . . 75.13 110.982 179.155 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.512 HG11 ' HE ' ' A' ' 19' ' ' ARG . 30.7 m -102.23 152.75 5.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.16 0.505 . . . . 43.53 111.318 -179.044 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.428 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 19.1 t -100.49 -179.83 4.22 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.126 -0.694 . . . . 51.42 109.126 -178.39 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.4 ' HD3' ' HA ' ' A' ' 45' ' ' ARG . 37.5 mmt180 -65.2 110.08 2.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.772 0.32 . . . . 71.44 111.397 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.96 -149.01 24.98 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 121.0 -0.619 . . . . 62.21 111.855 179.194 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -91.56 37.51 0.96 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.365 0.603 . . . . 71.43 110.464 179.465 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 29.8 mmm180 -88.49 108.26 19.3 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.81 -0.811 . . . . 74.21 108.81 176.886 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -77.95 145.39 36.11 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.676 -0.693 . . . . 74.41 111.113 -171.56 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.563 ' HA ' ' HA ' ' A' ' 73' ' ' CYS . 34.8 m -101.33 149.98 6.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.672 -0.694 . . . . 54.31 110.387 179.115 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.0 p -117.47 95.28 3.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 122.003 0.906 . . . . 73.23 109.405 169.043 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.26 171.83 33.46 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.735 -1.121 . . . . 43.0 111.382 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.549 ' HG2' HG23 ' A' ' 69' ' ' THR . 48.1 Cg_endo -77.06 71.92 6.07 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 121.756 1.637 . . . . 70.42 110.359 170.168 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.704 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 43.2 pttt -78.98 89.57 4.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.531 -0.759 . . . . 72.35 111.398 -173.172 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.39 128.57 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.578 0.704 . . . . 74.12 110.877 174.633 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.647 ' CZ ' ' HA ' ' A' ' 67' ' ' MET . 28.9 mmt85 -138.23 104.41 5.19 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.276 -0.875 . . . . 73.32 109.106 176.72 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -97.47 138.96 34.11 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.412 -0.358 . . . . 71.3 110.182 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.7 t -97.88 128.56 44.56 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.014 -0.539 . . . . 74.1 110.349 176.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 30.7 mt -108.13 -176.6 3.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.797 -0.638 . . . . 75.32 110.414 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -54.43 -35.08 62.56 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 121.037 0.446 . . . . 34.01 110.886 176.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -83.18 140.5 32.54 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.345 -0.613 . . . . 74.35 109.345 174.871 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -79.14 67.19 3.32 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 121.025 -0.607 . . . . 74.22 113.631 -172.034 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 32.2 m -155.38 139.31 16.32 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.839 -0.43 . . . . 64.31 109.839 174.073 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 66.4 m95 -72.28 129.6 38.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.03 -0.73 . . . . 65.43 109.03 177.33 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.6 p -70.78 13.94 0.16 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 115.24 1.57 . . . . 71.12 115.24 -166.555 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -159.03 42.96 0.24 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.302 -0.629 . . . . 71.12 109.302 177.036 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' MET . . . . . 0.647 ' HA ' ' CZ ' ' A' ' 56' ' ' ARG . 26.4 ttt -83.75 77.38 9.89 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 122.074 0.94 . . . . 72.34 111.38 -171.596 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -170.32 88.97 0.15 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 113.905 -1.498 . . . . 63.14 107.361 159.368 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.549 HG23 ' HG2' ' A' ' 53' ' ' PRO . 7.5 m -127.58 112.38 20.89 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 119.847 -0.741 . . . . 74.33 112.51 -167.363 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -74.05 114.77 4.12 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 122.913 2.408 . . . . 64.14 110.811 172.304 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.4 p -135.64 145.74 47.13 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.403 -0.362 . . . . 73.3 110.844 -175.619 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.5 ptp180 -140.8 136.42 32.44 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.204 -0.453 . . . . 75.3 110.122 -178.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 50' ' ' VAL . 0.9 OUTLIER -97.18 99.73 11.21 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.462 0.649 . . . . 74.22 111.101 176.783 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -131.94 134.09 60.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.028 -0.987 . . . . 70.53 108.837 178.128 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.381 -0.819 . . . . 74.41 110.948 -172.189 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.472 ' HA2' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.48 1.626 0 N-CA-C 111.465 -0.654 . . . . 72.35 111.465 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.472 ' HD3' ' HA2' ' A' ' 1' ' ' GLY . 11.6 Cg_exo -69.99 136.0 31.3 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.796 2.331 . . . . 72.1 111.844 -178.68 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 1.2 p -79.03 137.27 37.48 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.038 -0.528 . . . . 75.23 110.771 178.02 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.7 m -78.84 99.33 6.69 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.495 -0.557 . . . . 74.12 109.495 176.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -118.03 100.23 7.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.557 -0.747 . . . . 74.03 110.261 -175.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.881 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.54 145.32 10.96 Favored Glycine 0 N--CA 1.444 -0.833 0 N-CA-C 111.373 -0.691 . . . . 52.24 111.373 178.788 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 56.7 m -81.16 132.01 35.33 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 110.176 -0.305 . . . . 72.14 110.176 -179.459 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 -80.3 -176.55 5.69 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.995 0.426 . . . . 64.22 111.302 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 73.0 mt -84.86 136.34 22.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.498 -0.773 . . . . 73.43 109.046 178.392 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 14.1 mt -94.76 148.33 5.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 116.102 -0.499 . . . . 53.14 111.614 -169.074 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 10.8 p80 -61.69 136.29 94.64 Favored Pre-proline 0 C--O 1.233 0.211 0 CA-C-N 116.051 -0.522 . . . . 73.31 109.875 172.156 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.421 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 38.2 Cg_endo -66.9 119.77 6.82 Favored 'Trans proline' 0 N--CA 1.464 -0.248 0 C-N-CA 122.526 2.151 . . . . 62.52 111.951 179.148 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.48 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 5.1 Cg_exo -77.76 -129.8 0.01 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.272 0 C-N-CA 123.043 2.495 . . . . 72.42 111.49 178.052 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.48 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 39.3 t-105 -63.86 174.77 1.34 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 109.594 -0.521 . . . . 72.24 109.594 175.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -68.91 76.37 0.31 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.497 0.665 . . . . 74.13 112.321 -176.096 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.27 155.32 25.97 Favored Glycine 0 N--CA 1.438 -1.188 0 N-CA-C 109.729 -1.349 . . . . 71.54 109.729 173.082 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -106.06 -172.3 23.38 Favored Glycine 0 N--CA 1.44 -1.085 0 C-N-CA 119.811 -1.185 . . . . 73.45 112.017 -178.428 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.8 mt -132.16 131.75 61.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.197 0.523 . . . . 70.34 109.987 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.426 HH11 ' HD2' ' A' ' 19' ' ' ARG . 0.2 OUTLIER -113.41 122.28 46.87 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.39 -0.823 . . . . 74.22 109.341 -179.307 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -88.52 -172.71 3.86 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.878 0.371 . . . . 74.35 110.552 -175.082 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.5 ttm180 -89.18 -51.59 5.5 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.219 -0.446 . . . . 74.3 110.27 -177.39 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -137.27 13.07 3.8 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.805 -0.712 . . . . 71.12 112.736 -178.251 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 80.3 mt -89.96 129.29 36.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.106 0.479 . . . . 52.44 110.805 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.1 t -102.74 -178.27 3.62 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.577 -0.738 . . . . 75.32 110.085 178.601 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.484 ' C ' ' H ' ' A' ' 27' ' ' GLN . 60.6 mtp180 -69.3 -173.07 0.5 Allowed 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.535 -0.302 . . . . 73.32 111.28 -176.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 24.3 t70 69.79 -40.33 0.46 Allowed 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.444 0.698 . . . . 54.04 110.505 -172.383 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.49 ' O ' HG22 ' A' ' 28' ' ' VAL . 88.4 mt-30 -86.6 -161.12 0.63 Allowed 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.36 -0.836 . . . . 70.15 110.3 177.374 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.49 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.6 m 54.73 10.0 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.674 1.19 . . . . 75.0 113.247 177.185 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -97.25 -19.84 18.3 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.021 0.439 . . . . 71.12 110.027 175.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.64 94.07 1.85 Allowed 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.552 -0.749 . . . . 75.11 110.377 178.334 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -131.58 136.62 56.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.109 -0.7 . . . . 74.23 109.109 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -76.77 -67.02 0.74 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.959 0.409 . . . . 73.04 110.892 -177.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.881 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 61.8 m-85 -133.91 126.67 30.89 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.832 -0.622 . . . . 71.25 111.119 -175.742 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -85.13 134.11 41.58 Favored Pre-proline 0 C--N 1.324 -0.525 0 N-CA-C 108.969 -0.752 . . . . 73.11 108.969 171.234 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -63.08 141.18 82.34 Favored 'Trans proline' 0 C--O 1.239 0.545 0 C-N-CA 122.816 2.344 . . . . 63.24 112.906 -176.502 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.426 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 3.1 p -69.84 82.07 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 CA-C-O 121.719 0.771 . . . . 72.31 110.25 176.281 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.426 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 6.2 t70 172.44 -26.39 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.635 -1.166 . . . . 75.53 108.544 -175.873 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.459 ' OH ' ' HG ' ' A' ' 23' ' ' LEU . 6.1 t80 -74.04 146.38 43.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.217 -0.901 . . . . 74.11 110.822 -177.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -124.69 158.64 32.71 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 115.911 -0.586 . . . . 72.52 110.564 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.476 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 31.0 pt -139.5 149.27 22.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.15 -0.477 . . . . 75.11 110.67 177.017 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.542 ' HG2' ' H ' ' A' ' 42' ' ' TYR . 24.2 tt0 -112.81 167.37 10.55 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.161 -0.472 . . . . 74.33 109.902 178.272 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.542 ' H ' ' HG2' ' A' ' 41' ' ' GLU . 69.1 m-85 -112.44 102.42 10.54 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.077 0.465 . . . . 75.13 111.998 -177.195 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.0 m -96.21 153.6 3.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 109.074 -0.713 . . . . 43.53 109.074 171.384 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.591 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 34.2 t -89.07 167.49 13.1 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.138 -0.69 . . . . 51.42 109.138 179.554 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -59.25 117.09 4.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.024 0.44 . . . . 71.44 110.151 -176.427 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.76 -120.77 6.53 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 110.958 -0.857 . . . . 62.21 110.958 -176.436 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -130.04 25.61 5.24 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.359 0.6 . . . . 71.43 110.212 177.423 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.591 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 29.8 mmm180 -88.47 136.06 33.18 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.823 -0.626 . . . . 74.21 109.8 -177.435 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -95.47 159.19 15.12 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.046 -0.525 . . . . 74.41 109.811 -179.528 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.548 HG12 ' HA ' ' A' ' 73' ' ' CYS . 27.9 m -122.28 150.14 25.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.523 -0.308 . . . . 54.31 110.422 179.517 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 p -100.83 96.89 5.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 122.039 0.923 . . . . 73.23 109.295 171.837 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.23 172.11 33.45 Favored Glycine 0 N--CA 1.441 -0.997 0 CA-C-N 114.973 -1.012 . . . . 43.0 111.612 -176.675 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -74.07 55.69 3.5 Favored 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.249 1.966 . . . . 70.42 110.523 171.318 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.479 ' HD2' ' HG2' ' A' ' 41' ' ' GLU . 43.0 pttt -75.41 87.46 2.58 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 115.74 -0.664 . . . . 72.35 111.515 -173.689 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -161.41 129.21 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.439 -0.8 . . . . 74.12 109.45 172.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.521 HH22 ' CB ' ' A' ' 69' ' ' THR . 31.8 mmt180 -132.61 140.29 48.16 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.918 -0.401 . . . . 73.32 109.918 179.165 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -130.76 137.56 49.53 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.598 -0.519 . . . . 71.3 109.598 176.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 50.4 t -70.83 146.5 49.65 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.114 -0.494 . . . . 74.1 110.26 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 94.3 mt -116.86 -179.61 3.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.136 -0.484 . . . . 75.32 110.381 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.03 -8.39 59.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.917 0.389 . . . . 34.01 111.038 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -100.54 166.16 11.06 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.434 -0.58 . . . . 74.35 109.434 175.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.02 57.76 3.14 Favored Glycine 0 CA--C 1.516 0.131 0 C-N-CA 120.987 -0.625 . . . . 74.22 113.091 -177.193 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.2 t -172.96 171.03 4.35 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.209 -0.663 . . . . 64.31 109.209 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 40.5 m95 -99.98 -179.01 4.02 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 109.714 -0.476 . . . . 65.43 109.714 -178.716 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.0 p -49.63 -53.31 24.88 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.579 0.585 . . . . 71.12 112.579 -176.771 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -153.77 129.95 10.41 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.026 -1.102 . . . . 71.12 108.026 177.227 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 22.9 mmt -131.81 78.4 1.82 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 118.992 -1.083 . . . . 72.34 112.136 174.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 30.0 t0 -168.94 88.39 0.19 Allowed 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 107.805 -1.183 . . . . 63.14 107.805 157.326 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.521 ' CB ' HH22 ' A' ' 56' ' ' ARG . 1.3 m -149.32 94.6 3.92 Favored Pre-proline 0 C--N 1.314 -0.948 0 C-N-CA 120.913 -0.315 . . . . 74.33 110.313 -172.5 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.95 92.81 0.32 Allowed 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 122.487 2.125 . . . . 64.14 112.26 -179.061 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 17.0 m -79.68 115.8 19.49 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.942 -0.572 . . . . 73.3 109.811 177.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.5 ptp180 -79.68 133.73 36.39 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.715 -0.675 . . . . 75.3 111.655 -174.726 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.548 ' HA ' HG12 ' A' ' 50' ' ' VAL . 71.2 m -83.08 98.87 9.53 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.761 -0.654 . . . . 74.22 110.592 178.499 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.5 p -148.88 114.47 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.635 -0.711 . . . . 70.53 109.534 176.42 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 2.4 tmt_? . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.288 -0.863 . . . . 74.41 109.488 -173.206 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.801 0 N-CA-C 111.835 -0.506 . . . . 72.35 111.835 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -80.34 44.82 1.81 Allowed 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 123.091 2.527 . . . . 72.1 111.756 -179.063 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 12.3 p -117.61 139.88 50.4 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.564 -0.744 . . . . 75.23 111.039 -177.101 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.7 m -142.28 97.94 3.22 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.485 -0.561 . . . . 74.12 109.485 172.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 33.3 mm-40 -98.82 118.41 35.5 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.892 -0.595 . . . . 74.03 109.466 -179.562 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.521 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -153.73 152.14 23.78 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.124 -1.036 . . . . 52.24 113.152 -176.632 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.8 m -97.14 149.39 22.04 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.432 -0.581 . . . . 72.14 109.432 177.799 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -72.82 173.98 8.38 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.129 0.49 . . . . 64.22 112.171 -175.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.58 HD11 ' HB ' ' A' ' 31' ' ' ILE . 54.5 mt -88.5 126.9 41.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.522 -0.763 . . . . 73.43 110.458 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.1 mt -84.05 127.92 39.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.051 -0.522 . . . . 53.14 109.847 177.67 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -79.5 133.4 59.74 Favored Pre-proline 0 C--N 1.323 -0.583 0 N-CA-C 109.631 -0.507 . . . . 73.31 109.631 -177.355 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.451 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 72.3 Cg_exo -49.3 113.3 0.88 Allowed 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 123.451 2.767 . . . . 62.52 113.005 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.465 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 4.9 Cg_exo -80.52 -101.4 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 123.194 2.596 . . . . 72.42 112.827 -177.06 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.465 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 55.7 t-105 -80.76 177.11 9.24 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.777 -0.453 . . . . 72.24 109.777 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -54.84 101.21 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.409 0.623 . . . . 74.13 111.733 179.462 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.06 -145.43 9.44 Favored Glycine 0 N--CA 1.443 -0.872 0 CA-C-N 115.095 -0.957 . . . . 71.54 110.714 -177.473 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -176.42 -170.01 38.54 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 120.473 -0.87 . . . . 73.45 111.914 178.384 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.9 mt -125.52 125.65 69.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.272 0.558 . . . . 70.34 110.838 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.38 160.57 14.6 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.994 -1.003 . . . . 74.22 108.893 178.089 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -123.26 -171.12 2.24 Favored 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 120.797 -0.361 . . . . 74.35 110.398 -176.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.416 ' HB3' ' CE2' ' A' ' 38' ' ' TYR . 39.9 ttm180 -82.56 -36.58 26.12 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.46 -0.336 . . . . 74.3 110.345 -178.116 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.94 71.21 0.19 Allowed Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.588 -0.815 . . . . 71.12 112.53 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 62.5 mt -139.79 139.15 36.35 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.796 0.331 . . . . 52.44 110.751 178.594 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.3 t -92.67 -178.28 4.82 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.863 -0.608 . . . . 75.32 109.848 178.242 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.563 ' C ' ' H ' ' A' ' 27' ' ' GLN . 49.7 ptt85 -68.78 -175.89 0.75 Allowed 'General case' 0 C--O 1.234 0.285 0 C-N-CA 121.188 -0.205 . . . . 73.32 110.671 177.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 28.7 t70 62.64 -26.83 0.06 Allowed 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 123.725 0.81 . . . . 54.04 112.116 -173.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.563 ' H ' ' C ' ' A' ' 25' ' ' ARG . 10.0 mm-40 -71.25 178.7 3.2 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 123.227 0.611 . . . . 70.15 110.482 178.612 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.2 m 50.53 20.7 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 C-N-CA 124.364 1.065 . . . . 75.0 113.016 177.022 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 38.1 pttt -73.51 -23.29 60.01 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.041 0.448 . . . . 71.12 109.927 176.627 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.99 102.65 0.66 Allowed 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.281 -0.872 . . . . 75.11 110.373 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.58 ' HB ' HD11 ' A' ' 9' ' ' ILE . 50.6 mt -130.21 157.86 42.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 N-CA-C 108.315 -0.995 . . . . 74.23 108.315 175.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -88.92 -58.22 2.63 Favored 'General case' 0 C--N 1.321 -0.67 0 C-N-CA 120.825 -0.35 . . . . 73.04 110.45 179.424 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.521 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 86.7 m-85 -143.54 146.75 33.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.886 0.374 . . . . 71.25 111.067 -178.782 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.45 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.4 mm? -84.37 130.9 52.14 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 108.575 -0.898 . . . . 73.11 108.575 173.295 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 34' ' ' LEU . 17.4 Cg_exo -64.08 147.11 91.62 Favored 'Trans proline' 0 CA--C 1.527 0.15 0 C-N-CA 122.473 2.116 . . . . 63.24 112.848 -174.399 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.55 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 8.9 p -53.39 148.35 2.01 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 CA-C-N 115.832 -0.622 . . . . 72.31 110.413 173.469 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.55 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 7.9 t70 82.48 -28.93 0.1 Allowed 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.583 0.753 . . . . 75.53 111.513 -178.423 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.416 ' CE2' ' HB3' ' A' ' 21' ' ' ARG . 32.4 t80 -66.84 141.38 57.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.787 0.327 . . . . 74.11 110.544 -178.438 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 41.2 mt-10 -114.78 145.65 41.87 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.066 -0.515 . . . . 72.52 111.515 -177.21 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.554 HG12 ' HB2' ' A' ' 56' ' ' ARG . 43.8 pt -122.46 164.86 19.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.451 -0.795 . . . . 75.11 109.595 172.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.431 ' CG ' ' HD2' ' A' ' 54' ' ' LYS . 35.3 tt0 -135.89 142.71 44.75 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.987 0.422 . . . . 74.33 110.785 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -88.45 102.32 14.78 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.107 -0.497 . . . . 75.13 110.59 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.9 m -102.2 162.78 3.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.168 0.509 . . . . 43.53 110.856 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.584 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 15.8 t -104.0 -176.58 3.12 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.859 -0.61 . . . . 51.42 110.229 -176.566 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.5 mmt180 -56.27 121.43 9.49 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.111 -0.495 . . . . 71.44 111.419 -177.423 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 71.73 -95.86 0.64 Allowed Glycine 0 N--CA 1.446 -0.698 0 CA-C-N 115.724 -0.671 . . . . 62.21 111.998 178.549 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -146.83 47.52 1.17 Allowed 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.69 0.757 . . . . 71.43 109.716 177.375 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.584 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 13.3 mmm-85 -87.43 129.15 35.15 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.197 -0.91 . . . . 74.21 109.478 176.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.464 ' HB2' ' HB3' ' A' ' 75' ' ' ARG . 41.1 mt-10 -78.35 149.17 33.47 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.376 -0.374 . . . . 74.41 110.001 -179.615 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.456 HG12 ' HA ' ' A' ' 73' ' ' CYS . 34.9 m -127.06 150.14 32.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.96 -0.564 . . . . 54.31 110.678 -177.279 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 p -106.34 96.83 4.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.972 0.891 . . . . 73.23 109.235 171.187 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.773 ' HA3' ' HB3' ' A' ' 71' ' ' SER . . . -154.73 170.83 33.08 Favored Glycine 0 N--CA 1.441 -0.994 0 CA-C-N 114.831 -1.077 . . . . 43.0 111.175 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.24 60.33 7.4 Favored 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 122.282 1.988 . . . . 70.42 110.703 173.657 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.431 ' HD2' ' CG ' ' A' ' 41' ' ' GLU . 45.3 pttt -80.7 84.42 6.25 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-O 121.723 0.773 . . . . 72.35 111.436 -172.651 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.408 HG13 ' O ' ' A' ' 54' ' ' LYS . 1.1 m -158.66 126.48 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 114.594 -1.185 . . . . 74.12 108.462 172.308 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.554 ' HB2' HG12 ' A' ' 40' ' ' ILE . 32.3 mmt180 -141.1 100.07 3.73 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 110.073 -0.343 . . . . 73.32 110.073 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -92.5 125.32 37.09 Favored 'General case' 0 C--N 1.317 -0.822 0 N-CA-C 109.002 -0.74 . . . . 71.3 109.002 174.104 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 48.9 t -64.52 136.6 57.21 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.008 0.432 . . . . 74.1 110.247 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 76.6 mt -98.78 -178.92 4.12 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.661 -0.699 . . . . 75.32 110.717 -174.236 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -71.45 -9.71 58.62 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.449 0.642 . . . . 34.01 110.363 176.76 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -110.21 158.62 18.17 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 108.93 -0.767 . . . . 74.35 108.93 174.316 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -78.29 53.23 3.84 Favored Glycine 0 CA--C 1.519 0.333 0 C-N-CA 120.993 -0.622 . . . . 74.22 113.464 -173.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 18.6 m -155.06 161.92 41.19 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.37 -0.604 . . . . 64.31 109.37 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 70.5 m95 -91.89 179.51 5.59 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.835 -0.431 . . . . 65.43 109.835 -178.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 33.0 p -61.67 -38.79 89.06 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.923 0.392 . . . . 71.12 111.197 -178.611 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -146.59 136.26 23.12 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.06 -0.718 . . . . 71.12 109.06 178.341 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 10.4 tpt -119.54 74.38 1.0 Allowed 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 118.602 -1.239 . . . . 72.34 109.882 171.301 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -170.68 89.2 0.14 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.206 -1.361 . . . . 63.14 107.575 160.493 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.483 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 4.6 m -108.77 108.81 61.06 Favored Pre-proline 0 C--N 1.313 -1.017 0 C-N-CA 119.959 -0.696 . . . . 74.33 111.078 -170.642 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 14.8 Cg_endo -92.56 46.48 0.41 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 124.061 3.174 . . . . 64.14 112.803 -177.345 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.773 ' HB3' ' HA3' ' A' ' 52' ' ' GLY . 0.1 OUTLIER -73.91 126.21 29.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.5 -0.318 . . . . 73.3 110.687 177.561 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -109.55 149.05 30.21 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 110.177 -0.305 . . . . 75.3 110.177 -178.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.456 ' HA ' HG12 ' A' ' 50' ' ' VAL . 29.6 m -87.52 113.75 23.5 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.502 -0.317 . . . . 74.22 111.458 -175.635 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.1 p -155.8 134.94 3.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.576 -0.284 . . . . 70.53 110.563 179.078 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.464 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 3.0 ptm180 . . . . . 0 C--O 1.25 1.087 0 CA-C-N 116.318 -0.401 . . . . 74.41 109.971 178.019 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 1.496 0 N-CA-C 111.759 -0.536 . . . . 72.35 111.759 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.17 127.79 20.11 Favored 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 122.72 2.28 . . . . 72.1 111.499 176.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 5.7 t -134.1 99.36 4.39 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.803 0.811 . . . . 75.23 110.959 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.4 m -150.09 149.57 30.49 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.554 -0.748 . . . . 74.12 109.51 179.031 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -96.22 97.27 9.39 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.626 -0.509 . . . . 74.03 109.626 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -161.76 164.18 35.09 Favored Glycine 0 N--CA 1.441 -0.986 0 C-N-CA 120.807 -0.711 . . . . 52.24 112.396 -177.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.6 m -97.59 154.02 17.81 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 110.203 -0.295 . . . . 72.14 110.203 179.068 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -82.42 -179.69 7.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.338 0.589 . . . . 64.22 111.329 -178.466 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.3 mt -89.42 121.38 39.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.425 -0.807 . . . . 73.43 110.306 178.78 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 55.5 mt -72.15 129.03 35.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.915 -0.584 . . . . 53.14 110.111 178.391 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.5 t-80 -67.39 121.26 78.02 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 116.192 -0.458 . . . . 73.31 110.366 -178.114 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.544 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.4 Cg_exo -48.69 120.76 5.61 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.212 2.608 . . . . 62.52 112.783 -179.407 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.544 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 5.8 Cg_endo -86.68 -138.74 0.02 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 123.569 2.846 . . . . 72.42 112.656 -176.305 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.441 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 13.1 t-105 -66.85 -177.5 0.62 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 115.891 -0.595 . . . . 72.24 110.853 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -39.88 101.35 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.689 0.796 . . . . 74.13 112.835 -176.051 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.54 -168.56 33.25 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 111.341 -0.704 . . . . 71.54 111.341 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.82 24.0 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.942 -0.647 . . . . 73.45 111.563 179.402 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.4 mt -116.93 136.49 53.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.559 0.695 . . . . 70.34 111.216 -178.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.855 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 13.7 tpt180 -103.03 140.1 37.72 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.661 -1.154 . . . . 74.22 109.246 -179.681 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -108.29 -171.98 1.97 Allowed 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.591 -0.444 . . . . 74.35 110.765 -178.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.06 -45.33 9.22 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.001 0.429 . . . . 74.3 110.603 -174.284 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -151.09 53.38 0.49 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.811 -0.709 . . . . 71.12 112.181 -178.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 89.5 mt -136.55 127.55 27.73 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.607 0.241 . . . . 52.44 110.794 179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.0 t -86.39 -179.77 6.73 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.531 -0.544 . . . . 75.32 109.531 175.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.8 mpp_? -80.47 -172.85 3.77 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.818 -0.353 . . . . 73.32 111.456 -175.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.429 ' O ' ' HE2' ' A' ' 29' ' ' LYS . 28.7 t70 60.44 15.25 5.37 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 122.357 1.075 . . . . 54.04 109.583 -168.435 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.549 ' O ' HG22 ' A' ' 28' ' ' VAL . 98.8 mt-30 -134.57 -173.7 3.36 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.668 -1.151 . . . . 70.15 108.287 178.273 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.549 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.0 m 54.4 9.22 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 124.127 0.971 . . . . 75.0 112.51 -178.323 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.429 ' HE2' ' O ' ' A' ' 26' ' ' ASP . 46.3 pttt -79.41 -21.82 45.1 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.98 -0.555 . . . . 71.12 110.081 177.502 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.31 81.15 0.98 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.351 -0.84 . . . . 75.11 110.37 178.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 54.8 mt -119.61 139.11 48.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 108.939 -0.763 . . . . 74.23 108.939 176.338 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -69.54 -64.2 0.92 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.764 0.316 . . . . 73.04 111.115 -176.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -143.56 141.73 30.8 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.192 -0.458 . . . . 71.25 110.867 -177.371 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -92.01 115.71 65.13 Favored Pre-proline 0 C--N 1.321 -0.671 0 N-CA-C 108.564 -0.902 . . . . 73.11 108.564 172.14 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.59 142.71 38.97 Favored 'Trans proline' 0 C--O 1.238 0.515 0 C-N-CA 123.419 2.746 . . . . 63.24 113.217 -174.22 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.467 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 2.7 p -65.22 86.14 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-O 121.512 0.673 . . . . 72.31 111.173 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.467 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 31.6 t70 168.94 -26.84 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.834 -1.075 . . . . 75.53 108.28 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 6.9 t80 -68.74 144.82 54.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 114.618 -1.173 . . . . 74.11 110.486 179.418 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.408 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 40.0 mt-10 -127.09 145.53 50.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.274 -0.421 . . . . 72.52 110.121 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.486 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 38.0 pt -128.45 167.9 22.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-O 121.084 0.469 . . . . 75.11 111.86 -177.622 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.855 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 44.4 tt0 -131.82 164.81 25.22 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 115.374 -0.83 . . . . 74.33 110.13 -177.221 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.579 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 96.9 m-85 -117.1 102.93 9.72 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 122.354 0.262 . . . . 75.13 111.142 -178.584 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.8 m -98.26 157.41 3.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 120.766 0.317 . . . . 43.53 110.74 178.501 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.588 ' HB3' ' O ' ' A' ' 48' ' ' ARG . 43.5 t -92.21 177.89 6.02 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.976 -0.379 . . . . 51.42 109.976 178.51 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.498 ' C ' ' HD3' ' A' ' 45' ' ' ARG . 0.1 OUTLIER -69.59 117.04 10.69 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 116.171 -0.468 . . . . 71.44 110.469 -176.241 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 89.63 -125.23 7.74 Favored Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.972 -0.632 . . . . 62.21 112.352 175.559 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -116.23 26.02 10.23 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.002 0.429 . . . . 71.43 110.533 -179.787 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.588 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 28.6 mmm180 -88.64 119.02 28.72 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.829 -0.804 . . . . 74.21 108.829 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -79.26 159.98 27.04 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.04 0.448 . . . . 74.41 111.058 -177.325 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.589 HG12 ' HA ' ' A' ' 73' ' ' CYS . 27.5 m -126.83 139.15 52.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.796 -0.638 . . . . 54.31 110.369 179.083 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.9 p -103.19 95.53 3.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 122.093 0.949 . . . . 73.23 109.366 172.296 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.46 171.26 32.94 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 115.005 -0.998 . . . . 43.0 111.446 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -78.07 52.01 3.88 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.486 2.124 . . . . 70.42 111.145 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.709 ' HD3' ' HG3' ' A' ' 41' ' ' GLU . 0.0 OUTLIER -76.66 86.83 3.31 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 122.118 0.961 . . . . 72.35 111.972 -173.397 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -161.96 130.12 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 114.989 -1.005 . . . . 74.12 109.229 174.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.486 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 29.0 mmt180 -129.43 131.52 46.77 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 120.662 0.268 . . . . 73.32 110.484 178.462 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.458 ' HB2' ' HE3' ' A' ' 57' ' ' LYS . 35.2 ttmt -106.58 134.19 50.1 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.071 -0.715 . . . . 71.3 109.071 176.112 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.3 t -74.53 145.18 43.68 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.92 0.39 . . . . 74.1 110.734 -178.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.6 mt -112.87 -178.67 3.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.788 -0.642 . . . . 75.32 110.114 -177.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.25 27.54 0.33 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.019 0.438 . . . . 34.01 111.077 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -147.65 172.75 13.55 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.235 -0.654 . . . . 74.35 109.235 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -68.36 -19.03 72.11 Favored Glycine 0 CA--C 1.52 0.375 0 C-N-CA 120.815 -0.707 . . . . 74.22 113.755 -172.454 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 14.9 m -99.36 146.27 26.47 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.046 0.45 . . . . 64.31 111.089 -178.041 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.411 ' H ' ' HE3' ' A' ' 67' ' ' MET . 63.8 m95 -77.89 -179.05 5.79 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.732 -0.667 . . . . 65.43 110.481 179.687 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.456 HG23 ' O ' ' A' ' 57' ' ' LYS . 3.1 p -54.05 -49.93 67.87 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 113.064 0.764 . . . . 71.12 113.064 -176.547 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.447 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 14.0 t70 -140.06 141.7 36.21 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.57 -0.286 . . . . 71.12 110.26 -177.562 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' MET . . . . . 0.411 ' HE3' ' H ' ' A' ' 64' ' ' TRP . 65.9 mtt -140.07 80.01 1.74 Allowed 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 119.969 -0.692 . . . . 72.34 111.502 166.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -168.03 88.45 0.25 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.301 -1.0 . . . . 63.14 108.301 157.415 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.8 m -152.78 101.24 2.7 Favored Pre-proline 0 C--N 1.316 -0.848 0 C-N-CA 120.372 -0.531 . . . . 74.33 111.274 -172.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.66 114.64 4.01 Favored 'Trans proline' 0 C--O 1.237 0.438 0 C-N-CA 122.627 2.218 . . . . 64.14 111.553 175.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 t -92.42 134.44 34.95 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.162 0.506 . . . . 73.3 109.972 -179.554 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.0 ptp85 -101.88 123.32 45.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.801 -0.636 . . . . 75.3 110.811 -176.607 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.589 ' HA ' HG12 ' A' ' 50' ' ' VAL . 60.9 m -76.08 98.17 4.27 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.419 -0.586 . . . . 74.22 109.419 176.616 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 10.7 p 177.04 151.76 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.088 -0.96 . . . . 70.53 108.412 -176.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.424 HH11 ' HD3' ' A' ' 75' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.943 0 CA-C-O 118.335 -0.841 . . . . 74.41 110.292 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.704 0 N-CA-C 111.91 -0.476 . . . . 72.35 111.91 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -83.73 16.74 1.83 Allowed 'Trans proline' 0 CA--C 1.531 0.363 0 C-N-CA 122.978 2.452 . . . . 72.1 113.044 -177.418 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 2.6 p -85.22 111.82 20.18 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.256 -0.429 . . . . 75.23 111.22 179.088 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.6 p -133.16 102.66 5.67 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.125 -0.489 . . . . 74.12 110.42 177.515 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -70.22 116.63 10.79 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.852 0.358 . . . . 74.03 110.36 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.458 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.12 160.21 31.44 Favored Glycine 0 N--CA 1.44 -1.059 0 CA-C-N 115.66 -0.7 . . . . 52.24 111.374 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 38.1 m -92.74 147.17 23.08 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 110.185 -0.302 . . . . 72.14 110.185 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -85.53 -177.65 6.48 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.073 0.463 . . . . 64.22 110.826 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 51.9 mt -86.77 125.43 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 CA-C-N 115.989 -0.55 . . . . 73.43 109.8 175.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 56.1 mt -80.12 136.63 23.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.572 -0.74 . . . . 53.14 110.106 -179.222 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 45.5 m170 -54.49 128.57 60.74 Favored Pre-proline 0 C--N 1.329 -0.295 0 N-CA-C 109.843 -0.429 . . . . 73.31 109.843 173.178 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.484 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.5 Cg_exo -51.24 122.45 10.1 Favored 'Trans proline' 0 N--CA 1.461 -0.408 0 C-N-CA 122.501 2.134 . . . . 62.52 111.479 177.704 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 15.7 Cg_exo -69.09 -159.05 0.05 OUTLIER 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 123.081 2.52 . . . . 72.42 111.747 179.838 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -59.93 159.81 8.67 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.557 -0.534 . . . . 72.24 109.557 176.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -39.42 100.9 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 113.687 0.995 . . . . 74.13 113.687 -169.348 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -167.76 -140.2 2.86 Favored Glycine 0 N--CA 1.444 -0.821 0 CA-C-N 114.287 -1.324 . . . . 71.54 110.368 179.3 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -170.28 -171.01 35.3 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.521 -0.847 . . . . 73.45 112.088 176.196 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 18.5 mt -136.49 136.17 48.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.299 0.571 . . . . 70.34 111.005 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.82 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 19.1 tpt85 -107.86 119.23 38.87 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 115.266 -0.879 . . . . 74.22 110.179 -176.591 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.637 ' HB3' ' HE1' ' A' ' 38' ' ' TYR . 99.5 m-85 -96.2 -171.3 2.28 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.223 -0.444 . . . . 74.35 110.872 -179.474 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.427 HH11 ' HD3' ' A' ' 21' ' ' ARG . 1.5 mmp_? -91.39 -72.2 0.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.981 -0.554 . . . . 74.3 111.466 -178.395 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -128.2 63.85 0.61 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.494 -0.86 . . . . 71.12 112.157 -176.712 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.485 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 75.4 mt -125.15 121.29 33.79 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.895 0.379 . . . . 52.44 110.832 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.5 t -83.01 -179.47 7.45 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 115.664 -0.698 . . . . 75.32 109.944 176.238 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' A' ' 25' ' ' ARG . 10.3 mmt180 -76.09 -174.56 2.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.093 0.473 . . . . 73.32 111.817 -175.654 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 24.4 t70 55.2 27.69 10.04 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.121 -0.945 . . . . 54.04 110.169 -175.447 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.466 ' O ' HG22 ' A' ' 28' ' ' VAL . 87.7 mt-30 -134.03 -164.32 1.48 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.519 -0.764 . . . . 70.15 110.271 -178.097 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.466 HG22 ' O ' ' A' ' 27' ' ' GLN . 4.6 m 53.59 15.0 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 124.757 1.223 . . . . 75.0 112.765 178.562 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -89.46 -19.11 25.51 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.419 -0.355 . . . . 71.12 110.687 178.152 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.47 86.96 0.81 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.008 0.432 . . . . 75.11 111.037 178.327 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.5 mt -128.45 106.88 15.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 108.855 -0.794 . . . . 74.23 108.855 176.436 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -73.14 -40.0 65.26 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.261 -0.427 . . . . 73.04 111.855 -172.276 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.458 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 81.9 m-85 -135.55 116.9 14.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.085 0.469 . . . . 71.25 111.929 -176.267 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -81.58 135.78 49.28 Favored Pre-proline 0 C--N 1.321 -0.633 0 N-CA-C 108.883 -0.784 . . . . 73.11 108.883 169.54 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.36 153.3 61.34 Favored 'Trans proline' 0 C--O 1.238 0.481 0 C-N-CA 122.327 2.018 . . . . 63.24 112.929 -176.068 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.496 HG23 ' HA ' ' A' ' 59' ' ' LEU . 2.9 p -68.19 85.72 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.351 0 CA-C-O 122.04 0.924 . . . . 72.31 109.629 174.781 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 16.6 t70 175.32 -39.46 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.86 -1.064 . . . . 75.53 109.666 -170.456 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.637 ' HE1' ' HB3' ' A' ' 20' ' ' TYR . 0.2 OUTLIER -74.02 126.86 31.43 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.987 -1.006 . . . . 74.11 112.405 -171.979 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.532 ' HG2' ' HB2' ' A' ' 57' ' ' LYS . 40.9 mt-10 -107.84 127.52 53.79 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.427 -0.806 . . . . 72.52 109.278 172.834 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 44.8 pt -110.0 142.82 21.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.005 0.431 . . . . 75.11 111.441 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.82 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.3 tt0 -107.54 147.87 29.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.706 -0.679 . . . . 74.33 109.918 176.314 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.521 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 94.4 m-85 -103.83 101.88 11.69 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.406 -0.361 . . . . 75.13 110.046 177.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -95.2 170.45 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.714 0.292 . . . . 43.53 111.006 -178.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.553 ' HB2' HG13 ' A' ' 50' ' ' VAL . 26.1 t -93.27 179.8 5.3 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.644 -0.502 . . . . 51.42 109.644 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 2.0 tmt_? -78.59 93.37 4.83 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.847 0.356 . . . . 71.44 110.932 -175.806 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.49 -136.16 13.35 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.742 -0.742 . . . . 62.21 112.445 175.075 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 8.0 mp0 -89.89 14.88 10.95 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.269 0.557 . . . . 71.43 109.736 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.493 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 15.7 mmt-85 -88.56 137.53 32.24 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.53 -0.759 . . . . 74.21 109.203 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -105.46 165.06 11.4 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.054 0.454 . . . . 74.41 110.614 176.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.553 HG13 ' HB2' ' A' ' 44' ' ' CYS . 34.2 m -121.87 136.09 59.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.793 -0.639 . . . . 54.31 109.486 177.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.418 HG13 ' O ' ' A' ' 51' ' ' VAL . 7.2 p -93.0 95.75 5.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 122.275 1.036 . . . . 73.23 109.018 174.341 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.87 171.8 33.22 Favored Glycine 0 N--CA 1.443 -0.863 0 CA-C-N 114.567 -1.197 . . . . 43.0 111.375 -178.547 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -82.28 42.22 1.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.594 2.196 . . . . 70.42 110.387 175.641 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.634 ' HD3' ' HG3' ' A' ' 41' ' ' GLU . 0.0 OUTLIER -75.13 86.39 2.39 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.796 0.807 . . . . 72.35 112.871 -170.394 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.454 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.4 p -161.85 126.5 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-N 114.903 -1.044 . . . . 74.12 109.026 169.359 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.454 ' HD3' ' O ' ' A' ' 55' ' ' VAL . 22.4 mmt180 -134.89 128.43 32.59 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.28 -0.418 . . . . 73.32 110.076 -178.19 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.532 ' HB2' ' HG2' ' A' ' 39' ' ' GLU . 38.4 ttpt -107.23 136.4 47.13 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 116.05 -0.523 . . . . 71.3 110.031 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 43.8 t -77.53 134.35 38.32 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.203 -0.453 . . . . 74.1 110.179 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.496 ' HA ' HG23 ' A' ' 36' ' ' VAL . 97.8 mt -102.9 -178.74 3.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.127 -0.488 . . . . 75.32 109.811 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.42 51.76 0.9 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.328 0.585 . . . . 34.01 111.029 179.662 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -160.65 170.67 20.36 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.279 -0.873 . . . . 74.35 108.926 177.852 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -85.46 38.53 3.01 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 120.721 -0.752 . . . . 74.22 113.802 -173.286 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.3 m -156.67 151.71 26.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 117.229 0.515 . . . . 64.31 110.537 178.377 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 71.2 m95 -79.29 167.91 20.27 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.179 -0.464 . . . . 65.43 109.975 178.068 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 17.8 p -55.19 -65.29 0.61 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.043 0.449 . . . . 71.12 111.99 -177.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -125.85 97.19 5.03 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.976 -0.75 . . . . 71.12 108.976 176.538 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 27.0 ttt -100.69 76.25 1.79 Allowed 'General case' 0 C--N 1.321 -0.663 0 C-N-CA 118.817 -1.153 . . . . 72.34 110.7 -178.325 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -171.76 89.89 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.276 -1.329 . . . . 63.14 108.568 160.733 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.5 m -135.46 119.41 13.07 Favored Pre-proline 0 C--N 1.317 -0.832 0 C-N-CA 119.758 -0.777 . . . . 74.33 112.004 -172.712 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -83.1 106.85 1.44 Allowed 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.867 2.378 . . . . 64.14 112.576 178.651 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.495 ' HB2' HG21 ' A' ' 50' ' ' VAL . 12.1 p -95.39 105.41 17.37 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.042 0.449 . . . . 73.3 110.813 178.634 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.8 ptp85 -89.18 125.18 34.95 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.159 -0.473 . . . . 75.3 110.955 -177.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.445 ' HA ' HG12 ' A' ' 50' ' ' VAL . 59.7 m -72.44 122.06 20.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.123 -0.49 . . . . 74.22 110.572 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 85.8 t -137.56 136.15 46.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.763 -0.458 . . . . 70.53 109.763 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.247 0.939 0 CA-C-O 119.079 -0.486 . . . . 74.41 110.669 -179.093 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.623 0 N-CA-C 111.812 -0.515 . . . . 72.35 111.812 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -84.83 30.95 0.5 Allowed 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 123.188 2.592 . . . . 72.1 112.462 -176.758 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 30.4 p -79.59 98.97 7.11 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.927 0.394 . . . . 75.23 110.183 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 27.5 m -128.36 98.63 5.12 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.238 0.542 . . . . 74.12 110.579 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -101.85 99.13 9.32 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.696 -0.853 . . . . 74.03 108.696 174.234 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -160.64 164.34 34.55 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.535 -0.84 . . . . 52.24 112.573 -174.862 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.429 ' N ' ' SG ' ' A' ' 58' ' ' CYS . 35.2 m -105.06 150.41 25.01 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 109.49 -0.559 . . . . 72.14 109.49 -178.612 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -73.44 179.67 3.91 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.113 0.483 . . . . 64.22 110.607 177.262 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.4 tt -88.24 140.64 15.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.755 -0.657 . . . . 73.43 110.201 -178.643 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 57.3 mt -96.25 135.91 28.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.388 -0.369 . . . . 53.14 110.937 -176.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' HIS . . . . . 0.406 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 2.5 t-80 -89.29 130.94 42.14 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 115.928 -0.578 . . . . 73.31 109.485 178.487 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 33.5 Cg_exo -57.86 109.99 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.795 2.33 . . . . 62.52 112.393 -178.741 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -75.67 -59.09 0.04 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.437 0 C-N-CA 122.691 2.261 . . . . 72.42 112.298 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -91.59 -178.43 5.08 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.102 -0.499 . . . . 72.24 109.851 -176.664 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -71.29 15.64 0.12 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 112.237 0.458 . . . . 74.13 112.237 -177.623 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.542 ' HA2' ' H ' ' A' ' 45' ' ' ARG . . . -96.65 -147.56 22.83 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.508 -0.637 . . . . 71.54 111.508 175.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.74 -170.56 30.84 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 121.071 -0.585 . . . . 73.45 111.78 179.524 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.1 mt -129.38 134.89 62.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.093 0.473 . . . . 70.34 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -106.77 135.41 48.34 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.44 -0.8 . . . . 74.22 109.931 -178.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.501 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 91.4 m-85 -101.02 -171.35 1.98 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.305 -0.407 . . . . 74.35 110.017 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 21.6 mtt180 -80.17 -44.49 19.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.814 0.34 . . . . 74.3 111.435 -179.014 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.38 61.61 0.24 Allowed Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.583 -0.818 . . . . 71.12 112.13 -178.515 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 80.7 mt -120.81 116.76 25.82 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.79 0.329 . . . . 52.44 110.456 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.3 t -78.89 -179.44 6.6 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.636 -0.711 . . . . 75.32 109.734 175.774 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.426 ' C ' ' H ' ' A' ' 27' ' ' GLN . 99.4 mtt180 -67.8 -172.75 0.29 Allowed 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.741 0.305 . . . . 73.32 111.479 -177.418 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 30.5 t70 68.09 -42.79 0.47 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.629 0.772 . . . . 54.04 110.882 -171.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.573 ' O ' HG22 ' A' ' 28' ' ' VAL . 94.7 mt-30 -71.87 -179.49 2.72 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.328 -0.396 . . . . 70.15 110.806 176.594 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.8 m 57.45 9.88 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 124.559 1.144 . . . . 75.0 112.347 -178.609 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -82.71 -17.73 43.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.272 0.558 . . . . 71.12 109.896 175.17 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -161.9 94.53 0.94 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.091 -0.959 . . . . 75.11 110.191 179.127 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 57.8 mt -131.98 130.27 61.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.578 -0.737 . . . . 74.23 109.42 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -89.95 -51.87 5.26 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.379 -0.373 . . . . 73.04 111.301 -175.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -134.72 131.48 37.69 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.296 0.569 . . . . 71.25 112.133 -175.245 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -97.59 117.42 65.39 Favored Pre-proline 0 C--N 1.322 -0.622 0 N-CA-C 107.876 -1.157 . . . . 73.11 107.876 168.201 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -56.52 147.13 71.23 Favored 'Trans proline' 0 C--O 1.237 0.434 0 C-N-CA 123.205 2.603 . . . . 63.24 113.373 -173.196 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.55 83.87 0.05 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.323 0 CA-C-O 121.85 0.833 . . . . 72.31 110.771 177.132 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.8 t70 168.45 -33.46 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 114.578 -1.192 . . . . 75.53 108.942 -176.484 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.501 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 14.1 t80 -67.56 141.11 56.95 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.324 -0.853 . . . . 74.11 110.636 -177.227 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.457 ' HG2' ' HE2' ' A' ' 57' ' ' LYS . 10.5 mt-10 -125.36 142.15 51.67 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.53 -0.759 . . . . 72.52 110.083 -177.029 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.655 HG13 ' HB2' ' A' ' 56' ' ' ARG . 46.4 pt -130.65 169.31 21.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.715 0.293 . . . . 75.11 110.694 178.748 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -128.52 139.24 52.41 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.189 -0.459 . . . . 74.33 110.981 -178.781 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.41 ' O ' HG21 ' A' ' 50' ' ' VAL . 5.1 m-30 -83.65 102.32 12.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.765 -0.652 . . . . 75.13 110.349 176.161 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.9 m -108.31 170.93 2.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 120.898 0.38 . . . . 43.53 110.909 -178.535 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.714 ' HB2' HG13 ' A' ' 50' ' ' VAL . 10.5 t -109.64 143.63 39.12 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.06 -0.718 . . . . 51.42 109.06 175.012 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.542 ' H ' ' HA2' ' A' ' 16' ' ' GLY . 75.7 ttt180 -77.58 133.68 38.42 Favored 'General case' 0 N--CA 1.44 -0.974 0 CA-C-N 115.029 -0.987 . . . . 71.44 110.588 -172.818 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.13 -149.84 18.81 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.799 -0.715 . . . . 62.21 111.688 -178.77 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.455 ' CD ' ' H ' ' A' ' 47' ' ' GLU . 1.0 OUTLIER -93.66 16.08 14.72 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.406 0.622 . . . . 71.43 109.646 176.799 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.654 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 40.8 mmm-85 -89.22 118.94 29.28 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.317 -0.856 . . . . 74.21 109.169 178.074 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.523 ' HB2' ' HA ' ' A' ' 75' ' ' ARG . 48.8 mt-10 -95.92 171.37 8.68 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.991 -0.374 . . . . 74.41 109.991 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.714 HG13 ' HB2' ' A' ' 44' ' ' CYS . 5.5 m -129.86 126.25 62.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.948 0.404 . . . . 54.31 111.545 -177.593 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.601 HG12 ' HB ' ' A' ' 74' ' ' VAL . 3.5 p -96.37 95.76 5.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 108.463 -0.94 . . . . 73.23 108.463 167.642 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.51 172.73 33.01 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.373 -0.83 . . . . 43.0 112.497 -173.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -75.27 52.98 3.31 Favored 'Trans proline' 0 N--CA 1.462 -0.335 0 C-N-CA 123.012 2.475 . . . . 70.42 110.734 173.341 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.418 ' HD3' HG23 ' A' ' 50' ' ' VAL . 19.4 pttp -72.11 89.54 1.15 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.512 -0.767 . . . . 72.35 111.863 -174.163 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -160.54 132.24 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.821 -0.627 . . . . 74.12 110.574 176.581 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.655 ' HB2' HG13 ' A' ' 40' ' ' ILE . 55.1 mmt-85 -138.35 126.8 23.24 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.933 -0.576 . . . . 73.32 110.195 176.728 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.457 ' HE2' ' HG2' ' A' ' 39' ' ' GLU . 37.3 ttmt -125.08 137.48 54.2 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.007 -0.738 . . . . 71.3 109.007 175.149 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 7' ' ' CYS . 53.3 t -81.31 144.17 31.7 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.894 0.378 . . . . 74.1 111.073 -176.117 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 94.4 mt -100.95 -179.07 3.94 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.716 -0.675 . . . . 75.32 111.005 -178.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.92 -20.58 60.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.185 0.517 . . . . 34.01 110.374 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -101.43 169.1 9.1 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.397 -0.82 . . . . 74.35 109.313 175.283 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.75 60.56 3.36 Favored Glycine 0 CA--C 1.518 0.253 0 C-N-CA 120.83 -0.7 . . . . 74.22 113.28 -175.251 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 49.4 m -158.63 144.31 16.65 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 122.789 0.436 . . . . 64.31 109.939 177.747 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 75.7 m95 -81.19 161.65 23.93 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.75 -0.463 . . . . 65.43 109.75 177.47 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 p -52.9 -39.14 62.47 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.221 0.823 . . . . 71.12 113.221 -174.152 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -134.03 140.86 46.95 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 110.186 -0.302 . . . . 71.12 110.186 178.588 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 50.5 mtt -144.36 80.01 1.63 Allowed 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.367 -0.533 . . . . 72.34 111.453 167.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -168.6 88.85 0.22 Allowed 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.416 -0.957 . . . . 63.14 108.416 156.463 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.8 m -155.83 90.11 2.83 Favored Pre-proline 0 C--N 1.317 -0.823 0 C-N-CA 120.283 -0.567 . . . . 74.33 111.283 -172.076 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -74.18 90.28 1.0 Allowed 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.689 2.26 . . . . 64.14 110.396 172.407 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.2 t -69.26 116.93 10.25 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.985 -0.552 . . . . 73.3 110.724 -175.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.0 ptp180 -79.57 130.67 35.6 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.534 -0.757 . . . . 75.3 110.409 179.122 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.584 ' HA ' HG12 ' A' ' 50' ' ' VAL . 73.6 m -81.02 97.89 7.71 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.309 0.576 . . . . 74.22 110.013 178.261 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.601 ' HB ' HG12 ' A' ' 51' ' ' VAL . 59.6 t -136.68 117.99 18.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.184 -0.916 . . . . 70.53 108.653 177.773 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.523 ' HA ' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.556 -0.735 . . . . 74.41 111.161 -176.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.769 0 N-CA-C 111.67 -0.572 . . . . 72.35 111.67 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -70.08 92.81 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.796 2.331 . . . . 72.1 111.549 177.151 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 27.1 m -151.82 139.31 19.56 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.036 -0.529 . . . . 75.23 109.984 -178.01 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.0 m -143.06 99.5 3.47 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.74 -0.467 . . . . 74.12 109.74 177.676 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -75.43 99.44 4.17 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.222 -0.445 . . . . 74.03 110.617 -178.647 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.57 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -159.91 152.56 23.44 Favored Glycine 0 N--CA 1.441 -1.002 0 C-N-CA 120.572 -0.823 . . . . 52.24 112.694 -179.144 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.1 m -86.52 158.76 19.47 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 110.13 -0.322 . . . . 72.14 110.13 178.137 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 -88.86 -177.19 5.44 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.052 0.453 . . . . 64.22 111.192 -179.106 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.543 HD11 ' HB ' ' A' ' 31' ' ' ILE . 60.7 mt -87.49 138.16 19.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.615 -0.72 . . . . 73.43 110.487 -177.715 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 64.8 mt -99.78 131.06 47.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.18 -0.464 . . . . 53.14 109.929 178.199 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -76.55 126.09 86.59 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.868 -0.605 . . . . 73.31 110.171 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_endo -58.51 112.69 1.26 Allowed 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.72 2.28 . . . . 62.52 111.921 179.266 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -74.87 -87.6 0.0 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.393 0 C-N-CA 122.481 2.121 . . . . 72.42 113.091 -176.059 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 27.8 t-105 -101.37 -177.84 3.56 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.999 -0.371 . . . . 72.24 109.999 -178.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 56.7 mm-40 -39.81 101.93 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.746 0.818 . . . . 74.13 111.98 177.688 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.436 ' HA2' ' HA ' ' A' ' 44' ' ' CYS . . . 171.32 -167.6 40.72 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.39 -0.91 . . . . 71.54 112.637 177.876 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -159.17 -170.52 23.81 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.989 -0.844 . . . . 73.45 110.989 178.806 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.464 HG23 ' HB ' ' A' ' 40' ' ' ILE . 16.6 mt -135.05 135.59 52.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.449 0.642 . . . . 70.34 111.835 -177.06 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.49 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 55.6 ttm-85 -99.49 138.56 36.4 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.081 -0.963 . . . . 74.22 110.578 178.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.506 ' HB3' ' HE1' ' A' ' 38' ' ' TYR . 89.1 m-85 -110.76 -168.03 1.26 Allowed 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.132 -0.321 . . . . 74.35 110.132 177.565 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -62.04 -57.82 10.2 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 120.88 0.371 . . . . 74.3 110.487 178.708 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -161.55 67.76 0.24 Allowed Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 121.055 -0.593 . . . . 71.12 111.872 178.489 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 92.7 mt -118.12 126.77 52.91 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.965 0.412 . . . . 52.44 110.949 -179.18 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.8 t -85.03 -176.71 6.32 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.387 -0.824 . . . . 75.32 110.46 176.43 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 29.9 ptt180 -61.94 -173.51 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 115.923 -0.58 . . . . 73.32 111.818 -177.116 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.9 t70 65.06 -46.14 0.35 Allowed 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 123.894 0.878 . . . . 54.04 112.263 -179.116 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.547 ' O ' HG22 ' A' ' 28' ' ' VAL . 91.7 mt-30 -68.96 -169.76 0.19 Allowed 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 123.079 0.552 . . . . 70.15 111.257 -179.284 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.547 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.2 m 55.61 15.66 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 124.264 1.026 . . . . 75.0 111.832 -178.206 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.416 ' H ' ' HG2' ' A' ' 29' ' ' LYS . 40.1 pttt -81.42 -14.33 57.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.829 -0.623 . . . . 71.12 110.066 175.822 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -161.21 117.48 2.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.601 -0.727 . . . . 75.11 110.436 177.154 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.543 ' HB ' HD11 ' A' ' 9' ' ' ILE . 42.1 mt -138.6 152.71 25.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 109.105 -0.702 . . . . 74.23 109.105 179.161 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -105.07 -65.09 1.07 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.673 0.273 . . . . 73.04 110.646 179.018 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.57 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 96.5 m-85 -140.73 128.61 21.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.412 -0.358 . . . . 71.25 110.704 -179.203 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -88.08 119.59 70.43 Favored Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 109.158 -0.682 . . . . 73.11 109.158 175.27 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.01 152.47 43.76 Favored 'Trans proline' 0 C--O 1.236 0.402 0 C-N-CA 122.899 2.4 . . . . 63.24 113.29 -176.681 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.433 HG23 ' HA ' ' A' ' 59' ' ' LEU . 3.5 p -62.63 94.93 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-O 121.707 0.765 . . . . 72.31 111.023 178.235 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.0 t70 173.85 -43.41 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.574 -1.194 . . . . 75.53 109.36 -177.424 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.506 ' HE1' ' HB3' ' A' ' 20' ' ' TYR . 5.3 m-85 -50.41 123.01 7.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.039 -0.982 . . . . 74.11 112.596 -175.742 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.586 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 35.2 mt-10 -114.18 100.01 8.05 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.849 -1.069 . . . . 72.52 108.575 172.349 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.576 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 34.7 pt -90.7 143.64 10.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.142 0.496 . . . . 75.11 111.3 -175.772 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.49 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 42.5 tt0 -109.82 136.49 49.05 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.481 -0.781 . . . . 74.33 110.269 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.485 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 95.5 m-85 -85.43 100.58 11.97 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 116.216 -0.447 . . . . 75.13 110.051 175.473 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.3 m -100.98 163.39 3.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.045 -0.525 . . . . 43.53 110.199 179.389 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.805 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 3.4 t -90.38 147.07 23.68 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 107.93 -1.137 . . . . 51.42 107.93 173.112 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -59.72 108.61 0.77 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.17 0.509 . . . . 71.44 110.942 -170.907 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.21 -137.21 13.13 Favored Glycine 0 N--CA 1.448 -0.563 0 CA-C-N 115.703 -0.68 . . . . 62.21 112.086 178.612 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.475 ' CD ' ' H ' ' A' ' 47' ' ' GLU . 0.5 OUTLIER -101.22 33.53 2.85 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.301 0.572 . . . . 71.43 110.278 -179.274 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.805 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 30.1 mmm180 -89.22 145.49 25.37 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.786 -0.643 . . . . 74.21 109.974 179.682 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.617 ' HB2' ' HB3' ' A' ' 75' ' ' ARG . 43.1 mt-10 -91.57 148.96 21.9 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.231 0.538 . . . . 74.41 112.201 -174.295 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.742 HG13 ' HB2' ' A' ' 44' ' ' CYS . 11.6 m -138.64 150.46 23.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.368 -0.833 . . . . 54.31 110.131 178.083 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -135.65 97.35 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 122.019 0.914 . . . . 73.23 109.558 170.863 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.42 173.09 32.26 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-N 114.462 -1.245 . . . . 43.0 110.6 -177.647 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.497 ' HG2' HG21 ' A' ' 69' ' ' THR . 69.9 Cg_endo -77.17 57.38 5.81 Favored 'Trans proline' 0 C--O 1.235 0.358 0 C-N-CA 122.068 1.845 . . . . 70.42 110.733 176.813 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.485 ' HB2' ' H ' ' A' ' 42' ' ' TYR . 20.9 pttp -76.4 87.04 3.16 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.383 -0.826 . . . . 72.35 111.608 -173.08 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -162.57 128.54 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.397 -0.82 . . . . 74.12 109.906 172.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.586 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 26.9 mmt180 -130.1 123.69 31.0 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.622 -0.51 . . . . 73.32 109.622 175.281 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.7 ttmm -105.08 122.7 46.42 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.537 -0.542 . . . . 71.3 109.537 178.805 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.5 t -74.56 142.51 44.71 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.309 -0.405 . . . . 74.1 110.635 -179.571 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.433 ' HA ' HG23 ' A' ' 36' ' ' VAL . 94.7 mt -128.64 -179.24 4.95 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.844 -0.616 . . . . 75.32 109.516 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.02 59.27 2.13 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.367 0.603 . . . . 34.01 111.654 -177.669 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -160.52 165.05 31.55 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.802 -0.814 . . . . 74.35 108.802 175.328 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -80.73 40.27 2.45 Favored Glycine 0 CA--C 1.517 0.214 0 C-N-CA 120.662 -0.78 . . . . 74.22 113.067 -175.676 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 27.6 t -161.84 163.32 29.4 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.234 -0.654 . . . . 64.31 109.234 -178.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 52.8 m95 -97.16 -179.8 4.65 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 110.033 -0.358 . . . . 65.43 110.033 -176.486 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -56.35 -24.73 46.02 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 112.776 0.658 . . . . 71.12 112.776 -176.814 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.529 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 11.2 t70 -160.71 137.02 8.54 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.384 -0.599 . . . . 71.12 109.384 178.304 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 65.9 mtt -130.38 77.0 1.76 Allowed 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.436 -0.906 . . . . 72.34 110.611 164.655 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -170.83 88.63 0.12 Allowed 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 108.855 -0.795 . . . . 63.14 108.855 157.482 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.497 HG21 ' HG2' ' A' ' 53' ' ' PRO . 4.7 m -153.5 107.32 2.56 Favored Pre-proline 0 C--N 1.317 -0.809 0 C-N-CA 120.817 -0.353 . . . . 74.33 110.681 -176.867 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -70.21 95.52 0.59 Allowed 'Trans proline' 0 N--CA 1.462 -0.329 0 C-N-CA 122.694 2.263 . . . . 64.14 112.031 178.002 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 m -78.36 109.44 12.51 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.175 0.512 . . . . 73.3 109.775 177.069 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.402 ' H ' ' HG2' ' A' ' 72' ' ' ARG . 11.1 ptt180 -97.51 130.6 44.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.574 -0.739 . . . . 75.3 112.085 -172.204 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.513 ' HA ' HG12 ' A' ' 50' ' ' VAL . 81.2 m -82.66 118.25 23.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.665 -0.698 . . . . 74.22 109.824 175.03 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 p -156.36 136.44 4.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 121.082 0.467 . . . . 70.53 110.309 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.617 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 16.1 ptm180 . . . . . 0 C--O 1.244 0.765 0 CA-C-N 115.693 -0.685 . . . . 74.41 109.626 -178.167 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.545 0 N-CA-C 112.066 -0.413 . . . . 72.35 112.066 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -74.87 74.32 3.97 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.49 2.127 . . . . 72.1 112.845 -177.014 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 37.2 p -104.51 115.98 31.3 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.006 -0.543 . . . . 75.23 110.292 175.639 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.6 m -109.82 98.02 7.43 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.8 -0.444 . . . . 74.12 109.8 179.557 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -112.98 98.42 7.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.911 -0.586 . . . . 74.03 109.614 -177.512 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.741 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -162.2 152.57 22.94 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.492 -0.861 . . . . 52.24 112.7 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 60.7 m -90.11 147.53 23.56 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.985 -0.376 . . . . 72.14 109.985 176.77 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -85.81 -179.54 6.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.777 0.322 . . . . 64.22 110.892 -179.324 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.67 HD11 ' HB ' ' A' ' 31' ' ' ILE . 56.3 mt -88.16 130.62 37.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.939 -0.573 . . . . 73.43 110.313 176.831 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 68.7 mt -73.25 136.18 26.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.745 -0.661 . . . . 53.14 110.239 179.032 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.6 t-80 -68.81 138.1 90.39 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 115.989 -0.55 . . . . 73.31 109.936 -178.03 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_exo -40.97 118.87 0.72 Allowed 'Trans proline' 0 C--N 1.351 0.694 0 C-N-CA 123.716 2.944 . . . . 62.52 113.826 -176.723 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.457 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 81.7 Cg_endo -87.5 -149.02 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.128 2.552 . . . . 72.42 112.728 -179.51 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.457 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 9.1 t-105 -75.15 -179.01 4.14 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.69 -0.686 . . . . 72.24 110.516 -177.773 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -46.03 100.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 123.234 0.613 . . . . 74.13 112.172 177.267 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.13 -156.86 28.99 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.331 -0.708 . . . . 71.54 111.331 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.85 -171.23 24.4 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.562 -0.828 . . . . 73.45 111.925 178.028 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.63 131.44 66.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.651 0.738 . . . . 70.34 111.531 -178.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.707 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 7.9 tpm_? -96.92 104.56 16.58 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 114.298 -1.319 . . . . 74.22 110.064 -178.285 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.472 ' HA ' HG22 ' A' ' 40' ' ' ILE . 97.7 m-85 -80.5 -171.46 3.07 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.519 -0.309 . . . . 74.35 110.187 177.782 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.7 ttm180 -78.96 -65.35 1.01 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.67 0.272 . . . . 74.3 110.411 -178.843 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -136.16 37.4 1.89 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.423 -0.894 . . . . 71.12 112.275 -178.694 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.461 HD13 HG12 ' A' ' 28' ' ' VAL . 80.6 mt -102.52 119.73 39.32 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.925 0.393 . . . . 52.44 111.359 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.4 t -94.64 -177.2 4.13 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.712 -0.676 . . . . 75.32 109.662 175.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 77.5 mtt180 -66.88 -173.43 0.24 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.047 0.451 . . . . 73.32 111.627 -176.466 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.0 t0 59.07 19.24 7.1 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 122.029 0.919 . . . . 54.04 110.183 -177.796 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -140.35 -165.19 1.86 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.887 -1.052 . . . . 70.15 109.971 -178.39 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.461 HG12 HD13 ' A' ' 23' ' ' LEU . 11.5 m 49.44 24.01 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.312 1.045 . . . . 75.0 112.29 178.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -88.54 -22.38 23.61 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.789 -0.641 . . . . 71.12 110.758 -179.318 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.42 101.07 0.6 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.884 -0.598 . . . . 75.11 110.434 176.6 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.67 ' HB ' HD11 ' A' ' 9' ' ' ILE . 69.0 mt -127.99 138.24 55.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.155 -0.683 . . . . 74.23 109.155 177.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -79.83 -58.25 3.26 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.864 0.364 . . . . 73.04 110.543 -176.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.741 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 82.2 m-85 -139.27 138.4 36.73 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.971 -0.559 . . . . 71.25 110.953 -176.58 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.95 142.65 32.35 Favored Pre-proline 0 C--N 1.322 -0.593 0 N-CA-C 109.11 -0.7 . . . . 73.11 109.11 172.78 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -61.33 161.68 22.73 Favored 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 122.648 2.232 . . . . 63.24 112.727 -179.187 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 p -68.11 143.62 15.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.763 -0.653 . . . . 72.31 110.886 -178.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.5 t70 68.13 19.73 9.13 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.663 0.744 . . . . 75.53 110.942 -178.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -78.12 132.02 37.49 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.742 -0.836 . . . . 74.11 108.742 173.234 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -123.1 138.28 54.71 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.461 -0.336 . . . . 72.52 110.404 -175.147 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.615 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 14.5 pt -129.88 150.17 34.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.807 -0.633 . . . . 75.11 110.684 -177.69 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.707 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 37.7 tt0 -115.44 152.3 33.17 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.946 -0.57 . . . . 74.33 110.551 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.412 ' HE2' ' HG2' ' A' ' 56' ' ' ARG . 81.6 m-85 -100.11 101.87 13.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.256 -0.429 . . . . 75.13 110.854 178.122 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.3 m -94.55 155.02 3.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 120.727 0.299 . . . . 43.53 110.244 177.323 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 9.8 t -90.91 -179.3 5.45 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.405 -0.591 . . . . 51.42 109.405 -178.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.473 ' HD3' ' HA ' ' A' ' 45' ' ' ARG . 2.3 mmt180 -81.5 153.99 26.53 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.744 -0.382 . . . . 71.44 111.342 -179.167 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.12 -138.44 24.47 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 110.856 -0.898 . . . . 62.21 110.856 -174.175 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -111.08 19.83 18.04 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.475 0.655 . . . . 71.43 109.389 174.545 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.584 ' HA ' ' HD2' ' A' ' 75' ' ' ARG . 7.4 mmm180 -88.9 150.9 22.64 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.269 -0.878 . . . . 74.21 109.556 -177.408 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.496 ' H ' ' HB3' ' A' ' 75' ' ' ARG . 37.6 mt-10 -120.99 170.44 9.51 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.868 0.366 . . . . 74.41 111.005 -171.277 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.405 HG12 ' HA ' ' A' ' 73' ' ' CYS . 22.7 m -118.3 150.5 20.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.202 -0.453 . . . . 54.31 110.903 -177.634 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.66 HG12 ' HB ' ' A' ' 74' ' ' VAL . 6.4 p -113.01 96.76 4.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 122.156 0.979 . . . . 73.23 109.116 170.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.55 173.4 33.01 Favored Glycine 0 N--CA 1.442 -0.966 0 CA-C-N 114.834 -1.076 . . . . 43.0 110.874 -177.408 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.49 ' HG2' HG21 ' A' ' 69' ' ' THR . 47.9 Cg_endo -72.39 60.32 3.3 Favored 'Trans proline' 0 CA--C 1.529 0.26 0 C-N-CA 122.191 1.927 . . . . 70.42 110.304 170.008 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.569 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 32.1 pttt -73.62 89.52 1.74 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.139 -0.937 . . . . 72.35 111.209 -175.411 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.9 p -160.08 132.71 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.727 -0.67 . . . . 74.12 110.51 178.183 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.615 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 24.2 mmt180 -125.68 114.96 19.36 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.185 -0.672 . . . . 73.32 109.185 173.126 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 41.9 tptt -102.54 116.95 33.64 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.459 -0.791 . . . . 71.3 109.914 -176.147 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' CYS . . . . . 0.563 ' HB2' ' CZ3' ' A' ' 64' ' ' TRP . 49.3 t -87.91 124.5 33.74 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.137 -0.483 . . . . 74.1 110.074 177.779 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.415 HD11 HG21 ' A' ' 65' ' ' THR . 41.9 mt -105.08 -177.55 3.4 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.814 -0.63 . . . . 75.32 109.43 176.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -56.63 -32.29 65.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.091 0.472 . . . . 34.01 110.431 174.042 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -81.06 132.08 35.34 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.44 -0.578 . . . . 74.35 109.44 172.767 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -77.82 64.1 3.38 Favored Glycine 0 N--CA 1.451 -0.313 0 N-CA-C 114.299 0.479 . . . . 74.22 114.299 -171.164 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 58.2 m -157.14 142.27 17.11 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.539 -0.541 . . . . 64.31 109.539 172.278 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.563 ' CZ3' ' HB2' ' A' ' 58' ' ' CYS . 23.1 m95 -78.19 124.4 28.02 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.05 -0.722 . . . . 65.43 109.05 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.415 HG21 HD11 ' A' ' 59' ' ' LEU . 17.2 p -75.62 33.03 0.11 Allowed 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 114.358 1.244 . . . . 71.12 114.358 -167.805 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -160.75 13.91 0.11 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.865 0.364 . . . . 71.12 110.056 176.224 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 26.1 ttt -76.65 78.94 3.3 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-O 121.875 0.845 . . . . 72.34 112.416 -165.62 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -169.68 88.88 0.17 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 114.382 -1.281 . . . . 63.14 107.783 159.284 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.49 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.7 OUTLIER -152.78 117.86 2.93 Favored Pre-proline 0 C--N 1.318 -0.801 0 C-N-CA 120.19 -0.604 . . . . 74.33 111.345 -169.751 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -78.72 100.53 1.37 Allowed 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.885 2.39 . . . . 64.14 111.318 174.399 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.7 p -79.39 116.83 19.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.051 0.453 . . . . 73.3 111.112 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.8 ptp180 -89.47 129.2 36.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.729 -0.668 . . . . 75.3 111.285 -177.223 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.405 ' HA ' HG12 ' A' ' 50' ' ' VAL . 62.3 m -82.88 105.5 13.94 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.718 -0.475 . . . . 74.22 109.718 178.481 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.66 ' HB ' HG12 ' A' ' 51' ' ' VAL . 49.1 t -128.33 84.27 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 121.072 0.463 . . . . 70.53 109.76 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.584 ' HD2' ' HA ' ' A' ' 48' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.751 0 N-CA-C 108.54 -0.911 . . . . 74.41 108.54 -178.728 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.582 0 N-CA-C 111.964 -0.454 . . . . 72.35 111.964 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -69.6 92.9 0.5 Allowed 'Trans proline' 0 C--O 1.236 0.413 0 C-N-CA 122.723 2.282 . . . . 72.1 111.098 176.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 16.9 p -91.82 99.26 12.16 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.941 -0.572 . . . . 75.23 112.369 -173.668 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.3 m -95.24 107.59 19.7 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.354 -0.98 . . . . 74.12 108.354 169.66 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -78.2 99.88 6.41 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.275 0.56 . . . . 74.03 111.195 -172.145 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.6 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -159.47 146.96 13.64 Favored Glycine 0 N--CA 1.44 -1.054 0 CA-C-N 115.239 -0.891 . . . . 52.24 111.678 179.464 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.9 m -92.88 142.93 26.77 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 110.05 -0.352 . . . . 72.14 110.05 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -76.02 -177.62 3.99 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.884 0.374 . . . . 64.22 111.055 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 61.3 mt -87.38 137.66 20.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.057 -0.52 . . . . 73.43 111.176 -175.838 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 27.5 mt -84.13 156.57 3.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.5 -0.773 . . . . 53.14 110.217 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -82.68 141.47 44.77 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.64 -0.255 . . . . 73.31 110.67 -177.559 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.54 131.32 21.3 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.74 2.293 . . . . 62.52 112.462 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -87.6 -140.1 0.02 OUTLIER 'Trans proline' 0 CA--C 1.533 0.43 0 C-N-CA 123.176 2.584 . . . . 72.42 112.393 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.523 ' HD1' ' H ' ' A' ' 15' ' ' GLU . 1.9 t90 -67.54 -179.44 1.08 Allowed 'General case' 0 CA--C 1.537 0.452 0 CA-C-N 116.071 -0.513 . . . . 72.24 109.641 178.248 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.523 ' H ' ' HD1' ' A' ' 14' ' ' TRP . 29.3 mm-40 -43.2 102.38 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 123.629 0.772 . . . . 74.13 112.886 -176.343 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.08 -154.82 25.66 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 110.224 -1.15 . . . . 71.54 110.224 -177.285 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.95 -171.36 37.61 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.224 -0.989 . . . . 73.45 112.064 176.668 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.7 mt -111.54 128.88 67.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.745 0.783 . . . . 70.34 111.279 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.76 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 9.2 tpt180 -96.76 127.3 42.61 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.581 -1.191 . . . . 74.22 108.966 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.525 ' HA ' HG22 ' A' ' 40' ' ' ILE . 77.4 m-85 -91.02 -172.46 3.34 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.341 -0.544 . . . . 74.35 110.021 178.647 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 21' ' ' ARG . 18.9 ttt85 -80.69 -62.78 1.57 Allowed 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.602 -0.439 . . . . 74.3 110.753 -172.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -146.98 57.02 0.5 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.693 -0.765 . . . . 71.12 111.986 177.768 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 93.2 mt -119.41 139.5 51.92 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.975 0.417 . . . . 52.44 111.246 -176.637 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.8 t -86.47 173.11 9.84 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.928 -0.578 . . . . 75.32 109.49 174.528 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.503 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 31.7 ptt180 -79.83 -171.52 2.91 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 121.12 -0.232 . . . . 73.32 110.581 -177.135 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.503 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 12.6 t70 72.77 -38.9 0.43 Allowed 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 109.178 -0.675 . . . . 54.04 109.178 -168.663 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.509 ' O ' HG22 ' A' ' 28' ' ' VAL . 96.6 mt-30 -83.33 -169.12 2.38 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.602 -0.888 . . . . 70.15 108.602 167.096 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.509 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.2 m 55.6 9.54 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 C-N-CA 124.219 1.008 . . . . 75.0 113.593 174.629 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -92.99 -29.13 16.0 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.076 0.465 . . . . 71.12 109.827 176.541 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.36 91.8 1.63 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.766 -0.652 . . . . 75.11 110.561 177.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.9 mt -115.79 135.7 55.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.706 -0.679 . . . . 74.23 109.209 177.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 15.5 m120 -72.94 -59.76 2.56 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.684 0.278 . . . . 73.04 110.925 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.6 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 74.4 m-85 -131.88 129.9 40.94 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.819 0.343 . . . . 71.25 111.171 -177.163 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.417 ' HA ' ' HD2' ' A' ' 35' ' ' PRO . 3.7 mm? -90.96 113.05 56.81 Favored Pre-proline 0 C--N 1.322 -0.619 0 N-CA-C 108.181 -1.044 . . . . 73.11 108.181 169.026 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.417 ' HD2' ' HA ' ' A' ' 34' ' ' LEU . 11.6 Cg_endo -53.61 156.27 11.88 Favored 'Trans proline' 0 C--O 1.234 0.28 0 C-N-CA 123.432 2.755 . . . . 63.24 113.549 -172.516 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.516 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 13.3 p -54.78 147.44 3.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.484 -0.78 . . . . 72.31 111.098 178.861 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.516 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 15.0 m-20 79.23 5.05 2.23 Favored 'General case' 0 N--CA 1.467 0.425 0 C-N-CA 123.654 0.782 . . . . 75.53 111.571 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.511 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 24.3 t80 -82.75 144.97 29.82 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.808 0.337 . . . . 74.11 110.241 178.406 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.537 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 37.0 mt-10 -135.25 138.16 43.27 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.916 -0.584 . . . . 72.52 110.283 -177.374 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.645 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 20.3 pt -125.76 158.94 34.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 120.805 0.335 . . . . 75.11 110.77 177.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.76 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 49.8 tt0 -116.16 149.86 38.37 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.859 -0.61 . . . . 74.33 110.976 -174.773 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.409 ' HE2' ' CG ' ' A' ' 56' ' ' ARG . 8.2 m-85 -94.33 102.01 13.99 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.28 -0.418 . . . . 75.13 110.185 175.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.602 HG11 HH11 ' A' ' 19' ' ' ARG . 18.2 m -108.42 156.43 8.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.109 0.481 . . . . 43.53 111.63 -177.46 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.546 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 5.2 t -96.35 158.47 15.42 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.193 -1.04 . . . . 51.42 108.193 178.437 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -65.59 117.72 8.47 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.26 0.467 . . . . 71.44 112.26 -174.407 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.34 -137.32 13.65 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.587 -0.733 . . . . 62.21 111.807 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -98.79 22.67 9.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.864 0.84 . . . . 71.43 109.077 174.223 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.594 ' HD2' ' OXT' ' A' ' 75' ' ' ARG . 10.7 mmm180 -88.18 134.19 33.84 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.642 -1.163 . . . . 74.21 109.184 -178.816 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.618 ' H ' ' HB3' ' A' ' 75' ' ' ARG . 46.4 mt-10 -116.66 170.1 8.85 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 120.98 0.419 . . . . 74.41 110.924 -179.06 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.54 HG12 ' HA ' ' A' ' 73' ' ' CYS . 28.9 m -116.85 149.53 19.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.405 -0.816 . . . . 54.31 109.206 174.199 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -106.12 95.09 3.52 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 122.035 0.922 . . . . 73.23 108.681 170.84 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.74 172.58 33.8 Favored Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 114.607 -1.179 . . . . 43.0 111.667 -176.041 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.506 ' HG2' ' CG2' ' A' ' 69' ' ' THR . 56.5 Cg_endo -73.72 53.1 2.68 Favored 'Trans proline' 0 CA--C 1.532 0.413 0 C-N-CA 122.494 2.129 . . . . 70.42 110.713 171.076 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 48.2 pttt -69.03 91.34 0.48 Allowed 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 114.805 -1.089 . . . . 72.35 111.948 -173.436 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.2 p -160.83 132.11 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.553 0.692 . . . . 74.12 110.912 175.057 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.645 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 42.9 mmt180 -121.23 113.82 20.5 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.528 -0.76 . . . . 73.32 109.128 172.402 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -108.78 129.78 55.38 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.155 -0.475 . . . . 71.3 110.084 -177.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 52.4 t -96.72 113.86 25.45 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.26 -0.427 . . . . 74.1 110.244 178.41 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.551 ' HB2' ' OD1' ' A' ' 61' ' ' ASN . 35.9 mt -96.45 -176.05 3.51 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.121 -0.696 . . . . 75.32 109.121 177.439 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -71.4 55.81 0.23 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-O 121.214 0.53 . . . . 34.01 111.18 177.685 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.551 ' OD1' ' HB2' ' A' ' 59' ' ' LEU . 4.4 p-10 -160.34 167.64 26.99 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.706 -0.85 . . . . 74.35 108.706 178.914 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -91.79 47.15 2.73 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.488 -0.863 . . . . 74.22 113.62 -171.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 38.9 m -160.59 136.33 8.22 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 117.041 0.42 . . . . 64.31 110.797 178.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' TRP . . . . . 0.433 ' HB2' ' CG ' ' A' ' 67' ' ' MET . 63.0 m95 -71.41 123.22 21.88 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.02 -1.104 . . . . 65.43 108.02 171.628 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.543 HG21 HD12 ' A' ' 59' ' ' LEU . 13.6 p -77.23 38.23 0.22 Allowed 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 115.074 1.509 . . . . 71.12 115.074 -164.329 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -162.51 20.16 0.09 Allowed 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 120.413 -0.515 . . . . 71.12 111.818 173.662 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' MET . . . . . 0.433 ' CG ' ' HB2' ' A' ' 64' ' ' TRP . 58.3 mtm -76.28 79.53 3.05 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 119.311 -0.956 . . . . 72.34 112.412 -168.793 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -169.76 89.27 0.17 Allowed 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 107.495 -1.298 . . . . 63.14 107.495 161.359 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.506 ' CG2' ' HG2' ' A' ' 53' ' ' PRO . 2.8 m -147.2 124.63 5.84 Favored Pre-proline 0 C--N 1.321 -0.65 0 C-N-CA 119.595 -0.842 . . . . 74.33 112.387 -168.265 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' PRO . . . . . 0.486 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 9.6 Cg_endo -89.21 90.49 0.38 Allowed 'Trans proline' 0 N--CA 1.451 -0.989 0 C-N-CA 123.388 2.725 . . . . 64.14 111.62 174.471 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.1 m -90.31 118.17 29.6 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.263 -0.426 . . . . 73.3 110.149 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.5 ptp180 -89.15 119.47 29.68 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.054 -0.521 . . . . 75.3 111.334 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.54 ' HA ' HG12 ' A' ' 50' ' ' VAL . 41.1 t -72.52 105.5 4.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.068 -0.515 . . . . 74.22 110.243 179.155 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.5 t -135.69 100.53 2.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.899 -0.591 . . . . 70.53 110.503 -177.778 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.618 ' HB3' ' H ' ' A' ' 49' ' ' GLU . 15.1 ttm180 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 118.451 -0.785 . . . . 74.41 109.558 176.159 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.478 ' HA2' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.485 1.93 0 N-CA-C 111.807 -0.517 . . . . 72.35 111.807 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.478 ' HD3' ' HA2' ' A' ' 1' ' ' GLY . 1.0 OUTLIER -82.01 86.61 1.52 Allowed 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 123.15 2.567 . . . . 72.1 112.507 -177.831 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 20.7 p -116.0 99.44 7.27 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.277 0.56 . . . . 75.23 110.728 178.007 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.8 m -126.41 99.75 5.97 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.106 -0.497 . . . . 74.12 111.212 -176.748 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -121.67 103.8 9.15 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.497 -0.557 . . . . 74.03 109.497 176.045 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -159.87 171.15 36.16 Favored Glycine 0 N--CA 1.443 -0.894 0 C-N-CA 120.481 -0.866 . . . . 52.24 112.86 -175.461 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 58.3 m -106.47 148.06 28.62 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.843 -0.429 . . . . 72.14 109.843 -178.907 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 19.2 pt20 -84.21 -179.9 7.32 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.001 0.429 . . . . 64.22 111.192 -178.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.584 HD12 ' H ' ' A' ' 31' ' ' ILE . 42.1 mt -88.68 143.67 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.596 -0.729 . . . . 73.43 110.343 177.686 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.1 mt -98.91 166.66 2.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.705 -0.68 . . . . 53.14 109.968 -177.117 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 76.5 m-70 -89.71 138.66 27.96 Favored Pre-proline 0 C--N 1.325 -0.458 0 N-CA-C 109.899 -0.408 . . . . 73.31 109.899 178.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.406 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 55.4 Cg_endo -72.36 106.34 2.05 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.29 1.993 . . . . 62.52 111.384 174.512 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 11.5 Cg_endo -88.85 -74.96 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 123.054 2.502 . . . . 72.42 113.566 -174.114 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 32.9 t-105 -100.29 -176.46 3.23 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.19 -0.459 . . . . 72.24 109.834 -175.526 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -49.85 -29.36 7.92 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 122.896 0.478 . . . . 74.13 111.539 178.092 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.25 102.3 1.35 Allowed Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.715 -0.755 . . . . 71.54 111.813 176.433 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -88.98 -169.74 44.81 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 121.148 -0.549 . . . . 73.45 112.052 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 28.4 mt -116.11 137.95 48.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.795 0.807 . . . . 70.34 112.337 -174.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 19' ' ' ARG . 11.2 tpt180 -116.59 132.78 56.59 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 114.287 -1.324 . . . . 74.22 108.825 -179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.573 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 56.0 m-85 -92.33 -172.03 2.98 Favored 'General case' 0 C--N 1.318 -0.772 0 C-N-CA 120.703 -0.399 . . . . 74.35 110.604 -179.578 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.521 ' HB2' ' O ' ' A' ' 39' ' ' GLU . 7.4 tmm_? -112.64 -42.21 3.68 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.126 0.489 . . . . 74.3 110.287 -171.75 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -146.09 56.54 0.52 Allowed Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 121.008 -0.615 . . . . 71.12 111.716 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 40.9 mt -143.15 141.68 31.25 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.946 0.403 . . . . 52.44 110.555 179.263 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -99.65 -178.95 4.04 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.691 -0.686 . . . . 75.32 110.197 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.475 ' C ' ' H ' ' A' ' 27' ' ' GLN . 33.0 ptt180 -66.55 -172.63 0.17 Allowed 'General case' 0 C--O 1.234 0.243 0 CA-C-N 116.051 -0.522 . . . . 73.32 111.409 -179.411 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.6 t70 70.24 -38.67 0.42 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.318 0.647 . . . . 54.04 111.043 -176.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.54 ' O ' HG22 ' A' ' 28' ' ' VAL . 90.2 mt-30 -94.73 -153.25 0.38 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.605 -0.725 . . . . 70.15 109.847 176.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.54 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.6 m 57.8 13.16 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 124.584 1.154 . . . . 75.0 112.939 176.349 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 56.7 mtpt -106.1 -38.42 6.29 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.928 0.394 . . . . 71.12 110.218 176.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.22 86.71 2.25 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.032 -0.531 . . . . 75.11 110.704 177.071 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.584 ' H ' HD12 ' A' ' 9' ' ' ILE . 70.7 mt -134.68 121.98 37.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 N-CA-C 108.521 -0.918 . . . . 74.23 108.521 176.524 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 15.0 p-10 -84.1 -24.46 30.31 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 113.229 0.826 . . . . 73.04 113.229 -170.334 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 -140.15 109.42 6.16 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 113.06 0.763 . . . . 71.25 113.06 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.45 112.18 48.32 Favored Pre-proline 0 C--N 1.323 -0.548 0 N-CA-C 107.77 -1.196 . . . . 73.11 107.77 165.166 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -58.85 152.0 60.7 Favored 'Trans proline' 0 N--CA 1.474 0.362 0 C-N-CA 123.057 2.504 . . . . 63.24 113.63 -170.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.482 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 2.5 p -61.48 94.92 0.08 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 115.559 -0.746 . . . . 72.31 110.58 175.697 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.482 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 18.3 t70 160.92 -29.9 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 114.488 -1.233 . . . . 75.53 108.367 -174.815 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.573 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 6.4 t80 -73.72 146.66 44.24 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.625 -1.171 . . . . 74.11 111.818 -173.891 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.521 ' O ' ' HB2' ' A' ' 21' ' ' ARG . 27.0 mt-10 -125.74 150.47 47.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.5 -0.773 . . . . 72.52 109.883 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.613 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 38.3 pt -132.99 149.31 31.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.948 0.404 . . . . 75.11 110.879 174.17 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.462 ' HG3' ' HD3' ' A' ' 54' ' ' LYS . 41.3 tt0 -118.64 171.44 8.19 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.476 -0.783 . . . . 74.33 109.396 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' TYR . . . . . 0.414 ' N ' ' HG2' ' A' ' 41' ' ' GLU . 73.1 m-85 -113.65 100.86 8.8 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.869 0.366 . . . . 75.13 111.176 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.6 m -96.98 132.1 42.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.013 0.435 . . . . 43.53 109.94 175.294 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.509 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 39.1 t -89.16 148.51 23.61 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.265 0.555 . . . . 51.42 110.941 -174.085 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -59.11 133.62 56.26 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.579 -1.191 . . . . 71.44 110.702 -176.239 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 86.29 -119.24 5.09 Favored Glycine 0 N--CA 1.444 -0.823 0 N-CA-C 110.67 -0.972 . . . . 62.21 110.67 -173.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -141.5 83.1 1.85 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.411 0.624 . . . . 71.43 109.812 173.149 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.647 ' HB3' ' HB2' ' A' ' 73' ' ' CYS . 42.7 mmt180 -132.89 130.05 39.18 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.434 -0.803 . . . . 74.21 110.081 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -86.25 139.69 30.8 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 109.958 -0.386 . . . . 74.41 109.958 178.04 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.444 HG12 ' HB3' ' A' ' 73' ' ' CYS . 30.5 m -97.82 127.32 50.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.224 -0.444 . . . . 54.31 111.096 -178.874 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.8 p -98.68 94.08 3.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 122.246 1.022 . . . . 73.23 109.287 174.042 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -156.82 171.06 34.29 Favored Glycine 0 N--CA 1.44 -1.059 0 CA-C-N 114.485 -1.234 . . . . 43.0 111.292 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -73.19 55.07 2.88 Favored 'Trans proline' 0 CA--C 1.531 0.341 0 C-N-CA 122.553 2.168 . . . . 70.42 110.255 168.252 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.585 ' O ' ' HD2' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -72.04 93.54 1.41 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.899 0.856 . . . . 72.35 112.718 -170.878 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.497 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.2 p -161.57 128.75 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 115.527 -0.76 . . . . 74.12 109.862 170.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.613 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 29.1 mmt180 -132.83 115.62 15.52 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.303 -0.629 . . . . 73.32 109.303 177.261 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.43 ' HE2' ' HG2' ' A' ' 39' ' ' GLU . 37.2 ttmt -115.02 136.91 52.61 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 108.986 -0.746 . . . . 71.3 108.986 178.328 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.7 t -73.78 139.95 45.54 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.826 0.346 . . . . 74.1 110.856 -176.333 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.481 ' C ' ' H ' ' A' ' 61' ' ' ASN . 87.3 mt -96.57 -179.53 4.64 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.779 -0.646 . . . . 75.32 110.548 -178.372 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.47 36.98 0.26 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-O 121.877 0.846 . . . . 34.01 109.304 174.128 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.481 ' H ' ' C ' ' A' ' 59' ' ' LEU . 0.9 OUTLIER -157.33 155.99 31.58 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.408 -1.269 . . . . 74.35 108.226 -172.37 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -74.45 50.31 2.06 Favored Glycine 0 CA--C 1.52 0.368 0 C-N-CA 121.114 -0.565 . . . . 74.22 113.215 -176.793 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 55.6 m -159.32 149.86 19.41 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 123.088 0.555 . . . . 64.31 109.518 178.787 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -83.53 175.19 9.96 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 110.171 -0.307 . . . . 65.43 110.171 -176.87 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 57' ' ' LYS . 1.4 p -50.56 -48.21 57.5 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.444 0.535 . . . . 71.12 112.444 -177.55 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -153.86 140.45 18.89 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.673 -0.862 . . . . 71.12 108.673 179.512 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 23.1 mmt -139.59 79.54 1.72 Allowed 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 120.235 -0.586 . . . . 72.34 110.557 168.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -168.48 87.93 0.21 Allowed 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 108.032 -1.099 . . . . 63.14 108.032 163.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.42 ' CB ' HH22 ' A' ' 56' ' ' ARG . 1.1 m -152.42 128.96 5.38 Favored Pre-proline 0 C--N 1.319 -0.751 0 C-N-CA 120.433 -0.507 . . . . 74.33 111.064 -169.82 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -74.99 69.29 5.58 Favored 'Trans proline' 0 CA--C 1.532 0.398 0 C-N-CA 122.772 2.315 . . . . 64.14 112.596 177.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 8.5 p -78.28 121.11 23.99 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.748 -0.464 . . . . 73.3 109.748 175.468 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.2 ptp85 -133.28 141.62 48.09 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.8 0.333 . . . . 75.3 111.624 -174.16 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.647 ' HB2' ' HB3' ' A' ' 48' ' ' ARG . 1.8 p -107.58 104.22 13.71 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.819 -0.628 . . . . 74.22 110.373 178.219 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.82 9.02 5.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.443 0.639 . . . . 70.53 110.755 -174.626 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.6 ttp180 . . . . . 0 C--O 1.246 0.901 0 CA-C-O 118.659 -0.686 . . . . 74.41 109.998 178.371 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.9 m . . . . . 0 N--CA 1.449 -0.509 0 CA-C-O 121.306 0.574 . . . . 74.12 109.631 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -114.16 97.91 6.64 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.844 -0.617 . . . . 74.03 109.756 -177.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -163.16 171.1 38.82 Favored Glycine 0 N--CA 1.439 -1.113 0 C-N-CA 120.728 -0.749 . . . . 52.24 112.223 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 26.0 m -104.32 153.53 20.92 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.74 -0.467 . . . . 72.14 109.74 177.035 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.401 ' HB2' HE21 ' A' ' 8' ' ' GLN . 2.5 pt20 -89.6 -178.86 5.66 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.927 0.394 . . . . 64.22 111.13 -179.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.617 HD11 ' HB ' ' A' ' 31' ' ' ILE . 26.6 mt -87.98 120.55 37.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.928 -0.578 . . . . 73.43 110.022 177.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 63.1 mt -74.95 138.38 21.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.212 -0.904 . . . . 53.14 110.525 -178.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 81.1 m-70 -80.54 132.09 59.45 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 116.118 -0.492 . . . . 73.31 109.768 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.463 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.6 Cg_exo -51.05 113.18 0.98 Allowed 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 123.319 2.679 . . . . 62.52 112.838 -178.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 4.7 Cg_exo -76.51 -80.0 0.01 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.43 0 C-N-CA 122.881 2.388 . . . . 72.42 112.278 -178.615 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.0 t-105 -101.39 -178.09 3.63 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.602 -0.518 . . . . 72.24 109.602 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -58.71 100.54 0.07 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.133 0.492 . . . . 74.13 111.086 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.509 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . 175.81 -158.29 25.11 Favored Glycine 0 N--CA 1.443 -0.847 0 C-N-CA 120.854 -0.688 . . . . 71.54 112.009 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -161.1 -171.28 26.88 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 111.296 -0.721 . . . . 73.45 111.296 178.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.9 mt -125.68 131.4 72.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.792 0.806 . . . . 70.34 111.804 -178.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.797 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 23.3 tpp180 -93.51 110.65 22.23 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.317 -1.31 . . . . 74.22 109.935 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -90.95 -171.52 3.03 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.778 0.323 . . . . 74.35 110.358 177.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.456 ' NH2' ' HB2' ' A' ' 39' ' ' GLU . 97.8 mtt180 -109.72 -86.58 0.52 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.446 -0.343 . . . . 74.3 110.894 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -88.4 48.06 3.54 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 121.18 -0.533 . . . . 71.12 112.702 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 91.8 mt -137.91 133.41 33.77 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.09 -0.337 . . . . 52.44 110.09 178.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.4 t -95.99 179.55 5.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.745 -0.465 . . . . 75.32 109.745 174.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' GLN . 63.9 mtm-85 -79.54 -171.38 2.76 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.581 -0.282 . . . . 73.32 110.962 -177.438 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.474 ' O ' ' HE2' ' A' ' 29' ' ' LYS . 34.7 t70 68.5 -27.03 0.14 Allowed 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 123.329 0.652 . . . . 54.04 110.928 -170.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ARG . 19.4 mt-30 -90.33 -146.07 0.18 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.703 -0.681 . . . . 70.15 110.028 175.169 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.467 HG22 ' O ' ' A' ' 27' ' ' GLN . 4.8 m 54.26 19.75 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.509 1.123 . . . . 75.0 112.733 177.293 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.474 ' HE2' ' O ' ' A' ' 26' ' ' ASP . 49.9 mtmt -101.41 -74.85 0.61 Allowed 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.823 -0.436 . . . . 71.12 109.823 175.145 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.11 89.53 4.06 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.448 0.642 . . . . 75.11 111.253 178.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.617 ' HB ' HD11 ' A' ' 9' ' ' ILE . 64.9 mt -125.44 138.86 53.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.255 -0.884 . . . . 74.23 108.634 175.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 37.4 m-80 -74.39 -70.2 0.41 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.636 0.255 . . . . 73.04 110.864 -177.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -141.55 139.43 33.2 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.017 0.437 . . . . 71.25 111.301 -177.026 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -78.85 147.0 69.74 Favored Pre-proline 0 C--N 1.321 -0.646 0 N-CA-C 109.079 -0.711 . . . . 73.11 109.079 172.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -61.47 151.36 80.26 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.684 2.256 . . . . 63.24 112.26 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.2 p -61.13 138.24 22.22 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 CA-C-N 116.388 -0.369 . . . . 72.31 110.132 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 16.8 t70 61.97 75.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.817 0.818 . . . . 75.53 110.421 -172.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -133.28 124.68 27.75 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 107.464 -1.31 . . . . 74.11 107.464 175.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.714 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 39.5 mt-10 -111.98 124.9 53.38 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.099 0.476 . . . . 72.52 111.537 -172.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.489 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 32.6 pt -116.0 167.28 9.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.122 -0.944 . . . . 75.11 111.019 -177.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.797 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 44.7 tt0 -125.05 146.2 49.55 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.855 -0.611 . . . . 74.33 110.542 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.494 ' HE2' ' HG3' ' A' ' 56' ' ' ARG . 25.8 m-85 -97.67 103.07 14.97 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.323 -0.399 . . . . 75.13 110.762 178.078 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 32.7 m -97.58 157.45 3.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 120.825 0.345 . . . . 43.53 111.055 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.541 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 48.3 t -89.53 158.42 17.68 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-N 116.037 -0.529 . . . . 51.42 109.608 178.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . 0.509 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 31.3 ttt180 -58.13 121.24 10.21 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.858 -1.065 . . . . 71.44 111.873 -169.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 93.61 -128.95 9.67 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.874 -0.891 . . . . 62.21 110.874 -176.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -114.95 37.98 3.31 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.5 0.667 . . . . 71.43 110.009 172.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.541 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 27.3 mmt180 -88.84 146.44 24.96 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.434 -0.803 . . . . 74.21 109.356 178.194 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -103.46 166.18 10.58 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.04 0.448 . . . . 74.41 110.848 -177.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.571 HG12 ' HA ' ' A' ' 73' ' ' CYS . 35.4 m -132.97 145.96 33.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 115.921 -0.581 . . . . 54.31 109.835 177.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.6 p -108.18 95.81 4.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 122.195 0.998 . . . . 73.23 109.42 172.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.82 172.82 33.23 Favored Glycine 0 N--CA 1.443 -0.893 0 CA-C-N 114.47 -1.241 . . . . 43.0 110.801 -178.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.77 67.27 5.74 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.773 1.649 . . . . 70.42 110.552 172.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.555 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 31.9 pttt -84.32 87.65 7.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.36 -0.836 . . . . 72.35 111.532 -173.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -160.89 129.18 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.262 -0.881 . . . . 74.12 109.286 174.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.714 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 28.7 mmt85 -133.18 109.95 9.8 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 116.531 -0.304 . . . . 73.32 110.584 -177.261 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -96.66 118.6 33.48 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.822 -0.436 . . . . 71.3 109.822 178.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.8 t -62.62 132.74 53.37 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.919 -0.582 . . . . 74.1 110.954 177.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 90.2 mt -97.42 -178.58 4.2 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.873 -0.603 . . . . 75.32 110.61 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.19 -1.87 34.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.04 0.448 . . . . 34.01 111.043 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -119.63 169.78 9.78 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.41 -0.589 . . . . 74.35 109.41 177.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -75.33 62.35 2.65 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.079 -0.582 . . . . 74.22 113.35 -175.266 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 27.6 t -170.28 160.55 7.82 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.674 -0.491 . . . . 64.31 109.674 176.289 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 58.5 m95 -97.03 174.63 6.67 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.482 -0.562 . . . . 65.43 109.482 -177.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -49.89 -75.4 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.382 0 N-CA-C 112.815 0.672 . . . . 71.12 112.815 -176.026 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -115.89 94.76 4.81 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.377 -0.601 . . . . 71.12 109.377 176.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 13.5 tpt -93.42 75.35 4.49 Favored 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 119.192 -1.003 . . . . 72.34 110.253 -177.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -172.65 96.73 0.14 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.585 -1.188 . . . . 63.14 108.235 159.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.6 m -142.07 108.91 5.87 Favored Pre-proline 0 C--N 1.317 -0.846 0 C-N-CA 119.671 -0.812 . . . . 74.33 111.714 -172.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -77.56 93.84 1.08 Allowed 'Trans proline' 0 N--CA 1.458 -0.582 0 C-N-CA 122.62 2.213 . . . . 64.14 111.834 176.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 35.8 p -81.34 107.34 14.04 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.054 -0.521 . . . . 73.3 110.368 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -78.84 120.07 22.94 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.245 0.545 . . . . 75.3 110.477 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.571 ' HA ' HG12 ' A' ' 50' ' ' VAL . 24.0 t -72.32 110.1 6.51 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.559 -0.746 . . . . 74.22 109.799 -178.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 98.4 t -134.37 126.13 48.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.973 -0.558 . . . . 70.53 110.293 -174.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 75' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.229 -0.891 . . . . 74.41 109.79 178.415 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.3 m . . . . . 0 N--CA 1.449 -0.478 0 N-CA-C 109.499 -0.556 . . . . 74.12 109.499 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 49.1 mm-40 -83.11 109.19 16.94 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.986 -0.552 . . . . 74.03 110.538 -177.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.602 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -150.26 141.54 8.86 Favored Glycine 0 N--CA 1.443 -0.895 0 C-N-CA 120.737 -0.744 . . . . 52.24 112.365 -178.193 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 37.4 m -88.96 154.03 20.55 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 110.109 -0.33 . . . . 72.14 110.109 178.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -86.89 177.76 7.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.017 0.437 . . . . 64.22 111.681 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.575 HD11 ' HB ' ' A' ' 31' ' ' ILE . 72.0 mt -87.79 118.9 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.527 -0.76 . . . . 73.43 109.982 177.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 44.2 mt -71.25 145.36 12.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.904 -0.589 . . . . 53.14 110.923 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -81.02 137.78 49.7 Favored Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 109.587 -0.523 . . . . 73.31 109.587 174.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -64.11 116.47 3.73 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.457 2.105 . . . . 62.52 111.634 176.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.75 -85.01 0.01 OUTLIER 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.541 2.161 . . . . 72.42 112.134 -178.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.6 t-105 -101.97 -178.08 3.6 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.843 -0.799 . . . . 72.24 108.843 173.371 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -50.67 100.9 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.189 0.518 . . . . 74.13 111.761 178.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.81 -147.29 5.65 Favored Glycine 0 N--CA 1.444 -0.83 0 CA-C-N 115.485 -0.78 . . . . 71.54 111.325 178.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -178.5 -170.86 41.13 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 120.869 -0.682 . . . . 73.45 111.42 177.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mt -123.11 133.11 70.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.518 0.675 . . . . 70.34 111.325 -179.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.926 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 7.2 tpt180 -96.31 132.85 41.37 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.634 -1.166 . . . . 74.22 108.448 177.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.542 ' HB3' ' HH ' ' A' ' 38' ' ' TYR . 97.1 m-85 -103.77 -171.53 1.95 Allowed 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 120.417 -0.513 . . . . 74.35 111.636 -173.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.68 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 49.1 ttt180 -113.36 -44.04 3.28 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.576 -0.738 . . . . 74.3 110.263 -170.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -148.03 40.01 0.97 Allowed Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.647 -0.706 . . . . 71.12 111.968 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.435 HD13 HG12 ' A' ' 28' ' ' VAL . 84.7 mt -122.21 130.07 52.85 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.832 0.349 . . . . 52.44 110.504 179.463 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 11.0 t -90.72 -179.33 5.5 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.939 -0.573 . . . . 75.32 110.158 177.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 5.6 ptm180 -73.66 -173.49 1.49 Allowed 'General case' 0 C--O 1.234 0.286 0 CA-C-O 120.978 0.418 . . . . 73.32 112.125 -174.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 31.1 t70 56.17 12.77 1.03 Allowed 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 115.353 -0.839 . . . . 54.04 111.609 -174.694 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.504 ' O ' HG22 ' A' ' 28' ' ' VAL . 25.5 mt-30 -124.47 -162.69 1.1 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.849 -0.614 . . . . 70.15 109.538 -179.636 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.504 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.3 m 56.92 13.83 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.452 1.101 . . . . 75.0 112.892 174.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 53.0 pttt -96.34 -27.6 14.87 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.021 0.438 . . . . 71.12 109.856 176.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.49 95.29 2.42 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.74 -0.664 . . . . 75.11 110.412 177.167 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.575 ' HB ' HD11 ' A' ' 9' ' ' ILE . 62.7 mt -132.21 148.12 32.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 108.707 -0.849 . . . . 74.23 108.707 177.578 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.3 m-80 -75.77 -69.04 0.51 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.031 0.443 . . . . 73.04 109.967 -178.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.602 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 87.4 m-85 -141.44 150.15 41.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.872 -0.604 . . . . 71.25 110.713 -177.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -91.54 136.6 26.53 Favored Pre-proline 0 C--N 1.323 -0.55 0 N-CA-C 109.403 -0.591 . . . . 73.11 109.403 174.237 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.88 143.41 95.86 Favored 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 122.866 2.377 . . . . 63.24 113.055 -176.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.447 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 3.6 p -70.11 84.41 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 CA-C-O 122.031 0.919 . . . . 72.31 110.643 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.447 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 35.2 t70 167.2 -27.51 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.493 -1.23 . . . . 75.53 108.766 -174.553 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.542 ' HH ' ' HB3' ' A' ' 20' ' ' TYR . 4.2 t80 -64.86 137.38 57.73 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 114.681 -1.145 . . . . 74.11 111.713 -174.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.68 ' H ' ' HD2' ' A' ' 21' ' ' ARG . 41.4 mt-10 -120.29 139.16 53.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.928 -0.578 . . . . 72.52 109.593 177.239 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.481 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 37.3 pt -126.2 162.72 29.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.121 0.486 . . . . 75.11 112.019 -178.673 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.926 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.9 tt0 -124.57 153.69 41.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.231 -0.895 . . . . 74.33 109.811 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.601 ' O ' HG11 ' A' ' 50' ' ' VAL . 97.2 m-85 -101.9 101.59 12.04 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.439 0.162 . . . . 75.13 110.996 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.541 HG13 ' HB2' ' A' ' 19' ' ' ARG . 15.5 m -97.13 170.96 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 120.861 0.363 . . . . 43.53 111.24 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.403 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 26.5 t -114.73 171.15 7.81 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.015 -0.539 . . . . 51.42 109.922 -176.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 14.4 mmm180 -72.57 110.67 7.11 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 120.798 0.332 . . . . 71.44 110.547 179.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.17 -108.83 3.02 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.717 -0.754 . . . . 62.21 112.073 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -155.11 49.07 0.56 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.185 0.517 . . . . 71.43 111.269 -177.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.574 ' HB2' ' HB2' ' A' ' 73' ' ' CYS . 17.3 mmt180 -88.31 145.71 25.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.152 -0.477 . . . . 74.21 110.072 177.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.4 mm-40 -80.62 112.88 18.4 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.005 0.431 . . . . 74.41 109.977 176.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.601 HG11 ' O ' ' A' ' 42' ' ' TYR . 3.8 p -92.67 115.73 32.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.293 0.568 . . . . 54.31 110.769 -178.471 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.7 p -100.61 97.3 5.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 122.125 0.964 . . . . 73.23 110.613 178.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.91 170.68 32.56 Favored Glycine 0 N--CA 1.441 -0.989 0 CA-C-N 114.71 -1.132 . . . . 43.0 110.284 175.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -71.96 67.0 3.26 Favored 'Trans proline' 0 C--O 1.235 0.334 0 C-N-CA 122.047 1.831 . . . . 70.42 110.529 170.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.525 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 41.5 pttt -84.75 87.3 7.3 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.552 0.691 . . . . 72.35 112.086 -170.277 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.514 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.6 p -161.05 127.05 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.556 -0.747 . . . . 74.12 109.226 171.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.57 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 28.3 mmt180 -133.15 112.85 12.09 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.103 -0.332 . . . . 73.32 110.103 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.426 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 38.6 ttmt -101.52 123.92 46.34 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 109.375 -0.602 . . . . 71.3 109.375 179.368 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.3 t -67.3 119.52 12.3 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.233 -0.44 . . . . 74.1 110.246 -179.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 80.1 mt -101.28 -179.93 4.18 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.897 -0.592 . . . . 75.32 110.369 -177.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.81 59.5 3.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.129 0.49 . . . . 34.01 111.15 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.4 p-10 -161.78 167.4 24.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.328 -0.851 . . . . 74.35 108.786 175.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -82.83 36.93 2.66 Favored Glycine 0 CA--C 1.521 0.409 0 C-N-CA 120.699 -0.762 . . . . 74.22 113.45 -174.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.4 m -156.43 157.24 35.18 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.93 0.365 . . . . 64.31 110.176 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 87.3 m95 -83.36 179.17 7.75 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.53 -0.305 . . . . 65.43 110.464 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.8 m -56.74 -53.22 60.24 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 116.025 -0.534 . . . . 71.12 112.053 -176.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -148.03 129.66 15.03 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.514 -0.55 . . . . 71.12 109.514 -177.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 56.1 mtm -133.64 78.25 1.76 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 119.21 -0.996 . . . . 72.34 110.759 172.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -168.82 89.16 0.21 Allowed 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 106.942 -1.503 . . . . 63.14 106.942 162.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.42 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 3.6 m -139.82 121.28 9.65 Favored Pre-proline 0 C--N 1.312 -1.023 0 C-N-CA 119.837 -0.745 . . . . 74.33 111.984 -165.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 5.1 Cg_exo -77.24 58.13 6.12 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.094 2.529 . . . . 64.14 111.635 177.12 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.4 p -78.76 101.29 7.5 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.121 -0.49 . . . . 73.3 110.355 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.434 HH11 ' HD2' ' A' ' 72' ' ' ARG . 7.5 ptp85 -91.55 142.02 28.1 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.981 -0.554 . . . . 75.3 110.044 -178.123 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.574 ' HB2' ' HB2' ' A' ' 48' ' ' ARG . 2.0 p -106.65 99.91 9.46 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.427 0.632 . . . . 74.22 109.681 173.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.6 p -121.0 153.68 24.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.341 -0.845 . . . . 70.53 111.011 -170.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 65.8 ttt-85 . . . . . 0 C--O 1.245 0.862 0 CA-C-O 118.582 -0.723 . . . . 74.41 109.701 176.299 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 21.7 m . . . . . 0 N--CA 1.446 -0.652 0 N-CA-C 109.421 -0.585 . . . . 74.12 109.421 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -123.83 112.74 17.65 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.905 -0.588 . . . . 74.03 109.491 -177.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.656 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.5 163.35 33.96 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.576 -0.821 . . . . 52.24 111.759 179.05 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 83.9 m -84.03 134.29 34.63 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 110.062 -0.347 . . . . 72.14 110.062 177.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -77.39 179.37 6.49 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.172 0.51 . . . . 64.22 111.609 -176.183 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.562 HD11 ' HB ' ' A' ' 31' ' ' ILE . 59.5 mt -88.07 119.1 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.191 -0.913 . . . . 73.43 110.295 178.294 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.6 mt -82.69 131.5 33.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.853 -0.612 . . . . 53.14 109.984 178.25 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 83.7 m-70 -84.07 117.94 70.0 Favored Pre-proline 0 C--N 1.323 -0.557 0 N-CA-C 109.59 -0.522 . . . . 73.31 109.59 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.418 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 52.1 Cg_exo -54.53 110.1 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 122.985 2.457 . . . . 62.52 112.153 -178.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 14.0 Cg_exo -69.2 -56.81 0.14 Allowed 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.924 2.416 . . . . 72.42 112.295 -176.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.428 ' HA ' ' CE3' ' A' ' 14' ' ' TRP . 6.0 t-105 -100.07 -177.8 3.65 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.868 -0.605 . . . . 72.24 109.807 -176.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -68.7 -5.05 18.15 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.858 0.361 . . . . 74.13 111.329 178.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.07 121.92 5.76 Favored Glycine 0 N--CA 1.444 -0.784 0 N-CA-C 110.832 -0.907 . . . . 71.54 110.832 171.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -95.72 -170.7 35.72 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.529 -0.844 . . . . 73.45 112.447 -175.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.515 HD13 HD12 ' A' ' 40' ' ' ILE . 27.3 mt -115.45 129.25 72.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.632 0.73 . . . . 70.34 111.124 -178.426 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -97.21 144.54 26.93 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.597 -1.183 . . . . 74.22 109.593 -178.071 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -115.88 -170.73 1.84 Allowed 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.346 -0.613 . . . . 74.35 109.346 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 -115.6 -53.84 2.56 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.5 -0.48 . . . . 74.3 110.309 178.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -110.19 26.43 13.66 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.727 -0.749 . . . . 71.12 112.634 -177.261 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.464 HD13 HG12 ' A' ' 28' ' ' VAL . 95.9 mt -119.86 121.91 40.12 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.888 -0.412 . . . . 52.44 109.888 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.2 t -105.71 -178.79 3.75 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.779 -0.646 . . . . 75.32 112.17 -171.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.41 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 49.6 mtp180 -57.49 125.33 22.39 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.359 -0.837 . . . . 73.32 111.603 177.671 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.421 ' O ' ' HD2' ' A' ' 29' ' ' LYS . 33.7 t70 92.91 3.96 0.06 Allowed 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.735 1.214 . . . . 54.04 110.353 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.456 ' O ' HG22 ' A' ' 28' ' ' VAL . 10.4 mm100 -94.57 -178.88 4.7 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 108.925 -0.769 . . . . 70.15 108.925 170.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.464 HG12 HD13 ' A' ' 23' ' ' LEU . 3.7 m 52.36 18.78 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 124.238 1.015 . . . . 75.0 113.064 178.707 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.421 ' HD2' ' O ' ' A' ' 26' ' ' ASP . 18.1 ptmt -82.62 -19.47 38.28 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.789 -0.449 . . . . 71.12 109.789 178.67 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -168.03 107.81 0.54 Allowed 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.602 -0.726 . . . . 75.11 110.477 175.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.562 ' HB ' HD11 ' A' ' 9' ' ' ILE . 55.6 mt -138.14 151.86 25.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.155 -0.683 . . . . 74.23 109.155 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -89.19 -66.34 0.93 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.717 0.294 . . . . 73.04 110.467 175.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.656 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 71.1 m-85 -136.66 143.06 43.25 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.827 0.346 . . . . 71.25 110.821 -178.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.416 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.9 mm? -84.8 144.0 41.45 Favored Pre-proline 0 C--N 1.323 -0.555 0 CA-C-N 115.86 -0.609 . . . . 73.11 109.654 175.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 34' ' ' LEU . 27.0 Cg_exo -62.26 154.7 61.45 Favored 'Trans proline' 0 C--O 1.235 0.352 0 C-N-CA 122.913 2.409 . . . . 63.24 112.599 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 8.4 p -61.22 140.14 19.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.658 -0.701 . . . . 72.31 111.135 -177.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 66.63 16.88 10.51 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.395 -0.82 . . . . 75.53 112.878 178.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 40.6 t80 -71.8 146.69 47.87 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.011 -0.737 . . . . 74.11 109.011 172.102 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -116.22 126.31 53.45 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.695 0.283 . . . . 72.52 111.246 -172.731 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.545 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 46.9 pt -121.72 155.99 25.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.28 -0.418 . . . . 75.11 110.316 175.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -130.73 147.0 52.34 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.381 -0.372 . . . . 74.33 110.533 -175.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.592 ' HB2' ' HB3' ' A' ' 54' ' ' LYS . 27.6 m-85 -96.44 101.85 13.54 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.326 -0.25 . . . . 75.13 110.326 178.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.9 m -113.79 170.07 4.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.025 0.44 . . . . 43.53 111.38 -176.122 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.668 ' HB2' HG13 ' A' ' 50' ' ' VAL . 16.7 t -95.37 127.23 41.25 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 109.282 -0.636 . . . . 51.42 109.282 177.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 47.0 ttt180 -59.41 121.94 12.73 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.853 -1.067 . . . . 71.44 111.057 -176.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 113.0 -128.3 8.34 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-N 115.845 -0.616 . . . . 62.21 111.977 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -122.17 11.91 10.22 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.247 0.546 . . . . 71.43 110.666 -179.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 19.2 mmm180 -89.34 160.18 16.99 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.616 -0.72 . . . . 74.21 109.562 177.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.612 ' HB2' ' HG2' ' A' ' 75' ' ' ARG . 39.4 mt-10 -121.22 163.94 17.73 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.996 0.427 . . . . 74.41 111.359 -174.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.668 HG13 ' HB2' ' A' ' 44' ' ' CYS . 26.8 m -128.51 150.27 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.618 -0.719 . . . . 54.31 110.093 -178.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.435 HG13 ' HD2' ' A' ' 72' ' ' ARG . 3.1 p -119.57 96.59 4.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 122.059 0.933 . . . . 73.23 109.921 171.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.24 172.8 32.83 Favored Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 114.636 -1.166 . . . . 43.0 110.925 -178.322 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -78.55 60.66 7.67 Favored 'Trans proline' 0 N--CA 1.46 -0.448 0 C-N-CA 122.097 1.865 . . . . 70.42 110.455 174.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.592 ' HB3' ' HB2' ' A' ' 42' ' ' TYR . 0.0 OUTLIER -86.31 86.39 7.34 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-N 115.333 -0.849 . . . . 72.35 112.028 -171.369 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -162.41 128.99 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 115.316 -0.856 . . . . 74.12 109.557 173.185 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.545 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 4.8 mmt85 -130.58 120.57 24.21 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.712 -0.477 . . . . 73.32 109.712 176.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 22.6 ttpp -103.61 125.31 50.05 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 109.159 -0.682 . . . . 71.3 109.159 177.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 49.6 t -64.75 149.23 49.62 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.743 0.306 . . . . 74.1 110.334 179.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 87.0 mt -116.22 -179.0 3.54 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.167 -0.47 . . . . 75.32 110.166 -178.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -81.44 -0.76 43.03 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.97 0.414 . . . . 34.01 110.539 178.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -113.58 164.65 13.39 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.399 -0.593 . . . . 74.35 109.399 175.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 6' ' ' GLY . . . -79.43 51.9 4.02 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.012 -0.613 . . . . 74.22 113.541 -173.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 28.2 m -156.62 146.87 21.29 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.92 -0.4 . . . . 64.31 109.92 177.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 89.8 m95 -82.01 177.54 8.78 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.227 -0.657 . . . . 65.43 109.227 175.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.8 p -66.59 -27.5 67.76 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 112.276 0.473 . . . . 71.12 112.276 -177.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -160.48 140.1 10.98 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.95 -0.389 . . . . 71.12 109.95 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 66.9 mtt -129.95 76.38 1.72 Allowed 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 119.814 -0.755 . . . . 72.34 110.164 165.011 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -170.61 89.18 0.14 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.335 -0.848 . . . . 63.14 108.803 161.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.2 m -148.12 102.96 3.57 Favored Pre-proline 0 C--N 1.317 -0.819 0 C-N-CA 119.936 -0.706 . . . . 74.33 111.399 -176.09 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.24 95.7 1.01 Allowed 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 122.998 2.466 . . . . 64.14 111.44 175.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 10.6 p -75.57 113.37 12.91 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.12 -0.491 . . . . 73.3 110.479 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.435 ' HD2' HG13 ' A' ' 51' ' ' VAL . 5.3 ptp180 -79.68 114.77 18.85 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.155 0.502 . . . . 75.3 111.151 -178.045 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.593 ' HA ' HG12 ' A' ' 50' ' ' VAL . 48.9 t -80.08 100.95 8.44 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.962 -0.563 . . . . 74.22 109.902 176.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.2 p -165.2 141.31 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.544 -0.753 . . . . 70.53 109.564 -178.448 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.612 ' HG2' ' HB2' ' A' ' 49' ' ' GLU . 1.5 tmm_? . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.697 -0.668 . . . . 74.41 110.248 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.6 m . . . . . 0 N--CA 1.451 -0.396 0 CA-C-O 121.254 0.55 . . . . 74.12 109.585 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -126.44 109.26 12.01 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.724 -0.671 . . . . 74.03 109.286 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.723 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -157.5 159.98 30.23 Favored Glycine 0 N--CA 1.438 -1.227 0 C-N-CA 120.066 -1.064 . . . . 52.24 112.841 -176.412 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.0 m -105.9 142.58 35.38 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.531 -0.544 . . . . 72.14 109.531 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.423 HE21 ' HB2' ' A' ' 8' ' ' GLN . 2.1 pt20 -74.77 -178.4 3.66 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.247 0.546 . . . . 64.22 111.929 -175.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.502 HD11 ' HB ' ' A' ' 31' ' ' ILE . 41.8 mt -88.25 119.37 35.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.524 -0.762 . . . . 73.43 110.316 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.467 HD11 ' CD1' ' A' ' 64' ' ' TRP . 47.4 mt -76.86 142.44 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.603 -0.726 . . . . 53.14 110.825 -177.016 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -79.85 126.8 79.34 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 73.31 109.867 175.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.429 ' HA ' ' HD2' ' A' ' 13' ' ' PRO . 27.2 Cg_exo -62.73 113.65 2.06 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 122.46 2.107 . . . . 62.52 111.417 175.28 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 12' ' ' PRO . 30.4 Cg_endo -65.55 -69.19 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.491 2.127 . . . . 72.42 112.481 -177.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 19.5 t-105 -100.39 -179.3 4.07 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.108 -0.701 . . . . 72.24 109.108 178.07 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.3 mm-40 -65.54 92.47 0.14 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.577 0.703 . . . . 74.13 111.413 -177.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.558 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . -160.31 -153.78 7.07 Favored Glycine 0 N--CA 1.442 -0.94 0 CA-C-N 114.85 -1.068 . . . . 71.54 110.458 178.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.17 -171.74 31.77 Favored Glycine 0 N--CA 1.443 -0.88 0 C-N-CA 120.224 -0.989 . . . . 73.45 112.02 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.402 HD13 HD12 ' A' ' 40' ' ' ILE . 22.1 mt -128.78 134.93 63.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.681 0.753 . . . . 70.34 111.422 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.801 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 16.9 tpp180 -99.33 126.63 45.23 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 114.684 -1.144 . . . . 74.22 110.326 -178.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -99.01 -170.84 1.98 Allowed 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.218 -0.66 . . . . 74.35 109.218 175.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 43.4 ttm-85 -103.4 -65.71 0.99 Allowed 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.34 -0.544 . . . . 74.3 110.421 -179.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -110.58 47.5 1.04 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.669 -0.777 . . . . 71.12 112.116 -179.027 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 94.3 mt -135.74 104.45 5.77 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.809 0.338 . . . . 52.44 110.842 -178.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.7 t -87.14 -177.78 6.09 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.745 -0.662 . . . . 75.32 110.019 174.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.426 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 34.7 ptt180 -64.77 -173.05 0.09 Allowed 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 111.922 0.342 . . . . 73.32 111.922 -176.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.426 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 13.0 t70 68.63 -45.74 0.54 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 123.477 0.711 . . . . 54.04 110.854 -170.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.404 ' HB3' ' H ' ' A' ' 28' ' ' VAL . 25.1 mt-30 -76.42 -155.92 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.301 -0.409 . . . . 70.15 110.495 175.056 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.404 ' H ' ' HB3' ' A' ' 27' ' ' GLN . 11.2 m 49.31 27.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 124.225 1.01 . . . . 75.0 111.987 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 34.9 pttt -97.02 -28.92 13.94 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.429 -0.805 . . . . 71.12 110.652 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.12 95.66 1.63 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.378 0.609 . . . . 75.11 111.055 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.502 ' HB ' HD11 ' A' ' 9' ' ' ILE . 46.8 mt -129.33 140.45 49.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.491 -0.929 . . . . 74.23 108.491 175.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.6 m-80 -107.56 -36.68 6.39 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 120.614 -0.434 . . . . 73.04 110.513 -178.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.723 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 90.6 m-85 -135.74 109.24 7.93 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.753 0.311 . . . . 71.25 111.097 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -80.17 122.62 83.13 Favored Pre-proline 0 C--N 1.325 -0.463 0 N-CA-C 108.463 -0.94 . . . . 73.11 108.463 169.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.453 ' O ' ' HB2' ' A' ' 38' ' ' TYR . 5.9 Cg_endo -47.31 138.72 17.33 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 123.378 2.719 . . . . 63.24 113.618 -172.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.413 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 7.2 p -50.3 143.51 2.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.651 -0.704 . . . . 72.31 111.008 175.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.413 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 27.6 t70 80.16 -4.0 1.91 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 123.685 0.794 . . . . 75.53 111.727 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.453 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 17.6 t80 -66.68 141.29 57.82 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 109.475 -0.565 . . . . 74.11 109.475 175.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.692 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.8 mt-10 -118.49 120.57 37.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.681 0.277 . . . . 72.52 111.181 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.521 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 46.3 pt -112.9 161.38 11.86 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 CA-C-N 116.335 -0.393 . . . . 75.11 110.599 177.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.801 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.0 tt0 -125.61 152.36 45.25 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.965 -0.561 . . . . 74.33 111.031 -175.699 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.623 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 25.3 m-85 -101.3 102.51 13.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.343 -0.39 . . . . 75.13 111.089 -179.289 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.3 m -103.93 166.83 2.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 116.232 -0.44 . . . . 43.53 110.365 177.01 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.561 ' HB3' ' O ' ' A' ' 48' ' ' ARG . 34.8 t -91.6 172.31 8.58 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.603 -0.517 . . . . 51.42 109.603 178.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . 0.558 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -76.98 98.19 4.87 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.928 0.394 . . . . 71.44 110.692 -175.557 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.32 -122.02 7.44 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.975 -0.631 . . . . 62.21 113.341 172.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -105.1 32.91 3.91 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.25 0.548 . . . . 71.43 110.96 -174.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.561 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 28.4 mmm180 -113.19 144.03 43.38 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.759 -0.655 . . . . 74.21 109.351 178.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.1 mp0 -106.67 164.35 12.16 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.254 0.55 . . . . 74.41 111.696 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.56 HG13 ' HB2' ' A' ' 44' ' ' CYS . 35.3 m -129.15 152.5 37.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.349 -0.841 . . . . 54.31 110.105 -178.315 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.2 p -115.22 97.5 5.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.751 0.786 . . . . 73.23 109.922 171.312 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.0 166.75 32.6 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-N 115.68 -0.691 . . . . 43.0 112.086 178.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -74.53 65.57 5.6 Favored 'Trans proline' 0 CA--C 1.531 0.346 0 C-N-CA 122.326 2.017 . . . . 70.42 110.676 169.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.623 ' HB2' ' H ' ' A' ' 42' ' ' TYR . 16.0 pttp -77.8 89.47 4.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.297 -0.865 . . . . 72.35 111.605 -174.445 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -160.44 129.44 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.611 -0.722 . . . . 74.12 110.288 176.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.692 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 25.8 mmt180 -129.98 136.37 49.36 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.097 -0.501 . . . . 73.32 110.131 177.283 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.42 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 37.2 ttmt -123.36 124.42 42.9 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.193 -0.669 . . . . 71.3 109.193 174.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.3 t -67.41 137.5 55.97 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.148 -0.478 . . . . 74.1 110.703 -177.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 93.6 mt -103.46 -179.05 3.84 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.0 -0.546 . . . . 75.32 110.868 -176.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.4 22.41 0.56 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.08 0.467 . . . . 34.01 111.183 178.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -139.07 171.8 13.77 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.194 -0.669 . . . . 74.35 109.194 178.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -79.23 52.4 4.04 Favored Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.995 -0.621 . . . . 74.22 113.664 -174.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 11.9 t -170.48 159.52 6.95 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.898 -0.408 . . . . 64.31 109.898 177.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.467 ' CD1' HD11 ' A' ' 10' ' ' ILE . 69.9 m95 -87.06 178.97 6.76 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.228 -0.442 . . . . 65.43 110.086 -178.328 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -57.76 -35.41 70.71 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 112.622 0.601 . . . . 71.12 112.622 -176.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -149.72 144.55 26.15 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 110.193 -0.299 . . . . 71.12 110.193 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 63.3 mtt -136.39 76.56 1.6 Allowed 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.11 -0.636 . . . . 72.34 109.943 163.036 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -169.88 89.29 0.17 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.133 -0.94 . . . . 63.14 108.613 163.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.445 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 10.5 m -144.56 113.51 5.1 Favored Pre-proline 0 C--N 1.314 -0.946 0 C-N-CA 120.302 -0.559 . . . . 74.33 110.731 -175.681 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 4.3 Cg_exo -77.23 59.77 6.72 Favored 'Trans proline' 0 N--CA 1.463 -0.29 0 C-N-CA 123.415 2.743 . . . . 64.14 112.489 -178.241 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.9 p -70.37 98.83 1.47 Allowed 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.367 -0.605 . . . . 73.3 109.367 175.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 72' ' ' ARG . 5.0 ptp180 -101.69 141.34 34.7 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.635 -0.711 . . . . 75.3 111.679 -172.674 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 58.9 m -75.61 115.37 15.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.316 -0.856 . . . . 74.22 109.977 178.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.6 p -149.6 128.44 3.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.124 0.488 . . . . 70.53 110.095 -178.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.335 -0.841 . . . . 74.41 110.162 -177.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 20.2 m . . . . . 0 N--CA 1.446 -0.645 0 N-CA-C 109.386 -0.598 . . . . 74.12 109.386 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -88.87 114.6 25.67 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.862 -0.608 . . . . 74.03 110.044 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -148.42 -179.82 24.68 Favored Glycine 0 N--CA 1.44 -1.058 0 CA-C-N 115.527 -0.76 . . . . 52.24 111.432 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.0 m -97.47 136.12 38.35 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 110.122 -0.325 . . . . 72.14 110.122 -179.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.418 HE21 ' HB2' ' A' ' 8' ' ' GLN . 1.9 pt20 -72.82 177.57 4.76 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.228 0.537 . . . . 64.22 111.464 -179.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.572 HD11 ' HB ' ' A' ' 31' ' ' ILE . 52.4 mt -88.29 116.39 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-N 115.728 -0.669 . . . . 73.43 110.172 177.179 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 41.5 mt -69.65 140.93 17.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.395 -0.82 . . . . 53.14 109.861 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 23.4 m170 -73.55 137.37 77.56 Favored Pre-proline 0 C--N 1.323 -0.544 0 N-CA-C 109.503 -0.554 . . . . 73.31 109.503 175.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -57.12 117.48 4.18 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.544 2.162 . . . . 62.52 111.57 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.465 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 83.9 Cg_endo -78.23 -146.22 0.03 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.809 2.339 . . . . 72.42 111.748 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.465 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 67.9 t-105 -56.56 148.56 19.33 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.74 -0.467 . . . . 72.24 109.74 177.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 33.9 mm-40 -44.2 101.31 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.793 1.034 . . . . 74.13 113.793 -172.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.97 -120.91 0.79 Allowed Glycine 0 N--CA 1.442 -0.908 0 CA-C-N 114.283 -1.326 . . . . 71.54 110.131 174.382 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 179.86 -171.85 43.41 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.781 -0.723 . . . . 73.45 111.644 173.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 mt -142.28 129.35 19.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.549 0.69 . . . . 70.34 110.929 177.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.742 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 5.8 tpt180 -102.09 140.67 36.07 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.821 -1.082 . . . . 74.22 108.687 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.52 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 88.7 m-85 -107.15 -173.51 2.31 Favored 'General case' 0 C--N 1.319 -0.758 0 C-N-CA 120.077 -0.649 . . . . 74.35 110.263 -178.335 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -132.89 -14.89 2.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.129 0.49 . . . . 74.3 110.521 -175.106 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -145.82 27.14 1.77 Allowed Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 111.568 -0.613 . . . . 71.12 111.568 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 89.3 mt -143.54 132.82 23.22 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.683 0.278 . . . . 52.44 110.281 -178.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.9 t -91.45 -178.55 5.14 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.008 -0.542 . . . . 75.32 109.999 177.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 66.5 mtm180 -73.05 -174.14 1.45 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.901 0.382 . . . . 73.32 111.843 -175.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.6 t70 51.29 33.01 9.03 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.665 0.745 . . . . 54.04 111.474 -177.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 -132.59 -164.62 1.49 Allowed 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.091 -0.504 . . . . 70.15 110.386 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.509 HG12 HD12 ' A' ' 31' ' ' ILE . 32.3 m 48.76 36.57 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 O-C-N 124.251 0.97 . . . . 75.0 112.384 177.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -78.8 -39.91 34.43 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.378 0.608 . . . . 71.12 109.413 177.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.07 89.01 1.49 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.49 -0.777 . . . . 75.11 110.644 176.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.572 ' HB ' HD11 ' A' ' 9' ' ' ILE . 52.1 mt -120.62 136.16 58.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.93 -0.767 . . . . 74.23 108.93 175.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -79.73 -49.27 12.31 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.753 0.311 . . . . 73.04 110.921 -175.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -139.37 138.03 36.23 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.186 -0.461 . . . . 71.25 111.275 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -85.96 138.5 35.0 Favored Pre-proline 0 C--N 1.321 -0.631 0 N-CA-C 108.717 -0.845 . . . . 73.11 108.717 170.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.29 145.46 97.75 Favored 'Trans proline' 0 CA--C 1.529 0.25 0 C-N-CA 122.677 2.252 . . . . 63.24 112.822 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.453 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 7.4 p -62.68 145.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.988 -0.551 . . . . 72.31 110.34 177.104 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.453 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 35.3 t70 79.18 3.44 2.34 Favored 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.776 0.672 . . . . 75.53 110.864 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.52 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 47.3 t80 -79.17 148.69 32.2 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.003 -0.369 . . . . 74.11 110.003 175.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.433 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 26.2 mt-10 -124.16 144.25 50.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.314 -0.403 . . . . 72.52 110.884 -176.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.619 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 25.4 pt -136.54 153.93 31.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-N 116.342 -0.39 . . . . 75.11 110.634 174.153 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.742 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.6 tt0 -116.67 155.68 28.4 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.948 -0.569 . . . . 74.33 110.179 -178.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.485 ' HE2' ' CG ' ' A' ' 56' ' ' ARG . 34.2 m-85 -104.81 101.1 10.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.595 0.236 . . . . 75.13 110.818 176.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.501 HG13 ' HB2' ' A' ' 19' ' ' ARG . 26.8 m -90.91 170.37 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 109.8 -0.444 . . . . 43.53 109.8 176.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.528 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 7.3 t -100.39 173.11 6.74 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.27 -0.641 . . . . 51.42 109.27 178.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 15.4 mmt180 -59.88 116.12 3.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.111 0.482 . . . . 71.44 110.769 178.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.21 -132.71 11.33 Favored Glycine 0 N--CA 1.446 -0.645 0 CA-C-N 115.723 -0.671 . . . . 62.21 111.996 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -114.88 34.88 4.56 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.14 0.495 . . . . 71.43 111.237 -177.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.528 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 15.0 mmm180 -89.65 120.15 30.68 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.768 -0.651 . . . . 74.21 109.371 177.2 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -78.86 147.48 33.14 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.161 0.505 . . . . 74.41 110.311 -178.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.42 HG12 ' HA ' ' A' ' 73' ' ' CYS . 21.6 m -115.24 145.95 20.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.064 -0.516 . . . . 54.31 110.824 -178.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 51' ' ' VAL . 4.5 p -104.8 96.26 4.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 122.017 0.913 . . . . 73.23 109.333 171.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.84 171.82 33.2 Favored Glycine 0 N--CA 1.441 -1.0 0 CA-C-N 115.225 -0.898 . . . . 43.0 111.748 -177.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.573 ' HG2' HG21 ' A' ' 69' ' ' THR . 64.3 Cg_endo -74.66 56.45 4.05 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.757 2.305 . . . . 70.42 110.329 171.083 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.449 ' HD2' ' CG ' ' A' ' 41' ' ' GLU . 43.7 pttt -77.83 86.2 4.08 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.32 -0.855 . . . . 72.35 111.717 -172.292 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -162.47 128.39 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.264 -0.88 . . . . 74.12 109.928 172.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.619 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 24.5 mmt180 -117.85 119.63 35.44 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 108.91 -0.774 . . . . 73.32 108.91 174.439 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.407 ' HB3' ' CG2' ' A' ' 65' ' ' THR . 37.2 ttmt -104.62 120.6 41.69 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.455 -0.572 . . . . 71.3 109.455 178.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 16.5 t -78.54 133.19 37.38 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.923 0.392 . . . . 74.1 109.995 -179.386 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 85.4 mt -117.05 -178.61 3.48 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.013 -0.539 . . . . 75.32 110.85 -173.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.26 -9.29 58.72 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.127 0.489 . . . . 34.01 110.518 178.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -94.44 151.64 19.22 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.214 -0.661 . . . . 74.35 109.214 172.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -77.27 54.02 3.54 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 121.09 -0.576 . . . . 74.22 113.762 -173.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 67.4 p -166.98 154.02 8.8 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.403 -0.592 . . . . 64.31 109.403 177.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.538 ' HB2' ' HB3' ' A' ' 67' ' ' MET . 84.3 m95 -75.02 165.83 24.63 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.802 -0.444 . . . . 65.43 109.802 178.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.407 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 0.9 OUTLIER -50.57 -42.78 55.95 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 113.052 0.76 . . . . 71.12 113.052 -176.915 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -157.93 74.88 0.74 Allowed 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.574 -0.528 . . . . 71.12 109.574 177.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . 0.538 ' HB3' ' HB2' ' A' ' 64' ' ' TRP . 22.3 ptt? -88.7 80.24 7.3 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 118.837 -1.145 . . . . 72.34 111.497 -173.496 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -167.96 88.95 0.27 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.271 -1.331 . . . . 63.14 107.757 163.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.573 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.2 OUTLIER -158.43 115.77 1.74 Allowed Pre-proline 0 C--N 1.317 -0.846 0 C-N-CA 120.461 -0.496 . . . . 74.33 111.221 -169.35 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -81.52 124.91 4.84 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.497 2.131 . . . . 64.14 111.807 174.364 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 12.6 p -81.01 133.29 35.46 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.992 0.425 . . . . 73.3 110.085 177.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 38.3 mtp180 -96.34 99.26 10.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.312 -0.404 . . . . 75.3 111.364 -171.353 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.42 ' HA ' HG12 ' A' ' 50' ' ' VAL . 8.7 m -69.12 101.98 1.56 Allowed 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.799 -0.445 . . . . 74.22 109.799 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 94.7 t -136.41 120.15 23.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 121.026 0.441 . . . . 70.53 111.805 -173.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 67.8 mtt180 . . . . . 0 C--O 1.244 0.797 0 CA-C-N 115.627 -0.715 . . . . 74.41 109.694 170.892 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.1 m . . . . . 0 N--CA 1.45 -0.461 0 N-CA-C 108.882 -0.784 . . . . 74.12 108.882 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -95.58 109.09 21.38 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.176 0.512 . . . . 74.03 110.949 -174.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.517 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -161.21 -179.6 36.04 Favored Glycine 0 N--CA 1.443 -0.899 0 CA-C-N 115.299 -0.864 . . . . 52.24 111.323 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 15.0 m -99.12 145.1 27.52 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 109.912 -0.403 . . . . 72.14 109.912 178.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -88.36 -177.82 5.74 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.668 0.271 . . . . 64.22 110.522 179.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.0 mt -87.95 123.78 40.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.16 0.505 . . . . 73.43 110.041 178.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.449 HD11 ' CD1' ' A' ' 64' ' ' TRP . 9.8 mt -79.93 150.53 4.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.782 -0.645 . . . . 53.14 110.347 -178.347 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 16.2 p80 -62.54 141.07 96.81 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 109.525 -0.546 . . . . 73.31 109.525 172.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.45 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 23.5 Cg_exo -64.8 149.47 89.58 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.459 2.106 . . . . 62.52 111.715 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.461 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 3.0 Cg_exo -76.88 -132.04 0.01 OUTLIER 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.979 2.453 . . . . 72.42 110.998 174.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.461 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 3.8 t-105 -75.38 -179.57 4.61 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.433 -0.58 . . . . 72.24 109.433 176.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -43.95 101.05 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 112.742 0.645 . . . . 74.13 112.742 -176.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 174.74 -143.71 7.0 Favored Glycine 0 N--CA 1.441 -1.028 0 N-CA-C 110.869 -0.893 . . . . 71.54 110.869 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.74 -169.97 35.94 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.655 -0.783 . . . . 73.45 112.174 177.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.2 mt -118.81 125.39 74.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 121.364 0.602 . . . . 70.34 110.891 179.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.3 tpt180 -99.79 114.27 27.31 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.129 -0.941 . . . . 74.22 109.077 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.499 ' HA ' HG22 ' A' ' 40' ' ' ILE . 88.6 m-85 -76.75 -172.4 2.24 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.588 -0.278 . . . . 74.35 110.905 -175.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -87.49 -40.61 14.17 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.15 0.5 . . . . 74.3 110.417 -174.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -152.94 60.01 0.4 Allowed Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.881 -0.676 . . . . 71.12 112.208 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.471 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 76.1 mt -135.03 128.98 33.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.121 0.486 . . . . 52.44 110.998 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.2 t -96.15 -176.4 3.66 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.373 -0.83 . . . . 75.32 110.296 176.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.498 ' C ' ' H ' ' A' ' 27' ' ' GLN . 22.1 mmt180 -60.7 -172.08 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 116.351 -0.386 . . . . 73.32 111.512 178.31 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.425 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 23.9 t70 69.4 -35.86 0.32 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.191 0.597 . . . . 54.04 111.447 -175.399 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.529 ' O ' HG22 ' A' ' 28' ' ' VAL . 13.7 mt-30 -90.48 -169.08 2.28 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.806 -0.634 . . . . 70.15 111.067 -178.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.8 m 59.45 11.88 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 125.073 1.349 . . . . 75.0 112.754 173.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.403 ' HG2' ' H ' ' A' ' 29' ' ' LYS . 36.3 pttt -77.87 -27.64 49.76 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.28 0.562 . . . . 71.12 110.341 176.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.13 91.16 0.46 Allowed 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.442 -0.799 . . . . 75.11 110.339 177.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 57.9 mt -109.94 125.84 67.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 108.973 -0.751 . . . . 74.23 108.973 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -79.67 -46.45 17.11 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.138 -0.483 . . . . 73.04 110.187 -175.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.517 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 95.7 m-85 -146.47 121.31 9.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.992 -0.549 . . . . 71.25 111.127 -178.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -78.57 151.91 77.69 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.191 -0.459 . . . . 73.11 109.834 173.297 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -64.82 160.35 41.24 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.618 2.212 . . . . 63.24 112.449 177.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 14.3 p -71.06 145.94 12.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.334 -0.394 . . . . 72.31 110.938 -177.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 38.3 t70 69.93 9.61 7.17 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 123.65 0.78 . . . . 75.53 111.245 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.471 ' OH ' ' HG ' ' A' ' 23' ' ' LEU . 25.3 t80 -72.03 139.32 48.47 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 108.719 -0.845 . . . . 74.11 108.719 174.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.606 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.9 mt-10 -126.38 154.66 43.27 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.805 0.336 . . . . 72.52 111.007 -175.46 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.499 HG22 ' HA ' ' A' ' 20' ' ' TYR . 24.3 pt -133.7 162.72 39.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.418 0 CA-C-N 116.06 -0.518 . . . . 75.11 111.776 -177.156 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.453 ' HG3' ' HD2' ' A' ' 54' ' ' LYS . 78.1 tt0 -122.37 149.08 44.28 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.518 -0.765 . . . . 74.33 110.14 177.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -95.5 102.5 14.31 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.201 -0.454 . . . . 75.13 110.152 177.214 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 16.8 m -101.18 144.1 13.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.903 0.382 . . . . 43.53 111.013 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.438 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 28.9 t -91.46 176.74 6.44 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.264 -0.643 . . . . 51.42 109.264 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.95 129.68 41.44 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.63 0.252 . . . . 71.44 111.492 -178.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 62.84 -131.71 43.29 Favored Glycine 0 N--CA 1.45 -0.427 0 CA-C-N 115.855 -0.611 . . . . 62.21 112.237 178.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -98.5 83.81 3.08 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.739 0.78 . . . . 71.43 110.4 176.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.642 HH11 ' HB3' ' A' ' 75' ' ' ARG . 30.2 mmt180 -145.2 132.52 20.62 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.182 -0.917 . . . . 74.21 109.943 178.307 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.2 mp0 -102.21 152.53 20.93 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.049 -0.523 . . . . 74.41 110.548 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.577 HG12 ' HA ' ' A' ' 73' ' ' CYS . 34.7 m -114.58 120.52 64.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.68 -0.691 . . . . 54.31 109.257 171.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.418 ' O ' HG13 ' A' ' 51' ' ' VAL . 6.3 p -83.71 94.24 3.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 122.503 1.144 . . . . 73.23 109.617 178.16 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.22 172.53 33.47 Favored Glycine 0 N--CA 1.441 -0.991 0 CA-C-N 114.34 -1.3 . . . . 43.0 110.764 -177.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -73.3 58.59 3.68 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.225 1.95 . . . . 70.42 110.646 173.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.453 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 42.3 pttt -78.09 85.6 4.29 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-O 121.691 0.758 . . . . 72.35 111.46 -174.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.48 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 6.1 p -162.68 128.61 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.227 -0.897 . . . . 74.12 109.015 171.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.606 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 20.4 mmt180 -130.6 124.42 31.71 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.591 -0.522 . . . . 73.32 109.591 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.475 ' O ' HG23 ' A' ' 65' ' ' THR . 23.7 ttmm -99.68 131.52 45.61 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.875 -0.417 . . . . 71.3 109.875 178.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 48.1 t -80.2 137.64 36.71 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 109.638 -0.504 . . . . 74.1 109.638 176.206 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 89.0 mt -115.25 -178.96 3.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.41 -0.359 . . . . 75.32 110.322 -178.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -66.42 -27.48 67.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.133 0.492 . . . . 34.01 110.61 178.148 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -79.55 150.92 30.96 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.457 -0.571 . . . . 74.35 109.457 174.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -75.6 66.03 2.41 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 121.033 -0.603 . . . . 74.22 113.528 -175.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 13.8 t -174.19 149.09 1.38 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.674 -0.491 . . . . 64.31 109.674 175.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.449 ' CD1' HD11 ' A' ' 10' ' ' ILE . 64.9 m95 -77.27 157.4 30.8 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.199 -0.667 . . . . 65.43 109.199 177.313 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.475 HG23 ' O ' ' A' ' 57' ' ' LYS . 16.0 p -50.71 -46.72 59.09 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 113.319 0.859 . . . . 71.12 113.319 -173.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -128.52 118.17 22.57 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.704 -0.226 . . . . 71.12 110.495 -173.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 55.5 mtt -125.76 78.31 1.73 Allowed 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 119.346 -0.941 . . . . 72.34 110.741 168.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -170.26 89.05 0.15 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.618 -0.719 . . . . 63.14 109.143 163.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 60.3 m -160.29 107.88 1.38 Allowed Pre-proline 0 C--N 1.321 -0.645 0 CA-C-O 120.874 0.368 . . . . 74.33 111.463 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -76.92 91.92 1.14 Allowed 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.175 1.917 . . . . 64.14 110.943 170.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 16.8 p -70.42 110.9 5.6 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.803 -0.635 . . . . 73.3 110.577 -177.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 21.4 ptt-85 -79.26 119.21 22.01 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.381 0.61 . . . . 75.3 111.137 -176.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.577 ' HA ' HG12 ' A' ' 50' ' ' VAL . 42.5 t -80.37 110.14 15.53 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.363 -0.835 . . . . 74.22 109.502 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.7 p -155.98 130.45 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.375 0.607 . . . . 70.53 111.521 -174.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.642 ' HB3' HH11 ' A' ' 48' ' ' ARG . 22.3 ttm180 . . . . . 0 C--O 1.247 0.934 0 CA-C-N 115.601 -0.727 . . . . 74.41 109.095 175.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.4 m . . . . . 0 N--CA 1.453 -0.307 0 CA-C-O 121.205 0.526 . . . . 74.12 111.602 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -118.86 100.23 7.25 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.674 -0.694 . . . . 74.03 109.339 173.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.74 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -158.89 147.33 14.74 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.039 -1.077 . . . . 52.24 113.231 -177.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.6 m -83.47 157.8 22.28 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.87 -0.418 . . . . 72.14 109.87 176.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -84.85 -178.23 6.79 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.124 0.488 . . . . 64.22 111.265 179.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.66 HD11 ' H ' ' A' ' 31' ' ' ILE . 56.5 mt -87.05 117.05 30.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.617 -0.72 . . . . 73.43 109.371 174.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.9 pt -90.18 149.23 4.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.528 -0.76 . . . . 53.14 110.665 -178.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . 0.431 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 19.9 m-70 -88.32 143.47 32.61 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 116.246 -0.434 . . . . 73.31 111.24 -175.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 16.7 Cg_exo -67.82 135.06 34.22 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 123.053 2.502 . . . . 62.52 111.963 178.056 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 82.4 Cg_endo -88.07 -150.22 0.04 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 123.002 2.468 . . . . 72.42 112.475 179.525 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.0 t-105 -63.48 -177.59 0.22 Allowed 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 115.812 -0.631 . . . . 72.24 110.697 178.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -38.82 100.33 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 123.876 0.87 . . . . 74.13 112.928 -173.065 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.85 -172.43 43.75 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 114.989 -1.005 . . . . 71.54 110.722 -178.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -156.91 -171.12 22.64 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.747 -0.74 . . . . 73.45 112.07 179.183 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.3 mt -129.7 137.37 56.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.381 0.61 . . . . 70.34 111.24 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.417 HH11 ' HD2' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -117.08 119.14 34.34 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.164 -0.925 . . . . 74.22 109.776 -177.612 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.424 ' HA ' HG22 ' A' ' 40' ' ' ILE . 95.0 m-85 -84.69 -171.7 3.78 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.749 0.309 . . . . 74.35 110.623 -178.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.1 ttm180 -93.26 -55.85 3.16 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.985 0.421 . . . . 74.3 109.993 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -144.89 67.74 0.42 Allowed Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.753 -0.737 . . . . 71.12 112.325 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 76.5 mt -139.07 118.33 12.72 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.995 -0.372 . . . . 52.44 109.995 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.2 t -81.0 178.9 8.13 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.297 -0.41 . . . . 75.32 110.189 178.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.429 ' C ' ' H ' ' A' ' 27' ' ' GLN . 95.2 mtt180 -78.09 -171.92 2.54 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 120.491 0.186 . . . . 73.32 111.343 -175.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.402 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 11.6 t70 67.38 -42.79 0.44 Allowed 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 123.305 0.642 . . . . 54.04 110.885 -168.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' HG22 ' A' ' 28' ' ' VAL . 21.0 mt-30 -70.57 -170.34 0.4 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.217 -0.447 . . . . 70.15 110.137 173.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.9 m 57.9 9.38 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.272 1.029 . . . . 75.0 112.134 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 52.7 pttt -83.49 -19.98 34.8 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.789 -0.819 . . . . 71.12 108.789 172.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.14 102.05 2.11 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 114.885 -1.052 . . . . 75.11 110.026 177.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.66 ' H ' HD11 ' A' ' 9' ' ' ILE . 57.3 mt -120.83 144.72 28.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 109.031 -0.729 . . . . 74.23 109.031 176.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -88.69 -65.61 1.0 Allowed 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.94 -0.393 . . . . 73.04 109.94 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.74 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 56.0 m-85 -143.42 140.84 30.61 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.239 -0.437 . . . . 71.25 110.487 177.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.463 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.7 mm? -82.82 132.23 52.01 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 109.331 -0.618 . . . . 73.11 109.331 174.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -58.24 139.34 90.14 Favored 'Trans proline' 0 C--O 1.236 0.382 0 C-N-CA 122.615 2.21 . . . . 63.24 112.227 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 p -67.3 84.59 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 CA-C-O 121.905 0.86 . . . . 72.31 111.272 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.6 t70 165.59 -30.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.179 -1.373 . . . . 75.53 108.925 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.405 ' HH ' ' HB3' ' A' ' 20' ' ' TYR . 9.3 t80 -57.22 138.18 55.0 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.895 -1.048 . . . . 74.11 111.277 -174.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.51 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 18.9 mt-10 -122.54 139.38 53.96 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.511 -0.768 . . . . 72.52 110.39 -176.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.493 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 35.5 pt -128.17 156.95 40.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.354 -0.384 . . . . 75.11 110.856 178.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -119.83 151.58 38.62 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.016 -0.538 . . . . 74.33 110.508 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -99.05 102.47 14.19 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.072 -0.513 . . . . 75.13 111.052 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.4 m -96.82 163.82 2.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 N-CA-C 110.028 -0.36 . . . . 43.53 110.028 175.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.574 ' HB2' HG13 ' A' ' 50' ' ' VAL . 31.5 t -89.68 175.11 7.38 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.457 -0.572 . . . . 51.42 109.457 178.127 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.66 119.2 19.37 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.95 0.405 . . . . 71.44 110.797 -174.5 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.06 -100.27 2.65 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.846 -0.616 . . . . 62.21 112.863 174.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -133.81 21.8 3.88 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.987 0.422 . . . . 71.43 111.233 -174.077 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.562 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 11.4 mmt180 -96.35 142.88 27.95 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.168 -0.469 . . . . 74.21 110.972 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.824 ' HB2' ' HD2' ' A' ' 75' ' ' ARG . 2.2 mp0 -94.37 153.78 17.81 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.125 -0.489 . . . . 74.41 110.867 177.071 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.574 HG13 ' HB2' ' A' ' 44' ' ' CYS . 28.0 m -118.49 151.31 20.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.688 -0.687 . . . . 54.31 109.882 176.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.9 p -114.9 96.19 4.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.913 0.863 . . . . 73.23 110.008 173.215 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.11 170.91 33.31 Favored Glycine 0 N--CA 1.445 -0.711 0 CA-C-N 115.2 -0.909 . . . . 43.0 111.602 179.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -73.59 60.01 4.17 Favored 'Trans proline' 0 CA--C 1.531 0.353 0 C-N-CA 122.482 2.121 . . . . 70.42 110.88 170.449 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 44.3 pttt -77.23 89.44 3.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.583 -0.735 . . . . 72.35 112.392 -171.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.9 p -160.8 135.11 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.892 -0.595 . . . . 74.12 109.605 171.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.51 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 24.6 mmt180 -131.12 120.8 23.88 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.41 -0.359 . . . . 73.32 110.537 177.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.464 ' HB3' ' CG2' ' A' ' 65' ' ' THR . 39.4 ttmt -102.73 129.63 49.42 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 109.094 -0.706 . . . . 71.3 109.094 174.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 45.6 t -67.92 143.51 55.64 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.469 -0.332 . . . . 74.1 110.327 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.451 HD11 ' HA ' ' A' ' 65' ' ' THR . 88.6 mt -110.89 -178.38 3.46 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.369 -0.378 . . . . 75.32 110.615 -176.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -79.82 14.56 1.7 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.974 0.416 . . . . 34.01 111.161 178.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.478 ' ND2' ' H ' ' A' ' 63' ' ' SER . 4.6 p-10 -141.44 -178.62 5.71 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.772 -0.649 . . . . 74.35 109.62 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -66.04 -29.68 75.47 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 114.771 0.668 . . . . 74.22 114.771 -171.252 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.478 ' H ' ' ND2' ' A' ' 61' ' ' ASN . 78.5 p -93.23 163.27 13.68 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.473 0.636 . . . . 64.31 111.458 -175.659 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -92.89 -179.86 5.25 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.877 -0.601 . . . . 65.43 110.005 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.464 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 3.2 p -49.59 -69.72 0.11 Allowed 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 113.558 0.947 . . . . 71.12 113.558 -174.169 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -133.21 48.59 2.38 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.649 -0.501 . . . . 71.12 109.649 -177.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 28.0 ttt -80.65 81.92 6.78 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.382 -0.927 . . . . 72.34 111.831 -170.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -166.65 87.6 0.32 Allowed 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 106.72 -1.585 . . . . 63.14 106.72 158.196 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.404 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 1.5 m -157.79 113.41 1.81 Allowed Pre-proline 0 C--N 1.316 -0.889 0 CA-C-N 116.284 -0.416 . . . . 74.33 110.051 -168.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 16.8 Cg_exo -66.68 97.6 0.39 Allowed 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.61 2.206 . . . . 64.14 112.164 179.169 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.1 p -78.73 101.63 7.66 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.212 -0.662 . . . . 73.3 109.212 173.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -78.94 126.58 30.88 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.315 0.579 . . . . 75.3 111.091 -171.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.556 ' HA ' HG12 ' A' ' 50' ' ' VAL . 41.8 t -82.03 98.74 8.77 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.499 -0.773 . . . . 74.22 109.865 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.3 p -176.98 152.44 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.992 -0.744 . . . . 70.53 108.992 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.824 ' HD2' ' HB2' ' A' ' 49' ' ' GLU . 2.5 ptm180 . . . . . 0 C--O 1.245 0.859 0 CA-C-O 119.168 -0.444 . . . . 74.41 110.367 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.4 m . . . . . 0 N--CA 1.448 -0.535 0 N-CA-C 110.209 -0.293 . . . . 74.12 110.209 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . 0.465 ' CD ' ' H ' ' A' ' 5' ' ' GLU . 0.9 OUTLIER -70.03 107.57 3.68 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.833 -0.803 . . . . 74.03 108.833 175.863 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.822 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -157.63 126.28 1.7 Allowed Glycine 0 N--CA 1.443 -0.847 0 C-N-CA 120.288 -0.958 . . . . 52.24 113.035 -176.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 64.8 m -90.59 152.32 20.94 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.546 -0.539 . . . . 72.14 109.546 175.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.419 HE21 ' HB2' ' A' ' 8' ' ' GLN . 1.9 pt20 -81.77 -178.02 6.81 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.916 0.389 . . . . 64.22 111.233 -178.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.598 HD11 ' HB ' ' A' ' 31' ' ' ILE . 46.2 mt -87.39 121.6 38.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.873 -0.603 . . . . 73.43 110.691 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 56.9 mt -73.86 114.21 13.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.03 -0.532 . . . . 53.14 109.581 175.051 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 31.9 m-70 -75.44 129.08 82.95 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 110.09 -0.337 . . . . 73.31 110.09 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.511 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 7.3 Cg_endo -49.19 118.77 3.83 Favored 'Trans proline' 0 C--N 1.349 0.556 0 C-N-CA 123.447 2.765 . . . . 62.52 112.429 -177.222 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.511 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 4.0 Cg_exo -76.38 -84.03 0.0 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 122.996 2.464 . . . . 72.42 112.325 -177.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.7 t-105 -100.93 -178.36 3.73 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.228 -0.442 . . . . 72.24 109.925 -177.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -47.68 102.31 0.03 OUTLIER 'General case' 0 C--O 1.234 0.275 0 O-C-N 123.791 0.682 . . . . 74.13 112.242 177.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.07 -157.14 28.97 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.352 -0.84 . . . . 71.54 111.099 -179.211 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -161.13 -171.08 26.63 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 111.338 -0.705 . . . . 73.45 111.338 177.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.5 mt -127.77 129.43 70.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.669 0.747 . . . . 70.34 111.363 -179.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.895 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 5.1 tpt180 -93.62 132.75 37.64 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 114.438 -1.256 . . . . 74.22 109.486 -179.021 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.515 ' HB3' ' HH ' ' A' ' 38' ' ' TYR . 97.1 m-85 -106.55 -171.28 1.86 Allowed 'General case' 0 C--N 1.32 -0.678 0 C-N-CA 120.845 -0.342 . . . . 74.35 110.735 -178.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.411 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 19.1 ttt-85 -114.68 -51.69 2.73 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.944 0.402 . . . . 74.3 110.264 -174.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -136.83 30.57 2.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 71.12 112.807 -177.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 80.3 mt -109.72 129.7 55.59 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 122.595 -0.356 . . . . 52.44 110.255 177.544 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.4 t -80.33 -179.81 7.31 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.112 -0.495 . . . . 75.32 110.1 178.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.404 ' C ' ' H ' ' A' ' 27' ' ' GLN . 38.3 ptt180 -73.48 -174.16 1.6 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.325 -0.398 . . . . 73.32 110.752 -178.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 21.8 t70 67.32 -44.5 0.46 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.859 0.864 . . . . 54.04 111.619 -177.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.637 ' O ' HG22 ' A' ' 28' ' ' VAL . 28.1 mt-30 -68.03 -163.62 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 122.896 0.478 . . . . 70.15 111.554 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.637 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.0 m 61.11 13.93 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 124.538 1.135 . . . . 75.0 111.347 -177.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -90.99 -29.02 17.63 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.342 -0.614 . . . . 71.12 109.342 176.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.65 89.68 1.27 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.714 -0.676 . . . . 75.11 111.003 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.598 ' HB ' HD11 ' A' ' 9' ' ' ILE . 57.3 mt -126.66 134.28 66.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 108.818 -0.808 . . . . 74.23 108.818 175.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -77.54 -56.42 4.54 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.815 0.34 . . . . 73.04 111.043 -177.093 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.822 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 65.9 m-85 -136.33 145.61 45.63 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.082 0.467 . . . . 71.25 111.375 -175.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.594 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.7 mm? -103.8 139.11 19.8 Favored Pre-proline 0 C--N 1.323 -0.564 0 N-CA-C 108.993 -0.743 . . . . 73.11 108.993 170.223 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -58.89 159.76 20.28 Favored 'Trans proline' 0 N--CA 1.476 0.5 0 C-N-CA 123.203 2.602 . . . . 63.24 113.315 -176.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.4 ' HB ' ' HB2' ' A' ' 5' ' ' GLU . 9.9 p -71.64 2.75 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 CA-C-O 121.648 0.737 . . . . 72.31 111.473 -176.7 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -134.4 92.78 2.97 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.093 0.473 . . . . 75.53 109.798 170.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.589 ' O ' ' HA ' ' A' ' 57' ' ' LYS . 20.2 t80 -157.18 135.02 10.86 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.633 -0.712 . . . . 74.11 109.301 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 38.9 mt-10 -113.4 130.29 56.33 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.242 0.339 . . . . 72.52 110.784 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.574 HG12 ' HB2' ' A' ' 56' ' ' ARG . 43.6 pt -121.68 158.09 25.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.369 -0.378 . . . . 75.11 110.89 175.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.895 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 41.3 tt0 -127.19 154.36 44.9 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.868 -0.605 . . . . 74.33 110.598 -177.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 65.3 m-85 -100.03 102.29 13.6 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.328 -0.396 . . . . 75.13 110.612 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.3 m -109.2 164.78 5.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.371 -0.377 . . . . 43.53 111.202 -178.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.512 ' HB2' ' HB2' ' A' ' 48' ' ' ARG . 86.3 m -110.85 179.32 4.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.1 -0.5 . . . . 51.42 110.388 177.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -76.92 102.36 6.35 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.071 0.463 . . . . 71.44 110.375 178.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.35 -166.81 25.76 Favored Glycine 0 N--CA 1.445 -0.704 0 N-CA-C 111.05 -0.82 . . . . 62.21 111.05 -176.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -82.59 77.66 9.32 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.526 0.679 . . . . 71.43 111.281 178.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.512 ' HB2' ' HB2' ' A' ' 44' ' ' CYS . 14.1 mtm-85 -127.87 118.34 23.46 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.754 -0.832 . . . . 74.21 108.754 176.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -88.2 154.11 20.7 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.064 -0.516 . . . . 74.41 111.099 -172.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.588 HG12 ' HA ' ' A' ' 73' ' ' CYS . 27.2 m -119.23 130.77 73.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.798 -0.637 . . . . 54.31 109.969 178.48 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.0 p -95.04 94.08 4.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-O 122.217 1.008 . . . . 73.23 109.857 175.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -157.26 170.9 34.51 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 114.223 -1.353 . . . . 43.0 110.514 177.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.514 ' HG2' HG21 ' A' ' 69' ' ' THR . 55.9 Cg_endo -75.19 77.88 3.08 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.621 1.547 . . . . 70.42 110.536 168.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.603 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 43.6 pttt -86.84 88.48 7.69 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.656 0.741 . . . . 72.35 111.048 -174.392 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.508 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 6.8 p -160.19 128.99 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.496 -0.775 . . . . 74.12 109.814 176.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.574 ' HB2' HG12 ' A' ' 40' ' ' ILE . 23.1 mmt180 -137.12 125.65 23.61 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.924 -0.58 . . . . 73.32 110.028 178.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 38' ' ' TYR . 35.4 ttmt -124.6 137.4 54.39 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 108.775 -0.824 . . . . 71.3 108.775 168.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.5 t -67.27 142.86 56.75 Favored 'General case' 0 C--N 1.323 -0.575 0 O-C-N 123.337 0.398 . . . . 74.1 110.279 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.9 mt -119.46 -178.1 3.52 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.141 -0.481 . . . . 75.32 110.228 -177.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.62 -4.98 43.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.066 0.46 . . . . 34.01 110.884 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -99.62 163.38 12.52 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.774 -0.648 . . . . 74.35 109.422 173.535 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -78.53 47.96 3.09 Favored Glycine 0 CA--C 1.521 0.449 0 C-N-CA 120.917 -0.659 . . . . 74.22 113.678 -174.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.0 t -165.9 170.55 13.64 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.259 -0.645 . . . . 64.31 109.259 178.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 61.1 m95 -87.44 178.12 6.91 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.836 -0.431 . . . . 65.43 109.836 -177.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.401 HG23 ' O ' ' A' ' 57' ' ' LYS . 2.9 p -49.86 -50.8 44.3 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 113.394 0.887 . . . . 71.12 113.394 -173.064 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -148.25 66.08 1.08 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.569 0.224 . . . . 71.12 110.445 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 60.1 ttp -87.1 79.83 8.53 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 118.921 -1.112 . . . . 72.34 110.934 -176.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -169.31 89.67 0.2 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.446 -1.252 . . . . 63.14 107.72 162.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.514 HG21 ' HG2' ' A' ' 53' ' ' PRO . 1.4 m -151.39 127.29 5.02 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 120.314 -0.554 . . . . 74.33 111.339 -170.354 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -78.61 93.95 1.08 Allowed 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.574 2.182 . . . . 64.14 112.159 175.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.9 p -92.9 114.61 27.22 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.081 -0.509 . . . . 73.3 110.782 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.7 ptp85 -94.28 128.67 40.9 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.056 -0.52 . . . . 75.3 111.045 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.588 ' HA ' HG12 ' A' ' 50' ' ' VAL . 18.2 t -89.44 112.2 23.28 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.001 -0.545 . . . . 74.22 109.748 179.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.97 115.03 14.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.478 -0.328 . . . . 70.53 111.168 -174.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.4 ' HA ' ' HD2' ' A' ' 75' ' ' ARG . 12.0 tpt180 . . . . . 0 C--O 1.244 0.795 0 CA-C-O 118.479 -0.772 . . . . 74.41 109.723 174.16 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 28.1 m . . . . . 0 N--CA 1.451 -0.399 0 N-CA-C 109.683 -0.488 . . . . 74.12 109.683 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -76.19 105.41 7.22 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.106 -0.497 . . . . 74.03 109.795 -179.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.727 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -149.53 143.1 10.4 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.624 -0.798 . . . . 52.24 112.529 -178.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 69.2 m -92.47 151.83 20.0 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 110.213 -0.292 . . . . 72.14 110.213 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.452 ' H ' ' HG3' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -87.15 -179.43 6.45 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.633 -0.258 . . . . 64.22 111.521 -177.683 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 40.4 mt -88.61 112.57 24.13 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.246 -0.434 . . . . 73.43 111.294 -171.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 38.7 mt -70.82 146.12 12.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.74 -0.663 . . . . 53.14 110.443 179.139 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . 0.43 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 72.2 m-70 -88.24 141.85 31.23 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 116.524 -0.307 . . . . 73.31 110.39 177.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 12.8 Cg_exo -71.4 122.08 8.32 Favored 'Trans proline' 0 CA--C 1.529 0.253 0 C-N-CA 122.934 2.423 . . . . 62.52 111.644 176.071 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 59.8 Cg_endo -91.19 -94.73 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 123.008 2.472 . . . . 72.42 112.782 -177.6 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -89.99 -176.0 4.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.088 -0.708 . . . . 72.24 109.088 178.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -57.48 -16.21 9.02 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 112.11 0.411 . . . . 74.13 112.11 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.38 91.41 0.3 Allowed Glycine 0 N--CA 1.448 -0.502 0 N-CA-C 110.648 -0.981 . . . . 71.54 110.648 167.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -91.16 -170.21 42.58 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 121.168 -0.539 . . . . 73.45 112.982 -173.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -115.55 136.23 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 CA-C-O 121.72 0.772 . . . . 70.34 112.083 -174.632 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.786 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 15.4 tpt180 -116.4 145.8 42.98 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.182 -1.372 . . . . 74.22 109.049 -178.047 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 68.6 m-85 -108.95 -172.89 2.14 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.805 -0.442 . . . . 74.35 109.805 178.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 25.6 mtm180 -98.41 -38.48 9.2 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.57 -0.452 . . . . 74.3 110.885 -178.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -160.56 52.95 0.34 Allowed Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.644 -0.789 . . . . 71.12 112.467 178.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 93.7 mt -116.73 115.94 26.57 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.942 0.401 . . . . 52.44 110.352 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.6 t -80.79 -179.2 7.16 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.656 -0.702 . . . . 75.32 110.307 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.5 ' C ' ' H ' ' A' ' 27' ' ' GLN . 39.5 mmt180 -67.4 -174.99 0.44 Allowed 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.684 0.278 . . . . 73.32 111.308 -176.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 23.4 t70 65.64 -34.26 0.19 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.638 0.775 . . . . 54.04 112.172 -175.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.5 ' H ' ' C ' ' A' ' 25' ' ' ARG . 20.6 mt-30 -80.89 -166.3 1.09 Allowed 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 122.542 0.337 . . . . 70.15 110.664 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 27' ' ' GLN . 5.8 m 52.89 18.5 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 124.548 1.139 . . . . 75.0 113.068 177.009 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 50.8 pttt -111.37 -21.85 11.62 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.808 0.337 . . . . 71.12 110.285 177.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.74 16.03 2.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.346 -0.388 . . . . 75.11 111.664 -178.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 60.8 mt -73.22 103.38 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 109.404 -0.591 . . . . 74.23 109.404 176.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -58.01 -50.07 74.66 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.145 -0.48 . . . . 73.04 112.184 -173.066 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.727 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 91.0 m-85 -133.31 128.54 35.96 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.818 0.342 . . . . 71.25 110.821 -177.24 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -83.23 126.87 70.93 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 108.485 -0.931 . . . . 73.11 108.485 171.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -51.24 145.46 26.77 Favored 'Trans proline' 0 C--O 1.234 0.283 0 C-N-CA 123.361 2.707 . . . . 63.24 112.92 -176.118 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 p -59.74 142.41 15.21 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 CA-C-N 115.792 -0.64 . . . . 72.31 110.99 -178.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.8 t70 78.75 -11.96 1.14 Allowed 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.238 -0.892 . . . . 75.53 111.947 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 47.3 t80 -67.05 120.31 13.46 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 108.877 -0.786 . . . . 74.11 108.877 176.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.477 ' HG2' ' HA ' ' A' ' 57' ' ' LYS . 43.6 mt-10 -104.77 146.84 28.4 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.131 -0.486 . . . . 72.52 110.836 -176.147 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.598 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 21.1 pt -120.2 155.56 23.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.824 -0.626 . . . . 75.11 110.415 177.748 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.786 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.4 tt0 -107.21 165.84 11.07 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.588 -0.733 . . . . 74.33 110.268 -174.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.441 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 5.2 m-85 -120.47 101.43 7.77 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.775 0.321 . . . . 75.13 110.838 178.048 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 20.3 m -103.01 168.15 2.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.139 -0.482 . . . . 43.53 110.429 178.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.598 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 28.3 t -90.57 140.76 29.44 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.472 -0.566 . . . . 51.42 109.472 178.52 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -59.12 117.12 4.36 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.818 -0.628 . . . . 71.44 110.218 -176.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 114.18 -112.91 2.92 Favored Glycine 0 N--CA 1.444 -0.808 0 N-CA-C 111.093 -0.803 . . . . 62.21 111.093 -176.051 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -149.77 65.76 0.99 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.347 0.594 . . . . 71.43 110.834 177.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.598 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 35.0 mmt180 -126.57 136.27 52.34 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.265 -0.425 . . . . 74.21 110.047 179.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.52 157.01 27.52 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.958 -0.386 . . . . 74.41 109.958 176.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.53 HG12 ' HB3' ' A' ' 73' ' ' CYS . 33.2 m -130.29 149.69 33.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.245 -0.434 . . . . 54.31 110.68 -177.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -116.34 95.47 3.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 122.298 1.047 . . . . 73.23 108.929 169.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.47 172.33 33.61 Favored Glycine 0 N--CA 1.444 -0.824 0 CA-C-N 114.496 -1.229 . . . . 43.0 111.173 -178.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.5 ' HG2' HG21 ' A' ' 69' ' ' THR . 69.3 Cg_endo -75.91 60.02 5.96 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.326 2.017 . . . . 70.42 110.782 173.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.602 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 40.0 pttt -71.65 88.93 0.98 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.452 -0.794 . . . . 72.35 111.328 -175.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -161.88 131.89 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 116.046 -0.525 . . . . 74.12 110.946 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.598 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 22.3 mmt180 -127.78 111.07 13.24 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.504 -0.924 . . . . 73.32 108.504 169.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.477 ' HA ' ' HG2' ' A' ' 39' ' ' GLU . 20.5 ttmm -97.99 122.39 41.05 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.954 -0.387 . . . . 71.3 109.954 -178.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 49.8 t -69.65 126.97 31.33 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.772 -0.455 . . . . 74.1 109.772 177.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 95.0 mt -97.03 -178.94 4.37 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.054 -0.521 . . . . 75.32 110.831 -175.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.29 -17.03 61.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 34.01 110.687 178.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.3 p-10 -101.18 165.8 11.11 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.305 -0.628 . . . . 74.35 109.305 174.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.97 52.42 3.28 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 121.026 -0.607 . . . . 74.22 113.51 -174.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.8 m -157.5 157.7 34.35 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.523 -0.547 . . . . 64.31 109.523 177.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -88.27 173.51 8.73 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.603 -0.517 . . . . 65.43 109.603 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.425 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 3.0 p -57.73 -73.18 0.08 Allowed 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 112.27 0.47 . . . . 71.12 112.27 -177.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -125.31 121.13 33.09 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.215 -0.661 . . . . 71.12 109.215 178.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 62.3 mtm -120.45 79.6 1.5 Allowed 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 119.259 -0.976 . . . . 72.34 111.149 173.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -168.34 89.79 0.26 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 114.735 -1.121 . . . . 63.14 108.316 162.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.5 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.2 OUTLIER -159.02 102.23 1.58 Allowed Pre-proline 0 C--N 1.315 -0.932 0 C-N-CA 120.581 -0.448 . . . . 74.33 110.693 -171.814 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -75.33 105.17 2.03 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.359 2.039 . . . . 64.14 111.576 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 7.6 p -75.22 102.41 4.99 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.228 0.537 . . . . 73.3 110.852 -178.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.1 ptp180 -79.97 115.61 19.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.696 -0.684 . . . . 75.3 111.252 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.53 ' HB3' HG12 ' A' ' 50' ' ' VAL . 0.7 OUTLIER -87.25 99.04 11.67 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.984 -0.553 . . . . 74.22 110.689 174.761 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.7 p -115.53 129.13 72.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.611 -0.722 . . . . 70.53 109.54 176.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.637 -0.697 . . . . 74.41 109.875 -176.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.0 m . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 108.794 -0.817 . . . . 74.12 108.794 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -119.1 99.2 6.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.698 -0.683 . . . . 74.03 110.524 -174.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.468 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -161.74 165.54 35.74 Favored Glycine 0 N--CA 1.437 -1.235 0 CA-C-N 115.612 -0.722 . . . . 52.24 111.363 178.234 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 13.3 m -84.61 139.74 31.86 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 110.078 -0.341 . . . . 72.14 110.078 178.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.402 HE21 ' HB2' ' A' ' 8' ' ' GLN . 1.6 pt20 -83.14 -178.67 7.18 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.204 0.526 . . . . 64.22 111.087 -178.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.544 HD11 ' HB ' ' A' ' 31' ' ' ILE . 58.2 mt -87.43 105.04 14.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.809 -0.632 . . . . 73.43 109.366 178.087 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 20.8 pt -72.18 169.93 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 114.721 -1.127 . . . . 53.14 111.556 -177.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -69.39 135.79 88.72 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.009 -0.541 . . . . 73.31 109.745 173.576 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -59.78 143.99 99.53 Favored 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.117 1.878 . . . . 62.52 111.147 172.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.21 -160.05 0.09 OUTLIER 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.489 2.126 . . . . 72.42 112.441 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 14.9 t-105 -68.8 -175.94 0.76 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.969 -0.56 . . . . 72.24 109.787 177.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 66.9 mm-40 -37.86 100.53 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.553 0.741 . . . . 74.13 112.655 -172.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.532 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . 163.6 -132.39 2.72 Favored Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.322 -0.853 . . . . 71.54 111.643 -179.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -179.64 -166.2 34.93 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.495 -0.642 . . . . 73.45 111.495 178.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.3 mt -127.95 130.11 69.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.463 0.649 . . . . 70.34 111.189 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.741 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 23.2 tpt180 -96.64 135.3 38.75 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 114.759 -1.109 . . . . 74.22 109.255 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.588 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 98.0 m-85 -93.17 -171.23 2.61 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.836 -0.346 . . . . 74.35 110.613 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.598 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 49.1 ttt180 -106.43 -75.86 0.62 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 120.757 0.313 . . . . 74.3 110.893 -170.346 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -114.19 43.68 1.65 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.886 -0.597 . . . . 71.12 112.097 -177.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 75.1 mt -133.69 144.67 49.3 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 110.243 -0.28 . . . . 52.44 110.243 178.094 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.0 t -97.04 175.01 6.48 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.062 -0.517 . . . . 75.32 109.821 176.007 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.458 ' C ' ' H ' ' A' ' 27' ' ' GLN . 34.7 ptt180 -74.43 -172.42 1.46 Allowed 'General case' 0 C--O 1.236 0.389 0 C-N-CA 121.439 -0.104 . . . . 73.32 110.815 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 27.4 t70 69.27 -2.27 1.9 Allowed 'General case' 0 N--CA 1.474 0.774 0 CA-C-O 122.055 0.931 . . . . 54.04 109.945 -175.589 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.458 ' H ' ' C ' ' A' ' 25' ' ' ARG . 21.6 mt-30 -119.98 -156.51 0.67 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.777 -1.102 . . . . 70.15 108.518 178.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.423 HG12 HD11 ' A' ' 31' ' ' ILE . 15.2 m 47.83 27.57 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.778 0.831 . . . . 75.0 112.263 176.343 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.413 ' H ' ' HG2' ' A' ' 29' ' ' LYS . 26.3 pttt -92.74 -22.44 19.37 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.39 -0.823 . . . . 71.12 110.445 -175.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.6 81.54 0.66 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.809 -0.632 . . . . 75.11 110.677 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.544 ' HB ' HD11 ' A' ' 9' ' ' ILE . 48.0 mt -103.4 146.78 10.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.829 -0.623 . . . . 74.23 109.533 178.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -85.56 -67.92 0.77 Allowed 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.978 -0.379 . . . . 73.04 109.978 177.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.468 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 75.8 m-85 -136.32 145.72 45.8 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.021 -0.536 . . . . 71.25 110.641 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -92.32 142.59 26.25 Favored Pre-proline 0 C--N 1.321 -0.645 0 N-CA-C 109.762 -0.459 . . . . 73.11 109.762 175.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -62.77 147.15 95.05 Favored 'Trans proline' 0 C--O 1.237 0.442 0 C-N-CA 122.725 2.284 . . . . 63.24 113.03 -178.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 6.4 p -70.39 80.75 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 CA-C-O 122.159 0.98 . . . . 72.31 110.502 177.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.0 t70 172.94 -27.78 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 114.461 -1.245 . . . . 75.53 108.739 -175.095 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.588 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 7.9 t80 -72.15 142.9 49.09 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 114.751 -1.113 . . . . 74.11 111.185 -176.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.598 ' H ' ' HD2' ' A' ' 21' ' ' ARG . 54.9 mt-10 -124.61 153.76 41.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.032 -0.531 . . . . 72.52 109.93 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.645 HD11 ' HE1' ' A' ' 67' ' ' MET . 35.0 pt -126.68 165.65 24.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 120.763 0.316 . . . . 75.11 111.435 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.741 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.7 tt0 -130.89 147.47 52.54 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.955 -0.566 . . . . 74.33 110.268 178.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -94.84 102.27 14.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.285 -0.416 . . . . 75.13 110.678 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.5 m -103.48 170.67 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 120.9 0.381 . . . . 43.53 111.141 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 49.7 t -115.9 175.18 5.65 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.301 -0.409 . . . . 51.42 110.055 -178.378 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . 0.532 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 2.0 tmt_? -77.09 99.63 5.43 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.631 -0.507 . . . . 71.44 109.631 -178.185 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.18 -160.63 28.44 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.929 -0.653 . . . . 62.21 111.691 -178.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -85.18 69.52 10.77 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.745 0.783 . . . . 71.43 111.002 -179.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 26.5 mmm180 -124.51 107.72 11.36 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.139 -1.059 . . . . 74.21 108.139 174.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -79.8 139.31 37.28 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.999 0.428 . . . . 74.41 111.508 -170.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' A' ' 73' ' ' CYS . 33.7 m -94.53 150.12 4.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.707 -0.678 . . . . 54.31 111.292 -176.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -114.42 95.06 3.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.822 0.82 . . . . 73.23 109.17 169.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.57 171.66 33.63 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.155 -0.93 . . . . 43.0 111.664 -178.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -83.58 71.25 6.03 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.158 1.905 . . . . 70.42 110.336 169.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.462 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 21.1 pttp -81.61 86.95 6.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.655 0.741 . . . . 72.35 111.629 -170.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.6 p -161.9 128.0 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.362 -0.836 . . . . 74.12 109.315 172.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.493 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 35.1 mmt180 -145.19 118.22 8.83 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.322 -0.622 . . . . 73.32 109.322 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -106.03 139.7 40.16 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.958 0.409 . . . . 71.3 109.958 177.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.9 t -70.47 149.66 46.98 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.556 -0.747 . . . . 74.1 111.911 -175.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.3 mt -113.15 -178.02 3.28 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.187 -0.915 . . . . 75.32 109.943 179.307 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -83.44 28.97 0.52 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.869 0.366 . . . . 34.01 111.277 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -146.56 169.85 18.11 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.161 -0.472 . . . . 74.35 109.946 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -69.2 -34.44 75.46 Favored Glycine 0 C--N 1.33 0.236 0 C-N-CA 121.348 -0.453 . . . . 74.22 114.039 -169.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.8 m -89.79 142.06 28.04 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 121.124 0.488 . . . . 64.31 111.054 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 59.7 m95 -73.82 -179.29 3.59 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.086 -0.507 . . . . 65.43 110.732 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.9 p -56.33 -56.12 25.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.312 -0.404 . . . . 71.12 111.792 -178.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.44 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 10.6 t70 -142.66 127.0 17.66 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.742 -0.466 . . . . 71.12 109.742 174.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . 0.645 ' HE1' HD11 ' A' ' 40' ' ' ILE . 24.2 mmt -127.75 78.68 1.84 Allowed 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 119.112 -1.035 . . . . 72.34 110.531 165.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -167.08 87.85 0.3 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 113.843 -1.526 . . . . 63.14 107.544 159.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 91.5 m -160.33 109.0 1.37 Allowed Pre-proline 0 C--N 1.317 -0.825 0 N-CA-C 109.651 -0.5 . . . . 74.33 109.651 -172.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.53 99.52 0.94 Allowed 'Trans proline' 0 C--O 1.233 0.24 0 C-N-CA 122.68 2.253 . . . . 64.14 113.213 -174.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 11.8 p -91.58 98.58 11.74 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.519 -0.548 . . . . 73.3 109.519 173.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.424 HH11 ' HD2' ' A' ' 72' ' ' ARG . 7.0 ptp180 -91.29 140.66 29.57 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.163 -0.471 . . . . 75.3 110.852 -175.493 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.599 ' HA ' ' HA ' ' A' ' 50' ' ' VAL . 3.4 p -106.59 122.25 45.95 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.847 -0.615 . . . . 74.22 111.119 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 18.4 t -127.14 -95.64 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 108.892 -0.781 . . . . 70.53 108.892 175.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.536 -0.745 . . . . 74.41 109.673 178.208 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.5 m . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 109.829 -0.434 . . . . 74.12 109.829 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -96.74 96.69 8.77 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.644 -0.502 . . . . 74.03 109.644 178.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.81 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -164.15 136.91 4.46 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.742 -0.742 . . . . 52.24 112.565 -179.131 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.8 m -80.01 133.84 36.18 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.81 -0.811 . . . . 72.14 108.81 172.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.577 ' HA ' ' O ' ' A' ' 32' ' ' ASN . 2.2 pt20 -73.31 177.62 5.05 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.624 0.726 . . . . 64.22 112.41 -174.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.3 mt -88.97 127.09 41.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.876 -1.056 . . . . 73.43 110.326 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 58.6 mt -76.21 140.92 16.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.502 -0.772 . . . . 53.14 110.75 -177.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -62.9 138.0 97.06 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 115.49 -0.777 . . . . 73.31 110.188 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.496 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 75.6 Cg_exo -41.48 118.85 0.88 Allowed 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 123.852 3.034 . . . . 62.52 113.74 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.496 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 6.7 Cg_endo -88.79 -145.18 0.03 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.657 0 C-N-CA 123.685 2.924 . . . . 72.42 112.436 -178.551 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.442 ' CG ' ' N ' ' A' ' 15' ' ' GLU . 69.0 t-105 -68.36 -179.67 1.38 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 115.907 -0.588 . . . . 72.24 110.893 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.442 ' N ' ' CG ' ' A' ' 14' ' ' TRP . 16.8 mm-40 -47.99 101.5 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.182 0 C-N-CA 123.972 0.909 . . . . 74.13 112.336 178.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 153.56 -142.58 9.3 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 120.722 -0.751 . . . . 71.54 111.911 178.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -168.72 -169.99 32.82 Favored Glycine 0 N--CA 1.442 -0.959 0 N-CA-C 111.459 -0.656 . . . . 73.45 111.459 -179.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.5 mt -113.81 128.17 70.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.735 0.778 . . . . 70.34 111.432 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.855 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 20.5 tpp180 -86.24 113.14 22.01 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 114.54 -1.209 . . . . 74.22 109.541 179.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.42 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 86.2 m-85 -86.71 -171.54 3.58 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.953 0.406 . . . . 74.35 110.875 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -108.34 -32.51 7.42 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.131 0.491 . . . . 74.3 110.066 -177.47 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -158.62 54.51 0.37 Allowed Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.799 -0.715 . . . . 71.12 112.155 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 88.8 mt -138.61 111.62 7.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.681 0.277 . . . . 52.44 110.95 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.7 t -85.28 -179.91 7.07 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.166 -0.47 . . . . 75.32 109.859 175.229 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.499 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 9.5 ptp85 -72.77 -171.36 0.83 Allowed 'General case' 0 C--O 1.237 0.398 0 N-CA-C 110.027 -0.361 . . . . 73.32 110.027 178.001 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.499 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 9.7 t70 73.24 -40.77 0.48 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 121.251 0.548 . . . . 54.04 110.071 -176.191 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.425 ' O ' HG22 ' A' ' 28' ' ' VAL . 24.6 mt-30 -85.33 -164.64 1.03 Allowed 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 115.497 -0.774 . . . . 70.15 109.156 171.357 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.493 HG12 HD12 ' A' ' 31' ' ' ILE . 9.0 m 50.87 20.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 C-N-CA 124.079 0.952 . . . . 75.0 112.432 178.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 17.9 ptmt -79.78 -18.99 49.69 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.803 -0.635 . . . . 71.12 110.525 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.95 35.97 0.05 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.315 -0.857 . . . . 75.11 110.753 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.493 HD12 HG12 ' A' ' 28' ' ' VAL . 45.6 mt -75.69 136.88 23.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 109.003 -0.74 . . . . 74.23 109.003 175.052 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.577 ' O ' ' HA ' ' A' ' 8' ' ' GLN . 87.4 m-20 -115.76 -25.06 7.93 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 111.981 0.363 . . . . 73.04 111.981 -172.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.81 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 41.5 m-85 -132.01 109.48 10.06 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.958 0.408 . . . . 71.25 111.673 -174.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.405 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.8 mm? -87.66 129.63 50.08 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 109.355 -0.609 . . . . 73.11 109.355 173.054 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -62.21 161.34 27.08 Favored 'Trans proline' 0 N--CA 1.472 0.261 0 C-N-CA 122.868 2.378 . . . . 63.24 113.538 -175.365 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.465 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 12.4 p -63.1 157.68 3.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 CA-C-N 115.355 -0.839 . . . . 72.31 110.602 179.026 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.465 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 32.2 t70 77.12 -3.85 2.42 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.424 0.69 . . . . 75.53 111.004 178.623 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.42 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 4.4 t80 -80.39 123.56 28.13 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.133 -0.485 . . . . 74.11 110.18 -179.185 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.483 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.6 mt-10 -116.37 141.74 47.77 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 110.014 -0.365 . . . . 72.52 110.014 175.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.525 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 33.6 pt -121.26 160.89 21.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 120.965 0.412 . . . . 75.11 111.503 -177.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.855 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 46.2 tt0 -120.52 152.07 38.53 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.546 -0.752 . . . . 74.33 110.101 179.715 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -101.7 102.83 13.56 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.742 0.306 . . . . 75.13 110.982 179.155 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.512 HG11 ' HE ' ' A' ' 19' ' ' ARG . 30.7 m -102.23 152.75 5.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.16 0.505 . . . . 43.53 111.318 -179.044 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.428 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 19.1 t -100.49 -179.83 4.22 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.126 -0.694 . . . . 51.42 109.126 -178.39 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . 0.4 ' HD3' ' HA ' ' A' ' 45' ' ' ARG . 37.5 mmt180 -65.2 110.08 2.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.772 0.32 . . . . 71.44 111.397 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.96 -149.01 24.98 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 121.0 -0.619 . . . . 62.21 111.855 179.194 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -91.56 37.51 0.96 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.365 0.603 . . . . 71.43 110.464 179.465 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 29.8 mmm180 -88.49 108.26 19.3 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.81 -0.811 . . . . 74.21 108.81 176.886 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -77.95 145.39 36.11 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.676 -0.693 . . . . 74.41 111.113 -171.56 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.563 ' HA ' ' HA ' ' A' ' 73' ' ' CYS . 34.8 m -101.33 149.98 6.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.672 -0.694 . . . . 54.31 110.387 179.115 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.0 p -117.47 95.28 3.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 122.003 0.906 . . . . 73.23 109.405 169.043 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.26 171.83 33.46 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.735 -1.121 . . . . 43.0 111.382 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.549 ' HG2' HG23 ' A' ' 69' ' ' THR . 48.1 Cg_endo -77.06 71.92 6.07 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 121.756 1.637 . . . . 70.42 110.359 170.168 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.704 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 43.2 pttt -78.98 89.57 4.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.531 -0.759 . . . . 72.35 111.398 -173.172 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.39 128.57 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.578 0.704 . . . . 74.12 110.877 174.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.647 ' CZ ' ' HA ' ' A' ' 67' ' ' MET . 28.9 mmt85 -138.23 104.41 5.19 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.276 -0.875 . . . . 73.32 109.106 176.72 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -97.47 138.96 34.11 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.412 -0.358 . . . . 71.3 110.182 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.7 t -97.88 128.56 44.56 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.014 -0.539 . . . . 74.1 110.349 176.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 30.7 mt -108.13 -176.6 3.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.797 -0.638 . . . . 75.32 110.414 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -54.43 -35.08 62.56 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 121.037 0.446 . . . . 34.01 110.886 176.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -83.18 140.5 32.54 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.345 -0.613 . . . . 74.35 109.345 174.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -79.14 67.19 3.32 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 121.025 -0.607 . . . . 74.22 113.631 -172.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 32.2 m -155.38 139.31 16.32 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.839 -0.43 . . . . 64.31 109.839 174.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 66.4 m95 -72.28 129.6 38.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.03 -0.73 . . . . 65.43 109.03 177.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.6 p -70.78 13.94 0.16 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 115.24 1.57 . . . . 71.12 115.24 -166.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -159.03 42.96 0.24 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.302 -0.629 . . . . 71.12 109.302 177.036 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . 0.647 ' HA ' ' CZ ' ' A' ' 56' ' ' ARG . 26.4 ttt -83.75 77.38 9.89 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 122.074 0.94 . . . . 72.34 111.38 -171.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -170.32 88.97 0.15 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 113.905 -1.498 . . . . 63.14 107.361 159.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.549 HG23 ' HG2' ' A' ' 53' ' ' PRO . 7.5 m -127.58 112.38 20.89 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 119.847 -0.741 . . . . 74.33 112.51 -167.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -74.05 114.77 4.12 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 122.913 2.408 . . . . 64.14 110.811 172.304 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.4 p -135.64 145.74 47.13 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.403 -0.362 . . . . 73.3 110.844 -175.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.5 ptp180 -140.8 136.42 32.44 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.204 -0.453 . . . . 75.3 110.122 -178.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 50' ' ' VAL . 0.9 OUTLIER -97.18 99.73 11.21 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.462 0.649 . . . . 74.22 111.101 176.783 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -131.94 134.09 60.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.028 -0.987 . . . . 70.53 108.837 178.128 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.381 -0.819 . . . . 74.41 110.948 -172.189 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.7 m . . . . . 0 N--CA 1.451 -0.404 0 N-CA-C 109.495 -0.557 . . . . 74.12 109.495 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -118.03 100.23 7.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.557 -0.747 . . . . 74.03 110.261 -175.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.881 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.54 145.32 10.96 Favored Glycine 0 N--CA 1.444 -0.833 0 N-CA-C 111.373 -0.691 . . . . 52.24 111.373 178.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 56.7 m -81.16 132.01 35.33 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 110.176 -0.305 . . . . 72.14 110.176 -179.459 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -80.3 -176.55 5.69 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.995 0.426 . . . . 64.22 111.302 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 73.0 mt -84.86 136.34 22.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.498 -0.773 . . . . 73.43 109.046 178.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 14.1 mt -94.76 148.33 5.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 116.102 -0.499 . . . . 53.14 111.614 -169.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 10.8 p80 -61.69 136.29 94.64 Favored Pre-proline 0 C--O 1.233 0.211 0 CA-C-N 116.051 -0.522 . . . . 73.31 109.875 172.156 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.421 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 38.2 Cg_endo -66.9 119.77 6.82 Favored 'Trans proline' 0 N--CA 1.464 -0.248 0 C-N-CA 122.526 2.151 . . . . 62.52 111.951 179.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.48 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 5.1 Cg_exo -77.76 -129.8 0.01 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.272 0 C-N-CA 123.043 2.495 . . . . 72.42 111.49 178.052 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.48 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 39.3 t-105 -63.86 174.77 1.34 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 109.594 -0.521 . . . . 72.24 109.594 175.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -68.91 76.37 0.31 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.497 0.665 . . . . 74.13 112.321 -176.096 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.27 155.32 25.97 Favored Glycine 0 N--CA 1.438 -1.188 0 N-CA-C 109.729 -1.349 . . . . 71.54 109.729 173.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -106.06 -172.3 23.38 Favored Glycine 0 N--CA 1.44 -1.085 0 C-N-CA 119.811 -1.185 . . . . 73.45 112.017 -178.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.8 mt -132.16 131.75 61.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.197 0.523 . . . . 70.34 109.987 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.426 HH11 ' HD2' ' A' ' 19' ' ' ARG . 0.2 OUTLIER -113.41 122.28 46.87 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.39 -0.823 . . . . 74.22 109.341 -179.307 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -88.52 -172.71 3.86 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.878 0.371 . . . . 74.35 110.552 -175.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.5 ttm180 -89.18 -51.59 5.5 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.219 -0.446 . . . . 74.3 110.27 -177.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -137.27 13.07 3.8 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.805 -0.712 . . . . 71.12 112.736 -178.251 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 80.3 mt -89.96 129.29 36.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.106 0.479 . . . . 52.44 110.805 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.1 t -102.74 -178.27 3.62 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.577 -0.738 . . . . 75.32 110.085 178.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.484 ' C ' ' H ' ' A' ' 27' ' ' GLN . 60.6 mtp180 -69.3 -173.07 0.5 Allowed 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.535 -0.302 . . . . 73.32 111.28 -176.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 24.3 t70 69.79 -40.33 0.46 Allowed 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.444 0.698 . . . . 54.04 110.505 -172.383 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.49 ' O ' HG22 ' A' ' 28' ' ' VAL . 18.1 mt-30 -86.6 -161.12 0.63 Allowed 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.36 -0.836 . . . . 70.15 110.3 177.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.49 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.6 m 54.73 10.0 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.674 1.19 . . . . 75.0 113.247 177.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -97.25 -19.84 18.3 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.021 0.439 . . . . 71.12 110.027 175.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.64 94.07 1.85 Allowed 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.552 -0.749 . . . . 75.11 110.377 178.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -131.58 136.62 56.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.109 -0.7 . . . . 74.23 109.109 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -76.77 -67.02 0.74 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.959 0.409 . . . . 73.04 110.892 -177.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.881 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 61.8 m-85 -133.91 126.67 30.89 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.832 -0.622 . . . . 71.25 111.119 -175.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -85.13 134.11 41.58 Favored Pre-proline 0 C--N 1.324 -0.525 0 N-CA-C 108.969 -0.752 . . . . 73.11 108.969 171.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -63.08 141.18 82.34 Favored 'Trans proline' 0 C--O 1.239 0.545 0 C-N-CA 122.816 2.344 . . . . 63.24 112.906 -176.502 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.426 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 3.1 p -69.84 82.07 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 CA-C-O 121.719 0.771 . . . . 72.31 110.25 176.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.426 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 6.2 t70 172.44 -26.39 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.635 -1.166 . . . . 75.53 108.544 -175.873 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.459 ' OH ' ' HG ' ' A' ' 23' ' ' LEU . 6.1 t80 -74.04 146.38 43.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.217 -0.901 . . . . 74.11 110.822 -177.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -124.69 158.64 32.71 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 115.911 -0.586 . . . . 72.52 110.564 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.476 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 31.0 pt -139.5 149.27 22.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.15 -0.477 . . . . 75.11 110.67 177.017 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.542 ' HG2' ' H ' ' A' ' 42' ' ' TYR . 24.2 tt0 -112.81 167.37 10.55 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.161 -0.472 . . . . 74.33 109.902 178.272 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.542 ' H ' ' HG2' ' A' ' 41' ' ' GLU . 69.1 m-85 -112.44 102.42 10.54 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.077 0.465 . . . . 75.13 111.998 -177.195 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.0 m -96.21 153.6 3.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 109.074 -0.713 . . . . 43.53 109.074 171.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.591 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 34.2 t -89.07 167.49 13.1 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.138 -0.69 . . . . 51.42 109.138 179.554 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -59.25 117.09 4.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.024 0.44 . . . . 71.44 110.151 -176.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.76 -120.77 6.53 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 110.958 -0.857 . . . . 62.21 110.958 -176.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -130.04 25.61 5.24 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.359 0.6 . . . . 71.43 110.212 177.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.591 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 29.8 mmm180 -88.47 136.06 33.18 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.823 -0.626 . . . . 74.21 109.8 -177.435 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -95.47 159.19 15.12 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.046 -0.525 . . . . 74.41 109.811 -179.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.548 HG12 ' HA ' ' A' ' 73' ' ' CYS . 27.9 m -122.28 150.14 25.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.523 -0.308 . . . . 54.31 110.422 179.517 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 p -100.83 96.89 5.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 122.039 0.923 . . . . 73.23 109.295 171.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.23 172.11 33.45 Favored Glycine 0 N--CA 1.441 -0.997 0 CA-C-N 114.973 -1.012 . . . . 43.0 111.612 -176.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -74.07 55.69 3.5 Favored 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.249 1.966 . . . . 70.42 110.523 171.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.479 ' HD2' ' HG2' ' A' ' 41' ' ' GLU . 43.0 pttt -75.41 87.46 2.58 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 115.74 -0.664 . . . . 72.35 111.515 -173.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -161.41 129.21 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.439 -0.8 . . . . 74.12 109.45 172.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.521 HH22 ' CB ' ' A' ' 69' ' ' THR . 31.8 mmt180 -132.61 140.29 48.16 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.918 -0.401 . . . . 73.32 109.918 179.165 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -130.76 137.56 49.53 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.598 -0.519 . . . . 71.3 109.598 176.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 50.4 t -70.83 146.5 49.65 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.114 -0.494 . . . . 74.1 110.26 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 94.3 mt -116.86 -179.61 3.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.136 -0.484 . . . . 75.32 110.381 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.03 -8.39 59.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.917 0.389 . . . . 34.01 111.038 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -100.54 166.16 11.06 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.434 -0.58 . . . . 74.35 109.434 175.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.02 57.76 3.14 Favored Glycine 0 CA--C 1.516 0.131 0 C-N-CA 120.987 -0.625 . . . . 74.22 113.091 -177.193 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.2 t -172.96 171.03 4.35 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.209 -0.663 . . . . 64.31 109.209 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 40.5 m95 -99.98 -179.01 4.02 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 109.714 -0.476 . . . . 65.43 109.714 -178.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.0 p -49.63 -53.31 24.88 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.579 0.585 . . . . 71.12 112.579 -176.771 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -153.77 129.95 10.41 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.026 -1.102 . . . . 71.12 108.026 177.227 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 22.9 mmt -131.81 78.4 1.82 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 118.992 -1.083 . . . . 72.34 112.136 174.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 30.0 t0 -168.94 88.39 0.19 Allowed 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 107.805 -1.183 . . . . 63.14 107.805 157.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.521 ' CB ' HH22 ' A' ' 56' ' ' ARG . 1.3 m -149.32 94.6 3.92 Favored Pre-proline 0 C--N 1.314 -0.948 0 C-N-CA 120.913 -0.315 . . . . 74.33 110.313 -172.5 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.95 92.81 0.32 Allowed 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 122.487 2.125 . . . . 64.14 112.26 -179.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 17.0 m -79.68 115.8 19.49 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.942 -0.572 . . . . 73.3 109.811 177.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.5 ptp180 -79.68 133.73 36.39 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.715 -0.675 . . . . 75.3 111.655 -174.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.548 ' HA ' HG12 ' A' ' 50' ' ' VAL . 71.2 m -83.08 98.87 9.53 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.761 -0.654 . . . . 74.22 110.592 178.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.5 p -148.88 114.47 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.635 -0.711 . . . . 70.53 109.534 176.42 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 2.4 tmt_? . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.288 -0.863 . . . . 74.41 109.488 -173.206 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.7 m . . . . . 0 N--CA 1.446 -0.636 0 N-CA-C 109.485 -0.561 . . . . 74.12 109.485 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 33.3 mm-40 -98.82 118.41 35.5 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.892 -0.595 . . . . 74.03 109.466 -179.562 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.521 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -153.73 152.14 23.78 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.124 -1.036 . . . . 52.24 113.152 -176.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.8 m -97.14 149.39 22.04 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.432 -0.581 . . . . 72.14 109.432 177.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -72.82 173.98 8.38 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.129 0.49 . . . . 64.22 112.171 -175.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.58 HD11 ' HB ' ' A' ' 31' ' ' ILE . 54.5 mt -88.5 126.9 41.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.522 -0.763 . . . . 73.43 110.458 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.1 mt -84.05 127.92 39.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.051 -0.522 . . . . 53.14 109.847 177.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -79.5 133.4 59.74 Favored Pre-proline 0 C--N 1.323 -0.583 0 N-CA-C 109.631 -0.507 . . . . 73.31 109.631 -177.355 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.451 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 72.3 Cg_exo -49.3 113.3 0.88 Allowed 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 123.451 2.767 . . . . 62.52 113.005 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.465 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 4.9 Cg_exo -80.52 -101.4 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 123.194 2.596 . . . . 72.42 112.827 -177.06 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.465 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 55.7 t-105 -80.76 177.11 9.24 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.777 -0.453 . . . . 72.24 109.777 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -54.84 101.21 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.409 0.623 . . . . 74.13 111.733 179.462 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.06 -145.43 9.44 Favored Glycine 0 N--CA 1.443 -0.872 0 CA-C-N 115.095 -0.957 . . . . 71.54 110.714 -177.473 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -176.42 -170.01 38.54 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 120.473 -0.87 . . . . 73.45 111.914 178.384 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.9 mt -125.52 125.65 69.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.272 0.558 . . . . 70.34 110.838 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.38 160.57 14.6 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.994 -1.003 . . . . 74.22 108.893 178.089 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -123.26 -171.12 2.24 Favored 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 120.797 -0.361 . . . . 74.35 110.398 -176.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.416 ' HB3' ' CE2' ' A' ' 38' ' ' TYR . 39.9 ttm180 -82.56 -36.58 26.12 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.46 -0.336 . . . . 74.3 110.345 -178.116 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.94 71.21 0.19 Allowed Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.588 -0.815 . . . . 71.12 112.53 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 62.5 mt -139.79 139.15 36.35 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.796 0.331 . . . . 52.44 110.751 178.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.3 t -92.67 -178.28 4.82 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.863 -0.608 . . . . 75.32 109.848 178.242 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.563 ' C ' ' H ' ' A' ' 27' ' ' GLN . 49.7 ptt85 -68.78 -175.89 0.75 Allowed 'General case' 0 C--O 1.234 0.285 0 C-N-CA 121.188 -0.205 . . . . 73.32 110.671 177.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 28.7 t70 62.64 -26.83 0.06 Allowed 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 123.725 0.81 . . . . 54.04 112.116 -173.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.563 ' H ' ' C ' ' A' ' 25' ' ' ARG . 8.1 mm100 -71.25 178.7 3.2 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 123.227 0.611 . . . . 70.15 110.482 178.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.2 m 50.53 20.7 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 C-N-CA 124.364 1.065 . . . . 75.0 113.016 177.022 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 38.1 pttt -73.51 -23.29 60.01 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.041 0.448 . . . . 71.12 109.927 176.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.99 102.65 0.66 Allowed 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.281 -0.872 . . . . 75.11 110.373 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.58 ' HB ' HD11 ' A' ' 9' ' ' ILE . 50.6 mt -130.21 157.86 42.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 N-CA-C 108.315 -0.995 . . . . 74.23 108.315 175.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -88.92 -58.22 2.63 Favored 'General case' 0 C--N 1.321 -0.67 0 C-N-CA 120.825 -0.35 . . . . 73.04 110.45 179.424 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.521 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 86.7 m-85 -143.54 146.75 33.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.886 0.374 . . . . 71.25 111.067 -178.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.45 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.4 mm? -84.37 130.9 52.14 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 108.575 -0.898 . . . . 73.11 108.575 173.295 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 34' ' ' LEU . 17.4 Cg_exo -64.08 147.11 91.62 Favored 'Trans proline' 0 CA--C 1.527 0.15 0 C-N-CA 122.473 2.116 . . . . 63.24 112.848 -174.399 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.55 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 8.9 p -53.39 148.35 2.01 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 CA-C-N 115.832 -0.622 . . . . 72.31 110.413 173.469 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.55 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 7.9 t70 82.48 -28.93 0.1 Allowed 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.583 0.753 . . . . 75.53 111.513 -178.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.416 ' CE2' ' HB3' ' A' ' 21' ' ' ARG . 32.4 t80 -66.84 141.38 57.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.787 0.327 . . . . 74.11 110.544 -178.438 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 41.2 mt-10 -114.78 145.65 41.87 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.066 -0.515 . . . . 72.52 111.515 -177.21 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.554 HG12 ' HB2' ' A' ' 56' ' ' ARG . 43.8 pt -122.46 164.86 19.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.451 -0.795 . . . . 75.11 109.595 172.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.431 ' CG ' ' HD2' ' A' ' 54' ' ' LYS . 35.3 tt0 -135.89 142.71 44.75 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.987 0.422 . . . . 74.33 110.785 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -88.45 102.32 14.78 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.107 -0.497 . . . . 75.13 110.59 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.9 m -102.2 162.78 3.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.168 0.509 . . . . 43.53 110.856 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.584 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 15.8 t -104.0 -176.58 3.12 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.859 -0.61 . . . . 51.42 110.229 -176.566 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.5 mmt180 -56.27 121.43 9.49 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.111 -0.495 . . . . 71.44 111.419 -177.423 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 71.73 -95.86 0.64 Allowed Glycine 0 N--CA 1.446 -0.698 0 CA-C-N 115.724 -0.671 . . . . 62.21 111.998 178.549 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -146.83 47.52 1.17 Allowed 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.69 0.757 . . . . 71.43 109.716 177.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.584 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 13.3 mmm-85 -87.43 129.15 35.15 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.197 -0.91 . . . . 74.21 109.478 176.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.464 ' HB2' ' HB3' ' A' ' 75' ' ' ARG . 41.1 mt-10 -78.35 149.17 33.47 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.376 -0.374 . . . . 74.41 110.001 -179.615 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.456 HG12 ' HA ' ' A' ' 73' ' ' CYS . 34.9 m -127.06 150.14 32.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.96 -0.564 . . . . 54.31 110.678 -177.279 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 p -106.34 96.83 4.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.972 0.891 . . . . 73.23 109.235 171.187 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.773 ' HA3' ' HB3' ' A' ' 71' ' ' SER . . . -154.73 170.83 33.08 Favored Glycine 0 N--CA 1.441 -0.994 0 CA-C-N 114.831 -1.077 . . . . 43.0 111.175 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.24 60.33 7.4 Favored 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 122.282 1.988 . . . . 70.42 110.703 173.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.431 ' HD2' ' CG ' ' A' ' 41' ' ' GLU . 45.3 pttt -80.7 84.42 6.25 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-O 121.723 0.773 . . . . 72.35 111.436 -172.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.408 HG13 ' O ' ' A' ' 54' ' ' LYS . 1.1 m -158.66 126.48 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 114.594 -1.185 . . . . 74.12 108.462 172.308 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.554 ' HB2' HG12 ' A' ' 40' ' ' ILE . 32.3 mmt180 -141.1 100.07 3.73 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 110.073 -0.343 . . . . 73.32 110.073 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -92.5 125.32 37.09 Favored 'General case' 0 C--N 1.317 -0.822 0 N-CA-C 109.002 -0.74 . . . . 71.3 109.002 174.104 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 48.9 t -64.52 136.6 57.21 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.008 0.432 . . . . 74.1 110.247 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 76.6 mt -98.78 -178.92 4.12 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.661 -0.699 . . . . 75.32 110.717 -174.236 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -71.45 -9.71 58.62 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.449 0.642 . . . . 34.01 110.363 176.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -110.21 158.62 18.17 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 108.93 -0.767 . . . . 74.35 108.93 174.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -78.29 53.23 3.84 Favored Glycine 0 CA--C 1.519 0.333 0 C-N-CA 120.993 -0.622 . . . . 74.22 113.464 -173.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 18.6 m -155.06 161.92 41.19 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.37 -0.604 . . . . 64.31 109.37 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 70.5 m95 -91.89 179.51 5.59 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.835 -0.431 . . . . 65.43 109.835 -178.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 33.0 p -61.67 -38.79 89.06 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.923 0.392 . . . . 71.12 111.197 -178.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -146.59 136.26 23.12 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.06 -0.718 . . . . 71.12 109.06 178.341 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 10.4 tpt -119.54 74.38 1.0 Allowed 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 118.602 -1.239 . . . . 72.34 109.882 171.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -170.68 89.2 0.14 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.206 -1.361 . . . . 63.14 107.575 160.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.483 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 4.6 m -108.77 108.81 61.06 Favored Pre-proline 0 C--N 1.313 -1.017 0 C-N-CA 119.959 -0.696 . . . . 74.33 111.078 -170.642 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 14.8 Cg_endo -92.56 46.48 0.41 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 124.061 3.174 . . . . 64.14 112.803 -177.345 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.773 ' HB3' ' HA3' ' A' ' 52' ' ' GLY . 0.1 OUTLIER -73.91 126.21 29.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.5 -0.318 . . . . 73.3 110.687 177.561 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -109.55 149.05 30.21 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 110.177 -0.305 . . . . 75.3 110.177 -178.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.456 ' HA ' HG12 ' A' ' 50' ' ' VAL . 29.6 m -87.52 113.75 23.5 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.502 -0.317 . . . . 74.22 111.458 -175.635 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.1 p -155.8 134.94 3.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.576 -0.284 . . . . 70.53 110.563 179.078 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.464 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 3.0 ptm180 . . . . . 0 C--O 1.25 1.087 0 CA-C-N 116.318 -0.401 . . . . 74.41 109.971 178.019 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.4 m . . . . . 0 N--CA 1.455 -0.2 0 N-CA-C 109.51 -0.552 . . . . 74.12 109.51 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -96.22 97.27 9.39 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.626 -0.509 . . . . 74.03 109.626 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -161.76 164.18 35.09 Favored Glycine 0 N--CA 1.441 -0.986 0 C-N-CA 120.807 -0.711 . . . . 52.24 112.396 -177.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.6 m -97.59 154.02 17.81 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 110.203 -0.295 . . . . 72.14 110.203 179.068 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 -82.42 -179.69 7.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.338 0.589 . . . . 64.22 111.329 -178.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.3 mt -89.42 121.38 39.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.425 -0.807 . . . . 73.43 110.306 178.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 55.5 mt -72.15 129.03 35.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.915 -0.584 . . . . 53.14 110.111 178.391 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.5 t-80 -67.39 121.26 78.02 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 116.192 -0.458 . . . . 73.31 110.366 -178.114 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.544 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.4 Cg_exo -48.69 120.76 5.61 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.212 2.608 . . . . 62.52 112.783 -179.407 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.544 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 5.8 Cg_endo -86.68 -138.74 0.02 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 123.569 2.846 . . . . 72.42 112.656 -176.305 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.441 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 13.1 t-105 -66.85 -177.5 0.62 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 115.891 -0.595 . . . . 72.24 110.853 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -39.88 101.35 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.689 0.796 . . . . 74.13 112.835 -176.051 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.54 -168.56 33.25 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 111.341 -0.704 . . . . 71.54 111.341 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.82 24.0 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.942 -0.647 . . . . 73.45 111.563 179.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.4 mt -116.93 136.49 53.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.559 0.695 . . . . 70.34 111.216 -178.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.855 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 13.7 tpt180 -103.03 140.1 37.72 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.661 -1.154 . . . . 74.22 109.246 -179.681 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -108.29 -171.98 1.97 Allowed 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.591 -0.444 . . . . 74.35 110.765 -178.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.06 -45.33 9.22 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.001 0.429 . . . . 74.3 110.603 -174.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -151.09 53.38 0.49 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.811 -0.709 . . . . 71.12 112.181 -178.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 89.5 mt -136.55 127.55 27.73 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.607 0.241 . . . . 52.44 110.794 179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.0 t -86.39 -179.77 6.73 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.531 -0.544 . . . . 75.32 109.531 175.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.8 mpp_? -80.47 -172.85 3.77 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.818 -0.353 . . . . 73.32 111.456 -175.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.429 ' O ' ' HE2' ' A' ' 29' ' ' LYS . 28.7 t70 60.44 15.25 5.37 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 122.357 1.075 . . . . 54.04 109.583 -168.435 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.549 ' O ' HG22 ' A' ' 28' ' ' VAL . 24.3 mt-30 -134.57 -173.7 3.36 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.668 -1.151 . . . . 70.15 108.287 178.273 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.549 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.0 m 54.4 9.22 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 124.127 0.971 . . . . 75.0 112.51 -178.323 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.429 ' HE2' ' O ' ' A' ' 26' ' ' ASP . 46.3 pttt -79.41 -21.82 45.1 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.98 -0.555 . . . . 71.12 110.081 177.502 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.31 81.15 0.98 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.351 -0.84 . . . . 75.11 110.37 178.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 54.8 mt -119.61 139.11 48.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 108.939 -0.763 . . . . 74.23 108.939 176.338 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -69.54 -64.2 0.92 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.764 0.316 . . . . 73.04 111.115 -176.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -143.56 141.73 30.8 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.192 -0.458 . . . . 71.25 110.867 -177.371 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -92.01 115.71 65.13 Favored Pre-proline 0 C--N 1.321 -0.671 0 N-CA-C 108.564 -0.902 . . . . 73.11 108.564 172.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.59 142.71 38.97 Favored 'Trans proline' 0 C--O 1.238 0.515 0 C-N-CA 123.419 2.746 . . . . 63.24 113.217 -174.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.467 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 2.7 p -65.22 86.14 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-O 121.512 0.673 . . . . 72.31 111.173 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.467 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 31.6 t70 168.94 -26.84 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.834 -1.075 . . . . 75.53 108.28 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 6.9 t80 -68.74 144.82 54.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 114.618 -1.173 . . . . 74.11 110.486 179.418 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.408 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 40.0 mt-10 -127.09 145.53 50.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.274 -0.421 . . . . 72.52 110.121 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.486 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 38.0 pt -128.45 167.9 22.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-O 121.084 0.469 . . . . 75.11 111.86 -177.622 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.855 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 44.4 tt0 -131.82 164.81 25.22 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 115.374 -0.83 . . . . 74.33 110.13 -177.221 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.579 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 96.9 m-85 -117.1 102.93 9.72 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 122.354 0.262 . . . . 75.13 111.142 -178.584 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.8 m -98.26 157.41 3.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 120.766 0.317 . . . . 43.53 110.74 178.501 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.588 ' HB3' ' O ' ' A' ' 48' ' ' ARG . 43.5 t -92.21 177.89 6.02 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.976 -0.379 . . . . 51.42 109.976 178.51 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . 0.498 ' HD3' ' C ' ' A' ' 45' ' ' ARG . 0.1 OUTLIER -69.59 117.04 10.69 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 116.171 -0.468 . . . . 71.44 110.469 -176.241 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 89.63 -125.23 7.74 Favored Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.972 -0.632 . . . . 62.21 112.352 175.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -116.23 26.02 10.23 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.002 0.429 . . . . 71.43 110.533 -179.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.588 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 28.6 mmm180 -88.64 119.02 28.72 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.829 -0.804 . . . . 74.21 108.829 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -79.26 159.98 27.04 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.04 0.448 . . . . 74.41 111.058 -177.325 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.589 HG12 ' HA ' ' A' ' 73' ' ' CYS . 27.5 m -126.83 139.15 52.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.796 -0.638 . . . . 54.31 110.369 179.083 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.9 p -103.19 95.53 3.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 122.093 0.949 . . . . 73.23 109.366 172.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.46 171.26 32.94 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 115.005 -0.998 . . . . 43.0 111.446 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -78.07 52.01 3.88 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.486 2.124 . . . . 70.42 111.145 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.709 ' HD3' ' HG3' ' A' ' 41' ' ' GLU . 0.0 OUTLIER -76.66 86.83 3.31 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 122.118 0.961 . . . . 72.35 111.972 -173.397 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -161.96 130.12 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 114.989 -1.005 . . . . 74.12 109.229 174.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.486 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 29.0 mmt180 -129.43 131.52 46.77 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 120.662 0.268 . . . . 73.32 110.484 178.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.458 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 35.2 ttmt -106.58 134.19 50.1 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.071 -0.715 . . . . 71.3 109.071 176.112 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.3 t -74.53 145.18 43.68 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.92 0.39 . . . . 74.1 110.734 -178.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.6 mt -112.87 -178.67 3.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.788 -0.642 . . . . 75.32 110.114 -177.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.25 27.54 0.33 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.019 0.438 . . . . 34.01 111.077 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.402 HD22 ' H ' ' A' ' 63' ' ' SER . 5.4 p-10 -147.65 172.75 13.55 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.235 -0.654 . . . . 74.35 109.235 -179.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -68.36 -19.03 72.11 Favored Glycine 0 CA--C 1.52 0.375 0 C-N-CA 120.815 -0.707 . . . . 74.22 113.755 -172.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.402 ' H ' HD22 ' A' ' 61' ' ' ASN . 14.9 m -99.36 146.27 26.47 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.046 0.45 . . . . 64.31 111.089 -178.041 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.411 ' H ' ' HE3' ' A' ' 67' ' ' MET . 63.8 m95 -77.89 -179.05 5.79 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.732 -0.667 . . . . 65.43 110.481 179.687 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.456 HG23 ' O ' ' A' ' 57' ' ' LYS . 3.1 p -54.05 -49.93 67.87 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 113.064 0.764 . . . . 71.12 113.064 -176.547 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.447 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 14.0 t70 -140.06 141.7 36.21 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.57 -0.286 . . . . 71.12 110.26 -177.562 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . 0.411 ' HE3' ' H ' ' A' ' 64' ' ' TRP . 65.9 mtt -140.07 80.01 1.74 Allowed 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 119.969 -0.692 . . . . 72.34 111.502 166.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -168.03 88.45 0.25 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.301 -1.0 . . . . 63.14 108.301 157.415 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.8 m -152.78 101.24 2.7 Favored Pre-proline 0 C--N 1.316 -0.848 0 C-N-CA 120.372 -0.531 . . . . 74.33 111.274 -172.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.66 114.64 4.01 Favored 'Trans proline' 0 C--O 1.237 0.438 0 C-N-CA 122.627 2.218 . . . . 64.14 111.553 175.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 t -92.42 134.44 34.95 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.162 0.506 . . . . 73.3 109.972 -179.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.0 ptp85 -101.88 123.32 45.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.801 -0.636 . . . . 75.3 110.811 -176.607 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.589 ' HA ' HG12 ' A' ' 50' ' ' VAL . 60.9 m -76.08 98.17 4.27 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.419 -0.586 . . . . 74.22 109.419 176.616 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 10.7 p 177.04 151.76 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.088 -0.96 . . . . 70.53 108.412 -176.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.424 HH11 ' HD3' ' A' ' 75' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.943 0 CA-C-O 118.335 -0.841 . . . . 74.41 110.292 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.6 p . . . . . 0 N--CA 1.451 -0.42 0 CA-C-O 120.711 0.291 . . . . 74.12 110.42 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -70.22 116.63 10.79 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.852 0.358 . . . . 74.03 110.36 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.458 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.12 160.21 31.44 Favored Glycine 0 N--CA 1.44 -1.059 0 CA-C-N 115.66 -0.7 . . . . 52.24 111.374 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 38.1 m -92.74 147.17 23.08 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 110.185 -0.302 . . . . 72.14 110.185 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -85.53 -177.65 6.48 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.073 0.463 . . . . 64.22 110.826 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 51.9 mt -86.77 125.43 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 CA-C-N 115.989 -0.55 . . . . 73.43 109.8 175.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 56.1 mt -80.12 136.63 23.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.572 -0.74 . . . . 53.14 110.106 -179.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 45.5 m170 -54.49 128.57 60.74 Favored Pre-proline 0 C--N 1.329 -0.295 0 N-CA-C 109.843 -0.429 . . . . 73.31 109.843 173.178 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.484 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.5 Cg_exo -51.24 122.45 10.1 Favored 'Trans proline' 0 N--CA 1.461 -0.408 0 C-N-CA 122.501 2.134 . . . . 62.52 111.479 177.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 15.7 Cg_exo -69.09 -159.05 0.05 OUTLIER 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 123.081 2.52 . . . . 72.42 111.747 179.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -59.93 159.81 8.67 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.557 -0.534 . . . . 72.24 109.557 176.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -39.42 100.9 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 113.687 0.995 . . . . 74.13 113.687 -169.348 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -167.76 -140.2 2.86 Favored Glycine 0 N--CA 1.444 -0.821 0 CA-C-N 114.287 -1.324 . . . . 71.54 110.368 179.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -170.28 -171.01 35.3 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.521 -0.847 . . . . 73.45 112.088 176.196 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 18.5 mt -136.49 136.17 48.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.299 0.571 . . . . 70.34 111.005 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.82 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 19.1 tpt85 -107.86 119.23 38.87 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 115.266 -0.879 . . . . 74.22 110.179 -176.591 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.637 ' HB3' ' HE1' ' A' ' 38' ' ' TYR . 99.5 m-85 -96.2 -171.3 2.28 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.223 -0.444 . . . . 74.35 110.872 -179.474 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.427 HH11 ' HD3' ' A' ' 21' ' ' ARG . 1.5 mmp_? -91.39 -72.2 0.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.981 -0.554 . . . . 74.3 111.466 -178.395 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -128.2 63.85 0.61 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.494 -0.86 . . . . 71.12 112.157 -176.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.485 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 75.4 mt -125.15 121.29 33.79 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.895 0.379 . . . . 52.44 110.832 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.5 t -83.01 -179.47 7.45 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 115.664 -0.698 . . . . 75.32 109.944 176.238 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' A' ' 25' ' ' ARG . 10.3 mmt180 -76.09 -174.56 2.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.093 0.473 . . . . 73.32 111.817 -175.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 24.4 t70 55.2 27.69 10.04 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.121 -0.945 . . . . 54.04 110.169 -175.447 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.466 ' O ' HG22 ' A' ' 28' ' ' VAL . 26.9 mt-30 -134.03 -164.32 1.48 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.519 -0.764 . . . . 70.15 110.271 -178.097 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.466 HG22 ' O ' ' A' ' 27' ' ' GLN . 4.6 m 53.59 15.0 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 124.757 1.223 . . . . 75.0 112.765 178.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -89.46 -19.11 25.51 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.419 -0.355 . . . . 71.12 110.687 178.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.47 86.96 0.81 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.008 0.432 . . . . 75.11 111.037 178.327 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.5 mt -128.45 106.88 15.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 108.855 -0.794 . . . . 74.23 108.855 176.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -73.14 -40.0 65.26 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.261 -0.427 . . . . 73.04 111.855 -172.276 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.458 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 81.9 m-85 -135.55 116.9 14.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.085 0.469 . . . . 71.25 111.929 -176.267 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -81.58 135.78 49.28 Favored Pre-proline 0 C--N 1.321 -0.633 0 N-CA-C 108.883 -0.784 . . . . 73.11 108.883 169.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.36 153.3 61.34 Favored 'Trans proline' 0 C--O 1.238 0.481 0 C-N-CA 122.327 2.018 . . . . 63.24 112.929 -176.068 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.496 HG23 ' HA ' ' A' ' 59' ' ' LEU . 2.9 p -68.19 85.72 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.351 0 CA-C-O 122.04 0.924 . . . . 72.31 109.629 174.781 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 16.6 t70 175.32 -39.46 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.86 -1.064 . . . . 75.53 109.666 -170.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.637 ' HE1' ' HB3' ' A' ' 20' ' ' TYR . 0.2 OUTLIER -74.02 126.86 31.43 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.987 -1.006 . . . . 74.11 112.405 -171.979 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.532 ' HG2' ' HB2' ' A' ' 57' ' ' LYS . 40.9 mt-10 -107.84 127.52 53.79 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.427 -0.806 . . . . 72.52 109.278 172.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 44.8 pt -110.0 142.82 21.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.005 0.431 . . . . 75.11 111.441 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.82 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.3 tt0 -107.54 147.87 29.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.706 -0.679 . . . . 74.33 109.918 176.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.521 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 94.4 m-85 -103.83 101.88 11.69 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.406 -0.361 . . . . 75.13 110.046 177.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -95.2 170.45 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.714 0.292 . . . . 43.53 111.006 -178.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.553 ' HB2' HG13 ' A' ' 50' ' ' VAL . 26.1 t -93.27 179.8 5.3 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.644 -0.502 . . . . 51.42 109.644 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 2.0 tmt_? -78.59 93.37 4.83 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.847 0.356 . . . . 71.44 110.932 -175.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.49 -136.16 13.35 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.742 -0.742 . . . . 62.21 112.445 175.075 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 8.0 mp0 -89.89 14.88 10.95 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.269 0.557 . . . . 71.43 109.736 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.493 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 15.7 mmt-85 -88.56 137.53 32.24 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.53 -0.759 . . . . 74.21 109.203 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -105.46 165.06 11.4 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.054 0.454 . . . . 74.41 110.614 176.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.553 HG13 ' HB2' ' A' ' 44' ' ' CYS . 34.2 m -121.87 136.09 59.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.793 -0.639 . . . . 54.31 109.486 177.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.418 HG13 ' O ' ' A' ' 51' ' ' VAL . 7.2 p -93.0 95.75 5.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 122.275 1.036 . . . . 73.23 109.018 174.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.87 171.8 33.22 Favored Glycine 0 N--CA 1.443 -0.863 0 CA-C-N 114.567 -1.197 . . . . 43.0 111.375 -178.547 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -82.28 42.22 1.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.594 2.196 . . . . 70.42 110.387 175.641 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.634 ' HD3' ' HG3' ' A' ' 41' ' ' GLU . 0.0 OUTLIER -75.13 86.39 2.39 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.796 0.807 . . . . 72.35 112.871 -170.394 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.454 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.4 p -161.85 126.5 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-N 114.903 -1.044 . . . . 74.12 109.026 169.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.454 ' HD3' ' O ' ' A' ' 55' ' ' VAL . 22.4 mmt180 -134.89 128.43 32.59 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.28 -0.418 . . . . 73.32 110.076 -178.19 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.532 ' HB2' ' HG2' ' A' ' 39' ' ' GLU . 38.4 ttpt -107.23 136.4 47.13 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 116.05 -0.523 . . . . 71.3 110.031 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 43.8 t -77.53 134.35 38.32 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.203 -0.453 . . . . 74.1 110.179 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.496 ' HA ' HG23 ' A' ' 36' ' ' VAL . 97.8 mt -102.9 -178.74 3.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.127 -0.488 . . . . 75.32 109.811 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.42 51.76 0.9 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.328 0.585 . . . . 34.01 111.029 179.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -160.65 170.67 20.36 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.279 -0.873 . . . . 74.35 108.926 177.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -85.46 38.53 3.01 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 120.721 -0.752 . . . . 74.22 113.802 -173.286 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.3 m -156.67 151.71 26.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 117.229 0.515 . . . . 64.31 110.537 178.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 71.2 m95 -79.29 167.91 20.27 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.179 -0.464 . . . . 65.43 109.975 178.068 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 17.8 p -55.19 -65.29 0.61 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.043 0.449 . . . . 71.12 111.99 -177.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -125.85 97.19 5.03 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.976 -0.75 . . . . 71.12 108.976 176.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 27.0 ttt -100.69 76.25 1.79 Allowed 'General case' 0 C--N 1.321 -0.663 0 C-N-CA 118.817 -1.153 . . . . 72.34 110.7 -178.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -171.76 89.89 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.276 -1.329 . . . . 63.14 108.568 160.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.5 m -135.46 119.41 13.07 Favored Pre-proline 0 C--N 1.317 -0.832 0 C-N-CA 119.758 -0.777 . . . . 74.33 112.004 -172.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -83.1 106.85 1.44 Allowed 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.867 2.378 . . . . 64.14 112.576 178.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.495 ' HB2' HG21 ' A' ' 50' ' ' VAL . 12.1 p -95.39 105.41 17.37 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.042 0.449 . . . . 73.3 110.813 178.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.8 ptp85 -89.18 125.18 34.95 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.159 -0.473 . . . . 75.3 110.955 -177.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.445 ' HA ' HG12 ' A' ' 50' ' ' VAL . 59.7 m -72.44 122.06 20.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.123 -0.49 . . . . 74.22 110.572 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 85.8 t -137.56 136.15 46.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.763 -0.458 . . . . 70.53 109.763 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.247 0.939 0 CA-C-O 119.079 -0.486 . . . . 74.41 110.669 -179.093 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.448 -0.556 0 CA-C-O 121.238 0.542 . . . . 74.12 110.579 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -101.85 99.13 9.32 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.696 -0.853 . . . . 74.03 108.696 174.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -160.64 164.34 34.55 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.535 -0.84 . . . . 52.24 112.573 -174.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.429 ' N ' ' SG ' ' A' ' 58' ' ' CYS . 35.2 m -105.06 150.41 25.01 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 109.49 -0.559 . . . . 72.14 109.49 -178.612 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.4 pt20 -73.44 179.67 3.91 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.113 0.483 . . . . 64.22 110.607 177.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.4 tt -88.24 140.64 15.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.755 -0.657 . . . . 73.43 110.201 -178.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 57.3 mt -96.25 135.91 28.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.388 -0.369 . . . . 53.14 110.937 -176.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . 0.406 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 2.5 t-80 -89.29 130.94 42.14 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 115.928 -0.578 . . . . 73.31 109.485 178.487 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 33.5 Cg_exo -57.86 109.99 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.795 2.33 . . . . 62.52 112.393 -178.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -75.67 -59.09 0.04 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.437 0 C-N-CA 122.691 2.261 . . . . 72.42 112.298 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -91.59 -178.43 5.08 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.102 -0.499 . . . . 72.24 109.851 -176.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -71.29 15.64 0.12 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 112.237 0.458 . . . . 74.13 112.237 -177.623 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.542 ' HA2' ' H ' ' A' ' 45' ' ' ARG . . . -96.65 -147.56 22.83 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.508 -0.637 . . . . 71.54 111.508 175.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.74 -170.56 30.84 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 121.071 -0.585 . . . . 73.45 111.78 179.524 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.1 mt -129.38 134.89 62.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.093 0.473 . . . . 70.34 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -106.77 135.41 48.34 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.44 -0.8 . . . . 74.22 109.931 -178.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.501 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 91.4 m-85 -101.02 -171.35 1.98 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.305 -0.407 . . . . 74.35 110.017 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 21.6 mtt180 -80.17 -44.49 19.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.814 0.34 . . . . 74.3 111.435 -179.014 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.38 61.61 0.24 Allowed Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.583 -0.818 . . . . 71.12 112.13 -178.515 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 80.7 mt -120.81 116.76 25.82 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.79 0.329 . . . . 52.44 110.456 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.3 t -78.89 -179.44 6.6 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.636 -0.711 . . . . 75.32 109.734 175.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.426 ' C ' ' H ' ' A' ' 27' ' ' GLN . 99.4 mtt180 -67.8 -172.75 0.29 Allowed 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.741 0.305 . . . . 73.32 111.479 -177.418 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 30.5 t70 68.09 -42.79 0.47 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.629 0.772 . . . . 54.04 110.882 -171.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.573 ' O ' HG22 ' A' ' 28' ' ' VAL . 20.4 mt-30 -71.87 -179.49 2.72 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.328 -0.396 . . . . 70.15 110.806 176.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.8 m 57.45 9.88 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 124.559 1.144 . . . . 75.0 112.347 -178.609 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -82.71 -17.73 43.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.272 0.558 . . . . 71.12 109.896 175.17 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -161.9 94.53 0.94 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.091 -0.959 . . . . 75.11 110.191 179.127 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 57.8 mt -131.98 130.27 61.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.578 -0.737 . . . . 74.23 109.42 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -89.95 -51.87 5.26 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.379 -0.373 . . . . 73.04 111.301 -175.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -134.72 131.48 37.69 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.296 0.569 . . . . 71.25 112.133 -175.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -97.59 117.42 65.39 Favored Pre-proline 0 C--N 1.322 -0.622 0 N-CA-C 107.876 -1.157 . . . . 73.11 107.876 168.201 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -56.52 147.13 71.23 Favored 'Trans proline' 0 C--O 1.237 0.434 0 C-N-CA 123.205 2.603 . . . . 63.24 113.373 -173.196 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.55 83.87 0.05 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.323 0 CA-C-O 121.85 0.833 . . . . 72.31 110.771 177.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.8 t70 168.45 -33.46 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 114.578 -1.192 . . . . 75.53 108.942 -176.484 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.501 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 14.1 t80 -67.56 141.11 56.95 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.324 -0.853 . . . . 74.11 110.636 -177.227 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.457 ' HG2' ' HE2' ' A' ' 57' ' ' LYS . 10.5 mt-10 -125.36 142.15 51.67 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.53 -0.759 . . . . 72.52 110.083 -177.029 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.655 HG13 ' HB2' ' A' ' 56' ' ' ARG . 46.4 pt -130.65 169.31 21.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.715 0.293 . . . . 75.11 110.694 178.748 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -128.52 139.24 52.41 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.189 -0.459 . . . . 74.33 110.981 -178.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.41 ' O ' HG21 ' A' ' 50' ' ' VAL . 5.1 m-30 -83.65 102.32 12.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.765 -0.652 . . . . 75.13 110.349 176.161 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.9 m -108.31 170.93 2.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 120.898 0.38 . . . . 43.53 110.909 -178.535 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.714 ' HB2' HG13 ' A' ' 50' ' ' VAL . 10.5 t -109.64 143.63 39.12 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.06 -0.718 . . . . 51.42 109.06 175.012 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . 0.542 ' H ' ' HA2' ' A' ' 16' ' ' GLY . 75.7 ttt180 -77.58 133.68 38.42 Favored 'General case' 0 N--CA 1.44 -0.974 0 CA-C-N 115.029 -0.987 . . . . 71.44 110.588 -172.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.13 -149.84 18.81 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.799 -0.715 . . . . 62.21 111.688 -178.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.455 ' CD ' ' H ' ' A' ' 47' ' ' GLU . 1.0 OUTLIER -93.66 16.08 14.72 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.406 0.622 . . . . 71.43 109.646 176.799 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.654 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 40.8 mmm-85 -89.22 118.94 29.28 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.317 -0.856 . . . . 74.21 109.169 178.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.523 ' HB2' ' HA ' ' A' ' 75' ' ' ARG . 48.8 mt-10 -95.92 171.37 8.68 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.991 -0.374 . . . . 74.41 109.991 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.714 HG13 ' HB2' ' A' ' 44' ' ' CYS . 5.5 m -129.86 126.25 62.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.948 0.404 . . . . 54.31 111.545 -177.593 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.601 HG12 ' HB ' ' A' ' 74' ' ' VAL . 3.5 p -96.37 95.76 5.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 108.463 -0.94 . . . . 73.23 108.463 167.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.51 172.73 33.01 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.373 -0.83 . . . . 43.0 112.497 -173.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -75.27 52.98 3.31 Favored 'Trans proline' 0 N--CA 1.462 -0.335 0 C-N-CA 123.012 2.475 . . . . 70.42 110.734 173.341 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.418 ' HD3' HG23 ' A' ' 50' ' ' VAL . 19.4 pttp -72.11 89.54 1.15 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.512 -0.767 . . . . 72.35 111.863 -174.163 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -160.54 132.24 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.821 -0.627 . . . . 74.12 110.574 176.581 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.655 ' HB2' HG13 ' A' ' 40' ' ' ILE . 55.1 mmt-85 -138.35 126.8 23.24 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.933 -0.576 . . . . 73.32 110.195 176.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.457 ' HE2' ' HG2' ' A' ' 39' ' ' GLU . 37.3 ttmt -125.08 137.48 54.2 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.007 -0.738 . . . . 71.3 109.007 175.149 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 7' ' ' CYS . 53.3 t -81.31 144.17 31.7 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.894 0.378 . . . . 74.1 111.073 -176.117 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 94.4 mt -100.95 -179.07 3.94 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.716 -0.675 . . . . 75.32 111.005 -178.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.92 -20.58 60.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.185 0.517 . . . . 34.01 110.374 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -101.43 169.1 9.1 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.397 -0.82 . . . . 74.35 109.313 175.283 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.75 60.56 3.36 Favored Glycine 0 CA--C 1.518 0.253 0 C-N-CA 120.83 -0.7 . . . . 74.22 113.28 -175.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 49.4 m -158.63 144.31 16.65 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 122.789 0.436 . . . . 64.31 109.939 177.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 75.7 m95 -81.19 161.65 23.93 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.75 -0.463 . . . . 65.43 109.75 177.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 p -52.9 -39.14 62.47 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.221 0.823 . . . . 71.12 113.221 -174.152 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -134.03 140.86 46.95 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 110.186 -0.302 . . . . 71.12 110.186 178.588 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 50.5 mtt -144.36 80.01 1.63 Allowed 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.367 -0.533 . . . . 72.34 111.453 167.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -168.6 88.85 0.22 Allowed 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.416 -0.957 . . . . 63.14 108.416 156.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.8 m -155.83 90.11 2.83 Favored Pre-proline 0 C--N 1.317 -0.823 0 C-N-CA 120.283 -0.567 . . . . 74.33 111.283 -172.076 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -74.18 90.28 1.0 Allowed 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.689 2.26 . . . . 64.14 110.396 172.407 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.2 t -69.26 116.93 10.25 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.985 -0.552 . . . . 73.3 110.724 -175.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.0 ptp180 -79.57 130.67 35.6 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.534 -0.757 . . . . 75.3 110.409 179.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.584 ' HA ' HG12 ' A' ' 50' ' ' VAL . 73.6 m -81.02 97.89 7.71 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.309 0.576 . . . . 74.22 110.013 178.261 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.601 ' HB ' HG12 ' A' ' 51' ' ' VAL . 59.6 t -136.68 117.99 18.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.184 -0.916 . . . . 70.53 108.653 177.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.523 ' HA ' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.556 -0.735 . . . . 74.41 111.161 -176.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.45 -0.438 0 N-CA-C 109.74 -0.467 . . . . 74.12 109.74 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -75.43 99.44 4.17 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.222 -0.445 . . . . 74.03 110.617 -178.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.57 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -159.91 152.56 23.44 Favored Glycine 0 N--CA 1.441 -1.002 0 C-N-CA 120.572 -0.823 . . . . 52.24 112.694 -179.144 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.1 m -86.52 158.76 19.47 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 110.13 -0.322 . . . . 72.14 110.13 178.137 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.435 HE21 ' HB2' ' A' ' 8' ' ' GLN . 1.8 pt20 -88.86 -177.19 5.44 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.052 0.453 . . . . 64.22 111.192 -179.106 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.543 HD11 ' HB ' ' A' ' 31' ' ' ILE . 60.7 mt -87.49 138.16 19.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.615 -0.72 . . . . 73.43 110.487 -177.715 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 64.8 mt -99.78 131.06 47.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.18 -0.464 . . . . 53.14 109.929 178.199 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -76.55 126.09 86.59 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.868 -0.605 . . . . 73.31 110.171 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_endo -58.51 112.69 1.26 Allowed 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.72 2.28 . . . . 62.52 111.921 179.266 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -74.87 -87.6 0.0 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.393 0 C-N-CA 122.481 2.121 . . . . 72.42 113.091 -176.059 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 27.8 t-105 -101.37 -177.84 3.56 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.999 -0.371 . . . . 72.24 109.999 -178.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 56.7 mm-40 -39.81 101.93 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.746 0.818 . . . . 74.13 111.98 177.688 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.436 ' HA2' ' HA ' ' A' ' 44' ' ' CYS . . . 171.32 -167.6 40.72 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.39 -0.91 . . . . 71.54 112.637 177.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -159.17 -170.52 23.81 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.989 -0.844 . . . . 73.45 110.989 178.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.464 HG23 ' HB ' ' A' ' 40' ' ' ILE . 16.6 mt -135.05 135.59 52.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.449 0.642 . . . . 70.34 111.835 -177.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.49 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 55.6 ttm-85 -99.49 138.56 36.4 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.081 -0.963 . . . . 74.22 110.578 178.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.506 ' HB3' ' HE1' ' A' ' 38' ' ' TYR . 89.1 m-85 -110.76 -168.03 1.26 Allowed 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.132 -0.321 . . . . 74.35 110.132 177.565 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -62.04 -57.82 10.2 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 120.88 0.371 . . . . 74.3 110.487 178.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -161.55 67.76 0.24 Allowed Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 121.055 -0.593 . . . . 71.12 111.872 178.489 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 92.7 mt -118.12 126.77 52.91 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.965 0.412 . . . . 52.44 110.949 -179.18 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.8 t -85.03 -176.71 6.32 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.387 -0.824 . . . . 75.32 110.46 176.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 29.9 ptt180 -61.94 -173.51 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 115.923 -0.58 . . . . 73.32 111.818 -177.116 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.9 t70 65.06 -46.14 0.35 Allowed 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 123.894 0.878 . . . . 54.04 112.263 -179.116 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.547 ' O ' HG22 ' A' ' 28' ' ' VAL . 18.4 mt-30 -68.96 -169.76 0.19 Allowed 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 123.079 0.552 . . . . 70.15 111.257 -179.284 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.547 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.2 m 55.61 15.66 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 124.264 1.026 . . . . 75.0 111.832 -178.206 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.416 ' H ' ' HG2' ' A' ' 29' ' ' LYS . 40.1 pttt -81.42 -14.33 57.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.829 -0.623 . . . . 71.12 110.066 175.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -161.21 117.48 2.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.601 -0.727 . . . . 75.11 110.436 177.154 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.543 ' HB ' HD11 ' A' ' 9' ' ' ILE . 42.1 mt -138.6 152.71 25.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 109.105 -0.702 . . . . 74.23 109.105 179.161 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -105.07 -65.09 1.07 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.673 0.273 . . . . 73.04 110.646 179.018 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.57 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 96.5 m-85 -140.73 128.61 21.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.412 -0.358 . . . . 71.25 110.704 -179.203 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -88.08 119.59 70.43 Favored Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 109.158 -0.682 . . . . 73.11 109.158 175.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.01 152.47 43.76 Favored 'Trans proline' 0 C--O 1.236 0.402 0 C-N-CA 122.899 2.4 . . . . 63.24 113.29 -176.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.433 HG23 ' HA ' ' A' ' 59' ' ' LEU . 3.5 p -62.63 94.93 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-O 121.707 0.765 . . . . 72.31 111.023 178.235 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.0 t70 173.85 -43.41 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.574 -1.194 . . . . 75.53 109.36 -177.424 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.506 ' HE1' ' HB3' ' A' ' 20' ' ' TYR . 5.3 m-85 -50.41 123.01 7.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.039 -0.982 . . . . 74.11 112.596 -175.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.586 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 35.2 mt-10 -114.18 100.01 8.05 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.849 -1.069 . . . . 72.52 108.575 172.349 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.576 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 34.7 pt -90.7 143.64 10.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.142 0.496 . . . . 75.11 111.3 -175.772 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.49 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 42.5 tt0 -109.82 136.49 49.05 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.481 -0.781 . . . . 74.33 110.269 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.485 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 95.5 m-85 -85.43 100.58 11.97 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 116.216 -0.447 . . . . 75.13 110.051 175.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.3 m -100.98 163.39 3.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.045 -0.525 . . . . 43.53 110.199 179.389 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.805 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 3.4 t -90.38 147.07 23.68 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 107.93 -1.137 . . . . 51.42 107.93 173.112 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -59.72 108.61 0.77 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.17 0.509 . . . . 71.44 110.942 -170.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.21 -137.21 13.13 Favored Glycine 0 N--CA 1.448 -0.563 0 CA-C-N 115.703 -0.68 . . . . 62.21 112.086 178.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.475 ' CD ' ' H ' ' A' ' 47' ' ' GLU . 0.5 OUTLIER -101.22 33.53 2.85 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.301 0.572 . . . . 71.43 110.278 -179.274 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.805 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 30.1 mmm180 -89.22 145.49 25.37 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.786 -0.643 . . . . 74.21 109.974 179.682 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.617 ' HB2' ' HB3' ' A' ' 75' ' ' ARG . 43.1 mt-10 -91.57 148.96 21.9 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.231 0.538 . . . . 74.41 112.201 -174.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.742 HG13 ' HB2' ' A' ' 44' ' ' CYS . 11.6 m -138.64 150.46 23.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.368 -0.833 . . . . 54.31 110.131 178.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -135.65 97.35 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 122.019 0.914 . . . . 73.23 109.558 170.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.42 173.09 32.26 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-N 114.462 -1.245 . . . . 43.0 110.6 -177.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.497 ' HG2' HG21 ' A' ' 69' ' ' THR . 69.9 Cg_endo -77.17 57.38 5.81 Favored 'Trans proline' 0 C--O 1.235 0.358 0 C-N-CA 122.068 1.845 . . . . 70.42 110.733 176.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.485 ' HB2' ' H ' ' A' ' 42' ' ' TYR . 20.9 pttp -76.4 87.04 3.16 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.383 -0.826 . . . . 72.35 111.608 -173.08 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -162.57 128.54 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.397 -0.82 . . . . 74.12 109.906 172.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.586 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 26.9 mmt180 -130.1 123.69 31.0 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.622 -0.51 . . . . 73.32 109.622 175.281 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.7 ttmm -105.08 122.7 46.42 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.537 -0.542 . . . . 71.3 109.537 178.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.5 t -74.56 142.51 44.71 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.309 -0.405 . . . . 74.1 110.635 -179.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.433 ' HA ' HG23 ' A' ' 36' ' ' VAL . 94.7 mt -128.64 -179.24 4.95 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.844 -0.616 . . . . 75.32 109.516 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.02 59.27 2.13 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.367 0.603 . . . . 34.01 111.654 -177.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -160.52 165.05 31.55 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.802 -0.814 . . . . 74.35 108.802 175.328 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -80.73 40.27 2.45 Favored Glycine 0 CA--C 1.517 0.214 0 C-N-CA 120.662 -0.78 . . . . 74.22 113.067 -175.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 27.6 t -161.84 163.32 29.4 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.234 -0.654 . . . . 64.31 109.234 -178.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 52.8 m95 -97.16 -179.8 4.65 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 110.033 -0.358 . . . . 65.43 110.033 -176.486 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -56.35 -24.73 46.02 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 112.776 0.658 . . . . 71.12 112.776 -176.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.529 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 11.2 t70 -160.71 137.02 8.54 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.384 -0.599 . . . . 71.12 109.384 178.304 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 65.9 mtt -130.38 77.0 1.76 Allowed 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.436 -0.906 . . . . 72.34 110.611 164.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -170.83 88.63 0.12 Allowed 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 108.855 -0.795 . . . . 63.14 108.855 157.482 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.497 HG21 ' HG2' ' A' ' 53' ' ' PRO . 4.7 m -153.5 107.32 2.56 Favored Pre-proline 0 C--N 1.317 -0.809 0 C-N-CA 120.817 -0.353 . . . . 74.33 110.681 -176.867 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -70.21 95.52 0.59 Allowed 'Trans proline' 0 N--CA 1.462 -0.329 0 C-N-CA 122.694 2.263 . . . . 64.14 112.031 178.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 m -78.36 109.44 12.51 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.175 0.512 . . . . 73.3 109.775 177.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.402 ' H ' ' HG2' ' A' ' 72' ' ' ARG . 11.1 ptt180 -97.51 130.6 44.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.574 -0.739 . . . . 75.3 112.085 -172.204 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.513 ' HA ' HG12 ' A' ' 50' ' ' VAL . 81.2 m -82.66 118.25 23.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.665 -0.698 . . . . 74.22 109.824 175.03 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 p -156.36 136.44 4.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 121.082 0.467 . . . . 70.53 110.309 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.617 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 16.1 ptm180 . . . . . 0 C--O 1.244 0.765 0 CA-C-N 115.693 -0.685 . . . . 74.41 109.626 -178.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.6 m . . . . . 0 N--CA 1.451 -0.395 0 N-CA-C 109.8 -0.444 . . . . 74.12 109.8 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -112.98 98.42 7.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.911 -0.586 . . . . 74.03 109.614 -177.512 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.741 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -162.2 152.57 22.94 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.492 -0.861 . . . . 52.24 112.7 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 60.7 m -90.11 147.53 23.56 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.985 -0.376 . . . . 72.14 109.985 176.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -85.81 -179.54 6.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.777 0.322 . . . . 64.22 110.892 -179.324 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.67 HD11 ' HB ' ' A' ' 31' ' ' ILE . 56.3 mt -88.16 130.62 37.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.939 -0.573 . . . . 73.43 110.313 176.831 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 68.7 mt -73.25 136.18 26.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.745 -0.661 . . . . 53.14 110.239 179.032 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.6 t-80 -68.81 138.1 90.39 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 115.989 -0.55 . . . . 73.31 109.936 -178.03 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_exo -40.97 118.87 0.72 Allowed 'Trans proline' 0 C--N 1.351 0.694 0 C-N-CA 123.716 2.944 . . . . 62.52 113.826 -176.723 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.457 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 81.7 Cg_endo -87.5 -149.02 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.128 2.552 . . . . 72.42 112.728 -179.51 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.457 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 9.1 t-105 -75.15 -179.01 4.14 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.69 -0.686 . . . . 72.24 110.516 -177.773 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -46.03 100.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 123.234 0.613 . . . . 74.13 112.172 177.267 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.13 -156.86 28.99 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.331 -0.708 . . . . 71.54 111.331 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.85 -171.23 24.4 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.562 -0.828 . . . . 73.45 111.925 178.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.63 131.44 66.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.651 0.738 . . . . 70.34 111.531 -178.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.707 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 7.9 tpm_? -96.92 104.56 16.58 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 114.298 -1.319 . . . . 74.22 110.064 -178.285 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.472 ' HA ' HG22 ' A' ' 40' ' ' ILE . 97.7 m-85 -80.5 -171.46 3.07 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.519 -0.309 . . . . 74.35 110.187 177.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.7 ttm180 -78.96 -65.35 1.01 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.67 0.272 . . . . 74.3 110.411 -178.843 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -136.16 37.4 1.89 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.423 -0.894 . . . . 71.12 112.275 -178.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.461 HD13 HG12 ' A' ' 28' ' ' VAL . 80.6 mt -102.52 119.73 39.32 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.925 0.393 . . . . 52.44 111.359 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.4 t -94.64 -177.2 4.13 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.712 -0.676 . . . . 75.32 109.662 175.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 77.5 mtt180 -66.88 -173.43 0.24 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.047 0.451 . . . . 73.32 111.627 -176.466 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.0 t0 59.07 19.24 7.1 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 122.029 0.919 . . . . 54.04 110.183 -177.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 23.4 mt-30 -140.35 -165.19 1.86 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.887 -1.052 . . . . 70.15 109.971 -178.39 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.461 HG12 HD13 ' A' ' 23' ' ' LEU . 11.5 m 49.44 24.01 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.312 1.045 . . . . 75.0 112.29 178.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -88.54 -22.38 23.61 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.789 -0.641 . . . . 71.12 110.758 -179.318 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.42 101.07 0.6 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.884 -0.598 . . . . 75.11 110.434 176.6 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.67 ' HB ' HD11 ' A' ' 9' ' ' ILE . 69.0 mt -127.99 138.24 55.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.155 -0.683 . . . . 74.23 109.155 177.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -79.83 -58.25 3.26 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.864 0.364 . . . . 73.04 110.543 -176.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.741 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 82.2 m-85 -139.27 138.4 36.73 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.971 -0.559 . . . . 71.25 110.953 -176.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.95 142.65 32.35 Favored Pre-proline 0 C--N 1.322 -0.593 0 N-CA-C 109.11 -0.7 . . . . 73.11 109.11 172.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -61.33 161.68 22.73 Favored 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 122.648 2.232 . . . . 63.24 112.727 -179.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 p -68.11 143.62 15.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.763 -0.653 . . . . 72.31 110.886 -178.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.5 t70 68.13 19.73 9.13 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.663 0.744 . . . . 75.53 110.942 -178.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -78.12 132.02 37.49 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.742 -0.836 . . . . 74.11 108.742 173.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -123.1 138.28 54.71 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.461 -0.336 . . . . 72.52 110.404 -175.147 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.615 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 14.5 pt -129.88 150.17 34.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.807 -0.633 . . . . 75.11 110.684 -177.69 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.707 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 37.7 tt0 -115.44 152.3 33.17 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.946 -0.57 . . . . 74.33 110.551 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.412 ' HE2' ' HG2' ' A' ' 56' ' ' ARG . 81.6 m-85 -100.11 101.87 13.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.256 -0.429 . . . . 75.13 110.854 178.122 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.3 m -94.55 155.02 3.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 120.727 0.299 . . . . 43.53 110.244 177.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 9.8 t -90.91 -179.3 5.45 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.405 -0.591 . . . . 51.42 109.405 -178.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . 0.473 ' HD3' ' HA ' ' A' ' 45' ' ' ARG . 2.3 mmt180 -81.5 153.99 26.53 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.744 -0.382 . . . . 71.44 111.342 -179.167 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.12 -138.44 24.47 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 110.856 -0.898 . . . . 62.21 110.856 -174.175 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -111.08 19.83 18.04 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.475 0.655 . . . . 71.43 109.389 174.545 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.584 ' HA ' ' HD2' ' A' ' 75' ' ' ARG . 7.4 mmm180 -88.9 150.9 22.64 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.269 -0.878 . . . . 74.21 109.556 -177.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.496 ' H ' ' HB3' ' A' ' 75' ' ' ARG . 37.6 mt-10 -120.99 170.44 9.51 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.868 0.366 . . . . 74.41 111.005 -171.277 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.405 HG12 ' HA ' ' A' ' 73' ' ' CYS . 22.7 m -118.3 150.5 20.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.202 -0.453 . . . . 54.31 110.903 -177.634 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.66 HG12 ' HB ' ' A' ' 74' ' ' VAL . 6.4 p -113.01 96.76 4.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 122.156 0.979 . . . . 73.23 109.116 170.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.55 173.4 33.01 Favored Glycine 0 N--CA 1.442 -0.966 0 CA-C-N 114.834 -1.076 . . . . 43.0 110.874 -177.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.49 ' HG2' HG21 ' A' ' 69' ' ' THR . 47.9 Cg_endo -72.39 60.32 3.3 Favored 'Trans proline' 0 CA--C 1.529 0.26 0 C-N-CA 122.191 1.927 . . . . 70.42 110.304 170.008 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.569 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 32.1 pttt -73.62 89.52 1.74 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.139 -0.937 . . . . 72.35 111.209 -175.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.9 p -160.08 132.71 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.727 -0.67 . . . . 74.12 110.51 178.183 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.615 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 24.2 mmt180 -125.68 114.96 19.36 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.185 -0.672 . . . . 73.32 109.185 173.126 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 41.9 tptt -102.54 116.95 33.64 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.459 -0.791 . . . . 71.3 109.914 -176.147 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . 0.563 ' HB2' ' CZ3' ' A' ' 64' ' ' TRP . 49.3 t -87.91 124.5 33.74 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.137 -0.483 . . . . 74.1 110.074 177.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.415 HD11 HG21 ' A' ' 65' ' ' THR . 41.9 mt -105.08 -177.55 3.4 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.814 -0.63 . . . . 75.32 109.43 176.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -56.63 -32.29 65.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.091 0.472 . . . . 34.01 110.431 174.042 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -81.06 132.08 35.34 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.44 -0.578 . . . . 74.35 109.44 172.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -77.82 64.1 3.38 Favored Glycine 0 N--CA 1.451 -0.313 0 N-CA-C 114.299 0.479 . . . . 74.22 114.299 -171.164 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 58.2 m -157.14 142.27 17.11 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.539 -0.541 . . . . 64.31 109.539 172.278 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.563 ' CZ3' ' HB2' ' A' ' 58' ' ' CYS . 23.1 m95 -78.19 124.4 28.02 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.05 -0.722 . . . . 65.43 109.05 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.415 HG21 HD11 ' A' ' 59' ' ' LEU . 17.2 p -75.62 33.03 0.11 Allowed 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 114.358 1.244 . . . . 71.12 114.358 -167.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -160.75 13.91 0.11 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.865 0.364 . . . . 71.12 110.056 176.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 26.1 ttt -76.65 78.94 3.3 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-O 121.875 0.845 . . . . 72.34 112.416 -165.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -169.68 88.88 0.17 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 114.382 -1.281 . . . . 63.14 107.783 159.284 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.49 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.7 OUTLIER -152.78 117.86 2.93 Favored Pre-proline 0 C--N 1.318 -0.801 0 C-N-CA 120.19 -0.604 . . . . 74.33 111.345 -169.751 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -78.72 100.53 1.37 Allowed 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.885 2.39 . . . . 64.14 111.318 174.399 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.7 p -79.39 116.83 19.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.051 0.453 . . . . 73.3 111.112 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.8 ptp180 -89.47 129.2 36.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.729 -0.668 . . . . 75.3 111.285 -177.223 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.405 ' HA ' HG12 ' A' ' 50' ' ' VAL . 62.3 m -82.88 105.5 13.94 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.718 -0.475 . . . . 74.22 109.718 178.481 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.66 ' HB ' HG12 ' A' ' 51' ' ' VAL . 49.1 t -128.33 84.27 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 121.072 0.463 . . . . 70.53 109.76 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.584 ' HD2' ' HA ' ' A' ' 48' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.751 0 N-CA-C 108.54 -0.911 . . . . 74.41 108.54 -178.728 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.3 m . . . . . 0 N--CA 1.451 -0.422 0 N-CA-C 108.354 -0.98 . . . . 74.12 108.354 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -78.2 99.88 6.41 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.275 0.56 . . . . 74.03 111.195 -172.145 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.6 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -159.47 146.96 13.64 Favored Glycine 0 N--CA 1.44 -1.054 0 CA-C-N 115.239 -0.891 . . . . 52.24 111.678 179.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.9 m -92.88 142.93 26.77 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 110.05 -0.352 . . . . 72.14 110.05 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -76.02 -177.62 3.99 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.884 0.374 . . . . 64.22 111.055 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 61.3 mt -87.38 137.66 20.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.057 -0.52 . . . . 73.43 111.176 -175.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 27.5 mt -84.13 156.57 3.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.5 -0.773 . . . . 53.14 110.217 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -82.68 141.47 44.77 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.64 -0.255 . . . . 73.31 110.67 -177.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.54 131.32 21.3 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.74 2.293 . . . . 62.52 112.462 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -87.6 -140.1 0.02 OUTLIER 'Trans proline' 0 CA--C 1.533 0.43 0 C-N-CA 123.176 2.584 . . . . 72.42 112.393 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.523 ' HD1' ' H ' ' A' ' 15' ' ' GLU . 1.9 t90 -67.54 -179.44 1.08 Allowed 'General case' 0 CA--C 1.537 0.452 0 CA-C-N 116.071 -0.513 . . . . 72.24 109.641 178.248 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.523 ' H ' ' HD1' ' A' ' 14' ' ' TRP . 29.3 mm-40 -43.2 102.38 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 123.629 0.772 . . . . 74.13 112.886 -176.343 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.08 -154.82 25.66 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 110.224 -1.15 . . . . 71.54 110.224 -177.285 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.95 -171.36 37.61 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.224 -0.989 . . . . 73.45 112.064 176.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.7 mt -111.54 128.88 67.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.745 0.783 . . . . 70.34 111.279 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.76 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 9.2 tpt180 -96.76 127.3 42.61 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.581 -1.191 . . . . 74.22 108.966 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.525 ' HA ' HG22 ' A' ' 40' ' ' ILE . 77.4 m-85 -91.02 -172.46 3.34 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.341 -0.544 . . . . 74.35 110.021 178.647 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 21' ' ' ARG . 18.9 ttt85 -80.69 -62.78 1.57 Allowed 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.602 -0.439 . . . . 74.3 110.753 -172.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -146.98 57.02 0.5 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.693 -0.765 . . . . 71.12 111.986 177.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 93.2 mt -119.41 139.5 51.92 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.975 0.417 . . . . 52.44 111.246 -176.637 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.8 t -86.47 173.11 9.84 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.928 -0.578 . . . . 75.32 109.49 174.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.503 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 31.7 ptt180 -79.83 -171.52 2.91 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 121.12 -0.232 . . . . 73.32 110.581 -177.135 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.503 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 12.6 t70 72.77 -38.9 0.43 Allowed 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 109.178 -0.675 . . . . 54.04 109.178 -168.663 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.509 ' O ' HG22 ' A' ' 28' ' ' VAL . 24.0 mt-30 -83.33 -169.12 2.38 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.602 -0.888 . . . . 70.15 108.602 167.096 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.509 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.2 m 55.6 9.54 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 C-N-CA 124.219 1.008 . . . . 75.0 113.593 174.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -92.99 -29.13 16.0 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.076 0.465 . . . . 71.12 109.827 176.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.36 91.8 1.63 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.766 -0.652 . . . . 75.11 110.561 177.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.9 mt -115.79 135.7 55.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.706 -0.679 . . . . 74.23 109.209 177.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 15.5 m120 -72.94 -59.76 2.56 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.684 0.278 . . . . 73.04 110.925 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.6 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 74.4 m-85 -131.88 129.9 40.94 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.819 0.343 . . . . 71.25 111.171 -177.163 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.417 ' HA ' ' HD2' ' A' ' 35' ' ' PRO . 3.7 mm? -90.96 113.05 56.81 Favored Pre-proline 0 C--N 1.322 -0.619 0 N-CA-C 108.181 -1.044 . . . . 73.11 108.181 169.026 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.417 ' HD2' ' HA ' ' A' ' 34' ' ' LEU . 11.6 Cg_endo -53.61 156.27 11.88 Favored 'Trans proline' 0 C--O 1.234 0.28 0 C-N-CA 123.432 2.755 . . . . 63.24 113.549 -172.516 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.516 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 13.3 p -54.78 147.44 3.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.484 -0.78 . . . . 72.31 111.098 178.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.516 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 15.0 m-20 79.23 5.05 2.23 Favored 'General case' 0 N--CA 1.467 0.425 0 C-N-CA 123.654 0.782 . . . . 75.53 111.571 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.511 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 24.3 t80 -82.75 144.97 29.82 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.808 0.337 . . . . 74.11 110.241 178.406 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.537 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 37.0 mt-10 -135.25 138.16 43.27 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.916 -0.584 . . . . 72.52 110.283 -177.374 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.645 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 20.3 pt -125.76 158.94 34.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 120.805 0.335 . . . . 75.11 110.77 177.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.76 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 49.8 tt0 -116.16 149.86 38.37 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.859 -0.61 . . . . 74.33 110.976 -174.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.409 ' HE2' ' CG ' ' A' ' 56' ' ' ARG . 8.2 m-85 -94.33 102.01 13.99 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.28 -0.418 . . . . 75.13 110.185 175.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.602 HG11 HH11 ' A' ' 19' ' ' ARG . 18.2 m -108.42 156.43 8.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.109 0.481 . . . . 43.53 111.63 -177.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.546 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 5.2 t -96.35 158.47 15.42 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.193 -1.04 . . . . 51.42 108.193 178.437 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -65.59 117.72 8.47 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.26 0.467 . . . . 71.44 112.26 -174.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.34 -137.32 13.65 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.587 -0.733 . . . . 62.21 111.807 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -98.79 22.67 9.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.864 0.84 . . . . 71.43 109.077 174.223 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.594 ' HD2' ' OXT' ' A' ' 75' ' ' ARG . 10.7 mmm180 -88.18 134.19 33.84 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.642 -1.163 . . . . 74.21 109.184 -178.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.618 ' H ' ' HB3' ' A' ' 75' ' ' ARG . 46.4 mt-10 -116.66 170.1 8.85 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 120.98 0.419 . . . . 74.41 110.924 -179.06 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.54 HG12 ' HA ' ' A' ' 73' ' ' CYS . 28.9 m -116.85 149.53 19.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.405 -0.816 . . . . 54.31 109.206 174.199 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -106.12 95.09 3.52 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 122.035 0.922 . . . . 73.23 108.681 170.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.74 172.58 33.8 Favored Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 114.607 -1.179 . . . . 43.0 111.667 -176.041 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.506 ' HG2' ' CG2' ' A' ' 69' ' ' THR . 56.5 Cg_endo -73.72 53.1 2.68 Favored 'Trans proline' 0 CA--C 1.532 0.413 0 C-N-CA 122.494 2.129 . . . . 70.42 110.713 171.076 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 48.2 pttt -69.03 91.34 0.48 Allowed 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 114.805 -1.089 . . . . 72.35 111.948 -173.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.2 p -160.83 132.11 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.553 0.692 . . . . 74.12 110.912 175.057 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.645 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 42.9 mmt180 -121.23 113.82 20.5 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.528 -0.76 . . . . 73.32 109.128 172.402 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -108.78 129.78 55.38 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.155 -0.475 . . . . 71.3 110.084 -177.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 52.4 t -96.72 113.86 25.45 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.26 -0.427 . . . . 74.1 110.244 178.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.551 ' HB2' ' OD1' ' A' ' 61' ' ' ASN . 35.9 mt -96.45 -176.05 3.51 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.121 -0.696 . . . . 75.32 109.121 177.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -71.4 55.81 0.23 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-O 121.214 0.53 . . . . 34.01 111.18 177.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.551 ' OD1' ' HB2' ' A' ' 59' ' ' LEU . 4.4 p-10 -160.34 167.64 26.99 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.706 -0.85 . . . . 74.35 108.706 178.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -91.79 47.15 2.73 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.488 -0.863 . . . . 74.22 113.62 -171.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 38.9 m -160.59 136.33 8.22 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 117.041 0.42 . . . . 64.31 110.797 178.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . 0.433 ' HB2' ' CG ' ' A' ' 67' ' ' MET . 63.0 m95 -71.41 123.22 21.88 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.02 -1.104 . . . . 65.43 108.02 171.628 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.543 HG21 HD12 ' A' ' 59' ' ' LEU . 13.6 p -77.23 38.23 0.22 Allowed 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 115.074 1.509 . . . . 71.12 115.074 -164.329 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -162.51 20.16 0.09 Allowed 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 120.413 -0.515 . . . . 71.12 111.818 173.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . 0.433 ' CG ' ' HB2' ' A' ' 64' ' ' TRP . 58.3 mtm -76.28 79.53 3.05 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 119.311 -0.956 . . . . 72.34 112.412 -168.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -169.76 89.27 0.17 Allowed 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 107.495 -1.298 . . . . 63.14 107.495 161.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.506 ' CG2' ' HG2' ' A' ' 53' ' ' PRO . 2.8 m -147.2 124.63 5.84 Favored Pre-proline 0 C--N 1.321 -0.65 0 C-N-CA 119.595 -0.842 . . . . 74.33 112.387 -168.265 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . 0.486 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 9.6 Cg_endo -89.21 90.49 0.38 Allowed 'Trans proline' 0 N--CA 1.451 -0.989 0 C-N-CA 123.388 2.725 . . . . 64.14 111.62 174.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.1 m -90.31 118.17 29.6 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.263 -0.426 . . . . 73.3 110.149 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.5 ptp180 -89.15 119.47 29.68 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.054 -0.521 . . . . 75.3 111.334 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.54 ' HA ' HG12 ' A' ' 50' ' ' VAL . 41.1 t -72.52 105.5 4.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.068 -0.515 . . . . 74.22 110.243 179.155 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.5 t -135.69 100.53 2.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.899 -0.591 . . . . 70.53 110.503 -177.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.618 ' HB3' ' H ' ' A' ' 49' ' ' GLU . 15.1 ttm180 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 118.451 -0.785 . . . . 74.41 109.558 176.159 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.8 m . . . . . 0 N--CA 1.453 -0.289 0 CA-C-O 120.847 0.356 . . . . 74.12 111.212 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -121.67 103.8 9.15 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.497 -0.557 . . . . 74.03 109.497 176.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -159.87 171.15 36.16 Favored Glycine 0 N--CA 1.443 -0.894 0 C-N-CA 120.481 -0.866 . . . . 52.24 112.86 -175.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 58.3 m -106.47 148.06 28.62 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.843 -0.429 . . . . 72.14 109.843 -178.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -84.21 -179.9 7.32 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.001 0.429 . . . . 64.22 111.192 -178.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.584 HD12 ' H ' ' A' ' 31' ' ' ILE . 42.1 mt -88.68 143.67 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.596 -0.729 . . . . 73.43 110.343 177.686 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.1 mt -98.91 166.66 2.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.705 -0.68 . . . . 53.14 109.968 -177.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 76.5 m-70 -89.71 138.66 27.96 Favored Pre-proline 0 C--N 1.325 -0.458 0 N-CA-C 109.899 -0.408 . . . . 73.31 109.899 178.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.406 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 55.4 Cg_endo -72.36 106.34 2.05 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.29 1.993 . . . . 62.52 111.384 174.512 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 11.5 Cg_endo -88.85 -74.96 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 123.054 2.502 . . . . 72.42 113.566 -174.114 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 32.9 t-105 -100.29 -176.46 3.23 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.19 -0.459 . . . . 72.24 109.834 -175.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -49.85 -29.36 7.92 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 122.896 0.478 . . . . 74.13 111.539 178.092 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.25 102.3 1.35 Allowed Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.715 -0.755 . . . . 71.54 111.813 176.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -88.98 -169.74 44.81 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 121.148 -0.549 . . . . 73.45 112.052 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 28.4 mt -116.11 137.95 48.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.795 0.807 . . . . 70.34 112.337 -174.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 19' ' ' ARG . 11.2 tpt180 -116.59 132.78 56.59 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 114.287 -1.324 . . . . 74.22 108.825 -179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.573 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 56.0 m-85 -92.33 -172.03 2.98 Favored 'General case' 0 C--N 1.318 -0.772 0 C-N-CA 120.703 -0.399 . . . . 74.35 110.604 -179.578 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.521 ' HB2' ' O ' ' A' ' 39' ' ' GLU . 7.4 tmm_? -112.64 -42.21 3.68 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.126 0.489 . . . . 74.3 110.287 -171.75 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -146.09 56.54 0.52 Allowed Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 121.008 -0.615 . . . . 71.12 111.716 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 40.9 mt -143.15 141.68 31.25 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.946 0.403 . . . . 52.44 110.555 179.263 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -99.65 -178.95 4.04 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.691 -0.686 . . . . 75.32 110.197 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.475 ' C ' ' H ' ' A' ' 27' ' ' GLN . 33.0 ptt180 -66.55 -172.63 0.17 Allowed 'General case' 0 C--O 1.234 0.243 0 CA-C-N 116.051 -0.522 . . . . 73.32 111.409 -179.411 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.6 t70 70.24 -38.67 0.42 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.318 0.647 . . . . 54.04 111.043 -176.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.54 ' O ' HG22 ' A' ' 28' ' ' VAL . 17.7 mt-30 -94.73 -153.25 0.38 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.605 -0.725 . . . . 70.15 109.847 176.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.54 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.6 m 57.8 13.16 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 124.584 1.154 . . . . 75.0 112.939 176.349 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 56.7 mtpt -106.1 -38.42 6.29 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.928 0.394 . . . . 71.12 110.218 176.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.22 86.71 2.25 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.032 -0.531 . . . . 75.11 110.704 177.071 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.584 ' H ' HD12 ' A' ' 9' ' ' ILE . 70.7 mt -134.68 121.98 37.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 N-CA-C 108.521 -0.918 . . . . 74.23 108.521 176.524 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.502 HD22 ' H ' ' A' ' 32' ' ' ASN . 0.1 OUTLIER -84.1 -24.46 30.31 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 113.229 0.826 . . . . 73.04 113.229 -170.334 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 -140.15 109.42 6.16 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 113.06 0.763 . . . . 71.25 113.06 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.45 112.18 48.32 Favored Pre-proline 0 C--N 1.323 -0.548 0 N-CA-C 107.77 -1.196 . . . . 73.11 107.77 165.166 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -58.85 152.0 60.7 Favored 'Trans proline' 0 N--CA 1.474 0.362 0 C-N-CA 123.057 2.504 . . . . 63.24 113.63 -170.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.482 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 2.5 p -61.48 94.92 0.08 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 115.559 -0.746 . . . . 72.31 110.58 175.697 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.482 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 18.3 t70 160.92 -29.9 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 114.488 -1.233 . . . . 75.53 108.367 -174.815 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.573 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 6.4 t80 -73.72 146.66 44.24 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.625 -1.171 . . . . 74.11 111.818 -173.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.521 ' O ' ' HB2' ' A' ' 21' ' ' ARG . 27.0 mt-10 -125.74 150.47 47.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.5 -0.773 . . . . 72.52 109.883 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.613 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 38.3 pt -132.99 149.31 31.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.948 0.404 . . . . 75.11 110.879 174.17 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.462 ' HG3' ' HD3' ' A' ' 54' ' ' LYS . 41.3 tt0 -118.64 171.44 8.19 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.476 -0.783 . . . . 74.33 109.396 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . 0.414 ' N ' ' HG2' ' A' ' 41' ' ' GLU . 73.1 m-85 -113.65 100.86 8.8 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.869 0.366 . . . . 75.13 111.176 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.6 m -96.98 132.1 42.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.013 0.435 . . . . 43.53 109.94 175.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.509 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 39.1 t -89.16 148.51 23.61 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.265 0.555 . . . . 51.42 110.941 -174.085 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -59.11 133.62 56.26 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.579 -1.191 . . . . 71.44 110.702 -176.239 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 86.29 -119.24 5.09 Favored Glycine 0 N--CA 1.444 -0.823 0 N-CA-C 110.67 -0.972 . . . . 62.21 110.67 -173.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -141.5 83.1 1.85 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.411 0.624 . . . . 71.43 109.812 173.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.647 ' HB3' ' HB2' ' A' ' 73' ' ' CYS . 42.7 mmt180 -132.89 130.05 39.18 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.434 -0.803 . . . . 74.21 110.081 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -86.25 139.69 30.8 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 109.958 -0.386 . . . . 74.41 109.958 178.04 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.444 HG12 ' HB3' ' A' ' 73' ' ' CYS . 30.5 m -97.82 127.32 50.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.224 -0.444 . . . . 54.31 111.096 -178.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.8 p -98.68 94.08 3.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 122.246 1.022 . . . . 73.23 109.287 174.042 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -156.82 171.06 34.29 Favored Glycine 0 N--CA 1.44 -1.059 0 CA-C-N 114.485 -1.234 . . . . 43.0 111.292 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -73.19 55.07 2.88 Favored 'Trans proline' 0 CA--C 1.531 0.341 0 C-N-CA 122.553 2.168 . . . . 70.42 110.255 168.252 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.585 ' O ' ' HD2' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -72.04 93.54 1.41 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.899 0.856 . . . . 72.35 112.718 -170.878 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.497 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.2 p -161.57 128.75 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 115.527 -0.76 . . . . 74.12 109.862 170.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.613 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 29.1 mmt180 -132.83 115.62 15.52 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.303 -0.629 . . . . 73.32 109.303 177.261 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.43 ' HE2' ' HG2' ' A' ' 39' ' ' GLU . 37.2 ttmt -115.02 136.91 52.61 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 108.986 -0.746 . . . . 71.3 108.986 178.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.7 t -73.78 139.95 45.54 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.826 0.346 . . . . 74.1 110.856 -176.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.481 ' C ' ' H ' ' A' ' 61' ' ' ASN . 87.3 mt -96.57 -179.53 4.64 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.779 -0.646 . . . . 75.32 110.548 -178.372 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.47 36.98 0.26 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-O 121.877 0.846 . . . . 34.01 109.304 174.128 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.481 ' H ' ' C ' ' A' ' 59' ' ' LEU . 0.9 OUTLIER -157.33 155.99 31.58 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.408 -1.269 . . . . 74.35 108.226 -172.37 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -74.45 50.31 2.06 Favored Glycine 0 CA--C 1.52 0.368 0 C-N-CA 121.114 -0.565 . . . . 74.22 113.215 -176.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 55.6 m -159.32 149.86 19.41 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 123.088 0.555 . . . . 64.31 109.518 178.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -83.53 175.19 9.96 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 110.171 -0.307 . . . . 65.43 110.171 -176.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 57' ' ' LYS . 1.4 p -50.56 -48.21 57.5 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.444 0.535 . . . . 71.12 112.444 -177.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -153.86 140.45 18.89 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.673 -0.862 . . . . 71.12 108.673 179.512 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 23.1 mmt -139.59 79.54 1.72 Allowed 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 120.235 -0.586 . . . . 72.34 110.557 168.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -168.48 87.93 0.21 Allowed 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 108.032 -1.099 . . . . 63.14 108.032 163.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.42 ' CB ' HH22 ' A' ' 56' ' ' ARG . 1.1 m -152.42 128.96 5.38 Favored Pre-proline 0 C--N 1.319 -0.751 0 C-N-CA 120.433 -0.507 . . . . 74.33 111.064 -169.82 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -74.99 69.29 5.58 Favored 'Trans proline' 0 CA--C 1.532 0.398 0 C-N-CA 122.772 2.315 . . . . 64.14 112.596 177.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 8.5 p -78.28 121.11 23.99 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.748 -0.464 . . . . 73.3 109.748 175.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.2 ptp85 -133.28 141.62 48.09 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.8 0.333 . . . . 75.3 111.624 -174.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.647 ' HB2' ' HB3' ' A' ' 48' ' ' ARG . 1.8 p -107.58 104.22 13.71 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.819 -0.628 . . . . 74.22 110.373 178.219 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.82 9.02 5.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.443 0.639 . . . . 70.53 110.755 -174.626 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.6 ttp180 . . . . . 0 C--O 1.246 0.901 0 CA-C-O 118.659 -0.686 . . . . 74.41 109.998 178.371 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.716 0 N-CA-C 111.677 -0.569 . . . . 72.35 111.677 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -75.33 142.14 26.53 Favored 'Trans proline' 0 C--O 1.235 0.369 0 C-N-CA 122.778 2.319 . . . . 72.1 112.279 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 40.0 p -102.98 113.33 26.7 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.333 -0.394 . . . . 75.23 110.411 177.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.9 m -79.97 98.86 7.36 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.306 0.574 . . . . 74.12 109.631 177.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -114.16 97.91 6.64 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.844 -0.617 . . . . 74.03 109.756 -177.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -163.16 171.1 38.82 Favored Glycine 0 N--CA 1.439 -1.113 0 C-N-CA 120.728 -0.749 . . . . 52.24 112.223 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 26.0 m -104.32 153.53 20.92 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.74 -0.467 . . . . 72.14 109.74 177.035 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.401 ' HB2' HE21 ' A' ' 8' ' ' GLN . 2.5 pt20 -89.6 -178.86 5.66 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.927 0.394 . . . . 64.22 111.13 -179.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.617 HD11 ' HB ' ' A' ' 31' ' ' ILE . 26.6 mt -87.98 120.55 37.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.928 -0.578 . . . . 73.43 110.022 177.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 63.1 mt -74.95 138.38 21.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.212 -0.904 . . . . 53.14 110.525 -178.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 81.1 m-70 -80.54 132.09 59.45 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 116.118 -0.492 . . . . 73.31 109.768 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.463 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.6 Cg_exo -51.05 113.18 0.98 Allowed 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 123.319 2.679 . . . . 62.52 112.838 -178.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 4.7 Cg_exo -76.51 -80.0 0.01 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.43 0 C-N-CA 122.881 2.388 . . . . 72.42 112.278 -178.615 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.0 t-105 -101.39 -178.09 3.63 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.602 -0.518 . . . . 72.24 109.602 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -58.71 100.54 0.07 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.133 0.492 . . . . 74.13 111.086 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.509 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . 175.81 -158.29 25.11 Favored Glycine 0 N--CA 1.443 -0.847 0 C-N-CA 120.854 -0.688 . . . . 71.54 112.009 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -161.1 -171.28 26.88 Favored Glycine 0 N--CA 1.446 -0.67 0 N-CA-C 111.296 -0.721 . . . . 73.45 111.296 178.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.9 mt -125.68 131.4 72.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.792 0.806 . . . . 70.34 111.804 -178.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.797 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 23.3 tpp180 -93.51 110.65 22.23 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.317 -1.31 . . . . 74.22 109.935 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -90.95 -171.52 3.03 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.778 0.323 . . . . 74.35 110.358 177.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.456 ' NH2' ' HB2' ' A' ' 39' ' ' GLU . 97.8 mtt180 -109.72 -86.58 0.52 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.446 -0.343 . . . . 74.3 110.894 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -88.4 48.06 3.54 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 121.18 -0.533 . . . . 71.12 112.702 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 91.8 mt -137.91 133.41 33.77 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 110.09 -0.337 . . . . 52.44 110.09 178.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.4 t -95.99 179.55 5.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.745 -0.465 . . . . 75.32 109.745 174.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' GLN . 63.9 mtm-85 -79.54 -171.38 2.76 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.581 -0.282 . . . . 73.32 110.962 -177.438 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.474 ' O ' ' HE2' ' A' ' 29' ' ' LYS . 34.7 t70 68.5 -27.03 0.14 Allowed 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 123.329 0.652 . . . . 54.04 110.928 -170.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ARG . 19.4 mt-30 -90.33 -146.07 0.18 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.703 -0.681 . . . . 70.15 110.028 175.169 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.467 HG22 ' O ' ' A' ' 27' ' ' GLN . 4.8 m 54.26 19.75 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.509 1.123 . . . . 75.0 112.733 177.293 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.474 ' HE2' ' O ' ' A' ' 26' ' ' ASP . 49.9 mtmt -101.41 -74.85 0.61 Allowed 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.823 -0.436 . . . . 71.12 109.823 175.145 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.11 89.53 4.06 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.448 0.642 . . . . 75.11 111.253 178.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.617 ' HB ' HD11 ' A' ' 9' ' ' ILE . 64.9 mt -125.44 138.86 53.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.255 -0.884 . . . . 74.23 108.634 175.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 37.4 m-80 -74.39 -70.2 0.41 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.636 0.255 . . . . 73.04 110.864 -177.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -141.55 139.43 33.2 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.017 0.437 . . . . 71.25 111.301 -177.026 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -78.85 147.0 69.74 Favored Pre-proline 0 C--N 1.321 -0.646 0 N-CA-C 109.079 -0.711 . . . . 73.11 109.079 172.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -61.47 151.36 80.26 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.684 2.256 . . . . 63.24 112.26 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.2 p -61.13 138.24 22.22 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 CA-C-N 116.388 -0.369 . . . . 72.31 110.132 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 16.8 t70 61.97 75.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.817 0.818 . . . . 75.53 110.421 -172.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -133.28 124.68 27.75 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 107.464 -1.31 . . . . 74.11 107.464 175.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.714 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 39.5 mt-10 -111.98 124.9 53.38 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.099 0.476 . . . . 72.52 111.537 -172.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.489 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 32.6 pt -116.0 167.28 9.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.122 -0.944 . . . . 75.11 111.019 -177.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.797 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 44.7 tt0 -125.05 146.2 49.55 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.855 -0.611 . . . . 74.33 110.542 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.494 ' HE2' ' HG3' ' A' ' 56' ' ' ARG . 25.8 m-85 -97.67 103.07 14.97 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.323 -0.399 . . . . 75.13 110.762 178.078 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 32.7 m -97.58 157.45 3.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 120.825 0.345 . . . . 43.53 111.055 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.541 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 48.3 t -89.53 158.42 17.68 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-N 116.037 -0.529 . . . . 51.42 109.608 178.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.509 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 31.3 ttt180 -58.13 121.24 10.21 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.858 -1.065 . . . . 71.44 111.873 -169.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 93.61 -128.95 9.67 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.874 -0.891 . . . . 62.21 110.874 -176.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -114.95 37.98 3.31 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.5 0.667 . . . . 71.43 110.009 172.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.541 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 27.3 mmt180 -88.84 146.44 24.96 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.434 -0.803 . . . . 74.21 109.356 178.194 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -103.46 166.18 10.58 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.04 0.448 . . . . 74.41 110.848 -177.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.571 HG12 ' HA ' ' A' ' 73' ' ' CYS . 35.4 m -132.97 145.96 33.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 115.921 -0.581 . . . . 54.31 109.835 177.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.6 p -108.18 95.81 4.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 122.195 0.998 . . . . 73.23 109.42 172.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.82 172.82 33.23 Favored Glycine 0 N--CA 1.443 -0.893 0 CA-C-N 114.47 -1.241 . . . . 43.0 110.801 -178.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.77 67.27 5.74 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.773 1.649 . . . . 70.42 110.552 172.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.555 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 31.9 pttt -84.32 87.65 7.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.36 -0.836 . . . . 72.35 111.532 -173.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -160.89 129.18 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.262 -0.881 . . . . 74.12 109.286 174.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.714 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 28.7 mmt85 -133.18 109.95 9.8 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 116.531 -0.304 . . . . 73.32 110.584 -177.261 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -96.66 118.6 33.48 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.822 -0.436 . . . . 71.3 109.822 178.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.8 t -62.62 132.74 53.37 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.919 -0.582 . . . . 74.1 110.954 177.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 90.2 mt -97.42 -178.58 4.2 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.873 -0.603 . . . . 75.32 110.61 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.19 -1.87 34.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.04 0.448 . . . . 34.01 111.043 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -119.63 169.78 9.78 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.41 -0.589 . . . . 74.35 109.41 177.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -75.33 62.35 2.65 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.079 -0.582 . . . . 74.22 113.35 -175.266 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 27.6 t -170.28 160.55 7.82 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.674 -0.491 . . . . 64.31 109.674 176.289 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 58.5 m95 -97.03 174.63 6.67 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.482 -0.562 . . . . 65.43 109.482 -177.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -49.89 -75.4 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.382 0 N-CA-C 112.815 0.672 . . . . 71.12 112.815 -176.026 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -115.89 94.76 4.81 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.377 -0.601 . . . . 71.12 109.377 176.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 13.5 tpt -93.42 75.35 4.49 Favored 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 119.192 -1.003 . . . . 72.34 110.253 -177.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -172.65 96.73 0.14 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.585 -1.188 . . . . 63.14 108.235 159.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.6 m -142.07 108.91 5.87 Favored Pre-proline 0 C--N 1.317 -0.846 0 C-N-CA 119.671 -0.812 . . . . 74.33 111.714 -172.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -77.56 93.84 1.08 Allowed 'Trans proline' 0 N--CA 1.458 -0.582 0 C-N-CA 122.62 2.213 . . . . 64.14 111.834 176.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 35.8 p -81.34 107.34 14.04 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.054 -0.521 . . . . 73.3 110.368 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -78.84 120.07 22.94 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.245 0.545 . . . . 75.3 110.477 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.571 ' HA ' HG12 ' A' ' 50' ' ' VAL . 24.0 t -72.32 110.1 6.51 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.559 -0.746 . . . . 74.22 109.799 -178.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 98.4 t -134.37 126.13 48.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.973 -0.558 . . . . 70.53 110.293 -174.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 75' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.229 -0.891 . . . . 74.41 109.79 178.415 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.738 0 N-CA-C 111.844 -0.502 . . . . 72.35 111.844 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -68.23 93.08 0.4 Allowed 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 122.696 2.264 . . . . 72.1 111.353 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 2.5 p -78.76 99.58 6.74 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.742 -0.663 . . . . 75.23 111.417 -175.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.3 m -118.53 100.67 7.6 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.693 -0.685 . . . . 74.12 109.499 176.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 49.1 mm-40 -83.11 109.19 16.94 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.986 -0.552 . . . . 74.03 110.538 -177.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.602 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -150.26 141.54 8.86 Favored Glycine 0 N--CA 1.443 -0.895 0 C-N-CA 120.737 -0.744 . . . . 52.24 112.365 -178.193 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 37.4 m -88.96 154.03 20.55 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 110.109 -0.33 . . . . 72.14 110.109 178.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -86.89 177.76 7.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.017 0.437 . . . . 64.22 111.681 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.575 HD11 ' HB ' ' A' ' 31' ' ' ILE . 72.0 mt -87.79 118.9 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.527 -0.76 . . . . 73.43 109.982 177.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 44.2 mt -71.25 145.36 12.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.904 -0.589 . . . . 53.14 110.923 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -81.02 137.78 49.7 Favored Pre-proline 0 C--N 1.324 -0.502 0 N-CA-C 109.587 -0.523 . . . . 73.31 109.587 174.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -64.11 116.47 3.73 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.457 2.105 . . . . 62.52 111.634 176.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.75 -85.01 0.01 OUTLIER 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.541 2.161 . . . . 72.42 112.134 -178.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.6 t-105 -101.97 -178.08 3.6 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.843 -0.799 . . . . 72.24 108.843 173.371 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -50.67 100.9 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.189 0.518 . . . . 74.13 111.761 178.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.81 -147.29 5.65 Favored Glycine 0 N--CA 1.444 -0.83 0 CA-C-N 115.485 -0.78 . . . . 71.54 111.325 178.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -178.5 -170.86 41.13 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 120.869 -0.682 . . . . 73.45 111.42 177.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.5 mt -123.11 133.11 70.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.518 0.675 . . . . 70.34 111.325 -179.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.926 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 7.2 tpt180 -96.31 132.85 41.37 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.634 -1.166 . . . . 74.22 108.448 177.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.542 ' HB3' ' HH ' ' A' ' 38' ' ' TYR . 97.1 m-85 -103.77 -171.53 1.95 Allowed 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 120.417 -0.513 . . . . 74.35 111.636 -173.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.68 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 49.1 ttt180 -113.36 -44.04 3.28 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.576 -0.738 . . . . 74.3 110.263 -170.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -148.03 40.01 0.97 Allowed Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.647 -0.706 . . . . 71.12 111.968 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.435 HD13 HG12 ' A' ' 28' ' ' VAL . 84.7 mt -122.21 130.07 52.85 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.832 0.349 . . . . 52.44 110.504 179.463 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 11.0 t -90.72 -179.33 5.5 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.939 -0.573 . . . . 75.32 110.158 177.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 5.6 ptm180 -73.66 -173.49 1.49 Allowed 'General case' 0 C--O 1.234 0.286 0 CA-C-O 120.978 0.418 . . . . 73.32 112.125 -174.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 31.1 t70 56.17 12.77 1.03 Allowed 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 115.353 -0.839 . . . . 54.04 111.609 -174.694 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.504 ' O ' HG22 ' A' ' 28' ' ' VAL . 25.5 mt-30 -124.47 -162.69 1.1 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.849 -0.614 . . . . 70.15 109.538 -179.636 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.504 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.3 m 56.92 13.83 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.452 1.101 . . . . 75.0 112.892 174.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 53.0 pttt -96.34 -27.6 14.87 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.021 0.438 . . . . 71.12 109.856 176.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.49 95.29 2.42 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.74 -0.664 . . . . 75.11 110.412 177.167 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.575 ' HB ' HD11 ' A' ' 9' ' ' ILE . 62.7 mt -132.21 148.12 32.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 108.707 -0.849 . . . . 74.23 108.707 177.578 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.3 m-80 -75.77 -69.04 0.51 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.031 0.443 . . . . 73.04 109.967 -178.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.602 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 87.4 m-85 -141.44 150.15 41.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.872 -0.604 . . . . 71.25 110.713 -177.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -91.54 136.6 26.53 Favored Pre-proline 0 C--N 1.323 -0.55 0 N-CA-C 109.403 -0.591 . . . . 73.11 109.403 174.237 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.88 143.41 95.86 Favored 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 122.866 2.377 . . . . 63.24 113.055 -176.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.447 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 3.6 p -70.11 84.41 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 CA-C-O 122.031 0.919 . . . . 72.31 110.643 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.447 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 35.2 t70 167.2 -27.51 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.493 -1.23 . . . . 75.53 108.766 -174.553 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.542 ' HH ' ' HB3' ' A' ' 20' ' ' TYR . 4.2 t80 -64.86 137.38 57.73 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 114.681 -1.145 . . . . 74.11 111.713 -174.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.68 ' H ' ' HD2' ' A' ' 21' ' ' ARG . 41.4 mt-10 -120.29 139.16 53.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.928 -0.578 . . . . 72.52 109.593 177.239 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.481 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 37.3 pt -126.2 162.72 29.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.121 0.486 . . . . 75.11 112.019 -178.673 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.926 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.9 tt0 -124.57 153.69 41.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.231 -0.895 . . . . 74.33 109.811 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.601 ' O ' HG11 ' A' ' 50' ' ' VAL . 97.2 m-85 -101.9 101.59 12.04 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.439 0.162 . . . . 75.13 110.996 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.541 HG13 ' HB2' ' A' ' 19' ' ' ARG . 15.5 m -97.13 170.96 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 120.861 0.363 . . . . 43.53 111.24 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.403 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 26.5 t -114.73 171.15 7.81 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.015 -0.539 . . . . 51.42 109.922 -176.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 14.4 mmm180 -72.57 110.67 7.11 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 120.798 0.332 . . . . 71.44 110.547 179.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.17 -108.83 3.02 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.717 -0.754 . . . . 62.21 112.073 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -155.11 49.07 0.56 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.185 0.517 . . . . 71.43 111.269 -177.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.574 ' HB2' ' HB2' ' A' ' 73' ' ' CYS . 17.3 mmt180 -88.31 145.71 25.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.152 -0.477 . . . . 74.21 110.072 177.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.4 mm-40 -80.62 112.88 18.4 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.005 0.431 . . . . 74.41 109.977 176.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.601 HG11 ' O ' ' A' ' 42' ' ' TYR . 3.8 p -92.67 115.73 32.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.293 0.568 . . . . 54.31 110.769 -178.471 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.7 p -100.61 97.3 5.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 122.125 0.964 . . . . 73.23 110.613 178.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.91 170.68 32.56 Favored Glycine 0 N--CA 1.441 -0.989 0 CA-C-N 114.71 -1.132 . . . . 43.0 110.284 175.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -71.96 67.0 3.26 Favored 'Trans proline' 0 C--O 1.235 0.334 0 C-N-CA 122.047 1.831 . . . . 70.42 110.529 170.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.525 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 41.5 pttt -84.75 87.3 7.3 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.552 0.691 . . . . 72.35 112.086 -170.277 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.514 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.6 p -161.05 127.05 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.556 -0.747 . . . . 74.12 109.226 171.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.57 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 28.3 mmt180 -133.15 112.85 12.09 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 110.103 -0.332 . . . . 73.32 110.103 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.426 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 38.6 ttmt -101.52 123.92 46.34 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 109.375 -0.602 . . . . 71.3 109.375 179.368 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.3 t -67.3 119.52 12.3 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.233 -0.44 . . . . 74.1 110.246 -179.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 80.1 mt -101.28 -179.93 4.18 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.897 -0.592 . . . . 75.32 110.369 -177.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.81 59.5 3.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.129 0.49 . . . . 34.01 111.15 -179.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.4 p-10 -161.78 167.4 24.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.328 -0.851 . . . . 74.35 108.786 175.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -82.83 36.93 2.66 Favored Glycine 0 CA--C 1.521 0.409 0 C-N-CA 120.699 -0.762 . . . . 74.22 113.45 -174.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.4 m -156.43 157.24 35.18 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.93 0.365 . . . . 64.31 110.176 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 87.3 m95 -83.36 179.17 7.75 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.53 -0.305 . . . . 65.43 110.464 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.8 m -56.74 -53.22 60.24 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 116.025 -0.534 . . . . 71.12 112.053 -176.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -148.03 129.66 15.03 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.514 -0.55 . . . . 71.12 109.514 -177.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 56.1 mtm -133.64 78.25 1.76 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 119.21 -0.996 . . . . 72.34 110.759 172.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -168.82 89.16 0.21 Allowed 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 106.942 -1.503 . . . . 63.14 106.942 162.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.42 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 3.6 m -139.82 121.28 9.65 Favored Pre-proline 0 C--N 1.312 -1.023 0 C-N-CA 119.837 -0.745 . . . . 74.33 111.984 -165.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 5.1 Cg_exo -77.24 58.13 6.12 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.094 2.529 . . . . 64.14 111.635 177.12 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.4 p -78.76 101.29 7.5 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.121 -0.49 . . . . 73.3 110.355 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.434 HH11 ' HD2' ' A' ' 72' ' ' ARG . 7.5 ptp85 -91.55 142.02 28.1 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.981 -0.554 . . . . 75.3 110.044 -178.123 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.574 ' HB2' ' HB2' ' A' ' 48' ' ' ARG . 2.0 p -106.65 99.91 9.46 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.427 0.632 . . . . 74.22 109.681 173.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.6 p -121.0 153.68 24.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.341 -0.845 . . . . 70.53 111.011 -170.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 65.8 ttt-85 . . . . . 0 C--O 1.245 0.862 0 CA-C-O 118.582 -0.723 . . . . 74.41 109.701 176.299 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.711 0 N-CA-C 111.842 -0.503 . . . . 72.35 111.842 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -79.02 2.21 8.49 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.793 2.329 . . . . 72.1 112.469 -177.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 7.2 p -79.46 99.54 7.27 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.625 -0.716 . . . . 75.23 111.515 -176.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 21.7 m -105.31 96.15 6.32 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.421 -0.585 . . . . 74.12 109.421 173.399 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -123.83 112.74 17.65 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.905 -0.588 . . . . 74.03 109.491 -177.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.656 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.5 163.35 33.96 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.576 -0.821 . . . . 52.24 111.759 179.05 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 83.9 m -84.03 134.29 34.63 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 110.062 -0.347 . . . . 72.14 110.062 177.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -77.39 179.37 6.49 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.172 0.51 . . . . 64.22 111.609 -176.183 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.562 HD11 ' HB ' ' A' ' 31' ' ' ILE . 59.5 mt -88.07 119.1 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.191 -0.913 . . . . 73.43 110.295 178.294 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.6 mt -82.69 131.5 33.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.853 -0.612 . . . . 53.14 109.984 178.25 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 83.7 m-70 -84.07 117.94 70.0 Favored Pre-proline 0 C--N 1.323 -0.557 0 N-CA-C 109.59 -0.522 . . . . 73.31 109.59 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.418 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 52.1 Cg_exo -54.53 110.1 0.48 Allowed 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 122.985 2.457 . . . . 62.52 112.153 -178.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 14.0 Cg_exo -69.2 -56.81 0.14 Allowed 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.924 2.416 . . . . 72.42 112.295 -176.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.428 ' HA ' ' CE3' ' A' ' 14' ' ' TRP . 6.0 t-105 -100.07 -177.8 3.65 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.868 -0.605 . . . . 72.24 109.807 -176.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -68.7 -5.05 18.15 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 120.858 0.361 . . . . 74.13 111.329 178.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.07 121.92 5.76 Favored Glycine 0 N--CA 1.444 -0.784 0 N-CA-C 110.832 -0.907 . . . . 71.54 110.832 171.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -95.72 -170.7 35.72 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.529 -0.844 . . . . 73.45 112.447 -175.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.515 HD13 HD12 ' A' ' 40' ' ' ILE . 27.3 mt -115.45 129.25 72.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.632 0.73 . . . . 70.34 111.124 -178.426 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -97.21 144.54 26.93 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.597 -1.183 . . . . 74.22 109.593 -178.071 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -115.88 -170.73 1.84 Allowed 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.346 -0.613 . . . . 74.35 109.346 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 -115.6 -53.84 2.56 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.5 -0.48 . . . . 74.3 110.309 178.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -110.19 26.43 13.66 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.727 -0.749 . . . . 71.12 112.634 -177.261 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.464 HD13 HG12 ' A' ' 28' ' ' VAL . 95.9 mt -119.86 121.91 40.12 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.888 -0.412 . . . . 52.44 109.888 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.2 t -105.71 -178.79 3.75 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.779 -0.646 . . . . 75.32 112.17 -171.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.41 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 49.6 mtp180 -57.49 125.33 22.39 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.359 -0.837 . . . . 73.32 111.603 177.671 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.421 ' O ' ' HD2' ' A' ' 29' ' ' LYS . 33.7 t70 92.91 3.96 0.06 Allowed 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.735 1.214 . . . . 54.04 110.353 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.456 ' O ' HG22 ' A' ' 28' ' ' VAL . 10.4 mm100 -94.57 -178.88 4.7 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 108.925 -0.769 . . . . 70.15 108.925 170.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.464 HG12 HD13 ' A' ' 23' ' ' LEU . 3.7 m 52.36 18.78 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 124.238 1.015 . . . . 75.0 113.064 178.707 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.421 ' HD2' ' O ' ' A' ' 26' ' ' ASP . 18.1 ptmt -82.62 -19.47 38.28 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.789 -0.449 . . . . 71.12 109.789 178.67 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -168.03 107.81 0.54 Allowed 'General case' 0 C--O 1.232 0.18 0 CA-C-N 115.602 -0.726 . . . . 75.11 110.477 175.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.562 ' HB ' HD11 ' A' ' 9' ' ' ILE . 55.6 mt -138.14 151.86 25.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.155 -0.683 . . . . 74.23 109.155 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -89.19 -66.34 0.93 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.717 0.294 . . . . 73.04 110.467 175.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.656 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 71.1 m-85 -136.66 143.06 43.25 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.827 0.346 . . . . 71.25 110.821 -178.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.416 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.9 mm? -84.8 144.0 41.45 Favored Pre-proline 0 C--N 1.323 -0.555 0 CA-C-N 115.86 -0.609 . . . . 73.11 109.654 175.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 34' ' ' LEU . 27.0 Cg_exo -62.26 154.7 61.45 Favored 'Trans proline' 0 C--O 1.235 0.352 0 C-N-CA 122.913 2.409 . . . . 63.24 112.599 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 8.4 p -61.22 140.14 19.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.658 -0.701 . . . . 72.31 111.135 -177.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 66.63 16.88 10.51 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.395 -0.82 . . . . 75.53 112.878 178.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 40.6 t80 -71.8 146.69 47.87 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.011 -0.737 . . . . 74.11 109.011 172.102 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -116.22 126.31 53.45 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.695 0.283 . . . . 72.52 111.246 -172.731 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.545 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 46.9 pt -121.72 155.99 25.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.28 -0.418 . . . . 75.11 110.316 175.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -130.73 147.0 52.34 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.381 -0.372 . . . . 74.33 110.533 -175.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.592 ' HB2' ' HB3' ' A' ' 54' ' ' LYS . 27.6 m-85 -96.44 101.85 13.54 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.326 -0.25 . . . . 75.13 110.326 178.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.9 m -113.79 170.07 4.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 121.025 0.44 . . . . 43.53 111.38 -176.122 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.668 ' HB2' HG13 ' A' ' 50' ' ' VAL . 16.7 t -95.37 127.23 41.25 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 109.282 -0.636 . . . . 51.42 109.282 177.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 47.0 ttt180 -59.41 121.94 12.73 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.853 -1.067 . . . . 71.44 111.057 -176.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 113.0 -128.3 8.34 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-N 115.845 -0.616 . . . . 62.21 111.977 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -122.17 11.91 10.22 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.247 0.546 . . . . 71.43 110.666 -179.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 19.2 mmm180 -89.34 160.18 16.99 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.616 -0.72 . . . . 74.21 109.562 177.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.612 ' HB2' ' HG2' ' A' ' 75' ' ' ARG . 39.4 mt-10 -121.22 163.94 17.73 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.996 0.427 . . . . 74.41 111.359 -174.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.668 HG13 ' HB2' ' A' ' 44' ' ' CYS . 26.8 m -128.51 150.27 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.618 -0.719 . . . . 54.31 110.093 -178.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.435 HG13 ' HD2' ' A' ' 72' ' ' ARG . 3.1 p -119.57 96.59 4.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 122.059 0.933 . . . . 73.23 109.921 171.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.24 172.8 32.83 Favored Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 114.636 -1.166 . . . . 43.0 110.925 -178.322 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -78.55 60.66 7.67 Favored 'Trans proline' 0 N--CA 1.46 -0.448 0 C-N-CA 122.097 1.865 . . . . 70.42 110.455 174.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.592 ' HB3' ' HB2' ' A' ' 42' ' ' TYR . 0.0 OUTLIER -86.31 86.39 7.34 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-N 115.333 -0.849 . . . . 72.35 112.028 -171.369 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.0 p -162.41 128.99 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 115.316 -0.856 . . . . 74.12 109.557 173.185 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.545 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 4.8 mmt85 -130.58 120.57 24.21 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.712 -0.477 . . . . 73.32 109.712 176.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 22.6 ttpp -103.61 125.31 50.05 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 109.159 -0.682 . . . . 71.3 109.159 177.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 49.6 t -64.75 149.23 49.62 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.743 0.306 . . . . 74.1 110.334 179.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 87.0 mt -116.22 -179.0 3.54 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.167 -0.47 . . . . 75.32 110.166 -178.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -81.44 -0.76 43.03 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.97 0.414 . . . . 34.01 110.539 178.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -113.58 164.65 13.39 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.399 -0.593 . . . . 74.35 109.399 175.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 6' ' ' GLY . . . -79.43 51.9 4.02 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.012 -0.613 . . . . 74.22 113.541 -173.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 28.2 m -156.62 146.87 21.29 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.92 -0.4 . . . . 64.31 109.92 177.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 89.8 m95 -82.01 177.54 8.78 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.227 -0.657 . . . . 65.43 109.227 175.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.8 p -66.59 -27.5 67.76 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 112.276 0.473 . . . . 71.12 112.276 -177.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -160.48 140.1 10.98 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.95 -0.389 . . . . 71.12 109.95 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 66.9 mtt -129.95 76.38 1.72 Allowed 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 119.814 -0.755 . . . . 72.34 110.164 165.011 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -170.61 89.18 0.14 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.335 -0.848 . . . . 63.14 108.803 161.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.2 m -148.12 102.96 3.57 Favored Pre-proline 0 C--N 1.317 -0.819 0 C-N-CA 119.936 -0.706 . . . . 74.33 111.399 -176.09 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.24 95.7 1.01 Allowed 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 122.998 2.466 . . . . 64.14 111.44 175.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 10.6 p -75.57 113.37 12.91 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.12 -0.491 . . . . 73.3 110.479 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.435 ' HD2' HG13 ' A' ' 51' ' ' VAL . 5.3 ptp180 -79.68 114.77 18.85 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.155 0.502 . . . . 75.3 111.151 -178.045 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.593 ' HA ' HG12 ' A' ' 50' ' ' VAL . 48.9 t -80.08 100.95 8.44 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.962 -0.563 . . . . 74.22 109.902 176.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.2 p -165.2 141.31 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.544 -0.753 . . . . 70.53 109.564 -178.448 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.612 ' HG2' ' HB2' ' A' ' 49' ' ' GLU . 1.5 tmm_? . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.697 -0.668 . . . . 74.41 110.248 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.775 0 N-CA-C 111.651 -0.58 . . . . 72.35 111.651 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -74.84 99.86 1.29 Allowed 'Trans proline' 0 C--O 1.236 0.386 0 C-N-CA 122.401 2.067 . . . . 72.1 111.939 177.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 20.7 p -121.48 121.56 37.79 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.332 0.587 . . . . 75.23 111.959 -177.462 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.6 m -125.59 98.67 5.67 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.941 -0.572 . . . . 74.12 109.585 169.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -126.44 109.26 12.01 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.724 -0.671 . . . . 74.03 109.286 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.723 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -157.5 159.98 30.23 Favored Glycine 0 N--CA 1.438 -1.227 0 C-N-CA 120.066 -1.064 . . . . 52.24 112.841 -176.412 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.0 m -105.9 142.58 35.38 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.531 -0.544 . . . . 72.14 109.531 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.423 HE21 ' HB2' ' A' ' 8' ' ' GLN . 2.1 pt20 -74.77 -178.4 3.66 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.247 0.546 . . . . 64.22 111.929 -175.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.502 HD11 ' HB ' ' A' ' 31' ' ' ILE . 41.8 mt -88.25 119.37 35.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.524 -0.762 . . . . 73.43 110.316 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.467 HD11 ' CD1' ' A' ' 64' ' ' TRP . 47.4 mt -76.86 142.44 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.603 -0.726 . . . . 53.14 110.825 -177.016 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -79.85 126.8 79.34 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 73.31 109.867 175.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.429 ' HA ' ' HD2' ' A' ' 13' ' ' PRO . 27.2 Cg_exo -62.73 113.65 2.06 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 122.46 2.107 . . . . 62.52 111.417 175.28 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 12' ' ' PRO . 30.4 Cg_endo -65.55 -69.19 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.491 2.127 . . . . 72.42 112.481 -177.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 19.5 t-105 -100.39 -179.3 4.07 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.108 -0.701 . . . . 72.24 109.108 178.07 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.3 mm-40 -65.54 92.47 0.14 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.577 0.703 . . . . 74.13 111.413 -177.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.558 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . -160.31 -153.78 7.07 Favored Glycine 0 N--CA 1.442 -0.94 0 CA-C-N 114.85 -1.068 . . . . 71.54 110.458 178.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.17 -171.74 31.77 Favored Glycine 0 N--CA 1.443 -0.88 0 C-N-CA 120.224 -0.989 . . . . 73.45 112.02 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.402 HD13 HD12 ' A' ' 40' ' ' ILE . 22.1 mt -128.78 134.93 63.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.681 0.753 . . . . 70.34 111.422 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.801 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 16.9 tpp180 -99.33 126.63 45.23 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 114.684 -1.144 . . . . 74.22 110.326 -178.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -99.01 -170.84 1.98 Allowed 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.218 -0.66 . . . . 74.35 109.218 175.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 43.4 ttm-85 -103.4 -65.71 0.99 Allowed 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.34 -0.544 . . . . 74.3 110.421 -179.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -110.58 47.5 1.04 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.669 -0.777 . . . . 71.12 112.116 -179.027 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 94.3 mt -135.74 104.45 5.77 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.809 0.338 . . . . 52.44 110.842 -178.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.7 t -87.14 -177.78 6.09 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.745 -0.662 . . . . 75.32 110.019 174.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.426 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 34.7 ptt180 -64.77 -173.05 0.09 Allowed 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 111.922 0.342 . . . . 73.32 111.922 -176.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.426 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 13.0 t70 68.63 -45.74 0.54 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 123.477 0.711 . . . . 54.04 110.854 -170.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.404 ' HB3' ' H ' ' A' ' 28' ' ' VAL . 25.1 mt-30 -76.42 -155.92 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.301 -0.409 . . . . 70.15 110.495 175.056 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.404 ' H ' ' HB3' ' A' ' 27' ' ' GLN . 11.2 m 49.31 27.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 124.225 1.01 . . . . 75.0 111.987 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 34.9 pttt -97.02 -28.92 13.94 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.429 -0.805 . . . . 71.12 110.652 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.12 95.66 1.63 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.378 0.609 . . . . 75.11 111.055 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.502 ' HB ' HD11 ' A' ' 9' ' ' ILE . 46.8 mt -129.33 140.45 49.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.491 -0.929 . . . . 74.23 108.491 175.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.6 m-80 -107.56 -36.68 6.39 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 120.614 -0.434 . . . . 73.04 110.513 -178.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.723 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 90.6 m-85 -135.74 109.24 7.93 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.753 0.311 . . . . 71.25 111.097 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -80.17 122.62 83.13 Favored Pre-proline 0 C--N 1.325 -0.463 0 N-CA-C 108.463 -0.94 . . . . 73.11 108.463 169.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.453 ' O ' ' HB2' ' A' ' 38' ' ' TYR . 5.9 Cg_endo -47.31 138.72 17.33 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 123.378 2.719 . . . . 63.24 113.618 -172.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.413 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 7.2 p -50.3 143.51 2.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.651 -0.704 . . . . 72.31 111.008 175.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.413 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 27.6 t70 80.16 -4.0 1.91 Allowed 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 123.685 0.794 . . . . 75.53 111.727 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.453 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 17.6 t80 -66.68 141.29 57.82 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 109.475 -0.565 . . . . 74.11 109.475 175.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.692 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.8 mt-10 -118.49 120.57 37.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.681 0.277 . . . . 72.52 111.181 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.521 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 46.3 pt -112.9 161.38 11.86 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 CA-C-N 116.335 -0.393 . . . . 75.11 110.599 177.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.801 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.0 tt0 -125.61 152.36 45.25 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.965 -0.561 . . . . 74.33 111.031 -175.699 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.623 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 25.3 m-85 -101.3 102.51 13.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.343 -0.39 . . . . 75.13 111.089 -179.289 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.3 m -103.93 166.83 2.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 116.232 -0.44 . . . . 43.53 110.365 177.01 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.561 ' HB3' ' O ' ' A' ' 48' ' ' ARG . 34.8 t -91.6 172.31 8.58 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.603 -0.517 . . . . 51.42 109.603 178.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.558 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -76.98 98.19 4.87 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.928 0.394 . . . . 71.44 110.692 -175.557 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.32 -122.02 7.44 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.975 -0.631 . . . . 62.21 113.341 172.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -105.1 32.91 3.91 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.25 0.548 . . . . 71.43 110.96 -174.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.561 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 28.4 mmm180 -113.19 144.03 43.38 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.759 -0.655 . . . . 74.21 109.351 178.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.1 mp0 -106.67 164.35 12.16 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.254 0.55 . . . . 74.41 111.696 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.56 HG13 ' HB2' ' A' ' 44' ' ' CYS . 35.3 m -129.15 152.5 37.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.349 -0.841 . . . . 54.31 110.105 -178.315 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.2 p -115.22 97.5 5.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.751 0.786 . . . . 73.23 109.922 171.312 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.0 166.75 32.6 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-N 115.68 -0.691 . . . . 43.0 112.086 178.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -74.53 65.57 5.6 Favored 'Trans proline' 0 CA--C 1.531 0.346 0 C-N-CA 122.326 2.017 . . . . 70.42 110.676 169.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.623 ' HB2' ' H ' ' A' ' 42' ' ' TYR . 16.0 pttp -77.8 89.47 4.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.297 -0.865 . . . . 72.35 111.605 -174.445 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -160.44 129.44 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.611 -0.722 . . . . 74.12 110.288 176.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.692 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 25.8 mmt180 -129.98 136.37 49.36 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.097 -0.501 . . . . 73.32 110.131 177.283 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.42 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 37.2 ttmt -123.36 124.42 42.9 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.193 -0.669 . . . . 71.3 109.193 174.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.3 t -67.41 137.5 55.97 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.148 -0.478 . . . . 74.1 110.703 -177.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 93.6 mt -103.46 -179.05 3.84 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.0 -0.546 . . . . 75.32 110.868 -176.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.4 22.41 0.56 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.08 0.467 . . . . 34.01 111.183 178.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -139.07 171.8 13.77 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.194 -0.669 . . . . 74.35 109.194 178.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -79.23 52.4 4.04 Favored Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.995 -0.621 . . . . 74.22 113.664 -174.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 11.9 t -170.48 159.52 6.95 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.898 -0.408 . . . . 64.31 109.898 177.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.467 ' CD1' HD11 ' A' ' 10' ' ' ILE . 69.9 m95 -87.06 178.97 6.76 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.228 -0.442 . . . . 65.43 110.086 -178.328 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -57.76 -35.41 70.71 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 112.622 0.601 . . . . 71.12 112.622 -176.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -149.72 144.55 26.15 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 110.193 -0.299 . . . . 71.12 110.193 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 63.3 mtt -136.39 76.56 1.6 Allowed 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.11 -0.636 . . . . 72.34 109.943 163.036 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -169.88 89.29 0.17 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.133 -0.94 . . . . 63.14 108.613 163.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.445 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 10.5 m -144.56 113.51 5.1 Favored Pre-proline 0 C--N 1.314 -0.946 0 C-N-CA 120.302 -0.559 . . . . 74.33 110.731 -175.681 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 4.3 Cg_exo -77.23 59.77 6.72 Favored 'Trans proline' 0 N--CA 1.463 -0.29 0 C-N-CA 123.415 2.743 . . . . 64.14 112.489 -178.241 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.9 p -70.37 98.83 1.47 Allowed 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.367 -0.605 . . . . 73.3 109.367 175.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 72' ' ' ARG . 5.0 ptp180 -101.69 141.34 34.7 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.635 -0.711 . . . . 75.3 111.679 -172.674 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 58.9 m -75.61 115.37 15.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.316 -0.856 . . . . 74.22 109.977 178.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.6 p -149.6 128.44 3.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.124 0.488 . . . . 70.53 110.095 -178.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.335 -0.841 . . . . 74.41 110.162 -177.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.638 0 N-CA-C 111.92 -0.472 . . . . 72.35 111.92 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -68.29 92.86 0.4 Allowed 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.877 2.384 . . . . 72.1 111.712 178.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 6.9 p -96.17 143.12 27.57 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.933 -0.576 . . . . 75.23 111.233 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 20.2 m -146.25 98.79 3.14 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.386 -0.598 . . . . 74.12 109.386 175.34 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -88.87 114.6 25.67 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.862 -0.608 . . . . 74.03 110.044 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -148.42 -179.82 24.68 Favored Glycine 0 N--CA 1.44 -1.058 0 CA-C-N 115.527 -0.76 . . . . 52.24 111.432 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.0 m -97.47 136.12 38.35 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 110.122 -0.325 . . . . 72.14 110.122 -179.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.418 HE21 ' HB2' ' A' ' 8' ' ' GLN . 1.9 pt20 -72.82 177.57 4.76 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.228 0.537 . . . . 64.22 111.464 -179.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.572 HD11 ' HB ' ' A' ' 31' ' ' ILE . 52.4 mt -88.29 116.39 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-N 115.728 -0.669 . . . . 73.43 110.172 177.179 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 41.5 mt -69.65 140.93 17.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.395 -0.82 . . . . 53.14 109.861 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 23.4 m170 -73.55 137.37 77.56 Favored Pre-proline 0 C--N 1.323 -0.544 0 N-CA-C 109.503 -0.554 . . . . 73.31 109.503 175.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -57.12 117.48 4.18 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.544 2.162 . . . . 62.52 111.57 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.465 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 83.9 Cg_endo -78.23 -146.22 0.03 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.809 2.339 . . . . 72.42 111.748 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.465 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 67.9 t-105 -56.56 148.56 19.33 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.74 -0.467 . . . . 72.24 109.74 177.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 33.9 mm-40 -44.2 101.31 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.793 1.034 . . . . 74.13 113.793 -172.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.97 -120.91 0.79 Allowed Glycine 0 N--CA 1.442 -0.908 0 CA-C-N 114.283 -1.326 . . . . 71.54 110.131 174.382 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 179.86 -171.85 43.41 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.781 -0.723 . . . . 73.45 111.644 173.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 mt -142.28 129.35 19.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.549 0.69 . . . . 70.34 110.929 177.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.742 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 5.8 tpt180 -102.09 140.67 36.07 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.821 -1.082 . . . . 74.22 108.687 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.52 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 88.7 m-85 -107.15 -173.51 2.31 Favored 'General case' 0 C--N 1.319 -0.758 0 C-N-CA 120.077 -0.649 . . . . 74.35 110.263 -178.335 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -132.89 -14.89 2.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.129 0.49 . . . . 74.3 110.521 -175.106 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -145.82 27.14 1.77 Allowed Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 111.568 -0.613 . . . . 71.12 111.568 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 89.3 mt -143.54 132.82 23.22 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.683 0.278 . . . . 52.44 110.281 -178.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 6.9 t -91.45 -178.55 5.14 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.008 -0.542 . . . . 75.32 109.999 177.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 66.5 mtm180 -73.05 -174.14 1.45 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.901 0.382 . . . . 73.32 111.843 -175.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.6 t70 51.29 33.01 9.03 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.665 0.745 . . . . 54.04 111.474 -177.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 -132.59 -164.62 1.49 Allowed 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.091 -0.504 . . . . 70.15 110.386 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.509 HG12 HD12 ' A' ' 31' ' ' ILE . 32.3 m 48.76 36.57 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 O-C-N 124.251 0.97 . . . . 75.0 112.384 177.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -78.8 -39.91 34.43 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.378 0.608 . . . . 71.12 109.413 177.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.07 89.01 1.49 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.49 -0.777 . . . . 75.11 110.644 176.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.572 ' HB ' HD11 ' A' ' 9' ' ' ILE . 52.1 mt -120.62 136.16 58.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.93 -0.767 . . . . 74.23 108.93 175.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -79.73 -49.27 12.31 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.753 0.311 . . . . 73.04 110.921 -175.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -139.37 138.03 36.23 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.186 -0.461 . . . . 71.25 111.275 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -85.96 138.5 35.0 Favored Pre-proline 0 C--N 1.321 -0.631 0 N-CA-C 108.717 -0.845 . . . . 73.11 108.717 170.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.29 145.46 97.75 Favored 'Trans proline' 0 CA--C 1.529 0.25 0 C-N-CA 122.677 2.252 . . . . 63.24 112.822 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.453 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 7.4 p -62.68 145.28 13.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.988 -0.551 . . . . 72.31 110.34 177.104 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.453 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 35.3 t70 79.18 3.44 2.34 Favored 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.776 0.672 . . . . 75.53 110.864 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.52 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 47.3 t80 -79.17 148.69 32.2 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 110.003 -0.369 . . . . 74.11 110.003 175.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.433 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 26.2 mt-10 -124.16 144.25 50.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.314 -0.403 . . . . 72.52 110.884 -176.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.619 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 25.4 pt -136.54 153.93 31.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-N 116.342 -0.39 . . . . 75.11 110.634 174.153 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.742 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.6 tt0 -116.67 155.68 28.4 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.948 -0.569 . . . . 74.33 110.179 -178.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.485 ' HE2' ' CG ' ' A' ' 56' ' ' ARG . 34.2 m-85 -104.81 101.1 10.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.595 0.236 . . . . 75.13 110.818 176.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.501 HG13 ' HB2' ' A' ' 19' ' ' ARG . 26.8 m -90.91 170.37 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 109.8 -0.444 . . . . 43.53 109.8 176.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.528 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 7.3 t -100.39 173.11 6.74 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.27 -0.641 . . . . 51.42 109.27 178.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 15.4 mmt180 -59.88 116.12 3.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.111 0.482 . . . . 71.44 110.769 178.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.21 -132.71 11.33 Favored Glycine 0 N--CA 1.446 -0.645 0 CA-C-N 115.723 -0.671 . . . . 62.21 111.996 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -114.88 34.88 4.56 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.14 0.495 . . . . 71.43 111.237 -177.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.528 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 15.0 mmm180 -89.65 120.15 30.68 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.768 -0.651 . . . . 74.21 109.371 177.2 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -78.86 147.48 33.14 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.161 0.505 . . . . 74.41 110.311 -178.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.42 HG12 ' HA ' ' A' ' 73' ' ' CYS . 21.6 m -115.24 145.95 20.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.064 -0.516 . . . . 54.31 110.824 -178.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 51' ' ' VAL . 4.5 p -104.8 96.26 4.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 122.017 0.913 . . . . 73.23 109.333 171.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.84 171.82 33.2 Favored Glycine 0 N--CA 1.441 -1.0 0 CA-C-N 115.225 -0.898 . . . . 43.0 111.748 -177.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.573 ' HG2' HG21 ' A' ' 69' ' ' THR . 64.3 Cg_endo -74.66 56.45 4.05 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.757 2.305 . . . . 70.42 110.329 171.083 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.449 ' HD2' ' CG ' ' A' ' 41' ' ' GLU . 43.7 pttt -77.83 86.2 4.08 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.32 -0.855 . . . . 72.35 111.717 -172.292 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -162.47 128.39 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.264 -0.88 . . . . 74.12 109.928 172.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.619 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 24.5 mmt180 -117.85 119.63 35.44 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 108.91 -0.774 . . . . 73.32 108.91 174.439 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.407 ' HB3' ' CG2' ' A' ' 65' ' ' THR . 37.2 ttmt -104.62 120.6 41.69 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.455 -0.572 . . . . 71.3 109.455 178.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 16.5 t -78.54 133.19 37.38 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.923 0.392 . . . . 74.1 109.995 -179.386 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 85.4 mt -117.05 -178.61 3.48 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.013 -0.539 . . . . 75.32 110.85 -173.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.26 -9.29 58.72 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.127 0.489 . . . . 34.01 110.518 178.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -94.44 151.64 19.22 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.214 -0.661 . . . . 74.35 109.214 172.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -77.27 54.02 3.54 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 121.09 -0.576 . . . . 74.22 113.762 -173.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 67.4 p -166.98 154.02 8.8 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.403 -0.592 . . . . 64.31 109.403 177.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.538 ' HB2' ' HB3' ' A' ' 67' ' ' MET . 84.3 m95 -75.02 165.83 24.63 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.802 -0.444 . . . . 65.43 109.802 178.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.407 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 0.9 OUTLIER -50.57 -42.78 55.95 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 113.052 0.76 . . . . 71.12 113.052 -176.915 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -157.93 74.88 0.74 Allowed 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.574 -0.528 . . . . 71.12 109.574 177.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . 0.538 ' HB3' ' HB2' ' A' ' 64' ' ' TRP . 22.3 ptt? -88.7 80.24 7.3 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 118.837 -1.145 . . . . 72.34 111.497 -173.496 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -167.96 88.95 0.27 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.271 -1.331 . . . . 63.14 107.757 163.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.573 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.2 OUTLIER -158.43 115.77 1.74 Allowed Pre-proline 0 C--N 1.317 -0.846 0 C-N-CA 120.461 -0.496 . . . . 74.33 111.221 -169.35 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -81.52 124.91 4.84 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.497 2.131 . . . . 64.14 111.807 174.364 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 12.6 p -81.01 133.29 35.46 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.992 0.425 . . . . 73.3 110.085 177.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 38.3 mtp180 -96.34 99.26 10.96 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.312 -0.404 . . . . 75.3 111.364 -171.353 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.42 ' HA ' HG12 ' A' ' 50' ' ' VAL . 8.7 m -69.12 101.98 1.56 Allowed 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.799 -0.445 . . . . 74.22 109.799 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 94.7 t -136.41 120.15 23.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 121.026 0.441 . . . . 70.53 111.805 -173.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 67.8 mtt180 . . . . . 0 C--O 1.244 0.797 0 CA-C-N 115.627 -0.715 . . . . 74.41 109.694 170.892 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.822 0 N-CA-C 111.967 -0.453 . . . . 72.35 111.967 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -60.04 113.38 1.63 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.694 2.262 . . . . 72.1 111.55 176.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 23.3 p -108.97 138.11 45.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.991 0.424 . . . . 75.23 111.598 -176.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.1 m -105.74 99.49 9.09 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.882 -0.784 . . . . 74.12 108.882 172.487 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -95.58 109.09 21.38 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.176 0.512 . . . . 74.03 110.949 -174.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.517 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -161.21 -179.6 36.04 Favored Glycine 0 N--CA 1.443 -0.899 0 CA-C-N 115.299 -0.864 . . . . 52.24 111.323 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 15.0 m -99.12 145.1 27.52 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 109.912 -0.403 . . . . 72.14 109.912 178.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -88.36 -177.82 5.74 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.668 0.271 . . . . 64.22 110.522 179.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.0 mt -87.95 123.78 40.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.16 0.505 . . . . 73.43 110.041 178.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.449 HD11 ' CD1' ' A' ' 64' ' ' TRP . 9.8 mt -79.93 150.53 4.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.782 -0.645 . . . . 53.14 110.347 -178.347 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 16.2 p80 -62.54 141.07 96.81 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 109.525 -0.546 . . . . 73.31 109.525 172.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.45 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 23.5 Cg_exo -64.8 149.47 89.58 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.459 2.106 . . . . 62.52 111.715 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.461 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 3.0 Cg_exo -76.88 -132.04 0.01 OUTLIER 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.979 2.453 . . . . 72.42 110.998 174.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.461 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 3.8 t-105 -75.38 -179.57 4.61 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.433 -0.58 . . . . 72.24 109.433 176.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -43.95 101.05 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 112.742 0.645 . . . . 74.13 112.742 -176.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 174.74 -143.71 7.0 Favored Glycine 0 N--CA 1.441 -1.028 0 N-CA-C 110.869 -0.893 . . . . 71.54 110.869 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.74 -169.97 35.94 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.655 -0.783 . . . . 73.45 112.174 177.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.2 mt -118.81 125.39 74.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 121.364 0.602 . . . . 70.34 110.891 179.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.3 tpt180 -99.79 114.27 27.31 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.129 -0.941 . . . . 74.22 109.077 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.499 ' HA ' HG22 ' A' ' 40' ' ' ILE . 88.6 m-85 -76.75 -172.4 2.24 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.588 -0.278 . . . . 74.35 110.905 -175.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -87.49 -40.61 14.17 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.15 0.5 . . . . 74.3 110.417 -174.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -152.94 60.01 0.4 Allowed Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.881 -0.676 . . . . 71.12 112.208 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.471 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 76.1 mt -135.03 128.98 33.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.121 0.486 . . . . 52.44 110.998 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.2 t -96.15 -176.4 3.66 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.373 -0.83 . . . . 75.32 110.296 176.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.498 ' C ' ' H ' ' A' ' 27' ' ' GLN . 22.1 mmt180 -60.7 -172.08 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 116.351 -0.386 . . . . 73.32 111.512 178.31 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.425 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 23.9 t70 69.4 -35.86 0.32 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.191 0.597 . . . . 54.04 111.447 -175.399 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.529 ' O ' HG22 ' A' ' 28' ' ' VAL . 13.7 mt-30 -90.48 -169.08 2.28 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.806 -0.634 . . . . 70.15 111.067 -178.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.8 m 59.45 11.88 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 125.073 1.349 . . . . 75.0 112.754 173.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.403 ' HG2' ' H ' ' A' ' 29' ' ' LYS . 36.3 pttt -77.87 -27.64 49.76 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.28 0.562 . . . . 71.12 110.341 176.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.13 91.16 0.46 Allowed 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.442 -0.799 . . . . 75.11 110.339 177.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 57.9 mt -109.94 125.84 67.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 108.973 -0.751 . . . . 74.23 108.973 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -79.67 -46.45 17.11 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.138 -0.483 . . . . 73.04 110.187 -175.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.517 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 95.7 m-85 -146.47 121.31 9.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.992 -0.549 . . . . 71.25 111.127 -178.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -78.57 151.91 77.69 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.191 -0.459 . . . . 73.11 109.834 173.297 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -64.82 160.35 41.24 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.618 2.212 . . . . 63.24 112.449 177.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 14.3 p -71.06 145.94 12.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.334 -0.394 . . . . 72.31 110.938 -177.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 38.3 t70 69.93 9.61 7.17 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 123.65 0.78 . . . . 75.53 111.245 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.471 ' OH ' ' HG ' ' A' ' 23' ' ' LEU . 25.3 t80 -72.03 139.32 48.47 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 108.719 -0.845 . . . . 74.11 108.719 174.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.606 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.9 mt-10 -126.38 154.66 43.27 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.805 0.336 . . . . 72.52 111.007 -175.46 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.499 HG22 ' HA ' ' A' ' 20' ' ' TYR . 24.3 pt -133.7 162.72 39.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.418 0 CA-C-N 116.06 -0.518 . . . . 75.11 111.776 -177.156 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.453 ' HG3' ' HD2' ' A' ' 54' ' ' LYS . 78.1 tt0 -122.37 149.08 44.28 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.518 -0.765 . . . . 74.33 110.14 177.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -95.5 102.5 14.31 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.201 -0.454 . . . . 75.13 110.152 177.214 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 16.8 m -101.18 144.1 13.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.903 0.382 . . . . 43.53 111.013 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.438 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 28.9 t -91.46 176.74 6.44 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.264 -0.643 . . . . 51.42 109.264 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.95 129.68 41.44 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.63 0.252 . . . . 71.44 111.492 -178.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 62.84 -131.71 43.29 Favored Glycine 0 N--CA 1.45 -0.427 0 CA-C-N 115.855 -0.611 . . . . 62.21 112.237 178.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -98.5 83.81 3.08 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.739 0.78 . . . . 71.43 110.4 176.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.642 HH11 ' HB3' ' A' ' 75' ' ' ARG . 30.2 mmt180 -145.2 132.52 20.62 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.182 -0.917 . . . . 74.21 109.943 178.307 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.2 mp0 -102.21 152.53 20.93 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.049 -0.523 . . . . 74.41 110.548 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.577 HG12 ' HA ' ' A' ' 73' ' ' CYS . 34.7 m -114.58 120.52 64.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.68 -0.691 . . . . 54.31 109.257 171.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.418 ' O ' HG13 ' A' ' 51' ' ' VAL . 6.3 p -83.71 94.24 3.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 122.503 1.144 . . . . 73.23 109.617 178.16 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.22 172.53 33.47 Favored Glycine 0 N--CA 1.441 -0.991 0 CA-C-N 114.34 -1.3 . . . . 43.0 110.764 -177.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -73.3 58.59 3.68 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.225 1.95 . . . . 70.42 110.646 173.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.453 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 42.3 pttt -78.09 85.6 4.29 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-O 121.691 0.758 . . . . 72.35 111.46 -174.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.48 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 6.1 p -162.68 128.61 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.227 -0.897 . . . . 74.12 109.015 171.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.606 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 20.4 mmt180 -130.6 124.42 31.71 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.591 -0.522 . . . . 73.32 109.591 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.475 ' O ' HG23 ' A' ' 65' ' ' THR . 23.7 ttmm -99.68 131.52 45.61 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.875 -0.417 . . . . 71.3 109.875 178.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 48.1 t -80.2 137.64 36.71 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 109.638 -0.504 . . . . 74.1 109.638 176.206 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 89.0 mt -115.25 -178.96 3.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.41 -0.359 . . . . 75.32 110.322 -178.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -66.42 -27.48 67.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.133 0.492 . . . . 34.01 110.61 178.148 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -79.55 150.92 30.96 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.457 -0.571 . . . . 74.35 109.457 174.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -75.6 66.03 2.41 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 121.033 -0.603 . . . . 74.22 113.528 -175.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 13.8 t -174.19 149.09 1.38 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.674 -0.491 . . . . 64.31 109.674 175.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.449 ' CD1' HD11 ' A' ' 10' ' ' ILE . 64.9 m95 -77.27 157.4 30.8 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.199 -0.667 . . . . 65.43 109.199 177.313 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.475 HG23 ' O ' ' A' ' 57' ' ' LYS . 16.0 p -50.71 -46.72 59.09 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 113.319 0.859 . . . . 71.12 113.319 -173.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -128.52 118.17 22.57 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.704 -0.226 . . . . 71.12 110.495 -173.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 55.5 mtt -125.76 78.31 1.73 Allowed 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 119.346 -0.941 . . . . 72.34 110.741 168.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -170.26 89.05 0.15 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.618 -0.719 . . . . 63.14 109.143 163.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 60.3 m -160.29 107.88 1.38 Allowed Pre-proline 0 C--N 1.321 -0.645 0 CA-C-O 120.874 0.368 . . . . 74.33 111.463 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -76.92 91.92 1.14 Allowed 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.175 1.917 . . . . 64.14 110.943 170.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 16.8 p -70.42 110.9 5.6 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.803 -0.635 . . . . 73.3 110.577 -177.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 21.4 ptt-85 -79.26 119.21 22.01 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.381 0.61 . . . . 75.3 111.137 -176.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.577 ' HA ' HG12 ' A' ' 50' ' ' VAL . 42.5 t -80.37 110.14 15.53 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.363 -0.835 . . . . 74.22 109.502 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.7 p -155.98 130.45 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.375 0.607 . . . . 70.53 111.521 -174.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.642 ' HB3' HH11 ' A' ' 48' ' ' ARG . 22.3 ttm180 . . . . . 0 C--O 1.247 0.934 0 CA-C-N 115.601 -0.727 . . . . 74.41 109.095 175.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.753 0 N-CA-C 111.861 -0.496 . . . . 72.35 111.861 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -78.96 33.55 0.49 Allowed 'Trans proline' 0 CA--C 1.531 0.342 0 C-N-CA 123.085 2.523 . . . . 72.1 113.094 -178.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 2.5 p -79.47 162.3 25.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.63 -0.259 . . . . 75.23 110.713 178.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.4 m -124.54 98.99 5.97 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.205 0.526 . . . . 74.12 111.602 -175.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -118.86 100.23 7.25 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.674 -0.694 . . . . 74.03 109.339 173.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.74 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -158.89 147.33 14.74 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.039 -1.077 . . . . 52.24 113.231 -177.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.6 m -83.47 157.8 22.28 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.87 -0.418 . . . . 72.14 109.87 176.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -84.85 -178.23 6.79 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.124 0.488 . . . . 64.22 111.265 179.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.66 HD11 ' H ' ' A' ' 31' ' ' ILE . 56.5 mt -87.05 117.05 30.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.617 -0.72 . . . . 73.43 109.371 174.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.9 pt -90.18 149.23 4.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.528 -0.76 . . . . 53.14 110.665 -178.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . 0.431 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 19.9 m-70 -88.32 143.47 32.61 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 116.246 -0.434 . . . . 73.31 111.24 -175.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 16.7 Cg_exo -67.82 135.06 34.22 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 123.053 2.502 . . . . 62.52 111.963 178.056 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 82.4 Cg_endo -88.07 -150.22 0.04 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 123.002 2.468 . . . . 72.42 112.475 179.525 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.0 t-105 -63.48 -177.59 0.22 Allowed 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 115.812 -0.631 . . . . 72.24 110.697 178.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -38.82 100.33 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 123.876 0.87 . . . . 74.13 112.928 -173.065 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.85 -172.43 43.75 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 114.989 -1.005 . . . . 71.54 110.722 -178.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -156.91 -171.12 22.64 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.747 -0.74 . . . . 73.45 112.07 179.183 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.3 mt -129.7 137.37 56.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.381 0.61 . . . . 70.34 111.24 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.417 HH11 ' HD2' ' A' ' 19' ' ' ARG . 0.9 OUTLIER -117.08 119.14 34.34 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.164 -0.925 . . . . 74.22 109.776 -177.612 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.424 ' HA ' HG22 ' A' ' 40' ' ' ILE . 95.0 m-85 -84.69 -171.7 3.78 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.749 0.309 . . . . 74.35 110.623 -178.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.1 ttm180 -93.26 -55.85 3.16 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.985 0.421 . . . . 74.3 109.993 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -144.89 67.74 0.42 Allowed Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.753 -0.737 . . . . 71.12 112.325 -178.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 76.5 mt -139.07 118.33 12.72 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.995 -0.372 . . . . 52.44 109.995 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.2 t -81.0 178.9 8.13 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.297 -0.41 . . . . 75.32 110.189 178.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.429 ' C ' ' H ' ' A' ' 27' ' ' GLN . 95.2 mtt180 -78.09 -171.92 2.54 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 120.491 0.186 . . . . 73.32 111.343 -175.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.402 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 11.6 t70 67.38 -42.79 0.44 Allowed 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 123.305 0.642 . . . . 54.04 110.885 -168.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' HG22 ' A' ' 28' ' ' VAL . 21.0 mt-30 -70.57 -170.34 0.4 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.217 -0.447 . . . . 70.15 110.137 173.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.9 m 57.9 9.38 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.272 1.029 . . . . 75.0 112.134 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 52.7 pttt -83.49 -19.98 34.8 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.789 -0.819 . . . . 71.12 108.789 172.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.14 102.05 2.11 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 114.885 -1.052 . . . . 75.11 110.026 177.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.66 ' H ' HD11 ' A' ' 9' ' ' ILE . 57.3 mt -120.83 144.72 28.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 109.031 -0.729 . . . . 74.23 109.031 176.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -88.69 -65.61 1.0 Allowed 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.94 -0.393 . . . . 73.04 109.94 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.74 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 56.0 m-85 -143.42 140.84 30.61 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.239 -0.437 . . . . 71.25 110.487 177.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.463 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.7 mm? -82.82 132.23 52.01 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 109.331 -0.618 . . . . 73.11 109.331 174.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -58.24 139.34 90.14 Favored 'Trans proline' 0 C--O 1.236 0.382 0 C-N-CA 122.615 2.21 . . . . 63.24 112.227 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 p -67.3 84.59 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 CA-C-O 121.905 0.86 . . . . 72.31 111.272 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.6 t70 165.59 -30.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.179 -1.373 . . . . 75.53 108.925 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.405 ' HH ' ' HB3' ' A' ' 20' ' ' TYR . 9.3 t80 -57.22 138.18 55.0 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.895 -1.048 . . . . 74.11 111.277 -174.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.51 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 18.9 mt-10 -122.54 139.38 53.96 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.511 -0.768 . . . . 72.52 110.39 -176.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.493 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 35.5 pt -128.17 156.95 40.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.354 -0.384 . . . . 75.11 110.856 178.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -119.83 151.58 38.62 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.016 -0.538 . . . . 74.33 110.508 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -99.05 102.47 14.19 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.072 -0.513 . . . . 75.13 111.052 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.4 m -96.82 163.82 2.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 N-CA-C 110.028 -0.36 . . . . 43.53 110.028 175.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.574 ' HB2' HG13 ' A' ' 50' ' ' VAL . 31.5 t -89.68 175.11 7.38 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.457 -0.572 . . . . 51.42 109.457 178.127 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.66 119.2 19.37 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.95 0.405 . . . . 71.44 110.797 -174.5 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.06 -100.27 2.65 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.846 -0.616 . . . . 62.21 112.863 174.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -133.81 21.8 3.88 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.987 0.422 . . . . 71.43 111.233 -174.077 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.562 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 11.4 mmt180 -96.35 142.88 27.95 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.168 -0.469 . . . . 74.21 110.972 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.824 ' HB2' ' HD2' ' A' ' 75' ' ' ARG . 2.2 mp0 -94.37 153.78 17.81 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.125 -0.489 . . . . 74.41 110.867 177.071 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.574 HG13 ' HB2' ' A' ' 44' ' ' CYS . 28.0 m -118.49 151.31 20.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.688 -0.687 . . . . 54.31 109.882 176.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.9 p -114.9 96.19 4.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.913 0.863 . . . . 73.23 110.008 173.215 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.11 170.91 33.31 Favored Glycine 0 N--CA 1.445 -0.711 0 CA-C-N 115.2 -0.909 . . . . 43.0 111.602 179.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -73.59 60.01 4.17 Favored 'Trans proline' 0 CA--C 1.531 0.353 0 C-N-CA 122.482 2.121 . . . . 70.42 110.88 170.449 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 44.3 pttt -77.23 89.44 3.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.583 -0.735 . . . . 72.35 112.392 -171.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 14.9 p -160.8 135.11 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.892 -0.595 . . . . 74.12 109.605 171.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.51 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 24.6 mmt180 -131.12 120.8 23.88 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.41 -0.359 . . . . 73.32 110.537 177.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.464 ' HB3' ' CG2' ' A' ' 65' ' ' THR . 39.4 ttmt -102.73 129.63 49.42 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 109.094 -0.706 . . . . 71.3 109.094 174.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 45.6 t -67.92 143.51 55.64 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.469 -0.332 . . . . 74.1 110.327 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.451 HD11 ' HA ' ' A' ' 65' ' ' THR . 88.6 mt -110.89 -178.38 3.46 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.369 -0.378 . . . . 75.32 110.615 -176.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -79.82 14.56 1.7 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.974 0.416 . . . . 34.01 111.161 178.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.478 ' ND2' ' H ' ' A' ' 63' ' ' SER . 4.6 p-10 -141.44 -178.62 5.71 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.772 -0.649 . . . . 74.35 109.62 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -66.04 -29.68 75.47 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 114.771 0.668 . . . . 74.22 114.771 -171.252 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.478 ' H ' ' ND2' ' A' ' 61' ' ' ASN . 78.5 p -93.23 163.27 13.68 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.473 0.636 . . . . 64.31 111.458 -175.659 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -92.89 -179.86 5.25 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.877 -0.601 . . . . 65.43 110.005 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.464 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 3.2 p -49.59 -69.72 0.11 Allowed 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 113.558 0.947 . . . . 71.12 113.558 -174.169 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -133.21 48.59 2.38 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.649 -0.501 . . . . 71.12 109.649 -177.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 28.0 ttt -80.65 81.92 6.78 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.382 -0.927 . . . . 72.34 111.831 -170.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -166.65 87.6 0.32 Allowed 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 106.72 -1.585 . . . . 63.14 106.72 158.196 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.404 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 1.5 m -157.79 113.41 1.81 Allowed Pre-proline 0 C--N 1.316 -0.889 0 CA-C-N 116.284 -0.416 . . . . 74.33 110.051 -168.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 16.8 Cg_exo -66.68 97.6 0.39 Allowed 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.61 2.206 . . . . 64.14 112.164 179.169 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.1 p -78.73 101.63 7.66 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.212 -0.662 . . . . 73.3 109.212 173.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -78.94 126.58 30.88 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.315 0.579 . . . . 75.3 111.091 -171.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.556 ' HA ' HG12 ' A' ' 50' ' ' VAL . 41.8 t -82.03 98.74 8.77 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.499 -0.773 . . . . 74.22 109.865 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.3 p -176.98 152.44 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.992 -0.744 . . . . 70.53 108.992 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.824 ' HD2' ' HB2' ' A' ' 49' ' ' GLU . 2.5 ptm180 . . . . . 0 C--O 1.245 0.859 0 CA-C-O 119.168 -0.444 . . . . 74.41 110.367 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.668 0 N-CA-C 111.23 -0.748 . . . . 72.35 111.23 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -61.65 141.83 92.32 Favored 'Trans proline' 0 N--CA 1.462 -0.357 0 C-N-CA 122.296 1.997 . . . . 72.1 111.1 177.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 52.5 p -78.57 99.45 6.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.102 0.477 . . . . 75.23 110.544 -179.556 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.4 m -101.23 116.56 33.08 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.758 -0.656 . . . . 74.12 110.209 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . 0.465 ' CD ' ' H ' ' A' ' 5' ' ' GLU . 0.9 OUTLIER -70.03 107.57 3.68 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.833 -0.803 . . . . 74.03 108.833 175.863 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.822 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -157.63 126.28 1.7 Allowed Glycine 0 N--CA 1.443 -0.847 0 C-N-CA 120.288 -0.958 . . . . 52.24 113.035 -176.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 64.8 m -90.59 152.32 20.94 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.546 -0.539 . . . . 72.14 109.546 175.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.419 HE21 ' HB2' ' A' ' 8' ' ' GLN . 1.9 pt20 -81.77 -178.02 6.81 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.916 0.389 . . . . 64.22 111.233 -178.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.598 HD11 ' HB ' ' A' ' 31' ' ' ILE . 46.2 mt -87.39 121.6 38.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.873 -0.603 . . . . 73.43 110.691 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 56.9 mt -73.86 114.21 13.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.03 -0.532 . . . . 53.14 109.581 175.051 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 31.9 m-70 -75.44 129.08 82.95 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 110.09 -0.337 . . . . 73.31 110.09 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.511 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 7.3 Cg_endo -49.19 118.77 3.83 Favored 'Trans proline' 0 C--N 1.349 0.556 0 C-N-CA 123.447 2.765 . . . . 62.52 112.429 -177.222 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.511 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 4.0 Cg_exo -76.38 -84.03 0.0 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 122.996 2.464 . . . . 72.42 112.325 -177.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.7 t-105 -100.93 -178.36 3.73 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.228 -0.442 . . . . 72.24 109.925 -177.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -47.68 102.31 0.03 OUTLIER 'General case' 0 C--O 1.234 0.275 0 O-C-N 123.791 0.682 . . . . 74.13 112.242 177.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.07 -157.14 28.97 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.352 -0.84 . . . . 71.54 111.099 -179.211 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -161.13 -171.08 26.63 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 111.338 -0.705 . . . . 73.45 111.338 177.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 21.5 mt -127.77 129.43 70.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.669 0.747 . . . . 70.34 111.363 -179.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.895 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 5.1 tpt180 -93.62 132.75 37.64 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 114.438 -1.256 . . . . 74.22 109.486 -179.021 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.515 ' HB3' ' HH ' ' A' ' 38' ' ' TYR . 97.1 m-85 -106.55 -171.28 1.86 Allowed 'General case' 0 C--N 1.32 -0.678 0 C-N-CA 120.845 -0.342 . . . . 74.35 110.735 -178.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.411 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 19.1 ttt-85 -114.68 -51.69 2.73 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.944 0.402 . . . . 74.3 110.264 -174.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -136.83 30.57 2.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 71.12 112.807 -177.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 80.3 mt -109.72 129.7 55.59 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 122.595 -0.356 . . . . 52.44 110.255 177.544 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.4 t -80.33 -179.81 7.31 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.112 -0.495 . . . . 75.32 110.1 178.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.404 ' C ' ' H ' ' A' ' 27' ' ' GLN . 38.3 ptt180 -73.48 -174.16 1.6 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.325 -0.398 . . . . 73.32 110.752 -178.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 21.8 t70 67.32 -44.5 0.46 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.859 0.864 . . . . 54.04 111.619 -177.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.637 ' O ' HG22 ' A' ' 28' ' ' VAL . 28.1 mt-30 -68.03 -163.62 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 122.896 0.478 . . . . 70.15 111.554 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.637 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.0 m 61.11 13.93 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 124.538 1.135 . . . . 75.0 111.347 -177.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -90.99 -29.02 17.63 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.342 -0.614 . . . . 71.12 109.342 176.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.65 89.68 1.27 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.714 -0.676 . . . . 75.11 111.003 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.598 ' HB ' HD11 ' A' ' 9' ' ' ILE . 57.3 mt -126.66 134.28 66.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 108.818 -0.808 . . . . 74.23 108.818 175.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -77.54 -56.42 4.54 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.815 0.34 . . . . 73.04 111.043 -177.093 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.822 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 65.9 m-85 -136.33 145.61 45.63 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.082 0.467 . . . . 71.25 111.375 -175.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.594 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.7 mm? -103.8 139.11 19.8 Favored Pre-proline 0 C--N 1.323 -0.564 0 N-CA-C 108.993 -0.743 . . . . 73.11 108.993 170.223 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -58.89 159.76 20.28 Favored 'Trans proline' 0 N--CA 1.476 0.5 0 C-N-CA 123.203 2.602 . . . . 63.24 113.315 -176.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.4 ' HB ' ' HB2' ' A' ' 5' ' ' GLU . 9.9 p -71.64 2.75 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 CA-C-O 121.648 0.737 . . . . 72.31 111.473 -176.7 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -134.4 92.78 2.97 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.093 0.473 . . . . 75.53 109.798 170.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.589 ' O ' ' HA ' ' A' ' 57' ' ' LYS . 20.2 t80 -157.18 135.02 10.86 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.633 -0.712 . . . . 74.11 109.301 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 38.9 mt-10 -113.4 130.29 56.33 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.242 0.339 . . . . 72.52 110.784 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.574 HG12 ' HB2' ' A' ' 56' ' ' ARG . 43.6 pt -121.68 158.09 25.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.369 -0.378 . . . . 75.11 110.89 175.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.895 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 41.3 tt0 -127.19 154.36 44.9 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.868 -0.605 . . . . 74.33 110.598 -177.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 65.3 m-85 -100.03 102.29 13.6 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.328 -0.396 . . . . 75.13 110.612 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.3 m -109.2 164.78 5.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.371 -0.377 . . . . 43.53 111.202 -178.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.512 ' HB2' ' HB2' ' A' ' 48' ' ' ARG . 86.3 m -110.85 179.32 4.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.1 -0.5 . . . . 51.42 110.388 177.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -76.92 102.36 6.35 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.071 0.463 . . . . 71.44 110.375 178.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.35 -166.81 25.76 Favored Glycine 0 N--CA 1.445 -0.704 0 N-CA-C 111.05 -0.82 . . . . 62.21 111.05 -176.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -82.59 77.66 9.32 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.526 0.679 . . . . 71.43 111.281 178.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.512 ' HB2' ' HB2' ' A' ' 44' ' ' CYS . 14.1 mtm-85 -127.87 118.34 23.46 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.754 -0.832 . . . . 74.21 108.754 176.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -88.2 154.11 20.7 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.064 -0.516 . . . . 74.41 111.099 -172.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.588 HG12 ' HA ' ' A' ' 73' ' ' CYS . 27.2 m -119.23 130.77 73.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.798 -0.637 . . . . 54.31 109.969 178.48 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.0 p -95.04 94.08 4.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-O 122.217 1.008 . . . . 73.23 109.857 175.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -157.26 170.9 34.51 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 114.223 -1.353 . . . . 43.0 110.514 177.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.514 ' HG2' HG21 ' A' ' 69' ' ' THR . 55.9 Cg_endo -75.19 77.88 3.08 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.621 1.547 . . . . 70.42 110.536 168.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.603 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 43.6 pttt -86.84 88.48 7.69 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.656 0.741 . . . . 72.35 111.048 -174.392 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.508 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 6.8 p -160.19 128.99 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.496 -0.775 . . . . 74.12 109.814 176.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.574 ' HB2' HG12 ' A' ' 40' ' ' ILE . 23.1 mmt180 -137.12 125.65 23.61 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.924 -0.58 . . . . 73.32 110.028 178.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 38' ' ' TYR . 35.4 ttmt -124.6 137.4 54.39 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 108.775 -0.824 . . . . 71.3 108.775 168.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.5 t -67.27 142.86 56.75 Favored 'General case' 0 C--N 1.323 -0.575 0 O-C-N 123.337 0.398 . . . . 74.1 110.279 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.9 mt -119.46 -178.1 3.52 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.141 -0.481 . . . . 75.32 110.228 -177.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -75.62 -4.98 43.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.066 0.46 . . . . 34.01 110.884 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -99.62 163.38 12.52 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.774 -0.648 . . . . 74.35 109.422 173.535 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -78.53 47.96 3.09 Favored Glycine 0 CA--C 1.521 0.449 0 C-N-CA 120.917 -0.659 . . . . 74.22 113.678 -174.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.0 t -165.9 170.55 13.64 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.259 -0.645 . . . . 64.31 109.259 178.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 61.1 m95 -87.44 178.12 6.91 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.836 -0.431 . . . . 65.43 109.836 -177.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.401 HG23 ' O ' ' A' ' 57' ' ' LYS . 2.9 p -49.86 -50.8 44.3 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 113.394 0.887 . . . . 71.12 113.394 -173.064 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -148.25 66.08 1.08 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.569 0.224 . . . . 71.12 110.445 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 60.1 ttp -87.1 79.83 8.53 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 118.921 -1.112 . . . . 72.34 110.934 -176.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -169.31 89.67 0.2 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.446 -1.252 . . . . 63.14 107.72 162.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.514 HG21 ' HG2' ' A' ' 53' ' ' PRO . 1.4 m -151.39 127.29 5.02 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 120.314 -0.554 . . . . 74.33 111.339 -170.354 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -78.61 93.95 1.08 Allowed 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.574 2.182 . . . . 64.14 112.159 175.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 9.9 p -92.9 114.61 27.22 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.081 -0.509 . . . . 73.3 110.782 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.7 ptp85 -94.28 128.67 40.9 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.056 -0.52 . . . . 75.3 111.045 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.588 ' HA ' HG12 ' A' ' 50' ' ' VAL . 18.2 t -89.44 112.2 23.28 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.001 -0.545 . . . . 74.22 109.748 179.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.97 115.03 14.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.478 -0.328 . . . . 70.53 111.168 -174.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.4 ' HA ' ' HD2' ' A' ' 75' ' ' ARG . 12.0 tpt180 . . . . . 0 C--O 1.244 0.795 0 CA-C-O 118.479 -0.772 . . . . 74.41 109.723 174.16 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.798 0 N-CA-C 111.809 -0.517 . . . . 72.35 111.809 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -78.62 113.82 3.37 Favored 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.911 2.407 . . . . 72.1 112.2 178.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 3.1 p -144.44 153.59 42.07 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.82 0.343 . . . . 75.23 110.845 178.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 28.1 m -149.07 104.48 3.43 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.683 -0.488 . . . . 74.12 109.683 177.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -76.19 105.41 7.22 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.106 -0.497 . . . . 74.03 109.795 -179.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.727 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -149.53 143.1 10.4 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.624 -0.798 . . . . 52.24 112.529 -178.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 69.2 m -92.47 151.83 20.0 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 110.213 -0.292 . . . . 72.14 110.213 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.452 ' H ' ' HG3' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -87.15 -179.43 6.45 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.633 -0.258 . . . . 64.22 111.521 -177.683 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 40.4 mt -88.61 112.57 24.13 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.246 -0.434 . . . . 73.43 111.294 -171.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 38.7 mt -70.82 146.12 12.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.74 -0.663 . . . . 53.14 110.443 179.139 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . 0.43 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 72.2 m-70 -88.24 141.85 31.23 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 116.524 -0.307 . . . . 73.31 110.39 177.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 12.8 Cg_exo -71.4 122.08 8.32 Favored 'Trans proline' 0 CA--C 1.529 0.253 0 C-N-CA 122.934 2.423 . . . . 62.52 111.644 176.071 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 59.8 Cg_endo -91.19 -94.73 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 123.008 2.472 . . . . 72.42 112.782 -177.6 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -89.99 -176.0 4.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.088 -0.708 . . . . 72.24 109.088 178.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -57.48 -16.21 9.02 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 112.11 0.411 . . . . 74.13 112.11 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.38 91.41 0.3 Allowed Glycine 0 N--CA 1.448 -0.502 0 N-CA-C 110.648 -0.981 . . . . 71.54 110.648 167.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -91.16 -170.21 42.58 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 121.168 -0.539 . . . . 73.45 112.982 -173.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -115.55 136.23 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 CA-C-O 121.72 0.772 . . . . 70.34 112.083 -174.632 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.786 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 15.4 tpt180 -116.4 145.8 42.98 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.182 -1.372 . . . . 74.22 109.049 -178.047 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 68.6 m-85 -108.95 -172.89 2.14 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.805 -0.442 . . . . 74.35 109.805 178.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 25.6 mtm180 -98.41 -38.48 9.2 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.57 -0.452 . . . . 74.3 110.885 -178.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -160.56 52.95 0.34 Allowed Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.644 -0.789 . . . . 71.12 112.467 178.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 93.7 mt -116.73 115.94 26.57 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.942 0.401 . . . . 52.44 110.352 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.6 t -80.79 -179.2 7.16 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.656 -0.702 . . . . 75.32 110.307 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.5 ' C ' ' H ' ' A' ' 27' ' ' GLN . 39.5 mmt180 -67.4 -174.99 0.44 Allowed 'General case' 0 C--O 1.233 0.215 0 CA-C-O 120.684 0.278 . . . . 73.32 111.308 -176.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 23.4 t70 65.64 -34.26 0.19 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.638 0.775 . . . . 54.04 112.172 -175.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.5 ' H ' ' C ' ' A' ' 25' ' ' ARG . 20.6 mt-30 -80.89 -166.3 1.09 Allowed 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 122.542 0.337 . . . . 70.15 110.664 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 27' ' ' GLN . 5.8 m 52.89 18.5 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 124.548 1.139 . . . . 75.0 113.068 177.009 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 50.8 pttt -111.37 -21.85 11.62 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.808 0.337 . . . . 71.12 110.285 177.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.74 16.03 2.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.346 -0.388 . . . . 75.11 111.664 -178.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 60.8 mt -73.22 103.38 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 109.404 -0.591 . . . . 74.23 109.404 176.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -58.01 -50.07 74.66 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.145 -0.48 . . . . 73.04 112.184 -173.066 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.727 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 91.0 m-85 -133.31 128.54 35.96 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.818 0.342 . . . . 71.25 110.821 -177.24 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -83.23 126.87 70.93 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 108.485 -0.931 . . . . 73.11 108.485 171.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -51.24 145.46 26.77 Favored 'Trans proline' 0 C--O 1.234 0.283 0 C-N-CA 123.361 2.707 . . . . 63.24 112.92 -176.118 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 p -59.74 142.41 15.21 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 CA-C-N 115.792 -0.64 . . . . 72.31 110.99 -178.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.8 t70 78.75 -11.96 1.14 Allowed 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.238 -0.892 . . . . 75.53 111.947 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 47.3 t80 -67.05 120.31 13.46 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 108.877 -0.786 . . . . 74.11 108.877 176.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.477 ' HG2' ' HA ' ' A' ' 57' ' ' LYS . 43.6 mt-10 -104.77 146.84 28.4 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.131 -0.486 . . . . 72.52 110.836 -176.147 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.598 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 21.1 pt -120.2 155.56 23.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.824 -0.626 . . . . 75.11 110.415 177.748 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.786 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.4 tt0 -107.21 165.84 11.07 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.588 -0.733 . . . . 74.33 110.268 -174.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.441 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 5.2 m-85 -120.47 101.43 7.77 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.775 0.321 . . . . 75.13 110.838 178.048 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 20.3 m -103.01 168.15 2.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.139 -0.482 . . . . 43.53 110.429 178.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.598 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 28.3 t -90.57 140.76 29.44 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.472 -0.566 . . . . 51.42 109.472 178.52 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -59.12 117.12 4.36 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.818 -0.628 . . . . 71.44 110.218 -176.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 114.18 -112.91 2.92 Favored Glycine 0 N--CA 1.444 -0.808 0 N-CA-C 111.093 -0.803 . . . . 62.21 111.093 -176.051 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -149.77 65.76 0.99 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.347 0.594 . . . . 71.43 110.834 177.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.598 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 35.0 mmt180 -126.57 136.27 52.34 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.265 -0.425 . . . . 74.21 110.047 179.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.52 157.01 27.52 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.958 -0.386 . . . . 74.41 109.958 176.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.53 HG12 ' HB3' ' A' ' 73' ' ' CYS . 33.2 m -130.29 149.69 33.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.245 -0.434 . . . . 54.31 110.68 -177.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -116.34 95.47 3.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 122.298 1.047 . . . . 73.23 108.929 169.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.47 172.33 33.61 Favored Glycine 0 N--CA 1.444 -0.824 0 CA-C-N 114.496 -1.229 . . . . 43.0 111.173 -178.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.5 ' HG2' HG21 ' A' ' 69' ' ' THR . 69.3 Cg_endo -75.91 60.02 5.96 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.326 2.017 . . . . 70.42 110.782 173.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.602 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 40.0 pttt -71.65 88.93 0.98 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.452 -0.794 . . . . 72.35 111.328 -175.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.6 p -161.88 131.89 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 116.046 -0.525 . . . . 74.12 110.946 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.598 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 22.3 mmt180 -127.78 111.07 13.24 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.504 -0.924 . . . . 73.32 108.504 169.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.477 ' HA ' ' HG2' ' A' ' 39' ' ' GLU . 20.5 ttmm -97.99 122.39 41.05 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.954 -0.387 . . . . 71.3 109.954 -178.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 49.8 t -69.65 126.97 31.33 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.772 -0.455 . . . . 74.1 109.772 177.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 95.0 mt -97.03 -178.94 4.37 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.054 -0.521 . . . . 75.32 110.831 -175.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.29 -17.03 61.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 34.01 110.687 178.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.3 p-10 -101.18 165.8 11.11 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.305 -0.628 . . . . 74.35 109.305 174.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.97 52.42 3.28 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 121.026 -0.607 . . . . 74.22 113.51 -174.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.8 m -157.5 157.7 34.35 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.523 -0.547 . . . . 64.31 109.523 177.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -88.27 173.51 8.73 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.603 -0.517 . . . . 65.43 109.603 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.425 ' CG2' ' HB3' ' A' ' 57' ' ' LYS . 3.0 p -57.73 -73.18 0.08 Allowed 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 112.27 0.47 . . . . 71.12 112.27 -177.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -125.31 121.13 33.09 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.215 -0.661 . . . . 71.12 109.215 178.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 62.3 mtm -120.45 79.6 1.5 Allowed 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 119.259 -0.976 . . . . 72.34 111.149 173.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -168.34 89.79 0.26 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 114.735 -1.121 . . . . 63.14 108.316 162.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.5 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.2 OUTLIER -159.02 102.23 1.58 Allowed Pre-proline 0 C--N 1.315 -0.932 0 C-N-CA 120.581 -0.448 . . . . 74.33 110.693 -171.814 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -75.33 105.17 2.03 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.359 2.039 . . . . 64.14 111.576 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 7.6 p -75.22 102.41 4.99 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.228 0.537 . . . . 73.3 110.852 -178.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.1 ptp180 -79.97 115.61 19.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.696 -0.684 . . . . 75.3 111.252 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.53 ' HB3' HG12 ' A' ' 50' ' ' VAL . 0.7 OUTLIER -87.25 99.04 11.67 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.984 -0.553 . . . . 74.22 110.689 174.761 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.7 p -115.53 129.13 72.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.611 -0.722 . . . . 70.53 109.54 176.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.637 -0.697 . . . . 74.41 109.875 -176.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.664 0 N-CA-C 111.441 -0.664 . . . . 72.35 111.441 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_exo -66.34 95.29 0.32 Allowed 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.825 2.35 . . . . 72.1 111.725 -179.441 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 7.5 p -96.22 129.88 43.42 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.044 -0.526 . . . . 75.23 111.242 -178.349 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.0 m -93.39 98.12 11.01 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.794 -0.817 . . . . 74.12 108.794 173.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -119.1 99.2 6.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.698 -0.683 . . . . 74.03 110.524 -174.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.468 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -161.74 165.54 35.74 Favored Glycine 0 N--CA 1.437 -1.235 0 CA-C-N 115.612 -0.722 . . . . 52.24 111.363 178.234 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 13.3 m -84.61 139.74 31.86 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 110.078 -0.341 . . . . 72.14 110.078 178.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.402 HE21 ' HB2' ' A' ' 8' ' ' GLN . 1.6 pt20 -83.14 -178.67 7.18 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.204 0.526 . . . . 64.22 111.087 -178.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.544 HD11 ' HB ' ' A' ' 31' ' ' ILE . 58.2 mt -87.43 105.04 14.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.809 -0.632 . . . . 73.43 109.366 178.087 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 20.8 pt -72.18 169.93 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 114.721 -1.127 . . . . 53.14 111.556 -177.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -69.39 135.79 88.72 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.009 -0.541 . . . . 73.31 109.745 173.576 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -59.78 143.99 99.53 Favored 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.117 1.878 . . . . 62.52 111.147 172.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.21 -160.05 0.09 OUTLIER 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.489 2.126 . . . . 72.42 112.441 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 14.9 t-105 -68.8 -175.94 0.76 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.969 -0.56 . . . . 72.24 109.787 177.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 66.9 mm-40 -37.86 100.53 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 123.553 0.741 . . . . 74.13 112.655 -172.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.532 ' HA2' ' N ' ' A' ' 45' ' ' ARG . . . 163.6 -132.39 2.72 Favored Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.322 -0.853 . . . . 71.54 111.643 -179.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -179.64 -166.2 34.93 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.495 -0.642 . . . . 73.45 111.495 178.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.3 mt -127.95 130.11 69.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.463 0.649 . . . . 70.34 111.189 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.741 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 23.2 tpt180 -96.64 135.3 38.75 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 114.759 -1.109 . . . . 74.22 109.255 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.588 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 98.0 m-85 -93.17 -171.23 2.61 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.836 -0.346 . . . . 74.35 110.613 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.598 ' HD2' ' H ' ' A' ' 39' ' ' GLU . 49.1 ttt180 -106.43 -75.86 0.62 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 120.757 0.313 . . . . 74.3 110.893 -170.346 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -114.19 43.68 1.65 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.886 -0.597 . . . . 71.12 112.097 -177.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 75.1 mt -133.69 144.67 49.3 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 110.243 -0.28 . . . . 52.44 110.243 178.094 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.0 t -97.04 175.01 6.48 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.062 -0.517 . . . . 75.32 109.821 176.007 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.458 ' C ' ' H ' ' A' ' 27' ' ' GLN . 34.7 ptt180 -74.43 -172.42 1.46 Allowed 'General case' 0 C--O 1.236 0.389 0 C-N-CA 121.439 -0.104 . . . . 73.32 110.815 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 27.4 t70 69.27 -2.27 1.9 Allowed 'General case' 0 N--CA 1.474 0.774 0 CA-C-O 122.055 0.931 . . . . 54.04 109.945 -175.589 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.458 ' H ' ' C ' ' A' ' 25' ' ' ARG . 21.6 mt-30 -119.98 -156.51 0.67 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.777 -1.102 . . . . 70.15 108.518 178.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.423 HG12 HD11 ' A' ' 31' ' ' ILE . 15.2 m 47.83 27.57 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.778 0.831 . . . . 75.0 112.263 176.343 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.413 ' H ' ' HG2' ' A' ' 29' ' ' LYS . 26.3 pttt -92.74 -22.44 19.37 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.39 -0.823 . . . . 71.12 110.445 -175.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.6 81.54 0.66 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.809 -0.632 . . . . 75.11 110.677 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.544 ' HB ' HD11 ' A' ' 9' ' ' ILE . 48.0 mt -103.4 146.78 10.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.829 -0.623 . . . . 74.23 109.533 178.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -85.56 -67.92 0.77 Allowed 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.978 -0.379 . . . . 73.04 109.978 177.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.468 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 75.8 m-85 -136.32 145.72 45.8 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.021 -0.536 . . . . 71.25 110.641 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -92.32 142.59 26.25 Favored Pre-proline 0 C--N 1.321 -0.645 0 N-CA-C 109.762 -0.459 . . . . 73.11 109.762 175.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -62.77 147.15 95.05 Favored 'Trans proline' 0 C--O 1.237 0.442 0 C-N-CA 122.725 2.284 . . . . 63.24 113.03 -178.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 6.4 p -70.39 80.75 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 CA-C-O 122.159 0.98 . . . . 72.31 110.502 177.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.0 t70 172.94 -27.78 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 114.461 -1.245 . . . . 75.53 108.739 -175.095 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.588 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 7.9 t80 -72.15 142.9 49.09 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 114.751 -1.113 . . . . 74.11 111.185 -176.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.598 ' H ' ' HD2' ' A' ' 21' ' ' ARG . 54.9 mt-10 -124.61 153.76 41.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.032 -0.531 . . . . 72.52 109.93 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.645 HD11 ' HE1' ' A' ' 67' ' ' MET . 35.0 pt -126.68 165.65 24.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 120.763 0.316 . . . . 75.11 111.435 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.741 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 43.7 tt0 -130.89 147.47 52.54 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.955 -0.566 . . . . 74.33 110.268 178.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -94.84 102.27 14.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.285 -0.416 . . . . 75.13 110.678 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.5 m -103.48 170.67 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 120.9 0.381 . . . . 43.53 111.141 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 49.7 t -115.9 175.18 5.65 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.301 -0.409 . . . . 51.42 110.055 -178.378 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.532 ' N ' ' HA2' ' A' ' 16' ' ' GLY . 2.0 tmt_? -77.09 99.63 5.43 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.631 -0.507 . . . . 71.44 109.631 -178.185 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.18 -160.63 28.44 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.929 -0.653 . . . . 62.21 111.691 -178.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -85.18 69.52 10.77 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.745 0.783 . . . . 71.43 111.002 -179.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 26.5 mmm180 -124.51 107.72 11.36 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.139 -1.059 . . . . 74.21 108.139 174.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -79.8 139.31 37.28 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.999 0.428 . . . . 74.41 111.508 -170.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' A' ' 73' ' ' CYS . 33.7 m -94.53 150.12 4.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.707 -0.678 . . . . 54.31 111.292 -176.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -114.42 95.06 3.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.822 0.82 . . . . 73.23 109.17 169.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.57 171.66 33.63 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.155 -0.93 . . . . 43.0 111.664 -178.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -83.58 71.25 6.03 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.158 1.905 . . . . 70.42 110.336 169.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.462 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 21.1 pttp -81.61 86.95 6.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.655 0.741 . . . . 72.35 111.629 -170.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.6 p -161.9 128.0 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.362 -0.836 . . . . 74.12 109.315 172.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.493 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 35.1 mmt180 -145.19 118.22 8.83 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.322 -0.622 . . . . 73.32 109.322 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -106.03 139.7 40.16 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.958 0.409 . . . . 71.3 109.958 177.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.9 t -70.47 149.66 46.98 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.556 -0.747 . . . . 74.1 111.911 -175.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.3 mt -113.15 -178.02 3.28 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.187 -0.915 . . . . 75.32 109.943 179.307 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -83.44 28.97 0.52 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.869 0.366 . . . . 34.01 111.277 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -146.56 169.85 18.11 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.161 -0.472 . . . . 74.35 109.946 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -69.2 -34.44 75.46 Favored Glycine 0 C--N 1.33 0.236 0 C-N-CA 121.348 -0.453 . . . . 74.22 114.039 -169.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.8 m -89.79 142.06 28.04 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 121.124 0.488 . . . . 64.31 111.054 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 59.7 m95 -73.82 -179.29 3.59 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.086 -0.507 . . . . 65.43 110.732 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 2.9 p -56.33 -56.12 25.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.312 -0.404 . . . . 71.12 111.792 -178.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.44 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 10.6 t70 -142.66 127.0 17.66 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.742 -0.466 . . . . 71.12 109.742 174.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . 0.645 ' HE1' HD11 ' A' ' 40' ' ' ILE . 24.2 mmt -127.75 78.68 1.84 Allowed 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 119.112 -1.035 . . . . 72.34 110.531 165.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -167.08 87.85 0.3 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 113.843 -1.526 . . . . 63.14 107.544 159.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 91.5 m -160.33 109.0 1.37 Allowed Pre-proline 0 C--N 1.317 -0.825 0 N-CA-C 109.651 -0.5 . . . . 74.33 109.651 -172.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.53 99.52 0.94 Allowed 'Trans proline' 0 C--O 1.233 0.24 0 C-N-CA 122.68 2.253 . . . . 64.14 113.213 -174.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 11.8 p -91.58 98.58 11.74 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.519 -0.548 . . . . 73.3 109.519 173.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.424 HH11 ' HD2' ' A' ' 72' ' ' ARG . 7.0 ptp180 -91.29 140.66 29.57 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.163 -0.471 . . . . 75.3 110.852 -175.493 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.599 ' HA ' ' HA ' ' A' ' 50' ' ' VAL . 3.4 p -106.59 122.25 45.95 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.847 -0.615 . . . . 74.22 111.119 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 18.4 t -127.14 -95.64 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 108.892 -0.781 . . . . 70.53 108.892 175.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.536 -0.745 . . . . 74.41 109.673 178.208 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.79 0 N-CA-C 112.089 -0.404 . . . . 72.35 112.089 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -73.63 88.36 1.04 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.745 2.297 . . . . 72.1 111.862 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 59.7 m -122.72 115.99 23.01 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.972 -0.558 . . . . 75.23 110.421 178.438 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.5 m -105.59 101.58 11.09 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.753 -0.658 . . . . 74.12 109.829 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -96.74 96.69 8.77 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.644 -0.502 . . . . 74.03 109.644 178.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.81 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -164.15 136.91 4.46 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.742 -0.742 . . . . 52.24 112.565 -179.131 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.8 m -80.01 133.84 36.18 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.81 -0.811 . . . . 72.14 108.81 172.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.577 ' HA ' ' O ' ' A' ' 32' ' ' ASN . 2.2 pt20 -73.31 177.62 5.05 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.624 0.726 . . . . 64.22 112.41 -174.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.3 mt -88.97 127.09 41.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.876 -1.056 . . . . 73.43 110.326 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 58.6 mt -76.21 140.92 16.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.502 -0.772 . . . . 53.14 110.75 -177.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -62.9 138.0 97.06 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 115.49 -0.777 . . . . 73.31 110.188 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.496 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 75.6 Cg_exo -41.48 118.85 0.88 Allowed 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 123.852 3.034 . . . . 62.52 113.74 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.496 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 6.7 Cg_endo -88.79 -145.18 0.03 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.657 0 C-N-CA 123.685 2.924 . . . . 72.42 112.436 -178.551 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.442 ' CG ' ' N ' ' A' ' 15' ' ' GLU . 69.0 t-105 -68.36 -179.67 1.38 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 115.907 -0.588 . . . . 72.24 110.893 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.442 ' N ' ' CG ' ' A' ' 14' ' ' TRP . 16.8 mm-40 -47.99 101.5 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.182 0 C-N-CA 123.972 0.909 . . . . 74.13 112.336 178.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 153.56 -142.58 9.3 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 120.722 -0.751 . . . . 71.54 111.911 178.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -168.72 -169.99 32.82 Favored Glycine 0 N--CA 1.442 -0.959 0 N-CA-C 111.459 -0.656 . . . . 73.45 111.459 -179.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.5 mt -113.81 128.17 70.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.735 0.778 . . . . 70.34 111.432 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.855 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 20.5 tpp180 -86.24 113.14 22.01 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 114.54 -1.209 . . . . 74.22 109.541 179.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.42 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 86.2 m-85 -86.71 -171.54 3.58 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.953 0.406 . . . . 74.35 110.875 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -108.34 -32.51 7.42 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.131 0.491 . . . . 74.3 110.066 -177.47 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -158.62 54.51 0.37 Allowed Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.799 -0.715 . . . . 71.12 112.155 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 88.8 mt -138.61 111.62 7.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.681 0.277 . . . . 52.44 110.95 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 13.7 t -85.28 -179.91 7.07 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.166 -0.47 . . . . 75.32 109.859 175.229 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.499 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 9.5 ptp85 -72.77 -171.36 0.83 Allowed 'General case' 0 C--O 1.237 0.398 0 N-CA-C 110.027 -0.361 . . . . 73.32 110.027 178.001 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.499 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 9.7 t70 73.24 -40.77 0.48 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 121.251 0.548 . . . . 54.04 110.071 -176.191 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.425 ' O ' HG22 ' A' ' 28' ' ' VAL . 24.6 mt-30 -85.33 -164.64 1.03 Allowed 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 115.497 -0.774 . . . . 70.15 109.156 171.357 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.493 HG12 HD12 ' A' ' 31' ' ' ILE . 9.0 m 50.87 20.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 C-N-CA 124.079 0.952 . . . . 75.0 112.432 178.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 17.9 ptmt -79.78 -18.99 49.69 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.803 -0.635 . . . . 71.12 110.525 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.95 35.97 0.05 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.315 -0.857 . . . . 75.11 110.753 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.493 HD12 HG12 ' A' ' 28' ' ' VAL . 45.6 mt -75.69 136.88 23.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 109.003 -0.74 . . . . 74.23 109.003 175.052 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.577 ' O ' ' HA ' ' A' ' 8' ' ' GLN . 87.4 m-20 -115.76 -25.06 7.93 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 111.981 0.363 . . . . 73.04 111.981 -172.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.81 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 41.5 m-85 -132.01 109.48 10.06 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.958 0.408 . . . . 71.25 111.673 -174.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.405 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.8 mm? -87.66 129.63 50.08 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 109.355 -0.609 . . . . 73.11 109.355 173.054 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -62.21 161.34 27.08 Favored 'Trans proline' 0 N--CA 1.472 0.261 0 C-N-CA 122.868 2.378 . . . . 63.24 113.538 -175.365 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.465 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 12.4 p -63.1 157.68 3.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 CA-C-N 115.355 -0.839 . . . . 72.31 110.602 179.026 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.465 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 32.2 t70 77.12 -3.85 2.42 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.424 0.69 . . . . 75.53 111.004 178.623 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.42 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 4.4 t80 -80.39 123.56 28.13 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.133 -0.485 . . . . 74.11 110.18 -179.185 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.483 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 45.6 mt-10 -116.37 141.74 47.77 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 110.014 -0.365 . . . . 72.52 110.014 175.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.525 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 33.6 pt -121.26 160.89 21.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 120.965 0.412 . . . . 75.11 111.503 -177.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.855 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 46.2 tt0 -120.52 152.07 38.53 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.546 -0.752 . . . . 74.33 110.101 179.715 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -101.7 102.83 13.56 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.742 0.306 . . . . 75.13 110.982 179.155 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.512 HG11 ' HE ' ' A' ' 19' ' ' ARG . 30.7 m -102.23 152.75 5.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.16 0.505 . . . . 43.53 111.318 -179.044 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.428 ' HB2' ' HB3' ' A' ' 73' ' ' CYS . 19.1 t -100.49 -179.83 4.22 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.126 -0.694 . . . . 51.42 109.126 -178.39 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.4 ' HD3' ' HA ' ' A' ' 45' ' ' ARG . 37.5 mmt180 -65.2 110.08 2.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.772 0.32 . . . . 71.44 111.397 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.96 -149.01 24.98 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 121.0 -0.619 . . . . 62.21 111.855 179.194 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -91.56 37.51 0.96 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.365 0.603 . . . . 71.43 110.464 179.465 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 29.8 mmm180 -88.49 108.26 19.3 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.81 -0.811 . . . . 74.21 108.81 176.886 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -77.95 145.39 36.11 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.676 -0.693 . . . . 74.41 111.113 -171.56 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.563 ' HA ' ' HA ' ' A' ' 73' ' ' CYS . 34.8 m -101.33 149.98 6.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.672 -0.694 . . . . 54.31 110.387 179.115 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.0 p -117.47 95.28 3.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 122.003 0.906 . . . . 73.23 109.405 169.043 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.26 171.83 33.46 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.735 -1.121 . . . . 43.0 111.382 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.549 ' HG2' HG23 ' A' ' 69' ' ' THR . 48.1 Cg_endo -77.06 71.92 6.07 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 121.756 1.637 . . . . 70.42 110.359 170.168 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.704 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 43.2 pttt -78.98 89.57 4.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.531 -0.759 . . . . 72.35 111.398 -173.172 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.39 128.57 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.578 0.704 . . . . 74.12 110.877 174.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.647 ' CZ ' ' HA ' ' A' ' 67' ' ' MET . 28.9 mmt85 -138.23 104.41 5.19 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.276 -0.875 . . . . 73.32 109.106 176.72 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -97.47 138.96 34.11 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.412 -0.358 . . . . 71.3 110.182 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 46.7 t -97.88 128.56 44.56 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.014 -0.539 . . . . 74.1 110.349 176.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 30.7 mt -108.13 -176.6 3.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.797 -0.638 . . . . 75.32 110.414 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -54.43 -35.08 62.56 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 121.037 0.446 . . . . 34.01 110.886 176.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -83.18 140.5 32.54 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.345 -0.613 . . . . 74.35 109.345 174.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -79.14 67.19 3.32 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 121.025 -0.607 . . . . 74.22 113.631 -172.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 32.2 m -155.38 139.31 16.32 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.839 -0.43 . . . . 64.31 109.839 174.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 66.4 m95 -72.28 129.6 38.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.03 -0.73 . . . . 65.43 109.03 177.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 6.6 p -70.78 13.94 0.16 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 115.24 1.57 . . . . 71.12 115.24 -166.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -159.03 42.96 0.24 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.302 -0.629 . . . . 71.12 109.302 177.036 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . 0.647 ' HA ' ' CZ ' ' A' ' 56' ' ' ARG . 26.4 ttt -83.75 77.38 9.89 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 122.074 0.94 . . . . 72.34 111.38 -171.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -170.32 88.97 0.15 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 113.905 -1.498 . . . . 63.14 107.361 159.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.549 HG23 ' HG2' ' A' ' 53' ' ' PRO . 7.5 m -127.58 112.38 20.89 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 119.847 -0.741 . . . . 74.33 112.51 -167.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -74.05 114.77 4.12 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 122.913 2.408 . . . . 64.14 110.811 172.304 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 5.4 p -135.64 145.74 47.13 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.403 -0.362 . . . . 73.3 110.844 -175.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.5 ptp180 -140.8 136.42 32.44 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.204 -0.453 . . . . 75.3 110.122 -178.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 50' ' ' VAL . 0.9 OUTLIER -97.18 99.73 11.21 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.462 0.649 . . . . 74.22 111.101 176.783 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -131.94 134.09 60.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.028 -0.987 . . . . 70.53 108.837 178.128 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.381 -0.819 . . . . 74.41 110.948 -172.189 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.472 ' HA2' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.48 1.626 0 N-CA-C 111.465 -0.654 . . . . 72.35 111.465 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.472 ' HD3' ' HA2' ' A' ' 1' ' ' GLY . 11.6 Cg_exo -69.99 136.0 31.3 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.796 2.331 . . . . 72.1 111.844 -178.68 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 1.2 p -79.03 137.27 37.48 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.038 -0.528 . . . . 75.23 110.771 178.02 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.7 m -78.84 99.33 6.69 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.495 -0.557 . . . . 74.12 109.495 176.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -118.03 100.23 7.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.557 -0.747 . . . . 74.03 110.261 -175.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.881 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.54 145.32 10.96 Favored Glycine 0 N--CA 1.444 -0.833 0 N-CA-C 111.373 -0.691 . . . . 52.24 111.373 178.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 56.7 m -81.16 132.01 35.33 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 110.176 -0.305 . . . . 72.14 110.176 -179.459 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -80.3 -176.55 5.69 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.995 0.426 . . . . 64.22 111.302 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 73.0 mt -84.86 136.34 22.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.498 -0.773 . . . . 73.43 109.046 178.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 14.1 mt -94.76 148.33 5.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 116.102 -0.499 . . . . 53.14 111.614 -169.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 10.8 p80 -61.69 136.29 94.64 Favored Pre-proline 0 C--O 1.233 0.211 0 CA-C-N 116.051 -0.522 . . . . 73.31 109.875 172.156 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.421 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 38.2 Cg_endo -66.9 119.77 6.82 Favored 'Trans proline' 0 N--CA 1.464 -0.248 0 C-N-CA 122.526 2.151 . . . . 62.52 111.951 179.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.48 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 5.1 Cg_exo -77.76 -129.8 0.01 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.272 0 C-N-CA 123.043 2.495 . . . . 72.42 111.49 178.052 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.48 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 39.3 t-105 -63.86 174.77 1.34 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 109.594 -0.521 . . . . 72.24 109.594 175.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -68.91 76.37 0.31 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.497 0.665 . . . . 74.13 112.321 -176.096 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -143.27 155.32 25.97 Favored Glycine 0 N--CA 1.438 -1.188 0 N-CA-C 109.729 -1.349 . . . . 71.54 109.729 173.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -106.06 -172.3 23.38 Favored Glycine 0 N--CA 1.44 -1.085 0 C-N-CA 119.811 -1.185 . . . . 73.45 112.017 -178.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 33.8 mt -132.16 131.75 61.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.197 0.523 . . . . 70.34 109.987 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.426 HH11 ' HD2' ' A' ' 19' ' ' ARG . 0.2 OUTLIER -113.41 122.28 46.87 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.39 -0.823 . . . . 74.22 109.341 -179.307 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -88.52 -172.71 3.86 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.878 0.371 . . . . 74.35 110.552 -175.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.5 ttm180 -89.18 -51.59 5.5 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.219 -0.446 . . . . 74.3 110.27 -177.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -137.27 13.07 3.8 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.805 -0.712 . . . . 71.12 112.736 -178.251 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 80.3 mt -89.96 129.29 36.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.106 0.479 . . . . 52.44 110.805 -179.701 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.1 t -102.74 -178.27 3.62 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.577 -0.738 . . . . 75.32 110.085 178.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.484 ' C ' ' H ' ' A' ' 27' ' ' GLN . 60.6 mtp180 -69.3 -173.07 0.5 Allowed 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.535 -0.302 . . . . 73.32 111.28 -176.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 24.3 t70 69.79 -40.33 0.46 Allowed 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.444 0.698 . . . . 54.04 110.505 -172.383 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.49 ' O ' HG22 ' A' ' 28' ' ' VAL . 18.1 mt-30 -86.6 -161.12 0.63 Allowed 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.36 -0.836 . . . . 70.15 110.3 177.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.49 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.6 m 54.73 10.0 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.674 1.19 . . . . 75.0 113.247 177.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -97.25 -19.84 18.3 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.021 0.439 . . . . 71.12 110.027 175.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.64 94.07 1.85 Allowed 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.552 -0.749 . . . . 75.11 110.377 178.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -131.58 136.62 56.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.109 -0.7 . . . . 74.23 109.109 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -76.77 -67.02 0.74 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.959 0.409 . . . . 73.04 110.892 -177.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.881 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 61.8 m-85 -133.91 126.67 30.89 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.832 -0.622 . . . . 71.25 111.119 -175.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -85.13 134.11 41.58 Favored Pre-proline 0 C--N 1.324 -0.525 0 N-CA-C 108.969 -0.752 . . . . 73.11 108.969 171.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -63.08 141.18 82.34 Favored 'Trans proline' 0 C--O 1.239 0.545 0 C-N-CA 122.816 2.344 . . . . 63.24 112.906 -176.502 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.426 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 3.1 p -69.84 82.07 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 CA-C-O 121.719 0.771 . . . . 72.31 110.25 176.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.426 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 6.2 t70 172.44 -26.39 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.635 -1.166 . . . . 75.53 108.544 -175.873 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.459 ' OH ' ' HG ' ' A' ' 23' ' ' LEU . 6.1 t80 -74.04 146.38 43.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.217 -0.901 . . . . 74.11 110.822 -177.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -124.69 158.64 32.71 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 115.911 -0.586 . . . . 72.52 110.564 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.476 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 31.0 pt -139.5 149.27 22.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.15 -0.477 . . . . 75.11 110.67 177.017 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.542 ' HG2' ' H ' ' A' ' 42' ' ' TYR . 24.2 tt0 -112.81 167.37 10.55 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.161 -0.472 . . . . 74.33 109.902 178.272 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.542 ' H ' ' HG2' ' A' ' 41' ' ' GLU . 69.1 m-85 -112.44 102.42 10.54 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.077 0.465 . . . . 75.13 111.998 -177.195 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.0 m -96.21 153.6 3.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 109.074 -0.713 . . . . 43.53 109.074 171.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.591 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 34.2 t -89.07 167.49 13.1 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.138 -0.69 . . . . 51.42 109.138 179.554 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -59.25 117.09 4.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.024 0.44 . . . . 71.44 110.151 -176.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.76 -120.77 6.53 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 110.958 -0.857 . . . . 62.21 110.958 -176.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -130.04 25.61 5.24 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.359 0.6 . . . . 71.43 110.212 177.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.591 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 29.8 mmm180 -88.47 136.06 33.18 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.823 -0.626 . . . . 74.21 109.8 -177.435 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -95.47 159.19 15.12 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.046 -0.525 . . . . 74.41 109.811 -179.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.548 HG12 ' HA ' ' A' ' 73' ' ' CYS . 27.9 m -122.28 150.14 25.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.523 -0.308 . . . . 54.31 110.422 179.517 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 p -100.83 96.89 5.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 122.039 0.923 . . . . 73.23 109.295 171.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.23 172.11 33.45 Favored Glycine 0 N--CA 1.441 -0.997 0 CA-C-N 114.973 -1.012 . . . . 43.0 111.612 -176.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -74.07 55.69 3.5 Favored 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.249 1.966 . . . . 70.42 110.523 171.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.479 ' HD2' ' HG2' ' A' ' 41' ' ' GLU . 43.0 pttt -75.41 87.46 2.58 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 115.74 -0.664 . . . . 72.35 111.515 -173.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -161.41 129.21 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.439 -0.8 . . . . 74.12 109.45 172.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.521 HH22 ' CB ' ' A' ' 69' ' ' THR . 31.8 mmt180 -132.61 140.29 48.16 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.918 -0.401 . . . . 73.32 109.918 179.165 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -130.76 137.56 49.53 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.598 -0.519 . . . . 71.3 109.598 176.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 50.4 t -70.83 146.5 49.65 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.114 -0.494 . . . . 74.1 110.26 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 94.3 mt -116.86 -179.61 3.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.136 -0.484 . . . . 75.32 110.381 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.03 -8.39 59.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.917 0.389 . . . . 34.01 111.038 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -100.54 166.16 11.06 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.434 -0.58 . . . . 74.35 109.434 175.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.02 57.76 3.14 Favored Glycine 0 CA--C 1.516 0.131 0 C-N-CA 120.987 -0.625 . . . . 74.22 113.091 -177.193 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.2 t -172.96 171.03 4.35 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.209 -0.663 . . . . 64.31 109.209 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 40.5 m95 -99.98 -179.01 4.02 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 109.714 -0.476 . . . . 65.43 109.714 -178.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.0 p -49.63 -53.31 24.88 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.579 0.585 . . . . 71.12 112.579 -176.771 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -153.77 129.95 10.41 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.026 -1.102 . . . . 71.12 108.026 177.227 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 22.9 mmt -131.81 78.4 1.82 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 118.992 -1.083 . . . . 72.34 112.136 174.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 30.0 t0 -168.94 88.39 0.19 Allowed 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 107.805 -1.183 . . . . 63.14 107.805 157.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.521 ' CB ' HH22 ' A' ' 56' ' ' ARG . 1.3 m -149.32 94.6 3.92 Favored Pre-proline 0 C--N 1.314 -0.948 0 C-N-CA 120.913 -0.315 . . . . 74.33 110.313 -172.5 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.95 92.81 0.32 Allowed 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 122.487 2.125 . . . . 64.14 112.26 -179.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 17.0 m -79.68 115.8 19.49 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.942 -0.572 . . . . 73.3 109.811 177.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.5 ptp180 -79.68 133.73 36.39 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.715 -0.675 . . . . 75.3 111.655 -174.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.548 ' HA ' HG12 ' A' ' 50' ' ' VAL . 71.2 m -83.08 98.87 9.53 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.761 -0.654 . . . . 74.22 110.592 178.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.5 p -148.88 114.47 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.635 -0.711 . . . . 70.53 109.534 176.42 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 2.4 tmt_? . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.288 -0.863 . . . . 74.41 109.488 -173.206 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.801 0 N-CA-C 111.835 -0.506 . . . . 72.35 111.835 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -80.34 44.82 1.81 Allowed 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 123.091 2.527 . . . . 72.1 111.756 -179.063 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 12.3 p -117.61 139.88 50.4 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.564 -0.744 . . . . 75.23 111.039 -177.101 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.7 m -142.28 97.94 3.22 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.485 -0.561 . . . . 74.12 109.485 172.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 33.3 mm-40 -98.82 118.41 35.5 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.892 -0.595 . . . . 74.03 109.466 -179.562 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.521 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -153.73 152.14 23.78 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.124 -1.036 . . . . 52.24 113.152 -176.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.8 m -97.14 149.39 22.04 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.432 -0.581 . . . . 72.14 109.432 177.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -72.82 173.98 8.38 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.129 0.49 . . . . 64.22 112.171 -175.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.58 HD11 ' HB ' ' A' ' 31' ' ' ILE . 54.5 mt -88.5 126.9 41.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.522 -0.763 . . . . 73.43 110.458 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.1 mt -84.05 127.92 39.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.051 -0.522 . . . . 53.14 109.847 177.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -79.5 133.4 59.74 Favored Pre-proline 0 C--N 1.323 -0.583 0 N-CA-C 109.631 -0.507 . . . . 73.31 109.631 -177.355 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.451 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 72.3 Cg_exo -49.3 113.3 0.88 Allowed 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 123.451 2.767 . . . . 62.52 113.005 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.465 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 4.9 Cg_exo -80.52 -101.4 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 123.194 2.596 . . . . 72.42 112.827 -177.06 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.465 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 55.7 t-105 -80.76 177.11 9.24 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.777 -0.453 . . . . 72.24 109.777 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -54.84 101.21 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.409 0.623 . . . . 74.13 111.733 179.462 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 169.06 -145.43 9.44 Favored Glycine 0 N--CA 1.443 -0.872 0 CA-C-N 115.095 -0.957 . . . . 71.54 110.714 -177.473 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -176.42 -170.01 38.54 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 120.473 -0.87 . . . . 73.45 111.914 178.384 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.9 mt -125.52 125.65 69.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.272 0.558 . . . . 70.34 110.838 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.38 160.57 14.6 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.994 -1.003 . . . . 74.22 108.893 178.089 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -123.26 -171.12 2.24 Favored 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 120.797 -0.361 . . . . 74.35 110.398 -176.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.416 ' HB3' ' CE2' ' A' ' 38' ' ' TYR . 39.9 ttm180 -82.56 -36.58 26.12 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.46 -0.336 . . . . 74.3 110.345 -178.116 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.94 71.21 0.19 Allowed Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.588 -0.815 . . . . 71.12 112.53 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 62.5 mt -139.79 139.15 36.35 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.796 0.331 . . . . 52.44 110.751 178.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.3 t -92.67 -178.28 4.82 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.863 -0.608 . . . . 75.32 109.848 178.242 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.563 ' C ' ' H ' ' A' ' 27' ' ' GLN . 49.7 ptt85 -68.78 -175.89 0.75 Allowed 'General case' 0 C--O 1.234 0.285 0 C-N-CA 121.188 -0.205 . . . . 73.32 110.671 177.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 28.7 t70 62.64 -26.83 0.06 Allowed 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 123.725 0.81 . . . . 54.04 112.116 -173.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.563 ' H ' ' C ' ' A' ' 25' ' ' ARG . 8.1 mm100 -71.25 178.7 3.2 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 123.227 0.611 . . . . 70.15 110.482 178.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.2 m 50.53 20.7 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 C-N-CA 124.364 1.065 . . . . 75.0 113.016 177.022 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 38.1 pttt -73.51 -23.29 60.01 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.041 0.448 . . . . 71.12 109.927 176.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.99 102.65 0.66 Allowed 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.281 -0.872 . . . . 75.11 110.373 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.58 ' HB ' HD11 ' A' ' 9' ' ' ILE . 50.6 mt -130.21 157.86 42.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 N-CA-C 108.315 -0.995 . . . . 74.23 108.315 175.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -88.92 -58.22 2.63 Favored 'General case' 0 C--N 1.321 -0.67 0 C-N-CA 120.825 -0.35 . . . . 73.04 110.45 179.424 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.521 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 86.7 m-85 -143.54 146.75 33.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.886 0.374 . . . . 71.25 111.067 -178.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.45 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.4 mm? -84.37 130.9 52.14 Favored Pre-proline 0 C--N 1.325 -0.467 0 N-CA-C 108.575 -0.898 . . . . 73.11 108.575 173.295 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 34' ' ' LEU . 17.4 Cg_exo -64.08 147.11 91.62 Favored 'Trans proline' 0 CA--C 1.527 0.15 0 C-N-CA 122.473 2.116 . . . . 63.24 112.848 -174.399 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.55 ' O ' ' HB3' ' A' ' 37' ' ' ASP . 8.9 p -53.39 148.35 2.01 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 CA-C-N 115.832 -0.622 . . . . 72.31 110.413 173.469 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.55 ' HB3' ' O ' ' A' ' 36' ' ' VAL . 7.9 t70 82.48 -28.93 0.1 Allowed 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.583 0.753 . . . . 75.53 111.513 -178.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.416 ' CE2' ' HB3' ' A' ' 21' ' ' ARG . 32.4 t80 -66.84 141.38 57.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.787 0.327 . . . . 74.11 110.544 -178.438 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 41.2 mt-10 -114.78 145.65 41.87 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.066 -0.515 . . . . 72.52 111.515 -177.21 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.554 HG12 ' HB2' ' A' ' 56' ' ' ARG . 43.8 pt -122.46 164.86 19.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.451 -0.795 . . . . 75.11 109.595 172.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.431 ' CG ' ' HD2' ' A' ' 54' ' ' LYS . 35.3 tt0 -135.89 142.71 44.75 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.987 0.422 . . . . 74.33 110.785 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -88.45 102.32 14.78 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.107 -0.497 . . . . 75.13 110.59 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.9 m -102.2 162.78 3.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.168 0.509 . . . . 43.53 110.856 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.584 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 15.8 t -104.0 -176.58 3.12 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.859 -0.61 . . . . 51.42 110.229 -176.566 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.5 mmt180 -56.27 121.43 9.49 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.111 -0.495 . . . . 71.44 111.419 -177.423 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 71.73 -95.86 0.64 Allowed Glycine 0 N--CA 1.446 -0.698 0 CA-C-N 115.724 -0.671 . . . . 62.21 111.998 178.549 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -146.83 47.52 1.17 Allowed 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.69 0.757 . . . . 71.43 109.716 177.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.584 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 13.3 mmm-85 -87.43 129.15 35.15 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.197 -0.91 . . . . 74.21 109.478 176.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.464 ' HB2' ' HB3' ' A' ' 75' ' ' ARG . 41.1 mt-10 -78.35 149.17 33.47 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.376 -0.374 . . . . 74.41 110.001 -179.615 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.456 HG12 ' HA ' ' A' ' 73' ' ' CYS . 34.9 m -127.06 150.14 32.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.96 -0.564 . . . . 54.31 110.678 -177.279 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 p -106.34 96.83 4.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.972 0.891 . . . . 73.23 109.235 171.187 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.773 ' HA3' ' HB3' ' A' ' 71' ' ' SER . . . -154.73 170.83 33.08 Favored Glycine 0 N--CA 1.441 -0.994 0 CA-C-N 114.831 -1.077 . . . . 43.0 111.175 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.24 60.33 7.4 Favored 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 122.282 1.988 . . . . 70.42 110.703 173.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.431 ' HD2' ' CG ' ' A' ' 41' ' ' GLU . 45.3 pttt -80.7 84.42 6.25 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-O 121.723 0.773 . . . . 72.35 111.436 -172.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.408 HG13 ' O ' ' A' ' 54' ' ' LYS . 1.1 m -158.66 126.48 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 114.594 -1.185 . . . . 74.12 108.462 172.308 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.554 ' HB2' HG12 ' A' ' 40' ' ' ILE . 32.3 mmt180 -141.1 100.07 3.73 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 110.073 -0.343 . . . . 73.32 110.073 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -92.5 125.32 37.09 Favored 'General case' 0 C--N 1.317 -0.822 0 N-CA-C 109.002 -0.74 . . . . 71.3 109.002 174.104 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 48.9 t -64.52 136.6 57.21 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.008 0.432 . . . . 74.1 110.247 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 76.6 mt -98.78 -178.92 4.12 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.661 -0.699 . . . . 75.32 110.717 -174.236 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -71.45 -9.71 58.62 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.449 0.642 . . . . 34.01 110.363 176.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -110.21 158.62 18.17 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 108.93 -0.767 . . . . 74.35 108.93 174.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -78.29 53.23 3.84 Favored Glycine 0 CA--C 1.519 0.333 0 C-N-CA 120.993 -0.622 . . . . 74.22 113.464 -173.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 18.6 m -155.06 161.92 41.19 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.37 -0.604 . . . . 64.31 109.37 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 70.5 m95 -91.89 179.51 5.59 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.835 -0.431 . . . . 65.43 109.835 -178.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 33.0 p -61.67 -38.79 89.06 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.923 0.392 . . . . 71.12 111.197 -178.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -146.59 136.26 23.12 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.06 -0.718 . . . . 71.12 109.06 178.341 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 10.4 tpt -119.54 74.38 1.0 Allowed 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 118.602 -1.239 . . . . 72.34 109.882 171.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -170.68 89.2 0.14 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.206 -1.361 . . . . 63.14 107.575 160.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.483 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 4.6 m -108.77 108.81 61.06 Favored Pre-proline 0 C--N 1.313 -1.017 0 C-N-CA 119.959 -0.696 . . . . 74.33 111.078 -170.642 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 14.8 Cg_endo -92.56 46.48 0.41 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 124.061 3.174 . . . . 64.14 112.803 -177.345 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.773 ' HB3' ' HA3' ' A' ' 52' ' ' GLY . 0.1 OUTLIER -73.91 126.21 29.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.5 -0.318 . . . . 73.3 110.687 177.561 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -109.55 149.05 30.21 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 110.177 -0.305 . . . . 75.3 110.177 -178.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.456 ' HA ' HG12 ' A' ' 50' ' ' VAL . 29.6 m -87.52 113.75 23.5 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.502 -0.317 . . . . 74.22 111.458 -175.635 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.1 p -155.8 134.94 3.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.576 -0.284 . . . . 70.53 110.563 179.078 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.464 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 3.0 ptm180 . . . . . 0 C--O 1.25 1.087 0 CA-C-N 116.318 -0.401 . . . . 74.41 109.971 178.019 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 1.496 0 N-CA-C 111.759 -0.536 . . . . 72.35 111.759 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.17 127.79 20.11 Favored 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 122.72 2.28 . . . . 72.1 111.499 176.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 5.7 t -134.1 99.36 4.39 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.803 0.811 . . . . 75.23 110.959 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.4 m -150.09 149.57 30.49 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.554 -0.748 . . . . 74.12 109.51 179.031 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -96.22 97.27 9.39 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.626 -0.509 . . . . 74.03 109.626 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -161.76 164.18 35.09 Favored Glycine 0 N--CA 1.441 -0.986 0 C-N-CA 120.807 -0.711 . . . . 52.24 112.396 -177.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 61.6 m -97.59 154.02 17.81 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 110.203 -0.295 . . . . 72.14 110.203 179.068 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 -82.42 -179.69 7.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.338 0.589 . . . . 64.22 111.329 -178.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.3 mt -89.42 121.38 39.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.425 -0.807 . . . . 73.43 110.306 178.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 55.5 mt -72.15 129.03 35.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.915 -0.584 . . . . 53.14 110.111 178.391 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.5 t-80 -67.39 121.26 78.02 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 116.192 -0.458 . . . . 73.31 110.366 -178.114 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.544 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.4 Cg_exo -48.69 120.76 5.61 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.212 2.608 . . . . 62.52 112.783 -179.407 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.544 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 5.8 Cg_endo -86.68 -138.74 0.02 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 123.569 2.846 . . . . 72.42 112.656 -176.305 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.441 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 13.1 t-105 -66.85 -177.5 0.62 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 115.891 -0.595 . . . . 72.24 110.853 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -39.88 101.35 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.689 0.796 . . . . 74.13 112.835 -176.051 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.54 -168.56 33.25 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 111.341 -0.704 . . . . 71.54 111.341 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.82 24.0 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.942 -0.647 . . . . 73.45 111.563 179.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.4 mt -116.93 136.49 53.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.559 0.695 . . . . 70.34 111.216 -178.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.855 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 13.7 tpt180 -103.03 140.1 37.72 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.661 -1.154 . . . . 74.22 109.246 -179.681 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -108.29 -171.98 1.97 Allowed 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.591 -0.444 . . . . 74.35 110.765 -178.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.06 -45.33 9.22 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.001 0.429 . . . . 74.3 110.603 -174.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -151.09 53.38 0.49 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.811 -0.709 . . . . 71.12 112.181 -178.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 89.5 mt -136.55 127.55 27.73 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.607 0.241 . . . . 52.44 110.794 179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 15.0 t -86.39 -179.77 6.73 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.531 -0.544 . . . . 75.32 109.531 175.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.8 mpp_? -80.47 -172.85 3.77 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.818 -0.353 . . . . 73.32 111.456 -175.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.429 ' O ' ' HE2' ' A' ' 29' ' ' LYS . 28.7 t70 60.44 15.25 5.37 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 122.357 1.075 . . . . 54.04 109.583 -168.435 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.549 ' O ' HG22 ' A' ' 28' ' ' VAL . 24.3 mt-30 -134.57 -173.7 3.36 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.668 -1.151 . . . . 70.15 108.287 178.273 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.549 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.0 m 54.4 9.22 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 124.127 0.971 . . . . 75.0 112.51 -178.323 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.429 ' HE2' ' O ' ' A' ' 26' ' ' ASP . 46.3 pttt -79.41 -21.82 45.1 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.98 -0.555 . . . . 71.12 110.081 177.502 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.31 81.15 0.98 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.351 -0.84 . . . . 75.11 110.37 178.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 54.8 mt -119.61 139.11 48.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 108.939 -0.763 . . . . 74.23 108.939 176.338 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -69.54 -64.2 0.92 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.764 0.316 . . . . 73.04 111.115 -176.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -143.56 141.73 30.8 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.192 -0.458 . . . . 71.25 110.867 -177.371 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -92.01 115.71 65.13 Favored Pre-proline 0 C--N 1.321 -0.671 0 N-CA-C 108.564 -0.902 . . . . 73.11 108.564 172.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.59 142.71 38.97 Favored 'Trans proline' 0 C--O 1.238 0.515 0 C-N-CA 123.419 2.746 . . . . 63.24 113.217 -174.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.467 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 2.7 p -65.22 86.14 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-O 121.512 0.673 . . . . 72.31 111.173 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.467 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 31.6 t70 168.94 -26.84 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.834 -1.075 . . . . 75.53 108.28 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 6.9 t80 -68.74 144.82 54.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 114.618 -1.173 . . . . 74.11 110.486 179.418 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.408 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 40.0 mt-10 -127.09 145.53 50.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.274 -0.421 . . . . 72.52 110.121 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.486 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 38.0 pt -128.45 167.9 22.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-O 121.084 0.469 . . . . 75.11 111.86 -177.622 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.855 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 44.4 tt0 -131.82 164.81 25.22 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 115.374 -0.83 . . . . 74.33 110.13 -177.221 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.579 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 96.9 m-85 -117.1 102.93 9.72 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 122.354 0.262 . . . . 75.13 111.142 -178.584 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.8 m -98.26 157.41 3.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 120.766 0.317 . . . . 43.53 110.74 178.501 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.588 ' HB3' ' O ' ' A' ' 48' ' ' ARG . 43.5 t -92.21 177.89 6.02 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.976 -0.379 . . . . 51.42 109.976 178.51 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.498 ' HD3' ' C ' ' A' ' 45' ' ' ARG . 0.1 OUTLIER -69.59 117.04 10.69 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 116.171 -0.468 . . . . 71.44 110.469 -176.241 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 89.63 -125.23 7.74 Favored Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.972 -0.632 . . . . 62.21 112.352 175.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -116.23 26.02 10.23 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.002 0.429 . . . . 71.43 110.533 -179.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.588 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 28.6 mmm180 -88.64 119.02 28.72 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.829 -0.804 . . . . 74.21 108.829 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -79.26 159.98 27.04 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.04 0.448 . . . . 74.41 111.058 -177.325 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.589 HG12 ' HA ' ' A' ' 73' ' ' CYS . 27.5 m -126.83 139.15 52.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.796 -0.638 . . . . 54.31 110.369 179.083 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.9 p -103.19 95.53 3.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 122.093 0.949 . . . . 73.23 109.366 172.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.46 171.26 32.94 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 115.005 -0.998 . . . . 43.0 111.446 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -78.07 52.01 3.88 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.486 2.124 . . . . 70.42 111.145 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.709 ' HD3' ' HG3' ' A' ' 41' ' ' GLU . 0.0 OUTLIER -76.66 86.83 3.31 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 122.118 0.961 . . . . 72.35 111.972 -173.397 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -161.96 130.12 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 114.989 -1.005 . . . . 74.12 109.229 174.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.486 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 29.0 mmt180 -129.43 131.52 46.77 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 120.662 0.268 . . . . 73.32 110.484 178.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.458 ' HE3' ' HB2' ' A' ' 57' ' ' LYS . 35.2 ttmt -106.58 134.19 50.1 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.071 -0.715 . . . . 71.3 109.071 176.112 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.3 t -74.53 145.18 43.68 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.92 0.39 . . . . 74.1 110.734 -178.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.6 mt -112.87 -178.67 3.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.788 -0.642 . . . . 75.32 110.114 -177.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.25 27.54 0.33 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.019 0.438 . . . . 34.01 111.077 -179.243 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.402 HD22 ' H ' ' A' ' 63' ' ' SER . 5.4 p-10 -147.65 172.75 13.55 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.235 -0.654 . . . . 74.35 109.235 -179.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -68.36 -19.03 72.11 Favored Glycine 0 CA--C 1.52 0.375 0 C-N-CA 120.815 -0.707 . . . . 74.22 113.755 -172.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.402 ' H ' HD22 ' A' ' 61' ' ' ASN . 14.9 m -99.36 146.27 26.47 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.046 0.45 . . . . 64.31 111.089 -178.041 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.411 ' H ' ' HE3' ' A' ' 67' ' ' MET . 63.8 m95 -77.89 -179.05 5.79 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.732 -0.667 . . . . 65.43 110.481 179.687 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.456 HG23 ' O ' ' A' ' 57' ' ' LYS . 3.1 p -54.05 -49.93 67.87 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 113.064 0.764 . . . . 71.12 113.064 -176.547 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.447 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 14.0 t70 -140.06 141.7 36.21 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.57 -0.286 . . . . 71.12 110.26 -177.562 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . 0.411 ' HE3' ' H ' ' A' ' 64' ' ' TRP . 65.9 mtt -140.07 80.01 1.74 Allowed 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 119.969 -0.692 . . . . 72.34 111.502 166.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -168.03 88.45 0.25 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.301 -1.0 . . . . 63.14 108.301 157.415 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.8 m -152.78 101.24 2.7 Favored Pre-proline 0 C--N 1.316 -0.848 0 C-N-CA 120.372 -0.531 . . . . 74.33 111.274 -172.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.66 114.64 4.01 Favored 'Trans proline' 0 C--O 1.237 0.438 0 C-N-CA 122.627 2.218 . . . . 64.14 111.553 175.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 t -92.42 134.44 34.95 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.162 0.506 . . . . 73.3 109.972 -179.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.0 ptp85 -101.88 123.32 45.62 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.801 -0.636 . . . . 75.3 110.811 -176.607 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.589 ' HA ' HG12 ' A' ' 50' ' ' VAL . 60.9 m -76.08 98.17 4.27 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.419 -0.586 . . . . 74.22 109.419 176.616 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 10.7 p 177.04 151.76 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.088 -0.96 . . . . 70.53 108.412 -176.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.424 HH11 ' HD3' ' A' ' 75' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.943 0 CA-C-O 118.335 -0.841 . . . . 74.41 110.292 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.704 0 N-CA-C 111.91 -0.476 . . . . 72.35 111.91 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -83.73 16.74 1.83 Allowed 'Trans proline' 0 CA--C 1.531 0.363 0 C-N-CA 122.978 2.452 . . . . 72.1 113.044 -177.418 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 2.6 p -85.22 111.82 20.18 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.256 -0.429 . . . . 75.23 111.22 179.088 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.6 p -133.16 102.66 5.67 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.125 -0.489 . . . . 74.12 110.42 177.515 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -70.22 116.63 10.79 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.852 0.358 . . . . 74.03 110.36 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.458 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -160.12 160.21 31.44 Favored Glycine 0 N--CA 1.44 -1.059 0 CA-C-N 115.66 -0.7 . . . . 52.24 111.374 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 38.1 m -92.74 147.17 23.08 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 110.185 -0.302 . . . . 72.14 110.185 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -85.53 -177.65 6.48 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.073 0.463 . . . . 64.22 110.826 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 51.9 mt -86.77 125.43 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 CA-C-N 115.989 -0.55 . . . . 73.43 109.8 175.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 56.1 mt -80.12 136.63 23.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.572 -0.74 . . . . 53.14 110.106 -179.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 45.5 m170 -54.49 128.57 60.74 Favored Pre-proline 0 C--N 1.329 -0.295 0 N-CA-C 109.843 -0.429 . . . . 73.31 109.843 173.178 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.484 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 77.5 Cg_exo -51.24 122.45 10.1 Favored 'Trans proline' 0 N--CA 1.461 -0.408 0 C-N-CA 122.501 2.134 . . . . 62.52 111.479 177.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 15.7 Cg_exo -69.09 -159.05 0.05 OUTLIER 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 123.081 2.52 . . . . 72.42 111.747 179.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -59.93 159.81 8.67 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.557 -0.534 . . . . 72.24 109.557 176.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -39.42 100.9 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 113.687 0.995 . . . . 74.13 113.687 -169.348 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -167.76 -140.2 2.86 Favored Glycine 0 N--CA 1.444 -0.821 0 CA-C-N 114.287 -1.324 . . . . 71.54 110.368 179.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -170.28 -171.01 35.3 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.521 -0.847 . . . . 73.45 112.088 176.196 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 18.5 mt -136.49 136.17 48.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.299 0.571 . . . . 70.34 111.005 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.82 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 19.1 tpt85 -107.86 119.23 38.87 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 115.266 -0.879 . . . . 74.22 110.179 -176.591 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.637 ' HB3' ' HE1' ' A' ' 38' ' ' TYR . 99.5 m-85 -96.2 -171.3 2.28 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.223 -0.444 . . . . 74.35 110.872 -179.474 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.427 HH11 ' HD3' ' A' ' 21' ' ' ARG . 1.5 mmp_? -91.39 -72.2 0.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.981 -0.554 . . . . 74.3 111.466 -178.395 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -128.2 63.85 0.61 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.494 -0.86 . . . . 71.12 112.157 -176.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.485 ' HG ' ' OH ' ' A' ' 38' ' ' TYR . 75.4 mt -125.15 121.29 33.79 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.895 0.379 . . . . 52.44 110.832 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.5 t -83.01 -179.47 7.45 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 115.664 -0.698 . . . . 75.32 109.944 176.238 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' A' ' 25' ' ' ARG . 10.3 mmt180 -76.09 -174.56 2.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.093 0.473 . . . . 73.32 111.817 -175.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 24.4 t70 55.2 27.69 10.04 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.121 -0.945 . . . . 54.04 110.169 -175.447 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.466 ' O ' HG22 ' A' ' 28' ' ' VAL . 26.9 mt-30 -134.03 -164.32 1.48 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.519 -0.764 . . . . 70.15 110.271 -178.097 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.466 HG22 ' O ' ' A' ' 27' ' ' GLN . 4.6 m 53.59 15.0 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 124.757 1.223 . . . . 75.0 112.765 178.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -89.46 -19.11 25.51 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.419 -0.355 . . . . 71.12 110.687 178.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.47 86.96 0.81 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.008 0.432 . . . . 75.11 111.037 178.327 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.5 mt -128.45 106.88 15.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 108.855 -0.794 . . . . 74.23 108.855 176.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -73.14 -40.0 65.26 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.261 -0.427 . . . . 73.04 111.855 -172.276 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.458 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 81.9 m-85 -135.55 116.9 14.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.085 0.469 . . . . 71.25 111.929 -176.267 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -81.58 135.78 49.28 Favored Pre-proline 0 C--N 1.321 -0.633 0 N-CA-C 108.883 -0.784 . . . . 73.11 108.883 169.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.36 153.3 61.34 Favored 'Trans proline' 0 C--O 1.238 0.481 0 C-N-CA 122.327 2.018 . . . . 63.24 112.929 -176.068 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.496 HG23 ' HA ' ' A' ' 59' ' ' LEU . 2.9 p -68.19 85.72 0.14 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.351 0 CA-C-O 122.04 0.924 . . . . 72.31 109.629 174.781 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 16.6 t70 175.32 -39.46 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.86 -1.064 . . . . 75.53 109.666 -170.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.637 ' HE1' ' HB3' ' A' ' 20' ' ' TYR . 0.2 OUTLIER -74.02 126.86 31.43 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.987 -1.006 . . . . 74.11 112.405 -171.979 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.532 ' HG2' ' HB2' ' A' ' 57' ' ' LYS . 40.9 mt-10 -107.84 127.52 53.79 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.427 -0.806 . . . . 72.52 109.278 172.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 44.8 pt -110.0 142.82 21.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.005 0.431 . . . . 75.11 111.441 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.82 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 40.3 tt0 -107.54 147.87 29.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.706 -0.679 . . . . 74.33 109.918 176.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.521 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 94.4 m-85 -103.83 101.88 11.69 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.406 -0.361 . . . . 75.13 110.046 177.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -95.2 170.45 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.714 0.292 . . . . 43.53 111.006 -178.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.553 ' HB2' HG13 ' A' ' 50' ' ' VAL . 26.1 t -93.27 179.8 5.3 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.644 -0.502 . . . . 51.42 109.644 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 2.0 tmt_? -78.59 93.37 4.83 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.847 0.356 . . . . 71.44 110.932 -175.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.49 -136.16 13.35 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.742 -0.742 . . . . 62.21 112.445 175.075 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 8.0 mp0 -89.89 14.88 10.95 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.269 0.557 . . . . 71.43 109.736 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.493 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 15.7 mmt-85 -88.56 137.53 32.24 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.53 -0.759 . . . . 74.21 109.203 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -105.46 165.06 11.4 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.054 0.454 . . . . 74.41 110.614 176.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.553 HG13 ' HB2' ' A' ' 44' ' ' CYS . 34.2 m -121.87 136.09 59.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.793 -0.639 . . . . 54.31 109.486 177.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.418 HG13 ' O ' ' A' ' 51' ' ' VAL . 7.2 p -93.0 95.75 5.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 122.275 1.036 . . . . 73.23 109.018 174.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.87 171.8 33.22 Favored Glycine 0 N--CA 1.443 -0.863 0 CA-C-N 114.567 -1.197 . . . . 43.0 111.375 -178.547 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -82.28 42.22 1.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.594 2.196 . . . . 70.42 110.387 175.641 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.634 ' HD3' ' HG3' ' A' ' 41' ' ' GLU . 0.0 OUTLIER -75.13 86.39 2.39 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.796 0.807 . . . . 72.35 112.871 -170.394 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.454 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.4 p -161.85 126.5 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-N 114.903 -1.044 . . . . 74.12 109.026 169.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.454 ' HD3' ' O ' ' A' ' 55' ' ' VAL . 22.4 mmt180 -134.89 128.43 32.59 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.28 -0.418 . . . . 73.32 110.076 -178.19 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.532 ' HB2' ' HG2' ' A' ' 39' ' ' GLU . 38.4 ttpt -107.23 136.4 47.13 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 116.05 -0.523 . . . . 71.3 110.031 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 43.8 t -77.53 134.35 38.32 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.203 -0.453 . . . . 74.1 110.179 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.496 ' HA ' HG23 ' A' ' 36' ' ' VAL . 97.8 mt -102.9 -178.74 3.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.127 -0.488 . . . . 75.32 109.811 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.42 51.76 0.9 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.328 0.585 . . . . 34.01 111.029 179.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -160.65 170.67 20.36 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.279 -0.873 . . . . 74.35 108.926 177.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -85.46 38.53 3.01 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 120.721 -0.752 . . . . 74.22 113.802 -173.286 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.3 m -156.67 151.71 26.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 117.229 0.515 . . . . 64.31 110.537 178.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 71.2 m95 -79.29 167.91 20.27 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.179 -0.464 . . . . 65.43 109.975 178.068 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 17.8 p -55.19 -65.29 0.61 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.043 0.449 . . . . 71.12 111.99 -177.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -125.85 97.19 5.03 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.976 -0.75 . . . . 71.12 108.976 176.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 27.0 ttt -100.69 76.25 1.79 Allowed 'General case' 0 C--N 1.321 -0.663 0 C-N-CA 118.817 -1.153 . . . . 72.34 110.7 -178.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -171.76 89.89 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.276 -1.329 . . . . 63.14 108.568 160.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.5 m -135.46 119.41 13.07 Favored Pre-proline 0 C--N 1.317 -0.832 0 C-N-CA 119.758 -0.777 . . . . 74.33 112.004 -172.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -83.1 106.85 1.44 Allowed 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.867 2.378 . . . . 64.14 112.576 178.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.495 ' HB2' HG21 ' A' ' 50' ' ' VAL . 12.1 p -95.39 105.41 17.37 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.042 0.449 . . . . 73.3 110.813 178.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.8 ptp85 -89.18 125.18 34.95 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.159 -0.473 . . . . 75.3 110.955 -177.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.445 ' HA ' HG12 ' A' ' 50' ' ' VAL . 59.7 m -72.44 122.06 20.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.123 -0.49 . . . . 74.22 110.572 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 85.8 t -137.56 136.15 46.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.763 -0.458 . . . . 70.53 109.763 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.247 0.939 0 CA-C-O 119.079 -0.486 . . . . 74.41 110.669 -179.093 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.623 0 N-CA-C 111.812 -0.515 . . . . 72.35 111.812 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -84.83 30.95 0.5 Allowed 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 123.188 2.592 . . . . 72.1 112.462 -176.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 30.4 p -79.59 98.97 7.11 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.927 0.394 . . . . 75.23 110.183 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 27.5 m -128.36 98.63 5.12 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.238 0.542 . . . . 74.12 110.579 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -101.85 99.13 9.32 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.696 -0.853 . . . . 74.03 108.696 174.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -160.64 164.34 34.55 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.535 -0.84 . . . . 52.24 112.573 -174.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.429 ' N ' ' SG ' ' A' ' 58' ' ' CYS . 35.2 m -105.06 150.41 25.01 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 109.49 -0.559 . . . . 72.14 109.49 -178.612 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.4 pt20 -73.44 179.67 3.91 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.113 0.483 . . . . 64.22 110.607 177.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.4 tt -88.24 140.64 15.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.755 -0.657 . . . . 73.43 110.201 -178.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 57.3 mt -96.25 135.91 28.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.388 -0.369 . . . . 53.14 110.937 -176.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . 0.406 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 2.5 t-80 -89.29 130.94 42.14 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 115.928 -0.578 . . . . 73.31 109.485 178.487 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 11' ' ' HIS . 33.5 Cg_exo -57.86 109.99 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.795 2.33 . . . . 62.52 112.393 -178.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -75.67 -59.09 0.04 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.437 0 C-N-CA 122.691 2.261 . . . . 72.42 112.298 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -91.59 -178.43 5.08 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.102 -0.499 . . . . 72.24 109.851 -176.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -71.29 15.64 0.12 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 112.237 0.458 . . . . 74.13 112.237 -177.623 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.542 ' HA2' ' H ' ' A' ' 45' ' ' ARG . . . -96.65 -147.56 22.83 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.508 -0.637 . . . . 71.54 111.508 175.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.74 -170.56 30.84 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 121.071 -0.585 . . . . 73.45 111.78 179.524 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.1 mt -129.38 134.89 62.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.093 0.473 . . . . 70.34 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -106.77 135.41 48.34 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.44 -0.8 . . . . 74.22 109.931 -178.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.501 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 91.4 m-85 -101.02 -171.35 1.98 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.305 -0.407 . . . . 74.35 110.017 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 21.6 mtt180 -80.17 -44.49 19.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.814 0.34 . . . . 74.3 111.435 -179.014 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.38 61.61 0.24 Allowed Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.583 -0.818 . . . . 71.12 112.13 -178.515 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 80.7 mt -120.81 116.76 25.82 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.79 0.329 . . . . 52.44 110.456 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.3 t -78.89 -179.44 6.6 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.636 -0.711 . . . . 75.32 109.734 175.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.426 ' C ' ' H ' ' A' ' 27' ' ' GLN . 99.4 mtt180 -67.8 -172.75 0.29 Allowed 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.741 0.305 . . . . 73.32 111.479 -177.418 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 30.5 t70 68.09 -42.79 0.47 Allowed 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.629 0.772 . . . . 54.04 110.882 -171.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.573 ' O ' HG22 ' A' ' 28' ' ' VAL . 20.4 mt-30 -71.87 -179.49 2.72 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.328 -0.396 . . . . 70.15 110.806 176.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 27' ' ' GLN . 2.8 m 57.45 9.88 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 124.559 1.144 . . . . 75.0 112.347 -178.609 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -82.71 -17.73 43.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.272 0.558 . . . . 71.12 109.896 175.17 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -161.9 94.53 0.94 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.091 -0.959 . . . . 75.11 110.191 179.127 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 57.8 mt -131.98 130.27 61.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.578 -0.737 . . . . 74.23 109.42 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -89.95 -51.87 5.26 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.379 -0.373 . . . . 73.04 111.301 -175.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -134.72 131.48 37.69 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.296 0.569 . . . . 71.25 112.133 -175.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -97.59 117.42 65.39 Favored Pre-proline 0 C--N 1.322 -0.622 0 N-CA-C 107.876 -1.157 . . . . 73.11 107.876 168.201 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -56.52 147.13 71.23 Favored 'Trans proline' 0 C--O 1.237 0.434 0 C-N-CA 123.205 2.603 . . . . 63.24 113.373 -173.196 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.55 83.87 0.05 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.323 0 CA-C-O 121.85 0.833 . . . . 72.31 110.771 177.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.8 t70 168.45 -33.46 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 114.578 -1.192 . . . . 75.53 108.942 -176.484 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.501 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 14.1 t80 -67.56 141.11 56.95 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.324 -0.853 . . . . 74.11 110.636 -177.227 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.457 ' HG2' ' HE2' ' A' ' 57' ' ' LYS . 10.5 mt-10 -125.36 142.15 51.67 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.53 -0.759 . . . . 72.52 110.083 -177.029 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.655 HG13 ' HB2' ' A' ' 56' ' ' ARG . 46.4 pt -130.65 169.31 21.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.715 0.293 . . . . 75.11 110.694 178.748 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -128.52 139.24 52.41 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.189 -0.459 . . . . 74.33 110.981 -178.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.41 ' O ' HG21 ' A' ' 50' ' ' VAL . 5.1 m-30 -83.65 102.32 12.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.765 -0.652 . . . . 75.13 110.349 176.161 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.9 m -108.31 170.93 2.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 120.898 0.38 . . . . 43.53 110.909 -178.535 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.714 ' HB2' HG13 ' A' ' 50' ' ' VAL . 10.5 t -109.64 143.63 39.12 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.06 -0.718 . . . . 51.42 109.06 175.012 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.542 ' H ' ' HA2' ' A' ' 16' ' ' GLY . 75.7 ttt180 -77.58 133.68 38.42 Favored 'General case' 0 N--CA 1.44 -0.974 0 CA-C-N 115.029 -0.987 . . . . 71.44 110.588 -172.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.13 -149.84 18.81 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.799 -0.715 . . . . 62.21 111.688 -178.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.455 ' CD ' ' H ' ' A' ' 47' ' ' GLU . 1.0 OUTLIER -93.66 16.08 14.72 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.406 0.622 . . . . 71.43 109.646 176.799 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.654 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 40.8 mmm-85 -89.22 118.94 29.28 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.317 -0.856 . . . . 74.21 109.169 178.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.523 ' HB2' ' HA ' ' A' ' 75' ' ' ARG . 48.8 mt-10 -95.92 171.37 8.68 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.991 -0.374 . . . . 74.41 109.991 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.714 HG13 ' HB2' ' A' ' 44' ' ' CYS . 5.5 m -129.86 126.25 62.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.948 0.404 . . . . 54.31 111.545 -177.593 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.601 HG12 ' HB ' ' A' ' 74' ' ' VAL . 3.5 p -96.37 95.76 5.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 108.463 -0.94 . . . . 73.23 108.463 167.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.51 172.73 33.01 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.373 -0.83 . . . . 43.0 112.497 -173.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -75.27 52.98 3.31 Favored 'Trans proline' 0 N--CA 1.462 -0.335 0 C-N-CA 123.012 2.475 . . . . 70.42 110.734 173.341 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.418 ' HD3' HG23 ' A' ' 50' ' ' VAL . 19.4 pttp -72.11 89.54 1.15 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.512 -0.767 . . . . 72.35 111.863 -174.163 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.1 p -160.54 132.24 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.821 -0.627 . . . . 74.12 110.574 176.581 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.655 ' HB2' HG13 ' A' ' 40' ' ' ILE . 55.1 mmt-85 -138.35 126.8 23.24 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.933 -0.576 . . . . 73.32 110.195 176.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.457 ' HE2' ' HG2' ' A' ' 39' ' ' GLU . 37.3 ttmt -125.08 137.48 54.2 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.007 -0.738 . . . . 71.3 109.007 175.149 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 7' ' ' CYS . 53.3 t -81.31 144.17 31.7 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.894 0.378 . . . . 74.1 111.073 -176.117 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 94.4 mt -100.95 -179.07 3.94 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.716 -0.675 . . . . 75.32 111.005 -178.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -73.92 -20.58 60.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.185 0.517 . . . . 34.01 110.374 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -101.43 169.1 9.1 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.397 -0.82 . . . . 74.35 109.313 175.283 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -76.75 60.56 3.36 Favored Glycine 0 CA--C 1.518 0.253 0 C-N-CA 120.83 -0.7 . . . . 74.22 113.28 -175.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 49.4 m -158.63 144.31 16.65 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 122.789 0.436 . . . . 64.31 109.939 177.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 75.7 m95 -81.19 161.65 23.93 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.75 -0.463 . . . . 65.43 109.75 177.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.9 p -52.9 -39.14 62.47 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.221 0.823 . . . . 71.12 113.221 -174.152 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -134.03 140.86 46.95 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 110.186 -0.302 . . . . 71.12 110.186 178.588 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 50.5 mtt -144.36 80.01 1.63 Allowed 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.367 -0.533 . . . . 72.34 111.453 167.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -168.6 88.85 0.22 Allowed 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.416 -0.957 . . . . 63.14 108.416 156.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.8 m -155.83 90.11 2.83 Favored Pre-proline 0 C--N 1.317 -0.823 0 C-N-CA 120.283 -0.567 . . . . 74.33 111.283 -172.076 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -74.18 90.28 1.0 Allowed 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.689 2.26 . . . . 64.14 110.396 172.407 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.2 t -69.26 116.93 10.25 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.985 -0.552 . . . . 73.3 110.724 -175.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.0 ptp180 -79.57 130.67 35.6 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.534 -0.757 . . . . 75.3 110.409 179.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.584 ' HA ' HG12 ' A' ' 50' ' ' VAL . 73.6 m -81.02 97.89 7.71 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.309 0.576 . . . . 74.22 110.013 178.261 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.601 ' HB ' HG12 ' A' ' 51' ' ' VAL . 59.6 t -136.68 117.99 18.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.184 -0.916 . . . . 70.53 108.653 177.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.523 ' HA ' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.556 -0.735 . . . . 74.41 111.161 -176.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.769 0 N-CA-C 111.67 -0.572 . . . . 72.35 111.67 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -70.08 92.81 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.796 2.331 . . . . 72.1 111.549 177.151 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 27.1 m -151.82 139.31 19.56 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.036 -0.529 . . . . 75.23 109.984 -178.01 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.0 m -143.06 99.5 3.47 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.74 -0.467 . . . . 74.12 109.74 177.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -75.43 99.44 4.17 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.222 -0.445 . . . . 74.03 110.617 -178.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.57 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -159.91 152.56 23.44 Favored Glycine 0 N--CA 1.441 -1.002 0 C-N-CA 120.572 -0.823 . . . . 52.24 112.694 -179.144 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.1 m -86.52 158.76 19.47 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 110.13 -0.322 . . . . 72.14 110.13 178.137 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.435 HE21 ' HB2' ' A' ' 8' ' ' GLN . 1.8 pt20 -88.86 -177.19 5.44 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.052 0.453 . . . . 64.22 111.192 -179.106 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.543 HD11 ' HB ' ' A' ' 31' ' ' ILE . 60.7 mt -87.49 138.16 19.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.615 -0.72 . . . . 73.43 110.487 -177.715 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 64.8 mt -99.78 131.06 47.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.18 -0.464 . . . . 53.14 109.929 178.199 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -76.55 126.09 86.59 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.868 -0.605 . . . . 73.31 110.171 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_endo -58.51 112.69 1.26 Allowed 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.72 2.28 . . . . 62.52 111.921 179.266 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -74.87 -87.6 0.0 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.393 0 C-N-CA 122.481 2.121 . . . . 72.42 113.091 -176.059 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 27.8 t-105 -101.37 -177.84 3.56 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.999 -0.371 . . . . 72.24 109.999 -178.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 56.7 mm-40 -39.81 101.93 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.746 0.818 . . . . 74.13 111.98 177.688 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.436 ' HA2' ' HA ' ' A' ' 44' ' ' CYS . . . 171.32 -167.6 40.72 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.39 -0.91 . . . . 71.54 112.637 177.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -159.17 -170.52 23.81 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.989 -0.844 . . . . 73.45 110.989 178.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.464 HG23 ' HB ' ' A' ' 40' ' ' ILE . 16.6 mt -135.05 135.59 52.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.449 0.642 . . . . 70.34 111.835 -177.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.49 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 55.6 ttm-85 -99.49 138.56 36.4 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.081 -0.963 . . . . 74.22 110.578 178.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.506 ' HB3' ' HE1' ' A' ' 38' ' ' TYR . 89.1 m-85 -110.76 -168.03 1.26 Allowed 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.132 -0.321 . . . . 74.35 110.132 177.565 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -62.04 -57.82 10.2 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 120.88 0.371 . . . . 74.3 110.487 178.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -161.55 67.76 0.24 Allowed Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 121.055 -0.593 . . . . 71.12 111.872 178.489 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 92.7 mt -118.12 126.77 52.91 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.965 0.412 . . . . 52.44 110.949 -179.18 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 12.8 t -85.03 -176.71 6.32 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.387 -0.824 . . . . 75.32 110.46 176.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 29.9 ptt180 -61.94 -173.51 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 115.923 -0.58 . . . . 73.32 111.818 -177.116 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.9 t70 65.06 -46.14 0.35 Allowed 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 123.894 0.878 . . . . 54.04 112.263 -179.116 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.547 ' O ' HG22 ' A' ' 28' ' ' VAL . 18.4 mt-30 -68.96 -169.76 0.19 Allowed 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 123.079 0.552 . . . . 70.15 111.257 -179.284 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.547 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.2 m 55.61 15.66 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 124.264 1.026 . . . . 75.0 111.832 -178.206 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.416 ' H ' ' HG2' ' A' ' 29' ' ' LYS . 40.1 pttt -81.42 -14.33 57.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.829 -0.623 . . . . 71.12 110.066 175.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -161.21 117.48 2.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.601 -0.727 . . . . 75.11 110.436 177.154 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.543 ' HB ' HD11 ' A' ' 9' ' ' ILE . 42.1 mt -138.6 152.71 25.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 N-CA-C 109.105 -0.702 . . . . 74.23 109.105 179.161 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -105.07 -65.09 1.07 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.673 0.273 . . . . 73.04 110.646 179.018 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.57 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 96.5 m-85 -140.73 128.61 21.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.412 -0.358 . . . . 71.25 110.704 -179.203 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -88.08 119.59 70.43 Favored Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 109.158 -0.682 . . . . 73.11 109.158 175.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.01 152.47 43.76 Favored 'Trans proline' 0 C--O 1.236 0.402 0 C-N-CA 122.899 2.4 . . . . 63.24 113.29 -176.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.433 HG23 ' HA ' ' A' ' 59' ' ' LEU . 3.5 p -62.63 94.93 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-O 121.707 0.765 . . . . 72.31 111.023 178.235 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.0 t70 173.85 -43.41 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.574 -1.194 . . . . 75.53 109.36 -177.424 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.506 ' HE1' ' HB3' ' A' ' 20' ' ' TYR . 5.3 m-85 -50.41 123.01 7.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.039 -0.982 . . . . 74.11 112.596 -175.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.586 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 35.2 mt-10 -114.18 100.01 8.05 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.849 -1.069 . . . . 72.52 108.575 172.349 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.576 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 34.7 pt -90.7 143.64 10.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.142 0.496 . . . . 75.11 111.3 -175.772 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.49 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 42.5 tt0 -109.82 136.49 49.05 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.481 -0.781 . . . . 74.33 110.269 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.485 ' H ' ' HB2' ' A' ' 54' ' ' LYS . 95.5 m-85 -85.43 100.58 11.97 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 116.216 -0.447 . . . . 75.13 110.051 175.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.3 m -100.98 163.39 3.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.045 -0.525 . . . . 43.53 110.199 179.389 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.805 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 3.4 t -90.38 147.07 23.68 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 107.93 -1.137 . . . . 51.42 107.93 173.112 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -59.72 108.61 0.77 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.17 0.509 . . . . 71.44 110.942 -170.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.21 -137.21 13.13 Favored Glycine 0 N--CA 1.448 -0.563 0 CA-C-N 115.703 -0.68 . . . . 62.21 112.086 178.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.475 ' CD ' ' H ' ' A' ' 47' ' ' GLU . 0.5 OUTLIER -101.22 33.53 2.85 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.301 0.572 . . . . 71.43 110.278 -179.274 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.805 ' HB2' ' HB3' ' A' ' 44' ' ' CYS . 30.1 mmm180 -89.22 145.49 25.37 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.786 -0.643 . . . . 74.21 109.974 179.682 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.617 ' HB2' ' HB3' ' A' ' 75' ' ' ARG . 43.1 mt-10 -91.57 148.96 21.9 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.231 0.538 . . . . 74.41 112.201 -174.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.742 HG13 ' HB2' ' A' ' 44' ' ' CYS . 11.6 m -138.64 150.46 23.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.368 -0.833 . . . . 54.31 110.131 178.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -135.65 97.35 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 122.019 0.914 . . . . 73.23 109.558 170.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.42 173.09 32.26 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-N 114.462 -1.245 . . . . 43.0 110.6 -177.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.497 ' HG2' HG21 ' A' ' 69' ' ' THR . 69.9 Cg_endo -77.17 57.38 5.81 Favored 'Trans proline' 0 C--O 1.235 0.358 0 C-N-CA 122.068 1.845 . . . . 70.42 110.733 176.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.485 ' HB2' ' H ' ' A' ' 42' ' ' TYR . 20.9 pttp -76.4 87.04 3.16 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.383 -0.826 . . . . 72.35 111.608 -173.08 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.4 p -162.57 128.54 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.397 -0.82 . . . . 74.12 109.906 172.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.586 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 26.9 mmt180 -130.1 123.69 31.0 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.622 -0.51 . . . . 73.32 109.622 175.281 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.7 ttmm -105.08 122.7 46.42 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.537 -0.542 . . . . 71.3 109.537 178.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.5 t -74.56 142.51 44.71 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.309 -0.405 . . . . 74.1 110.635 -179.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.433 ' HA ' HG23 ' A' ' 36' ' ' VAL . 94.7 mt -128.64 -179.24 4.95 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.844 -0.616 . . . . 75.32 109.516 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.02 59.27 2.13 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.367 0.603 . . . . 34.01 111.654 -177.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -160.52 165.05 31.55 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.802 -0.814 . . . . 74.35 108.802 175.328 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -80.73 40.27 2.45 Favored Glycine 0 CA--C 1.517 0.214 0 C-N-CA 120.662 -0.78 . . . . 74.22 113.067 -175.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 27.6 t -161.84 163.32 29.4 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.234 -0.654 . . . . 64.31 109.234 -178.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 52.8 m95 -97.16 -179.8 4.65 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 110.033 -0.358 . . . . 65.43 110.033 -176.486 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 1.1 p -56.35 -24.73 46.02 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 112.776 0.658 . . . . 71.12 112.776 -176.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.529 ' HB3' ' NH1' ' A' ' 56' ' ' ARG . 11.2 t70 -160.71 137.02 8.54 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.384 -0.599 . . . . 71.12 109.384 178.304 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 65.9 mtt -130.38 77.0 1.76 Allowed 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 119.436 -0.906 . . . . 72.34 110.611 164.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -170.83 88.63 0.12 Allowed 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 108.855 -0.795 . . . . 63.14 108.855 157.482 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.497 HG21 ' HG2' ' A' ' 53' ' ' PRO . 4.7 m -153.5 107.32 2.56 Favored Pre-proline 0 C--N 1.317 -0.809 0 C-N-CA 120.817 -0.353 . . . . 74.33 110.681 -176.867 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -70.21 95.52 0.59 Allowed 'Trans proline' 0 N--CA 1.462 -0.329 0 C-N-CA 122.694 2.263 . . . . 64.14 112.031 178.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.2 m -78.36 109.44 12.51 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.175 0.512 . . . . 73.3 109.775 177.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.402 ' H ' ' HG2' ' A' ' 72' ' ' ARG . 11.1 ptt180 -97.51 130.6 44.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.574 -0.739 . . . . 75.3 112.085 -172.204 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.513 ' HA ' HG12 ' A' ' 50' ' ' VAL . 81.2 m -82.66 118.25 23.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.665 -0.698 . . . . 74.22 109.824 175.03 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 p -156.36 136.44 4.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 121.082 0.467 . . . . 70.53 110.309 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.617 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 16.1 ptm180 . . . . . 0 C--O 1.244 0.765 0 CA-C-N 115.693 -0.685 . . . . 74.41 109.626 -178.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.545 0 N-CA-C 112.066 -0.413 . . . . 72.35 112.066 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -74.87 74.32 3.97 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.49 2.127 . . . . 72.1 112.845 -177.014 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 37.2 p -104.51 115.98 31.3 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.006 -0.543 . . . . 75.23 110.292 175.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.6 m -109.82 98.02 7.43 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.8 -0.444 . . . . 74.12 109.8 179.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -112.98 98.42 7.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.911 -0.586 . . . . 74.03 109.614 -177.512 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.741 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -162.2 152.57 22.94 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.492 -0.861 . . . . 52.24 112.7 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 60.7 m -90.11 147.53 23.56 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.985 -0.376 . . . . 72.14 109.985 176.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -85.81 -179.54 6.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.777 0.322 . . . . 64.22 110.892 -179.324 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.67 HD11 ' HB ' ' A' ' 31' ' ' ILE . 56.3 mt -88.16 130.62 37.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.939 -0.573 . . . . 73.43 110.313 176.831 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 68.7 mt -73.25 136.18 26.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.745 -0.661 . . . . 53.14 110.239 179.032 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 2.6 t-80 -68.81 138.1 90.39 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 115.989 -0.55 . . . . 73.31 109.936 -178.03 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_exo -40.97 118.87 0.72 Allowed 'Trans proline' 0 C--N 1.351 0.694 0 C-N-CA 123.716 2.944 . . . . 62.52 113.826 -176.723 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.457 ' HB2' ' H ' ' A' ' 14' ' ' TRP . 81.7 Cg_endo -87.5 -149.02 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.128 2.552 . . . . 72.42 112.728 -179.51 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.457 ' H ' ' HB2' ' A' ' 13' ' ' PRO . 9.1 t-105 -75.15 -179.01 4.14 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.69 -0.686 . . . . 72.24 110.516 -177.773 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -46.03 100.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 123.234 0.613 . . . . 74.13 112.172 177.267 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.13 -156.86 28.99 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.331 -0.708 . . . . 71.54 111.331 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.85 -171.23 24.4 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.562 -0.828 . . . . 73.45 111.925 178.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.63 131.44 66.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.651 0.738 . . . . 70.34 111.531 -178.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.707 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 7.9 tpm_? -96.92 104.56 16.58 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 114.298 -1.319 . . . . 74.22 110.064 -178.285 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.472 ' HA ' HG22 ' A' ' 40' ' ' ILE . 97.7 m-85 -80.5 -171.46 3.07 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.519 -0.309 . . . . 74.35 110.187 177.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.7 ttm180 -78.96 -65.35 1.01 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.67 0.272 . . . . 74.3 110.411 -178.843 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -136.16 37.4 1.89 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.423 -0.894 . . . . 71.12 112.275 -178.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.461 HD13 HG12 ' A' ' 28' ' ' VAL . 80.6 mt -102.52 119.73 39.32 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.925 0.393 . . . . 52.44 111.359 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.4 t -94.64 -177.2 4.13 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.712 -0.676 . . . . 75.32 109.662 175.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 77.5 mtt180 -66.88 -173.43 0.24 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.047 0.451 . . . . 73.32 111.627 -176.466 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.0 t0 59.07 19.24 7.1 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 122.029 0.919 . . . . 54.04 110.183 -177.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 23.4 mt-30 -140.35 -165.19 1.86 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.887 -1.052 . . . . 70.15 109.971 -178.39 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.461 HG12 HD13 ' A' ' 23' ' ' LEU . 11.5 m 49.44 24.01 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.312 1.045 . . . . 75.0 112.29 178.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -88.54 -22.38 23.61 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.789 -0.641 . . . . 71.12 110.758 -179.318 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.42 101.07 0.6 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.884 -0.598 . . . . 75.11 110.434 176.6 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.67 ' HB ' HD11 ' A' ' 9' ' ' ILE . 69.0 mt -127.99 138.24 55.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.155 -0.683 . . . . 74.23 109.155 177.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -79.83 -58.25 3.26 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.864 0.364 . . . . 73.04 110.543 -176.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.741 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 82.2 m-85 -139.27 138.4 36.73 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.971 -0.559 . . . . 71.25 110.953 -176.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.95 142.65 32.35 Favored Pre-proline 0 C--N 1.322 -0.593 0 N-CA-C 109.11 -0.7 . . . . 73.11 109.11 172.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -61.33 161.68 22.73 Favored 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 122.648 2.232 . . . . 63.24 112.727 -179.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 p -68.11 143.62 15.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.763 -0.653 . . . . 72.31 110.886 -178.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.5 t70 68.13 19.73 9.13 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.663 0.744 . . . . 75.53 110.942 -178.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -78.12 132.02 37.49 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.742 -0.836 . . . . 74.11 108.742 173.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -123.1 138.28 54.71 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.461 -0.336 . . . . 72.52 110.404 -175.147 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.615 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 14.5 pt -129.88 150.17 34.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.807 -0.633 . . . . 75.11 110.684 -177.69 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.707 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 37.7 tt0 -115.44 152.3 33.17 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.946 -0.57 . . . . 74.33 110.551 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.412 ' HE2' ' HG2' ' A' ' 56' ' ' ARG . 81.6 m-85 -100.11 101.87 13.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.256 -0.429 . . . . 75.13 110.854 178.122 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 33.3 m -94.55 155.02 3.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 120.727 0.299 . . . . 43.53 110.244 177.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 9.8 t -90.91 -179.3 5.45 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.405 -0.591 . . . . 51.42 109.405 -178.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.473 ' HD3' ' HA ' ' A' ' 45' ' ' ARG . 2.3 mmt180 -81.5 153.99 26.53 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.744 -0.382 . . . . 71.44 111.342 -179.167 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.12 -138.44 24.47 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 110.856 -0.898 . . . . 62.21 110.856 -174.175 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -111.08 19.83 18.04 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.475 0.655 . . . . 71.43 109.389 174.545 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.584 ' HA ' ' HD2' ' A' ' 75' ' ' ARG . 7.4 mmm180 -88.9 150.9 22.64 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.269 -0.878 . . . . 74.21 109.556 -177.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.496 ' H ' ' HB3' ' A' ' 75' ' ' ARG . 37.6 mt-10 -120.99 170.44 9.51 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.868 0.366 . . . . 74.41 111.005 -171.277 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.405 HG12 ' HA ' ' A' ' 73' ' ' CYS . 22.7 m -118.3 150.5 20.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.202 -0.453 . . . . 54.31 110.903 -177.634 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.66 HG12 ' HB ' ' A' ' 74' ' ' VAL . 6.4 p -113.01 96.76 4.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 122.156 0.979 . . . . 73.23 109.116 170.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.55 173.4 33.01 Favored Glycine 0 N--CA 1.442 -0.966 0 CA-C-N 114.834 -1.076 . . . . 43.0 110.874 -177.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.49 ' HG2' HG21 ' A' ' 69' ' ' THR . 47.9 Cg_endo -72.39 60.32 3.3 Favored 'Trans proline' 0 CA--C 1.529 0.26 0 C-N-CA 122.191 1.927 . . . . 70.42 110.304 170.008 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.569 ' HD2' ' HG3' ' A' ' 41' ' ' GLU . 32.1 pttt -73.62 89.52 1.74 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.139 -0.937 . . . . 72.35 111.209 -175.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.9 p -160.08 132.71 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.727 -0.67 . . . . 74.12 110.51 178.183 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.615 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 24.2 mmt180 -125.68 114.96 19.36 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.185 -0.672 . . . . 73.32 109.185 173.126 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 41.9 tptt -102.54 116.95 33.64 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.459 -0.791 . . . . 71.3 109.914 -176.147 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . 0.563 ' HB2' ' CZ3' ' A' ' 64' ' ' TRP . 49.3 t -87.91 124.5 33.74 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.137 -0.483 . . . . 74.1 110.074 177.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.415 HD11 HG21 ' A' ' 65' ' ' THR . 41.9 mt -105.08 -177.55 3.4 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.814 -0.63 . . . . 75.32 109.43 176.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -56.63 -32.29 65.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.091 0.472 . . . . 34.01 110.431 174.042 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -81.06 132.08 35.34 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.44 -0.578 . . . . 74.35 109.44 172.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -77.82 64.1 3.38 Favored Glycine 0 N--CA 1.451 -0.313 0 N-CA-C 114.299 0.479 . . . . 74.22 114.299 -171.164 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 58.2 m -157.14 142.27 17.11 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.539 -0.541 . . . . 64.31 109.539 172.278 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.563 ' CZ3' ' HB2' ' A' ' 58' ' ' CYS . 23.1 m95 -78.19 124.4 28.02 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.05 -0.722 . . . . 65.43 109.05 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.415 HG21 HD11 ' A' ' 59' ' ' LEU . 17.2 p -75.62 33.03 0.11 Allowed 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 114.358 1.244 . . . . 71.12 114.358 -167.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -160.75 13.91 0.11 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.865 0.364 . . . . 71.12 110.056 176.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 26.1 ttt -76.65 78.94 3.3 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-O 121.875 0.845 . . . . 72.34 112.416 -165.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -169.68 88.88 0.17 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 114.382 -1.281 . . . . 63.14 107.783 159.284 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.49 HG21 ' HG2' ' A' ' 53' ' ' PRO . 0.7 OUTLIER -152.78 117.86 2.93 Favored Pre-proline 0 C--N 1.318 -0.801 0 C-N-CA 120.19 -0.604 . . . . 74.33 111.345 -169.751 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -78.72 100.53 1.37 Allowed 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.885 2.39 . . . . 64.14 111.318 174.399 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.7 p -79.39 116.83 19.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.051 0.453 . . . . 73.3 111.112 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.8 ptp180 -89.47 129.2 36.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.729 -0.668 . . . . 75.3 111.285 -177.223 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.405 ' HA ' HG12 ' A' ' 50' ' ' VAL . 62.3 m -82.88 105.5 13.94 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.718 -0.475 . . . . 74.22 109.718 178.481 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.66 ' HB ' HG12 ' A' ' 51' ' ' VAL . 49.1 t -128.33 84.27 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 121.072 0.463 . . . . 70.53 109.76 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.584 ' HD2' ' HA ' ' A' ' 48' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.751 0 N-CA-C 108.54 -0.911 . . . . 74.41 108.54 -178.728 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.582 0 N-CA-C 111.964 -0.454 . . . . 72.35 111.964 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -69.6 92.9 0.5 Allowed 'Trans proline' 0 C--O 1.236 0.413 0 C-N-CA 122.723 2.282 . . . . 72.1 111.098 176.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 16.9 p -91.82 99.26 12.16 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.941 -0.572 . . . . 75.23 112.369 -173.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.3 m -95.24 107.59 19.7 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.354 -0.98 . . . . 74.12 108.354 169.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -78.2 99.88 6.41 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.275 0.56 . . . . 74.03 111.195 -172.145 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.6 ' HA3' ' HB3' ' A' ' 33' ' ' PHE . . . -159.47 146.96 13.64 Favored Glycine 0 N--CA 1.44 -1.054 0 CA-C-N 115.239 -0.891 . . . . 52.24 111.678 179.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 59.9 m -92.88 142.93 26.77 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 110.05 -0.352 . . . . 72.14 110.05 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -76.02 -177.62 3.99 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.884 0.374 . . . . 64.22 111.055 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 61.3 mt -87.38 137.66 20.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.057 -0.52 . . . . 73.43 111.176 -175.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 27.5 mt -84.13 156.57 3.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.5 -0.773 . . . . 53.14 110.217 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -82.68 141.47 44.77 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.64 -0.255 . . . . 73.31 110.67 -177.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.54 131.32 21.3 Favored 'Trans proline' 0 C--O 1.235 0.362 0 C-N-CA 122.74 2.293 . . . . 62.52 112.462 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -87.6 -140.1 0.02 OUTLIER 'Trans proline' 0 CA--C 1.533 0.43 0 C-N-CA 123.176 2.584 . . . . 72.42 112.393 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.523 ' HD1' ' H ' ' A' ' 15' ' ' GLU . 1.9 t90 -67.54 -179.44 1.08 Allowed 'General case' 0 CA--C 1.537 0.452 0 CA-C-N 116.071 -0.513 . . . . 72.24 109.641 178.248 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.523 ' H ' ' HD1' ' A' ' 14' ' ' TRP . 29.3 mm-40 -43.2 102.38 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 123.629 0.772 . . . . 74.13 112.886 -176.343 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.08 -154.82 25.66 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 110.224 -1.15 . . . . 71.54 110.224 -177.285 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.95 -171.36 37.61 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.224 -0.989 . . . . 73.45 112.064 176.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 22.7 mt -111.54 128.88 67.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.745 0.783 . . . . 70.34 111.279 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.76 ' HB3' ' HB3' ' A' ' 41' ' ' GLU . 9.2 tpt180 -96.76 127.3 42.61 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.581 -1.191 . . . . 74.22 108.966 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.525 ' HA ' HG22 ' A' ' 40' ' ' ILE . 77.4 m-85 -91.02 -172.46 3.34 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.341 -0.544 . . . . 74.35 110.021 178.647 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 21' ' ' ARG . 18.9 ttt85 -80.69 -62.78 1.57 Allowed 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.602 -0.439 . . . . 74.3 110.753 -172.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -146.98 57.02 0.5 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.693 -0.765 . . . . 71.12 111.986 177.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 93.2 mt -119.41 139.5 51.92 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.975 0.417 . . . . 52.44 111.246 -176.637 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 14.8 t -86.47 173.11 9.84 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.928 -0.578 . . . . 75.32 109.49 174.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.503 ' O ' ' HB3' ' A' ' 26' ' ' ASP . 31.7 ptt180 -79.83 -171.52 2.91 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 121.12 -0.232 . . . . 73.32 110.581 -177.135 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.503 ' HB3' ' O ' ' A' ' 25' ' ' ARG . 12.6 t70 72.77 -38.9 0.43 Allowed 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 109.178 -0.675 . . . . 54.04 109.178 -168.663 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.509 ' O ' HG22 ' A' ' 28' ' ' VAL . 24.0 mt-30 -83.33 -169.12 2.38 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.602 -0.888 . . . . 70.15 108.602 167.096 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.509 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.2 m 55.6 9.54 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 C-N-CA 124.219 1.008 . . . . 75.0 113.593 174.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -92.99 -29.13 16.0 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.076 0.465 . . . . 71.12 109.827 176.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.36 91.8 1.63 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.766 -0.652 . . . . 75.11 110.561 177.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.9 mt -115.79 135.7 55.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.706 -0.679 . . . . 74.23 109.209 177.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 15.5 m120 -72.94 -59.76 2.56 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.684 0.278 . . . . 73.04 110.925 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.6 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . 74.4 m-85 -131.88 129.9 40.94 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.819 0.343 . . . . 71.25 111.171 -177.163 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.417 ' HA ' ' HD2' ' A' ' 35' ' ' PRO . 3.7 mm? -90.96 113.05 56.81 Favored Pre-proline 0 C--N 1.322 -0.619 0 N-CA-C 108.181 -1.044 . . . . 73.11 108.181 169.026 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.417 ' HD2' ' HA ' ' A' ' 34' ' ' LEU . 11.6 Cg_endo -53.61 156.27 11.88 Favored 'Trans proline' 0 C--O 1.234 0.28 0 C-N-CA 123.432 2.755 . . . . 63.24 113.549 -172.516 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.516 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 13.3 p -54.78 147.44 3.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.484 -0.78 . . . . 72.31 111.098 178.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.516 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 15.0 m-20 79.23 5.05 2.23 Favored 'General case' 0 N--CA 1.467 0.425 0 C-N-CA 123.654 0.782 . . . . 75.53 111.571 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.511 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 24.3 t80 -82.75 144.97 29.82 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.808 0.337 . . . . 74.11 110.241 178.406 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.537 ' HA ' ' O ' ' A' ' 56' ' ' ARG . 37.0 mt-10 -135.25 138.16 43.27 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.916 -0.584 . . . . 72.52 110.283 -177.374 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.645 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 20.3 pt -125.76 158.94 34.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 120.805 0.335 . . . . 75.11 110.77 177.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.76 ' HB3' ' HB3' ' A' ' 19' ' ' ARG . 49.8 tt0 -116.16 149.86 38.37 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.859 -0.61 . . . . 74.33 110.976 -174.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.409 ' HE2' ' CG ' ' A' ' 56' ' ' ARG . 8.2 m-85 -94.33 102.01 13.99 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.28 -0.418 . . . . 75.13 110.185 175.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.602 HG11 HH11 ' A' ' 19' ' ' ARG . 18.2 m -108.42 156.43 8.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.109 0.481 . . . . 43.53 111.63 -177.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.546 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 5.2 t -96.35 158.47 15.42 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.193 -1.04 . . . . 51.42 108.193 178.437 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -65.59 117.72 8.47 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.26 0.467 . . . . 71.44 112.26 -174.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.34 -137.32 13.65 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.587 -0.733 . . . . 62.21 111.807 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -98.79 22.67 9.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.864 0.84 . . . . 71.43 109.077 174.223 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.594 ' HD2' ' OXT' ' A' ' 75' ' ' ARG . 10.7 mmm180 -88.18 134.19 33.84 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.642 -1.163 . . . . 74.21 109.184 -178.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.618 ' H ' ' HB3' ' A' ' 75' ' ' ARG . 46.4 mt-10 -116.66 170.1 8.85 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 120.98 0.419 . . . . 74.41 110.924 -179.06 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.54 HG12 ' HA ' ' A' ' 73' ' ' CYS . 28.9 m -116.85 149.53 19.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.405 -0.816 . . . . 54.31 109.206 174.199 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.6 p -106.12 95.09 3.52 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 122.035 0.922 . . . . 73.23 108.681 170.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -155.74 172.58 33.8 Favored Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 114.607 -1.179 . . . . 43.0 111.667 -176.041 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.506 ' HG2' ' CG2' ' A' ' 69' ' ' THR . 56.5 Cg_endo -73.72 53.1 2.68 Favored 'Trans proline' 0 CA--C 1.532 0.413 0 C-N-CA 122.494 2.129 . . . . 70.42 110.713 171.076 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 48.2 pttt -69.03 91.34 0.48 Allowed 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 114.805 -1.089 . . . . 72.35 111.948 -173.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 8.2 p -160.83 132.11 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.553 0.692 . . . . 74.12 110.912 175.057 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.645 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 42.9 mmt180 -121.23 113.82 20.5 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.528 -0.76 . . . . 73.32 109.128 172.402 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -108.78 129.78 55.38 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.155 -0.475 . . . . 71.3 110.084 -177.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 52.4 t -96.72 113.86 25.45 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.26 -0.427 . . . . 74.1 110.244 178.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.551 ' HB2' ' OD1' ' A' ' 61' ' ' ASN . 35.9 mt -96.45 -176.05 3.51 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.121 -0.696 . . . . 75.32 109.121 177.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -71.4 55.81 0.23 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-O 121.214 0.53 . . . . 34.01 111.18 177.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.551 ' OD1' ' HB2' ' A' ' 59' ' ' LEU . 4.4 p-10 -160.34 167.64 26.99 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.706 -0.85 . . . . 74.35 108.706 178.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -91.79 47.15 2.73 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.488 -0.863 . . . . 74.22 113.62 -171.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 38.9 m -160.59 136.33 8.22 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 117.041 0.42 . . . . 64.31 110.797 178.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . 0.433 ' HB2' ' CG ' ' A' ' 67' ' ' MET . 63.0 m95 -71.41 123.22 21.88 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.02 -1.104 . . . . 65.43 108.02 171.628 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.543 HG21 HD12 ' A' ' 59' ' ' LEU . 13.6 p -77.23 38.23 0.22 Allowed 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 115.074 1.509 . . . . 71.12 115.074 -164.329 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -162.51 20.16 0.09 Allowed 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 120.413 -0.515 . . . . 71.12 111.818 173.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . 0.433 ' CG ' ' HB2' ' A' ' 64' ' ' TRP . 58.3 mtm -76.28 79.53 3.05 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 119.311 -0.956 . . . . 72.34 112.412 -168.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -169.76 89.27 0.17 Allowed 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 107.495 -1.298 . . . . 63.14 107.495 161.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.506 ' CG2' ' HG2' ' A' ' 53' ' ' PRO . 2.8 m -147.2 124.63 5.84 Favored Pre-proline 0 C--N 1.321 -0.65 0 C-N-CA 119.595 -0.842 . . . . 74.33 112.387 -168.265 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . 0.486 ' HD3' ' HA ' ' A' ' 69' ' ' THR . 9.6 Cg_endo -89.21 90.49 0.38 Allowed 'Trans proline' 0 N--CA 1.451 -0.989 0 C-N-CA 123.388 2.725 . . . . 64.14 111.62 174.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.1 m -90.31 118.17 29.6 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.263 -0.426 . . . . 73.3 110.149 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.5 ptp180 -89.15 119.47 29.68 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.054 -0.521 . . . . 75.3 111.334 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.54 ' HA ' HG12 ' A' ' 50' ' ' VAL . 41.1 t -72.52 105.5 4.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.068 -0.515 . . . . 74.22 110.243 179.155 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.5 t -135.69 100.53 2.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.899 -0.591 . . . . 70.53 110.503 -177.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.618 ' HB3' ' H ' ' A' ' 49' ' ' GLU . 15.1 ttm180 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 118.451 -0.785 . . . . 74.41 109.558 176.159 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.478 ' HA2' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.485 1.93 0 N-CA-C 111.807 -0.517 . . . . 72.35 111.807 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.478 ' HD3' ' HA2' ' A' ' 1' ' ' GLY . 1.0 OUTLIER -82.01 86.61 1.52 Allowed 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 123.15 2.567 . . . . 72.1 112.507 -177.831 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 20.7 p -116.0 99.44 7.27 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.277 0.56 . . . . 75.23 110.728 178.007 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.8 m -126.41 99.75 5.97 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.106 -0.497 . . . . 74.12 111.212 -176.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -121.67 103.8 9.15 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.497 -0.557 . . . . 74.03 109.497 176.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -159.87 171.15 36.16 Favored Glycine 0 N--CA 1.443 -0.894 0 C-N-CA 120.481 -0.866 . . . . 52.24 112.86 -175.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 58.3 m -106.47 148.06 28.62 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.843 -0.429 . . . . 72.14 109.843 -178.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -84.21 -179.9 7.32 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.001 0.429 . . . . 64.22 111.192 -178.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.584 HD12 ' H ' ' A' ' 31' ' ' ILE . 42.1 mt -88.68 143.67 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.596 -0.729 . . . . 73.43 110.343 177.686 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.1 mt -98.91 166.66 2.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.705 -0.68 . . . . 53.14 109.968 -177.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 76.5 m-70 -89.71 138.66 27.96 Favored Pre-proline 0 C--N 1.325 -0.458 0 N-CA-C 109.899 -0.408 . . . . 73.31 109.899 178.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.406 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 55.4 Cg_endo -72.36 106.34 2.05 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.29 1.993 . . . . 62.52 111.384 174.512 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' PRO . 11.5 Cg_endo -88.85 -74.96 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.74 0 C-N-CA 123.054 2.502 . . . . 72.42 113.566 -174.114 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 32.9 t-105 -100.29 -176.46 3.23 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.19 -0.459 . . . . 72.24 109.834 -175.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -49.85 -29.36 7.92 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 122.896 0.478 . . . . 74.13 111.539 178.092 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.25 102.3 1.35 Allowed Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.715 -0.755 . . . . 71.54 111.813 176.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -88.98 -169.74 44.81 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 121.148 -0.549 . . . . 73.45 112.052 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 28.4 mt -116.11 137.95 48.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.795 0.807 . . . . 70.34 112.337 -174.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 19' ' ' ARG . 11.2 tpt180 -116.59 132.78 56.59 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 114.287 -1.324 . . . . 74.22 108.825 -179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.573 ' HB3' ' OH ' ' A' ' 38' ' ' TYR . 56.0 m-85 -92.33 -172.03 2.98 Favored 'General case' 0 C--N 1.318 -0.772 0 C-N-CA 120.703 -0.399 . . . . 74.35 110.604 -179.578 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.521 ' HB2' ' O ' ' A' ' 39' ' ' GLU . 7.4 tmm_? -112.64 -42.21 3.68 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.126 0.489 . . . . 74.3 110.287 -171.75 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -146.09 56.54 0.52 Allowed Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 121.008 -0.615 . . . . 71.12 111.716 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 40.9 mt -143.15 141.68 31.25 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.946 0.403 . . . . 52.44 110.555 179.263 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -99.65 -178.95 4.04 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.691 -0.686 . . . . 75.32 110.197 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.475 ' C ' ' H ' ' A' ' 27' ' ' GLN . 33.0 ptt180 -66.55 -172.63 0.17 Allowed 'General case' 0 C--O 1.234 0.243 0 CA-C-N 116.051 -0.522 . . . . 73.32 111.409 -179.411 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.6 t70 70.24 -38.67 0.42 Allowed 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.318 0.647 . . . . 54.04 111.043 -176.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.54 ' O ' HG22 ' A' ' 28' ' ' VAL . 17.7 mt-30 -94.73 -153.25 0.38 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.605 -0.725 . . . . 70.15 109.847 176.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.54 HG22 ' O ' ' A' ' 27' ' ' GLN . 3.6 m 57.8 13.16 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 124.584 1.154 . . . . 75.0 112.939 176.349 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 56.7 mtpt -106.1 -38.42 6.29 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.928 0.394 . . . . 71.12 110.218 176.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.22 86.71 2.25 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.032 -0.531 . . . . 75.11 110.704 177.071 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.584 ' H ' HD12 ' A' ' 9' ' ' ILE . 70.7 mt -134.68 121.98 37.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 N-CA-C 108.521 -0.918 . . . . 74.23 108.521 176.524 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.502 HD22 ' H ' ' A' ' 32' ' ' ASN . 0.1 OUTLIER -84.1 -24.46 30.31 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 113.229 0.826 . . . . 73.04 113.229 -170.334 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 -140.15 109.42 6.16 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 113.06 0.763 . . . . 71.25 113.06 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -88.45 112.18 48.32 Favored Pre-proline 0 C--N 1.323 -0.548 0 N-CA-C 107.77 -1.196 . . . . 73.11 107.77 165.166 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -58.85 152.0 60.7 Favored 'Trans proline' 0 N--CA 1.474 0.362 0 C-N-CA 123.057 2.504 . . . . 63.24 113.63 -170.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.482 ' O ' ' HB2' ' A' ' 37' ' ' ASP . 2.5 p -61.48 94.92 0.08 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 115.559 -0.746 . . . . 72.31 110.58 175.697 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.482 ' HB2' ' O ' ' A' ' 36' ' ' VAL . 18.3 t70 160.92 -29.9 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 114.488 -1.233 . . . . 75.53 108.367 -174.815 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.573 ' OH ' ' HB3' ' A' ' 20' ' ' TYR . 6.4 t80 -73.72 146.66 44.24 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.625 -1.171 . . . . 74.11 111.818 -173.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.521 ' O ' ' HB2' ' A' ' 21' ' ' ARG . 27.0 mt-10 -125.74 150.47 47.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.5 -0.773 . . . . 72.52 109.883 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.613 ' CG1' ' HB2' ' A' ' 56' ' ' ARG . 38.3 pt -132.99 149.31 31.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.948 0.404 . . . . 75.11 110.879 174.17 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.462 ' HG3' ' HD3' ' A' ' 54' ' ' LYS . 41.3 tt0 -118.64 171.44 8.19 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.476 -0.783 . . . . 74.33 109.396 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . 0.414 ' N ' ' HG2' ' A' ' 41' ' ' GLU . 73.1 m-85 -113.65 100.86 8.8 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.869 0.366 . . . . 75.13 111.176 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.6 m -96.98 132.1 42.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.013 0.435 . . . . 43.53 109.94 175.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.509 ' HB3' ' HB2' ' A' ' 48' ' ' ARG . 39.1 t -89.16 148.51 23.61 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.265 0.555 . . . . 51.42 110.941 -174.085 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? -59.11 133.62 56.26 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.579 -1.191 . . . . 71.44 110.702 -176.239 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 86.29 -119.24 5.09 Favored Glycine 0 N--CA 1.444 -0.823 0 N-CA-C 110.67 -0.972 . . . . 62.21 110.67 -173.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -141.5 83.1 1.85 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.411 0.624 . . . . 71.43 109.812 173.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.647 ' HB3' ' HB2' ' A' ' 73' ' ' CYS . 42.7 mmt180 -132.89 130.05 39.18 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.434 -0.803 . . . . 74.21 110.081 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 -86.25 139.69 30.8 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 109.958 -0.386 . . . . 74.41 109.958 178.04 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.444 HG12 ' HB3' ' A' ' 73' ' ' CYS . 30.5 m -97.82 127.32 50.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.224 -0.444 . . . . 54.31 111.096 -178.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.8 p -98.68 94.08 3.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 122.246 1.022 . . . . 73.23 109.287 174.042 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -156.82 171.06 34.29 Favored Glycine 0 N--CA 1.44 -1.059 0 CA-C-N 114.485 -1.234 . . . . 43.0 111.292 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -73.19 55.07 2.88 Favored 'Trans proline' 0 CA--C 1.531 0.341 0 C-N-CA 122.553 2.168 . . . . 70.42 110.255 168.252 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.585 ' O ' ' HD2' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -72.04 93.54 1.41 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.899 0.856 . . . . 72.35 112.718 -170.878 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.497 ' O ' ' HD3' ' A' ' 56' ' ' ARG . 7.2 p -161.57 128.75 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 115.527 -0.76 . . . . 74.12 109.862 170.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.613 ' HB2' ' CG1' ' A' ' 40' ' ' ILE . 29.1 mmt180 -132.83 115.62 15.52 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.303 -0.629 . . . . 73.32 109.303 177.261 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.43 ' HE2' ' HG2' ' A' ' 39' ' ' GLU . 37.2 ttmt -115.02 136.91 52.61 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 108.986 -0.746 . . . . 71.3 108.986 178.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' CYS . . . . . . . . . . . . . 42.7 t -73.78 139.95 45.54 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.826 0.346 . . . . 74.1 110.856 -176.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.481 ' C ' ' H ' ' A' ' 61' ' ' ASN . 87.3 mt -96.57 -179.53 4.64 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.779 -0.646 . . . . 75.32 110.548 -178.372 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -78.47 36.98 0.26 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-O 121.877 0.846 . . . . 34.01 109.304 174.128 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.481 ' H ' ' C ' ' A' ' 59' ' ' LEU . 0.9 OUTLIER -157.33 155.99 31.58 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.408 -1.269 . . . . 74.35 108.226 -172.37 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -74.45 50.31 2.06 Favored Glycine 0 CA--C 1.52 0.368 0 C-N-CA 121.114 -0.565 . . . . 74.22 113.215 -176.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 55.6 m -159.32 149.86 19.41 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 123.088 0.555 . . . . 64.31 109.518 178.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -83.53 175.19 9.96 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 110.171 -0.307 . . . . 65.43 110.171 -176.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 57' ' ' LYS . 1.4 p -50.56 -48.21 57.5 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.444 0.535 . . . . 71.12 112.444 -177.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -153.86 140.45 18.89 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.673 -0.862 . . . . 71.12 108.673 179.512 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 23.1 mmt -139.59 79.54 1.72 Allowed 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 120.235 -0.586 . . . . 72.34 110.557 168.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -168.48 87.93 0.21 Allowed 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 108.032 -1.099 . . . . 63.14 108.032 163.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.42 ' CB ' HH22 ' A' ' 56' ' ' ARG . 1.1 m -152.42 128.96 5.38 Favored Pre-proline 0 C--N 1.319 -0.751 0 C-N-CA 120.433 -0.507 . . . . 74.33 111.064 -169.82 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -74.99 69.29 5.58 Favored 'Trans proline' 0 CA--C 1.532 0.398 0 C-N-CA 122.772 2.315 . . . . 64.14 112.596 177.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 8.5 p -78.28 121.11 23.99 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.748 -0.464 . . . . 73.3 109.748 175.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.2 ptp85 -133.28 141.62 48.09 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.8 0.333 . . . . 75.3 111.624 -174.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.647 ' HB2' ' HB3' ' A' ' 48' ' ' ARG . 1.8 p -107.58 104.22 13.71 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.819 -0.628 . . . . 74.22 110.373 178.219 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.82 9.02 5.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 121.443 0.639 . . . . 70.53 110.755 -174.626 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.6 ttp180 . . . . . 0 C--O 1.246 0.901 0 CA-C-O 118.659 -0.686 . . . . 74.41 109.998 178.371 . . . . . . . . 0 0 . 1 stop_ save_